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Cervical Cancer is one of the leading cancers among women, especially in developing 
countries. Prevention and control are the most important public health strategies. 
Empowerment of women, education, “earlier” screening by affordable technologies 
like visual inspection, and treatment of precancers by cryotherapy/ LEEP are the most 
promising interventions to reduce the burden of cervical cancer.Dr Rajamanickam 
Rajkumar had the privilege of establishing a rural population based cancer registry 
in South India in 1996, as well as planning and implementing a large scale screening 
program for cervical cancer in 2000. The program was able to show a reduction in the 
incidence rate of cervical cancer by 25%, and reduction in mortality rate by 35%. This 
was the greatest inspiration for him to work on cerrvical cancer prevention, and he 
edited this book to inspire others to initiate such programs in developing countries. 
InTech - Open Access Publisher plays a major role in this crusade against cancer, and 
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Dr Rajamanickam Rajkumar (BSC, MBBS, MD, PhD, 
Colposcopy (UK & Ireland), FUICC, Hon. Member 
SCCPS Singapore) was inspired to become a doctor at 
school age by Christine Matthews - an Irish Missionary 
who worked at the Christian Medical College, Vellore. 
He did his postgraduate in Community Medicine and 
worked at the Christian Fellowship Community Health 
Centre, Ambillikai, Tamil Nadu – under the mentorship of Padmabhushan 
Dr Jacob Cherian. Burdened by the large number of cervical cancer cases 
in this small rural hospital, Dr Rajkumar wrote to IARC/WHO for guid-
ance to prevent and control cervical cancer. He initiated a rural popula-
tion-based cancer registry with IARC in 1996, and following training in 
colposcopy and precancer management in UK and Ireland, he implement-
ed a large scale screening program using the village workers in 2001. This 
IARC project was a great success. In 2011, in collaboration with the Society 
for Colposcopy and Cervical Pathology Singapore and The Ohio State 
University Medical Center, USA, Dr Rajkumar is forming the “Colposcopy 
and Cervical Pathology Society in South India – COLPI” for training doc-
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Preface 
Cervical cancer is one of the leading cancers in women, especially among those living 
in the poor socioeconomic conditions in the developing world. Much research has 
been done into possible treatments and preventative measures to hep combat the 
disease, and while there is a wealth of information and statistical evidence in terms of 
incidence, survival and mortality rates the challenge is to communicate what this 
means to the average person on the street. 
If we can ensure that cervical cancer can be screened for at an early stage, effective 
precancer treatment can be given and an evidence-based cure can be developed by 
meticulous follow up, then, we are justified. Women empowerment, education and 
screening/treatment of cervical cancer preceded by affordable, acceptable and 
accessible strategies, will play a critical role. 
This book by InTech – Open Access Publisher is a commendable project. If the 
chapters could inspire a worldwide crusade to prevent cerrvical cancer, especially 
among the most underprivileged women in the developing countries, the mission is 
fulfilled.   
Dr Rajamanickam Rajkumar 
Professor, Community Medicine 
Meenakshi Medical College Hospital & Research Institute, 
Kanchipuram Tamil Nadu 
India 
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Predictors of Cervical Cancer Screening:  
An Application of Health Belief Model 
Sedigheh Sadat Tavafian 
Tarbiat Modares University 
Iran 
1. Introduction 
Worldwide, cervical carcinoma is one of the most common gynecologic malignant tumors 
and a leading cause of death from genital malignancies in women. Although, pap smear as a 
screening method has the potential to identify pre-cancerous lesions and could massively 
reduce the invasive disease in developed countries, developing countries could not 
significantly lower the rate of cervical cancer among general population through using this 
screening test. This chapter will review the factors influencing cervical cancer screening 
behavior. First, the state of pap smear up taking - as a method of screening - among women 
is described. Second, the structure of Health Belief Model and how the constructs of the 
model could predict health behavior of cervical cancer screening will be explained. Finally, 
the application of Health Belief Model intervention to improve the behavior of cervical 
cancer screening among women will be discussed. 
2. Pap smear as a cervical cancer screening test 
Cervical cancer is the second leading cause of death worldwide and the tenth leading cause 
of cancer-related deaths among women in the United States (Ben-Natan, & Adir, 2009). 
Despite, fully preventable, cervical cancer is a major health problem in developing countries 
(Sankaranarayanan et al., 2008 ; Tristen et al., 1996; Abdullahi, 2009; Akbari et al., 2010). 
Cervical cancer is also a common type of cancer among women, especially in women 20–39 
years of age. In several developed countries, the incidence of invasive cervical cancer has 
declined, which is largely attributed to early detection efforts. However, several 
subpopulations remain under screened, Active young women, minority women with 
language difficulties, and women with specific cultural health beliefs are at risk for this 
disease (Harlan et al., 1996; Snider 1996). It has been argued that the majority of cervical 
cancer as well as the most related deaths occur in low and medium income countries 
(Akbari et al., 2010). The patients who have been early diagnosed had survival rate much 
more than who suffering from more advanced stage of the disease. Papanicolaou or Pap 
smear test is a powerful cervical cytology screening test that could detect cervical cancer in 
premalignant stage that could be fully curable (Gakidou et al., 2008). This method of cervical 
cancer screening detects abnormal precancerous cells before they advance to cancer. Routine 
cervical cancer screening - every one to three years - is recommended by American Society 
for Colposcopy and Cervical Pathology to be begun in women three years after becoming  
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sexually active or no later than by age 21 and continue to age 65 depending on screening 
history . In developed countries, extensive screening program through pap smear test, has 
declined the incidence of cervical cancer. In contrast, in most developing countries, 
comprehensive cervical cancer screenings are rare. Low participation of cervical cancer 
screening and low follow up of screening were evidenced by studies done in low resource 
countries like Botswana (Ibekwe1 2010; McFarland, 2003). However, in spite of advances in 
screening and treatment of cervical cancer during the past several decades, this disease 
remain a major health problem for Hispanic women, as many women have never had a 
Papanicolaou smear, or were not tested regularly (Harlan et al., 1991; Matuk,1996, Salazar, 
1996). It has been stated that current screening programs in developing countries or among 
minorities faced obstacles such as insufficient supplies, inadequate trained health care 
providers; limited available services and lake of patient follow up procedure. Additionally, 
lack of appropriate programs in these countries indicates that the population may be at 
relatively higher risk for cancer mortality and morbidity due to delayed diagnosis. 
Inappropriate allocation of funds and human resources could also be a barrier to an effective 
and organized screening program in developing countries. These deficiencies caused the 
majority of cervical cancer cases referred to health care providers with late stage disease 
(Were, 2011). There are many evidences from different countries to suggest that women of 
lower socio-economic status (SES) are less likely to participate in cancer screening than those 
who are more advantaged (Coughlin et al., 2006, Datta et al., 2006, Lofters et al., 2007, 
Ackerson 2010) . In addition, lack of enough knowledge regarding preventable cervical 
cancer and also socio-cultural barriers such as embarrassment for pelvic examination have 
been argued as leading factors of not using available screening services regularly 
(Sankaranarayanan, 2008). Fear of the result of the test is another socio cultural barrier 
among different countries. Studies with Hispanic women reported fear of cancer, 
embarrassment, and limited English ability as major perceived barriers. In Hispanic women, 
great fear of cancer was associated with extreme fatalism about the disease. Most believed 
that cancer cannot be cured, and a diagnosis is considered a death sentence. This fear leaded 
to the avoidance of the subject and discussion of cancer (Bakemeier et al., 1995, , Frank-
Stromborg et al., 1998) As a result, educational programs were often avoided, contributing 
to lack of optimal knowledge of screening practices (Chavez , 1997, Mandelblatt , 1999). 
Embarrassment was a stronger predictor of screening than perceived susceptibility and 
perceived benefits of early detection in a study conducted by Richardson and colleagues 
(Richardson, 1987). A previous study examined the association between inadequate 
functional health literacy in Spanish among low-income Latinas and cervical cancer 
screening knowledge and behavior (Garbers & Chiasson, 2004). This study showed in 
compared to women with adequate and marginal health literacy, women with inadequate 
functional health literacy were significantly less likely to have ever had a Papanicolaou (Pap) 
test (odds ratio, 0.12; 95% confidence interval [CI], 0.04-0.37) or in the last three years (odds 
ratio, 0.35; 95% CI, 0.18-0.68) .This study verified even when controlling for other factors, 
women with inadequate health literacy were 16.7 times less likely to have ever had a Pap 
test. In 2006, American Cancer Society reported the American African women have a higher 
mortality rate due to cervical cancer when compared to all other groups of women. 
According to this report about 70 % of women diagnosed with cervical cancer had not 
received the Papanicolaou (Pap smear) test within the previous 5 years or had never 
obtained the screening test (American Cancer Society, 2006). One of the reasons for the 
deference in the mortality rate for American African women was that they tend to have less  
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frequent screenings as compared to other racial groups of women. Subsequently, this group 
of women experienced discrepancies in mortality rates related to cervical cancer when 
compared to other groups It has been showed that individuals’ beliefs about the causes and 
significance of a particular illness were interconnected with their healthcare seeking 
behaviors. Al-Neggar RA and co-workers concluded that despite adequate knowledge 
regarding risk factors of cervical cancer, some misconceptions and wrong beliefs among 
young women could be resulted in poor practice of pap smear test ( Al- Neggar et al , 2010). 
One of theoretical models that could assess the beliefs of people regarding healthy behavior 
is Health Belief Model. In this section, the structure of Health Belief Model and its capability 
to predict the behaviors is explained. According to concepts of Health Belief Model, if 
individuals regard themselves as susceptible to a condition, believe that a course of action 
available to them would be beneficial in reducing either their susceptibility to or severity of 
the condition, and believe the anticipated benefit of taking action outweigh the barrier to 
action, they are more likely to take action so that their beliefs will reduce their risks.  
3. Health belief model as a framework for predicting behaviors 
The Health belief model was originally developed in the 1950s by a social psychologist in 
the U.S public Health Service to explain the widespread failure of people to participate in 
programs to prevent and detect disease. Later, the model was extended to study peoples’ 
responses to symptoms and their behaviors in response to diagnosed illness, specially 
adherence to medical regimens (Glanz et al., 2008). This model aims to explain preventive 
health behaviors rather than behaviors in time of illness (Ben-Natan & Adir, 2009). Major 
health behaviors emphasized by the Health Belief Model focus on prevention exposure of 
diseases at their asymptomatic stage (Lee, 2000). The Health Belief Model contains several 
primary concepts that predict why people will take action to prevent, to screen for, or to 
control disease conditions. Thus, this model assumes that health behaviors are motivated by 
five elements of perceived susceptibility, perceived seriousness, perceived benefits and 
perceived barriers to behavior, cues to action and most recently factor of perceived self 
efficacy (Champion & Skinner, 2008).  
3.1 Application of the Health Belief Model to cervical cancer screening behavior 
The Health Belief Model has been used extensively to determine relationship between health 
beliefs and health behaviors as well as to inform interventions. In this section, the constructs 
of Health Belief Model is explained at the first and then the application of Health Belief 
Model constructs in the area of cervical cancer screening behavior is discussed.  
3.1.1 Perceived susceptibility 
The perceived susceptibility refers to beliefs about the likelihood of getting a disease or 
condition. Perceived risk of contracting a disease refers to individuals’ subjective perception 
of their susceptibility to the disease. For example, women must believe there is a possibility 
of getting cervical cancer before they will be interested in uptaking Pap smear. The health 
belief model predicts that women will be more likely to adhere the cervical cancer screening 
recommendation if they feel that they are susceptible to cervical cancer (Glanz et al., 2008). 
Previous study has shown that individuals who believed they had risk factors for cervical 
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cancer, were more likwely to take action to prevent an adverse outcome subsequent to 
getting the disease (Saslow et al., 2002). Perception of not being at risk for cervical cancer has 
been verified as a reason for not obtaining pap smear test in previous studies (Mutyaba et al, 
2006; Basu et al, 2006, Winkler et al, 2008 , Ibekwe1, 2010). A common emerging belief to 
cervical cancer screening in Hispanic women is that it is unnecessary or not needed to 
prevent cervical cancer. Among this target group a substantial proportion of women 
perceived Papanicolaou smears as unnecessary diagnostic procedures, rather than 
preventive health measures. In a study (Stein & Fox , 1990) showed Hispanic women do not 
view preventive health, such as cancer prevention, as a priority; as a result, they have an 
increased risk for diseases because of their curative rather than preventive health practices. 
In this regard, Hispanic women do not perceive their own vulnerability to cervical cancer 
and do not see themselves at risk.  
3.1.2 Perceived severity 
The perceived severity of a disease refers to the severity of a health problem as assessed by 
the individual. This variable refers to feeling about the seriousness of contracting an illness 
or of leaving it untreated include evaluations of medical/ clinical consequences like death, 
disability and pain or social consequences such as effects of the conditions on work, family 
life and social relations. For example, if women think that cervical cancer is a sever disease 
and believe that getting cervical cancer would have serious medical, social and economical 
consequences for them, it is more likely to obtain cervical cancer screening test. Having 
personal knowledge regarding the importance of the Pap smear has been evidenced as an 
important factor to take action to prevent the adverse outcome of cervical cancer (Saslow et 
al., 2002). A survey on the severity of cervical cancer among adult females in Quebec, found 
that 57% of women were afraid of developing cervical cancer sometime in their life, and 93% 
thought cervical cancer has serious consequences. Cervical cancer related anxiety and 
perceived seriousness did not vary by age group or level of education (Sauvageau et al., 
2007). Although most participants perceived cervical cancer as serious, the thought of 
believing that there was no treatment of cervical cancer, makes them uninterested to doing 
cervical cancer screening test (Ibekwe1, 2010) . However, Hoque and coworkers, compared 
two groups of ever screened and never screened for cervical cancer. In a cross sectional 
study. in this evaluation, it was observed that both groups equally believed that there is 
effective treatments for cervical cancer, and that cervical cancer makes a woman’s life 
difficult. Both the screened and the never screened believed that cervical cancer is as serious 
as other cancers; that it causes infertility and that death from cervical cancer is not rare. This 
study showed no significant association between perceived severity and screening for 
cervical cancer that differs with the hypothesis of the Health belief model that predicts 
perceived seriousness of a disease necessitate people to engage in preventive actions. 
Further research should be done to explore the reasons why at risk women fail to participate 
in cervical cancer screening (Hoque, 2009).  
3.1.3 Perceived benefits 
Even if a person perceives personal susceptibility to a serious health condition (perceived 
treat) , whether this perception leads to behavior change will be influenced by the person 's 
belief regarding the perceived benefits of the various available actions for reducing the  
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Belief about the Chances of 
experiencing a risk or getting a 
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Perceived 
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condition and its sequel are 
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,when; Clarify the positive effects to 
be expected 
Beliefs in efficacy of the advised 
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Belief about the tangible and 
psychological costs of the 
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awareness, Use appropriate reminder 
systems 
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Table 1. Description of HEALTH BELIEF MODEL constructs. 
disease treat (Glanz et al., 2008 ). For example, women must believe that a course of 
preventive behaviors available would be beneficial in reducing the risk of getting cervical 
cancer. Therefore, individuals exhibiting optimal beliefs in susceptibility and severity are 
not expected to accept any recommended health action unless they also perceive the action 
as potentially beneficial by reducing the treat. Ibekwe1 explored that either screened or 
never screened research participants overwhelmingly agree or strongly agree that it is 
important to do cervical cancer screening (Ibekwe1, 2010). This is consistent with studies in 
which the majority of subjects agreed that regular pap smear screening will give them peace 
of mind, find a problem before they become cancer and very necessary even if there is no 
family history of cancer (Leyva et al., 2006). The major reasons while both screeners and 
never screeners in Ibekwe1 study believed was that it is important to do cervical cancer 
screen because it could find changes in the cervix before they get cancer and the disease 
could easily be cured when found early. These reasons are consistent with findings of other 
studies (Agurto et al., 2004 ; Ibekwe1, 2010). As it was discussed before,Health belief model 
predicts that those with perceived benefits are more likely to take preventive actions, than 
those with no perceived benefits or low perceived benefits. Thus, it is most likely that the 
low uptake of cervical cancer screening among the participants took part in Ibekwel syudy 
could be attributed to other factors other than lack of perceived benefits (Ibekwe1, 2010). 
When in Ibekwe1 study participants and non-participants in cervical cancer screening were 
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never screened research participants overwhelmingly agree or strongly agree that it is 
important to do cervical cancer screening (Ibekwe1, 2010). This is consistent with studies in 
which the majority of subjects agreed that regular pap smear screening will give them peace 
of mind, find a problem before they become cancer and very necessary even if there is no 
family history of cancer (Leyva et al., 2006). The major reasons while both screeners and 
never screeners in Ibekwe1 study believed was that it is important to do cervical cancer 
screen because it could find changes in the cervix before they get cancer and the disease 
could easily be cured when found early. These reasons are consistent with findings of other 
studies (Agurto et al., 2004 ; Ibekwe1, 2010). As it was discussed before,Health belief model 
predicts that those with perceived benefits are more likely to take preventive actions, than 
those with no perceived benefits or low perceived benefits. Thus, it is most likely that the 
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could be attributed to other factors other than lack of perceived benefits (Ibekwe1, 2010). 
When in Ibekwe1 study participants and non-participants in cervical cancer screening were 
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compared, it was found that there was no significant association between perceived benefits 
of doing cervical cancer screening and cervical cancer screening , and this was consistent 
with previous studies (Agurto et al., 2004; Leyva et al., 2006). The study did not find any 
significant association between socio-demographic characteristics and perceived benefits of 
doing cervical cancer screening as both the ever screened and the never screened 
irrespective of their socio-demographic characteristics overwhelming agree or strongly 
agree that it was important to do cervical cancer screening. (Ibekwe1, 2010). This finding is 
consistent with findings of other studies in which participants across all socio-demographic 
characteristics generally were aware of the benefits of cervical cancer screening (Leyva et al., 
2006). However, continue education to clear misconceptions are still required to ensure 
increased uptake of cervical cancer screening among the eligible women especially among 
those that are high risk ( Ibekwe1, 2010). 
3.1.4 Perceived barriers 
Perceived barriers to action refers to the negative aspects of health-oriented actions or which 
serve as barriers to action and/or that arouse conflicting incentives to avoid action. 
Perceived barrier refers to the potential negative aspects of particular health action may act 
as impediments to undertaking recommended behaviors. A kind of nonconscious, cost 
effective analysis occurs wherein individuals weight the action expected benefits with 
perceived barriers such as it could help me, but it may be expensive, have negative side 
effects, and be unpleasant, inconvenient or time consuming. Thus combined levels of 
susceptibility and severity provide the energy of force to act and the perception of benefits 
(minus barrier) provide a proffered path of action (Glanz et al., 2008). For example, if 
women believe that anticipated benefit of doing behaviors to prevent cervical cancer 
outweigh the barriers to or cost of the preventive behaviors, they are more probably to 
obtain cervical cancer screening test. Previous researchers also have reported that women 
who perceived the Pap smear testing process as painful and embarrassing due to visiting by 
male provider had lower rates of routine cervical cancer screening (Boyer etal.,2001 ; Hoyo 
et al., 2005; Jennings, 1997, Ackerson K , 2010, Abdullahi 2009). In this study, Some 
participants from the focus groups and interviews mentioned off-putting experiences that 
they had experienced themselves or heard from others acting as a barrier to attending 
screening. Such negative experiences included experiencing pain, bleeding and being faced 
with inexperienced sample takers who did not explain the process or enable them to ask 
questions (Abdullahi 2009). In this study, language difficulties were thought to not only 
detract from women’s understanding of the test and thus the perceived need for screening, 
but also to prevent some women from attending, due to anxiety about not being able to 
understand the sample taker or not being able to ask questions and form a trusting 
relationship. Even if the participants took part in the study appreciated the need for 
screening, fear of the test was cited as a hindrance to some women, Furthermore, the metal 
speculum was perceived as a painful instrument and some did not trust the sterilization 
process. Fear of the test results was also thought to prevent some women from coming 
forward for screening. (Abdullahi 2009). Fear that abnormal test results mean existing 
cancer has been reported as a barrier to do Pap smear in previous researches (Mutyaba et al, 
2006; Basu et al, 2006 ; Winkler et al., 2008, Were E1, 2011). The other factors that appeared 
to cause negative perceptions and act as barriers to cervical cancer screening was a previous 
history of trauma like childhood sexual abuse, intimate partner violence, and trauma related 
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to medical procedures which was mentioned in previous study( Ackerson K , 2010). 
However, in previous research, a link between an interpersonal or medical trauma history 
and routine screening was not indicated (Bazargan et al., 2004; Hoyo et al., 2005). Chung HH 
conducted a cross sectional study to document currently cervical cancer screening practices 
of physicians in Korea These researchers verified that cost has been a major reason for 
selecting screening method of liquid-based cytology instead of Pap smear (Chung, 2006). 
Obesity was reported as a barrier for cervical cancer screening in previous study(Wee, 2002). 
In this study. it was shown that overweight and obese women were less likely to be 
screened for cervical cancer with Pap smears, even after adjustment for other known 
barriers. In a study was conducted in 1998, it was revealed that among women who sought 
outpatient care, screening rates decreased while co - morbidity/chronic disease increased 
(Kiefe, 1998). Embarrassment is known to be a barrier to cervical screening, regardless of 
ethnic background, but in the study conducted among some Somali women, there was 
additional embarrassment associated with the potential reaction of the sample taker when 
faced with a circumcised woman. The anxiety of potentially being faced with a male sample 
taker was a significant problem for these Muslim women (Abdullahi, 2009, Naish, 1994, 
Nichols, 1987). Time consuming was a barrier to cancer prevention in previous syudy. A 
study addressed the house staff adherence to cervical cancer screening recommendations by 
United States Preventive Services Task Force, reported lack of time during postgraduate 
training was frequently reported as a barrier to obtaining preventive care( Ross et al, 2006). 
Low socioeconomic status, poverty, low levels of education, lack of knowledge, and 
acculturation have been established as reasons for the low screening rates in Hispanic 
women. Cost of cytology have been cited as problems for Hispanic women in the United 
States (Austin et al, 2002). Many Hispanic women strongly believed that the fear of finding 
cancer would deter them from screening (Salazar MK. , 1996). Several studies reported that 
many Hispanic women would prefer not to know the diagnosis of cervical cancer (Hubbell 
et al., 1996; Mandelblatt , 1999 ). Suarez and associates (Suarez , 1993) noted that 48% of the 
Mexican-American women they surveyed thought that their chances of surviving cervical 
cancer were poor and those who preferred to speak in Spanish tended to have more 
fatalistic attitudes. They often believed that there was nothing one could do to prevent 
cervical cancer. This powerlessness may account for some of the anxiety associated with 
cancer. According previous evidences, a major barrier to cancer screening was culturally 
based embarrassment and similar emotions ( Coyne , 1992, Bakemeier et al., 1995, Stein , 
1990). The inability to speak English fluently interferes with Hispanic women’s ability to 
obtain important health information and to communicate with health professionals. Women 
speaking only, or mostly, Spanish were consistently less likely to be screened for breast and 
cervical cancer. Language difficulties can deter referral and impede delivery of medical care 
(Harlan , et al1991).  
3.1.5 Cues to action 
Various early information of the Health Belief Model included the concept of cues that can 
trigger actions. Readiness to action (Perceived susceptibility and perceived benefits) could 
only be potentiated by other factors particularly by cues to instigate action such as bodily 
events or by environmental events such as media publicity (Glanz et al., 2008). For example, 
women would be more likely to have preventive behavior like uptaking Pap smear if they 
be reminded by their family members or heath care providers. The influence of cues on  
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women to practice cervical cancer screening behavior has been reported by previous 
evidences. Ackerson has investigated the role of cues for obtaining pap smear test and 
resulted that health care providers were influential cues for studied participants by giving 
information regarding the importance of the test ( Ackerson K , 2010). Furthermore, the Pap 
smear users in Ackerson study were more encouraged by health care providers and family 
members to do the test compared to other individuals who did not obtain the test. In the 
country of Australia, health care system is a good cues for women to obtain cervical cancer 
screening .In this country all people accessing high quality cancer control, whether it be 
prevention, screening, treatment or education. In addition, non-government organizations 
(NGOs) specializing in cancer control have been providing free or highly subsidized 
support services to patients and their families for over half a century in most states. These 
NGOs have also been very active in public education about cancer, especially cancer 
prevention and act as cues for women (Burton, 2002). In previous research recommendation 
by GPs and health care providers as well as written and oral information were considered as 
cues to action for cervical cancer screening (Abdullahi 2009). According to this study, many 
participants had first attended screening as a result of their GP’s advice so that GPs were 
proactive in encouraging Somali women to take up screening. Regarding preferred formats 
of screening information, Somalian participants stated that it was necessary for information 
to be given in Somali language. They explained that, in view of the cultural significance of 
talking in this culture, they responded better to verbal than written information, such as 
being told by a friend or a Somali community worker through talks or workshops in 
community settings. Written information was considered unsuitable cues to action by some 
due to low levels of literacy among Somalis, although others felt that it was a useful adjunct 
(Abdullahi 2009). The integral role of nurses in educating women regarding health 
preventive care, especially the importance of routine cervical cancer screening was stressed 
in other study(Ackerson, 2010). This study confirmed nurses are in a position to influence 
positive health behavior, so they should inform women about the purpose of the Pap smear 
test, while assessing the woman’s personal risk factors for cervical cancer, and her beliefs 
and perceptions regarding Pap smears. Many studies have identified positive cues to cancer 
screening in Hispanic women. These include physician recommendation, lay health workers, 
written materials, and media. Physician recommendation is one of the most important cues 
to cancer screening. Physicians play a key role in informing women of the benefits of 
screening (O’Malley , 2001) . Similar results were observed in previous evidence (Zambrana 
et al , 1999). The respect for authority is an important characteristic of Hispanic culture. 
Latinas consider doctors as powerful authority figures and have a tendency to listen to what 
doctors say, but rarely show self-initiated health care behaviors. The role of physician is 
especially important for older minority women ( Rimer , 1994, Mandelblatt & Yabroff , 2000). 
Community outreach strategies are the most common health promotion, and probably most 
effective strategies employed by health care workers, researchers, and health promotion 
officers. Community outreach strategies include the use of appropriate language materials, 
involvement of lay health workers, and presentations at community and workplace settings. 
Lay health workers are trained personnel from the Hispanic community whose main job is 
to educate women on the benefits of Papanicolaou screening and mammography to reduce 
perceived barriers to screening. Several studies report that the involvement of the 
community is effective in the development, planning, and delivery of the screening 
programs (Eng et al., 1997, Zavertnik, 1993). Impressive results in cervical and breast 
screening behaviors were obtained in the Hispanic community living in California  
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(Perez-Stable , 1992). In Ontario, lay health workers have been found to be important 
positive cues to action for Hispanic women. Churches are also important vehicles to reach 
Hispanic women. Castro et al, reported positive church involvement in cancer screening 
practices of Latina women (Castro , 1995). Other researchers have found that churches 
provide a social influence to participation in cancer screening among Hispanic women 
(Frank-Stromborg , 1998, Zavertnik , 1993, Davis , 1994) The “Companeros en la Salud” 
program delivers educational programs at churches, and preliminary results are expected to 
show an increase in Papanicolaou smears and mammography among Latina women. 
Written materials are also used as cues to action. Specific educational materials (e.g., 
brochures, community newspapers), usually apart from community outreach programs, are 
effective in providing information to Hispanics if they are culturally sensitive, and written 
in Spanish at a grade (Snider et al., 1996) reading level to improve understanding among 
low-literacy individuals. One effective way to reach Hispanic women may be through 
media-based public health campaigns. However, such programs are effective only when 
delivered and implemented in a culturally meaningful and sensitive manner. Vellozzi et al. 
indicated that Hispanic women may be more receptive to media messages than are other 
ethnic groups (Vellozzi , 1996). In “A Su Salad” program, media messages (TV, radio, and 
newspaper) have been integrated successfully with community-based outreach( Suarez, 
1993b, Anderson et al., 2009). Salazar indicated that the media increased Hispanic women’s 
willingness to openly discuss breast cancer ( Salazar , 1996). 
3.1.6 Perceived self efficacy 
Perceived self efficacy is defined as the conviction that one can successfully execute the 
behavior required to produce the outcomes. For behavior change to succeed, people must 
feel threatened by their current behavioral pattern ( perceived susceptibility and severity ) 
and believe that change of a specific kind will result in a valued outcome at an acceptable 
cost ( perceived benefit ). Then, they also must feel themselves competent (self – efficacious) 
to overcome perceived barriers to take actions. For example, women should be confident 
that they could uptake pop smear in a regular manner.  
3.1.7 Other variables 
Divers demographic, sociopsychological, knowledge, socio cultural, race , education and 
structural variables may influence perception and thus, indirectly affect on health related 
behavior (Glanze 2008). For example , socio demographic factors , particularly educational 
attainment, are believed to have an indirect effect on behavior of cervical cancer screening , 
through influencing the perception of susceptibility to getting the disease, severity of the 
disease and benefits of this screen behavior that overcome to the perceived barriers. Studies 
conducted among divers samples have found some differences in the specific types of 
beliefs about susceptibility, benefits and barriers among different racial and ethnic groups. 
Different groups have different beliefs about the causes of cervical cancer, which can affect 
perceived susceptibility. Hispanic women were afraid that they would not be able to cope 
with the disease. One research group noted that low-acculturated Mexican-American 
women expressed a stronger fear of cancer than did high-acculturated women (Balcazar , 
1995). A study conducted in somali showed that knowledge about the purpose of cervical 
screening was limited among Somali women. There was also a lack of understanding of risk 
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women to practice cervical cancer screening behavior has been reported by previous 
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(Perez-Stable , 1992). In Ontario, lay health workers have been found to be important 
positive cues to action for Hispanic women. Churches are also important vehicles to reach 
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women expressed a stronger fear of cancer than did high-acculturated women (Balcazar , 
1995). A study conducted in somali showed that knowledge about the purpose of cervical 
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factors for cervical cancer, and many of the women held fatalistic attitudes, associated with 
the idea of ‘God’s will’, about this cancer and other aspects of health. Somalis are almost all 
Muslim and their view of health is typically shaped by a combination of traditional Somali 
and Islamic beliefs, with most believing that illness and healing only occur by the will of 
God. It is important therefore to recognize that some Somalis may wrongly interpret Islam 
as not allowing disease prevention interventions (Abduullahi 2009). Researchers have found 
that Latinas hold more fatalistic attitudes about cervical cancer (Chavez , 1997). This attitude 
stemed from the belief that there was little an individual could do to alter fate or prevent 
cancer. Latinas often believed that cancer is God’s punishment for improper or immoral 
behavior (Hubbell FA, 1996). Another culturally specific barrier was embarrassment 
associated with female circumcision, i.e. female genital mutilation. Embarrassment about 
discussion of private body parts and embarrassment at exposing private body parts during 
a physical examination may pose a barrier for some Hispanics, especially if examined by a 
male physician ( Frank-Stromborg et al., 1998), Accordingly, gender of the physician may 
determine breast and cervical cancer screening uptake and compliance in this community. 
Hispanic women may also be embarrassed to disclose personal information related to their 
sexual activity to another person besides their partner. Limited proficiency in the language 
of the host country has also been identified as a barrier to cancer screening. This variable has 
been shown to provide a reliable prediction of the use of preventive health care among 
minority women ( Stein & Fox , 1990). The other culturally barrier that was consistently 
mentioned by the participants who took part in the focus groups and interviewees from 
Somali was embarrassment as a hindrance to attending screening. Most of these women 
viewed the test as intrusive and uncomfortable, both physically and emotionally. For some, 
the embarrassment associated with having been circumcised was an additional barrier. 
Although they were not ashamed of this, they anticipated embarrassment associated with 
the shocked reaction of the sample taker to their circumcision. In all of the focus group 
discussions and six of the eight interviews, participants explained that for Muslim women, 
the possibility of having a man perform the test was a significant barrier. Many participants 
were unaware that they could request a woman to undertake the test ( Abdullahi 
2009) .Other variables suggested by the participants were: lack of knowledge about the need 
for cervical screening, practical problems such as appointment times and childcare needs, 
language difficulties, fear of the test and negative past experiences. Determinants of uptake 
of cervical cancer screening services include age, education, contraception use and being 
married (Objechina, 2009). Women with low educational achievement, low awareness of the 
risk factors for cervical cancer, and who do not have support from their husbands may also 
have poor uptake of screening services (Allahverdipour H, 2008; Abdullahi, 2009). In 
previous study which was conducted by Ackerson K, twenty-four participants were divided 
into two groups based on whether they did or did not get routine Pap smears . The results 
showed there were differences between the two groups in terms of demographic and social 
characteristics, having previous health care experience as well as cognitive appraisal related 
to beliefs and perceptions of vulnerability (Ackerson K , 2010). Monthly income and 
residential area were significantly associated with perceived severity (Houqe 2009). Certain 
types of barriers are more or less important for particular cultural or ethnic subgroups. Thus, 
women who had such belief might consider their susceptibility to cervical cancer was quite 
low. In a systematic review was conducted by Johnson CE in 2008, commonly held beliefs 
across several cultural groups emerged included fatalistic attitudes, a lack of knowledge 
about cervical cancer, fear of Pap smears threatening one's virginity, as well as beliefs that a 
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Pap smear is unnecessary unless one is ill (Johnson CE, 2008). This study revealed that some 
unique beliefs were common among specific cultural groups. For example, Hispanic women 
noted some body-focused notions and believed that childbirth, menses, sex, and stress play 
a role in one's susceptibility to cervical cancer. African Americans identified administrative 
processes in establishing health care as barriers to screening, whereas Asian immigrants 
held a variety of misconceptions concerning one's susceptibility to cancer as well as 
stigmatization imposed by their own community and providers. This study concluded 
health care providers and policy makers must be cognizant of the various sociocultural 
factors influencing health-related beliefs and health care utilization among immigrant and 
ethnic minorities in the United States. Culturally relevant screening strategies and programs 
that address these socio cultural factors must be developed to address the growing disparity 
in cervical cancer burden among underserved, resource-poor populations in the United 
States . Vietnamese American women are five times more likely to be diagnosed with 
cervical cancer than their White counterparts. Previous research has demonstrated low 
levels of Papanicolaou (Pap) testing among Vietnamese. Taylor VM and co-workers 
conducted a population-based, in-person survey of Vietnamese women aged 18 - 64 years to 
examine factors associated with interval Pap testing adherence. In this study the beliefs 
including Pap tests decrease the risk of cervical cancer , cervical cancer is curable if detected 
early, testing is necessary for women who are asymptomatic, sexually inactive, or 
postmenopausal , concern about pain/discomfort as a barrier to screening; family member(s) 
and friend(s) had suggested testing (social support); doctor(s) had recommended testing 
communication with health care providers were explored as predictor variables for 
obtaining pap smear (Taylor VM, 2004). In a multivariate analysis, this study showed being 
married, knowing Pap testing is necessary for asymptomatic women, doctor(s) had 
recommended testing, and had asked doctor(s) for testing were independently associated 
with screening participation (Taylor et al., 2004) . Fear, embarrassment, and cost were more 
likely to be barrier to adherence cervical cancer screening recommendation among Asian 
women compared to white women ( Ross, 2008). Finally, in addition to differences in 
specific perceptions about susceptibility, benefits and barriers among different racial or 
ethnic groups, researchers have found differences by race in exploratory of Health Belief 
Model constructs. Racial and ethnic disparities in cervical cancer screening have been 
attributed to socioeconomic, insurance, and cultural differences. A previous study evaluated 
the relationship between U.S. citizenship status and the receipt of Pap smears among 
immigrant women in this study California Citizen immigrants were significantly more 
likely to report receiving a Pap smear ever (adjusted prevalence ratio [aPR], 1.05; 95% 
confidence interval [CI], 1.01 to 1.08), a recent Pap smear (aPR, 1.07; 95% CI, 1.03 to 1.11) as 
compared to immigrants who are not U.S. citizens (DE Alba, 2005).. Also variables like 
income, having a usual source care, and having health insurance were associated with 
receiving cancer screening. This study showed Hispanic women were more likely to receive 
Pap smears as compared to whites and Asians (DE Alba, 2005). Foreign birthplace may 
explain some disparities previously attributed to race or ethnicity, and is an important 
barrier to cancer screening, even after adjustment for other factors. Increasing access to 
health care may improve disparities among foreign-born persons to some degree. Results 
from previous research, showed black respondents were as or more likely to report cancer 
screening than white respondents; however, Hispanic and Asian-American and Pacific 
Islander (AAPI) respondents were significantly less likely to report screening for most 
cancers. When race/ethnicity and birthplace were considered together, U.S.-born Hispanic  
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and AAPI respondents were as likely to report cancer screening as U.S.-born whites; 
however, foreign-born white (adjusted odds ratio [AOR], 0.58; 95% confidence interval 
[CI], 0.41 to 0.82), Hispanic (AOR, 0.65; 95% CI, 0.53 to 0.79), and AAPI respondents 
(AOR,0.28; 95% CI, 0.19 to 0.39) were less likely than U.S.-born whites to report Pap 
smears ( Goel etal., 2003). A cross-sectional survey that was conducted among a 
convenience sample of 204 female post-graduate physicians examined adherence to 
United States Preventive Services Task Force cervical cancer screening recommendations, 
perception of adherence to recommendations, and barriers to obtaining care. This study 
showed just 83% of women were adherent to screening recommendations and 84% 
accurately perceived adherence or non-adherence. Women who self-identified as Asian 
were significantly less adherent when compared with women who self-identified as white 
(69% vs. 87%; Relative Risk [RR]=0.79, 95% Confidence Interval [CI], 0.64-0.97; P<0.01). 
Women who self-identified as East Indian were significantly less likely to accurately 
perceive adherence or non-adherence when compared to women who self-identified as 
white (64% vs. 88%; RR=0.73, 95% CI, 0.49-1.09, P=0.04). Women who self-identified as 
Asian were significantly more likely to report any barrier to obtaining care when 
compared with women who self-identified as white (60% vs. 35%; RR=1.75, 95% CI, 1.24-
2.47; P=0.001). Women who self-identified as East Indian being more likely to report any 
barrier to obtaining care when compared with women who self-identified as white (60% 
vs. 34%; RR=1.74, 95% CI, 1.06-2.83; P=0.06) (Ross et al., 2008). A systematic review was 
conducted in 2008 showed most consistent associations between obesity and cervical 
cancer screening behavior. According to this review, most studies reported an inverse 
relation between decreased cervical cancer screening and increasing body size, and 
several studies reported that the association was more consistent among white women 
than among black women (Cohen et al., 2008). Participants from the focus groups and 
interviews in Abdullah study 2009 tended to discuss what they thought were other Somali 
women’s reasons for not attending screening rather than the reason for their own non 
attendance. This study highlighted that 38% of participants had never been screened. Of 
these, when probed, four women said that they had never even heard of the screening 
test, eight said that they had never been sexual active and so thought that they did not 
need to attend for screening, and seven cited other reasons, including lack of 
understanding of the need to attend screening, hearing others’ negative stories about the 
test, lack of knowledge and embarrassment. Participants within all focus groups and in 
the interviews identified that many Somali women had poor understanding of the need 
for cervical screening, and that this prevented them from attending screening. There is no 
cervical screening program in Somalia and the concept of preventative health was thought 
to be unfamiliar to many Somalis, especially to those new to the UK (Abdullahi 2009).  
4. Cervical cancer screening behavior intervention based on Health Belief 
Model 
A number of cervical cancer screening behavior promotion interventions have addressed at 
least one Health Belief Model construct – usually perceived barriers – and have had 
significant effects on cervical cancer screening behavior outcomes . This model, which 
emerged in the late 1950s, was used as an exploratory model to assess why people did not 
use preventive health services and eventually to understand why people use or fail to use 
health services. Many researchers now employ this model to guide the development of  
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health interventions with the aim of changing behaviors. Here, the findings from several 
different types of interventions based on Health Belief Model are summarized. Perhaps 
because constructs in the Health Belief Model are fairly intuitive, they have been used in a 
number of community based interventions conducted among underserved groups with 
lower socio economic level. The development of efficacious theory-based, culturally relevant 
interventions to promote cervical cancer prevention among underserved populations is 
crucial to the elimination of cancer disparities. In a study by Scarinci and co-workers a 
theory-based, culturally relevant interventions used to promote cervical cancer prevention 
among underserved populations of Latina immigrants (Scarinci, 2011). The goal was to 
describe the development of a theory-based, culturally relevant intervention focusing on 
primary (sexual risk reduction) and secondary (Pap smear) prevention of cervical cancer 
among Latina immigrants using intervention mapping (IM). Health belief model provided 
theoretical guidance for the intervention development and implementation. IM provides a 
logical five-step framework in intervention development: delineating proximal program 
objectives, selecting theory-based intervention methods and strategies, developing a 
program plan, planning for adoption in implementation, and creating evaluation plans and 
instruments. We first conducted an extensive literature review and qualitatively examined 
the sociocultural factors associated with primary and secondary prevention of cervical 
cancer. We then proceeded to quantitatively validate the qualitative findings, which led to 
development matrices linking the theoretical constructs with intervention objectives and 
strategies as well as evaluation. IM was a helpful tool in the development of a theory-based, 
culturally relevant intervention addressing primary and secondary prevention among 
Latina immigrants (Scarinci,2011). To address the barrier of negative experience, in a 
qualitative study was performed in Somali, it was suggested that providing an explanation 
of the procedure prior to the test and allowing adequate time for questions could help to 
overcome negative past experiences. Some participants in focus group believed that 
attending as part of a group with a Somali-speaking community worker would make the 
experience less daunting, especially for first-time attendees. It was suggested by two 
participants in different groups and one interviewee that the fear of pain and poor hygiene 
could be helped by the provision of disposable plastic speculums, which were considered 
less aggressive and more hygienic (Abdullahi 2009). Beach and others in 2007 revealed in 
their study that the language could be as one potentially key factor in cancer screening 
disparities. They carried out secondary analyses of data from a randomized clinical trial that 
aimed to increase breast, cervical, and colorectal cancer screenings. The randomized clinical 
trial tested whether the intervention by Prevention Care Manager (PCM) which provided 
language-appropriate telephone support to help patients overcome barriers to cancer 
screening, was effective in helping women become up-to-date on these screening tests. Up-
to-date status was based on recommendations of the U.S. Preventive Services Task Force 
.The intervention improved women’s up-to-date status on all three screening tests, as 
reported elsewhere. This study included Spanish-speaking women seemed to benefit more 
than did English-speaking women from a bilingual telephone support intervention aimed at 
increasing cancer screening rates. (Beach et al, 2007). Some studies have compared the 
effectiveness of different media for delivering intervention addressing Health Belief Model 
constructs to women in clinic setting. Just as the Health Belief Model has guided community 
based interventions to deliver information or persuasive message to change perception and 
reduce barriers to cervical cancer screening behavior, it has guided interventions delivered 
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crucial to the elimination of cancer disparities. In a study by Scarinci and co-workers a 
theory-based, culturally relevant interventions used to promote cervical cancer prevention 
among underserved populations of Latina immigrants (Scarinci, 2011). The goal was to 
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through television campaign. To encourage the right women to attend for cervical cancer 
screening, a media complain program was developed and tested. In addition to drawing on 
findings from the published literature to assist campaign development, in-depth telephone 
interviews were conducted with 32 women aged from 30 to 69 who had previously had 
regular Pap tests, but had lapsed in their cervical screening for at least 3 years, to determine 
the barriers to returning for another test. There were three salient reasons for lapsing. A 
major factor was that women expressed a negative emotional disposition to Pap tests, 
indicating dislike, embarrassment, discomfort or anxiety about having the test. Second, for 
some women, Pap tests were not considered a high priority, in that they did not believe they 
were at risk of cervical cancer. Finally, a small group of women believed that they did not 
need a Pap test because they considered they would know if something was wrong with 
their own bodies. It was noted that lack of knowledge of the appropriate time interval 
between tests was not a barrier for these women, since they were aware that they were 
overdue for a Pap test. The findings from the interviews were used to develop a brief for an 
advertising agency to develop concepts for further testing with women. The brief Targeted 
cervical screening media campaign focused particularly on the importance of overcoming 
emotional barriers to having a Pap test. Ultimately, two rounds of focus groups were 
conducted (nine groups of women aged >40, some adequately screened and some lapsed 
screeners) to develop the final advertisement. A 30-s television advertisement was 
produced, with a 15-s cut-down version. A radio advertisement was also developed, but is 
not discussed in this paper, as very few women heard the radio advertisement without also 
being exposed to the television advertisement. The television advertisement aimed to 
acknowledge women’s anxiety and discomfort about having the test, while reminding them 
there was a good reason for having one. However, it was also designed not to arouse 
concern for those women whose tests were up-to-date. The advertisement -Don’t just sit 
there- featured a series of women’s legs in a variety of situations and a voice-over 
acknowledging that although having a Pap test can be uncomfortable, being treated for 
cervical cancer can be far more uncomfortable. The voice-over concluded by saying If you 
haven’t had a Pap test in the last two years, stop putting it off. Make an appointment today 
with your doctor or community health centre. The tag line of the advertisement on the 
screen indicated _Pap tests. Every two years. It could save your life._ The advertisement was 
broadcast for nearly 4 weeks from Sunday 18 July to Thursday 12 August 2004. The media-
buying schedule indicated that during this time, the advertisement had the opportunity to 
be seen two or more times by 86% of women in the target age range and 73% would have 
had an opportunity to see it three or more times. Data were conducted at the last week of 
the media campaign. Numbers were randomly selected from the electronic telephone 
directory and trained female interviewers asked to speak to the woman in the household 
aged between 25 and 65 whose birthday was next. Contact was made with 3510 households 
and in 1600 of these someone was identified as being eligible to complete the survey. 
Overall, an interview was obtained in 63% of homes where someone had been identified as 
eligible. Among them, 1000 women completed the survey and 600 did not (433 refused, 114 
terminated during the interview, 53 agreed to complete it later but did not). Women were 
told that the research was being conducted on behalf of a well known Victorian health 
organization, was for public health research purposes and had been approved by an ethics 
committee. Up to five attempts were made to reach each of the selected numbers. While 
collecting data, the advertisement was then described to the women who either did not 
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recall a Pap screening advertisement at all or were unable to describe it accurately. A further 
393 (51.8% of those asked, 42.0% of the total sample) remembered it when prompted. Thus, 
overall 61% of the women surveyed were aware of the television advertisement (19% 
unprompted recall and 42% prompted recall). Most of the 568 women who had seen the 
advertisement could describe its main message. About half (54.2%) reported a general 
message of everyone needing a Pap test, some saying that it should be regular but without 
specifying what regular meant, and some that it should be two-yearly. Some women (20.5%) 
indicated a more specific response that acknowledged that Pap tests are uncomfortable but 
still important to have and 9.7% reported a general message about prevention being 
important. Only 3.5% reported that the message was that Pap tests are unpleasant without 
adding the key point that they are worth having anyway. When asked what action they 
planned to take in response to seeing the advertising, 51.9% of women indicated that they 
would not do anything. However, women were most likely to respond in this way if their 
last Pap test had been more recent. Women who were overdue or lapsed screeners were less 
likely not to plan to take action. Overall, 15.9% of women indicated that as a result of seeing 
the advertisement, they planned to have a Pap test soon. Women overdue for a Pap test 
were significantly more likely to respond in this way than those who had a Pap test more 
recently. In total, 18.4% of women indicated they planned to have a Pap test when it was 
due, with no differences according to how long it had been since their last Pap test ( Mullins, 
2008). Mass media campaigns have been used with some success to improve participation in 
health screening. A meta-analysis of media health campaigns found that campaigns 
promoting mammography and cervical cancer screening caused 4% of women changed 
their behavior in response to a televised marketing campaign prompting these types of 
screening for women (Snyder, 2004). Several studies have used Health Belief Model 
variables to tailor cervical cancer screening behavior for particular recipients. In general, 
tailoring messages for cervical cancer screening behavior using Health Belief Model 
constructs have been found to increase cervical cancer screening behavior. In this study, 
Forsyth County Cancer Screening (FoCaS) was designed to improve beliefs, attitudes, and 
screening behaviors of women age 40 and older who resided in low-income housing 
communities. To develop effective interventions, results from the baseline women’s survey, 
the health care provider survey, additional focus groups, and input from the Community 
Advisory Board were used. These sources provided information on barriers, attitudes, 
current breast and cervical cancer screening practices, and optimum strategies for delivering 
health education messages. The theoretical framework for the community-based 
interventions included the PRECEDE/PROCEED model for planning, the health belief 
model , for identifying and addressing barriers, social learning theory in terms of using lay 
health educators to deliver education messages and develop a sense of self-efficacy in the 
women, and the PENIII model, which incorporates cultural appropriateness and sensitivity 
in program development. Interventions implemented in the housing communities in 
Winston-Salem during the 2-year intervention period included: (a) “Women’s Fest,” a free 
party held in the community that included food, educational classes, cholesterol, blood 
pressure and diabetes screening, prizes, and information booths; (b) a church program that 
included a ministers’ luncheon and a lay health educator program, “Taking Care of our 
Sisters,” for female church members; (c) educational brochures especially designed to 
address identified barriers such as “Where to Get a Mammogram”; (d) mass media 
techniques (public bus ads, newspaper and radio ads on African-American media); (e) 
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monthly classes in each housing community conducted by a lay health educator; (f) birthday 
cards with the FoCaS logo; (g) targeted mailings and door knob hangers with invitations to 
events; and (h) one-on-one educational sessions in women’s homes. Clinic-focused 
interventions implemented at RHC were designed to address provider, system, and patient 
barriers to conducting breast and cervical cancer screening and included: (a) in-service and 
primary care conference training for providers on issues including clinical breast exam 
proficiency, cultural sensitivity, and techniques to integrate prevention in primary care; (b) 
visual prompts in the exam rooms, e.g., “Have you screened today?”; (c) educational games, 
e.g., “Find the Lump Game” to teach clinical breast exam techniques; (d) an abnormal test 
protocol that included alert stickers, a referral process for managing the care of women with 
abnormal test results, and a tracking system; (e) poster and literature distribution in the 
waiting rooms; and (f) one-on-one counseling sessions and personalized letters for follow-
up testing for women who had abnormal test results. The delivery of the intervention 
components was monitored by the project manager through weekly reports, observations of 
classes, and process evaluation measures such as attendance rolls, number of classes taught, 
brochures distributed, and letters mailed. Results of this study showed the proportion of 
women who received a Pap smear within the last 3 years increased in the intervention city 
from 73 to 87%. The proportion of women reporting a Pap smear in the last 3 years in the 
comparison city decreased over time, from 67 to 60%. Thus, the Pap smear usage rate 
increased by 14 percentage points in the intervention city and decreased by 7 percentage 
points in the comparison city for an overall net change of 21 percentage points in favor of 
the intervention city (P 5 0.004, unadjusted Wald x2 test). Older women (65 and over) were 
less likely than younger women to have had a Pap smear within guidelines (70 versus 78%; P 
5 0.013). Women who received regular examinations were more likely to have had a Pap 
smear within guidelines (79 versus 51%; P , 0.001). The more correct knowledge women had, 
the more likely they were to be within screening guidelines (P 5 0.001), and women who 
reported a higher number of barriers were less likely to be compliant with guidelines (P 5 
0.005) than those reporting the least number of barriers. In the comparison city, married 
women were more likely than non married women (including divorced, separated, 
widowed, and never married) to be within guidelines (79 versus 60%). For Pap smears, 
significantly more women in the intervention city reported no barriers to screening at 
follow-up compared with women in the comparison city (55 versus 29%; P, 0.05). No 
significant differences were noted between the two cities in either time period in the 
proportion of women reporting positive beliefs (two or more) about cervical cancer and 
screening or the proportion of women with good knowledge (five or more correct answers) 
about cervical cancer and screening ( Pasket al., 1999). Building on the tailored print cervical 
cancer screening behavior intervention finding, Dignan and co – workers examined the 
effects of health education on Increasing Screening for Cervical Cancer among Eastern-Band 
Cherokee Indian Women in North Carolina. The North Carolina Native American Cervical 
Cancer Prevention Project was a 5-year, National Cancer Institute-funded trial of health 
education designed to increase screening for cervical cancer among Native- American 
women in North Carolina.. This study was conducted to evaluate the effectiveness of this 
education program in the Eastern-Band Cherokee target population. Cherokee tribal lands 
were mapped and all households (N = 2223) were listed to ensure maximum coverage of the 
eligible population (women, aged 18 years and older, who were enrolled tribal members). 
Eligible women were identified by the use of a brief questionnaire administered to an adult 
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member of the household. Of the 1279 households with eligible women, 1020 (79.8%) agreed 
to participate. The intervention was an individualized health education program delivered 
by female Cherokee lay health educators based on several theories and models including 
Health belief model. The participants were randomly assigned to receive or not to receive 
the intervention (i.e., to program and control groups, respectively) by use of the Solomon 
Four-Group design. Data were collected in face-to-face interviews conducted in the 
participant's home. Of the 996 women who were ultimately enrolled, 540 were randomly 
assigned to receive a pretest (pre intervention) interview that involved administration of a 
96-item questionnaire designed to collect data on knowledge, intentions, and behaviors 
related to cervical cancer; of these 540 women, 263 were randomly assigned to receive the 
education program. The remaining 456 women did not receive the pretest, but 218 were 
randomly assigned to receive the education program. Six months after receiving the 
education program, the women in all four groups were administered a post-test that was 
identical to the pretest Logistic regression was used to assess the effects of the pretest and 
the educational program. All P values resulted from two-sided statistical tests. Results of 
this study showed eight hundred and fifteen (81.8%) of the 996 participants completed the 
post-test interview. The remaining 181 women who were lost to follow-up were evenly 
distributed among the four study groups. At the post-test, 282 (73.2%) of the 385 women 
who received the education program reported having had a Pap smear following the 
intervention, compared with 275 (64%) of the 430 control subjects. Women who received the 
education program were more likely to answer all knowledge items correctly on the post-
test (odds ratio [OR] = 2.18, 95% confidence interval [CI] = 1.08- 439) and to report having 
obtained a Pap smear in the past year (OR = 2.06, 95% CI = 1.14-3.72) than women in the 
control groups. This study concluded women who received the education program 
exhibited a greater knowledge about cervical cancer prevention and were more likely to 
have reported having had a Pap smear within the past year than women who did not 
receive the program (DIgnan, 1996).  
HEALTH BELIEF MODEL variables have also formed the basis for an interventional 
program to improve beliefs and behaviors of screening for cervical cancer among Iranian 
people. A quasi-experimental study was conducted in Hamadan , Iran, in 2010. In this 
study, 70 women - aged 16 to 54 years - who had never done Pap test until the date of the 
study, participated voluntarily. The volunteers were divided into several small groups. For 
each group, 2-hour training session was held. The data collection tool was a self-
administered multi-choice questionnaire that was developed based on HBM constructs. 
Health beliefs and practice of the target group were evaluated pre intervention and four 
months later. The findings indicated that education based on HBM was effective and could 
enhance the participants' knowledge significantly and improve the HBM constructs 
including perceived susceptibility, severity, benefits, and barriers. The training program 
enhanced the practice of screening test significantly. This study concluded that education 
program based on HBM can enhance women's knowledge of cervical cancer, change their 
health beliefs and improve their behaviors regarding screening programs like Pap test 
(Shojaeizadeh, 2011). In study that was conducted in Somali education about the purpose of 
the screening test and the programme was considered as key procedure in encouraging 
Somalis to take up screening. The participants felt that Somali health advocates or 
community workers should provide this information in a community setting. In their 
opinion, this would help women to understand the value of the test, and should aim to 
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health beliefs and improve their behaviors regarding screening programs like Pap test 
(Shojaeizadeh, 2011). In study that was conducted in Somali education about the purpose of 
the screening test and the programme was considered as key procedure in encouraging 
Somalis to take up screening. The participants felt that Somali health advocates or 
community workers should provide this information in a community setting. In their 
opinion, this would help women to understand the value of the test, and should aim to 
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address some women’s misinterpretation of the Islamic perspective regarding disease 
prevention and help to overcome fatalistic barriers to screening . Participants favored 
education from Somali speakers, and no participant suggested the need for increased 
opportunities to learn English. Overall, participants favored verbal modes of 
communication, reflecting Somali people having an oral culture. Participants suggested 
improving awareness of screening via the use of video, DVDs, CDs and audiotapes 
(Abdullahi , 2009) . In previous evidence, possible solutions suggested by the participants 
included the provision of education and information about cervical screening in the Somali 
language by Somali community workers. They also suggested that healthcare staff should 
be trained about Somali culture, particularly regarding female circumcision, and that 
general practitioners should more proactively encourage Somali women to attend screening 
(Abdullahi 2009). 
5. Conclusion 
This chapter highlighted the concepts of Health Belief Model that could be applied for 
cervical cancer screening test. In summary, Health Belief Model constructs generally have 
been found to predict participation in cervical cancer screening. In addition, a large number 
of interventions studied addressing Health Belief Model constructs have resulted in 
increased cervical cancer screening behavior. The interventions tailored to address 
recipient’s specific Health Belief Model beliefs have been found to be particularly effective. 
It is entirely consistent with the Health Belief Model that intervention will be more effective 
if address the persons' specific perception about susceptibility, barrier and self efficacy. 
Women who already believe they are at risk for developing cervical cancer screening 
behavior do not need messages trying to conceive them to their susceptibility, those who 
know where to get a free pap smear but cannot find a way to get there need intervention 
addressing transportation not cost Just as it is important to be able to measure validity of 
Health Belief Model construct, tailoring technology has allowed interventions to address 
Health Belief Model constructs most relevant for particular intervention. Also in this 
chapter, the literature review summarized cervical cancer screening beliefs and attitudes of 
Hispanic women using the Health Belief Model. Perceived barriers (e.g., fear of cancer, 
embarrassment, fatalistic views of cancer, and language), as well as perceived susceptibility 
(e.g., belief that screening tests are not necessary/ needed impede screening. Physician 
recommendations and community outreach programs are effective strategies to increase 
breast and cervical cancer screening uptake among Hispanic women. The specific findings 
of this literature review indicate that cancer-screening programs should use multi sectorial 
approaches to address culture-specific issues and provide culturally sensitive and 
competent services.  
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Community Based Cancer Screening –  
The 12 “ I ”s Strategy for Success 
Rajamanickam Rajkumar 
Meenakshi Medical College Hospital and Research Institute,  
Enathur, Kanchipuram, Tamil Nadu 
India 
1. Introduction 
Background of the study, in which the Editor has served as the Investigator at source 1.  
Cluster Randomized Controlled Trial of Visual Screening for Cervical Cancer in 
Dindigul District, Tamil Nadu, India 
Supported by the Bill & Melinda Gates Foundation through the Alliance for Cervical Cancer 
Prevention (ACCP) 
Collaborators: 
1. Christian Fellowship Community Health Centre (CFCHC), Ambillikai, India 
2. Cancer Institute (WIA), Chennai (Madras), India 
3. PSG Institute of Medical Sciences and Research (PSGIMSR),  Coimbatore, India 
4. World Health Organization-International Agency for Research Cancer  (WHO-IARC), 
Lyon, France  
A communtiy based screening program was planned and the editor used the following 
strategies which ensured success: 
The 12 “ I”s Strategy 
“Our experience in a Community Based Cervical Cancer Screening Programme and the 
strategies which helped us to be successful” 
The 12 “ I ” s 
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Fig. 1. Geographical location of the study area 
 

















Table 1. Cancer Incidence in SE Asia: The need for screening is based on the following 
tables, showing high incidence of cervical cancer 
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Table 1. Cancer Incidence in SE Asia: The need for screening is based on the following 
tables, showing high incidence of cervical cancer 
 













7All sites but non-melanoma skin 
C91-C95 221134683943.13.2973644.14.2129485Leukaemia 
C90 84521279250.91.0298391.21.339192Multiple myeloma 
C81 87449201780.30.383520.80.824111Hodgkin lymphoma 
C82-C85,C96 324184862212.32.4729554.04.1125448Non-Hodgkin lymphoma 
C73 394698893150.80.8240783.33.4103589Thyroid 
C70-C72 118861377212.02.0616162.62.681264Brain, nervous system 
C67 249966646731.11.2366992.52.782699Bladder 
C64-C66,C68 223235572341.21.3391992.52.679257Kidney etc. 
C56,C57.0-4 5384991537614.04.11248606.66.6204499Ovary etc. 
C54 7755421835281.61.6503276.56.5198783Corpus uteri 









C18-C21 13151953629117.68.125053214.615.4472687Colon and rectum 
C16 5221561664367.98.325429710.410.7330518Stomach 
C15 129394541593.94.11247304.74.8146723Oesophagus 
C09-C10,C12-C14 52905166300.50.5160290.80.824077Other pharynx 
C11 63235177860.50.5154190.80.824247Nasopharynx 












Table 2. Cancer Incidence Rates- World – Females 
 




Incidence: Local (regional) data 
Mortality: Incidence and survival 
Prevalence: Incidence and survival
India - Females
Crude and Age-Standardised (World) rates, per 100,000
GLOBOCAN 2002, IARC
C00-C96/C44 108912530653267.656.5284636104.488.8447592All sites but non-melanoma skin 
C91-C95 1063041641.71.679772.11.99778Leukaemia 
C90 424915490.50.420440.60.52525Multiple myeloma 
C81 652316740.20.210470.50.42155Hodgkin lymphoma 
C82-C85,C96 1471841901.21.052271.71.57389Non-Hodgkin lymphoma 
C73 3191871871.00.945381.91.78686Thyroid 
C70-C72 1052535701.41.261491.61.57530Brain, nervous system 
C67 845223190.50.419070.70.63031Bladder 
C64-C66,C68 468512470.30.314590.50.42129Kidney etc. 
C56,C57.0-4 53627153393.83.2163194.94.221146Ovary etc. 
C54 2358460460.70.527071.71.46937Corpus uteri 
C53 37024310158317.814.77411830.726.2132082Cervix uteri 
C50 2694707149310.48.94479519.116.582951Breast 





C18-C21 3301595342.21.993513.22.713555Colon and rectum 
C16 1599656362.42.099622.82.311743Stomach 
C15 1744274184.43.6179385.14.120805Oesophagus 
C09-C10,C12-C14 1455849791.41.258581.81.67793Other pharynx 
C11 29128540.20.28410.30.21150Nasopharynx 
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2. INITIATION – of cancer registry 
 POPULATION BASED CANCER REGISTRY IS A MUST FOR THE SUCCESSFUL 
IMPLEMENTAION OF A SCREENING PROGRAM 
 There are Urban and Rural Population based Cancer registries 
 Cancer registry is important to know the cancer pattern 
 Priority for preventable cancers by screening, is an important use 
 Our Ambillikai Cancer Registry, was population based rural cancer registry in India 
started in 1995, and its an Associate Member of the International Association of Cancer 
Registries  
3. INFERENCE – of the cancer pattern 
 Leads for the planning of control strategies 
 Ambillikai cancer registry recorded one of the highest ASR for cancer cervix (65.4/ 100 000) 
 This gave the lead for a community based cervical cancer screening programme 
Supported by our publication: 
“Leads to cancer control based on cancer patterns in a rural population in  South India” 
R.Rajkumar, R.Sankaranarayanan, A.Esmi, R.Jeyaraman, J.Cherian & D.M.Parkin,  
Cancer Causes and Control 2000; 11:433-39 
4. IMBIBE – the appropriate technology 
 Developing countries can seek technical support from developed nations 
 Low resource settings need appropriate, affordable and accessible technologies 
 Technical & Financial constraints to be overcome by resource development 
 In rural India – Cervical Cancer Screening was not a health care priority 
 Hence we offered once a life time – VIA, Colposcopy 
 High risk approach is needed for selected population 
 80% PARTICIPATION was targeted, and achieved 
Supported by our publication: 
“Effective screening programmes for cervical cancer in low-and middle - income developing 
countries” 
Rengasamy Sankaranarayanan, Atul Madhukar Budukh, Rajamanickam Rajkumar, 
Bulletein World Health Organisation, 2001, 79(10) 954-962 
5. INSTALL – resources 
 Political Will & Commitment 
 Manpower – train local health staff 
 Materials – locally available equipments and local maintenance expertise 
 Money – internal and/or external funds 
Supported by our publication: 
“Early detection of cervical cancer with visual inspection methods, A summary of 
completed and on – going studies in India”.  
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R.Sankaranarayanan , IARC/WHO, B.M. Nene , K.Dinshaw , R.Rajkumar , S.Shastri , 
R.Wesley ,P.Basu , R.Sharma , S.Thara , A.Budukh , D.M. Parkin , IARC/WHO 
Public Health Journal of Mexico (Revista de Salud Publica de Mexico) 
In commemoration with 80th Anniversary School of Public Health & 15th Anniversary 
National 








Fig. 3. Use local manpower 
6. INSPIRE – personnel 
 Lighted to lighten, the health care providers play key role 
 Financial incentives, motivates them 
 Social recognition is very important in team work 
 Appreciation means a lot for the workers 
 Awards, titles, honours, cost little but the gain is big 
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 Our Ambillikai Cancer Registry, was population based rural cancer registry in India 
started in 1995, and its an Associate Member of the International Association of Cancer 
Registries  
3. INFERENCE – of the cancer pattern 
 Leads for the planning of control strategies 
 Ambillikai cancer registry recorded one of the highest ASR for cancer cervix (65.4/ 100 000) 
 This gave the lead for a community based cervical cancer screening programme 
Supported by our publication: 
“Leads to cancer control based on cancer patterns in a rural population in  South India” 
R.Rajkumar, R.Sankaranarayanan, A.Esmi, R.Jeyaraman, J.Cherian & D.M.Parkin,  
Cancer Causes and Control 2000; 11:433-39 
4. IMBIBE – the appropriate technology 
 Developing countries can seek technical support from developed nations 
 Low resource settings need appropriate, affordable and accessible technologies 
 Technical & Financial constraints to be overcome by resource development 
 In rural India – Cervical Cancer Screening was not a health care priority 
 Hence we offered once a life time – VIA, Colposcopy 
 High risk approach is needed for selected population 
 80% PARTICIPATION was targeted, and achieved 
Supported by our publication: 
“Effective screening programmes for cervical cancer in low-and middle - income developing 
countries” 
Rengasamy Sankaranarayanan, Atul Madhukar Budukh, Rajamanickam Rajkumar, 
Bulletein World Health Organisation, 2001, 79(10) 954-962 
5. INSTALL – resources 
 Political Will & Commitment 
 Manpower – train local health staff 
 Materials – locally available equipments and local maintenance expertise 
 Money – internal and/or external funds 
Supported by our publication: 
“Early detection of cervical cancer with visual inspection methods, A summary of 
completed and on – going studies in India”.  
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R.Sankaranarayanan , IARC/WHO, B.M. Nene , K.Dinshaw , R.Rajkumar , S.Shastri , 
R.Wesley ,P.Basu , R.Sharma , S.Thara , A.Budukh , D.M. Parkin , IARC/WHO 
Public Health Journal of Mexico (Revista de Salud Publica de Mexico) 
In commemoration with 80th Anniversary School of Public Health & 15th Anniversary 
National 
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6. INSPIRE – personnel 
 Lighted to lighten, the health care providers play key role 
 Financial incentives, motivates them 
 Social recognition is very important in team work 
 Appreciation means a lot for the workers 
 Awards, titles, honours, cost little but the gain is big 
 




Fig. 4. Inspiration and motivation of the Health care providers ensure success 
 Even in the Olympics it is a small “MEDAL” which matters  
7. INVOLVEMENT 
 Involve both “ providers” & “recipients” 
 All levels of micro & macro planning 
 All levels of implementation 
 When we hear we forget 
 When we see we remember 
 When we do we know 
8. INVITE 
 It is humans’ innate desire to be invited for participation 
 Advertisements, Propaganda, Bombardment with information – may not work 
 Invitation with genuine Interest by Influencers works well  
Methods of Invitation 
 Mass – Appeal to “Emotions” – Use the words “Mothers”, “ Wives”, “Sisters” instead of 
Women 
 Families – Appeal to “Responsibilities” of the family towards the motherhood and their 
duty for “ mother’s” health 
 Individuals – Appeal to their “self care and self esteem”  
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Who would invite ? 
 The “Influencers” 
 Medical personnel, village leaders, religious leaders, local healers, teachers 
 Satisfied Customers 
 Peer groups 
 Family members 
 Educating the school children have resulted in them bringing their mothers for 
screening – “tender roots split hard rock” 
9. INSURE – holistic health 
 Rural community does not appreciate “organ specific approach” 
 Wholesome approach for holistic health is the demand 
 Do whatever possible for total care – even counseling and advice are well received  
 Health is a state of complete physical, mental and social well being and not merely an 
absence of disease or infirmity – Health for All  
 
Fig. 5. A woman expects holistic health care from the provider 
10. INDIGENOUS 
 In thoughts, words and deeds 
 “Cancer” is scaring, terrifying and people are afraid to get diagnosed as to have cancer 
 Start from what they know and build from what they have 
 Address their common complaints like “wdpv”, “abnormal bleeding pv” and then 
explain about precancer and cancer. 
 Perform VIA, colposcopy and cryotherapy/LEEP and the “women get rid of their 
complaints” and we have done our “screening for cervical cancer” . Thus we have made 
the very “problem” as “indigenous” 
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Indigenous - Screening Environment 
 People in villages are reluctant to get in to the huge vans or buses for screening as these 
are unusual environments to them 
 Hence, screening clinics could be arranged in places which are frequently visited by the 
people, like health centre buildings, schools, ration shops, public utility buildings  
Indigenous – Health personnel 
 Like begets like 
 Birds of the same feather flock together 
 Screening could be done by trained local nurses and health workers 
 Examination – Female to female and male to male 
 Identification with the people in all possible ways ensures good compliance 
Indigenous in attitude 
 Never say that the other is wrong, only that they may not be right 
 Never call the local customs, beliefs, hopes, attitudes and practices as superstitions. It 
will hurt the feelings. Just guide them rightly. 
 Screening clinics should ensure privacy, confidentiality in a pleasant atmosphere. 
 All services under one roof and cordial relationship to be maintained 
 No outside prescriptions, referrals  
 Counsel the family as a whole, whenever possible  
11. INSTITUTE – follow up 
 In rural India, people greet each other by asking “ How are you ? ”  
 People appreciate this gesture very much as it coveys one’s concern and regard 
 If this is done in a scientific way it is called the “ follow up ”, and it should be done 
meticulously and frequently. The possible outcomes of the screening should be well 
explained before hand and the need for passive follow up should be well understood by 
the beneficiaries and their families. 
How we tackled some of the problems! 
Post cryotherapy period 
↓ 
Long term serous discharge 
↓ 
Very distressing for women 
↓ 
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Post Cryo - LEEP period 
↓ 









 Dialogues, Discussions would definitely Dissolve many of the Deterrent factors  
 Communication gap closes the doors 
 Careful and considerate listening are very important for community based programmes 
 Counseling increases the community’s compliance for the programme  
Determinants of Participation 
 Educational level 
 Social status 
 Economic status 
 Type of family 
 Severity of the disease 
 Satisfactory services 
Supported by our publication: 
“Determinants of participation of women in a cervical cancer visual screening trial in rural 
south India” 
Rengaswamy Sankaranarayanan, Rajamanickam Rajkumar, Silvina Arrossi, Rajapandian 
Theresa, Pulikattil Okkaru Esmy, Cerdric Mahe, Richard Muwonge, Donald Maxwell 
Parkin, Jacob Cherian 
Cancer Detection and Prevention 27 (2003) 457 – 465 
12. ILLUSTRATE – study findings 
 The above strategies helped us to successfully complete one of the largest cervical 
cancer screening programmes done in rural areas. 
Supported by our publication:  
“Initial results from a randomized trial of Cervical Visual Screening in rural South India”. 
R. Sankaranarayanan. R. Rajkumar, et al. 
International Journal of Cancer 2004; 109, 461 – 467 
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Allocated to VIA screening 57 
clusters (n= 48,225)
124,144 PYO
Allocated to control group 




Did not receive VIA 
screening (n= 17,648)
34 invasive cancers diagnosed
CR: 37.7/100,000 PYO
ASR: 43.1/100,000 PYO
 i asi e c cers i se
: . / ,  















Clinically detected invasive cancer 
n=28 
97 invasive cancers diagnosed
CR: 78.1/100,000 PYO
ASR: 92.4/100,000 PYO
 i asi e c cers ia se
: . / , 0 
: 2. / ,  
PYO: person years of observation; CR: crude incidence rate; ASR: age-
standardized incidence rate; CIN: cervical intraepithelial neoplasia; Percentages 
refer to proportion of screened women (N=30,577) except for treatment where they 
refer to lesion detected
Flow chart of the design and preliminary results of the study
DINDIGUL RCT OF CERVICAL SCREENING, INDIA
Sankaranarayanan et al.,





Successful completion of a program improves capabilities of the health care providers and it 
leads to further research, like our other studies:  
HPV Studies: 
Study 1 
Papillomavirus infection in rural women in southern India 
Franceschi, R Rajkumar, PJF Snijders, A Arslan1, C Mahe, M Plummer, R Sankaranarayanan, J 
Cherian, CJLM Meijer and E Weiderpass, British Journal of Cancer (2005) 92, 601 – 606  
Study 2 
Worldwide distribution of HPV Types in Cytologically Normal Women: Pooled Analysis of 
the IARC HPV Prevalence Surveys 
G. Clifford (PhD), S. Gallus (ScD), R. Herrero (MD), N. Muñoz (MD), P.J.F. Snijders (PhD), S. 
Vaccarella (ScD), P.T.H Anh (MD), C. Ferreccio (MD), N.T Hieu (MD), E. Matos (MD), M. 
Molano (PhD), R. Rajkumar (MD), G. Ronco (MD), S. de Sanjosé (MD), H.R. Shin (MD), S. 
Sukvirach (MD), J.O. Thomas (MD), S. Tunsakul (MS), C.J.L.M. Meijer (MD), S. Franceschi (MD) 
and the IARC HPV Prevalence Surveys (IHPS) Study Group, Lancet 2005;366(9490):991-8. 
 




HPV vaccine trial 
“Preparation of a large, simple “phase IV” study of anti- HPV Vaccination in Asia” 
Silvia Franceschi IARC/WHO, Richard Peto, T.Rajkumar, R.Rajkumar, Rengaswamy 
Sankaranarayanan, Soina Pagliusi, Teresa Aguado & Thomas Cherian, Scientific Paper 
Submitted to the HPV International Conference – Floriano polis – June 2001. 
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Challenges to Cervical Cancer in the  
Developing Countries: South African Context 
Nokuthula Sibiya 
Durban University of Technology,  
Head of Nursing Department, Durban 
South Africa 
1. Introduction 
Despite the fact that cancer of the cervix is preventable, it is the commonest cancer cause of 
death in women in sub-Saharan Africa, Melanesia, South Central and South East Asia, the 
Caribbean and Latin America (Parkin et al., 2005). Southern Africa has one of the highest 
incident rates in the world, and in South Africa alone it caused the deaths of 3 700 women in 
2002 (Denny, 2006). According to the International Agency for Research on Cancer (IARC), 
cervical cancer accounts for 23% of all cancers diagnosed in South Africa (International 
Agency for Research on Cancer, 2006 as cited in le Riche, 2006). Cervical cancer is the second 
most common cancer among South African women, with 1 in 41 women developing the 
disease in her lifetime (Sitas et al., 1998). Adar & Stevens (2000) noted that it was responsible 
for nearly 2% of deaths of women aged 15-44 years and 4% of women aged 45-59 years. In 
South Africa, the total age-adjusted incidence rate (ASIR) of cancer in Africans is far lower 
than that in the corresponding white population. According to the KwaZulu-Natal 
Department of Health (2004) in South Africa, cervical cancer accounts for 18.5% of female 
cancers, with approximately 5 000 new cases reported annually and black women being 
most at risk of getting cervical cancer compared to white and coloured women. African 
women seek help only when their particular disorder/disease is far advanced, thereby, as in 
the case of cervical cancer, rendering cure or control nearly impossible (Walker et al., 2002). 
A study done by De Jonge et al. (1999) found more aggressive tumours in black women 
compared to white women with cervical cancer in South Africa. In women of all race 
groups, the age specific cervical cancer rates for 1992 remained low up to 30 years of age, 
but thereafter increased rapidly until they peaked at 50 to 59 years (Denny, 2006). Similarly, 
Sitas et al. (1998) reported that the incidence of invasive cancer rises in the age group 35-39, 
with 87% of cases occurring in women over 35 years of age. It is a common cancer in poor 
women due to inadequate mass cervical cancer screening, and their cure rates are low as 
they present late (Denny, 2006). 
The South African National Department of Health identified cervical cancer as a health 
priority and in 2000 introduced a national screening programme, based on models of the 
natural history of the disease (Department of Health, 2000). The cervical screening policy 
states that every woman attending public sector health services is entitled to three free 
smears from the age of 30 years at intervals of ten years provided no smears have been 
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disease in her lifetime (Sitas et al., 1998). Adar & Stevens (2000) noted that it was responsible 
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than that in the corresponding white population. According to the KwaZulu-Natal 
Department of Health (2004) in South Africa, cervical cancer accounts for 18.5% of female 
cancers, with approximately 5 000 new cases reported annually and black women being 
most at risk of getting cervical cancer compared to white and coloured women. African 
women seek help only when their particular disorder/disease is far advanced, thereby, as in 
the case of cervical cancer, rendering cure or control nearly impossible (Walker et al., 2002). 
A study done by De Jonge et al. (1999) found more aggressive tumours in black women 
compared to white women with cervical cancer in South Africa. In women of all race 
groups, the age specific cervical cancer rates for 1992 remained low up to 30 years of age, 
but thereafter increased rapidly until they peaked at 50 to 59 years (Denny, 2006). Similarly, 
Sitas et al. (1998) reported that the incidence of invasive cancer rises in the age group 35-39, 
with 87% of cases occurring in women over 35 years of age. It is a common cancer in poor 
women due to inadequate mass cervical cancer screening, and their cure rates are low as 
they present late (Denny, 2006). 
The South African National Department of Health identified cervical cancer as a health 
priority and in 2000 introduced a national screening programme, based on models of the 
natural history of the disease (Department of Health, 2000). The cervical screening policy 
states that every woman attending public sector health services is entitled to three free 
smears from the age of 30 years at intervals of ten years provided no smears have been 
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taken within the previous five years and a total of three smears will be taken in a woman’s 
lifetime. The starting age was based on the fact that the disease affects women in early to 
late middle age. The goal is to screen 70% of women in the target age group within 10 years 
of initiating the programme. This model aims to decrease cancer incidence by 64% (Miller, 
1992 as cited in Smith et al., 2003). According to Walraven (2003), cervical cancer develops 
slowly. Invasive cancer is usually preceded by long phases of pre-invasive disease 
(Sankaranarayanan & Wesley, 2003) and high-grade dysplasia can generally be detected 10 
years before cancer develops (Population Reference Bureau & Alliance for Cervical Cancer 
Screening, 2004). It is widely believed that that invasive cervical cancer develops from 
dysplastic precursor lesions, progressing steadily from mild to moderate to severe 
dysplasia, then to carcinoma in situ, and finally to cancer. Based on resource considerations 
and best available evidence, the policy adopted a public health approach by targeting the 
age group most at risk of developing high-grade, precursor lesions of the cervix. The policy 
conformed to the recommendations of the World Health Organization [WHO] (1999 as cited 
in Smith et al., 2003) for the screening protocol for regions with limited resource. 
There has been much debate as to the most suitable screening policy, particularly with age 
commencement and appropriate time intervals between smears. A number of studies 
revealed that nurses were opposed to and misunderstood the screening policy, probably 
limiting the performance of screening (Smith & Hoffman, 2000; Smith et al., 2003; Sibiya & 
Grainger, 2010). They were of the opinion that women should have their first smears at the 
age of 20 and thereafter at intervals of five years because women become sexually active at 
an early age. Screening programmes are effective provided that they are well organized (le 
Riche et al., 2006; Gaym et al., 2007). The aim of cervical cytology screening programme is to 
detect pre-malignant lesions on the transformation zone of the cervix. Those patients with 
abnormal cytologic results are then referred for further management, usually at dedicated 
colposcopy clinics. The current referral criteria are a single smear with a high-grade 
squamous intra-epithelial lesion (HSIL) or two low-grade squamous intra-epithelial lesion 
(LSIL) smears. The aim of colposcopy is to detect the most abnormal area on the cervix and 
to direct the clinician to the area of biopsy. 
2. Cervical cytology screening programmes in developing countries 
Cervical cytology screening programmes have been introduced in low- and middle-income 
developing countries, but generally have achieved very limited success (WHO, 2001). 
Although cytological screening is being carried out in some developing countries, there are 
no organized programmes. As a result, there has been a very limited impact on the 
incidence of cervical cancer, despite the large numbers of cytological smears taken in some 
countries such as Cuba and Mexico (Sankaranarayanan et al., 2001). Only 5% of women in 
developing countries undergo cervical screening compared with 40-50% in the developed 
world. Substantial costs are involved in providing the infrastructure, manpower, follow up 
and surveillance for cervical screening programmes. Owing to their limited health care 
resources, developing countries cannot afford the models of frequently repeated screening 
of women over a wide age range that is used in developed countries (Sankaranarayanan et 
al., 2001). Cervical cancer has been described as “a disease of the economically 
disadvantaged” because even in developed countries such as the United States, cervical 
cancer mostly affects women of low socio-economic status, rural and poor women (Dickson-
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Tetteh, 1998). Lower socio-economic status has been associated with higher risk of 
developing cancer probably due to lack of access to good health care and screening 
programmes (Mqoqi, 2003). Barriers to screening uptake include a lack of knowledge about 
the disease, the geographical and economic inaccessibility of care, the poor quality of 
services and lack of support from families. Abrahams et al. (1996) state that in order for the 
cervical screening programme to be successful, among other things, strategies in low-
resource settings should be socially and culturally appropriate. 
3. Cervical screening in South Africa 
South Africa, one of the better-resourced countries in sub-Saharan Africa provides 
opportunistic screening. Despite the existence of the guidelines, difficulties have occurred 
with the implementation of the South African cervical screening programme. A number of 
attempts were made in the past to introduce cervical screening programmes at national, 
provincial and local levels in South Africa. In the 1970s the Department of Health suggested 
that a Pap smear should be taken only if the cervix appears abnormal (Performance of the 
National Health System [NHS] Cervical Screening Programme in England, 1998 as cited by 
Hoffman et al., 2003). A number of cervical screening programmes that were introduced in 
the 1980s failed due to poor attendance of women at the health services. The findings of the 
study that was conducted by Abrahams et al. (1996) revealed that the poor attendance of 
women was due to lack of knowledge about cervical cancer and the significance of cancer 
screening. Fonn (2003) reported that implementation was slow, whilst Moodley et al., (2006) 
found that cervical screening in the public health service was conducted in an ad hoc 
manner and focused on younger women attending family planning and ante natal services. 
In South Africa, women have access to cervical screening at primary health care (PHC) 
clinics. The clinics serve a demarcated area and offer a variety of services. Due to the 
demand of services, it is not possible to concentrate on the prevention of cervical cancer, as 
cervical screening is one aspect of the total services rendered. This is a great concern given 
that the likelihood of reducing the incidence of cervical cancer is dependent upon a well-
organized programme. A study was conducted in the eThekwini Region, previously named 
Ilembe in the province of KwaZulu-Natal on the evaluation of the implementation of the 
cervical screening programme in PHC clinics (Sibiya & Grainger, 2007). This study consisted 
of a record review, a clinic audit and focus group discussions with the nurses. The findings 
confirmed that follow-up of clients was problematic, referral hospital feedback was poor, 
record keeping was inadequate, and rural clinics lacked resources. Despite the positive 
aspects, such as the good quality of smears and adequate drugs, the problems overall would 
have resulted in an ineffective programme. The following factors have been identified as the 
contributory factors to ineffective screening in South Africa: 
3.1 Shortage of health care workers 
According to the South African cervical screening policy, all service providers are expected 
to participate in the screening programme (Department of Health, 2000). The South African 
screening policy states that women should have Pap smears at least once every 10 years as 
from the age of 30 years. Therefore, the annual number of women requiring a Pap smear is 
the total number in the province divided by 10. It is worth noting that the finding of the 
study that was conducted by Fonn (2003) revealed that in order to achieve 100% coverage of 
 
Topics on Cervical Cancer with an Advocacy for Prevention 
 
40
taken within the previous five years and a total of three smears will be taken in a woman’s 
lifetime. The starting age was based on the fact that the disease affects women in early to 
late middle age. The goal is to screen 70% of women in the target age group within 10 years 
of initiating the programme. This model aims to decrease cancer incidence by 64% (Miller, 
1992 as cited in Smith et al., 2003). According to Walraven (2003), cervical cancer develops 
slowly. Invasive cancer is usually preceded by long phases of pre-invasive disease 
(Sankaranarayanan & Wesley, 2003) and high-grade dysplasia can generally be detected 10 
years before cancer develops (Population Reference Bureau & Alliance for Cervical Cancer 
Screening, 2004). It is widely believed that that invasive cervical cancer develops from 
dysplastic precursor lesions, progressing steadily from mild to moderate to severe 
dysplasia, then to carcinoma in situ, and finally to cancer. Based on resource considerations 
and best available evidence, the policy adopted a public health approach by targeting the 
age group most at risk of developing high-grade, precursor lesions of the cervix. The policy 
conformed to the recommendations of the World Health Organization [WHO] (1999 as cited 
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There has been much debate as to the most suitable screening policy, particularly with age 
commencement and appropriate time intervals between smears. A number of studies 
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incidence of cervical cancer, despite the large numbers of cytological smears taken in some 
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al., 2001). Cervical cancer has been described as “a disease of the economically 
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Tetteh, 1998). Lower socio-economic status has been associated with higher risk of 
developing cancer probably due to lack of access to good health care and screening 
programmes (Mqoqi, 2003). Barriers to screening uptake include a lack of knowledge about 
the disease, the geographical and economic inaccessibility of care, the poor quality of 
services and lack of support from families. Abrahams et al. (1996) state that in order for the 
cervical screening programme to be successful, among other things, strategies in low-
resource settings should be socially and culturally appropriate. 
3. Cervical screening in South Africa 
South Africa, one of the better-resourced countries in sub-Saharan Africa provides 
opportunistic screening. Despite the existence of the guidelines, difficulties have occurred 
with the implementation of the South African cervical screening programme. A number of 
attempts were made in the past to introduce cervical screening programmes at national, 
provincial and local levels in South Africa. In the 1970s the Department of Health suggested 
that a Pap smear should be taken only if the cervix appears abnormal (Performance of the 
National Health System [NHS] Cervical Screening Programme in England, 1998 as cited by 
Hoffman et al., 2003). A number of cervical screening programmes that were introduced in 
the 1980s failed due to poor attendance of women at the health services. The findings of the 
study that was conducted by Abrahams et al. (1996) revealed that the poor attendance of 
women was due to lack of knowledge about cervical cancer and the significance of cancer 
screening. Fonn (2003) reported that implementation was slow, whilst Moodley et al., (2006) 
found that cervical screening in the public health service was conducted in an ad hoc 
manner and focused on younger women attending family planning and ante natal services. 
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demand of services, it is not possible to concentrate on the prevention of cervical cancer, as 
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that the likelihood of reducing the incidence of cervical cancer is dependent upon a well-
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record keeping was inadequate, and rural clinics lacked resources. Despite the positive 
aspects, such as the good quality of smears and adequate drugs, the problems overall would 
have resulted in an ineffective programme. The following factors have been identified as the 
contributory factors to ineffective screening in South Africa: 
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According to the South African cervical screening policy, all service providers are expected 
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women eligible for screening over a 10-year period, each nurse would have to perform on 
average less than one Pap smear per day. This author further argues that there is spare 
capacity and that any potential underestimate in the number of Pap smears required per 
year could be relatively easily accommodated. According to the Department of Health 
(2006) nurses constitute the largest professional group in South Africa’s health care services 
and form the backbone of PHC in South Africa. Nurses provide the bulk of service provision 
in the public health sector. This emphasis is most striking at the primary care level. Given 
the emphasis the need for well-trained primary level staff is imperative. The South African 
yearbook (2004/05) states that patients visiting PHC clinics are treated mainly by PHC-
trained nurses, or at some clinics, by doctors yet according to the Department of Health 
(2004) only about 40% of facilities have PHC qualified nurses. This means that the pace of 
training has been slower than planned. However, migration of nurses has also impacted on 
these figures. The gross shortage of health workers in developing countries may be a further 
limitation to effective screening. 
A number of research studies have attempted to explore the ‘push and pull’ factors that lead 
to South African nurses working in other countries. Emigration is a commonly cited cause of 
PHC attrition rate in South Africa. Migration of health personnel, also dubbed the brain 
drain, partly from rural to urban areas, but more particularly out of the country, has become 
a debated issue in human resource circles not only in South Africa, but also on the continent 
of Africa itself. According to the Department of Health (2006) for many years before 1994 
South Africa constituted a preferred destination for many health professionals, the majority 
being doctors from the African continent. This situation has however changed since the late 
1990’s when a policy of not recruiting from fellow developing African countries was 
adopted at the Southern African Development Community (SADC) Health Minister’s level. 
The findings of the study that was done by Oosthuizen & Ehlers (2007) indicated that 
nurses’ inadequate remuneration, poor working conditions, excessive workloads, lack of 
personal growth and career advancement possibilities were major factors that influenced 
nurses’ decision to emigrate. Lucas (2005) argues that although African countries have a 
shortage of health workers, they continue to migrate from Africa to more developed 
countries. Tarimo (1991) argues that it is unrealistic to expect good performances under the 
difficult conditions from workers who are poorly rewarded. However, financial incentives 
alone are insufficient to improve health worker motivation. Investing in a functional health 
care system in which nurses feel motivated to work is an important part of human resource 
planning. 
The capacity to read cervical smears at public sector laboratory level is limited in South 
Africa. The South African guidelines indicate that cyto-technologists reading population-
based smears are expected to screen six smears per hour and to work for no longer than 8 
hours per day, i.e. total of 48 smears per day. Thus if all technologists employed by the state 
only read cervical smears we would have just enough technologists employed in the public 
sector. However, they also have other smears to read (Fonn, 2003). It is important to note 
that if the first smear is done at the age of 20 years, it would mean that the annual number of 
smears would increase from 85 0740 to 127 5016. This would mean that cyto-technicians 
would have to read 69 smears per day. The capacity to read the cervical smears at public 
sector laboratory is limited (Fonn, 2003). In developing countries, because of lack of the 
trained cyto-technicians, there is often a long interval of 1-3 months between the Pap 
screening and when the test result is available (Jeronimo et al., 2005). This is further 
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supported by the findings of the study that was conducted by Moodley et al. (2006) which 
revealed that long cytology turnaround time is attributed to poorly functioning 
administrative and transportation systems. The study that was conducted by Denny et al, 
(2006) revealed that a large number of women did not return for the cervical screening 
results. Cytology-based screening programmes can only be successful if infrastructure is in 
place and laboratory quality assurance is consistent (Alliance for Cervical Cancer 
Prevention, 2004). 
3.2 Poor system of follow up and referral process 
The South African policy on cervical screening maintains that a working follow-up system 
needs to be in place for effective implementation of the cervical screening programme 
(Department of Health, 2000). The policy further states that the time lapse between 
screening and follow-up should be 1–4 weeks depending on the circumstances and every 
attempt possible should be made to find those patients who do not return voluntarily. The 
results of the study that was done in the KwaZulu-Natal province of South Africa revealed 
that there was poor follow up of patients with abnormal smears and that if patients were 
referred to the hospital from the PHC settings there was no feedback that was provided to 
the clinic (Sibiya & Grainger, 2007). Lack of capacity in terms of infrastructure and human 
resources were cited as factors for poor follow up and referral process. However, the 
findings of the study that was conducted by Nene et al., (2007) showed that the lowest 
compliance rate with follow-up care was found among unmarried women, those with low 
level of education and those with a high number of pregnancies. Some studies have 
reported that women with abnormal screening results were confused and did not 
understand the information provided by the nurse (Kavanagh et al., 1997; Yabroff et al., 
2000 as cited in by Nene et al., 2007). 
There are also challenges regarding the referral process of women with abnormal smears for 
further investigation and management.When the protocol for cervical screening was 
evaluated in the province of KwaZulu-Natal, the results reveled that none of the 88 
reviewed documents showed evidence of feedback from the referral hospital (Sibiya & 
Grainger, 2007). Interview data with nurses revealed that none of the referral hospital 
provided feedback to the referral hospital. This means that there was lack of effective liaison 
with referral centres for diagnosis and treatment to ensure follow-up and monitoring. 
According to Smith and Hoffman (2000) nurses work diligently to achieve good rates of 
follow-up but there is one group of women that they cannot monitor, namely those with 
high-grade lesions. Once a woman is referred for colposcopy, the nurses do not receive 
feedback regarding whether she kept her appointment, or what the outcome was. This is 
further supported by the findings of a study that was done by Abraham et al. (1996) where 
the health workers expressed disappointment that they continued to not receive feedback 
from hospital specialists to whom they referred women found to have abnormal smears, 
which merited further clinical investigations. The only way that feedback of a referral to a 
hospital was gained was that all patients were encouraged to report back to the clinic to give 
information as to the outcome of their hospital visit. Improving communication would 
allow the nurses to remain involved with their clients, and help to ensure that follow-up 
takes place. The referring doctor has a responsibility to the woman to ensure that she has 
fully understood the significance of her abnormal smear, the options for evaluation and 
management of that smear, and has been involved in the decision-making. 
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supported by the findings of the study that was conducted by Moodley et al. (2006) which 
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3.3 The impact of HIV and AIDS 
The growing number of women in resource-poor areas, such as sub-Saharan Africa, who 
have immunodeficiency virus (HIV), appears to compound the problem because they have 
an increased risk of human papillomavirus (HPV) infection, the causal agent of cervical 
cancer (Goldie et al., 2001). South Africa remains one of the countries with a high HIV and 
AIDS prevalence rate - there are currently about 5.27 million people who are infected with 
HIV and AIDS in South Africa (UNAIDS, 2008). About 70% of the HIV positive pregnant 
women attending antenatal clinics are below the age of 30 years (Department of Health, 
2007). The prevalence rate among young people aged 20-24 years was estimated to be 30%, 
with the highest prevalence rate of about 40% being among women aged 25-29 years. 
Cervical cancer is regarded as an important AIDS-related disease and since 1993 has been 
considered as an AIDS-defining illness in women with HIV virus (KwaZulu-Natal 
Department of Health, 2004). HIV positive women have a high rate of persistent HPV 
infections, and a higher rate than HIV negative women with the types of HPV that are 
associated with the development of high grade dysplasia and cervical cancer (Hoytt, 1998). 
HIV-positive women are almost five times more likely to present with dysplasia than HIV-
negative women (KwaZulu-Natal Department of Health, 2004). One case-controlled case 
study reported that 60% of HPV positive women had initiated sex prior to reaching 16 years 
old. The report further stated that this may expose women to STIs, which may lower a 
woman’s immune response and contribute to malignant transformation of HPV infections 
(Kenney, 1994).  
Of particular concern was the lack of acceptance of the age at first screening criterion. 
According to the findings of the study that was conducted by Smith et al (2003), of the 
interviewed nurses, 90% were that some screening policy exists, and 57% could correctly 
state the policy. However, all the participants were of the opinion that women should have 
their first smear at the start of the sexual activity, which is at the age of 20 years, and the 
interval period should be five years due to high rate of HIV/AIDS in this province. They 
argued that there was an association between cervical cancer and HIV/AIDS and STIs hence 
younger women were at risk. This is in contrast with what the policy states as discussed 
above (Sibiya & Grainger, 2010). Many health professionals feel that as a result of the 
increased incidence of HIV/AIDS and sexually transmitted infections (STIs), younger 
women are at risk of getting cervical cancer (Kenney, 1994; KwaZulu-Natal Department of 
Health, 1999). Smith & Hoffman (2000) reported that approximately half of the nurses they 
sampled in Mitchell's Plain, Cape Town were of the opinion that women should have their 
smears done at the start of sexual activity, whilst a quarter thought that this should occur 
when the woman is under the age of 30 years. The participants in our study also believed 
that the age for first smear should be lowered to 20 years and that they should be repeated 
at five year intervals thereafter. They recommended this because of the high rate of 
HIV/AIDS in this province. Such sentiments have been criticized on the grounds that the 
nurses do not understand the natural course of the disease or the rationale behind the 
screening programme (Fonn, 2003; Smith et al., 2003). Worth noting are the results of the 
study that was conducted in the province of KwaZulu-Natal in South Africa by Gaym et al. 
(2007), which revealed that all the high-grade squamous intra-epithelial lesions occurred in 
women younger than 30 years of age, which is much lower than the usual age distribution 
for high grade lesions (around 35-40 years of age). 
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4. Recommended measures to improve screening programmes in developing 
countries 
Many low-income developing countries currently have neither the financial and manpower 
resources nor the capacity in their health services to organize and sustain a screening 
programme of any sort (Sankaranarayanan et al., 2001). Efforts to organize effective 
screening programmes in developing countries will have to find adequate financial 
resources, develop the infrastructure, train the needed manpower, and elaborate 
surveillance mechanisms for screening, investigating, treating and follow-up of the targeted 
women. The following measures need to be put in place in order to improve cervical 
screening in developing countries: 
4.1 Effective screening tests 
The developing countries should consider cost effective screening test to use. Newer 
alternative methods for cervical screening have being developed and tested (Denny, et al., 
2000; Goldie et al., 2006; Sankaranarayanan et al., 1998). These include DNA testing for 
HPVand visual inspection with acetic acid (VIA). The most promising of these being DNA 
testing for HPV as cervical cancer is caused mainly by HPV. The key barriers to HPV testing 
in developing countries are the costs and technical requirements associated with the test 
(Sankaranarayanan et al., 2005). VIA also called cervicoscopy, consists of naked eye 
visualization of the uterine cervix after the application of diluted acetic acid, to screen for 
cervical abnormalities. A solution of 3% to 5% acetic acid is used, and the cervix is 
illuminated with a light source and the purpose is to identify aceto-white areas which may 
indicate tissue undergoing precancerous changes (Sankaranarayanan et al., 1998). A study of 
the cost effectiveness of several cervical cancer screening strategies, based on the South 
African experience, indicated that strategies using VIA or HPV DNA testing may offer 
attractive alternatives to cytology-based screening programmes in low-resource settings 
(Goldie et al., 2001). In developing countries, because of the lack of trained cytotechnologists 
and cytology laboratories, there is often a long interval (1-3 months) between the Pap 
screenings and when the test result is available. VIA has the advantage of requiring only 
low-technology equipment and the result is available immediately (Jeronimo et al., 2005). 
Therefore, the treatment of abnormal lesions can be done during the same consultation. This 
is further supported by the findings of the study that was conducted by Goldie et al., (2005) 
which revealed that VIA or HPV DNA testing offer cost-effective alternatives to 
conventional cytology-based screening in low resource settings as these require only one or 
two clinical visits. The results of the study that was conducted by Maree et al. (2009) 
revealed that VIA screening is acceptable to women due to the fact that the results are 
available immediately. The use of VIA as a screening tool should be considered as it is a 
realistic alternative for low-resource settings. VIA training should be instituted and 
registered nurses trained to perform it effectively. Part time registered nurses, possibly 
including the retired registered nurses, could perform VIAs at primary health care clinics, 
together with breast examinations. The major drawback of this approach that was identified 
by Sankaranarayanan et al. (1998) is that lesions are not detected early enough to prevent 
invasion because of a large proportion of the cancers detected are relatively advanced, 
requiring complex medical therapy that is difficult to provide in many settings. Cytology 
remains the best method available in screening for cervical cancer. However, in countries 
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with limited resources, an inexpensive and easy alternative is needed. Choosing a suitable 
screening test is only one aspect of a screening programme. A more fundamental and 
challenging issue is the organization of the programme in its totality. Whichever screening 
test is to be used, the challenges in organizing a screening programme are more or less the 
same. However, screening tests that require additional recalls and revisits for diagnostic 
evaluation and treatment may pose added logistic difficulties and these may emerge as 
another barrier for participation in low-resource settings (Sankaranarayanan et al., 2001).  
4.2 Improving health human resources 
Due to task shifting, cervical screening previously the exclusive domain of doctors and 
family planning nurses was extended to all registered nurses in the public sector 
(Department of Health, 2000). This led to the greater availability of screening services as 
well as increasing the demand for additional competent nurses to do Pap smears. Making 
the registered nurses the primary cervical screening providers is logical, given the need to 
increase the services. However, Kawonga & Fonn (2008) argues that this solution fails to 
recognize that a screening programme entails more than just taking Pap smears. These 
authors further argue that there are several components that should be well-co-ordinated 
including the facilities for follow-up and referral of women with abnormal smears. South 
Africa has not invested sufficiently in health systems strengthening nor in building the 
management capacity to co-ordinate and monitor the screening programme (Moodley et al., 
2006). In South Africa, registered nurses have an important responsibility for the 
implementation of the programme. Health workers in South Africa are poorly distributed, 
being concentrated in urban areas, private sectors and hospitals (Wadee & Khan, 2007). In 
order to ensure efficient utilization of registered nurses, appropriate skills mix at the PHC 
clinics must be ensured. 
According to the South African cervical screening policy, all nurses at the clinics are 
expected to conduct screening but this is not happening, mainly because nurses have not 
been equipped with knowledge and skills (Moodley et al., 2006; Sibiya & Grainger, 2007; 
Smith et al., 2003). In order for the nurses to be knowledgeable about the disease and 
understand, accept and comply with the programme, they must be trained through 
continuing professional development system. Education concerning the rationale of the 
policy, and the natural history of the disease, may encourage nurses to perform more 
screening tests. Zweigenthal (1998) found a correlation between a high level of screening 
and nurses’ knowledge or a personal interest in the level of nurses’ education. This 
researcher reported that the screening rates increased with an increase in the level of nurses’ 
education. If nurses have a positive attitude towards the cervical screening programme, they 
are likely to motivate women to have a smear done. According to the cervical screening 
policy, all service providers must have access to information and be technically competent 
to perform adequate smears with effective management of abnormal results. The policy 
further states that the adequacy rate of a screening facility must reach at least 70% and if the 
facility consistently achieves below 70%, the programme stipulates that the staff will have to 
be re-trained (Department of Health, 2000). Smith et al. (2003) suggested that low coverage 
may be due to nurses' opposition to and poor understanding of the programme. Given that 
the participants disagreed with the starting age and intervals for smears, and mentioned 
inappropriate criteria, there is a clear need for further training. 
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In order to address the limited capacity to read cervical smears, the alternative methods for 
cervical screening, for example the DNA testing for HPV and VIA will relieve pressure on 
the cyto-techicians. Additional posts will have to be established or, in addition, methods of 
contracting private sector resources could be investigated (Fonn, 2003).  
4.3 Good follow up and referral systems 
It is unethical to offer screening without ensuring that follow-up and treatment services are 
available for women with abnormal smears (Sackett, 1975 as cited in Kawonga & Fonn, 
2008). The WHO (2002) states that for success, the cervical screening programme must have 
the ability to "ensure high levels of coverage of the target population, to offer high quality, 
caring services, to develop and monitor good referral systems that ensure good patient 
follow-up and to ensure that the patients receive appropriate, acceptable and caring 
treatment in the context of informed consent." The manner in which the health professionals 
perform can have a profound effect on the achievement of these. The relationship between 
primary and referral sites and good monitoring systems is essential in order for a screening 
programme to be effective. The fact that screening services offered at PHC settings are not 
available outside office hours can also be seen as an obstacle. A system must be put in place 
to ensure that working women have access to the clinics even after office hours. A booking 
system can also be used to increase access of the screening services. 
5. Conclusion 
The South African government has produced a commendable screening programme and 
made a commitment to reduce cervical cancer. However, there are still challenges with the 
implementation of the cervical screening policy. South Africa is better placed than most sub-
Saharan countries, but will not attain a successful screening programme without increased 
effort. An important consideration that needs to be taken into account is the cost. Frequent 
screening of women has considerable cost and resource implications. The limited health care 
budgets in most developing countries preclude initiating and sustaining such programmes. 
Despite calls for screening, implementation difficulties include shortages both of health 
funds and of number of skilled personnel. Strategies to reduce the burden on registered 
nurses may include training of less skilled cadres of nurses, like enrolled nurses and 
enrolled nursing auxiliaries for cervical screening. In order for a cervical cancer screening 
programme to succeed in South Africa, there must be greater political commitment so as to 
improve resources that are required for implementing the policy. The political will to see a 
national screening programme implemented is required from government, the health sector, 
the various medical, nursing and allied health and professional boards. Communication 
methods and delivery strategies aimed at encouraging women from developing countries 
are needed in order to increase screening uptake.  
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1. Introduction 
“Cervical cancer is fully preventable and curable, at low cost and at low risk, when 
screening to facilitate the timely detection of early precursor lesions in asymptomatic 
women is available together with appropriate diagnosis, treatment and follow-up” (Lewis, 
M. Pan American Health Organization, 2004). 
The burden of cervical cancer is quite low in the developed countries of the world. The 
situation is quite the reverse in developing countries where it constitutes a major health 
problem. While the incidence is decreasing in the former, it is on the increase in the later. This 
is a source of great concern considering the fact that cervical cancer is preventable and curable 
at low cost with currently available methods. Sub Sahara Africa is the region with the highest 
incidence of cervical cancer in the world with concomitant high mortality affecting women at 
their prime. There are no screening programs for early detection of precancerous lesions 
within the countries of Sub Sahara Africa. Most screening activities are done as pilot or 
research projects which are discontinued on completion. South Africa is the only country in 
the region with a national cytology based screening program since 2001 but then coverage 
remains poor and the impact on invasive cervical cancer is unknown (Louie et al.2009). The 
onset of HIV/AIDS epidemic that is highest in the sub region has elevated the problem of 
cervical cancer to a serious level. To compound the problem is the widespread lack of 
resources associated with the region. The countries of Sub Sahara Africa are shown in figure 1.  
2. Aim 
The aim of this work is to appraise the incidence, mortality, state of prevention and 
treatment of cervical cancer in sub-Sahara Africa. This highlight is necessary so that health 
professionals, philanthropists, policy makers, advocates and other stake holders can 
appreciate and understand the state of the disease and respond through the development of 
treatment, preventive and control programs that will lessen the burden and mortality from 
this disease in the sub region. It is also aimed at highlighting the need to see that cervical 
cancer should be considered a public health problem in the region. 
3. Methods 
The method used was through the synthesis of data and information derived from available 
current published scientific works from peer reviewed journals, workshop proceedings,  
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Fig. 1. Map showing the countries of Sub Sahara Africa (Map Source: www.world map .org) 
(NB Southern Sudan became independent July 2011) 
hospital and regional based cancer registry figures , reports from specific centres, conference 
proceedings and a review of work done on cervical cancer in the authors institution The 
University College Hospital Ibadan Nigeria. 
4. Findings and discussions 
Cervical cancer occurs worldwide but the highest incidence and mortality rates of cervical 
cancer are in Eastern, Western, and Southern Africa, as well as South-Central Asia and South 
America. Rates are lowest in Western Asia, Australia/New Zealand as shown in table 1.  
In sub-Saharan Africa cervical cancer accounts for 22.2% of all cancers in women and it is 
also the most common cause of cancer death among women (Parkin et al.,2003). Cervical  
 
Cervical Cancer in Sub Sahara Africa 53 
World Area Incidence per 100,000 Mortality per 100,000 
Eastern Africa 34.5 25.3 
Western Africa 33.7 24.0 
Southern Africa 26.8 14.8 
South – Central Asia 24.6 14.1 
South America 24.1 10.8 
Melanesia 23.7 16.6 
Middle Africa 23.0 17.0 
Central America 22.2 11.1 
Caribbean 20.8 9.4 
South – Eastern Asia 15.8 8.3 
Central and Eastern Europe 14.5 6.3 
Micronesia/ Polynesia 13.4 4.9 
Eastern Asia 9.6 3.9 
Northern Europe 8.3 2.4 
Southern Europe 8.0 2.6 
Western Europe 6.9 2.0 
Northern Africa 6.6 4.0 
Northern America 5.7 1.7 
Australia/ New Zealand 5.0 1.0 
Western Asia 4.5 2.1 
Table 1. Age Standardized Cervical Cancer Incidence and Mortality Rates by World Area 
(Extracted from GLOBOCAN 2008 by Jemal et al., 2011). 
cancer is however the second common cancer among women after cancer of the breast in 
some areas like Ibadan in Nigeria (Adebamowo et al. 1999). About 60–75% of women in sub-
Saharan Africa who develop cervical cancer live in rural areas. Many of these women go 
untreated, mostly due to lack of access (financial and geographical) to health care. Women 
in sub-Saharan Africa lose more years to cervical cancer than to any other type of cancer. 
Unfortunately, it affects them at a time of life when they are critical to the social and 
economic stability of their families (Parkin et al., 2002).  
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The true incidence of cervical cancer in many African countries is unknown as there is gross 
under-reporting. Only very few countries have functional cancer registries and record-
keeping is minimal or non-existent in many countries. Some of the figures quoted in the 
literature are hospital-based, which represents a small fraction of women dying from 
cervical cancer, as most women cannot access hospital care and die at home. A mortality 
rate of 35 per 100,000 is reported in Eastern Africa. The reported mortality rates in 
developed countries with successful screening programs seldom exceed 5 per 100,000 
women (Chokunonga et al., 2002).  
4.1 Factors responsible for the high prevalence 
4.1.1 Socio-cultural factors 
Human papillioma virus (HPV) has been isolated in most cases of cervical cancer in all parts 
of the world. Epidemiologic studies have shown that the association of genital human 
papilloma virus (HPV) with cervical cancer is strong, independent of other risk factors, and 
consistent in several countries .The International Biological Study on Cervical Cancer 
(IBSCC) Study Group led by Bosch, F. in 1995 reported that HPV DNA was detected in 93% 
of the tumors, with no significant variation in HPV positivity among countries. HPV 16 was 
present in 50% of the specimens, HPV 18 in 14%, HPV 45 in 8%, and HPV 31 in 5%. HPV 16 
was the predominant type in all countries except Indonesia, where HPV 18 was more 
common. There was significant geographic variation in the prevalence of some less common 
virus types. A clustering of HPV 45 was apparent in western Africa, while HPV 39 and HPV 
59 were almost entirely confined to Central and South America. In squamous cell tumors, 
HPV 16 predominated (51% of such specimens), but HPV 18 predominated in 
adenocarcinomas (56% of such tumors) and adenosquamous tumors (39% of such tumors). 
The report concluded that the results confirm the role of genital HPVs, which are 
transmitted sexually, as the central etiologic factor in cervical cancer worldwide (Bosch F et 
al., 1995). Epidemiological studies employing a variety of HPV typing protocols have been 
collated in meta-analyses. HPV-16/18 is estimated to account for 70% of all cervical cancers 
worldwide, although the estimated HPV-16/18 fraction is slightly higher in more developed 
(72–77%) than in less developed (65–72%) regions. About 41–67% of high-grade squamous 
intraepithelial lesion (HSIL), 16–32% of low-grade squamous intraepithelial lesion (LSIL) 
and 6–27% of atypical squamous cells of undetermined significance (ASCUS) are also 
estimated to be HPV-16/18-positive, thus highlighting the increasing relative frequency of 
HPV-16/18 with increasing lesion severity. After HPV-16/18, the six most common HPV 
types are the same in all world regions, namely 31, 33, 35, 45, 52 and 58; these account for an 
additional 20% of cervical cancers worldwide.(Clifford et al., 2006) 
Human papillomavirus (HPV), the necessary cause of cervical cancer, is endemic in 
Africa. In a study to investigate the prevalence of and the risk factors for cervical infection 
with human papillomavirus (HPV) in an inner-city area of Ibadan, Nigeria, Thomas et al., 
(2004) interviewed and obtained a sample of cervical cells from 932 sexually active 
women aged 15 years or older. A total of 32 different HPV types were identified with an 
HPV prevalence of 26.3% overall and 24.8% among women without cervical lesions; or 
age-standardised to the world standard population of 28.3 and 27.3%, respectively. High-
risk HPV types predominated, most notably HPV 16, 31, 35 and 58. In all, 33.5% of 
infections involved more than one HPV type. Unlike most populations studied so far, 
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HPV prevalence was high not only among young women, but also in middle and old age. 
Single women (odds ratio, OR=2.1; 95% confidence interval, CI=1.1–3.9) and illiterate 
women (OR=1.7; 95% CI=1.1–2.5) showed increased HPV positivity.. High prevalence of 
HPV in all age groups may be a distinctive feature of populations where HPV 
transmission continues into middle age and cervical cancer incidence is very high. Many 
of the factors that increase both HPV acquisition and promote the oncogenic effect of the 
virus are also very widespread in Africa (Schmauz et al 1989). These include: early 
marriage, polygamous marriages and high parity. Polygamy is reported to increase the 
risk of cervical cancer two-fold and the risk increases with increasing number of wives 
(Bayo et al., 2002). This is part of the male factor in addition to prostitution that lead to the 
high prevalence of HPV in Sub Sahara Africa.  
High parity, which is the norm in some cultures in Africa, is also a recognised, HPV-related 
co-factor for the development of cervical cancer (Brinton et al 1989).  
The prevalence of HPV has been shown to be higher in uncircumcised men than in 
circumcised men. In a study to investigate the association between male circumcision 
(MC) and high risk human papilloma virus (HR-HPV) prevalence, Auvert and colleagues 
(2009) using urethral swabs collected during a period of 262 consecutive days among 
participants from the intervention (circumcised) and control (uncircumcised) groups who 
were reporting for a scheduled follow-up visit reported that HR-HPV prevalences among 
intervention and control groups were 14.8% (94/637) and 22.3% (140/627). Confounder 
factors (ethnic group, age, education, sexual behaviour including condom use, marital 
status, and HIV status) had no effect on the results. Multiple HR-HPV prevalence was 
7.0% (89/1267) It was significantly lower among men of the intervention group compared 
with men of the control group (4.2% vs. 9.9%) .The prevalence of HR-HPV infections in 
their study was even thought to be underestimated since detection in the urethra is 
significantly lower than detection in the glans, corona sulcus or the penis shaft. As a 
corollary, some randomized controlled trials have shown a partial protective effect of 
male circumcision (MC) on the acquisition of HIV by males in Africa. The effect of MC on 
HR-HPV reinforces the WHO-UNAIDS recommendation for the implementation of MC 
programs in countries with a high HIV prevalence, a low MC prevalence and a high MC 
acceptability (Auvert et al., 2009). In Sub Sahara Africa these countries are mainly in 
Southern and Eastern Africa. Drain et al., in 2006, published an analysis of classification of 
developing countries according to prevalence of male circumcision. The categories were 
low, 20%, intermediate 20-80% and high > 80%. The classification for developing countries 
in Africa is presented in table 2. 
This report noted that male circumcision, which is routinely practiced in the Middle East, 
Northern and Western Africa, and Western Asia, was associated with lower rates of certain 
STIs, HIV and cervical cancer (a proxy for HPV), but not with infections transmitted by non-
sexual routes. In general, more male circumcision was strongly associated with lower 
cervical cancer rates and fewer HIV cases, independent of religion. Furthermore, male 
circumcision was independently associated with HIV among countries with primarily 
heterosexual HIV transmission, and not among countries with primarily homosexual or 
injection drug use HIV transmission. These findings all suggest that male circumcision is a 
true protective factor that reduces the sexual transmission of HIV and possibly HPV, 
independent of Muslim and Christian religions. 
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The true incidence of cervical cancer in many African countries is unknown as there is gross 
under-reporting. Only very few countries have functional cancer registries and record-
keeping is minimal or non-existent in many countries. Some of the figures quoted in the 
literature are hospital-based, which represents a small fraction of women dying from 
cervical cancer, as most women cannot access hospital care and die at home. A mortality 
rate of 35 per 100,000 is reported in Eastern Africa. The reported mortality rates in 
developed countries with successful screening programs seldom exceed 5 per 100,000 
women (Chokunonga et al., 2002).  
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4.1.1 Socio-cultural factors 
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(IBSCC) Study Group led by Bosch, F. in 1995 reported that HPV DNA was detected in 93% 
of the tumors, with no significant variation in HPV positivity among countries. HPV 16 was 
present in 50% of the specimens, HPV 18 in 14%, HPV 45 in 8%, and HPV 31 in 5%. HPV 16 
was the predominant type in all countries except Indonesia, where HPV 18 was more 
common. There was significant geographic variation in the prevalence of some less common 
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59 were almost entirely confined to Central and South America. In squamous cell tumors, 
HPV 16 predominated (51% of such specimens), but HPV 18 predominated in 
adenocarcinomas (56% of such tumors) and adenosquamous tumors (39% of such tumors). 
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collated in meta-analyses. HPV-16/18 is estimated to account for 70% of all cervical cancers 
worldwide, although the estimated HPV-16/18 fraction is slightly higher in more developed 
(72–77%) than in less developed (65–72%) regions. About 41–67% of high-grade squamous 
intraepithelial lesion (HSIL), 16–32% of low-grade squamous intraepithelial lesion (LSIL) 
and 6–27% of atypical squamous cells of undetermined significance (ASCUS) are also 
estimated to be HPV-16/18-positive, thus highlighting the increasing relative frequency of 
HPV-16/18 with increasing lesion severity. After HPV-16/18, the six most common HPV 
types are the same in all world regions, namely 31, 33, 35, 45, 52 and 58; these account for an 
additional 20% of cervical cancers worldwide.(Clifford et al., 2006) 
Human papillomavirus (HPV), the necessary cause of cervical cancer, is endemic in 
Africa. In a study to investigate the prevalence of and the risk factors for cervical infection 
with human papillomavirus (HPV) in an inner-city area of Ibadan, Nigeria, Thomas et al., 
(2004) interviewed and obtained a sample of cervical cells from 932 sexually active 
women aged 15 years or older. A total of 32 different HPV types were identified with an 
HPV prevalence of 26.3% overall and 24.8% among women without cervical lesions; or 
age-standardised to the world standard population of 28.3 and 27.3%, respectively. High-
risk HPV types predominated, most notably HPV 16, 31, 35 and 58. In all, 33.5% of 
infections involved more than one HPV type. Unlike most populations studied so far, 
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HPV prevalence was high not only among young women, but also in middle and old age. 
Single women (odds ratio, OR=2.1; 95% confidence interval, CI=1.1–3.9) and illiterate 
women (OR=1.7; 95% CI=1.1–2.5) showed increased HPV positivity.. High prevalence of 
HPV in all age groups may be a distinctive feature of populations where HPV 
transmission continues into middle age and cervical cancer incidence is very high. Many 
of the factors that increase both HPV acquisition and promote the oncogenic effect of the 
virus are also very widespread in Africa (Schmauz et al 1989). These include: early 
marriage, polygamous marriages and high parity. Polygamy is reported to increase the 
risk of cervical cancer two-fold and the risk increases with increasing number of wives 
(Bayo et al., 2002). This is part of the male factor in addition to prostitution that lead to the 
high prevalence of HPV in Sub Sahara Africa.  
High parity, which is the norm in some cultures in Africa, is also a recognised, HPV-related 
co-factor for the development of cervical cancer (Brinton et al 1989).  
The prevalence of HPV has been shown to be higher in uncircumcised men than in 
circumcised men. In a study to investigate the association between male circumcision 
(MC) and high risk human papilloma virus (HR-HPV) prevalence, Auvert and colleagues 
(2009) using urethral swabs collected during a period of 262 consecutive days among 
participants from the intervention (circumcised) and control (uncircumcised) groups who 
were reporting for a scheduled follow-up visit reported that HR-HPV prevalences among 
intervention and control groups were 14.8% (94/637) and 22.3% (140/627). Confounder 
factors (ethnic group, age, education, sexual behaviour including condom use, marital 
status, and HIV status) had no effect on the results. Multiple HR-HPV prevalence was 
7.0% (89/1267) It was significantly lower among men of the intervention group compared 
with men of the control group (4.2% vs. 9.9%) .The prevalence of HR-HPV infections in 
their study was even thought to be underestimated since detection in the urethra is 
significantly lower than detection in the glans, corona sulcus or the penis shaft. As a 
corollary, some randomized controlled trials have shown a partial protective effect of 
male circumcision (MC) on the acquisition of HIV by males in Africa. The effect of MC on 
HR-HPV reinforces the WHO-UNAIDS recommendation for the implementation of MC 
programs in countries with a high HIV prevalence, a low MC prevalence and a high MC 
acceptability (Auvert et al., 2009). In Sub Sahara Africa these countries are mainly in 
Southern and Eastern Africa. Drain et al., in 2006, published an analysis of classification of 
developing countries according to prevalence of male circumcision. The categories were 
low, 20%, intermediate 20-80% and high > 80%. The classification for developing countries 
in Africa is presented in table 2. 
This report noted that male circumcision, which is routinely practiced in the Middle East, 
Northern and Western Africa, and Western Asia, was associated with lower rates of certain 
STIs, HIV and cervical cancer (a proxy for HPV), but not with infections transmitted by non-
sexual routes. In general, more male circumcision was strongly associated with lower 
cervical cancer rates and fewer HIV cases, independent of religion. Furthermore, male 
circumcision was independently associated with HIV among countries with primarily 
heterosexual HIV transmission, and not among countries with primarily homosexual or 
injection drug use HIV transmission. These findings all suggest that male circumcision is a 
true protective factor that reduces the sexual transmission of HIV and possibly HPV, 
independent of Muslim and Christian religions. 
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Male circumcision prevalence 
Low (<20%) Intermediate (20-80%) High (>80%) 
Botswana Central African Republic Algeria Guinea-Bissau 
Burundi Cote d’ivoire Angola Kenya 
Cape Verde Ethiopia Benin Liberia 
Malawi Lesotho Burkina Faso Libya 
Namibia Mozambique Cameroon Madagascar 
Rwanda South Africa Chad Mali 
Swaziland Sudan Congo (Brazzaville) Mauritania 
Zambia Tanzania Dem Rep of Congo Mauritius 
Zimbabwe Uganda Djibouti Morocco 
  Egypt Niger 
  Equatorial Guinea Nigeria 
  Eritrea Senegal 
  Gabon Sierra Leone 
  Gambia Somalia 
  Ghana Togo 
  Guinea Tunisia 
Table 2. Category of male circumcision prevalence for developing countries in Africa 
(Adapted from Drain et al., 2006)  
4.1.2 Socio-economic factors 
Worldwide women of low socio-economic status have a greater risk of having cervical 
cancer. Cervical cancer is often referred to as a disease of poverty and of poor women. A 
recent study in Mali in West Africa showed that within a population widely infected with 
HPV, poor social conditions, high parity and poor hygienic conditions were the main co-
factors for cervical cancer (Palacio-Mejia et al., 2003). Sub Sahara Africa also has widespread 
conditions that encourage sub standard living conditions. These include wars, political 
chaos, internal conflicts, natural disasters, famine and drought. These often lead to large 
populations being displaced externally and internally for long periods of time. Under this 
refugee- like conditions, social vices like rapes, prostitution and multiple marriages and 
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cohabitation prevail encouraging the transmission of HPV. War is associated with male 
sexual promiscuity, which in turn contributes to the development of cervical cancer among 
sexually monogamous women. In 1996, a case–control study sponsored by Stanford 
University documented that the Vietnam War had contributed substantially to the problem 
of cervical cancer in contemporary Vietnam, and the Vietnam/American Cervical Cancer 
Prevention Project was established as an all-volunteer non profit organization. Publication of 
data linking war to disease was delayed for 8 years in an attempt to ease the process of 
reconciliation by offering what most would acknowledge to be a remedy in advance of what 
some will perceive to be an accusation. (Suba et al., 2006)  
High rates of invasive cervical cancer was noted in coastal areas of Coasta Rica and this was 
attributed to difficulties in having access to treatment. Most countries of Sub Sahara Africa 
are located within the Tropical Rain Forest with difficult terrain as there are lots of swampy 
areas and thick and mountainous forests. This makes access to screening, health education 
and treatment difficult. 
4.1.3 Biological factors 
Poor nutritional status and infections, e.g. malaria, HIV and TB, are ravaging sub-Saharan 
Africa and have made many people immuno-compromised. Several studies have 
demonstrated the association of HIV with HPV. The prevalence of CIN has been estimated 
to be as high as 20–40% in HIV-positive women (Wright et al 1994). HIV-positive women are 
more likely to have persistent HPV infections than HIV-negative women. In a study of 2,198 
women who attended gynaecological clinics in Abidjan, Côte d'Ivoire, HIV-positive women 
had a significantly higher prevalence of squamous intraepithelial lesion (SIL) (La Ruche et 
al., 1998). Temmerman et al (1999) reported a five-fold increased risk of high-grade SIL 
among 513 HIV-positive women in a family planning clinic in Kenya. Other reports from the 
region show that women with HIV develop cervical cancer at an earlier age than women 
who are HIV-negative(Moodley 2001). Gichangi et al(2003) in Kenya found that young 
women under the age of 35 who had invasive cervical cancer were 2.6 times more likely to 
be HIV positive than controls of similar age (35% vs. 17%, OR 2.6, p=0.043). A recently 
published study from Tanzania showed that the prevalence of HIV-1 was much higher 
among the cervical cancer patients (21.0%) than among the controls (11.6%). HIV-1 was a 
significant risk factor for cancer of the cervix (OR=2.9, 95% CI=1.4–5.9).(Moodley et al., 2006) 
Sub-Saharan Africa harbours 67% of the world's population of people living with HIV and 
AIDS (Buga G 1998).  
4.1.4 Lack of awareness and knowledge of cervical cancer in Africa 
Cervical cancer is yet to be recognised as an important public health problem in sub-Saharan 
Africa. In Sub Sahara Africa, priority is given to infectious diseases such as malaria, 
tuberculosis, leprosy, diarrheal diseases, acute respiratory infections and HIV/AIDS all of 
which have preventive and management strategies. Several studies have shown poor 
knowledge of cervical cancer in Africa, which cuts across different literacy levels. Among 
500 attendees of a maternal and child health clinic in Lagos-Nigeria only 4.3% were found to 
be aware of cervical cancer. (Anorlu et al., 2004) In 2004, also in Lagos-Nigeria, 81.7% of 139 
patients with advanced cervical cancer had never heard of cervical cancer before, and 20%, 
30% and 10% respectively thought the symptoms they had were due to resumption of 
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cohabitation prevail encouraging the transmission of HPV. War is associated with male 
sexual promiscuity, which in turn contributes to the development of cervical cancer among 
sexually monogamous women. In 1996, a case–control study sponsored by Stanford 
University documented that the Vietnam War had contributed substantially to the problem 
of cervical cancer in contemporary Vietnam, and the Vietnam/American Cervical Cancer 
Prevention Project was established as an all-volunteer non profit organization. Publication of 
data linking war to disease was delayed for 8 years in an attempt to ease the process of 
reconciliation by offering what most would acknowledge to be a remedy in advance of what 
some will perceive to be an accusation. (Suba et al., 2006)  
High rates of invasive cervical cancer was noted in coastal areas of Coasta Rica and this was 
attributed to difficulties in having access to treatment. Most countries of Sub Sahara Africa 
are located within the Tropical Rain Forest with difficult terrain as there are lots of swampy 
areas and thick and mountainous forests. This makes access to screening, health education 
and treatment difficult. 
4.1.3 Biological factors 
Poor nutritional status and infections, e.g. malaria, HIV and TB, are ravaging sub-Saharan 
Africa and have made many people immuno-compromised. Several studies have 
demonstrated the association of HIV with HPV. The prevalence of CIN has been estimated 
to be as high as 20–40% in HIV-positive women (Wright et al 1994). HIV-positive women are 
more likely to have persistent HPV infections than HIV-negative women. In a study of 2,198 
women who attended gynaecological clinics in Abidjan, Côte d'Ivoire, HIV-positive women 
had a significantly higher prevalence of squamous intraepithelial lesion (SIL) (La Ruche et 
al., 1998). Temmerman et al (1999) reported a five-fold increased risk of high-grade SIL 
among 513 HIV-positive women in a family planning clinic in Kenya. Other reports from the 
region show that women with HIV develop cervical cancer at an earlier age than women 
who are HIV-negative(Moodley 2001). Gichangi et al(2003) in Kenya found that young 
women under the age of 35 who had invasive cervical cancer were 2.6 times more likely to 
be HIV positive than controls of similar age (35% vs. 17%, OR 2.6, p=0.043). A recently 
published study from Tanzania showed that the prevalence of HIV-1 was much higher 
among the cervical cancer patients (21.0%) than among the controls (11.6%). HIV-1 was a 
significant risk factor for cancer of the cervix (OR=2.9, 95% CI=1.4–5.9).(Moodley et al., 2006) 
Sub-Saharan Africa harbours 67% of the world's population of people living with HIV and 
AIDS (Buga G 1998).  
4.1.4 Lack of awareness and knowledge of cervical cancer in Africa 
Cervical cancer is yet to be recognised as an important public health problem in sub-Saharan 
Africa. In Sub Sahara Africa, priority is given to infectious diseases such as malaria, 
tuberculosis, leprosy, diarrheal diseases, acute respiratory infections and HIV/AIDS all of 
which have preventive and management strategies. Several studies have shown poor 
knowledge of cervical cancer in Africa, which cuts across different literacy levels. Among 
500 attendees of a maternal and child health clinic in Lagos-Nigeria only 4.3% were found to 
be aware of cervical cancer. (Anorlu et al., 2004) In 2004, also in Lagos-Nigeria, 81.7% of 139 
patients with advanced cervical cancer had never heard of cervical cancer before, and 20%, 
30% and 10% respectively thought the symptoms they had were due to resumption of 
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menses, lower genital infection and irregular menses. Almost all the women (98%) believed 
that their advanced disease was curable, 12% thought it was not a serious disease and only 
9% understood that it was cancer and therefore serious (Ajayi et al., 1998). Similar studies in 
Kenya and Tanzania also reported very poor knowledge of the disease in patients. (Gichangi 
et al., 2003 & Kidanto et al., 2002). Poor knowledge is not limited to patients alone, however; 
health care workers who are supposed to be better informed do not have good knowledge 
of the disease either. In Lagos Nigeria, delay by primary health care providers in referring 
cases of cervical cancer was found to be an important cause of women presenting with late-
stage disease. It took a mean of 9.35 ± 12.9 months for primary health care providers to 
diagnose and refer women with cervical cancer to a tertiary hospital for management. 
(Anorlu et al., 2004).  
Education improves knowledge and acceptability of preventive measures against cervical 
cancer. In a study on cervical cancer awareness and HPV vaccine acceptance among 375 
female university students in Northern Nigeria, a total of 133 participants knew of HPV 
(35.5%), 202 (53.9%) had heard of cervical carcinoma and 277 (74.0%) were willing to accept 
HPV vaccination. (Ilyasu et al., 2010). Apochie and colleague (2009) conducted a cross 
sectional survey among college students aged 18 years and above, attending a large 
university in Accra, Ghana. A sample of 157 students was selected to study knowledge and 
beliefs about cervical cancer screening. In general, respondents seemed to understand that 
cervical cancer screening had benefits. Over 64 percent believed that the test could find 
cervical changes before they became cancerous while 78.5% thought those changes could be 
easily cured. Among the perceived barriers to screening, the most prevalent perceived 
barrier was that only half of respondents believed that the purpose of cervical cancer was to 
diagnose cancer, the second commonest reported barrier (40.6%) was the belief that their 
partner would not allow them to obtain cervical cancer screening. The following barriers 
were also important; cost (23.2%), not knowing where to go (24.3%), and belief that 
everyone would think they were sexually active (24.6%). Encouragingly, few believed that a 
pap test would be painful (9.4%). While more than 68% perceived that young women were 
susceptible to cervical cancer, a lower percentage (52.5%) believed that they themselves 
were at risk for cervical cancer. About three quarters of respondents (73%) believed that 
cervical cancer was a serious disease that would make a woman's life difficult and about 
62% of students also believed that there were effective cures for cervical cancer. In general, a 
low percentage received screening cues from their social environment by way of knowing 
peers who had screened or from a healthcare worker‘s recommendation. Six of the fifteen 
respondents who had received at least one recommendation from a healthcare worker to get 
cervical screening, scheduled and obtained one. The subset reporting having received a 
health care worker recommendation but that reported not having the test, indicated the 
following reasons; they could not afford it, they did not know where to get screening, they 
had no time to schedule and obtain screening and they felt it was embarrassing to expose 
themselves for screening. About a third reported ever having heard a mass media 
discussion on cervical cancer while a fifth have at least once listened to a discussion on 
cervical cancer at a church or other social gathering. About half also stated that they would 
be willing to obtain the cheaper alternative cervical cancer screening using visual inspection 
and mild acetic acid, if a doctor recommended it. Overall there was good awareness of the 
issues related to screening, although there were specific gaps in knowledge about risk 
factors and screening intervals. For instance, it was found that although the relationship 
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between sex and cervical cancer was known, less was known about other risk factors like 
their partner's prior sexual experiences and very little was known about the link between 
HPV and cervical cancer. 
4.1.5 Poor cervical cancer screening 
Very few women in sub-Saharan Africa are ever screened for cervical cancer. None of the 
500 women attending a maternal and child health clinic in a poor area of Lagos in 1999 
had ever had a Pap smear .Only 9% of health care workers in two health institutions in 
Nigeria had ever had a Pap smear. In a study among medical workers in a Ugandan 
hospital (doctors , nurses and medical students) Only 19% of the female medical workers 
had ever had a cervical cancer screening test done. The reasons for not having been 
screened included: not feeling at risk, lack of symptoms, carelessness, fear of vaginal 
examination, lack of interest, test being unpleasant and not yet being of risky age. 
Moreover, 25% of the female respondents said that they would only accept a vaginal 
examination by a female health worker.(Mutyaba et al., 2006) In a similar study among 
nurses in a Tanzanian hospital concerning nurses' own cervical cancer screening practices 
most (116/137) of the respondents had never had a Pap smear the most common reason 
(54.7%) was not knowing where to go for the test, followed by seeing no reason for the 
test (13.1%), being afraid of the procedure (9.5%) and being afraid of bad results 
(7.3%).(Urasa & Darj 2009) 
Some of the few women who do have access to screening do not get themselves screened 
because they have wrong beliefs about cervical cancer. (Anorlu et al., 2007). Less than 1% of 
women in four West African countries had ever been screened (Gichangi et al., 2003). 
Moreover, there are very few cervical screening services in Africa and many of them are 
based in secondary and tertiary health care facilities located in urban areas. Only 5% of 504 
general practitioners in Lagos Nigeria in 2004 screened their patients (Denny et al 2006). 
Women who use these services are generally young, and smears are thus being taken from a 
relatively low-risk group. 
Screening in most developing countries like the countries within the sub region is mainly 
opportunistic, characterized by an estimated low coverage, coexisting with over-screening 
of women with access to health services, and an absence of quality control procedures. 
Policies for cervical cancer screening in most countries vary and, most often nonexistent . 
Formulation and ensuring compliance with national program guidelines is an essential step 
toward significantly reducing the burden of cervical cancer (Arrosi et al. 2010). This type of 
service does not reach women most at risk, i.e. older women aged 35–60 years, especially 
those who live in rural areas. Cytology-based screening, which is used in developed 
countries, is resource intensive, and difficult to realise in very many countries in sub-
Saharan Africa because of poor health care infrastructure and lack of resources. There are 
very few cytopathologists, cytoscreeners and cytotechnicians; some have inadequate 
training. Quality control is inadequate. Histopathological services are extremely limited in 
many countries. Malawi, a country with a cervical cancer incidence rate of 47 per 100,000 
women, had one pathologist, one colposcope, no cyto-technicians and no facilities for 
cervical cancer screening or treatment as at 2001. The situation is not much different 
presently. The default rate among those with cytological abnormalities reaches 60–80% due 
to the absence of effective mechanisms for recall of women with abnormal smears. 
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cases of cervical cancer was found to be an important cause of women presenting with late-
stage disease. It took a mean of 9.35 ± 12.9 months for primary health care providers to 
diagnose and refer women with cervical cancer to a tertiary hospital for management. 
(Anorlu et al., 2004).  
Education improves knowledge and acceptability of preventive measures against cervical 
cancer. In a study on cervical cancer awareness and HPV vaccine acceptance among 375 
female university students in Northern Nigeria, a total of 133 participants knew of HPV 
(35.5%), 202 (53.9%) had heard of cervical carcinoma and 277 (74.0%) were willing to accept 
HPV vaccination. (Ilyasu et al., 2010). Apochie and colleague (2009) conducted a cross 
sectional survey among college students aged 18 years and above, attending a large 
university in Accra, Ghana. A sample of 157 students was selected to study knowledge and 
beliefs about cervical cancer screening. In general, respondents seemed to understand that 
cervical cancer screening had benefits. Over 64 percent believed that the test could find 
cervical changes before they became cancerous while 78.5% thought those changes could be 
easily cured. Among the perceived barriers to screening, the most prevalent perceived 
barrier was that only half of respondents believed that the purpose of cervical cancer was to 
diagnose cancer, the second commonest reported barrier (40.6%) was the belief that their 
partner would not allow them to obtain cervical cancer screening. The following barriers 
were also important; cost (23.2%), not knowing where to go (24.3%), and belief that 
everyone would think they were sexually active (24.6%). Encouragingly, few believed that a 
pap test would be painful (9.4%). While more than 68% perceived that young women were 
susceptible to cervical cancer, a lower percentage (52.5%) believed that they themselves 
were at risk for cervical cancer. About three quarters of respondents (73%) believed that 
cervical cancer was a serious disease that would make a woman's life difficult and about 
62% of students also believed that there were effective cures for cervical cancer. In general, a 
low percentage received screening cues from their social environment by way of knowing 
peers who had screened or from a healthcare worker‘s recommendation. Six of the fifteen 
respondents who had received at least one recommendation from a healthcare worker to get 
cervical screening, scheduled and obtained one. The subset reporting having received a 
health care worker recommendation but that reported not having the test, indicated the 
following reasons; they could not afford it, they did not know where to get screening, they 
had no time to schedule and obtain screening and they felt it was embarrassing to expose 
themselves for screening. About a third reported ever having heard a mass media 
discussion on cervical cancer while a fifth have at least once listened to a discussion on 
cervical cancer at a church or other social gathering. About half also stated that they would 
be willing to obtain the cheaper alternative cervical cancer screening using visual inspection 
and mild acetic acid, if a doctor recommended it. Overall there was good awareness of the 
issues related to screening, although there were specific gaps in knowledge about risk 
factors and screening intervals. For instance, it was found that although the relationship 
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between sex and cervical cancer was known, less was known about other risk factors like 
their partner's prior sexual experiences and very little was known about the link between 
HPV and cervical cancer. 
4.1.5 Poor cervical cancer screening 
Very few women in sub-Saharan Africa are ever screened for cervical cancer. None of the 
500 women attending a maternal and child health clinic in a poor area of Lagos in 1999 
had ever had a Pap smear .Only 9% of health care workers in two health institutions in 
Nigeria had ever had a Pap smear. In a study among medical workers in a Ugandan 
hospital (doctors , nurses and medical students) Only 19% of the female medical workers 
had ever had a cervical cancer screening test done. The reasons for not having been 
screened included: not feeling at risk, lack of symptoms, carelessness, fear of vaginal 
examination, lack of interest, test being unpleasant and not yet being of risky age. 
Moreover, 25% of the female respondents said that they would only accept a vaginal 
examination by a female health worker.(Mutyaba et al., 2006) In a similar study among 
nurses in a Tanzanian hospital concerning nurses' own cervical cancer screening practices 
most (116/137) of the respondents had never had a Pap smear the most common reason 
(54.7%) was not knowing where to go for the test, followed by seeing no reason for the 
test (13.1%), being afraid of the procedure (9.5%) and being afraid of bad results 
(7.3%).(Urasa & Darj 2009) 
Some of the few women who do have access to screening do not get themselves screened 
because they have wrong beliefs about cervical cancer. (Anorlu et al., 2007). Less than 1% of 
women in four West African countries had ever been screened (Gichangi et al., 2003). 
Moreover, there are very few cervical screening services in Africa and many of them are 
based in secondary and tertiary health care facilities located in urban areas. Only 5% of 504 
general practitioners in Lagos Nigeria in 2004 screened their patients (Denny et al 2006). 
Women who use these services are generally young, and smears are thus being taken from a 
relatively low-risk group. 
Screening in most developing countries like the countries within the sub region is mainly 
opportunistic, characterized by an estimated low coverage, coexisting with over-screening 
of women with access to health services, and an absence of quality control procedures. 
Policies for cervical cancer screening in most countries vary and, most often nonexistent . 
Formulation and ensuring compliance with national program guidelines is an essential step 
toward significantly reducing the burden of cervical cancer (Arrosi et al. 2010). This type of 
service does not reach women most at risk, i.e. older women aged 35–60 years, especially 
those who live in rural areas. Cytology-based screening, which is used in developed 
countries, is resource intensive, and difficult to realise in very many countries in sub-
Saharan Africa because of poor health care infrastructure and lack of resources. There are 
very few cytopathologists, cytoscreeners and cytotechnicians; some have inadequate 
training. Quality control is inadequate. Histopathological services are extremely limited in 
many countries. Malawi, a country with a cervical cancer incidence rate of 47 per 100,000 
women, had one pathologist, one colposcope, no cyto-technicians and no facilities for 
cervical cancer screening or treatment as at 2001. The situation is not much different 
presently. The default rate among those with cytological abnormalities reaches 60–80% due 
to the absence of effective mechanisms for recall of women with abnormal smears. 
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The effectiveness of direct visual inspection [visual inspection with acetic acid (VIA) and 
visual inspection with Lugol's iodine (VILI)) as a form of population-based screening has 
been studied across the continent, mainly sponsored by international agencies (Chirenje et 
al., 2001) VIA is similar to colposcopy in that 4% acetic acid is applied to the cervix and any 
acetowhite lesion is visualized, although with VIA there is no magnification. It is a simple 
procedure and in most centres has been carried out by trained nurses. Candidates with 
suspicious lesions are selected for treatment. Studies have shown the sensitivity of VIA to be 
the same as that of Pap smear while its specificity is lower than 85% (Urasa & Darj 2011). 
The specificity is also noted to be even lower among HIV positive patients possibly due to 
high rates of coinfections in the lower genital tract (Denny et al., 2002). Visual inspection 
method is however a subjective method and prone to different interpretations by different 
observers depending on experience and competence. Other screening methods include HPV 
DNA assay (which has been shown to be even superior to PAP smear test) and colposcopy. 
4.1.6 Treatment of cervical cancer in sub-Saharan Africa 
Treatment of cervical cancer is dependent on the stage of the disease, age and medical state 
of the patient, tumor characteristics, patients' preferences and resources within the health 
sector of each country. Options can be monotherapy or combined; they range from 
conisation of the cervix, simple hysterectomy with or without lymphadenectomy, radical 
hysterectomy with pelvic lymphadenectomy, pelvic exenteration, chemotherapy, 
radiotherapy, to palliative chemotherapy. Treatment at an early stage has the best prognosis 
with the highest cure rates (Urasa & Darj 2011) 
4.1.6.1 Treatment of pre-invasive cervical cancer 
It may not be too wrong to say that there are apparently more cases of invasive cancer than 
pre-invasive cancer; this is mainly because there are very few facilities for screening and 
very poor access to the screening services. Because so few women are ever screened, not 
many cases of pre-cancerous lesions are diagnosed or detected. Colposcopy is available only 
in very few centres. Hysterectomy and cone biopsy are the usual treatment modalities for 
pre-cancerous lesions, as the equipment and expertise for large loop excision of the 
transformation zone (LLETZ), also known as loop electrosurgical excision (LEEP), are 
scarce.  
4.1.6.2 Treatment of invasive cervical cancer 
The treatment of invasive cervical cancer continues to be a major challenge in many sub-
Saharan African countries, due to the lack of surgical facilities, skilled providers and 
radiotherapy services. Management of women with invasive cervical cancer requires a 
multidisciplinary approach, including: gynaecologists, radiation oncologists, medical 
oncologists, pathologists, medical physicists, technicians, nurses and counsellors. These 
specialists are lacking in many places across the continent, and where they exist they tend to 
work in isolation rather than in teams. 
There are few cases that present in the operable stage of the disease. In Lagos Nigeria, less 
than 10% of cases are operable at the time of presentation. Some of the few who do present 
early may not have surgery as there are very few certified gynaecologists who perform 
radical gynaecological cancer surgery. Follow-up after surgery is often very poor as some 
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patients who believe they have been cured never come back. Others just cannot afford the 
cost of transportation back to urban centres for follow-up (Ashraf, H. 2003). For patients 
who present late, radiotherapy becomes the preferred treatment. Unfortunately, only a few 
receive this treatment due to the paucity of resources and very advanced disease at 
presentation. Chirenje et al. (2001) found in Harare, Zimbabwe that in 70% of patients, 
radiotherapy was the most commonly used treatment modality, as many of the cases 
presented with stage 2B and above.  
Radiotherapy is not available in many places in Sub Sahara Africa. In 1997, radiotherapy 
was not available in 32 African countries. (Levin et al.,1997). In 2003, 15 countries in Africa 
did not have a single radiotherapy machine. Nigeria, the most populous country in Africa, 
had only five radiotherapy centres as at 2009: four government-owned and one privately 
owned. WHO recommends 0.4 radiotherapy machines per million of population. Nigeria's 
five machines to 140 million people translates to ∼0.04 per million, well below WHO’s 
recommendation. In contrast, in the United States, there are 12 machines per million people. 
(Sepulveda et al., 2003). Besides few machines, those that exist frequently do not function 
most of the time because the resources for their proper maintenance and repair do not exist. 
In addition, there is a shortage of trained staff such as radiotherapists and medical 
physicists, as well as essential materials.  
4.1.7 Supportive care 
Pain is the most common presenting symptom in many cancer patients in Africa because of 
late presentation. In a survey of terminally ill patients in five countries in Africa – Uganda, 
Ethiopia, Tanzania, Zimbabwe and Botswana – the greatest need expressed by the patients 
was pain relief. (Harding et al., 2005) In another study comparing the concerns of terminally 
ill patients in a developed country (Scotland) and an African country (Kenya), it was found 
that the main concern of the Scottish patients was the emotional pain of facing death, while 
for their counterparts in Kenya it was physical pain and financial worries. Unfortunately, 
there is inadequate availability of pain-relieving medications, especially opioids. Only 11 
out of 47 African countries use morphine for chronic pain and of these 11, the amount 
consumed is small. (Murray et al 2003) . 
Oral morphine is not available to very many cancer patients in sub-Saharan Africa. 
Insufficient funds due to low priority accorded to palliative care by governments, regulatory 
and pricing obstacles, ignorance, and false beliefs are responsible. In some instances, where 
drugs are available to patients, sustainability of pain relief is hampered by poverty, as many 
cannot afford the cost of the drugs. Poverty, poor infrastructure, lack of health care workers 
adequately trained in palliative care and poor priority accorded to palliative care by African 
governments are all obstacles to effective palliative care in sub-Saharan Africa. There are 
very few hospices to take care of terminally ill patients. However, countries like South 
Africa, Uganda, Kenya, Tanzania, Nigeria and Zimbabwe have made some progress in 
palliative care. Uganda is the first African country to follow the WHO guidelines on 
palliative care. It has made oral morphine freely available to districts that have specialist 
palliative care nurses or clinical officers, and has promoted morphine use down to the 
villages. Laws have also been passed to allow trained nurses, especially those in the rural 
areas, where there are very few or no doctors, to prescribe morphine. Cancer is believed in 
certain cultures to be a punishment from the gods, and terminally ill patients often seek help 
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The effectiveness of direct visual inspection [visual inspection with acetic acid (VIA) and 
visual inspection with Lugol's iodine (VILI)) as a form of population-based screening has 
been studied across the continent, mainly sponsored by international agencies (Chirenje et 
al., 2001) VIA is similar to colposcopy in that 4% acetic acid is applied to the cervix and any 
acetowhite lesion is visualized, although with VIA there is no magnification. It is a simple 
procedure and in most centres has been carried out by trained nurses. Candidates with 
suspicious lesions are selected for treatment. Studies have shown the sensitivity of VIA to be 
the same as that of Pap smear while its specificity is lower than 85% (Urasa & Darj 2011). 
The specificity is also noted to be even lower among HIV positive patients possibly due to 
high rates of coinfections in the lower genital tract (Denny et al., 2002). Visual inspection 
method is however a subjective method and prone to different interpretations by different 
observers depending on experience and competence. Other screening methods include HPV 
DNA assay (which has been shown to be even superior to PAP smear test) and colposcopy. 
4.1.6 Treatment of cervical cancer in sub-Saharan Africa 
Treatment of cervical cancer is dependent on the stage of the disease, age and medical state 
of the patient, tumor characteristics, patients' preferences and resources within the health 
sector of each country. Options can be monotherapy or combined; they range from 
conisation of the cervix, simple hysterectomy with or without lymphadenectomy, radical 
hysterectomy with pelvic lymphadenectomy, pelvic exenteration, chemotherapy, 
radiotherapy, to palliative chemotherapy. Treatment at an early stage has the best prognosis 
with the highest cure rates (Urasa & Darj 2011) 
4.1.6.1 Treatment of pre-invasive cervical cancer 
It may not be too wrong to say that there are apparently more cases of invasive cancer than 
pre-invasive cancer; this is mainly because there are very few facilities for screening and 
very poor access to the screening services. Because so few women are ever screened, not 
many cases of pre-cancerous lesions are diagnosed or detected. Colposcopy is available only 
in very few centres. Hysterectomy and cone biopsy are the usual treatment modalities for 
pre-cancerous lesions, as the equipment and expertise for large loop excision of the 
transformation zone (LLETZ), also known as loop electrosurgical excision (LEEP), are 
scarce.  
4.1.6.2 Treatment of invasive cervical cancer 
The treatment of invasive cervical cancer continues to be a major challenge in many sub-
Saharan African countries, due to the lack of surgical facilities, skilled providers and 
radiotherapy services. Management of women with invasive cervical cancer requires a 
multidisciplinary approach, including: gynaecologists, radiation oncologists, medical 
oncologists, pathologists, medical physicists, technicians, nurses and counsellors. These 
specialists are lacking in many places across the continent, and where they exist they tend to 
work in isolation rather than in teams. 
There are few cases that present in the operable stage of the disease. In Lagos Nigeria, less 
than 10% of cases are operable at the time of presentation. Some of the few who do present 
early may not have surgery as there are very few certified gynaecologists who perform 
radical gynaecological cancer surgery. Follow-up after surgery is often very poor as some 
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patients who believe they have been cured never come back. Others just cannot afford the 
cost of transportation back to urban centres for follow-up (Ashraf, H. 2003). For patients 
who present late, radiotherapy becomes the preferred treatment. Unfortunately, only a few 
receive this treatment due to the paucity of resources and very advanced disease at 
presentation. Chirenje et al. (2001) found in Harare, Zimbabwe that in 70% of patients, 
radiotherapy was the most commonly used treatment modality, as many of the cases 
presented with stage 2B and above.  
Radiotherapy is not available in many places in Sub Sahara Africa. In 1997, radiotherapy 
was not available in 32 African countries. (Levin et al.,1997). In 2003, 15 countries in Africa 
did not have a single radiotherapy machine. Nigeria, the most populous country in Africa, 
had only five radiotherapy centres as at 2009: four government-owned and one privately 
owned. WHO recommends 0.4 radiotherapy machines per million of population. Nigeria's 
five machines to 140 million people translates to ∼0.04 per million, well below WHO’s 
recommendation. In contrast, in the United States, there are 12 machines per million people. 
(Sepulveda et al., 2003). Besides few machines, those that exist frequently do not function 
most of the time because the resources for their proper maintenance and repair do not exist. 
In addition, there is a shortage of trained staff such as radiotherapists and medical 
physicists, as well as essential materials.  
4.1.7 Supportive care 
Pain is the most common presenting symptom in many cancer patients in Africa because of 
late presentation. In a survey of terminally ill patients in five countries in Africa – Uganda, 
Ethiopia, Tanzania, Zimbabwe and Botswana – the greatest need expressed by the patients 
was pain relief. (Harding et al., 2005) In another study comparing the concerns of terminally 
ill patients in a developed country (Scotland) and an African country (Kenya), it was found 
that the main concern of the Scottish patients was the emotional pain of facing death, while 
for their counterparts in Kenya it was physical pain and financial worries. Unfortunately, 
there is inadequate availability of pain-relieving medications, especially opioids. Only 11 
out of 47 African countries use morphine for chronic pain and of these 11, the amount 
consumed is small. (Murray et al 2003) . 
Oral morphine is not available to very many cancer patients in sub-Saharan Africa. 
Insufficient funds due to low priority accorded to palliative care by governments, regulatory 
and pricing obstacles, ignorance, and false beliefs are responsible. In some instances, where 
drugs are available to patients, sustainability of pain relief is hampered by poverty, as many 
cannot afford the cost of the drugs. Poverty, poor infrastructure, lack of health care workers 
adequately trained in palliative care and poor priority accorded to palliative care by African 
governments are all obstacles to effective palliative care in sub-Saharan Africa. There are 
very few hospices to take care of terminally ill patients. However, countries like South 
Africa, Uganda, Kenya, Tanzania, Nigeria and Zimbabwe have made some progress in 
palliative care. Uganda is the first African country to follow the WHO guidelines on 
palliative care. It has made oral morphine freely available to districts that have specialist 
palliative care nurses or clinical officers, and has promoted morphine use down to the 
villages. Laws have also been passed to allow trained nurses, especially those in the rural 
areas, where there are very few or no doctors, to prescribe morphine. Cancer is believed in 
certain cultures to be a punishment from the gods, and terminally ill patients often seek help 
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from traditional healers and spiritual leaders. A good model for palliative care in Africa 
should therefore integrate the culture, beliefs and traditions of the people. Some countries 
are making efforts in this direction by incorporating traditional healers into mainstream 
medicine. However, a feasible, accessible, and effective palliative care is yet to be developed 
in sub-Saharan Africa. (Merriman & Kaur 2005).  
4.2 Improvements in outlook 
There is need to improve the outlook of this condition in Sub Sahara Africa. There should be 
improvement in attitude towards education needs of the populace so as to create and 
improve awareness and knowledge about the disease. Disease prevention requires social 
change, which in turn requires the participation of those for whom the change is intended, 
including demographic groups at high risk for disease, appropriate governmental 
authorities, and essential medical personnel. Both locally and globally, socio-political 
problems associated with sustaining working coalitions from groups with shared interests 
but competing incentives constitute critically important real-world obstacles to successful 
cervical cancer prevention and will remain so irrespective of the screening method(s) 
eventually used. In settings where health systems cannot afford to ignore such incentives, 
laboratory data constitute an essential yet sometimes overlooked fulcrum against which to 
leverage the social change required to preserve life (Suba et al., 2006)  
There is need for sensitisation of health workers about cervical cancer and importance of 
screening. Based on studies carried out in countries where organized screening is available, 
it is known that screening uptake can be influenced by cultural beliefs, the social position of 
women, characteristics of the health care system, the physician's attitudes towards screening 
and women's comprehension of the screening process. Embarrassments about undergoing a 
gynecological examination, fear of the procedure or belief that little can be done to prevent 
cancer are other factors that might decrease screening participation. Lower socio-economic 
background, lack of health insurance and low literacy also compromise participation in 
screening. Attending cervical cancer screening may have a negative connotation or stigma 
when it is combined with a gynecological examination and treatment for reproductive tract 
infections. The gender of health care professionals and limited time that they allocate to 
patient education may negatively influence screening participation as well. Other influences 
that may influence participation in screening in particular in low resource countries are 
gender imbalances and whether illness is perceived as traditional or modern. Adequate 
knowledge about cervical cancer influences early detection and treatment seeking pattern 
(Mutyaba et al., 2007). In Botswana a national cervical cytology screening committee was 
formed in 1996 with a role in planning and advising the government. Just six years later a 
national guidance document for the national cervical cytology programme was drawn up 
and implemented. In this short space of time public awareness has been successfully raised 
resulting in an increased uptake of Pap smears from 5000 per year before the start of the 
programme to an impressive 32,000 per year in 2009. Despite considerable success, progress 
is hampered by inadequate resources, the high prevalence of HIV in the country and the 
long waiting list for treatment. 
There is now a need to build upon the scope of cervical cancer prevention. This problem is 
not limited to Botswana as many African countries have similarly inadequate resources to 
treat patients even when abnormal cervical cytology is detected (sSACCWG 2010). Training 
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curricula of nurses and medical students need to be revised to include more practical 
cervical cancer screening skills. There is need to change attitudes that screening is only for 
gynaecologists. For opportunistic screening to work, health workers in other departments 
need to be sensitised on the gravity of cervical cancer and to remember to refer all eligible 
women who come into their care for screening (Mutyaba 2006). Nurses in high income 
countries play a role in cancer prevention and participate in cervical cancer screening by 
carrying out Pap smear tests . Due to the lack of logistics and scarcity of gynecologists and 
pathologists in Sub Sahara Africa ,nurses could be used effectively in the prevention of 
cervical cancer, by being enabled to collect Pap smear tests specimen and using the visual 
inspection by acetic acid technique which is less costly and does not require high expertise 
(Urasa & Darj 2011). 
Facilitation of screening activities through the provision of more PAP smear facilities while 
the evaluation and adoption of non cytological based screening methods such as use of VIA 
and Lugols iodine and HPV DNA testing and ensuring wider coverage of screening 
activities is desirable. In developed area with low mortality rates from cervical cancer , it has 
long been established that organized screening programs has great impact on the reduction 
of cervical cancer mortality. Time trends in mortality from cervical cancer in Denmark, 
Finland, Iceland, Norway, and Sweden since the early 1950s were investigated in relation to 
the extent and intensity of organised screening programmes in these countries. In all five 
countries the cumulative mortality rates (0-74 years) fell between 1965 and 1982. In Iceland, 
where the nationwide programme has the widest target age range, the fall in mortality was 
greatest (80%). Finland and Sweden have nationwide programmes also; the mortality fell by 
50% and 34%, respectively. In Denmark, where about 40% of the population are covered by 
organised programmes, the overall mortality fell by 25%, but in Norway, with only 5% of 
the population covered by organised screening, the mortality fell by only 10%. The results 
support the conclusion that organised screening programmes have had a major impact on 
the reduction in mortality from cervical cancer in the Nordic countries.(Laara E et al., 1987) 
It has been established that cytologic screening programs that detect and treat precancerous 
lesions decrease mortality from cervical cancer in countries that have been able to achieve 
broad screening coverage at frequent intervals. However, in the majority of low-income 
countries like Sub Sahara Africa, cytologic screening has proven difficult to sustain, in large 
part because of its reliance on highly trained cytotechnologists, high-quality laboratories, 
and an infrastructure to support up to 3 visits for screening, colposcopic evaluation of 
abnormalities, and treatment. 
Several factors have led to an expansion of the options for cervical cancer control. First, the 
availability of reliable HPV DNA assays has led to numerous studies documenting its higher 
sensitivity for detecting precancerous lesions compared with a single cytology test. Second, 
recent studies suggest that alternate screening strategies that use HPV DNA testing or simple 
visual screening methods may be more practical in some areas of the world like Sub Sahara 
Africa. Third, regardless of initial screening test (e.g., cervical cytology, HPV DNA testing, 
simple visual screening), strategies that enhance the linkage between screening and 
treatment, and seek to minimize loss to follow-up, have the best chance of measurable 
success. Additionally, economic evaluations of these alternatives have concluded that they 
are promising (Goldhaber-Fierbat & Goldie 2006). It has been suggested that the most 
efficient and cost-effective screening techniques in low-resource countries include visual 
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from traditional healers and spiritual leaders. A good model for palliative care in Africa 
should therefore integrate the culture, beliefs and traditions of the people. Some countries 
are making efforts in this direction by incorporating traditional healers into mainstream 
medicine. However, a feasible, accessible, and effective palliative care is yet to be developed 
in sub-Saharan Africa. (Merriman & Kaur 2005).  
4.2 Improvements in outlook 
There is need to improve the outlook of this condition in Sub Sahara Africa. There should be 
improvement in attitude towards education needs of the populace so as to create and 
improve awareness and knowledge about the disease. Disease prevention requires social 
change, which in turn requires the participation of those for whom the change is intended, 
including demographic groups at high risk for disease, appropriate governmental 
authorities, and essential medical personnel. Both locally and globally, socio-political 
problems associated with sustaining working coalitions from groups with shared interests 
but competing incentives constitute critically important real-world obstacles to successful 
cervical cancer prevention and will remain so irrespective of the screening method(s) 
eventually used. In settings where health systems cannot afford to ignore such incentives, 
laboratory data constitute an essential yet sometimes overlooked fulcrum against which to 
leverage the social change required to preserve life (Suba et al., 2006)  
There is need for sensitisation of health workers about cervical cancer and importance of 
screening. Based on studies carried out in countries where organized screening is available, 
it is known that screening uptake can be influenced by cultural beliefs, the social position of 
women, characteristics of the health care system, the physician's attitudes towards screening 
and women's comprehension of the screening process. Embarrassments about undergoing a 
gynecological examination, fear of the procedure or belief that little can be done to prevent 
cancer are other factors that might decrease screening participation. Lower socio-economic 
background, lack of health insurance and low literacy also compromise participation in 
screening. Attending cervical cancer screening may have a negative connotation or stigma 
when it is combined with a gynecological examination and treatment for reproductive tract 
infections. The gender of health care professionals and limited time that they allocate to 
patient education may negatively influence screening participation as well. Other influences 
that may influence participation in screening in particular in low resource countries are 
gender imbalances and whether illness is perceived as traditional or modern. Adequate 
knowledge about cervical cancer influences early detection and treatment seeking pattern 
(Mutyaba et al., 2007). In Botswana a national cervical cytology screening committee was 
formed in 1996 with a role in planning and advising the government. Just six years later a 
national guidance document for the national cervical cytology programme was drawn up 
and implemented. In this short space of time public awareness has been successfully raised 
resulting in an increased uptake of Pap smears from 5000 per year before the start of the 
programme to an impressive 32,000 per year in 2009. Despite considerable success, progress 
is hampered by inadequate resources, the high prevalence of HIV in the country and the 
long waiting list for treatment. 
There is now a need to build upon the scope of cervical cancer prevention. This problem is 
not limited to Botswana as many African countries have similarly inadequate resources to 
treat patients even when abnormal cervical cytology is detected (sSACCWG 2010). Training 
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curricula of nurses and medical students need to be revised to include more practical 
cervical cancer screening skills. There is need to change attitudes that screening is only for 
gynaecologists. For opportunistic screening to work, health workers in other departments 
need to be sensitised on the gravity of cervical cancer and to remember to refer all eligible 
women who come into their care for screening (Mutyaba 2006). Nurses in high income 
countries play a role in cancer prevention and participate in cervical cancer screening by 
carrying out Pap smear tests . Due to the lack of logistics and scarcity of gynecologists and 
pathologists in Sub Sahara Africa ,nurses could be used effectively in the prevention of 
cervical cancer, by being enabled to collect Pap smear tests specimen and using the visual 
inspection by acetic acid technique which is less costly and does not require high expertise 
(Urasa & Darj 2011). 
Facilitation of screening activities through the provision of more PAP smear facilities while 
the evaluation and adoption of non cytological based screening methods such as use of VIA 
and Lugols iodine and HPV DNA testing and ensuring wider coverage of screening 
activities is desirable. In developed area with low mortality rates from cervical cancer , it has 
long been established that organized screening programs has great impact on the reduction 
of cervical cancer mortality. Time trends in mortality from cervical cancer in Denmark, 
Finland, Iceland, Norway, and Sweden since the early 1950s were investigated in relation to 
the extent and intensity of organised screening programmes in these countries. In all five 
countries the cumulative mortality rates (0-74 years) fell between 1965 and 1982. In Iceland, 
where the nationwide programme has the widest target age range, the fall in mortality was 
greatest (80%). Finland and Sweden have nationwide programmes also; the mortality fell by 
50% and 34%, respectively. In Denmark, where about 40% of the population are covered by 
organised programmes, the overall mortality fell by 25%, but in Norway, with only 5% of 
the population covered by organised screening, the mortality fell by only 10%. The results 
support the conclusion that organised screening programmes have had a major impact on 
the reduction in mortality from cervical cancer in the Nordic countries.(Laara E et al., 1987) 
It has been established that cytologic screening programs that detect and treat precancerous 
lesions decrease mortality from cervical cancer in countries that have been able to achieve 
broad screening coverage at frequent intervals. However, in the majority of low-income 
countries like Sub Sahara Africa, cytologic screening has proven difficult to sustain, in large 
part because of its reliance on highly trained cytotechnologists, high-quality laboratories, 
and an infrastructure to support up to 3 visits for screening, colposcopic evaluation of 
abnormalities, and treatment. 
Several factors have led to an expansion of the options for cervical cancer control. First, the 
availability of reliable HPV DNA assays has led to numerous studies documenting its higher 
sensitivity for detecting precancerous lesions compared with a single cytology test. Second, 
recent studies suggest that alternate screening strategies that use HPV DNA testing or simple 
visual screening methods may be more practical in some areas of the world like Sub Sahara 
Africa. Third, regardless of initial screening test (e.g., cervical cytology, HPV DNA testing, 
simple visual screening), strategies that enhance the linkage between screening and 
treatment, and seek to minimize loss to follow-up, have the best chance of measurable 
success. Additionally, economic evaluations of these alternatives have concluded that they 
are promising (Goldhaber-Fierbat & Goldie 2006). It has been suggested that the most 
efficient and cost-effective screening techniques in low-resource countries include visual 
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inspection using either acetic acid or Lugol’s iodine and DNA testing for human 
papillomavirus (HPV) DNA in cervical cell samples (Sankaranarayanan et al., 2009 cited in 
Jemal A. et al., 2011) A recent clinical trial in rural India, a low-resource area, found that a 
single round of HPV DNA testing was associated with about a 50% reduction in the risk of 
developing advanced cervical cancer and associated deaths. The limitations of HPV DNA 
testing include the cost (i.e. US$20–30 per test), infrastructure, and time needed to obtain a 
result . However CareHPV (Qiagen Gaithersburg Inc., MD, USA) has been developed as a 
simple, rapid and operational HPV test for low-resource settings that can produce results 
within 3 h. The compact, portable and battery-operated technology has stable conditions, and 
the test can be conducted by workers with minimal training. Data from China showed that, 
compared to VIA, CareHPV has a higher sensitivity (90% vs. 41%) and a reasonably 
comparable specificity (84% vs. 94%) to detect high-grade lesions. Moreover, a modelling 
analysis found that CareHPV has the potential to reduce the incidence of cervical cancer by 
56% in China if given just three times over a woman’s lifetime and effective treatment is 
available, suggesting its potential impact in reducing the burden of invasive cervical cancer in 
comparable settings. Regulatory approval is anticipated in developing countries in the near 
future, and CareHPV test if provided at a low cost, represents a promising alternative 
screening test, however, its performance and diagnostic value to detect pre-cancerous lesions 
need to be evaluated in African settings (Louie et al., 2009). 
Widespread adoption of HPV vaccination to the recommended target population will 
reduce the disease incidence in the future. The vaccine is however seen to demobilize efforts 
towards setting up and improving screening services in places with poor screening 
coverage. The high cost of the vaccines is a constraint on low resource countries that have 
high incidence of the disease. It has been submitted that the vaccines if given to girls before 
onset of sexual activity, have the potential to dramatically reduce the incidence of HPV 
infection and therefore cervical cancer. Mclntyre, P. ( 2011) however also reported that one 
problem is that it is unlikely that the benefits will start to be felt in 15-20 years, and the full 
population impact will take 50 years or more to be felt. He is of the view that implementing 
an HPV Vaccination program is no substitute for organizing an effective screening system. 
The vaccine is of little value to the population of women who have already become sexually 
active as it cannot eradicate the virus if already present or retard the growth of incipient 
cancer. The report also noted that despite impressive results in clinical trials, they have not 
yet proven themselves in country programs. An example was the program in Romania 
where free vaccine was provided to girls 11 years old and a school – based campaign 
program of vaccination was started. It was reported that the take up rate was as low as 4%. 
Some parents prevented their daughters from getting vaccinated raising public health aspect 
issues towards high coverage and acceptance. The vaccine is therefore seen by some as a 
possible distraction from the main challenge as “the vaccine is not an alternative to cytology. 
We cannot fight cancer without regular cytology examination and that must be clearly 
stated” ( Chil, A., quoted in Mclntyre 2011) . The expectations that vaccines which primarily 
protect against the most common strains of HPV infections (HPV types 16 and 18), which 
cause about 70% of cervical cancers, may prevent cervical cancer worldwide are at present 
high. The vaccines have shown high safety, efficacy and immunogenicity for both the 
quadrivalent HPV 16  18  6  11 vaccine (Gardasil_, Merck & Co., Inc.) and the bivalent HPV 
16  18 vaccine (Cervarix_, GlaxoSmithKline Biologicals) (Schiller et al. 2008 cited in Louie Et 
al., 2009). A number of countries in sub-SaharanAfrica have licensed the HPV vaccines 
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(Table 3). However, implementation plans are lagging and will depend largely on the 
affordability of the vaccines, and a clear cost benefit ratio. However, affordable pricing is the 
most critical factor to facilitate the introduction of HPV vaccines in low- and medium-
resource countries like Sub Sahara Africa in the short term. It is also extremely important 
that women continue to receive screening services because the current vaccines are being 
given to adolescent girls only, and even vaccinated girls should begin screening when they  
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(Gardasil ® Merck, SA) 
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Table 3. HPV Vaccines licensure in Sub Sahara Africa as of March 2009 ( Source: HPV 
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HPV Prevalence
HPV type Any histology squamous cell carcinoma Adenocarcinoma unspecified 
6 0.4 0.2 0.0 1.4 
11 0.5 0.3 0.0 1.1 
16 51.6 53.4 36.5 49.4 
18 18.1 15.1 29.4 24.8 
31 2.5 2.8 0.0 2.3 
33 6.2 6.4 5.3 5.9 
35 4.1 2.5 1.5 8.4 
39 1.1 1.5 0.0 0.3 
45 9.1 8.3 8.2 11.3 
51 3.1 1.4 1.5 8.5 
52 3.4 1.9 0.0 8.7 
56 0.7 0.8 0.0 0.5 
58 1.3 1.1 0.0 2.4 
59 0.7 0.6 1.5 0.7 
66 0.6 0.6 0.0 0.8 
68 1.1 1.1 0.0 1.4 
70 0.1 0.0 0.0 0.0 
73 0.7 0.8 0.0 0.0 
82 0.0 0.0 0.0 0.0 
Table 4. Type – specific HPV prevalence among invasive cervical cancer cases in Africa by 
histology.( Source: WHO/IDC HPV information centre). 
reach the recommended screening age since the vaccines do not provide protection for the 
30% of chronic infections by HPV types other than HPV 16, 18, 6 and 11 that cause cervical 
cancer as shown in table 4 and that even in the recommended strains, protection is not 100% 
(Sankaranarayanan , 2009a, 2009b).  
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Prevention and early diagnosis through vaccination and screening requires effective 
mobilization of the target groups and this has been a problem in developing countries like 
the countries of Sub Sahara Africa. An approach to improve this has been formulated by 
Alliance for Cervical Cancer Prevention (ACCP) as follows. Since cultural and emotional 
barriers and practical needs are among the main reasons why women choose not to be 
screened, addressing these barriers and needs will help increase women’s awareness and 
willingness to seek services. Screening, treatment, and follow-up services need to address 
women’s cultural, emotional, and practical needs and concerns. 
Community involvement is essential for: Using a community-based education approach as a 
way of building a discourse with women and promoting women’s participation will help 
reduce fear and misunderstanding about cervical cancer screening and treatment and 
strengthen prevention knowledge and practices. Making women’s experiences with services 
more positive ensures greater follow-up rates and increases the likelihood that women will 
share information about their good experience with peers. Reducing their fear of screening 
and treatment Strengthening women’s understanding of prevention. Efforts in creating 
effective messages to improve women’s awareness is needed. Messages should be targeted 
to reach women at highest risk of cervical cancer (generally aged 30 -50 years). Women 
should be involved in creating prevention messages and programs. Recognized barriers to 
women’s participation in screening include: little understanding of cervical cancer, limited 
understanding of female reproductive organs and associated diseases , lack of access to 
services, shame and fear of a vaginal exam, fear of death from cancer, lack of trust in health 
care system, lack of community and family support. Common misconceptions about cervical 
cancer include the fact that people often do not know that it is preventable and the belief 
that screening involves Sexually Transmitted Infections (STI)/HIV screening including the 
belief that a positive/abnormal Pap smear result means a woman will die. In South Africa 
and Kenya, women often think a positive screening test means they have HIV infection 
While in Mexico, women fear that treatment will leave them sexually disabled. 
Direct personal contact can facilitate screening exercises. This can be done through 
community meetings, posters, pamphlet newspaper advertisements or articles and radio or 
television messages. Key sources of information include peers who have received messages 
or been screened, leaders or members of women’s groups, midwives and traditional healers 
,community health promoters, community leaders ,nurses, nurse practitioners, or doctors. 
The target groups have to be located. Places to reach women are local women’s groups 
community centres, women’s workplaces, places of worship ,health facilities, women’s 
homes, schools (parent’s groups) and markets and key cervical cancer prevention messages 
should include the facts that good health practices can help prevent cancer, cervical cancer 
develops slowly and is preventable, screening can detect treatable, precancerous lesions 
before they progress to cancer, women aged 30 and older are more likely to develop cervical 
cancer than younger women, women in their 30s and 40s should be screened and that the 
screening procedure is relatively simple, quick, and is not painful. A small number of 
women who need treatment after screening can receive a simple procedure to remove the 
lesion. Screening test that is positive is not a death sentence but it provides the opportunity 
to eliminate abnormal cells before they become cancerous 
Helping women discuss cervical cancer can bring the message home. This can be done 
through community health or outreach workers who can facilitate communication at the 
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community level. Counselling by health care providers can both inform women and help 
them talk to their families. Women who receive treatment for precancerous lesions and 
who must abstain from sexual intercourse for several weeks especially need good 
counselling 
To ensure women’s positive experiences with screening, there is need to build and maintain 
positive provider-client relationships. This is needed because women are more likely to 
participate when they are treated well, health care providers are sensitive, responsive and 
respectful. Health care providers should develop a respectful rapport with clients. Women 
with positive experiences will become advocates when talking to other women. 
Important counselling tips include listening and encouraging women to express their 
concerns being sensitive to cultural and religious considerations expressing support through 
non-verbal communication, such as nodding, keeping messages simple and answering 
questions directly, calmly, and in a reassuring manner and providing adequate information 
to remind them of the instructions. Services should be made accessible and appropriate 
through review of internal policies and procedures to ensure that programs are accessible 
and friendly to women. Having female health care providers in settings where women are 
uncomfortable with male health care providers, if possible can help. Ensuring affordability 
of the services and having settings that will ensure confidentiality and privacy including 
easy access to the women are essential. Local languages should be incorporated into the 
counselling medium. This can be done through involving women helps who can also assist 
in developing, implementing and evaluating programs and messages. Advisory team of 
women and other key community leaders can be consulted in order to deliver a package 
that will meet women’s cultural, emotional and practical needs. This is aimed at increasing 
women’s awareness of and willingness to seek services and improve women’s experience 
with cervical cancer prevention services in addition to increasing program participation 
among women at risk. 
High parity is associated with increased incidence of HPV infection leading to increased 
cases of cervical cancer. Most women in the region have high number of children resulting 
in worsening poverty and predisposition to the disease. Education on the need for reduced 
family size through the adoption of effective family planning methods can help in 
improving the general living condition of the people. This will eventually lead to sizeable 
population that can be easily reached with cervical cancer control programs. 
Onset of sexual activities among teenage girls in the sub region from the age of 15years is 
high . This predisposes such girls to high risk of cervical cancer. The promotion of use of 
condom early through sex education programs in early school days can also help in 
reducing the transmission of HPV in the sub region. Closely linked to this is the issue of 
circumcision which should be encouraged among those with low level of practice.  
Adoption of radiotherapy facilities based on less sophisticated technology like the Cobalt 60 
based teletherapy and brachytherapy equipments that give acceptable good treatment 
outcome can help in the treatment of those already diagnosed with the disease. At The 
University College Hospital, Ibadan Nigeria, cobalt 60 brachytherapy source is used for high 
dose brachytherapy services with satisfactory outcome. This has served the purpose and is 
quite economical as the source is changed every 5 years instead of every 4 months as the 
case with the more popular iridium 190 source.  
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The HIV epidemic in the sub region has further increased the problem of cervical cancer as 
those so infected have rapid progression of the disease and usually have poorer outcome. 
Efforts to improve the control of the infection will also lead to the reduction in the mortality 
of cervical cancer. 
4.2.1 Pre-requisites for cervical screening: Infrastructure, funding, training 
The following were the submissions of Oxford University’s Africa – Oxford Cancer 
Consortium (AFROX) meeting towards prevention of cervical cancer in Africa at St 
Catherin’s College Oxford in March 2009. The meeting was chaired by Professor David Kerr 
of Oxford University and Professor Fiander Alison of The University of Cardiff. The 
following were the suggested prerequisite towards setting up effective screening programs 
in the sub region. 
To set up a cervical screening programme, it is vital to address the associated infrastructure, 
funding and training needs. The delegates at this workshop recommended that it would be 
important for: 
 Screening to be free at point of service and ideally as close to the people as possible. 
 The health systems for African countries differ, and so a unique approach would be 
required for each country. However, each African Government should be lobbied to set 
aside a certain amount of money per year to carry out cervical screening. It would be 
important to have this recognised by a separate sub‐section of the national budget. 
Finding sustainable funding for screening programmes is important – one way to 
achieve this could be for donors to insist that they would only fund a cervical cancer 
screening programme if the government agreed to provide funding support for the 
programme to continue after set‐up funding ended. 
 Building up political will and support for national funding support towards cervical 
cancer screening would be required. The First Ladies of Africa could have an important 
role in leading this. In Nigeria, the Governors’ wives have been keen supporters of 
cervical cancer screening. Community advocates and the media would also need to be 
mobilised. These groups would also have a key role in raising public awareness about 
the causes of cervical cancer and why treatment would be important. 
 Records and documentation of those being screened should be kept so we can tell how 
often or if they go for screening. This would also help to monitor whether it was simply 
the same people getting screened, or if the programme was succeeding in reaching new 
women. 
 If possible, screening should be integrated into existing programmes, such as 
programmes for breast cancer screening, sexual health programmes, etc 
 Training of health professionals to take smear tests and/or HPV tests would be 
necessary. Training of pathologists to read smear tests would also be critical. 
4.2.2 Evaluation & cost effectiveness of cervical screening 
The participants of this workshop discussed how to evaluate and measure the cost 
effectiveness and success of cervical screening programmes. They identified the following 
areas as being critical for consideration: 
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1. Training 
- Are programs easy to staff? 
- Should pap smears be abandoned for developing countries due to lack of people to 
read them? 
- Work must be done by another health care level other than doctor – but problems 
arise when empowerment of lower personnel is met by resistance from doctors 
- Brain drain an issue – we must address the retention of health care personnel 
2. Cost 
- Need more interaction with health economists 
- Sustainability? 
- We must look into different financial flows, the idea of marketing campaigns and 
alternate financing schemes to raise substantial sums 
3. Coverage 
- Feasibility of “mother‐daughter” screening and vaccination project? 
- Feasibility of self‐screening? 
4. Political will 
- Need to sell a product to the policy makers? It is problematic to make a set of 
recommendations for African countries. The right screening depends on where you 
are. This is a highly heterogeneous environment and we can’t settle on a one‐size‐
fits‐all approach 
- Dogmatic decisions to be replaced by research‐based decisions…lobbying is good if 
it is on the basis of data. 
- Screening must be made part of a country’s health policy 
- Demonstration projects are a good way to show political leaders the efficacy of 
screening programs 
- Millennium Development Goals (MDG) goals 4 and 5 (reduction in child mortality 
and improvement in maternal health) are a useful platform to use – argue that HPV 
is part of maternal health. 
4.2.3 Creating a climate for informed decision-making in screening and vaccination 
The delegates at this workshop suggested the following steps should be taken, to create a 
climate of informed decision‐making about screening and vaccination programmes: 
 Informed consent has to be tailored appropriately to population. Informed consent 
means different things in different situations and with different people, so it has to be 
appropriate to population. 
 Screening should become part of routine care. 
 Policy makers are not yet aware of the cost/toll of cervical cancer in their countries. 
Consequently, the development of cancer registries is important. 
 Scientific evidence is important but a consensus statement can also be useful, for 
example from the world health organisation. 
 Need to show politicians that the impact of screening would be seen now. 
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 Survivors’ stories and the family stories of the women who have died of cervical cancer 
need to be told. Doctors and nurses should also tell stories about cervical cancer. We 
should not be afraid to tell individual stories; these are the ones that touch people. 
5. Conclusion 
Cervical cancer is still a problem in sub Sahara Africa. Concerted and focussed effort 
towards the reduction in the burden of the disease is urgently needed. The intensification of 
preventive, screening and therapeutic measures including education of the populace on 
these aspects can bring the disease under control as it is in the developed countries. Each 
country of Sub Sahara Africa should develop and implement sustainable preventive and 
screening programs using any of the available methods suitable and appropriate for their 
own setting instead of the present opportunistic screening activities prevalent in the region. 
Functional cancer registries are needed to analyze the pattern of the disease so as to help in 
planning control programs. There is also the need to address some of the conditions that 
predispose to practices that favor the development and spread of the disease. These 
conditions include poverty, illiteracy, political instability and widespread 
underdevelopment. 
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1. Introduction 
Cervical cancer is one of the most common cancers among women worldwide, currently 
ranked as the third cancer causing death for females (Ferlay et al., 2010). Since the screening 
programs have been implemented the incidence and mortality associated with cervical 
cancer have declined (Gustafsson et al., 1997) but in developing countries it still remains a 
cause of death in women.  
Although essential for the transformation of cervical epithelial cells, HPV is not sufficient, a 
number of other cofactors and molecular events being also incriminated (Woodman et al., 
2007). Cervical HPV infection is a sexually transmitted disease which occurs in women short 
time after beginning the sexual life. In young women, the disease is usually transient, its 
prevalence decreasing around 30 years (de Sanjosé et al., 2007). A second peak of infection is 
found in older women and is superposed to the peak of cervical cancer incidence (Anton et 
al., 2011). Near 40 of the more than 140 HPV types identified so far can infect the cervix 
(Bernard et al., 2010). Differences in carcinogenicity of cervix specific HPV types are 
partially related to the expression of the E6 and E7 oncogenes which, among other functions, 
interfere with tumour suppressor proteins p53 and pRb, respectively (Sinal et al., 2005). By 
these interactions viral oncogenes abrogate the mechanisms of cell-cycle control and 
apoptosis.  
As many studies sustain, in the absence of persistent infection the risk of cervical cancer is 
low (Schiffman et al., 2011). Persistent infection with high risk genotypes and the inability of 
the immune system to clear viral infection are the main factors contributing to tumors 
genesis. Thus, according to new concepts (Snijders et al, 2006), both the immune 
mechanisms of the host and the nature of infected cells are decisive for cervix lesions 
development. It takes 12-15 years before a hrHPV persistent infection may lead to cervical 
carcinoma, thus underlying the multistep process of cervical oncogenesis. Aberrant 
functions of tumour-suppressor genes as a result of their interaction with hrHPV viral 
genes, determine the genomic instability. These alterations cumulated with the action of 
various cofactors lead to progressive lesions and finally to cancer. The epithelial cells 
transformation is a 4 steps process, as proven by in vitro analysis: extended life span, 
immortalization, loss of anchorage and tumorigenic growth (Snijders et al, 2006). Each step 
is characterized by accumulation of (epi) genetic cell changes. 
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1. Introduction 
Cervical cancer is one of the most common cancers among women worldwide, currently 
ranked as the third cancer causing death for females (Ferlay et al., 2010). Since the screening 
programs have been implemented the incidence and mortality associated with cervical 
cancer have declined (Gustafsson et al., 1997) but in developing countries it still remains a 
cause of death in women.  
Although essential for the transformation of cervical epithelial cells, HPV is not sufficient, a 
number of other cofactors and molecular events being also incriminated (Woodman et al., 
2007). Cervical HPV infection is a sexually transmitted disease which occurs in women short 
time after beginning the sexual life. In young women, the disease is usually transient, its 
prevalence decreasing around 30 years (de Sanjosé et al., 2007). A second peak of infection is 
found in older women and is superposed to the peak of cervical cancer incidence (Anton et 
al., 2011). Near 40 of the more than 140 HPV types identified so far can infect the cervix 
(Bernard et al., 2010). Differences in carcinogenicity of cervix specific HPV types are 
partially related to the expression of the E6 and E7 oncogenes which, among other functions, 
interfere with tumour suppressor proteins p53 and pRb, respectively (Sinal et al., 2005). By 
these interactions viral oncogenes abrogate the mechanisms of cell-cycle control and 
apoptosis.  
As many studies sustain, in the absence of persistent infection the risk of cervical cancer is 
low (Schiffman et al., 2011). Persistent infection with high risk genotypes and the inability of 
the immune system to clear viral infection are the main factors contributing to tumors 
genesis. Thus, according to new concepts (Snijders et al, 2006), both the immune 
mechanisms of the host and the nature of infected cells are decisive for cervix lesions 
development. It takes 12-15 years before a hrHPV persistent infection may lead to cervical 
carcinoma, thus underlying the multistep process of cervical oncogenesis. Aberrant 
functions of tumour-suppressor genes as a result of their interaction with hrHPV viral 
genes, determine the genomic instability. These alterations cumulated with the action of 
various cofactors lead to progressive lesions and finally to cancer. The epithelial cells 
transformation is a 4 steps process, as proven by in vitro analysis: extended life span, 
immortalization, loss of anchorage and tumorigenic growth (Snijders et al, 2006). Each step 
is characterized by accumulation of (epi) genetic cell changes. 
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There is a continuing interest in the molecular mechanism of HPV oncogenic induction 
program, especially for clinicians who need new markers. Together with HPV DNA and 
PAP tests, these new markers may have additional value for risk assessment of cervical 
cancer and may reduce the number of biopsies. A major challenge for gynaecologists is to 
implement more markers in the routine practice, in order to have a better estimation of the 
risk a cervical lesion has to progress to cancer. Taking into account the contribution of 
oncogenic HPVs to malignant phenotype development by several interrelated mechanisms 
we evaluated the molecular markers (used in a variety of techniques) which might 
characterize different stages of HPV-associated epithelial lesions. The next step is to 
determine their suitability as "surrogate markers". In order to point host genes involvement, 
viral cell cycle has to be known. 
2. HPV life cycle 
All the HPV types infecting cervix are non-enveloped small sized viruses and have about 
8000-base pairs in their double-stranded circular DNA. Their genome has overlapped open 
reading frames, coding for eight proteins, divided into an early (genes E1-E7) and a late 
region (genes L1-L2). The early genes are expressed in the infected basal cells while the late 
proteins are synthesized only in well differentiated cells. The early proteins have regulatory 
functions, being involved in HPV genome replication and transcription, cell cycle, cell 
signalling and apoptosis control, immune modulation and structural modification of the 
infected cell (Molijn et al., 2005; Sinal & Woods, 2005).  
The replication cycle of HPV is tightly linked to differentiation of the epithelium it infects. 
For the initial infection to occur microlesions in the stratified epithelium are requested. 
Although some cell surface receptors have been mentioned, as heparin sulphate (Giroglou et 
al., 2001) and alpha-6 integrin, the controversy persists. It has been suggested that for a 
lesion to be maintained, the virus must infect an epithelial stem cell (Egawa, 2003). 
Following infection, in the basal cells of the epithelium, where low levels of viral early 
proteins (E1, E2, E5, E6 and E7) are observed, a low number of viral genome copies are 
maintained as episome. For viral DNA synthesis, beside E1 and E2 proteins that are 
necessary for viral replication, papilomaviruses use the host cell machinery. Viral 
transcription increases in differentiated cells while assembly of new virions occurs only in 
the squamous epithelia undergoing terminal differentiation. E4 is the first protein expressed 
late in infection and it may be accompanied by E5. The late proteins L1 and L2, are 
expressed in the granular layer of the epithelium and the assembled viruses are released 
from the fully differentiated cells. This pattern of gene expression is characteristic to 
productive infection and its pathological effect is specific for CIN 1 and some CIN 2 lesions. 
A deregulated E6 and E7 expression in proliferating cells and the interference of these viral 
oncogenes with tumour supressor genes p53 and pRB respectively, determine the cells to 
overcome senescence barrier and to develop a transformed phenotype (Fehrmann & 
Laimins, 2003). Recent studies have provided data on how different types of stimuli activate 
signalling pathways leading to senescence. It seems that these stimuli are funnelled through 
p53 and pRB (Narita et al., 2003) whose combined levels of activity determine the cells to 
enter senescence or to remain in a competent state for proliferation (Dirac & Bernards, 2003). 
Usually, the up-regulation of viral oncogenes expression is associated with viral genome 
integration into the host cell chromosome and with viral E2 gene disruption. Loss of the E2 
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leads to the uncontrolled expression of viral oncoproteins, which in turn leads to disruption 
of the normal cell cycle regulation and progres of HPV-associated cervical cancer (Hung et 
al., 2010). E6 and E7 oncoproteins are also required for the maintenance of the transformed 
status of infected cells (Longworth & Laimins, 2004). This pattern is characteristic for high 
grade CIN and carcinoma.  
In terms of HPV pathogenesis, depending on the HPV genotyope involved in the infections, 
there are three types of clinical manifestations: (a) productive infection, characterized by 
virions production and a strictly regulated expression of the viral genes at well defined sites. 
CIN 1 represents the histological manifestation of productive infections. (b) latent/inactive 
infection, rarely visible, without clinical signs (asymptomatic), characterized by 
maintenance of the viral genome in basal layers and early viral proteins expression at levels 
below those necessary to produce an effective immune response. Viral persistence may be 
the consequence of infection in case of immune system depletion and may result from 
silencing expression of viral gene through methylation (Kalantari et al., 2004). (c) abortive 
infection, as a precursor to cancer, is associated in particular with hrHPV genotypes which 
induce changes in virus-infected cells causing cancer. HPV-induced cancers often arise in 
sites which are non-optimal for productive infection. Low risk HPV types are only 
occasionally associated with mucosal cancers. 
3. Biomarkers – Indicators of the disease state 
According to Wentzensen and von Knebel Doeberitz (2007), there are several applications 
for the cancer biomarkers including: (1) early detection of cancers (identification of 
individuals prone to develop cancer at a time point that still allows for a successful curative 
intervention); (2) improved reproducibility of the histopathological diagnoses (allowing for 
risk assessment of detected lesions and stratify intermediate lesions); (3) surveillance of 
persons at risk (allowing for non-invasive monitoring or reduce invasive procedures); (4) 
post therapy monitoring (predicting the progression and monitoring recurrences after 
treatment).  
Approximately 80% of CIN1 lesions regress spontaneously (Follen and Richards-Kortum, 
2000) and usually are managed conservatively. On the other hand, CIN2 and CIN3 have a 
considerable risk of progression toward invasive cancer and are therefore usually treated by 
conization or other less invasive procedures. Anyway, despite its rather low rate of 
progression, CIN2 is frequently treated, fact that leads to contradictory discussions (Spitzer 
et al, 2006; Wright et al, 2003). In order to restrict treatment to CIN1/2 groups, there is a 
need for biomarkers that could discriminate between CIN1/2 with high risk of progression 
and those with high chance to regress spontaneously (Ozaki et al., 2011). Additional 
markers are also necessary to overcome diagnostic inaccuracies due to the existence of 
several CIN mimics, such as immature squamous metaplasia (Duggan et al, 2006; Geng et al, 
1999), or to heterogeneous distribution of dysplastic lesions that can result in over- and 
under-diagnosis.  
A hrHPV positive test without associated important cytological changes would always 
require monitoring. The risk of progression toward invasive cancer increases with the 
lesions’ grade (Ostor 1993), thus, biomarkers specifically associated with disease 
progression, allowing for a correct triage must improve the cervical cancer screening 
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status of infected cells (Longworth & Laimins, 2004). This pattern is characteristic for high 
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there are three types of clinical manifestations: (a) productive infection, characterized by 
virions production and a strictly regulated expression of the viral genes at well defined sites. 
CIN 1 represents the histological manifestation of productive infections. (b) latent/inactive 
infection, rarely visible, without clinical signs (asymptomatic), characterized by 
maintenance of the viral genome in basal layers and early viral proteins expression at levels 
below those necessary to produce an effective immune response. Viral persistence may be 
the consequence of infection in case of immune system depletion and may result from 
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infection, as a precursor to cancer, is associated in particular with hrHPV genotypes which 
induce changes in virus-infected cells causing cancer. HPV-induced cancers often arise in 
sites which are non-optimal for productive infection. Low risk HPV types are only 
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According to Wentzensen and von Knebel Doeberitz (2007), there are several applications 
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programs and the early detection of people at risk. Therefore, in order to be useful, the 
biomarkers must meet the following criteria: (1) they must be differently expressed in 
normal and high-risk tissues; (2) they should be synthesised in a well defined stage of 
carcinogenesis; (3) both the marker and its assay must be acceptable sensitive, specific and 
accurate; (4) they should be easily measured; (5) they should be correlated with a decrease in 
the cancer incidence rate (Follen and Schottenfeld, 2001). The inherent variability in 
interpretation between individuals has led to wide ranges in diagnostic precision between 
practices, but the advent of immunohistochemistry and the more recent discovery of new 
genes and their functions have resulted in the identification of cellular proteins that are 
differently expressed in tumours (Nucci et al., 2003).  
3.1 Cell cycle regulation markers 
The loss of cell-cycle control by HPV oncoproteins directly or indirectly interacting with the 
host genes (Giannoudis et al., 2000) leads to accelerated proliferation mirrored by an 
increased number of cells expressing specific markers. Among cyclins and cyclin dependent 
kinases (CDKs) that governed cell cycle, p53, Rb and CDK inhibitors (p15, p16, p18, p19, 
p21, p27) play a special role by arresting the cell cycle until damaged DNA is completely 
repaired. Therefore, the cell cycle regulators may shed light on the understanding of HPV-
mediated cervical carcinogenesis (Conesa-Zamora et al., 2009).  
The roles played by cyclins and CDKs in distinct phases of the cell cycle, suggest that they 
could be used as markers for cell proliferation in cervical malignancy (Skomedal et al., 1999).  
The ability of HPV oncoproteins to disrupt growth regulatory proteins may have effects 
on the cyclin-dependent kinase inhibitors linked to the G1- and G2- checkpoints. As 
mentioned before, cell cycle deregulation in cervical carcinogenesis is by far linked to p53 
and pRb. The degradation of p53 tumour-suppressor gene by E6 may result in 
accumulation of damaged DNA. By contrast with other cancers where p53 appears to be 
down-regulated by point mutations, in cervical cancer p53 expression seems to be 
increased; the levels of p53 in high-grade SIL (HSIL) and cervical carcinoma is higher than 
in low-grade SIL (LSIL) and normal cervix. There are authors who reported higher p53 
expression in cervical biopsy specimens from patients without HPV infection or who 
where infected with low-risk HPV (Tsuda et al., 2003). Conflicting results on this topic 
have been published: some studies showed a significant correlation of p53 expression 
with CIN 3 or carcinoma compared with normal cervix or LSIL (Bahnassy et al., 2007) 
whereas others showed no significant association. These results suggest that the absence 
of p53 immunostaining might be due to the capacity of some hrHPVs to down-regulate in 
different extent the p53 expression, probably via E6-induced ubiquitination. Over-
expression of p53 does not seem to be related to HPV oncoprotein action, as some authors 
noted higher expression of p53 protein in early lesions. These data support the hypothesis 
of a partially protective role of the wild-type p53 in the early stages of cervical lesions 
(Vassallo et al., 2000) and is correlated with the observation that high levels of p53 
expression are detected mostly in low-grade SILs (LSILs) and lrHPV-associated lesions 
(Kurvinen et al., 1996). Thus, p53 might function as a molecular marker for the risk of the 
progression of HPV-associated SILs. Øvestad et al, (2011) reported that CIN2–3 lesions 
regressed if higher epithelial pRb and p53 levels were present. Therefore, they proposed 
p53 and pRB as biomarkers. One paper noted that in HPV-positive or –negative low CIN 
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or ASCUS, in the majority of cases, p53 was overexpressed in the basal cell layer, thus 
presenting a positive response to viral infection or to the lesion (Cenci et al., 2005). A 
paper reported that the majority of CIN showed absent to focal staining while most of the 
invasive carcinoma showed regional to diffuse staining. A greater expression of p53 in the 
malignant cervical neoplasms than in the pre-malignant cervical lesions was noted, 
suggesting that p53 overexpression is not an early phenomenon in cervical cancer (Tan et 
al., 2007). p53 control the G1 transition to S phase and its abrogation affect the expression 
of p16, p21 and p27 cyclin inhibitors. p21, p27 and p57 CDK inhibitors inhibit the 
cyclin/CDK2, CDK4 complexes and causes G1 arrest. The levels of these proteins are of 
prognostic significance in cervical oncogenesis. p27 might be inactivated early in 
carcinogenesis by E7 hrHPV and may precede tumor invasion (Zur Hausen, 1994).  
p16 is a tumor suppressor protein belonging to the family of INK4 cyclin-dependent-kinase 
inhibitors whose increased expression has been associated with HPV-infected dysplastic 
and neoplastic epithelium of the cervix. p16 expression is the result of negative feedback on 
functional inactivation of pRb by E7 HPV (Zur Hausen 1994). p16 protein normally acts like 
a negative regulator of cellular proliferation, but its inhibitory action is not efficient in the 
case of proliferating hrHPV infected cells (Dray et al., 2005). Most studies confirm p16 
overexpression in all HSIL lesions but also in some normal epithelium of cervix at both 
protein (von Knebel Doeberitz et al., 2002) and messenger levels (Bleotu et al., 2009). On the 
other hand, p16 is not expressed in cervicitis nor is in squamous metaplasic epithelium (in 
the absence of CIN stages) (Hu et al., 2005). Still, other studies proved that p16 high level 
was found in cervical glandular epithelium and also in metaplasic epithelium. Therefore 
immunohistochemical analysis of p16 is considered a powerful tool in the identification of 
HPV-mediated premalignant and malignant lesions of the uterine cervix. Cytoplasm 
predominant localization of p16 seems to be related to the increasing histological grade of 
cervical lesion (Horn et al., 2006). Yldz et al. found strong and full thickness staining for 
p16 in the cervix epithelium in HSIL lesions and weak and basal/rare staining in LSIL. All 
hrHPV-positive cases were p16-positive, but no statistically significant relationship between 
HPV infection and the intensity and distribution of p16 was found (Yldz et al., 2007). 
Depending on the positive cells distribution, there have been recognised four patterns of p16 
staining which correlate to the lesion’s grade (Kostopoulou et al., 2011). 
Cyclins such as cyclin D1 are subjected to molecular alterations that characterize cervical 
carcinoma. Cyclin D1 forms a complex with CDK4 or CDK6 to carry out the 
phosphorylation of pRb. The phosphorilation of pRb leads to the release of the 
transcriptional factor E2F which, in turn, induces the expression of proteins required for S 
phase. Since D type cyclins and E7 HPV possess similar binding regions for pRb and pRb 
related pocket proteins, inactivation of pRb either by the cyclin/CDK complexes in G1 or by 
interaction with the E7 hrHPV may result in a decreased expression of cyclin D1. There are 
controversial results on the role of cyclin D1 in cervical carcinogenesis and clinical outcome 
(Goia et al., 2010). Although some studies reported no correlation between the expression of 
D1 cyclin and dysplasia (Goia et al., 2010) some authors associated overexpression of cyclin 
D1 with a poor prognosis in cervical carcinoma (Bae et al., 2001). An increase in cyclin D1 
expression was observed from CIN 3 to invasive carcinoma as a consequence of the inability 
of overexpressed p16 to inactivate CDK4/6, the partner of cyclin D1. The authors suggested 
that the immunohistochemical expression of cyclin D1 might be a marker in cervical cancer 
progression only if restricted beyond to the lower third layer (Conesa-Zamora et al, 2009). 
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Moreover, cytoplasmic staining is more noticeable in the basal and parabasal layers, 
suggesting a recently acquired alteration related to a high-grade dysplasia and the 
progression of the disease (Baldin et al., 1993). A significant increase in the cytoplasmic 
staining associated with an increasing degree of dysplasia was reported by Carreras et al. 
(2007) due to the fact that the number of cells in the S phase increases in severe lesions. This 
finding gives support to the cytoplasmic expression of p16 in lesions of higher grade since 
p16 is the inhibitor partner of cyclin D1 and they often appear together (Zhao M., et al., 
2006). The relationship between cyclin D1 expression and an increasing degree of dysplasia 
was not as remarkable as that seen for p16 but was statistically significant. 
Cyclin B1 complexes solely CDK1 (cdc2) to form the mitosis-promoting factor, which 
regulates the G2–M transition and is the primary regulator of mitosis. p53 was shown to 
prevent the G2–M transition by decreasing cyclin B levels. Some authors reported 
significantly cyclin B1 expression in invasive cervical cancer than in normal cervical tissue 
(Zhao P., et al., 2006).  
Cyclin E is expressed and associated with CDK2 near the G1-S boundary. Cyclin E 
hyperexpression is related to pRB inactivation by E7HPV but can not be correlated with 
hrHPV types. Recent studies have shown that cyclin E antigen correlates with the presence 
of HPV in atypical squamous epithelial cells. The association is stronger in LSIL, thus 
recommending this potential biomarker as a useful tool in distinguishing between 
benign/reactive changes from preneoplastic squamous atypia (Weaver et al., 2000). Much 
more common in cervical lesions versus non-neoplastic epithelium, cyclin E sensitivity may 
hamper its use as a marker (Crum, 2000). Other authors consider cyclin E together with p16 
as the most sensitive tools for LSIL and HSIL detection respectively (Keating et al., 2001). In 
ThinPrep samples, cyclin E and p21 expression seems to correlate better with HSIL (Moore 
et al., 2005). The Cyclin E/CDK2 complex phosphorylates p27, tagging it for degradation, 
thus promoting expression of cyclin A with progression toward the S phase. A close 
association between hrHPV and cyclin A1 was noted (Goia et al, 2010). This could be 
explained by its complex up-regulation by both E7 and E6 oncoproteins, making cyclin A 
active in both S phase and late G2 phase of the cell cycle. Cyclin A1 might be a useful 
marker of cell proliferation most notably orchestrated by the capability of E7 to abrogate the 
inhibitory activity of p21CIP1/WAF1/SDI1 on CDK and proliferating cell nuclear antigen–
dependent DNA replication necessary for the G1-S transition (Erlandsson, F. et al, 2006). 
Studies on cyclin A as prognostic marker are limited.  
Immunohistochemistry investigation of several cell markers (cyclin D1, cyclin E, CDK4, p53, 
mdm-2, p21, p27, p16, Rb and Ki-67) revealed that aberrations involving p27, cyclin E, CDK4 
and p16 are early events in HPV 16 and 18-associated cervical carcinoma, whereas cyclin D1 
and p53 pathway abnormalities are considered late events. Therefore, the authors 
considered that immunohistochemical tests for p16 and cyclin E could be useful in early 
diagnosis of cervical carcinoma (Bahnassy et al., 2007). 
E7 HPV binds to and blocks the function of p21 and p27 in a p53-independent manner 
(Zehbe et al., 1999). Both p21 and p27 are involved in cell cycle arrest through binding to G1 
phase cyclin–CDK complexes. E7 hrHPV modulates the cytoplasmic localization of p27 and 
inhibits p21 function. Some studies showed that p21 immunoreactivity seems to be 
significantly correlated with high grade stage of cervical disease. The protein was reported 
to be significantly increased in CIN3 and in situ carcinoma. On the other hand, p27 was 
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reported to decrease from normal cases to carcinoma (Cheung et al., 2001). On the other 
hand, Huang et al. (2010) reported that p21 expression decreased in HPV 18 positive 
carcinomas. The fact that aberrant expression of p27, cyclin E and p16 are early events in 
carcinogenesis (while p21 occur late in cervical carcinogenesis) might be of interest for early 
diagnostic and for monitoring patients with cervical dysplasia (Bahnassy et al, 2007). No 
established relationship was found between p27 expression and cell proliferation in cervical 
cancer (Kumar & Verma, 2006).  
3.2 Proliferation markers 
Those cells with high proliferative activity that allow the accumulation of transforming 
mutations are more likely to be associated with premalignant and malignant tissues. The 
proliferative aspects distribution in specific layers (basal vs. parabasal vs. superficial) might 
indicate growth-regulatory mechanisms; thus the relation between proliferation and growth 
deregulation is of interest (Heatley, 1998). Proliferation in the normal cervix, in cervical 
intraepithelial neoplasia and in invasive cervical carcinomas can be assessed by a range of 
techniques requiring technologies of varying sophistication and accessibility, considered in 
four broad groups (Heatley, 1998): (l) mitotic counts on routinely processed histological 
sections and cytological smears; (2) in vivo or in vitro incorporation of tritiated thymidine in 
actively proliferating cells, by injection into the cervix and by incubation with fresh tissue, 
respectively; (3) immunohistochemical techniques for Ki-67 labelling index and AgNOR 
counts; (4) flow cytometry.  
In the normal cervix, mitotic activity (quantified in routinely processed histological sections 
and cytological smears or by tritiated thymidine incorporation) is usually confined to the 
basal and parabasal layers, but in CIN the numbers and height of mitotic figures within the 
epithelium increases. The presence of mitotic figures is part of routine diagnosis and 
biomarker value is discussed as a whole.  
Flow cytometry DNA content analysis on minced biopsy specimens (Melsheimer et al. 2004) 
or smear (Tong et al., 2009) allow the association between aneuploidy and dysplasia degree. 
lrHPV types tend to be associated with polyclonal lesions whereas hrHPV types are 
associated with monoclonal lesions (Park et al, 1996). Ploidy appears to be a measurable 
biomarker and a good predictor of the biological behaviour with a better predictive value 
than the histopathologic characteristics (Follen and Schottenfeld, 2001). It is considered that 
in advanced dysplastic lesions, aneuploidy precedes HPV integration, further supporting 
the notion that integration of viral genomes is the consequence and not the cause of 
chromosomal instability and transformation (Melsheimer et al. 2004). Therefore, an 
increased aneuploid DNA value together with the increase in grades of cervical dysplasia 
are specific prognostic markers of malignancy (Kashyap & Das, 1998); flow cytometric 
analysis of DNA ploidy may be a potential means providing a strategic diagnostic tool for 
early detection of cervical cancer (Melsheimer et al. 2004). The combination of DNA ploidy 
(determined by cytometric test) with HPV screening and cytology is an optimal method to 
detect progressive lesions since it has the highest sensitivity and specificity (Singh et al. 
2008).  
Some proliferating molecules were investigated by immunohistochemistry like biomarkers 
in cervical precursor lesions: PCNA, Ki67, ICBP90, etc. 
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Ki-67 is a nonhistone protein expressed in the nucleus during the whole cell cycle, except 
for the early phases of G0 and G1. It constitutes a marker for proliferating cells and was 
associated with severe dysplasia and cervical cancer (Sarian et al., 2006). Ki-67 stains 
positive in the parabasal, basal and intermediate layers of condylomas, in the basal and 
parabasal layers of CIN; in addition, cells positive for Ki-67 staining are identified in 
intermediate and superficial layers of the squamous epithelium. Ki-67 expression 
correlates positively with histologic grade and distinguishes non-diagnostic atypia from 
SIL. The grade and pattern of Ki-67 expression in precursor lesions are still topics of 
debate (Vijayalakshmi et al., 2007). Even Ki-67 is not as specific as p16 for precancerous 
lesions, its immunohistochemical diffuse pattern is associated with a severe lesion. A lot 
of studies were conducted in order to establish the objective, reproducible, and reliable 
use of Ki-67 in the classification of dysplastic changes in cervical epithelium. Expression 
of Ki-67 (MIB-1) in the upper layers/superficial layers of the epithelium corroborated 
with more than 15% of basal cells positive for MIB-1 staining can be used to distinguish 
condyloma from inflammation or squamous metaplasia (Mittal and Palazzo, 1998). Ki-67 
evaluation can be also a valuable adjunct in the distinction of CIN from normal or benign 
cervical squamoepithelial lesions (Kruse et al., 2002; Keating et al., 2001). MIB-1 
expression in the basal and the upper-third layer proved useful in grading SIL with 
equivocal mitotic index (Popiolek et al., 2004). Immature squamous metaplasia can be 
MIB-1 cluster positive, but this false-positive case showed a special staining pattern, 
different from CIN: 1) MIB-1 staining in the nuclei is not diffuse (as in CIN) but clumped; 
2) positive nuclei are somewhat less densely packed than in CIN (Kruse et al., 2002). 
Noteworthy is that the presence of a cluster of at least two MIB-1-positive nuclei (MIB-C) 
in the upper two thirds of the epithelial thickness is a highly sensitive and specific marker 
to discriminate between normal epithelium and low-grade squamous intraepithelial 
lesion (Pirog et al., 2002). Cauterized dysplastic/condylomatous epithelium showed 
significantly greater expression of MIB-1 than cauterized normal epithelium, being a good 
marker (Mittal 1999).  
Recent studies showed that two cell cycle–related proteins, minichromosome maintenance 
protein-2 (MCM2) and topoisomerase II-α (TOP2A) are overexpressed in cervical cancer. 
Minichromosome maintenance protein 2 drives the formation of pre-replicative complexes 
in G1 phase; overexpression of MCM2 provides the link between oncogenic HPV infection 
and the molecular event of cervical dysplasia (Rihet et al, 1996). DNA TOP IIA is a nucleic 
enzyme that plays an important role in DNA replication, transcription, recombination, 
condensation, and segregation through interaction with the double-helix DNA (Ofner et al, 
1994). ProEx C is a cocktail of two monoclonal antibodies that targets the expression of these 
two proteins (MCM2 and TOP II A) and its increased expression is associated with HSIL 
lesions. The ProExC signal is intense, diffuse and comprises the entire thickness of the 
epithelium in HSIL, with a variable pattern of the staining in LSIL, and is usually negative in 
reparative or reactive immature squamous metaplasias (Pinto et al., 2010). ProEx C positive 
expression seems to be more specifically associated with SIL than Ki-67 positive expression 
(Conesa-Zamora et al, 2009). ProExC immunostaining, when compared with p16 
immunostaining, have similar specificity for CIN 2+ and higher specificity for CIN 3+ but 
lower sensitivity for CIN 2+ and CIN 3+ (Guo et al., 2011). Some reports suggested that 
ProExC can be more selective and informative for the progression of low-grade (CIN1) and 
moderate-grade (CIN2) lesions than Ki67 (Beccati et al., 2008). 
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ICBP90 protein is a member of a nuclear proteins family with DNA-binding properties 
involved in DNA replication. ICBP90 detection, used as a proliferation marker (Hopfner R, 
et al, 2000), gives information only concerning the number of cells that entered the cycle 
without any indication on the duration of the cycle. ICBP90 like Ki67 was linked to the 
development of an HSIL. 97.6% of HSILs positively stained for ICBP90; thus confirms it as a 
useful proliferation marker (Lorenzato et al., 2005). If an hrHPV type was present, the 
association of a suspect DNA profile with a positive proliferation marker could predict the 
presence of HSIL in a very accurate way. On the other hand the association of a suspect 
DNA profile with the presence of ICBP90-positive cells and MIB-1 in the upper two thirds of 
the epithelium could help to discriminate between an LSIL and an HSIL with high PPV, 
(Lorenzato et al., 2005).  
3.3 Markers of epithelial organization and differentiation 
The life cycle of human papillomaviruses (HPVs) is tightly linked to the differentiation 
program of the host's stratified epithelia that it infects. Viral infection induces changes in 
squamous differentiation, which is reflected by the pattern of cytokeratin polypeptide 
expression. By studying this pattern in relation with the presence of the virus, it was 
obtained an indication on the influence the virus has in individual cells, on the cellular 
differentiation. For example, E1-E4 contributes to different processes in both the early and 
late stages of the virus life cycle (Nakahara et al., 2005). The viral E1-E4 protein contributes 
to the replication of the viral genome as a nuclear plasmid in basal cells. Expression of the 
HPV-16 E1–E4 protein in human keratinocytes results in the total collapse of the cytokeratin 
matrix, but nuclear lamins and tubulin and actin networks are unaffected (Doorbar et al., 
1991). On the other hand, the presence of the skin-type cytokeratins CK1 and CK10 in 
condylomata accuminata derived from anogenital skin (HPV 6 and HPV 11 positive) was 
decreased, whereas CK13 and to a lesser degree CK4 appeared increased (Mullink et al., 
1991).  
HPV infection may alter the differentiation status of the epidermis leading to a major 
expression of K14 in the basal and suprabasal layers (like in HPV infected normal 
epithelium), up to the more superficial layers (like in epidermodysplasia verruciformis, EV) 
(Barcelos & Sotto, 2009). Comparing the morphologic distribution of cytokeratins 13 and 14 
and involucrin in naturally occurring low-grade SILs and high-grade SILs infected with a 
variety of HPV types, Southern et al., (2001) observed that: (1) the absence of cytokeratin 14 
expression is associated with high-risk HPV infection and occurs more frequently in high-
grade SILs; and (2) dedifferentiation, with loss of cytokeratin 13 or involucrin expression 
occurs only in high-grade lesions. Also, it was noted that in most LSILs infected with 
lrHPVs, cytokeratin 14 expression was present in all epithelial layers, with fewer lesions; the 
expression confined to the basal/parabasal layers with focal loss of expression. By contrast, 
only in few cases (11%) of LSILs infected with hrHPVs, cytokeratin 14 expressions was 
present in all epithelial layers; most of these lesions showed cytokeratin 14 expression 
confined to the basal/parabasal layers (56%), with a number of lesions showing focal loss of 
expression (33%) (Southern et al 2001). Loss/reduction of cytokeratin 14 protein expression 
level is associated with transformation but not immortalization because in HPV16 
immortalized keratinocytes downregulation of cytokeratin 14 occurred only at a 
transcriptional level (the protein level remaining normal) (Bowden et al, 1992). In 
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epidermodysplasia verruciformis CK1/10 showed retarded or negative expression and e-
cadherin is diminished in superficial koilocytotic cells' foci, more superficially in EV. 
Positive staining for K16 and K4 was observed in normal HPV infected epithelium as in EV 
(Barcelos & Sotto, 2009). 
Regauer & Reich (2007) found the following profile for the CK17: when antibodies against 
CK17 were used, the columnar endocervical epithelium showed no staining; basal 
keratinocytes in ectocervical glycogenated squamous epithelium have inconsistently, focally 
and weakly CK17 expression in cytoplasm; the proliferating cells of immature squamous 
metaplasia stain positive for CK17 in the subcolumnar reserve cells and in the proliferating 
basal and suprabasal cells, and negative for columnar cells; the mature metaplastic 
epithelium presents decreased or even lack of CK17 expression; high-grade dysplasia show 
concomitant staining of both CK17 and p16. They sustain a mutually exclusive 
immunohistochemical profile of CK17 and p16 that allows the separation of immature 
metaplasia with or without reactive atypia (characterized by strong, uniform CK17 staining 
of the proliferating cells with concomitant p16 negativity) from CIN III (characterised by 
strong diffuse staining of p16 in all dysplastic proliferating cells). The dual expression of 
CK17 and p16 in atypical squamous lesions with metaplastic features can sustain the 
hypothesis that CIN III alternatively may develop via HPV infection of metaplastic cells.  
Considering all these aspects, we can say that in order to establish the correct diagnostic, all 
potential markers involved in epithelial reorganization and differentiation must be 
synchronic evaluated with other proliferating markers.  
Plasma membrane expression of caveolin-1 (Cav-1), a constituent of lipid rafts and regulator 
of cell signalling, increases by the E5 HPV16 oncoprotein through the C-terminal 10 amino 
acids of E5. Moreover, E5 induces a 23- to 40-fold increase in the lipid raft component, 
ganglioside GM1, on the cell surface and mediates a dramatic increase in caveolin-1/GM1 
association, a potential mechanism for immune evasion by the papillomaviruses 
(Suprynowicz et al., 2008). This phenomenon is very important in productive infection, in 
production of viral progen. But, an inverse relationship between Cav-1 expression and 
transformation has been clearly established. Cav-1 levels are reduced in transformed cells 
and forced reexpression of Cav-1 could abrogate anchorage-independent growth in 
transformed cells (Williams & Lisanti, 2005). In HPV transformed cells, caveolin-1 is 
downregulated and its expression is reduce by E6 HPV (Razani et al, 2000). In a small 
percentage of cervical cancer tumors caveolin-1 silencing occurs via promoter methylation 
(Chan et al., 2003; Dueñas-González et al, 2005). 
E-cadherin is a transmembrane protein with a cytoplasmic domain connected to the actin 
cytoskeleton through association with cytoplasmic proteins, α-, β-, and γ-catenins 
(Piepenhagen & Nelson, 1993; Hinck et al, 1994). E-cadherin is essential for cell-to-cell 
junction and for cellular adhesion, being responsible for cellular interconnection, 
segregation of cell types, differentiation, epithelial polarization, cell stratification, signaling, 
cell motility and proliferation. Loss of E-cadherin function or expression has been implicated 
in cancer progression and metastasis. Down-regulation of E-cadherin was closely associated 
with progressive CIN and cell proliferation (Branca et al., 2006a) in HPV-positive tissue but 
not in the HPV-negative tissue (Samir et al., 2011). E-cadherin downregulation result in an 
increased cellular motility and metastasis.  
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Tissue transglutaminase 2 (TG2), member of calcium dependent enzymes family (Peng et 
al., 1999), is a cytosolic protein that catalyzes the formation of a covalent bond between the 
gamma carboxamide group of peptide bound to glutamine residue and the primary amino 
group of a wide variety of proteins leading to their post-translation modification (Boehm et 
al., 2002). TG2 induce polyamination of retinoblastoma protein, protecting it from caspase-
mediated cleavage (Boehm et al., 2002), but also of HPV E7 disruption (the interaction of 
HPV E7 and pRb is a major step for cervical carcinogenesis) (Jeon et al. 2003). 
TG2 levels in CIN1 are high, reflecting cellular response to inflammation and HPV 
infection and facilitating cell survival by its interaction with proteins involved in cell 
proliferation and cell death. In CIN2 and CIN3, the immunoreactivity for TG2 remains at 
moderately high levels, but typical for these cases, as compared with CIN1, it appears to 
be specifically expressed into nucleus. These nuclear translocations of TG2 in the high-
grade CIN were associated to cell survival or anti-apoptotic phenotype, and therefore aid 
the progression or persistence of the CIN lesion. TG2 is a potentially useful marker for 
low-grade dysplasia or CIN1 lesions because there are clear differences between normal 
and CIN1 epithelium. On the other hand, TG2 represents one potential biomarker due to 
the nuclear/nucleo-cytoplasmic staining of TG2 in high-grade dysplasia (CIN2/3); that 
type of staining is not observed in normal cervical epithelium or generally in CIN1 lesions 
(Gupta et al., 2010).  
3.4 Transcription factors and cell signalling pathway 
Transcription factors are the principal modulators of gene expression and are involved in 
various processes controlling normal and transformed cell behaviour. Viral transcription is 
known to be positively regulated by glucocorticoid hormones via the up-stream regulatory 
region, which may partly explain its contributing effect to the transformation (Gloss et al, 
1987; Mittal et al, 1993). However, in the complex picture of cervical cancer, hormone actions 
represent only one cofactor of HPV transformation. Thus, whatever the mechanism leading 
to carcinogenicity, there is a complex activation of transcription factors.  
Previous studies demonstrated a functional involvement of the AP1 transcription factor in 
HPV-induced cervical carcinogenesis. Transcriptional activation of HPV in a keratinocyte-
specific manner, depend on specific interaction between several nuclear factors and specific 
sites from LCR of certain HPV genotype. AP1 appears to be a common regulator of various 
HPV types expression, which act directly or through additional HPV type-specific that 
cooperate with AP1 to achieve full activation of virus gene expression (Butz & Hoppe-
Seyler, 1993; Mack & Laimins, 1991; Kyo et al., 1995; Chan et al., 1990; Chong et al., 1991). 
Transcriptional regulation of HPV16 is activated also by NF1, TEF- 1, TEF-2 and Oct1 factors 
(Chan et al., 1990; Chong et al., 1991; Ishiji et al., 1992).  
In HPV productive infection, E6/E7 transcripts were found to be expressed in most cellular 
layers with a reduced level of expression in the differentiated cells. E6/E7 expression was 
shown to correlate with AP1 factors distribution, suggesting that AP1 plays a significant role 
in the expression of viral oncogenes in uterine cervix differentiating epithelia. Co-expression 
of two proliferation inductors, AP1 and E6/E7, in undifferentiated cell layers might create a 
positive regulatory loop, contributing to the maintenance of initial HPV infection and 
subsequent activation in basal and suprabasal cellular layers (Kyo et al., 1997). 
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Aiming to obtain information about alterations in the expression of AP1 family members, de 
Wilde et al. (2008) found that, starting from immortal stages, c-Fos, Fra-2 and JunB 
expression became up regulated towards tumorigenicity while Fra-1, c-Jun, Notch1, Net and 
CADM1 became down regulated. They established that if the onset of deregulated 
expression of various AP1 family members became already manifest during the immortal 
state, a shift in AP1 complex composition appeared as a late event associated with 
tumorigenicity (de Wilde et al., 2008).  
Nuclear factor-kappa B (NF-kB) is a ubiquitously expressed transcription factor, which has 
an important role in intracellular regulation of immune response, inflammation, and cell 
cycle regulation (Nair et al., 2003; Niederberger & Geisslinger, 2010; Hayden & Ghosh, 
2011). NF-κB is one of the targets through which HPVs could interfere with the 
transcriptional control in cervical carcinogenesis (Spitkovsky et al., 2002; Fontaine et al., 
2000). The oncogenic HPVs action on NF-kB through several ways: 1) there is a functional 
NF-kB binding site within the HPV16 LCR (long control region), at position 7554–7563, 
acting as an effective repressor of HPV transcription (Fontaine et al., 2000); 2) involvement 
of viral oncogene: hrHPV E7 inhibits NF-kB activation and nuclear translocation and 
prevents its binding to the responsive DNA elements, e.g. the LCR of hrHPV. On the other 
hand, hrHPV E6 inhibits NF-kB (p65)-dependent transcriptional activity within the nucleus, 
thus further contributing to the escape of hrHPV from the transcriptional control of NF-kB 
(Spitkovsky et al., 2002; Nees et al., 2001). Thus, NF-kB is one of the targets through which 
these HPVs could interfere with the transcriptional control in cervical carcinogenesis.  
Using immunohistochemistry it was demonstrated that NF-kB is constitutively activated in 
high-grade CIN (Nair et al., 2003). In term of stain pattern, the intensity of cytoplasmic NF-
kB expression increased along with the increasing grade of CIN, being most frequent in 
invasive carcinomas. There was no detectable nuclear NF-kB expression in the normal cervix 
or CIN1 and CIN2 lesions; an intense nuclear expression appears very rare, even in CIN3 
and cervical cancer and is related to hrHPV (Branca et al., 2006b). Like biomarker, 
increased/normal cytoplasmic NF-kB expression can distinguish CIN with high specificity, 
but low sensitivity. On the other hand, the nuclear expression suffers from lower sensitivity. 
Studies accomplished by Branca et al, (2006b) clearly demonstrated that neither cytoplasmic 
nor nuclear NF-kB staining is a significant predictor of the clearance/persistence of hrHPV 
types after treatment of CIN.  
The ERK/MAPK cascade has been reported to be activated in cervical cancer cell lines both 
by hrHPV and by some low-risk HPV types. In normal squamous epithelium of the cervix 
as well as in metaplastic squamous cells, Branca et al (2004) found weak cytoplasmic ERK1 
expression confined mostly to the parabasal layers. Intranuclear staining is detected in CIN 
lesions that increase in both intensity and extent towards higher grade CIN lesions.  
ERK1 expression showed poor specificity for predicting hrHPV, and do not have a practical 
value as a predictor of hrHPV in cervical cancer and its precursors. Although E5 HPV seems 
to mediate overexpression and activation of the ERK/MAPK signalling cascade, multiple 
other mechanisms that mediate the activation of ERK/MAPK pathways might be involved. 
Despite the fact that ERK1 expression seems to be an early marker of cervical carcinogenesis, 
it is not a specific marker of hrHPV in CIN and cervical cancer, and does not predict disease 
outcome in the latter. 
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3.5 Apoptotic markers 
Apoptosis or programmed cell death is initiated by two types of biological signals: (1) 
extrinsic - the specific ligands activate their receptors (Fas-Fas ligand interaction) and (2) 
intrinsic – mitochondrial pathway used in response to non-specific stimuli (such as 
alteration of DNA, radiation and osmotic stress), leading to release of cytochrome c. Both 
paths lead to the activation of caspase 3.  
In HPV infected cells, inhibition of apoptosis may be a mechanism to promote viral 
persistence (Kanodia, 2007). HPVs exhibit several mechanisms for overcome the apoptotic 
program. E6 binding to p53 stimulates p53 degradation thus preventing p53-dependent 
apoptosis of infected cells. On the other hand, it suppresses FasL E5 mediated apoptosis and 
is associated with reduction to half of the Fas expression.  
Fas (APO-1/CD95) system regulates diverse physiological and pathological mechanisms 
for apoptosis. Interaction between Fas ligand and Fas receptor induces cell death, 
mechanism that could help to destroy HPV-infected keratinocytes. Facilitated cellular 
proliferation (Das et al., 2000), through reduced Fas mediated apoptosis has been 
described in cervical carcinogenesis by immunohistochemistry (Reesink-Peters et al., 
2005) and polymerase chain reaction (Das et al., 2000). On the other hand, the paracrine 
overproduction of Fas-L could facilitate tumour progression by inducing apoptosis of the 
immune cells usually expressing Fas in their membrane, such as CD8 and natural-killer 
cells. During HPV induced cervical carcinogenesis two Fas-related mechanisms may be 
taken into consideration: (a) suppression of apoptosis in infected keratinocytes by 
downregulation of Fas-R expression; and (b) active immunosuppression by Fas-L 
overproduction by tumor cells (Das et al., 2000; Griffith et al., 1995). Granular cytoplasmic 
and membranous Fas-R stains are identified by immunohistochemistry in the normal 
cervix, and their loss has been reported in approximately 50% of squamous intraepithelial 
lesion (SIL) and SCC (Jones & Munger, 1996; Lerma et al., 2008). Fas-R expression by 
tumor cells seems to be unrelated to the stage or quantity of the lymphoid infiltrate and it 
is a constitutive event independent of tumor progression (Lerma et al., 2008). Fas-L 
immunostaining in tumor cells is directly correlated with the tumor stages: 36.4% in stage 
I, 50% in stage II, and 75% in stage III, and inversely correlated with the presence of a 
florid lymphoid infiltrate. This suggest that Fas-L production by tumor cells results in 
decreased lymphoid cell reaction and might be a defence mechanism of the tumor against 
host’s immunity (Lerma et al., 2008). 
Bcl2 protein is localized in the mitochondrial membrane, the endoplasmic reticulum and in 
the nucleus. Bcl2 is an oncoprotein blocking cell apoptosis that can be induced by the 
absence of growth factors, alterations in DNA, viral infection, lymphokines action, cytostatic 
drug or radiation therapy. Its overexpression permits the malignant transformation of the 
cells and extends the survival potential of malignant cells. 
The prognostic value in predicting lesion progression is disputed. Guimarães et al., (2005) 
found by immunohistochemical techniques that expression of Bcl2 in HPV-infected cervical 
biopsies is not useful for predicting the progression of HPV-related SIL. On the other hand, 
Singh et al., (2009) noted cytoplasmic expression of Bcl2 protein in cervical dysplasia, a 
various intensity of immunoreactivity between different cytological grades of cervical 
smears and an association with the presence of HPV16/HPV18.  
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Follow-up data revealed that cases with high-risk HPV and co-induced expression of 
apoptosis-regulatory proteins presented a trend to progressive disease (Sing et al., 2009). 
These data confirm the observations of Fonseca-Moutinho et al., (2004), that Bcl2 is an 
independent factor in defining low risk of progression for CIN 3 and co-expression of 
estrogen receptor, progesterone receptor, and Bcl2 may be a useful tool in identifying the 
CIN 3 lesions with low risk of progression toward cervical cancer. Bcl2 has a more 
important value in cancer, the ratio of Bcl2 to Bax expression determining the survival or the 
death following an apoptotic stimulus. In order to establish a new predictor of the outcome 
of radiotherapy for human cervical carcinoma, Harima et al., (1998) established that the 
increased Bcl2 expression after radiotherapy is correlated with poor survival, while 
increased Bax expression after radiotherapy is correlated with good survival; these findings 
suggest that the levels of Bax and Bcl2 expression after radiotherapy are useful prognostic 
markers in patients with human cervical carcinoma (Harima et al., 1998). Some studies 
confirm that evaluation of Bax and Bcl2 expressions provide independent prognostic 
information for the clinical course of the disease and therefore could be developed as 
prognostic indicators for cervical cancer: Bax expression was associated with good survival 
while Bcl2expression was associated with poor survival, and combination of Bcl2+/Bax+ 
was significantly associated with poorer disease free survival (Wootipoom et al., 2004).  
3.6 Markers of chromosomal stability 
Cells that escape from senescence by gene inactivation continue to divide and suffer 
telomeres loss reaching the second proliferative block, stage 2 of mortality (M2); this is 
characterized by massive cell death caused by critical shortness of telomeres and telomeres 
dysfunction. The telomerase is a RNA-dependent DNA-polymerase that synthesizes 
telomeres DNA and provides molecular bases for unlimited proliferative potential. 
Telomerase activity is absent in most normal somatic cells but present in more than 90% of 
tumor cells and immortalized cells in vitro (Kim et al., 1994). Regarding cervical neoplasia, it 
is not clear whether telomerase is activated during the progression of this disease or 
whether HPV16 infection activates directly telomerase in vivo. Most studies on cervical 
tissue or cervical swabs indicate telomerase activation only after progression to 
intraepithelial lesion (Nowak, 2000). Taken together, in vitro and in vivo studies suggest that 
infection with HPV16 and the concomitant expression of E6 is associated with telomerase 
activation. Cervical lesions containing hrHPV in early stages does not present telomerase 
activity or present it at low levels (Nowak, 2000). Some results show that telomerase activity 
appears only when E6 is expressed at elevated levels. The hTERT expression (telomerase 
catalytic subunit) is in agreement with E6 hrHPV role in telomerase activation, but this 
association lost its significance due to strong association between hTERT and stage of 
intraepithelial lesion. One feasible explanation may be done by the recent experiments 
concerning the E6/ E7 dynamics and telomerase expression along with the progressive 
grades (Peitsaro et al., 2004). The initially high levels of E6 decrease dramatically, while 
hTERT mRNA expression and telomerase activity increase by 10 and respectively 4 fold. 
This means that the telomerase activation by E6 HPV is an early event and selection of 
clones with increased telomerase activity will lead to tumor progression and this intimate 
association with gradual lesions hides hTERT association with E6 hrHPV. Taking into 
account that HPV infections have been associated with cervical cancer, telomerase activity 
may be a central mechanism by which HPV infections can lead to malignant transformation 
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of cervical mucosa. Immunohystochemical studies on biopsy specimens have shown that 
normal epithelium is completely negative for hTERT or presents a profile scoring positive 
cells in parabasal layer. More positive cells were observed in the squamous metaplasia 
epithelium and sometimes in suprabasal metaplasia proliferating cells. Positive 
immunostaining was nuclear and limited to a few cells and stromal immunoreactivity was 
strictly associated to lymphocytes having constitutive hTERT expression. CIN lesions and 
cancer present a different pattern: hTERT-positive nuclei are present in all the layers of 
epithelium, but occasional cytoplasm expression can appear (Branca et al., 2006c). 
Paradoxically, there was a decrease in the nuclear staining intensity of hTERT in squamous 
cell carcinomas (Frost et al., 2000; Yan et al., 2004) with an increase in cytoplasm staining 
(Jarboe et al., 2002). Disturbance of the normal translocation mechanisms of hTERT to the 
nucleus, associated with cervical mucosa malignant transformation may be responsible for 
these differences in the expression pattern. Although it has been demonstrated that the loss 
of hTERT immunostaining may be associated with the deregulation of normal translocation 
mechanisms of hTERT to the nucleus, some authors suggest another mechanism involved in 
a reduced hTERT expression in human cancers: inactivation at the transcription level (Bleotu 
et al, 2010). The heterogeneity of both sensitivity and specificity in telomerase detection seen 
between different studies is due to: sample size (smear/lavage versus cervical biopsy), 
contamination with blood or necrotic cells (including telomerase inhibitors, which can lead 
to false-negative results) (Wang et al., 2004) or haemoglobin (a powerful inhibitor of PCR 
reaction). False positive results in strong inflammatory reactions may occur due to 
inflammatory infiltration. 
More recently, some epigenetic modifications were associated with cervix HPV infection. 
Modifications encompass three types of changes: chromatin modifications, DNA 
methylation and genomic imprinting, each of which is altered in cancer cell.  
Generally, HPV infections are followed by epigenetic changes such as methylation of viral 
genes or host genome. The pattern of HPV genes methylation varies depeding with the viral 
life cycle, the presence of disease and possibly the viral type. The de novo methylation of 
HPV DNA could be a host defence mechanism or a strategy that the virus uses to maintain a 
long-term infection, or both. Aberrant methylation of CpG islands in the promoter regions 
of tumour suppressor genes (TSG) is one of several epigenetic changes which contribute to 
carcinogenesis (Kumar & Verma, 2006). Viral oncogenes can induce tumor suppressor gene 
methylation following activation of DNA methyltransferases. For some genes, the 
prevalence of methylated forms increases with disease severity; for others, methylated 
forms are only detected in women with invasive disease. In a recent paper, aberrant DNA 
methylation was found as an early event in carcinogenesis and as an additional molecular 
marker for the early diagnosis. Among all studied genes, three were found as potential 
biomarkers of cervical cancer risk (hypermethylation of CDH13, DAPK1 and TWIST1 
promoters) (Missaoui et al., 2011).  
Aberrant methylation of the p16 gene occurs early within tumor cell populations. p16 is 
more frequently methylated in advanced tumors (Wong et al., 1999) thus suggesting that its 
reactivation could have therapeutic value. In a study performed on 62 cases of squamous 
cell carcinomas, Cheung et al showed that promoter methylation of PTEN was found in 58% 
of patients with persistent disease while those who died of the disease had a significantly 
higher percentage of PTEN methylation. Thus, PTEN was considered an important 
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Follow-up data revealed that cases with high-risk HPV and co-induced expression of 
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increased Bax expression after radiotherapy is correlated with good survival; these findings 
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intraepithelial lesion (Nowak, 2000). Taken together, in vitro and in vivo studies suggest that 
infection with HPV16 and the concomitant expression of E6 is associated with telomerase 
activation. Cervical lesions containing hrHPV in early stages does not present telomerase 
activity or present it at low levels (Nowak, 2000). Some results show that telomerase activity 
appears only when E6 is expressed at elevated levels. The hTERT expression (telomerase 
catalytic subunit) is in agreement with E6 hrHPV role in telomerase activation, but this 
association lost its significance due to strong association between hTERT and stage of 
intraepithelial lesion. One feasible explanation may be done by the recent experiments 
concerning the E6/ E7 dynamics and telomerase expression along with the progressive 
grades (Peitsaro et al., 2004). The initially high levels of E6 decrease dramatically, while 
hTERT mRNA expression and telomerase activity increase by 10 and respectively 4 fold. 
This means that the telomerase activation by E6 HPV is an early event and selection of 
clones with increased telomerase activity will lead to tumor progression and this intimate 
association with gradual lesions hides hTERT association with E6 hrHPV. Taking into 
account that HPV infections have been associated with cervical cancer, telomerase activity 
may be a central mechanism by which HPV infections can lead to malignant transformation 
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of cervical mucosa. Immunohystochemical studies on biopsy specimens have shown that 
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HPV DNA could be a host defence mechanism or a strategy that the virus uses to maintain a 
long-term infection, or both. Aberrant methylation of CpG islands in the promoter regions 
of tumour suppressor genes (TSG) is one of several epigenetic changes which contribute to 
carcinogenesis (Kumar & Verma, 2006). Viral oncogenes can induce tumor suppressor gene 
methylation following activation of DNA methyltransferases. For some genes, the 
prevalence of methylated forms increases with disease severity; for others, methylated 
forms are only detected in women with invasive disease. In a recent paper, aberrant DNA 
methylation was found as an early event in carcinogenesis and as an additional molecular 
marker for the early diagnosis. Among all studied genes, three were found as potential 
biomarkers of cervical cancer risk (hypermethylation of CDH13, DAPK1 and TWIST1 
promoters) (Missaoui et al., 2011).  
Aberrant methylation of the p16 gene occurs early within tumor cell populations. p16 is 
more frequently methylated in advanced tumors (Wong et al., 1999) thus suggesting that its 
reactivation could have therapeutic value. In a study performed on 62 cases of squamous 
cell carcinomas, Cheung et al showed that promoter methylation of PTEN was found in 58% 
of patients with persistent disease while those who died of the disease had a significantly 
higher percentage of PTEN methylation. Thus, PTEN was considered an important 
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significant predictor for both total and disease-free survival after controlling age, pathologic 
grade and clinical stage (Cheung et al., 2004). Another studied gene was E-cadherin which 
methylation frequency in cervical cancer varies between 28 and 80.5% (Widschwendter et 
al., 2004a). It appears that E cadherin methylation have prognostic significance, cases with 
no promoter methylation having a better outcome in univariate and multivariate analyses. 
New studies are focused on identification of the methylation status of several genes present 
in the serum or plasma of patients with cervical cancer with regard to their prognostic 
significance.  
In a study on 93 serum samples using the methyLight technique MYOD1 promoter 
methylation was strongly associated with shorter, disease-free and overall survival 
(Widschwendter et al., 2004b). Data suggesting that methylation of gene promoters in 
patients with cervical cancer is a common phenomenon have been reported. Strong 
correspondence between DAPK, p16, and MGMT genes methylation in serum and in 
primary tumors was noted thus allowing the discovery of a potential biomarker in sera. It 
has been found that parallel testing of HPV and PAX1 methylation in cervical swabs confers 
an improved sensitivity than HPV testing alone (80% vs. 66%) without compromising 
specificity (63% vs. 64%) for HSIL/SCC (Yang et al., 2003; Lai et al., 2008). When PAX1 
methylation marker is tested alone, the specificity for HSIL/SCC is 99%. These data 
encourage further studies to identify a set of methylated genes that would have prognostic 
significance as surrogate markers.  
Although the causal relationship between hrHPV infection and cervical cancer is 
demonstrated, HPV infection alone is not sufficient to induce the malignant transformation. 
Other genetic alterations, such as miRNAs, are required. MicroRNAs (miRNAs) are ~22 nt 
single-stranded, non-coding RNAs that generally negatively regulate their target mRNAs at 
a posttranscriptional level. The different expression of miRNAs in cervical cancer cells or 
tissues as compared with normal controls has been reported, and candidate miRNAs 
functioning as oncogenes (including miR-21, miR-127, miR-146a, miR-199a) and tumor 
suppressors (including miR-34a, miR-143, miR-145, miR-200a, miR-218) in cervical cancer 
carcinogenesis have been suggested (Lee et al., 2011 ). Using TaqMan MicroRNA Arrays, 
McBee and colab (McBee, et al, 2011) found that 18 miRNAs were overexpressed and 2 
underexpressed (miRs-218 and 433). Only five miRNAs (miR-21, miR-135b, miR- 223, and 
miR-301b) may have the potential to be used as markers for progression from dysplasia 
toward invasive cervical disease. Some miRNAs might be down regulated in cervical HPV 
infection through methylation (Botezatu et al., 2011).  
3.7 Markers of immune recognition 
HPV presents some features that allow a specific immune behaviour: bypass the immune 
response, persist in the lower genital tract, induce and promote the progression of cervical 
cancer. These characteristics are related to (i) preferential localization of intraepithelial HPV 
infection, (ii) the absence of viral infection on the impact keratinocytes, (iii) the ability of 
HPV to interfere with innate immunity, and (iv) the expression of late proteins antigens 
responsible for generating antibody response. The virus uses some mechanisms to evade 
immune system: (1) it maintain slow infection levels so that only a low amount of virus is 
exposed to the immune system; (2) it exploits the redundancy of genetic code; (3) it mimics 
host proteins; (4) it modulates the antigen presentation; (5) interfere with IFN; (6) inhibition 
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of cytokines and chemokine profile; (7) distortion of adhesion molecules; (8) modulation of 
adhesion molecules; (9) prevention of apoptosis; (10) inhibition of APC migration.  
Several studies have analyzed immunohistochemically different sub-types of immune cells 
in tumor tissue biopsies (TCD4, TCD8, TCD3, BCD20, CD45, CD57, CD68, etc.). The immune 
response to cervical neoplasia varies with the extension of the disease. In SIL, typically 
associated with persistent HPV infection and high viral load, the lymphocyte 
subpopulations percentages estimated by image analysis were 41% for CD4, 45% for CD8, 
7% for CD20, and 7% for CD56 (Kobayashi et al. 2004). Most researchers revealed the 
essential role intra-and peri-tumor cells play in the favourable development of cervical 
cancer, suggesting that certain survival predictors in cervical cancer relapse may be 
involved (Nedergaard et al., 2007, 2008). Such predictors are: inflammatory infiltrate (role in 
promoting long-term survival), low CD3 (role in predicting relapse), high CD8 cell density 
(involved in cervical cancer favourable prognosis) and low CD4 cell (involved in advanced 
stages of disease) (Nedergaard et al., 2007, 2008; Bell et al., 1995; Bethwaite et al., 1996; Chao 
et al., 1999).  
Cytokine profile distortion leads to inappropriate immune response, which may have 
immunosuppressive effects (failure to eliminate infection in host). HPV infections are focal 
and detection of systemic cytokine serum levels are not associated with the clearance or 
persistence of HPV infection (Hong et al., 2010). 
Evaluation of cytokines may predict high-risk HPV clearance or persistence in untreated 
patients with mild dysplasia or less. Among HPV-infected women, IFN-gamma is 
significantly associated with E6, E7 HPV16 and high-risk HPV viral load in the uterine 
cervix. Thus, increased intralesional IFN-gamma may be considered a prognostic marker for 
oncogenic potential of high-risk HPV (Song et al., 2007). The multivariate logistic regression 
analysis showed that IFN-gamma-positive results were significantly associated with 
clearance of high-risk HPV after 12 months of follow-up, suggesting that intralesional IFN-
gamma may be a prognostic marker for clearance of high-risk HPV (Song et al., 2008).  
Most studies regarding cytokine profiles in HPV associated cancers indicate that Th2 
cytokines correlate with progression toward invasive tumors (Bais et al., 2005). So, cervical 
tumors infiltrating lymphocytes have predominantly Th2/Tc2 polarity and regional lymph 
nodes seem to have a high proportion of T cells. However, this is due to the tumor rather 
than to the mechanisms of circumvention used by HPV. Comparing the cytokine profiles in 
cervical secretions of normal cervicitis, presenting or not HPV DNA, it were described high 
levels of IL-10 in HPV + samples (Azar et al., 2004). The early increase of IL-10 in cervical 
lesions can induce the inhibition of immune response against HPV infection. These data 
suggest that the cytokine profile distortion to an immunosuppressive profile can be induced 
by HPV and can cause the development of cancerous lesions (Kanodia et al., 2007). Several 
cytokines have been shown to reduce HPV transcription; this repression involves TGF-β, 
interleukin 1 and TNF-α (H. zur Hausen, 2002). TNF-α repression is lost during malignant 
conversion.  
4. Conclusions 
HPV associated cancer still remains a cause of death in women. Epidemiological studies and 
laboratory data confirmed that persistent infections with high risk human papillomaviruses 
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significant predictor for both total and disease-free survival after controlling age, pathologic 
grade and clinical stage (Cheung et al., 2004). Another studied gene was E-cadherin which 
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al., 2004a). It appears that E cadherin methylation have prognostic significance, cases with 
no promoter methylation having a better outcome in univariate and multivariate analyses. 
New studies are focused on identification of the methylation status of several genes present 
in the serum or plasma of patients with cervical cancer with regard to their prognostic 
significance.  
In a study on 93 serum samples using the methyLight technique MYOD1 promoter 
methylation was strongly associated with shorter, disease-free and overall survival 
(Widschwendter et al., 2004b). Data suggesting that methylation of gene promoters in 
patients with cervical cancer is a common phenomenon have been reported. Strong 
correspondence between DAPK, p16, and MGMT genes methylation in serum and in 
primary tumors was noted thus allowing the discovery of a potential biomarker in sera. It 
has been found that parallel testing of HPV and PAX1 methylation in cervical swabs confers 
an improved sensitivity than HPV testing alone (80% vs. 66%) without compromising 
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methylation marker is tested alone, the specificity for HSIL/SCC is 99%. These data 
encourage further studies to identify a set of methylated genes that would have prognostic 
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Although the causal relationship between hrHPV infection and cervical cancer is 
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single-stranded, non-coding RNAs that generally negatively regulate their target mRNAs at 
a posttranscriptional level. The different expression of miRNAs in cervical cancer cells or 
tissues as compared with normal controls has been reported, and candidate miRNAs 
functioning as oncogenes (including miR-21, miR-127, miR-146a, miR-199a) and tumor 
suppressors (including miR-34a, miR-143, miR-145, miR-200a, miR-218) in cervical cancer 
carcinogenesis have been suggested (Lee et al., 2011 ). Using TaqMan MicroRNA Arrays, 
McBee and colab (McBee, et al, 2011) found that 18 miRNAs were overexpressed and 2 
underexpressed (miRs-218 and 433). Only five miRNAs (miR-21, miR-135b, miR- 223, and 
miR-301b) may have the potential to be used as markers for progression from dysplasia 
toward invasive cervical disease. Some miRNAs might be down regulated in cervical HPV 
infection through methylation (Botezatu et al., 2011).  
3.7 Markers of immune recognition 
HPV presents some features that allow a specific immune behaviour: bypass the immune 
response, persist in the lower genital tract, induce and promote the progression of cervical 
cancer. These characteristics are related to (i) preferential localization of intraepithelial HPV 
infection, (ii) the absence of viral infection on the impact keratinocytes, (iii) the ability of 
HPV to interfere with innate immunity, and (iv) the expression of late proteins antigens 
responsible for generating antibody response. The virus uses some mechanisms to evade 
immune system: (1) it maintain slow infection levels so that only a low amount of virus is 
exposed to the immune system; (2) it exploits the redundancy of genetic code; (3) it mimics 
host proteins; (4) it modulates the antigen presentation; (5) interfere with IFN; (6) inhibition 
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of cytokines and chemokine profile; (7) distortion of adhesion molecules; (8) modulation of 
adhesion molecules; (9) prevention of apoptosis; (10) inhibition of APC migration.  
Several studies have analyzed immunohistochemically different sub-types of immune cells 
in tumor tissue biopsies (TCD4, TCD8, TCD3, BCD20, CD45, CD57, CD68, etc.). The immune 
response to cervical neoplasia varies with the extension of the disease. In SIL, typically 
associated with persistent HPV infection and high viral load, the lymphocyte 
subpopulations percentages estimated by image analysis were 41% for CD4, 45% for CD8, 
7% for CD20, and 7% for CD56 (Kobayashi et al. 2004). Most researchers revealed the 
essential role intra-and peri-tumor cells play in the favourable development of cervical 
cancer, suggesting that certain survival predictors in cervical cancer relapse may be 
involved (Nedergaard et al., 2007, 2008). Such predictors are: inflammatory infiltrate (role in 
promoting long-term survival), low CD3 (role in predicting relapse), high CD8 cell density 
(involved in cervical cancer favourable prognosis) and low CD4 cell (involved in advanced 
stages of disease) (Nedergaard et al., 2007, 2008; Bell et al., 1995; Bethwaite et al., 1996; Chao 
et al., 1999).  
Cytokine profile distortion leads to inappropriate immune response, which may have 
immunosuppressive effects (failure to eliminate infection in host). HPV infections are focal 
and detection of systemic cytokine serum levels are not associated with the clearance or 
persistence of HPV infection (Hong et al., 2010). 
Evaluation of cytokines may predict high-risk HPV clearance or persistence in untreated 
patients with mild dysplasia or less. Among HPV-infected women, IFN-gamma is 
significantly associated with E6, E7 HPV16 and high-risk HPV viral load in the uterine 
cervix. Thus, increased intralesional IFN-gamma may be considered a prognostic marker for 
oncogenic potential of high-risk HPV (Song et al., 2007). The multivariate logistic regression 
analysis showed that IFN-gamma-positive results were significantly associated with 
clearance of high-risk HPV after 12 months of follow-up, suggesting that intralesional IFN-
gamma may be a prognostic marker for clearance of high-risk HPV (Song et al., 2008).  
Most studies regarding cytokine profiles in HPV associated cancers indicate that Th2 
cytokines correlate with progression toward invasive tumors (Bais et al., 2005). So, cervical 
tumors infiltrating lymphocytes have predominantly Th2/Tc2 polarity and regional lymph 
nodes seem to have a high proportion of T cells. However, this is due to the tumor rather 
than to the mechanisms of circumvention used by HPV. Comparing the cytokine profiles in 
cervical secretions of normal cervicitis, presenting or not HPV DNA, it were described high 
levels of IL-10 in HPV + samples (Azar et al., 2004). The early increase of IL-10 in cervical 
lesions can induce the inhibition of immune response against HPV infection. These data 
suggest that the cytokine profile distortion to an immunosuppressive profile can be induced 
by HPV and can cause the development of cancerous lesions (Kanodia et al., 2007). Several 
cytokines have been shown to reduce HPV transcription; this repression involves TGF-β, 
interleukin 1 and TNF-α (H. zur Hausen, 2002). TNF-α repression is lost during malignant 
conversion.  
4. Conclusions 
HPV associated cancer still remains a cause of death in women. Epidemiological studies and 
laboratory data confirmed that persistent infections with high risk human papillomaviruses 
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(hrHPV) cause virtually all cases of invasive cervical cancer. Cofactors and additional 
molecular events are essential for the transformation of cervical epithelial cells. These events 
imply cell changes that can be quantified in order to evaluate the correct status of the 
disease. An ideal marker should be easy to assay in a not invasively collected sample and 
should have a good sensitivity, specificity, positive predictive value (PPV) and negative 
predictive value (NPV). To investigate the cancer risks associated with HPV infection, 
sensible tools to asses the risk hierarchysation are requested to be developed, since the 
cytological assessment alone is not sufficient to classify cervical dysplasia. Sometimes, in 
order to discriminate between productive and transforming infection, a combination of 
biomarkers is required. Such combination will allow a correct risks hierarchysation. 
Although there are many studies focused on new potential biomarker for cervical cancer, 
until now few are validated by the scientific community and health care units.  
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(hrHPV) cause virtually all cases of invasive cervical cancer. Cofactors and additional 
molecular events are essential for the transformation of cervical epithelial cells. These events 
imply cell changes that can be quantified in order to evaluate the correct status of the 
disease. An ideal marker should be easy to assay in a not invasively collected sample and 
should have a good sensitivity, specificity, positive predictive value (PPV) and negative 
predictive value (NPV). To investigate the cancer risks associated with HPV infection, 
sensible tools to asses the risk hierarchysation are requested to be developed, since the 
cytological assessment alone is not sufficient to classify cervical dysplasia. Sometimes, in 
order to discriminate between productive and transforming infection, a combination of 
biomarkers is required. Such combination will allow a correct risks hierarchysation. 
Although there are many studies focused on new potential biomarker for cervical cancer, 
until now few are validated by the scientific community and health care units.  
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1. Introduction 
In Japan, the elderly population has been rapidly increasing, and the “aging society” is 
currently considered one of the nation’s most important social concerns. According to 
statements by the Ministry of Health, Labour, and Welfare, the average life spans of men 
and women in 2008 were 79 and 86 years, respectively, and that of women in Japan is the 
longest in the world (Ministry of Health, Labour, and Welfare, 2009). The percentage of the 
elderly population in Japan will continue to increase. With the growing aging society, the 
number of elderly patients with various malignancies has been increasing. However, the 
rate of cancer in younger patients has also been increasing, due to changes in lifestyles, such 
as the increased popularity of Western food, viral infections, and genetic factors. In Japan, 
malignant neoplasms demonstrate the highest mortality rate, surpassing cerebrovascular 
and heart diseases since 1981, and lung cancer has demonstrated the highest mortality rate 
among every malignancy in both men and women. 
Cervical cancer affects a wide age demographic, but, recently, the prevalence of disease among 
young women has been emphasized. It is well known that the most common cause of cervical 
cancer is human papilloma virus (HPV). Sexual relationships in younger women with little 
knowledge of sexually transmitted diseases appear to be an important factor contributing to 
the prevalence of HPV infection. In Japan, the most commonly afflicted age group is women in 
their late 30s to early 40s. Cervical cancer is one of the most common forms of cancer women 
aged ≤ 39 years old. The prevalence rate decreases for women aged 50 to 60 years and 
increases again for women in their 70s. As a result of the aging society and re-increase of 
prevalence rate, the number of elderly patients with cervical cancer has been increasing in 
Japan. The number of elderly patients with cervical cancer in the Western counties with aging 
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1. Introduction 
In Japan, the elderly population has been rapidly increasing, and the “aging society” is 
currently considered one of the nation’s most important social concerns. According to 
statements by the Ministry of Health, Labour, and Welfare, the average life spans of men 
and women in 2008 were 79 and 86 years, respectively, and that of women in Japan is the 
longest in the world (Ministry of Health, Labour, and Welfare, 2009). The percentage of the 
elderly population in Japan will continue to increase. With the growing aging society, the 
number of elderly patients with various malignancies has been increasing. However, the 
rate of cancer in younger patients has also been increasing, due to changes in lifestyles, such 
as the increased popularity of Western food, viral infections, and genetic factors. In Japan, 
malignant neoplasms demonstrate the highest mortality rate, surpassing cerebrovascular 
and heart diseases since 1981, and lung cancer has demonstrated the highest mortality rate 
among every malignancy in both men and women. 
Cervical cancer affects a wide age demographic, but, recently, the prevalence of disease among 
young women has been emphasized. It is well known that the most common cause of cervical 
cancer is human papilloma virus (HPV). Sexual relationships in younger women with little 
knowledge of sexually transmitted diseases appear to be an important factor contributing to 
the prevalence of HPV infection. In Japan, the most commonly afflicted age group is women in 
their late 30s to early 40s. Cervical cancer is one of the most common forms of cancer women 
aged ≤ 39 years old. The prevalence rate decreases for women aged 50 to 60 years and 
increases again for women in their 70s. As a result of the aging society and re-increase of 
prevalence rate, the number of elderly patients with cervical cancer has been increasing in 
Japan. The number of elderly patients with cervical cancer in the Western counties with aging 
societies has also been increasing as in Japan. We should remember that a 77-year-old cervical 
cancer patient, for example, may live for 10 to 20 additional years if the disease is cured and 
that these elderly patients should be treated with radical modalities similar to those used on 
young patients to achieve successful outcome. However, treatment modalities should be 
selected carefully because of the high likelihood of toxicity from the treatment and concurrent 
medical problems, such as hypertension, diabetes mellitus, dementia, cerebral infarction, and 
other cancers. In the daily clinical setting, the opportunities for treating elderly patients with 
several concurrent medical problems are increasing. 
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The basic treatment modality for cervical cancer is a surgical approach or radiotherapy (RT). 
In general, surgery is performed for patients with early-stage cervical cancers. RT can be 
performed for the patients with early- to advanced-stage cervical cancer. Additionally, in 
the previous reports, the treatment results of surgery and RT for early-stage cervical cancer 
were similar (Landoni et al., 1997; Perez et al., 1995 and Yamashita et al., 2005). Furthermore, 
RT appears to be a less invasive modality compared to surgery. These facts indicate that RT 
is a more appropriate treatment for the elderly patient population. 
The aim of this chapter is to discuss the treatment modalities for elderly patients with 
cervical cancer with a focus on RT based on the knowledge from our experience and 
previous reports. 
2. Details of a standard RT method, including recommendations for elderly 
patients with cervical cancer and a review of treatment outcomes 
Selecting a treatment modality for elderly patients, cautious evaluation of their general 
condition, clinical staging, and concurrent medical problems are important because they 
usually do not tolerate treatment-related toxicity as well as do young patients. Inadequate 
treatment may result in lethal toxicity. Generally, RT is thought to be one of the most 
suitable modalities for preserving quality of life, and, therefore, RT is important for elderly 
patients. In this section, the general knowledge of clinical manifestations and pretreatment 
evaluation of elderly patients are described. Subsequently, the details of a standard RT 
method for cervical cancer, including recommendations for elderly patients, are illustrated, 
and the treatment outcomes of RT for elderly patients with cervical cancer are discussed.  
2.1 Clinical manifestations and pretreatment evaluation 
The most frequent and important clinical manifestation of cervical cancer is irregular 
vaginal bleeding. Other important clinical manifestations include bleeding during sexual 
activity, increase of vaginal discharge and lower-back pain. For advanced disease, the 
bleeding sometimes becomes severe, and blood transfusions are usually performed. Severe 
bleeding may have lethal results in elderly patients.  
Clinical staging is generally performed according to the International Federation of 
Gynecology and Obstetrics (FIGO) stages (Creasman, 1995). However, thoracic to pelvic 
computed tomography (CT) or pelvic magnet resonance imaging (MRI) must be performed 
in both elderly and younger patients. Additionally, positron emission tomography (PET) 
scans should also be performed, if possible. These imaging procedures are useful for clinical 
staging and are important for the determination of the treatment modality. Similarly, 
pretreatment evaluation, including concurrent medical problems and performance status, is 
also important because elderly patients usually do not tolerate treatment-related toxicity as 
well as do younger patients. Using these methods, adequate treatment modalities for elderly 
patients can be determined. 
2.2 Standard RT method for cervical cancer, including recommendations for elderly 
patients 
According to the Clinical Practice Guideline in Oncology from the National Comprehensive 
Cancer Network (NCCN) guidelines (National Comprehensive Cancer Network, 2011), RT 
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is recognized to be important in the definitive treatment. For FIGO stage IA2 disease, radical 
hysterectomomy (RH) + pelvic lymph node dissection (PLND) ± para-aortic lymph node 
sampling, or intracavitary brachytherapy (ICBT) ± pelvic RT, or radical trachelectomy + 
PLND ± para-aortic lymph node sampling is recommended. In addition, for FIGO stage IB1 
or IIA1, RH + PLND ± para-aortic lymph node sampling, or pelvic RT + ICBT, or radical 
trachelectomy for tumors ≤ 2 cm (stage 1B1) + PLND ± para-aortic lymph node sampling is 
recommended. These recommendations indicate that RT can be used in early-stage diseases, 
and its importance increases in advanced-stage diseases. In other words, RT can be used to 
treat cervical cancer at any stage, and it is the most important treatment modality for elderly 
patients. 
External beam radiotherapy (EBRT) combined with ICBT is the standard RT method for 
cervical cancer. For EBRT, patients were initially treated with whole-pelvic RT using a box 
field. The gross tumor, whole uterus, pelvic lymph nodes, parametria and uterosacral 
ligaments must be included in the RT field. Additionally, a sufficient vaginal margin from 
the gross disease (at least 3 cm) is necessary. In X-ray films, the superior limit is the upper 
border of the 5th lumber, and the inferior limit is the lower border of the obturator foramen 
for the anterior/posterior RT field. For the lateral RT field, the anterior limit is 
approximately 0.5 cm behind the pubic joint, and the posterior limit should involve the 
entire sacrum. In Japan, a centrally shielded field using an anterior/posterior opposed field 
is applied just before the starting ICBT subsequent to whole-pelvic RT to reduce the doses 
for organs at risk, especially the rectum and bladder. The daily fraction size of EBRT is 
approximately 1.8 to 2.0 Gy in general. The total dose of pelvic RT is 45.0 to 50.4 Gy. 
Although standard EBRT for cervical cancer is performed using a 3D technique, while a new 
RT method, which is known as intensity modulated radiotherapy (IMRT), has been 
expanding in many institutions. IMRT achieves the dose reduction of organs at risk, such as 
the rectum, bladder, colon, and small intestine, in the pelvic RT. Dose reduction for these 
organs will provide certain benefits, especially for elderly patients.  
ICBT using a distinctive dose prescription point known as “Point A” is performed to boost 
the primary tumor and is an indispensable procedure in the RT of cervical cancer. 
Traditionally, low-dose rate ICBT (LDR-ICBT) was usually used, but high-dose rate ICBT 
(HDR-ICBT) using a 192-iridium remote afterloading system has become favored over LDR-
ICBT. In Japan, most patients are treated with HDR-ICBT, and it is performed 3 to 5 times at 
1-week intervals during EBRT. Generally, the single fraction size of HDR-ICBT ranges from 
5.0 to 6.0 Gy, and the total dose is 15.0 to 29.0 Gy. Patients with higher stage diseases are 
usually treated with higher doses of whole-pelvic RT and lower doses of ICBT. Patients with 
lower-stage diseases are usually treated with higher doses of ICBT and lower doses of 
whole-pelvic RT. It is also important to reduce the doses for organs at risk in ICBT as well as 
EBRT. When performing ICBT, we should consider that toxicity from overdose to the 
rectum and bladder may lead to lethal results for elderly patients with cervical cancer. The 
doses for the rectum and bladder are evaluated according to the recommendation of ICRU 
Report 38 in most institutions (International Commission on Radiation Units and 
Measurements, 1985); however, these recommendations are based on the use of 2D 
treatment planning using X-ray films. Recently, 3D treatment planning systems for 
brachytherapy using CT or MRI, which are known as image-guided brachytherapy (IGBT), 
have been gradually expanding similarly to IMRT. Using this technique, the doses for the 
rectum and bladder are calculated more accurately compared to past treatment methods, 
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and a more adequate dose distribution for the gross tumor will be achieved. In the near 
future, IGBT will be the preferred method in the treatment planning of brachytherapy. In 
the treatment of elderly patients, RT induced toxicity must be reduced as much as possible. 
The standard definitive RT methods and doses for cervical cancer in Japan according to 
stage (tumor size) are described in Table 1 (Japan Society of Obstetrics and Gynecology, The 
Japanese Society of Pathology, Japan Radiological Society, 1997).  
 
stage (tumor size) 
EBRT (Gy) HDR-ICBT 
(Gy / fractions) whole pelvis cenrally-shielded 
I 0 45-50 29 / 5 
II (small) 0 45-50 29 / 5 
II (large) 20 30 23 /4 
III (small to middle) 20-30 20-30 23 /4 
III (large) 30-40 20-25 15-20 /3-4 
IVA 30-50 10-20 15-20 /3-4 
EBRT: External beam radiotherapy, HDR-ICBT: High dose rate intracavitary brachytherapy 
Table 1. Standard definitive RT methods and doses according to stage (tumor size) 
A boost to the primary tumor by EBRT is an alternative method for elderly patients because 
they are usually in poor condition, due to concomitant medical problems, and these patients 
may not be tolerant of ICBT. To reduce the irradiated volume, retreatment planning based 
on newly obtained CT scans should be performed just before the start of the boost. In our 
institution, the most commonly used dose is 10.0 Gy in 5 fractions. ICBT alone for small 
tumors is also a treatment choice for elderly patients who cannot continue long-term 
hospitalization because of dementia or other mental problems. Additionally, pelvic RT with 
smaller fields, reducing the dose of ICBT, and other efforts should be performed to avoid 
severe toxicity for elderly patients with poor performance statuses. 
A boost to the gross lymph node involvement on CT or MRI is often performed because the 
lymph node usually cannot be controlled by 50 Gy of pelvic RT. Although the boost to the 
lymph node involvement is important for cure, it may be too aggressive for elderly patients. 
Therefore, indication should be determined with caution. Patients with poor performance 
statuses from the beginning of RT, patients who experienced severe acute toxicity, or 
patients with multiple lymph node involvement (3 or more) should be excluded. Similar to 
the boost to the primary tumor by EBRT, retreatment planning based on newly obtained CT 
should be performed just before the start of the boost. In our institution, the most commonly 
used dose is 10.0 Gy in 5 fractions. Using IMRT will provide higher safety for elderly 
patients when the boost to the primary tumor or lymph node involvement is performed. 
Para-aortic lymph node involvement is an evidence of advanced disease. For these patients, 
extended-field RT including the entire pelvis and the para-aortic region is sometimes 
performed. Extended-field RT is an aggressive modality for elderly patients. Treatment 
delay will often occur, and some patients cannot complete RT. Moreover, patients with 
advanced disease usually demonstrate poor performance status. Therefore, extended-field 
RT does not seem to be suitable for elderly patients. Palliative RT should be recommended 
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for elderly patients with para-aortic lymph node involvement, while excluding patients in 
quite good condition.  
2.3 Treatment outcomes of definitive RT for elderly patients with cervical cancer 
Several reports have examined the treatment results of RT for elderly patients with cervical 
cancer. As for Japanese papers, Sakurai et al. retrospectively evaluated 380 patients with 
cervical cancer treated with definitive RT between 1970 and 1994 (Sakurai et al., 2000). Of 
the 380 patients, 215 were younger than 70 years, 124 were 70 to 79 years, and 41 were 80 
years or older. All of the patients were treated with EBRT combined with LDR-ICBT. They 
reported that the 5-year overall survival (OS) rate in the youngest (younger than 70 years), 
intermediate (70 to 79 years), and oldest (80 years or older) groups were 58%, 50%, and 33%, 
respectively. The 5-year OS rate in the oldest group was significantly worse than that of the 
youngest group. They also reported that the 5-year cause-specific survival (CSS) rate in the 
youngest, intermediate, and oldest groups were 68%, 70%, and 65%, respectively. The CSS 
rates were not significantly different among the 3 groups. For the chronic complications, 
Grade 3 or 4 occurred in 6.5% of the youngest, 11.3% of the intermediate, and 7.3% of the 
oldest group. No significant differences were observed in those complications among the 3 
groups. They concluded that EBRT combined with LDR-BT proved to be highly effective 
and safe for elderly patients with cervical cancer. Ikushima et al. retrospectively evaluated 
727 patients treated with definitive RT between 1970 and 1994 (Ikushima et al., 2007). In this 
report, 727 patients were also divided into 3 groups. Patients aged ≤ 64 years (n = 337) was 
defined as the younger group (YG), patients aged 65 – 74 years (n = 258) were defined as the 
young-old group (YOG), and patients aged ≥ 75 years (n = 132) composed the older group 
(OG). EBRT combined with LDR-ICBT was the basic treatment. However, 16 of 337 patients 
in the YG, 7 of 258 in the YOG, and 10 of 122 in the OG were not treated with LDT-ICBT. 
The 5- and 10-year OS rates were 59% and 49% in the YG, 68% and 51% in the YOG, and 
49% and 30% in the OG, respectively. The differences in the 5- and 10-year OS rates between 
the OG and other groups were significant. The 5- and 10-year disease-specific survival (DSS) 
rates were 60% and 52.5% in the YG, 75.7% and 67.8% in the YOG, and 65.9 % and 56.7% in 
the OG, respectively. In this study, the 5- and 10-year DSS rates in the YG were worse 
compared to the other groups, and the differences between the YG and the YOG were 
significant. Grade 2-4 late radiation morbidity in the bladder and/or rectum occurred in 
22% of the YG, 31% of the YOG, and 8% of the OG. Grade 3-4 morbidity did not occur in the 
OG. They concluded that age was not a significant prognostic factor, and, in the 
management of cervical cancer, advanced age was not a contraindication to radical RT. We 
also retrospectively evaluated 40 patients aged ≥ 75 years who were treated with RT 
between 2000 and 2009 (9 were treated between 2000 and 2005, and 31 were treated between 
2006 and 2009). In our study, 35 patients were treated with definitive RT, and 5 were treated 
with surgery + adjuvant RT (Yoshida et al., 2011). Among the 35 patients treated with 
definitive RT, 31 were treated with EBRT combined with HDR-ICBT. Of the remaining 4 
patients, 3 were treated with EBRT alone and 1 with HDR-ICBT alone because of their 
medical condition. Of the initial 40 patients, 38 completed the treatment as planned, 1 
completed with a delay, due to concomitant heart disease, and 1 could not complete the 
treatment because of acute toxicity. The 3-year OS and DSS rates for all of the patients were 
58% and 80%, respectively, with a median follow-up of 20 months. Both acute and late 
toxicity were evaluated in our study. Grade 3 acute toxicity occurred in 5 patients. Of the 3 
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RT does not seem to be suitable for elderly patients. Palliative RT should be recommended 
 
Cervical Cancer Treatment in Aging Women 
 
107 
for elderly patients with para-aortic lymph node involvement, while excluding patients in 
quite good condition.  
2.3 Treatment outcomes of definitive RT for elderly patients with cervical cancer 
Several reports have examined the treatment results of RT for elderly patients with cervical 
cancer. As for Japanese papers, Sakurai et al. retrospectively evaluated 380 patients with 
cervical cancer treated with definitive RT between 1970 and 1994 (Sakurai et al., 2000). Of 
the 380 patients, 215 were younger than 70 years, 124 were 70 to 79 years, and 41 were 80 
years or older. All of the patients were treated with EBRT combined with LDR-ICBT. They 
reported that the 5-year overall survival (OS) rate in the youngest (younger than 70 years), 
intermediate (70 to 79 years), and oldest (80 years or older) groups were 58%, 50%, and 33%, 
respectively. The 5-year OS rate in the oldest group was significantly worse than that of the 
youngest group. They also reported that the 5-year cause-specific survival (CSS) rate in the 
youngest, intermediate, and oldest groups were 68%, 70%, and 65%, respectively. The CSS 
rates were not significantly different among the 3 groups. For the chronic complications, 
Grade 3 or 4 occurred in 6.5% of the youngest, 11.3% of the intermediate, and 7.3% of the 
oldest group. No significant differences were observed in those complications among the 3 
groups. They concluded that EBRT combined with LDR-BT proved to be highly effective 
and safe for elderly patients with cervical cancer. Ikushima et al. retrospectively evaluated 
727 patients treated with definitive RT between 1970 and 1994 (Ikushima et al., 2007). In this 
report, 727 patients were also divided into 3 groups. Patients aged ≤ 64 years (n = 337) was 
defined as the younger group (YG), patients aged 65 – 74 years (n = 258) were defined as the 
young-old group (YOG), and patients aged ≥ 75 years (n = 132) composed the older group 
(OG). EBRT combined with LDR-ICBT was the basic treatment. However, 16 of 337 patients 
in the YG, 7 of 258 in the YOG, and 10 of 122 in the OG were not treated with LDT-ICBT. 
The 5- and 10-year OS rates were 59% and 49% in the YG, 68% and 51% in the YOG, and 
49% and 30% in the OG, respectively. The differences in the 5- and 10-year OS rates between 
the OG and other groups were significant. The 5- and 10-year disease-specific survival (DSS) 
rates were 60% and 52.5% in the YG, 75.7% and 67.8% in the YOG, and 65.9 % and 56.7% in 
the OG, respectively. In this study, the 5- and 10-year DSS rates in the YG were worse 
compared to the other groups, and the differences between the YG and the YOG were 
significant. Grade 2-4 late radiation morbidity in the bladder and/or rectum occurred in 
22% of the YG, 31% of the YOG, and 8% of the OG. Grade 3-4 morbidity did not occur in the 
OG. They concluded that age was not a significant prognostic factor, and, in the 
management of cervical cancer, advanced age was not a contraindication to radical RT. We 
also retrospectively evaluated 40 patients aged ≥ 75 years who were treated with RT 
between 2000 and 2009 (9 were treated between 2000 and 2005, and 31 were treated between 
2006 and 2009). In our study, 35 patients were treated with definitive RT, and 5 were treated 
with surgery + adjuvant RT (Yoshida et al., 2011). Among the 35 patients treated with 
definitive RT, 31 were treated with EBRT combined with HDR-ICBT. Of the remaining 4 
patients, 3 were treated with EBRT alone and 1 with HDR-ICBT alone because of their 
medical condition. Of the initial 40 patients, 38 completed the treatment as planned, 1 
completed with a delay, due to concomitant heart disease, and 1 could not complete the 
treatment because of acute toxicity. The 3-year OS and DSS rates for all of the patients were 
58% and 80%, respectively, with a median follow-up of 20 months. Both acute and late 
toxicity were evaluated in our study. Grade 3 acute toxicity occurred in 5 patients. Of the 3 
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patients, 3 were treated with surgery + adjuvant RT. Grade 4 toxicity did not occur. Grade 3 
late toxicity occurred in 2 patients. Of the two patients, one was treated with surgery + 
adjuvant RT, and the other was treated with BERT + HCR-ICBT with concurrent 
chemotherapy. Although the median follow-up was shorter, and a smaller number of 
patients were evaluated, our results were consistent with 2 large Japanese studies. We 
concluded that definitive RT for elderly patients was generally effective and safe, but 
aggressive treatment, such as surgery + adjuvant RT, concurrent chemoradiation, or a 
combination of these modalities, should be performed with caution.  
Studies from other countries have also reported results regarding elderly patients with 
cervical cancer treated with RT. Mitchell et al. retrospectively analyzed 398 patients 
treated with RT between 1975 and 1993. Patients were divided into nonelderly (ages 35-
69, n = 338) and elderly (ages ≥ 70, n = 60) groups (Mitchell et al., 1998). The basic RT 
method was a combination of EBRT and LDR-ICBT. However, 12.9% of the nonelderly 
group and 31.7% of the elderly group did not receive RT. The 5-year OS rates were 58.0% 
in the nonelderly group and 46.4% in the elderly group. The difference in the OS rate 
between the 2 groups was significant. However, the 5-year CSS rates were 76.3% in the 
nonelderly group and 84.1% in the elderly group. Unlike the OS rate, the CSS rate in the 
elderly group was better than in the nonelderly group, but this difference was not 
significant. The frequency and severity of acute and chronic toxicity were similar in both 
groups, and they concluded that definitive RT was effective and also well tolerated in 
elderly cervical cancer patients. Chen et al. described 295 patients treated with definitive 
RT between 1992 and 1997 and focused on HDR-ICBT (Chen et al., 2003). Patients were 
divided into 2 groups. Patients under 70 years of age (n = 179) were defined as a younger 
group, and patients aged 70 years or older (n = 79) were included in an older group. They 
used whole-pelvic RT with a total dose of 45-50 Gy in 20-25 fractions over 4-5 weeks. A 
boost for patients with FIGO IIB-IVA bilateral parametrial disease was performed up to 
54-58 Gy using central shielding. After the completion of whole-pelvic RT, HDR-ICBT was 
performed at 1-week intervals. The standard dose to Point A for three insertions (before 
July 1995) was 7.2 Gy or 6.0 Gy (after July 1995). The authors noted that the Point A dose 
was decreased to 5.0 Gy for all 79 patients in the older group. Survival was calculated 
according to age and clinical stage. The 5-year respective OS for the older and younger 
groups were 82% and 85% for stage IB, 65% and 65% for IIA, 61% and 71% for 2 IIB, and 
35% and 59% for 3 IIIA-B, respectively. No significant differences were observed. The 
respective 5-year CSS rates for the older and younger groups were 100% and 95% for IB, 
85% and 75% for IIA, 78% and 72% for IIB, and 42% and 61% for IIIA-B, respectively. No 
significant differences were observed. As for the complications, only 3 patients developed 
acute Grade 3-4 gastrointestinal complications (2 in the older and 1 in the younger group). 
Twelve (15%) patients in the older group and 14 (7.8%) in the younger group developed 
late Grade 3-4 rectal complications, while 7 (8.9%) patients in the older group and 10 
(5.6%) patients in the younger group developed Grade 3-4 small bowel complications. No 
significant difference was observed between the 2 groups for Grade 3-4 complications. 
The authors concluded that a combination of EBRT and HDR-ICBT was effective and 
tolerable for elderly patients.  
The results in these reports indicated that there were no significant differences in the CSS 
(DSS) rates between the elderly and younger patients. Although several papers noted that 
the OS rate in elderly patients was significantly worse than the younger patients, this result 
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was due to the increase of death from other causes in the elderly population and was 
expected. Toxicity due to RT was similar in both elderly and younger patients in all of the 
reports. Therefore, definitive RT, especially a combination of EBRT and ICBT, was equally 
effective for elderly patients and younger patients. Using IMRT, IGBT, or both, further 
reduction of treatment-related toxicity will be achieved with excellent treatment outcomes. 
In the near future, a combination of IMRT and IGBT will be the standard method of 
definitive RT for elderly patients with cervical cancer.  
3. Surgical approaches for elderly patients 
A surgical approach for elderly patients with cervical cancer is controversial. Conization of 
the cervix for FIGO stage 0 cancer is well tolerable, even for elderly patients, but the 
standard surgical approach, RH and PLND, appears to be invasive. Wright et al. 
retrospectively analyzed 1582 patients with cervical cancer who were treated between 1986 
and 2003 (Wright et al., 2005). Of the 1582 patients, 1385 were aged < 70 years, and 197 were 
aged ≥ 70 years. Surgery (including RH, modified RH, extrafascial hysterectomy, or 
trachelectomy) was performed for 753 of 1385 (54.4%) patients aged < 70 years and was 
performed for 32 of 197 (16.2%) patients aged ≥ 70 years. However, RT or chemoradiation 
(CRT) was performed for 605 of 1385 (43.7%) patients aged < 70 years and was performed 
for 156 of 197 (79.1%) patients aged ≥ 70 years. They stressed that younger patients were 
more likely to undergo surgery, and older patients were more likely to receive RT. There are 
several reports about RH for cervical cancer concerning age. Fuchtner et al. (1992) compared 
45 women older than 65 years treated with RH and 90 women less than 65 years treated 
similarly (Fuchtner et al., 1992). Although transfusions were required more frequently in the 
elderly patients, there were no significant differences in survival or complications. They 
concluded that age alone should not be a contraindication for RH in elderly patients with 
cervical cancer. Geisler et al. examined 62 patients aged over 65 years who underwent RH 
and a lymphadenectomy between 1965 and 1998 (Geisler et al., 2001). These patients were 
matched with 124 patients aged 50 years or younger who underwent the same procedure. 
Although the period of the postoperative hospital stay was longer in the elderly group than 
the younger group, there were no significant differences in the percentages of intraoperative 
and postoperative complications. They concluded that radical hysterectomy is a safe 
surgical procedure in a select population of patients aged 65 years or over. Mousavi et al. 
retrospectively evaluated 22 patients aged 60 years and above who underwent a Wertheim 
RH between 1999 and 2005, comparing 128 matched cases under 60 years who underwent 
the same procedure during the same period (Mousavi et al., 2008). There were no operative 
mortalities in either group, and there was no significant difference in morbidity between the 
2 groups. The mean postoperative hospital stay was significantly longer in the older 
patients. They concluded that Wertheim RH is a safe surgical procedure in the selected 
population of patients aged 60 years and older. From the results of these reports about RH, 
the authors emphasized that it was a safe treatment modality for elderly patients. However, 
they defined “elderly” as “60 years and above” or “over 65 years.” On the other hand, in the 
reports about RT, “elderly” was defined as “over 70 years” or “75 years or older.” In recent 
years, “elderly” generally includes patients aged 75 years or older or at least over 70 years. 
Therefore, patients defined as elderly in reports about RH were considered to be “middle 
aged.” Therefore, whether RH is safe for elderly patients aged “over 70 years” or “75 years 
or older” remains unclear. 
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patients, 3 were treated with surgery + adjuvant RT. Grade 4 toxicity did not occur. Grade 3 
late toxicity occurred in 2 patients. Of the two patients, one was treated with surgery + 
adjuvant RT, and the other was treated with BERT + HCR-ICBT with concurrent 
chemotherapy. Although the median follow-up was shorter, and a smaller number of 
patients were evaluated, our results were consistent with 2 large Japanese studies. We 
concluded that definitive RT for elderly patients was generally effective and safe, but 
aggressive treatment, such as surgery + adjuvant RT, concurrent chemoradiation, or a 
combination of these modalities, should be performed with caution.  
Studies from other countries have also reported results regarding elderly patients with 
cervical cancer treated with RT. Mitchell et al. retrospectively analyzed 398 patients 
treated with RT between 1975 and 1993. Patients were divided into nonelderly (ages 35-
69, n = 338) and elderly (ages ≥ 70, n = 60) groups (Mitchell et al., 1998). The basic RT 
method was a combination of EBRT and LDR-ICBT. However, 12.9% of the nonelderly 
group and 31.7% of the elderly group did not receive RT. The 5-year OS rates were 58.0% 
in the nonelderly group and 46.4% in the elderly group. The difference in the OS rate 
between the 2 groups was significant. However, the 5-year CSS rates were 76.3% in the 
nonelderly group and 84.1% in the elderly group. Unlike the OS rate, the CSS rate in the 
elderly group was better than in the nonelderly group, but this difference was not 
significant. The frequency and severity of acute and chronic toxicity were similar in both 
groups, and they concluded that definitive RT was effective and also well tolerated in 
elderly cervical cancer patients. Chen et al. described 295 patients treated with definitive 
RT between 1992 and 1997 and focused on HDR-ICBT (Chen et al., 2003). Patients were 
divided into 2 groups. Patients under 70 years of age (n = 179) were defined as a younger 
group, and patients aged 70 years or older (n = 79) were included in an older group. They 
used whole-pelvic RT with a total dose of 45-50 Gy in 20-25 fractions over 4-5 weeks. A 
boost for patients with FIGO IIB-IVA bilateral parametrial disease was performed up to 
54-58 Gy using central shielding. After the completion of whole-pelvic RT, HDR-ICBT was 
performed at 1-week intervals. The standard dose to Point A for three insertions (before 
July 1995) was 7.2 Gy or 6.0 Gy (after July 1995). The authors noted that the Point A dose 
was decreased to 5.0 Gy for all 79 patients in the older group. Survival was calculated 
according to age and clinical stage. The 5-year respective OS for the older and younger 
groups were 82% and 85% for stage IB, 65% and 65% for IIA, 61% and 71% for 2 IIB, and 
35% and 59% for 3 IIIA-B, respectively. No significant differences were observed. The 
respective 5-year CSS rates for the older and younger groups were 100% and 95% for IB, 
85% and 75% for IIA, 78% and 72% for IIB, and 42% and 61% for IIIA-B, respectively. No 
significant differences were observed. As for the complications, only 3 patients developed 
acute Grade 3-4 gastrointestinal complications (2 in the older and 1 in the younger group). 
Twelve (15%) patients in the older group and 14 (7.8%) in the younger group developed 
late Grade 3-4 rectal complications, while 7 (8.9%) patients in the older group and 10 
(5.6%) patients in the younger group developed Grade 3-4 small bowel complications. No 
significant difference was observed between the 2 groups for Grade 3-4 complications. 
The authors concluded that a combination of EBRT and HDR-ICBT was effective and 
tolerable for elderly patients.  
The results in these reports indicated that there were no significant differences in the CSS 
(DSS) rates between the elderly and younger patients. Although several papers noted that 
the OS rate in elderly patients was significantly worse than the younger patients, this result 
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was due to the increase of death from other causes in the elderly population and was 
expected. Toxicity due to RT was similar in both elderly and younger patients in all of the 
reports. Therefore, definitive RT, especially a combination of EBRT and ICBT, was equally 
effective for elderly patients and younger patients. Using IMRT, IGBT, or both, further 
reduction of treatment-related toxicity will be achieved with excellent treatment outcomes. 
In the near future, a combination of IMRT and IGBT will be the standard method of 
definitive RT for elderly patients with cervical cancer.  
3. Surgical approaches for elderly patients 
A surgical approach for elderly patients with cervical cancer is controversial. Conization of 
the cervix for FIGO stage 0 cancer is well tolerable, even for elderly patients, but the 
standard surgical approach, RH and PLND, appears to be invasive. Wright et al. 
retrospectively analyzed 1582 patients with cervical cancer who were treated between 1986 
and 2003 (Wright et al., 2005). Of the 1582 patients, 1385 were aged < 70 years, and 197 were 
aged ≥ 70 years. Surgery (including RH, modified RH, extrafascial hysterectomy, or 
trachelectomy) was performed for 753 of 1385 (54.4%) patients aged < 70 years and was 
performed for 32 of 197 (16.2%) patients aged ≥ 70 years. However, RT or chemoradiation 
(CRT) was performed for 605 of 1385 (43.7%) patients aged < 70 years and was performed 
for 156 of 197 (79.1%) patients aged ≥ 70 years. They stressed that younger patients were 
more likely to undergo surgery, and older patients were more likely to receive RT. There are 
several reports about RH for cervical cancer concerning age. Fuchtner et al. (1992) compared 
45 women older than 65 years treated with RH and 90 women less than 65 years treated 
similarly (Fuchtner et al., 1992). Although transfusions were required more frequently in the 
elderly patients, there were no significant differences in survival or complications. They 
concluded that age alone should not be a contraindication for RH in elderly patients with 
cervical cancer. Geisler et al. examined 62 patients aged over 65 years who underwent RH 
and a lymphadenectomy between 1965 and 1998 (Geisler et al., 2001). These patients were 
matched with 124 patients aged 50 years or younger who underwent the same procedure. 
Although the period of the postoperative hospital stay was longer in the elderly group than 
the younger group, there were no significant differences in the percentages of intraoperative 
and postoperative complications. They concluded that radical hysterectomy is a safe 
surgical procedure in a select population of patients aged 65 years or over. Mousavi et al. 
retrospectively evaluated 22 patients aged 60 years and above who underwent a Wertheim 
RH between 1999 and 2005, comparing 128 matched cases under 60 years who underwent 
the same procedure during the same period (Mousavi et al., 2008). There were no operative 
mortalities in either group, and there was no significant difference in morbidity between the 
2 groups. The mean postoperative hospital stay was significantly longer in the older 
patients. They concluded that Wertheim RH is a safe surgical procedure in the selected 
population of patients aged 60 years and older. From the results of these reports about RH, 
the authors emphasized that it was a safe treatment modality for elderly patients. However, 
they defined “elderly” as “60 years and above” or “over 65 years.” On the other hand, in the 
reports about RT, “elderly” was defined as “over 70 years” or “75 years or older.” In recent 
years, “elderly” generally includes patients aged 75 years or older or at least over 70 years. 
Therefore, patients defined as elderly in reports about RH were considered to be “middle 
aged.” Therefore, whether RH is safe for elderly patients aged “over 70 years” or “75 years 
or older” remains unclear. 
 
Topics on Cervical Cancer with an Advocacy for Prevention 
 
110 
Patients treated with RH + PLND with pathological risk factors, such as lymph node 
metastasis, lymphatic, vascular, or deep stromal invasion, should receive postoperative 
adjuvant RT. RH + PLND and adjuvant RT is considered an aggressive treatment and, 
generally, treatment-related toxicities, such as adhesive intestinal obstruction, or lymphatic 
edema of the lower extremities, increases compared to surgery or RT alone. Kashima et al. 
evaluated 149 patients with cervical cancer treated with RH or combined with postoperative 
RT between 1990 and 2004 (Kashima et al., 2010). Of the 149 patients, 41 were over 60 years, 
and 105 were under 59 years. The complications were significantly higher in the elderly 
patients and especially in those treated with RH combined with postoperative RT. In our 
study, 5 patients aged ≥ 75 years were treated with surgery (RH + PLND) and adjuvant RT. 
Three of the 5 patients experienced Grade 3 acute toxicity and 1 of the 5 patients experienced 
Grade 3 late toxicity. The results of these reports indicated that surgery and adjuvant RT 
were not safe for elderly patients. If adjuvant RT is necessary for elderly patients, IMRT may 
be used to limit severe toxicity.  
Overall, the standard surgical approach RH + PLND is generally safe for patients aged over 
60 or 65 years. However, the safety of RH + PLND for patients aged over 70 or 75 years is 
still unclear. Surgery and adjuvant RT must be performed with careful evaluation of 
pretreatment clinical staging, concurrent medical problems, and performance status for 
these age groups because severe life-threatening treatment-related toxicity may occur. More 
large-scale studies should be performed to confirm the safety of surgical approaches, 
including adjuvant RT for elderly patients. 
4. Concurrent CRT for elderly patients 
Concurrent CRT for elderly patients should also be discussed. Generally, in the treatment of 
cervical cancer, concurrent CRT is recommended, especially for locally advanced disease 
(Eifel et al., 2004; Rose et al, 1999; Whitney et al, 1999 and Pearcey et al., 2002). Weekly 
cisplatin (CDDP) is the most frequently used regimen. Concurrent CRT is also regarded as 
important for elderly patients because stage III-IVA disease usually cannot be cured by 
definitive RT alone. Therefore, CRT should be considered if the elderly patient is in good 
condition. Goodheart et al. retrospectively evaluated 96 patients treated with definitive RT 
between 1997 and 2001 (Goodheart et al., 2008). In their report, patients were divided into 2 
groups: nonelderly (< 65, n = 69) and elderly (≥ 65, n = 27). Chemotherapy administration 
was considered when the performance status and laboratory values were acceptable. Most 
of the patients were administered weekly CDDP. In the nonelderly group, 54 of 78 (78%) 
patients were treated with CRT, and, in the elderly group, 15 of 27 (56%) patients were 
treated with CRT. The 5-year CSS rates in the CRT and RT group were 68.5% and 49.7%, 
respectively. The 5-year CSS rates in the nonelderly and elderly groups were 61.6% and 
70.8%, respectively. Multivariate analyses showed a survival advantage for the 
administration of chemotherapy in addition to RT, and complication rates between the 2 
groups were similar. They concluded that CRT was associated with improved survival in 
elderly patients who had adequate performance status with no excess treatment-related 
morbidity when compared to younger patients. Kunos et al. also examined 335 patients with 
locally advanced cervical cancer treated with CRT using weekly CDDP (Kunos et al., 2009). 
Patients were also divided into 2 groups: age < 55 years (n = 232) and age ≥ 55 years (n = 
103). In their report, the survival of patients aged 55 or older was similar to that of the 
younger patients. The severity and frequency of treatment-related sequelae were also 
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similar. These authors emphasized that CRT for elderly patients was effective and safe, but 
they defined “elderly” as “≥ 65 years” or “≥ 55 years”, in accordance with the reports about 
RH. These age groups are usually not defined as “elderly.” Therefore, whether concurrent 
CRT is safe for elderly patients aged over 70 years or 75 years or older remains unclear. 
However, to achieve further improvement in survival outcomes for elderly patients with 
cervical cancer, especially locally advanced disease, CRT is a necessary modality. After 
performing large and prospective studies, concurrent CRT for selected patients aged ≥ 70 or 
75 years may provide excellent outcomes with acceptable toxicity. Published reports about 
elderly patients with cervical cancer are described in Table 2.  
 
Authors (year) No. of elderly patients (years) Modality Treatment results 
Mitchell. (1998) 60 (≥ 70) RT OS rate: 46% (5-y) CSS rate: 58% (5-y) 
Sakurai. (2000) 41 (≥ 80) RT OS rate: 33% (5-y) CSS rate: 65% (5-y) 
Lindegaard. (2000) 114 (≥ 70) RT 
Geisler. (2001) 62 (≥ 65) Surgery 
Chen. (2003) 79 (≥ 70) RT 
Brun. (2003) 31 (≥ 75) Surgery, RT OS rate: 42% (5-y) 
Wright. (2005) 197 (≥ 70) Surgery, RT, CRT 
Ikushima. (2007) 132 (≥ 75) RT OS rate: 49% (5-y) CSS rate: 66% (5-y) 
Goodheart. (2008) 27 (≥ 65) CRT OS rate: 44% (5-y) CSS rate: 71% (5-y) 
Magne. (2009) 113 (≥ 70) Surgery, RT OS rate: 89% (3-y) 
Kunos. (2009) 103 (≥ 55) CRT OS rate: 56 % (5-y) 
Yoshida. (2010) 40 (≥ 75) RT OS rate: 58%, (3-y) CSS rate: 80% (3-y) 
Kashima. (2010) 41 (≥ 60) Surgery ± adjuvant RT 
RT: Radiotherapy, CRT: Concurrent chemoradiation, OS: Overall survival, CSS: Cause specific survival 
Table 2. Published reports about elderly patients with cercical cancer 
5. Conclusions 
Selection of treatment modalities for elderly patients with cervical cancer is often limited 
compared to younger patients, but definitive RT, a combination of EBRT and ICBT is 
effective and safe. Indications for a surgical approach with or without adjuvant RT or 
concurrent CRT are still unclear because these aggressive modalities may cause severe 
treatment-related toxicity, especially for elderly patients. However, for locally advanced 
disease, CRT is an effective treatment. Therefore, large and prospective studies using CRT 
for patients aged at least ≥ 70 years with cervical cancer are needed. For RT, new techniques, 
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Patients treated with RH + PLND with pathological risk factors, such as lymph node 
metastasis, lymphatic, vascular, or deep stromal invasion, should receive postoperative 
adjuvant RT. RH + PLND and adjuvant RT is considered an aggressive treatment and, 
generally, treatment-related toxicities, such as adhesive intestinal obstruction, or lymphatic 
edema of the lower extremities, increases compared to surgery or RT alone. Kashima et al. 
evaluated 149 patients with cervical cancer treated with RH or combined with postoperative 
RT between 1990 and 2004 (Kashima et al., 2010). Of the 149 patients, 41 were over 60 years, 
and 105 were under 59 years. The complications were significantly higher in the elderly 
patients and especially in those treated with RH combined with postoperative RT. In our 
study, 5 patients aged ≥ 75 years were treated with surgery (RH + PLND) and adjuvant RT. 
Three of the 5 patients experienced Grade 3 acute toxicity and 1 of the 5 patients experienced 
Grade 3 late toxicity. The results of these reports indicated that surgery and adjuvant RT 
were not safe for elderly patients. If adjuvant RT is necessary for elderly patients, IMRT may 
be used to limit severe toxicity.  
Overall, the standard surgical approach RH + PLND is generally safe for patients aged over 
60 or 65 years. However, the safety of RH + PLND for patients aged over 70 or 75 years is 
still unclear. Surgery and adjuvant RT must be performed with careful evaluation of 
pretreatment clinical staging, concurrent medical problems, and performance status for 
these age groups because severe life-threatening treatment-related toxicity may occur. More 
large-scale studies should be performed to confirm the safety of surgical approaches, 
including adjuvant RT for elderly patients. 
4. Concurrent CRT for elderly patients 
Concurrent CRT for elderly patients should also be discussed. Generally, in the treatment of 
cervical cancer, concurrent CRT is recommended, especially for locally advanced disease 
(Eifel et al., 2004; Rose et al, 1999; Whitney et al, 1999 and Pearcey et al., 2002). Weekly 
cisplatin (CDDP) is the most frequently used regimen. Concurrent CRT is also regarded as 
important for elderly patients because stage III-IVA disease usually cannot be cured by 
definitive RT alone. Therefore, CRT should be considered if the elderly patient is in good 
condition. Goodheart et al. retrospectively evaluated 96 patients treated with definitive RT 
between 1997 and 2001 (Goodheart et al., 2008). In their report, patients were divided into 2 
groups: nonelderly (< 65, n = 69) and elderly (≥ 65, n = 27). Chemotherapy administration 
was considered when the performance status and laboratory values were acceptable. Most 
of the patients were administered weekly CDDP. In the nonelderly group, 54 of 78 (78%) 
patients were treated with CRT, and, in the elderly group, 15 of 27 (56%) patients were 
treated with CRT. The 5-year CSS rates in the CRT and RT group were 68.5% and 49.7%, 
respectively. The 5-year CSS rates in the nonelderly and elderly groups were 61.6% and 
70.8%, respectively. Multivariate analyses showed a survival advantage for the 
administration of chemotherapy in addition to RT, and complication rates between the 2 
groups were similar. They concluded that CRT was associated with improved survival in 
elderly patients who had adequate performance status with no excess treatment-related 
morbidity when compared to younger patients. Kunos et al. also examined 335 patients with 
locally advanced cervical cancer treated with CRT using weekly CDDP (Kunos et al., 2009). 
Patients were also divided into 2 groups: age < 55 years (n = 232) and age ≥ 55 years (n = 
103). In their report, the survival of patients aged 55 or older was similar to that of the 
younger patients. The severity and frequency of treatment-related sequelae were also 
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similar. These authors emphasized that CRT for elderly patients was effective and safe, but 
they defined “elderly” as “≥ 65 years” or “≥ 55 years”, in accordance with the reports about 
RH. These age groups are usually not defined as “elderly.” Therefore, whether concurrent 
CRT is safe for elderly patients aged over 70 years or 75 years or older remains unclear. 
However, to achieve further improvement in survival outcomes for elderly patients with 
cervical cancer, especially locally advanced disease, CRT is a necessary modality. After 
performing large and prospective studies, concurrent CRT for selected patients aged ≥ 70 or 
75 years may provide excellent outcomes with acceptable toxicity. Published reports about 
elderly patients with cervical cancer are described in Table 2.  
 
Authors (year) No. of elderly patients (years) Modality Treatment results 
Mitchell. (1998) 60 (≥ 70) RT OS rate: 46% (5-y) CSS rate: 58% (5-y) 
Sakurai. (2000) 41 (≥ 80) RT OS rate: 33% (5-y) CSS rate: 65% (5-y) 
Lindegaard. (2000) 114 (≥ 70) RT 
Geisler. (2001) 62 (≥ 65) Surgery 
Chen. (2003) 79 (≥ 70) RT 
Brun. (2003) 31 (≥ 75) Surgery, RT OS rate: 42% (5-y) 
Wright. (2005) 197 (≥ 70) Surgery, RT, CRT 
Ikushima. (2007) 132 (≥ 75) RT OS rate: 49% (5-y) CSS rate: 66% (5-y) 
Goodheart. (2008) 27 (≥ 65) CRT OS rate: 44% (5-y) CSS rate: 71% (5-y) 
Magne. (2009) 113 (≥ 70) Surgery, RT OS rate: 89% (3-y) 
Kunos. (2009) 103 (≥ 55) CRT OS rate: 56 % (5-y) 
Yoshida. (2010) 40 (≥ 75) RT OS rate: 58%, (3-y) CSS rate: 80% (3-y) 
Kashima. (2010) 41 (≥ 60) Surgery ± adjuvant RT 
RT: Radiotherapy, CRT: Concurrent chemoradiation, OS: Overall survival, CSS: Cause specific survival 
Table 2. Published reports about elderly patients with cercical cancer 
5. Conclusions 
Selection of treatment modalities for elderly patients with cervical cancer is often limited 
compared to younger patients, but definitive RT, a combination of EBRT and ICBT is 
effective and safe. Indications for a surgical approach with or without adjuvant RT or 
concurrent CRT are still unclear because these aggressive modalities may cause severe 
treatment-related toxicity, especially for elderly patients. However, for locally advanced 
disease, CRT is an effective treatment. Therefore, large and prospective studies using CRT 
for patients aged at least ≥ 70 years with cervical cancer are needed. For RT, new techniques, 
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such as IMRT, IGBT or a combination of both, may help to reduce the RT-induced toxicity in 
both definitive and adjuvant treatment. In the near future, IMRT combined with IGBT with 
or without new chemotherapeutic regimens will be the standard cervical cancer treatment in 
aging women. 
6. References 
Abridged life tables for Japan 2009, Ministry of Health, Labour and Welfare (2010). 
http://www.mhlw.go.jp/english/database/db-hw/lifetb09/index.html 
Brun, JL.; Stoven-Camou, D.; Trouette, R.; Lopez, M.; Chene, G. & Hocké, C. (2003). Survival 
and prognosis of women with invasive cervical cancer according to age. Gynecol 
Oncol. Vol. 91(2), pp. 395-401, ISSN 0090-8258 
Chen, SW.; Liang, JA.; Yang, SN. & Lin, FJ. (2010). High dose-rate brachytherapy for elderly 
patients with uterine cervical cancer. Jpn J Clin Oncol. Vol. 33(5), pp. 221-8, ISSN 
0368-2111 
Creasman, WT. (1995). New gynecologic cancer staging. Gynecol Oncol. Vol. 58(2), pp. 157-8, 
ISSN 0090-8258 
Eifel, PJ.; Winter, K.; Morris, M.; Levenback, C.; Grigsby, PW.; Cooper, J.; Rotman, M.; 
Gershenson, D. & Mutch DG. (2004). Pelvic irradiation with concurrent 
chemotherapy versus pelvic and para-aortic irradiation for high-risk cervical 
cancer: an update of radiation therapy oncology group trial (RTOG) 90-01. J Clin 
Oncol. Vol. 22(5), pp. 872-80, ISSN 0732-183X 
Fuchtner, C.; Manetta, A.; Walker, JL.; Emma, D.; Berman, M. & DiSaia, PJ. (1992). Radical 
hysterectomy in the elderly patient: analysis of morbidity. Am J Obstet Gynecol. Vol. 
166(2), pp. 593-7, ISSN 0002-9378 
Geisler, JP. & Geisler, HE. (2001). Radical hysterectomy in the elderly female: a comparison 
to patients age 50 or younger. Gynecol Oncol. Vol. 80(2), pp. 258-61, ISSN 0090-8258  
Goodheart, M.; Jacobson, G.; Smith, BJ. & Zhou, L. (2008). Chemoradiation for invasive 
cervical cancer in elderly patients: outcomes and morbidity. Int J Gynecol Cancer. 
Vol. 18(1), pp. 95-103, ISSN 1048-891X 
Ikushima, H.; Takegawa, Y.; Osaki, K.; Furutani, S.; Yamashita, K.; Kawanaka, T.; Kubo, A.; 
Kudoh, T. & Nishitani, H. Radiation therapy for cervical cancer in the elderly. 
Gynecol Oncol. Vol. 107(2), pp. 339-43, ISSN 0090-8258 
International Commission on Radiation Units and Measurements (1985). Dose and volume 
specification for intracavitary therapy in gynecology. ICRU report 38. ICRU, 
Washington,USA.  
Japan Society of Obstetrics and Gynecology, the Japanese Society of Pathology, Japan 
Radiological Society (1997). The General Rules for Clinical and Pathological 
Management of Uterine Cervical Cancer, October 1997 (The second Edition). ISBN 
4307300734, Tokyo, Japan. 
Kashima, K.; Yahata, T.; Fujita K. & Tanaka, K. (2010). Analysis of the complications after 
radical hysterectomy for stage IB, IIA and IIB uterine cervical cancer patients. J 
Obstet Gynaecol Res. Vol. 36(3), pp. 555-9, ISSN 1341-8076 
Kunos, C.; Tian, C.; Waggoner, S.; Rose, PG. & Lanciano, R. (2009). Retrospective analysis of 
concomitant Cisplatin during radiation in patients aged 55 years or older for 
treatment of advanced cervical cancer: a gynecologic oncology group study. Int J 
Gynecol Cancer. 2009 Vol. 19(7), pp. 1258-63, ISSN 1048-891X 
 
Cervical Cancer Treatment in Aging Women 
 
113 
Landoni, F.; Maneo, A.; Colombo, A.; Placa, F.; Milani, R.; Perego, P.; Favini, G.; Ferri, L. & 
Mangioni, C. (1997). Randomised study of radical surgery versus radiotherapy for 
stage Ib-IIa cervical cancer. Lancet. Vol. 350(9077), pp. 535-40, ISSN 0140-6736 
Lindegaard, JC.; Thranov, IR. & Engelholm SA. (2000). Radiotherapy in the management of 
cervical cancer in elderly patients. Radiother Oncol. Vol. 56(1), pp. 9-15, ISSN 0167-
8140 
Magné, N.; Mancy, NC.; Chajon, E.; Duvillard, P.; Pautier, P.; Castaigne, D.; Lhommé, C.; 
Moric, P. & Haie-Meder C. (2009). Patterns of care and outcome in elderly cervical 
cancer patients: a special focus on brachytherapy. Radiother Oncol. Vol. 91(2), pp. 
197-201, ISSN 0167-8140 
Mitchell, PA.; Waggoner, S.; Rotmensch, J. & Mundt AJ. (1998). Cervical cancer in the elderly 
treated with radiation therapy. Gynecol Oncol. Vol. 71(2), pp. 291-8, ISSN 0090-8258 
Mousavi, A.; Karimi Zarchi, M.; Gilani, MM.; Behtash, N.; Ghaemmaghami, F.; Shams, M. & 
Irvanipoor, M. (2008). Radical hysterectomy in the elderly. World J Surg Oncol. Vol. 
6:38, ISSN 1477-7819 
National Comprehensive Cancer Network (2011). NCCN Clinical Practice Guidelines in 
Oncology-Cervical Cancer-Version1. 2011.  
 http://www.nccn.org/professionals/physician_gls/pdf/cervical.pdf 
Pearcey, R.; Brundage, M.; Drouin, P.; Jeffrey, J.; Johnston, D.; Lukka, H.; MacLean, G.; 
Souhami, L.; Stuart G. & Tu, D. (2002). Phase III trial comparing radical 
radiotherapy with and without cisplatin chemotherapy in patients with advanced 
squamous cell cancer of the cervix. J Clin Oncol. Vol. 20(4), pp. 966-72, ISSN 0732-
183X 
Perez, CA.; Grigsby, PW.; Camel, HM.; Galakatos, AE.; Mutch, D. & Lockett, MA. (1995). 
Irradiation alone or combined with surgery in stage IB, IIA, and IIB carcinoma of 
uterine cervix: update of a nonrandomized comparison. Int J Radiat Oncol Biol Phys. 
Vol. 31(4), pp. 703-16, ISSN 0360-3016 
Rose, PG.; Bundy, BN.; Watkins, EB.; TClarke-Pearson, DL. & Insalaco S. (1999) Concurrent 
cisplatin-based radiotherapy and chemotherapy for locally advanced cervical 
cancer. N Engl J Med. Vol. 340(15), pp. 1144-53, ISSN 0028-4793 
Sakurai, H.; Mitsuhashi, N.; Takahashi, M.; Yamakawa, M.; Akimoto, T.; Hayakawa, K.; & 
Niibe, H. (2000). Radiation therapy for elderly patient with squamous cell 
carcinoma of the uterine cervix. Gynecol Oncol. Vol. 77(1), pp. 116-20, ISSN 0090-
8258 
Whitney, CW.; Sause, W.; Bundy, BN.; Malfetano, JH.; Hannigan, EV.; Fowler, WC Jr.; 
Clarke-Pearson, DL. & Liao, SY. (1999). Randomized comparison of fluorouracil 
plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-
IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic 
Oncology Group and Southwest Oncology Group study. J Clin Oncol. Vol, 17(5), 
pp. 1339-48, ISSN 0732-183X 
Wright, JD.; Gibb, RK.; Geevarghese, S.; Powell, MA.; Herzog, TJ.; Mutch, DG.; Grigsby, 
PW.; Gao, F.; Trinkaus, KM. & Rader JS. (2005). Cervical carcinoma in the elderly: 
an analysis of patterns of care and outcome. Cancer. Vol. 103(1), pp. 85-91, ISSN 
0008-543X 
Yamashita, H.; Nakagawa, K.; Tago, M.; Shiraishi, K.; Nakamura, N.; Ohtomo, K.; Oda, K.; 
Nakagawa, S.; Yasugi, T. & Taketani Y. (2005). Comparison between conventional 
 
Topics on Cervical Cancer with an Advocacy for Prevention 
 
112 
such as IMRT, IGBT or a combination of both, may help to reduce the RT-induced toxicity in 
both definitive and adjuvant treatment. In the near future, IMRT combined with IGBT with 
or without new chemotherapeutic regimens will be the standard cervical cancer treatment in 
aging women. 
6. References 
Abridged life tables for Japan 2009, Ministry of Health, Labour and Welfare (2010). 
http://www.mhlw.go.jp/english/database/db-hw/lifetb09/index.html 
Brun, JL.; Stoven-Camou, D.; Trouette, R.; Lopez, M.; Chene, G. & Hocké, C. (2003). Survival 
and prognosis of women with invasive cervical cancer according to age. Gynecol 
Oncol. Vol. 91(2), pp. 395-401, ISSN 0090-8258 
Chen, SW.; Liang, JA.; Yang, SN. & Lin, FJ. (2010). High dose-rate brachytherapy for elderly 
patients with uterine cervical cancer. Jpn J Clin Oncol. Vol. 33(5), pp. 221-8, ISSN 
0368-2111 
Creasman, WT. (1995). New gynecologic cancer staging. Gynecol Oncol. Vol. 58(2), pp. 157-8, 
ISSN 0090-8258 
Eifel, PJ.; Winter, K.; Morris, M.; Levenback, C.; Grigsby, PW.; Cooper, J.; Rotman, M.; 
Gershenson, D. & Mutch DG. (2004). Pelvic irradiation with concurrent 
chemotherapy versus pelvic and para-aortic irradiation for high-risk cervical 
cancer: an update of radiation therapy oncology group trial (RTOG) 90-01. J Clin 
Oncol. Vol. 22(5), pp. 872-80, ISSN 0732-183X 
Fuchtner, C.; Manetta, A.; Walker, JL.; Emma, D.; Berman, M. & DiSaia, PJ. (1992). Radical 
hysterectomy in the elderly patient: analysis of morbidity. Am J Obstet Gynecol. Vol. 
166(2), pp. 593-7, ISSN 0002-9378 
Geisler, JP. & Geisler, HE. (2001). Radical hysterectomy in the elderly female: a comparison 
to patients age 50 or younger. Gynecol Oncol. Vol. 80(2), pp. 258-61, ISSN 0090-8258  
Goodheart, M.; Jacobson, G.; Smith, BJ. & Zhou, L. (2008). Chemoradiation for invasive 
cervical cancer in elderly patients: outcomes and morbidity. Int J Gynecol Cancer. 
Vol. 18(1), pp. 95-103, ISSN 1048-891X 
Ikushima, H.; Takegawa, Y.; Osaki, K.; Furutani, S.; Yamashita, K.; Kawanaka, T.; Kubo, A.; 
Kudoh, T. & Nishitani, H. Radiation therapy for cervical cancer in the elderly. 
Gynecol Oncol. Vol. 107(2), pp. 339-43, ISSN 0090-8258 
International Commission on Radiation Units and Measurements (1985). Dose and volume 
specification for intracavitary therapy in gynecology. ICRU report 38. ICRU, 
Washington,USA.  
Japan Society of Obstetrics and Gynecology, the Japanese Society of Pathology, Japan 
Radiological Society (1997). The General Rules for Clinical and Pathological 
Management of Uterine Cervical Cancer, October 1997 (The second Edition). ISBN 
4307300734, Tokyo, Japan. 
Kashima, K.; Yahata, T.; Fujita K. & Tanaka, K. (2010). Analysis of the complications after 
radical hysterectomy for stage IB, IIA and IIB uterine cervical cancer patients. J 
Obstet Gynaecol Res. Vol. 36(3), pp. 555-9, ISSN 1341-8076 
Kunos, C.; Tian, C.; Waggoner, S.; Rose, PG. & Lanciano, R. (2009). Retrospective analysis of 
concomitant Cisplatin during radiation in patients aged 55 years or older for 
treatment of advanced cervical cancer: a gynecologic oncology group study. Int J 
Gynecol Cancer. 2009 Vol. 19(7), pp. 1258-63, ISSN 1048-891X 
 
Cervical Cancer Treatment in Aging Women 
 
113 
Landoni, F.; Maneo, A.; Colombo, A.; Placa, F.; Milani, R.; Perego, P.; Favini, G.; Ferri, L. & 
Mangioni, C. (1997). Randomised study of radical surgery versus radiotherapy for 
stage Ib-IIa cervical cancer. Lancet. Vol. 350(9077), pp. 535-40, ISSN 0140-6736 
Lindegaard, JC.; Thranov, IR. & Engelholm SA. (2000). Radiotherapy in the management of 
cervical cancer in elderly patients. Radiother Oncol. Vol. 56(1), pp. 9-15, ISSN 0167-
8140 
Magné, N.; Mancy, NC.; Chajon, E.; Duvillard, P.; Pautier, P.; Castaigne, D.; Lhommé, C.; 
Moric, P. & Haie-Meder C. (2009). Patterns of care and outcome in elderly cervical 
cancer patients: a special focus on brachytherapy. Radiother Oncol. Vol. 91(2), pp. 
197-201, ISSN 0167-8140 
Mitchell, PA.; Waggoner, S.; Rotmensch, J. & Mundt AJ. (1998). Cervical cancer in the elderly 
treated with radiation therapy. Gynecol Oncol. Vol. 71(2), pp. 291-8, ISSN 0090-8258 
Mousavi, A.; Karimi Zarchi, M.; Gilani, MM.; Behtash, N.; Ghaemmaghami, F.; Shams, M. & 
Irvanipoor, M. (2008). Radical hysterectomy in the elderly. World J Surg Oncol. Vol. 
6:38, ISSN 1477-7819 
National Comprehensive Cancer Network (2011). NCCN Clinical Practice Guidelines in 
Oncology-Cervical Cancer-Version1. 2011.  
 http://www.nccn.org/professionals/physician_gls/pdf/cervical.pdf 
Pearcey, R.; Brundage, M.; Drouin, P.; Jeffrey, J.; Johnston, D.; Lukka, H.; MacLean, G.; 
Souhami, L.; Stuart G. & Tu, D. (2002). Phase III trial comparing radical 
radiotherapy with and without cisplatin chemotherapy in patients with advanced 
squamous cell cancer of the cervix. J Clin Oncol. Vol. 20(4), pp. 966-72, ISSN 0732-
183X 
Perez, CA.; Grigsby, PW.; Camel, HM.; Galakatos, AE.; Mutch, D. & Lockett, MA. (1995). 
Irradiation alone or combined with surgery in stage IB, IIA, and IIB carcinoma of 
uterine cervix: update of a nonrandomized comparison. Int J Radiat Oncol Biol Phys. 
Vol. 31(4), pp. 703-16, ISSN 0360-3016 
Rose, PG.; Bundy, BN.; Watkins, EB.; TClarke-Pearson, DL. & Insalaco S. (1999) Concurrent 
cisplatin-based radiotherapy and chemotherapy for locally advanced cervical 
cancer. N Engl J Med. Vol. 340(15), pp. 1144-53, ISSN 0028-4793 
Sakurai, H.; Mitsuhashi, N.; Takahashi, M.; Yamakawa, M.; Akimoto, T.; Hayakawa, K.; & 
Niibe, H. (2000). Radiation therapy for elderly patient with squamous cell 
carcinoma of the uterine cervix. Gynecol Oncol. Vol. 77(1), pp. 116-20, ISSN 0090-
8258 
Whitney, CW.; Sause, W.; Bundy, BN.; Malfetano, JH.; Hannigan, EV.; Fowler, WC Jr.; 
Clarke-Pearson, DL. & Liao, SY. (1999). Randomized comparison of fluorouracil 
plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-
IVA carcinoma of the cervix with negative para-aortic lymph nodes: a Gynecologic 
Oncology Group and Southwest Oncology Group study. J Clin Oncol. Vol, 17(5), 
pp. 1339-48, ISSN 0732-183X 
Wright, JD.; Gibb, RK.; Geevarghese, S.; Powell, MA.; Herzog, TJ.; Mutch, DG.; Grigsby, 
PW.; Gao, F.; Trinkaus, KM. & Rader JS. (2005). Cervical carcinoma in the elderly: 
an analysis of patterns of care and outcome. Cancer. Vol. 103(1), pp. 85-91, ISSN 
0008-543X 
Yamashita, H.; Nakagawa, K.; Tago, M.; Shiraishi, K.; Nakamura, N.; Ohtomo, K.; Oda, K.; 
Nakagawa, S.; Yasugi, T. & Taketani Y. (2005). Comparison between conventional 
 
Topics on Cervical Cancer with an Advocacy for Prevention 
 
114 
surgery and radiotherapy for FIGO stage I-II cervical carcinoma: a retrospective 
Japanese study. Gynecol Oncol. Vol. 97(3), pp. 834-9, ISSN 0090-8258 
Yoshida, K.; Sasaki, R.; Nishimura, H.; Miyawaki, D.; Kawabe, T.; Okamoto, Y.; 
Nakabayashi, K.; Yoshida, S. & Sugimura K. (2011). Radiotherapy for Japanese 
elderly patients with cervical cancer: preliminary survival outcomes and evaluation 
of treatment-related toxicity. Arch Gynecol Obstet. Vol. 284(4), pp. 1007-14, ISSN 
0932-0067 
7 
Cervical Cancer Prevention by Liquid-Based 
Cytology in a Low-Resource Setting 
Mongkol Benjapibal and Somsak Laiwejpithaya 
Department of Obstetrics and Gynecology,  
Faculty of Medicine Siriraj Hospital,  
Mahidol University, Bangkok 
Thailand 
1. Introduction 
Cervical cancer is a major public health problem. Worldwide, it is the second most common 
cancer in women after breast cancer. Approximately 500,000 new cases of invasive cervical 
cancer have been diagnosed each year with more than 250,000 women dying of the disease. 
It is the most or second most common cancer among women in developing countries. In 
Thailand, a low-resource country, cervical cancer is the second most frequent cause of 
cancer in women, with nearly 10,000 new cases diagnosed and more than 5,200 dying from 
this disease each year (Ferlay et al., 2010). The incidence and mortality have declined during 
the last 50 years in developed countries because of increased availability of cervical cancer 
screening programs (Nieminen et al., 1995). However, cervical cancer continues to be a 
leading cause of cancer deaths in populations with a low socioeconomic level. 
2. Cervical cancer screening 
Screening is the use of methods to distinguish apparently unaffected people from those who 
may have a disease, or may develop it. It is a preliminary process to offer a diagnostic test 
and if required, treatment. Screening test is usually applied on a large scale and are 
generally offered to a population of people who have not sought medical attention on 
account of symptoms of the disease. The purpose of screening is to benefit the individuals 
being screened. Screening procedures are generally easier to perform and cheaper than 
diagnostic procedures. Although the screening test is harmless, it can cause anxiety and the 
subsequent investigations and treatment can be hazardous. Screening methods should 
provide the most attractive combination of negative predictive value (e.g., reassurance) and 
false positives that is attainable in a given setting and providers should ensure that a useful 
remedy is available for all individuals identified as being true positive. 
The most widely used screening method for cervical cancer is conventional cytology 
(conventional Pap smear). Nowadays, conventional cytology is still considered a standard 
screening method worldwide, especially in developing countries. Conventional cytology has 
been being used as a standard screening method for cervical cancer in Siriraj Hospital since 
1952. This cytological testing involves three major steps, i.e. collecting exfoliated cells from 
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remedy is available for all individuals identified as being true positive. 
The most widely used screening method for cervical cancer is conventional cytology 
(conventional Pap smear). Nowadays, conventional cytology is still considered a standard 
screening method worldwide, especially in developing countries. Conventional cytology has 
been being used as a standard screening method for cervical cancer in Siriraj Hospital since 
1952. This cytological testing involves three major steps, i.e. collecting exfoliated cells from 
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the cervix, spreading the cells onto a slide, and microscopically examining these cells after 
staining. Collection of specimens for conventional cytology is performed according to the 
standard vaginal-cervical-endocervical (VCE) smear technique. A wooden (Ayre’s) spatula 
and a cotton swab are used to collect cells from the posterior fornix, portio vaginalis and 
endocervix. The collected cells are then spread onto a glass slide and immediately immersed 
in 95% ethanol for fixation. Despite the proven effectiveness of cervical cytology screening 
in reducing the incidence of cervical cancer, over the last decade the accuracy of cervical 
cytology has been questioned. Two large meta-analyses have indicated that although the 
specificity of conventional cervical cytology is high, its sensitivity is much lower than 
previously estimated (Fahey et al., 1995; Nanda et al., 2000). Errors due to poor sampling 
and partial transferring of the collected sample onto a glass slide, consequently producing a 
nonrepresentative specimen, may account for up to 62% of false negative results (Gay et al., 
1985).  
3. Siriraj liquid-based cytology 
Liquid-based cytology (LBC) was introduced in the mid-1990s as a way to improve 
performance of the test. LBC can improve specimen quality by providing a standardized 
method of collecting cervicovaginal material, and dispersing cells in a thin layer with 
relatively free of inflammation (Austin et al.,1998; Mount et al.,2004; Vassilakos et al.,2002). 
This results in the decrease in incidence of unsatisfactory smears and increase in detection 
rate of cytologic abnormality (Bolick et al.,1998; Corkill et al.,1998; Diaz-Rosario et al.,1999; 
Dupree et al.,1998; Fremont-Smith et al.,2004; Papillo et al.,1998; Roberts et al.,1997). Besides, 
the leftover specimen for LBC can also be used for HPV DNA testing which is currently 
incorporated into the management guidelines and post-therapy surveillance of the patient in 
some institutes. Recently, a number of different LBC techniques are available worldwide. 
ThinPrep® and SurePath™ are prototypes of LBC technology. They have been approved by 
the Food and Drug Administration for cervical cancer screening in the USA and are the 
most commonly used LBC techniques (Bishop et al., 1998; Lee et al., 1997). LBC was 
introduced as a cervical cancer screening technique in Thailand in 1997. Nowadays there are 
at least three commercially available LBC in Thailand, e.g. ThinPrep®, SurePath™, and Liqui-
Prep®. Despite of their reputation, these LBC are still not in general use because of their cost. 
In the year 2005, we have developed an alcohol-based preservative solution, Siriraj liquid-
based solution, and applied a modified Saccomanno’s technique for cells preparation in our 
institute, and named this technology as the “Siriraj liquid-based cytology” or “Siriraj-LBC”. 
The collection of specimens for Siriraj-LBC is similar to that for conventional cytology, 
except that a special plastic spatula is used instead of the Ayre’s spatula and cotton swab. 
The plastic spatula has an extended endocervical tip at one end and a rounded rectangular 
tip at the other end, and scores at 4 cm from each end to facilitate spatula breaking (Figure 1). 
Immediately after cell collection, both ends of the spatula are manually broken at the scores, 
and put into a 30 mL plastic bottle containing 10 mL of Siriraj liquid-based solution. 
3.1 Processing of Siriraj-LBC 
The cell specimens are collected in bottles containing Siriraj liquid-based solution and keep 
at room temperature until processing. Siriraj-LBC slides are prepared according to the 
following steps (Bales, 2006) : agitate the bottle of specimen on a vortex mixer for 10 sec, and  
 




Fig. 1. Collecting devices for Siriraj-LBC: a 30-mL plastic bottle containing 10 mL of Siriraj 
liquid-based solution (A), and an extended-tip plastic spatula, arrow heads showing scores 
on the spatula (B) 
pour the suspension into a 15-mL centrifuge test tube; centrifuge the specimen at 1000 g. for 10 
min, and discard the supernatant; add Siriraj liquid-based solution (approximately 3 times of 
the sediment volume); agitate the test tube for 10 sec, aspirate 15-20 μL of the sample by using 
an auto-pipette, drop the sample onto a clean glass slide, smear the droplet to 2 cm in 
diameter, and let air dry at room temperature for 30 min; fix the slide in 95% ethanol for 20 
minutes, and finally stain it with the routine Papanicolaou’s staining technique (Figure 2). 
3.2 Performance of Siriraj-LBC 
Before a new screening or diagnostic tool is introduced into clinical use, it is necessary to 
evaluate its diagnostic performance. The best way for this evaluation is to compare the 
result from the new tool with that from the gold standard, revealing the performance 
parameters including sensitivity, specificity, positive predictive value (PPV), negative 
predictive value (NPV), false positive (FP), false negative (FN), and accuracy of the test. 
However, such parameters cannot be obtained in studies evaluating performance of cervical 
cytology methods because not all of the study population undergoes the gold standard 
testing, i.e. colposcopy or cervical histology. The gold standard is mostly lacking in the 
group of patients who have normal cervical cytology. Therefore, numerous studies have 
evaluated the comparative performance of the LBC methods and conventional cytology 
with respect to test positivity, i.e. the detection rate of squamous intraepithelial lesion (SIL). 
Most studies have utilized one to two types of study design, i.e. “split-sample” or “direct-to-
vial” study. With “split-sample” study, it is difficult to ensure that the two cytology 
specimens are comparable, since the specimen for conventional cytology slide is collected 
before the specimen for LBC. Therefore, this design seems to lead inherently to bias against 
LBC. With “direct-to-vial” study, the result of LBC is compared with that of conventional 
smear from historical data of an identical population; however, it is not certain that the two 
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in 95% ethanol for fixation. Despite the proven effectiveness of cervical cytology screening 
in reducing the incidence of cervical cancer, over the last decade the accuracy of cervical 
cytology has been questioned. Two large meta-analyses have indicated that although the 
specificity of conventional cervical cytology is high, its sensitivity is much lower than 
previously estimated (Fahey et al., 1995; Nanda et al., 2000). Errors due to poor sampling 
and partial transferring of the collected sample onto a glass slide, consequently producing a 
nonrepresentative specimen, may account for up to 62% of false negative results (Gay et al., 
1985).  
3. Siriraj liquid-based cytology 
Liquid-based cytology (LBC) was introduced in the mid-1990s as a way to improve 
performance of the test. LBC can improve specimen quality by providing a standardized 
method of collecting cervicovaginal material, and dispersing cells in a thin layer with 
relatively free of inflammation (Austin et al.,1998; Mount et al.,2004; Vassilakos et al.,2002). 
This results in the decrease in incidence of unsatisfactory smears and increase in detection 
rate of cytologic abnormality (Bolick et al.,1998; Corkill et al.,1998; Diaz-Rosario et al.,1999; 
Dupree et al.,1998; Fremont-Smith et al.,2004; Papillo et al.,1998; Roberts et al.,1997). Besides, 
the leftover specimen for LBC can also be used for HPV DNA testing which is currently 
incorporated into the management guidelines and post-therapy surveillance of the patient in 
some institutes. Recently, a number of different LBC techniques are available worldwide. 
ThinPrep® and SurePath™ are prototypes of LBC technology. They have been approved by 
the Food and Drug Administration for cervical cancer screening in the USA and are the 
most commonly used LBC techniques (Bishop et al., 1998; Lee et al., 1997). LBC was 
introduced as a cervical cancer screening technique in Thailand in 1997. Nowadays there are 
at least three commercially available LBC in Thailand, e.g. ThinPrep®, SurePath™, and Liqui-
Prep®. Despite of their reputation, these LBC are still not in general use because of their cost. 
In the year 2005, we have developed an alcohol-based preservative solution, Siriraj liquid-
based solution, and applied a modified Saccomanno’s technique for cells preparation in our 
institute, and named this technology as the “Siriraj liquid-based cytology” or “Siriraj-LBC”. 
The collection of specimens for Siriraj-LBC is similar to that for conventional cytology, 
except that a special plastic spatula is used instead of the Ayre’s spatula and cotton swab. 
The plastic spatula has an extended endocervical tip at one end and a rounded rectangular 
tip at the other end, and scores at 4 cm from each end to facilitate spatula breaking (Figure 1). 
Immediately after cell collection, both ends of the spatula are manually broken at the scores, 
and put into a 30 mL plastic bottle containing 10 mL of Siriraj liquid-based solution. 
3.1 Processing of Siriraj-LBC 
The cell specimens are collected in bottles containing Siriraj liquid-based solution and keep 
at room temperature until processing. Siriraj-LBC slides are prepared according to the 
following steps (Bales, 2006) : agitate the bottle of specimen on a vortex mixer for 10 sec, and  
 




Fig. 1. Collecting devices for Siriraj-LBC: a 30-mL plastic bottle containing 10 mL of Siriraj 
liquid-based solution (A), and an extended-tip plastic spatula, arrow heads showing scores 
on the spatula (B) 
pour the suspension into a 15-mL centrifuge test tube; centrifuge the specimen at 1000 g. for 10 
min, and discard the supernatant; add Siriraj liquid-based solution (approximately 3 times of 
the sediment volume); agitate the test tube for 10 sec, aspirate 15-20 μL of the sample by using 
an auto-pipette, drop the sample onto a clean glass slide, smear the droplet to 2 cm in 
diameter, and let air dry at room temperature for 30 min; fix the slide in 95% ethanol for 20 
minutes, and finally stain it with the routine Papanicolaou’s staining technique (Figure 2). 
3.2 Performance of Siriraj-LBC 
Before a new screening or diagnostic tool is introduced into clinical use, it is necessary to 
evaluate its diagnostic performance. The best way for this evaluation is to compare the 
result from the new tool with that from the gold standard, revealing the performance 
parameters including sensitivity, specificity, positive predictive value (PPV), negative 
predictive value (NPV), false positive (FP), false negative (FN), and accuracy of the test. 
However, such parameters cannot be obtained in studies evaluating performance of cervical 
cytology methods because not all of the study population undergoes the gold standard 
testing, i.e. colposcopy or cervical histology. The gold standard is mostly lacking in the 
group of patients who have normal cervical cytology. Therefore, numerous studies have 
evaluated the comparative performance of the LBC methods and conventional cytology 
with respect to test positivity, i.e. the detection rate of squamous intraepithelial lesion (SIL). 
Most studies have utilized one to two types of study design, i.e. “split-sample” or “direct-to-
vial” study. With “split-sample” study, it is difficult to ensure that the two cytology 
specimens are comparable, since the specimen for conventional cytology slide is collected 
before the specimen for LBC. Therefore, this design seems to lead inherently to bias against 
LBC. With “direct-to-vial” study, the result of LBC is compared with that of conventional 
smear from historical data of an identical population; however, it is not certain that the two 
 





Fig. 2. Stained slides of Siriraj-LBC and conventional smears (A); micrographs of cervical 
cytology at low magnification: conventional smear (B1), Siriraj-LBC smear (B2) 
populations are identical. The diagnostic performance of our home-made LBC has been 
evaluated in both the “split-sample” study and “direct-to-vial” study. 
3.3 A split-sample study (Laiwejpithaya et al., 2008) 
3.3.1 Study population and specimen processing 
A cross-sectional study was carried out in the Gynecologic Cytology Unit, Department of 
Obstetric and Gynecology, Faculty of Medicine Siriraj Hospital, Mahidol University from 
January to February 2005. Study population were randomly selected from women attending 
for pelvic examination and cervical cancer screening at the Gynecologic Outpatient 
Department, Siriraj Hospital during the study period, excluding the women who had 
previously undergone any surgical procedures of the cervix, were pregnant or suspected of 
being pregnant, used any kinds of vaginal preparations within previous 24 hours, or denied 
to participate in the study. Specimens were collected for “split-sample” study by residents 
 






Fig. 3. Micrographs of cervical cytology using Siriraj-LBC at high magnification: normal (A), 
atypical squamous cells of undetermined significance (B), atypical squamous cells cannot 
exclude HSIL (C), low-grade squamous intraepithelial lesion with koilocytosis (D), high-
grade squamous intraepithelial lesion (E), and squamous cell carcinoma (F) 
or gynecologists who were staff members of the Department of Obstetrics and Gynecology. 
The collected cells were initially prepared for conventional cytology. Leftover cells in the 
collecting instruments were then collected for Siriraj-LBC by putting the instruments into a 
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30 mL plastic bottle containing 10 mL of Siriraj liquid-based solution. Specimens for both 
techniques were transported to the Gynecologic Cytology Unit, and processed by 
experienced technicians. All of the slides were screened by a team of cytotechnologists. The 
abnormal slides were reviewed and diagnosis made by an experienced cytopathologist. 
Examples of various abnormal cervical cells are shown in Figure 3. Evaluation of slides for 
conventional cytology and Siriraj-LBC was made in a blind fashion, i.e. the interpretations of 
the results from one technique were made without knowledge of those from the other 
technique. The cytological interpretation was made according to the Bethesda system 2001 
as followed: negative for intraepithelial lesion or malignancy, reactive or reparative change, 
atypical squamous cells of undetermined significance (ASCUS), low-grade squamous 
intraepithelial lesion (LSIL), high grade squamous intraepithelial lesion (HSIL), atypical 
squamous cells cannot exclude HSIL (ASC-H), squamous cell carcinoma (SCC), atypical 
glandular cells (AGC), or adenocarcinoma (Solomon et al., 2002). Clinical management of 
abnormal cytology includes referral to colposcopy and treatment according to the guideline 
of Siriraj Hospital. The patients with cytology results of ASCUS or LSIL were suggested to 
have either colposcopy or repeat cervical cytology testing, and those with ASC-H, HSIL or 
more aggressive ones were referred to colposcopy. 
3.3.2 Performance of cytology as a screening test 
The performance of cytology was evaluated from detection rate of abnormal cervicovaginal 
cytology, and predictive values using colposcopy and/or histology as the gold standard. The 
data for calculating positive predictive value (PPV) were obtained from the patients who had 
abnormal results of Siriraj-LBC, and underwent operative procedures revealing histology. 
Those procedures included colposcopic directed cervical biopsy, loop electrosurgical excision 
procedure (LEEP), cold-knife conization, and hysterectomy. The data were presented in n (%), 
or odds ratio (OR) and 95% confidence interval (CI), as appropriate. Percentage of agreement 
was used to determine the diagnostic agreement between pairs of specimens evaluated by 
conventional cytology and Siriraj-LBC. Kappa and Spearman rho correlation coefficient were 
used to determine correlation of result between pairs of specimens. Chi-square test was used 
to compare frequency between the two cytology techniques. All tests were 2-sided, and a P 
value of less than 0.05 was considered statistically significant. 
3.3.3 Results 
There were 479 participants recruited during the study period. Their mean age was 
41.6+12.6 years. The Siriraj-LBC significantly increased overall detection rate of abnormal 
cytology compared to the conventional method, i.e. from 1.67% to 11.1%, P < 0.001 (Table 1). 
The data yielded a complete diagnostic agreement of 430 of 479 pairs of specimens (89.8%). 
Among these, HSIL was detected in both specimens in 2 cases and cancer in 1 case. There 
were 49 cases whose Siriraj-LBC revealed higher cytologic grading than the conventional 
cytology did; whereas, none of the conventional cytology showed the vise versa result. The 
highest disagreement was found in 18 cases which were interpreted as normal by 
conventional cytology, but as ASCUS by Siriraj-LBC. As a result, these two cytology 
techniques had minimal to fair correlation with a Kappa of 0.128 (P < 0.001) and a Spearman 
rho correlation coefficient of 0.394 (P < 0.001) (Table 2). 
Table 3 reveals final diagnoses by colposcopy or histology in 45 patients with abnormal 
cytological diagnoses by Siriraj-LBC. In this specific group, the Siriraj-LBC had a positive  
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Finding Conventional Siriraj-LBC P-value 
Overall 8 (1.67) 53 (11.1) <0.001 
ASCUS 2 (0.42) 18 (3.76)  
ASC-H 1 (0.21) 7 (1.46)  
LSIL 2 (0.42) 15 (3.13)  
HSIL 2 (0.42) 10 (2.09)  
Cancer 1 (0.21) 3 (0.63)  
[Data are n (%). The data were analyzed using Fisher’s exact test.] 
From Laiwejpithaya, S.; Rattanachaiyanont, M.; Benjapibal, M.; Khuakoonratt, N.; Boriboonhirunsarn, 
D.; Laiwejpithaya, S.; Sangkarat, S.; & Wongtiraporn, W. (2008). Comparison between Siriraj liquid-
based and conventional cytology for detection of abnormal cervicovaginal smears: A split-sample 
study. Asian Pacific J Cancer Prev, Vol.9, No.4, pp. 575-580. 
Table 1. Detection Rates of Abnormal Cervical Cytology by Conventional Cytology and 
Siriraj-LBC 
 
Siriraj-LBC Conventional cytology 
 Negative ASCUS ASC-H LSIL HSIL Cancer 
Negative 426 0 0 0 0 0 
ASCUS 18 0 0 0 0 0 
ASC-H 7 0 0 0 0 0 
LSIL 12 2 0 1 0 0 
HSIL 6 0 1 1 2 0 
Cancer 2 0 0 0 0 1 
(Data are number of cases. Identical diagnoses are shown in bold; cases with negative diagnosis by 
conventional cytology but abnormal diagnoses by Siriraj-LBC are in red; Spearman rho correlation = 
0.394, Kappa = 0.128, P <0.001.) 
From Laiwejpithaya, S.; Rattanachaiyanont, M.; Benjapibal, M.; Khuakoonratt, N.; Boriboonhirunsarn, 
D.; Laiwejpithaya, S.; Sangkarat, S.; & Wongtiraporn, W. (2008). Comparison between Siriraj liquid-
based and conventional cytology for detection of abnormal cervicovaginal smears: A split-sample 
study. Asian Pacific J Cancer Prev, Vol.9, No.4, pp. 575-580. 
Table 2. Comparison of Cytological Diagnoses between Conventional Cytology and Siriraj-
LBC in 479 Pairs of Samples 
predictive value (PPV) of 71.1% whereas conventional cytology had PPV and negative 
predictive value (NPV) of 85.7% and 31.6%, respectively. None of the ASCUS had cervical 
lesions beyond CIN1. Seven cases of ASC-H was found in Siriraj-LBC but only one in 
conventional cytology; one in seven (14.28%) of ASC-H had cervical lesion of CIN2/3. The 
Siriraj-LBC did not miss any high grade cervical lesions (CIN2/3 or cancer) but over-
diagnosed cancer in one case; whereas conventional cytology failed to detect 3/6 (50%) cases 
of CIN2/3 and 1/2 (50%) cases of cancer. 
3.3.4 Discussion 
The present study used the data of the year 2005 when the Siriraj-LBC was undergoing the 
development process. We found that the detection rate of abnormal cells in Siriraj-LBC 
(11.06%) was much higher than that in the conventional cytology (1.67%). Even though the 
“split-sample” study has potential bias against LBC, we were not encountered with this 
problem. It was possible that the specimen processing in the Siriraj-LBC, especially the  
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Cytology Diagnoses by Colposcopy or Histology
 Normal CIN1/HPV CIN2/3 Cancer 
Conventional   
Negative 12 22 3 1b 
ASCUS 1 1 0 0 
ASC-H 0 0 1 0 
LSIL 0 0 1 0 
HSIL 0 1 1 0 
Cancer 0 0 0 1c 
Siriraj-LBC   
Negative NA NA NA NA 
ASCUS 7 9 0 0 
ASC-H 3 3 1 0 
LSIL 1 8 0 0 
HSIL 1 4 5 0 
Cancer 1a 0 0 2b,c 
(Cytological vs. histological diagnoses: aadenocarcinoma of endometrium vs normal, badenocarcinoma 
of unknown origin vs. adenocarcinoma of peritoneum, and cadenocarcinoma of endometrium vs. 
squamous cell carcinoma. CIN = cervical intraepithelial neoplasia, HPV = human papilloma virus 
infection, NA = not applicable) 
From Laiwejpithaya, S.; Rattanachaiyanont, M.; Benjapibal, M.; Khuakoonratt, N.; Boriboonhirunsarn, 
D.; Laiwejpithaya, S.; Sangkarat, S.; & Wongtiraporn, W. (2008). Comparison between Siriraj liquid-
based and conventional cytology for detection of abnormal cervicovaginal smears: A split-sample 
study. Asian Pacific J Cancer Prev, Vol.9, No.4, pp. 575-580. 
Table 3. Final Diagnoses by Colposcopy or Histology in 45 patients with Abnormal 
Cytological Diagnoses 
agitation of collecting devices in the liquid-based solution would elude the entrapped cells 
into the solution, therefore more cells were collected into the solution, and then evenly 
sampling to put onto a glass slide. We found that the complete diagnostic agreement 
between our LBC and the standard cytology was in high level (89.77%). However, the 
Kappa and the correlation coefficient were not in that high level; this was due to the 
interesting fact that detection rate of abnormal cells was much higher in the Siriraj-LBC than 
in the conventional cytology. Our result was comparable with that of Park et al (2001) 
showing that the results of conventional cytology and LBC exactly agreed in 91.4% of cases. 
The increase in detection rate raised the concern of increase in false positive cytology. In the 
present study, 45 cases of the abnormal cytology detected by Siriraj- LBC undergone gold 
standard testing. We found that the overall PPV in the Siriraj-LBC was less than that in the 
conventional cytology (71.1% vs. 85.7%). This implied that the Siriraj-LBC increase false 
positive result from 7.7% to 100.0%. In this specific group of patients with positive result by 
Siriraj-LBC, the conventional cytology had an astounding high false negative result of 81.2%. 
The false negative result of Siriraj-LBC was unknown because none of the patients with 
negative cytology undergone gold standard testing, despites, we assumed that the Siriraj-
LBC would have less false negative result since none of the negative Siriraj-LBC had 
abnormal conventional cytology. However, we are aware that these numbers are not the real 
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false negative and false positive rates, as the actual rates cannot be obtained due to the 
limitation of this kind of study. 
The high false positive result by Siriraj-LBC caused only little concern. Considering that only 
HSIL or cancer needs further invasive investigation, e.g. conization and/or diagnostic 
curettage, two in 45 cases had risk of unnecessary further investigation if the Siriraj-LBC was 
used in place of conventional cytology; this risk returned with the benefit of detecting three 
more cases of CIN2/3 and one case of cancer which were cases with false negative result in 
the conventional cytology. Noteworthy, the missing cancer in conventional cytology was a 
case of peritoneal adenocarcinoma without lesion at the uterine cervix. 
Our limited data showed that the conventional cytology had high false negative result 
where as the Siriraj-LBC had high false positive result. It is estimated that approximately 
two thirds of false negative result in the conventional cytology are caused by sampling error 
due to limited transfer of cells from the collecting device onto the slide (Gay et al., 1985). The 
false positive result in the Siriraj-LBC was due to the increase in all types of abnormal 
epithelial cells. This may be due to the misinterpretation of immature squamous metaplastic 
or atrophic cells to be abnormal cells because the morphologies of these cells are alike. 
Moreover these cells could be more easily detected in the Siriraj-LBC than in the 
conventional cytology because of the better quality of slide. However, we could not 
disregard the fact that our novice in the LBC field also contributed to this false positive. We 
expect to get better results of this technique in the future. 
Our result was compatible with many previous reports. Nanda et al (2000) reviewed the 
accuracy of conventional and new methods of Papanicolaou (Pap) testing to detect cervical 
cancer and its precursors. Ninety-four studies of the conventional Pap test showed that, 
estimates of sensitivity and specificity varied greatly in individual studies. In the 12 studies 
with the least biased, estimates sensitivity ranged from 30-80% and specificity ranged from 
86-100%. Guo et al (2005) evaluated the accuracy of a LBC test, ThinPrep®, by comparing 
concurrent LBC and cervical biopsy results of 782 patients who were referred for colposcopy 
because of previously abnormal conventional cytology. They found that concurrent LBC has 
high diagnostic accuracy for SIL. Besides, several studies showed that the detection rates of 
LSIL and HSIL are improved by LBC but the effect of LBC on the detection of ASC-US is 
uncertain (Limaye et al., 2003; Mount et al., 2004). 
The results from Siriraj-LBC and conventional cytology have high diagnostic agreement and 
minimal to fair correlation. The Siriraj-LBC increases detection rate of abnormal 
cervicovaginal cells with probably decrease false negative but increase false positive from 
the baseline values by conventional cytology. Therefore the screening performance of Siriraj-
LBC is not inferior to the conventional cytology and may be used as an alternative screening 
method for cervical cancer. 
3.4 A direct-to-vial study (Laiwejpithaya et al., 2009) 
3.4.1 Study population and specimen processing 
The study was carried out in the Gynecologic Cytology Unit, Department of Obstetrics and 
Gynecology, Faculty of Medicine Siriraj Hospital, Mahidol University. Data were retrieved 
from the database of the Gynecologic Cytology Unit. The data of conventional cytology and 
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negative cytology undergone gold standard testing, despites, we assumed that the Siriraj-
LBC would have less false negative result since none of the negative Siriraj-LBC had 
abnormal conventional cytology. However, we are aware that these numbers are not the real 
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false negative and false positive rates, as the actual rates cannot be obtained due to the 
limitation of this kind of study. 
The high false positive result by Siriraj-LBC caused only little concern. Considering that only 
HSIL or cancer needs further invasive investigation, e.g. conization and/or diagnostic 
curettage, two in 45 cases had risk of unnecessary further investigation if the Siriraj-LBC was 
used in place of conventional cytology; this risk returned with the benefit of detecting three 
more cases of CIN2/3 and one case of cancer which were cases with false negative result in 
the conventional cytology. Noteworthy, the missing cancer in conventional cytology was a 
case of peritoneal adenocarcinoma without lesion at the uterine cervix. 
Our limited data showed that the conventional cytology had high false negative result 
where as the Siriraj-LBC had high false positive result. It is estimated that approximately 
two thirds of false negative result in the conventional cytology are caused by sampling error 
due to limited transfer of cells from the collecting device onto the slide (Gay et al., 1985). The 
false positive result in the Siriraj-LBC was due to the increase in all types of abnormal 
epithelial cells. This may be due to the misinterpretation of immature squamous metaplastic 
or atrophic cells to be abnormal cells because the morphologies of these cells are alike. 
Moreover these cells could be more easily detected in the Siriraj-LBC than in the 
conventional cytology because of the better quality of slide. However, we could not 
disregard the fact that our novice in the LBC field also contributed to this false positive. We 
expect to get better results of this technique in the future. 
Our result was compatible with many previous reports. Nanda et al (2000) reviewed the 
accuracy of conventional and new methods of Papanicolaou (Pap) testing to detect cervical 
cancer and its precursors. Ninety-four studies of the conventional Pap test showed that, 
estimates of sensitivity and specificity varied greatly in individual studies. In the 12 studies 
with the least biased, estimates sensitivity ranged from 30-80% and specificity ranged from 
86-100%. Guo et al (2005) evaluated the accuracy of a LBC test, ThinPrep®, by comparing 
concurrent LBC and cervical biopsy results of 782 patients who were referred for colposcopy 
because of previously abnormal conventional cytology. They found that concurrent LBC has 
high diagnostic accuracy for SIL. Besides, several studies showed that the detection rates of 
LSIL and HSIL are improved by LBC but the effect of LBC on the detection of ASC-US is 
uncertain (Limaye et al., 2003; Mount et al., 2004). 
The results from Siriraj-LBC and conventional cytology have high diagnostic agreement and 
minimal to fair correlation. The Siriraj-LBC increases detection rate of abnormal 
cervicovaginal cells with probably decrease false negative but increase false positive from 
the baseline values by conventional cytology. Therefore the screening performance of Siriraj-
LBC is not inferior to the conventional cytology and may be used as an alternative screening 
method for cervical cancer. 
3.4 A direct-to-vial study (Laiwejpithaya et al., 2009) 
3.4.1 Study population and specimen processing 
The study was carried out in the Gynecologic Cytology Unit, Department of Obstetrics and 
Gynecology, Faculty of Medicine Siriraj Hospital, Mahidol University. Data were retrieved 
from the database of the Gynecologic Cytology Unit. The data of conventional cytology and 
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LBC were recruited from records of the years 2004 and 2006, respectively. The specimens for 
either conventional cytology or LBC were obtained from patients who had pelvic 
examination at the Gynecologic Outpatient Department of Siriraj Hospital during the 
relevant study periods. Specimens were collected by residents and staff members of the 
Department of Obstetrics and Gynecology. Collection of specimens for conventional 
cytology was performed according to the standard VCE smear technique. The collection of 
specimens for Siriraj-LBC was similar to that for conventional cytology, except that a special 
plastic spatula was used instead of the Ayre’s spatula and cotton swab. All specimens were 
transported to the Gynecologic Cytology Unit, and processed by experienced technicians. 
All of the slides were screened by a team of cytotechnologists and the abnormal slides were 
reviewed and diagnosis made by an experienced cytopathologist. Clinical management of 
abnormal cytology includes referral to colposcopy and treatment according to the guideline 
of Siriraj Hospital as mentioned above. 
3.4.2 Performance of cytology as a screening test 
The performance of Siriraj-LBC was evaluated from the detection rate of abnormal cervical 
cytology, and predictive values using cervical histology as the gold standard. The data for 
calculating negative predictive value (NPV) were obtained from the patients who had 
normal results of pre-hysterectomy screening cervical cytology. The data for calculating 
positive predictive value (PPV) were obtained from the patients who had abnormal results 
of cervical cytology and underwent operative procedures revealing cervical histology. Those 
procedures included colposcopic directed cervical biopsy, loop electrosurgical excision 
procedure (LEEP), cold-knife conization, and hysterectomy. Normal cervical histology was 
considered when the cervical mucosa was clear from any neoplastic lesion, ignoring the 
histopathological result of endometrium. The data were presented as mean+standard 
deviation (SD), n (%), or % change, as appropriate. Data were analyzed using the t-test for 
continuous data or Chi-square test for categorical data. All tests were 2-sided, and a P-value 
of  < 0.05 was considered statistically significant. 
3.4.3 Results 
There were 23,676 records of conventional Papanicolaou’s smear and 25,510 records of 
Siriraj-LBC in the years 2004 and 2006, respectively. Almost all of the specimens came from 
Thai women. The mean age+SD of women in the years 2004 and 2006 were 40.67+12.54 and 
42.66+12.21 years, respectively, which were not statistically different. Compared with the 
conventional smear, the Siriraj-LBC significantly increased overall detection rate of 
abnormal cytology by 110.23% (from 1.76% to 3.70%, P < 0.001), as it increased the detection 
rate of ASCUS, LSIL, HSIL, ASC-H, and malignant cells, but it did not significantly increase 
the detection rate of atypical glandular cells (AGC). The Siriraj-LBC significantly reduced 
the number of smears that were deemed poor quality by 73.44% (from 18.60% to 4.94%, P < 
0.001), as it markedly decreased the smears with obscuring blood and inflammatory cells, 
thick smears (Fig. 1b and c), and the smears without transformation zone component. 
However, the Siriraj-LBC had a marked increase in scant cellular smears (Table 4). 
The predictive value of Siriraj-LBC was better than that of conventional smear. The NPV of 
Siriraj-LBC was apparently higher than that of conventional cytology (96.33% vs. 92.74%,  
P = 0.001). The PPV of both methods was > 80%, which did not demonstrate any significant  
 
Cervical Cancer Prevention by Liquid-Based Cytology in a Low-Resource Setting 
 
125 
 Siriraj-LBC (N= 25,510) 
Conventional 
(N= 23,676) % change P 
All abnormal cervical cells 944 (3.70) 417 (1.76) +110.23 <0.001 
ASCUS 251 (0.98) 100 (0.42) +133.33 <0.001 
LSIL 278 (1.09) 132 (0.56) +94.64 <0.001 
HSIL 213 (0.83) 94 (0.40) +107.50 <0.001 
ASC-H 117 (0.46) 41 (0.17) +170.59 <0.001 
AGC 25 (0.10) 16 (0.07) +42.86 0.243 
Malignant 60 (0.24) 34 (0.14) +71.43 0.020 
All poor quality slides 1261 (4.94) 4404 (18.60) -73.44 <0.001 
No transformation zone 
component 1094 (4.29) 3766 (15.91) -73.04 <0.001 
Scant cellular smears 153 (0.60) 51 (0.22) +172.73 <0.001 
Thick smears 2 (0.01) 212 (0.90) -98.89 <0.001 
Obscuring blood and 
inflammatory cells 12 (0.05) 375 (1.58) -96.84 <0.001 
[Note: Data are n (%). Percent change was the incremental (+) or decremental (_) rate of Siriraj-LBC 
comparing to the baseline rate of conventional cytology. The data were analyzed using Chi-square test.] 
From Laiwejpithaya, S.; Benjapibal, M.; Laiwejpithaya, S.; Wongtiraporn, W.; Sangkarat, S.; & 
Rattanachaiyanont, M.  (2009). Performance and cost analysis of Siriraj liquid-based cytology: a direct-
to-vial study. Eur J Obstet Gynecol Reprod Biol, Vol. 147, No.2, pp. 201-205. 
Table 4. Detection rates of abnormal cervical cells and quality of slides using Siriraj liquid-
based cytology (Siriraj-LBC, year 2006) and conventional Papanicolaou’s smear (year 2004) 
difference between the methods. The PPV for SCC was the highest; whereas that for 
abnormal glandular cell types was the lowest (Table 5). The cost of Siriraj-LBC was higher 
than that of the conventional cytology used in Siriraj Hospital but lower than that of the 
commercially available LBC in Thailand. When cost was estimated from the laboratory 
charge, it was found that the cost of Siriraj-LBC was 1.67, 0.50, and 0.30 times of those of the 
conventional cytology, Liqui-Prep®, and ThinPrep®, respectively (Table 6). 
 
Cervical cytology N Cervical histology, n (%) P 
  Normal Abnormal  
Normal     
Siriraj-LBC 1012 975 (96.33)(a) 37 (3.67) 0.001 
Conventional 744 690 (92.74) (a) 54 (7.26)  
Overall abnormalitie     
Siriraj-LBC 277 47 (16.97) 230 (83.03)(b) 0.285 
Conventional 167 22 (13.17) 145 (86.83)(b)  
ASCUS     
Siriraj-LBC 13 7 (53.85) 6 (46.15)(b) 0.342 
Conventional 9 3 (33.33) 6 (66.67)(b)  
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continuous data or Chi-square test for categorical data. All tests were 2-sided, and a P-value 
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 Siriraj-LBC (N= 25,510) 
Conventional 
(N= 23,676) % change P 
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ASC-H 117 (0.46) 41 (0.17) +170.59 <0.001 
AGC 25 (0.10) 16 (0.07) +42.86 0.243 
Malignant 60 (0.24) 34 (0.14) +71.43 0.020 
All poor quality slides 1261 (4.94) 4404 (18.60) -73.44 <0.001 
No transformation zone 
component 1094 (4.29) 3766 (15.91) -73.04 <0.001 
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Thick smears 2 (0.01) 212 (0.90) -98.89 <0.001 
Obscuring blood and 
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[Note: Data are n (%). Percent change was the incremental (+) or decremental (_) rate of Siriraj-LBC 
comparing to the baseline rate of conventional cytology. The data were analyzed using Chi-square test.] 
From Laiwejpithaya, S.; Benjapibal, M.; Laiwejpithaya, S.; Wongtiraporn, W.; Sangkarat, S.; & 
Rattanachaiyanont, M.  (2009). Performance and cost analysis of Siriraj liquid-based cytology: a direct-
to-vial study. Eur J Obstet Gynecol Reprod Biol, Vol. 147, No.2, pp. 201-205. 
Table 4. Detection rates of abnormal cervical cells and quality of slides using Siriraj liquid-
based cytology (Siriraj-LBC, year 2006) and conventional Papanicolaou’s smear (year 2004) 
difference between the methods. The PPV for SCC was the highest; whereas that for 
abnormal glandular cell types was the lowest (Table 5). The cost of Siriraj-LBC was higher 
than that of the conventional cytology used in Siriraj Hospital but lower than that of the 
commercially available LBC in Thailand. When cost was estimated from the laboratory 
charge, it was found that the cost of Siriraj-LBC was 1.67, 0.50, and 0.30 times of those of the 
conventional cytology, Liqui-Prep®, and ThinPrep®, respectively (Table 6). 
 
Cervical cytology N Cervical histology, n (%) P 
  Normal Abnormal  
Normal     
Siriraj-LBC 1012 975 (96.33)(a) 37 (3.67) 0.001 
Conventional 744 690 (92.74) (a) 54 (7.26)  
Overall abnormalitie     
Siriraj-LBC 277 47 (16.97) 230 (83.03)(b) 0.285 
Conventional 167 22 (13.17) 145 (86.83)(b)  
ASCUS     
Siriraj-LBC 13 7 (53.85) 6 (46.15)(b) 0.342 
Conventional 9 3 (33.33) 6 (66.67)(b)  
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Cervical cytology N Cervical histology, n (%) P 
  Normal Abnormal  
LSIL     
Siriraj-LBC 41 6 (14.63) 35 (85.37)(b) 0.597 
Conventional 29 3 (10.34) 26 (89.66)(b)  
HSIL     
Siriraj-LBC 124 10 (8.06) 114 (91.94)(b) 0.301 
Conventional 71 3 (4.23) 68 (95.77)(b)  
ASC-H     
Siriraj-LBC 33 4 (12.12) 29 (87.88)(b) 0.579 
Conventional 23 4 (17.39) 19 (82.61)(b)  
SCC     
Siriraj-LBC 26 0 (0.00) 26 (100.00)(b) 0.183 
Conventional 15 1 (6.67) 14 (93.33)(b)  
Abnormal glandular cell types (AGC+AIS+Adenocarcinoma)   
Siriraj-LBC 40 20 (50.00) 20 (50.00)(b) 0.464 
Conventional 20 8 (40.00) 12 (60.00)(b)  
[Note: Data are n (% of the corresponding row). The data were analyzed using Chisquare test. 
Abnormal cervical histology meant cervical tissue specimen showing intraepithelial neoplasia, 
squamous cell carcinoma, or adenocarcinoma. (a) Negative predictive value; (b) positive predictive 
value; AGC, atypical glandular cells; AIS, adenocarcinoma in situ; ASCUS, atypical squamous cells of 
undetermined significance; ASC-H, atypical squamous cells cannot exclude HSIL; CI, confidence 
interval; LSIL, low grade squamous intraepithelial lesion; HSIL, high-grade squamous intraepithelial 
lesion; SCC, squamous cell carcino] 
From Laiwejpithaya, S.; Benjapibal, M.; Laiwejpithaya, S.; Wongtiraporn, W.; Sangkarat, S.; & 
Rattanachaiyanont, M.  (2009). Performance and cost analysis of Siriraj liquid-based cytology: a direct-
to-vial study. Eur J Obstet Gynecol Reprod Biol, Vol. 147, No.2, pp. 201-205. 
Table 5. Predictive values of cervical cytology using Siriraj liquid-based cytology (Siriraj-
LBC, year 2006) and conventional Papanicolaou’s smear (year 2004) 
 
Costs Thai baht US dollars 
Siriraj liquid-based cytology 150.00 4.55 
Siriraj conventional cytology 90.00 2.72 
Commercially available liquid-based cytology techniques   
Liqui-Prep® 300.00 9.09 
ThinPrep® 500.00 15.15 
From Laiwejpithaya, S.; Benjapibal, M.; Laiwejpithaya, S.; Wongtiraporn, W.; Sangkarat, S.; & 
Rattanachaiyanont, M.  (2009). Performance and cost analysis of Siriraj liquid-based cytology: a direct-
to-vial study. Eur J Obstet Gynecol Reprod Biol, Vol. 147, No.2, pp. 201-205. 
Table 6. Costs of Siriraj liquid-based cytology, conventional cytology at Siriraj Hospital, and 
commercially available liquid-based cytology techniques in Thailand 
 




In the present direct-to-vial study, we compared the data of patients undergoing specimen 
collection for cervical cytology by the same physician group in two 12-month periods, 
targeting conventional Papanicolaou’s smear in 2004 and Siriraj-LBC in 2006. As expected, 
the Siriraj-LBC increased detection of precancerous lesions of the uterine cervix. From our 
previous split-sample study conducted during the development of this technology in 2005, 
the Siriraj-LBC showed a tremendously increased detection rate of abnormal cytology of 
565%, from 1.67% to 11.10%. However, the increase in the detection rate decreased to 100% 
in 2006 when the Siriraj-LBC was routinely used. The huge increase in 2005 was probably 
due to rigorous examination of slides during the development of the new technology. The 
increase in 2006 was less pronounced but still impressive even though the slides were 
routinely examined in the same manner as they were in 2004. 
The increase in detection rate of Siriraj-LBC was probably due to the benefit of improved 
slide quality. Whereas 18.60% of our conventional smears had limited quality due to no 
endocervical or transformation zone component, obscuring blood and inflammatory cells, 
thick smear, or scant cellular smears, only 4.94% of the Siriraj-LBC had smears limited by 
these factors. Our results were in line with the experience of others (Bolick et al.,1998; 
Corkill et al.,1998; Diaz-Rosario et al.,1999; Dupree et al.,1998; Fremont-Smith et al.,2004; 
Papillo et al.,1998; Roberts et al.,1997). The improvement in the quality of slides in 2006 is 
likely to be due to the property of Siriraj- LBC itself rather than other factors, since the 
detection rate and quality of slides before 2005 had never reached those of the slides in 2006. 
Our 3-year retrospective data from 2002 to 2004 showed that our conventional smears had 
detection rates varying from 1.7% to 2.1%, and the poor quality smears varying from 18.6% 
to 32.6%. 
The better detection rate of intraepithelial lesions is a common thread in studies on liquid-
based cervical cytology. The increase in detection rates in previous studies varied from 
12.0% to 106.8% (Bolick et al.,1998; Corkill et al.,1998; Diaz-Rosario et al.,1999; Dupree et 
al.,1998; Fremont-Smith et al.,2004; Papillo et al.,1998; Roberts et al.,1997). The reason for the 
wide range of this effect is not clear; but a wide range in detection rates of intraepithelial 
lesions by the conventional smear is also noted in the same studies, i.e. 1.1–2.7%. The 
increment seems higher in the studies with a low baseline detection rate using the 
conventional smear. In addition, this variation may represent regional or population-based 
differences, or different practice patterns. In our direct-to-vial study, Siriraj-LBC had a 100% 
increment for the detection of SIL from a baseline rate of 0.96% (LSIL = 0.56% and HSIL = 
0.40%). The overwhelming diagnostic improvement of Siriraj-LBC, especially with respect to 
HSIL detection, would enhance the success of cervical cancer screening in our institute. 
Owing to the fact that the LBC slide makes it easier for a cytologist to find small numbers of 
abnormal cells, the percentages of ASCUS and ASC-H were also higher with Siriraj-LBC 
compared with the conventional method. The results were welcomed by the gynecologists 
who were chronically in fear of false negative results. 
The increase in detection rate came with the concern of an increase in false positive cytology. 
From our cytology-histology paired data, Siriraj-LBC increased NPV without compromising 
PPV. This information implied that the Siriraj-LBC decreased false negative results, i.e. from 
7.26% to 3.67% (P = 0.001) without affecting the overall false positive result, i.e. 13.17% vs. 
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Cervical cytology N Cervical histology, n (%) P 
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Conventional 20 8 (40.00) 12 (60.00)(b)  
[Note: Data are n (% of the corresponding row). The data were analyzed using Chisquare test. 
Abnormal cervical histology meant cervical tissue specimen showing intraepithelial neoplasia, 
squamous cell carcinoma, or adenocarcinoma. (a) Negative predictive value; (b) positive predictive 
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Our 3-year retrospective data from 2002 to 2004 showed that our conventional smears had 
detection rates varying from 1.7% to 2.1%, and the poor quality smears varying from 18.6% 
to 32.6%. 
The better detection rate of intraepithelial lesions is a common thread in studies on liquid-
based cervical cytology. The increase in detection rates in previous studies varied from 
12.0% to 106.8% (Bolick et al.,1998; Corkill et al.,1998; Diaz-Rosario et al.,1999; Dupree et 
al.,1998; Fremont-Smith et al.,2004; Papillo et al.,1998; Roberts et al.,1997). The reason for the 
wide range of this effect is not clear; but a wide range in detection rates of intraepithelial 
lesions by the conventional smear is also noted in the same studies, i.e. 1.1–2.7%. The 
increment seems higher in the studies with a low baseline detection rate using the 
conventional smear. In addition, this variation may represent regional or population-based 
differences, or different practice patterns. In our direct-to-vial study, Siriraj-LBC had a 100% 
increment for the detection of SIL from a baseline rate of 0.96% (LSIL = 0.56% and HSIL = 
0.40%). The overwhelming diagnostic improvement of Siriraj-LBC, especially with respect to 
HSIL detection, would enhance the success of cervical cancer screening in our institute. 
Owing to the fact that the LBC slide makes it easier for a cytologist to find small numbers of 
abnormal cells, the percentages of ASCUS and ASC-H were also higher with Siriraj-LBC 
compared with the conventional method. The results were welcomed by the gynecologists 
who were chronically in fear of false negative results. 
The increase in detection rate came with the concern of an increase in false positive cytology. 
From our cytology-histology paired data, Siriraj-LBC increased NPV without compromising 
PPV. This information implied that the Siriraj-LBC decreased false negative results, i.e. from 
7.26% to 3.67% (P = 0.001) without affecting the overall false positive result, i.e. 13.17% vs. 
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16.97% (P = 0.285). However, we were aware that these numbers were not the real false 
negative and false positive rates, as the actual rates could not be obtained due to the 
limitations of this kind of study. The Siriraj-LBC displayed a higher false positive HSIL than 
the conventional method did, probably due to the morphological resemblance of immature 
squamous metaplastic or atrophic cells to HSIL. As these cells were easier to detect in the 
Siriraj-LBC than in the conventional smear, the higher false positive HSIL was not 
unexpected. However, as discussed in the split-sample study, we could not disregard the 
fact that our being novices in the LBC field could contribute to this false positivity. We 
expect to get better results using this technique in the future. 
When the laboratory cost of the various cervical cytology techniques was calculated, we 
found that the cost of Siriraj-LBC was only 67% higher than that of the conventional 
cytology technique used in Siriraj Hospital and was lower than that of the commercially 
available LBC techniques in Thailand. However, we did not directly compare the diagnostic 
performance among the LBC techniques; therefore we did not know which LBC technology 
was the most cost-effective for our population. Nevertheless, because of its low cost and 
better performance than conventional cytology, Siriraj-LBC would be an accessible LBC 
technology for women of low-socioeconomic level. As a result, Siriraj-LBC has replaced the 
conventional cytology in Siriraj Hospital  since 2006. 
The Siriraj-LBC shows an impressive improvement in the detection rate of abnormal cervical 
cells. The Siriraj-LBC has an acceptable performance and quality which are within the same 
range as other previously reported LBC techniques. Therefore, the Siriraj-LBC may be 
considered a better option for cervical cancer screening than the conventional method and 
more economical than the commercially available LBC. 
4. Conclusion 
The diagnostic performance of our home-made LBC has been evaluated in both the “split-
sample” study and “direct-to-vial” study and we have found that the screening performance 
of Siriraj-LBC was superior to that of conventional cytology. Our LBC does not require any 
expensive equipment; therefore its cost is much less than that of the commercial ones. 
Siriraj-LBC may be considered a better option for cervical cancer screening than the 
conventional method. For centers where conventional Pap smear does not perform well, the 
introduction of a low cost Siriraj-LBC may help to improve performance. We believe that the 
Siriraj-LBC will make a significant change in cervical cancer screening and patient 
management in our country. 
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1. Introduction 
There is a minimally invasive nosological entity among cervical precursor lesions and frank 
invasive cancer. Initially described by Mestwerdt in 1947, cases of microinvasive carcinoma 
of the uterine cervix represent a group of patients with better prognosis with the possibility 
of needing less radical treatment.1 Despite that microinvasion has been defined since the 
1940s, the depth of invasion, as well as the lateral extension, are subjects of various 
classifications and certain controversy. 
2. Definition 
There is a continuum of knowledge about microinvasive cervical cancer from its initial 
landmark in 1947, which must be understood so that we can reflect on the information and 
approaches recommended by different authors. 
The first conception of microinvasive squamous cell carcinoma of the cervix was presented 
by Mestwerdt in 1947, who strived to develop an early diagnosis of cervical carcinoma. In 
this first work, Mestwerdt cited that the discovery of 43 cases of microcarcinoma was 
possible with the combination of colposcopy and the iodine test with the standard histologic 
examination over a period of 9 ½ years. This author considered the attributes of 
microcarcinoma of cervix to be the following:  
- Size still at the microscopic level.  
- All originate from the squamous epithelium of the cervix to cervical canal up to its 
limit, but is still not associated with the surface.  
- They show all the phases of atypia. 
- Besides the complete structure of changes in all layers of the surface epithelium, where 
its construction is in the longer recognizable, there is simultaneous rupture of the basal 
membrane by glandular budding in the connective tissue. 
- Also observed on the surface is invasion of lymphatic spaces and blood vessels. 
The measurement of stromal invasion, always defined microscopically, should be done from 
the basement membrane. 1 In 1961, the International Federation of Gynecology and 
Obstetrics (FIGO) on proposing the classification cervical cancer, recommended the 
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subdivision of stage I into IA and IB. Stage IA would be defined as early stromal invasion. in 
1965, two groups published the problematization with respect to depth of invasion. 
Margulis and coworkers believed that the definition should include invasion of 5.0 mm of 
the stroma, while Ullery and coworkers considered invasion beyond the basement 
membrane of 3.0 mm.  
Temporarily, we can refer to 1971 when FIGO introduced the term “occult cancer of the 
cervix” for stage IA. In 1973, Burghardt proposed the study of the volume of the lesion, 
believing that 500 mm3 would be a better option for the definition in question.  
Despite the above mentioned proposal by FIGO, there was still no clear criteria for minimal 
stromal invasion. In 1974, the Society of Gynecologic Oncologists (SGO) proposed a 
definition for microinvasion as a lesion that invaded below the basement membrane to a 
depth of 3 mm or less, with no evidence of invasion of the lymphovascular space. SGO 
believed that the horizontal dimension would not enter into the classification of 
microinvasion. Despite new classifications in 1971 and 1975, with the introduction of the 
term occult carcinoma, FIGO would return in the 1980s with a definition that considered the 
measurement of the depth of invasion in cervical cancer in stage I. The preoccupation with 
the depth and extension of the lesion can also be observed in the study of Averette and 
coworkers, which in 1976 led to expectations regarding lesions of up to 1 mm, and in the 
study of Sedlis and colleagues, who determined a maximal extension of 4 mm for the 
definition of microinvasive cancer. The new definition from FIGO in 1985 brought criteria 
for carcinomas referred to as pre-clinical, dividing them into two groups: IA1 with minimal 
stromal invasion and IA2 with invasion up to 5 mm and not exceeding 7 mm. Again, in 
referring to the FIGO classification, we observe the reiteration of not considering the 
influence of the invasion of the lymphatic space in the stage. 
In 1994, FIGO presented the classification of cervical cancer that put together clear 
measurements for the invasion of the stroma in stages IA1 and IA2. This classification was 
revised in 2009, and the term microscopic cancer was proposed for stage IA. Therefore, all 
gross lesions, even if superficial, were considered stage IB. The invasion was limited to 5 
mm in depth and 7 mm of extension. The involvement of the lymphovascular space 
continued to have no effect on staging, but did influence the treatment. The invasion of the 
stroma up to 3 mm in depth and 7 mm of extension characterized stage IA1, and invasion of 
the stroma between 3 mm and 5 mm in depth and 7 mm of extension, stage IA2. 2, 3 
Certainly one of the main factors involved in the definition of the depth of invasion and in 
the classification of microinvasion was the involvement of the lymphovascular space and 
consequently the possibility of lymph node metastasis in the pelvis and vaginal 
recurrence. The role of lymphovascular invasion and the possibility of lymph node 
metastasis are also the subject of many speculations about the treatment of microinvasive 
cervical carcinoma. 
3. Diagnosis 
Over the last years this early invasive carcinoma has become an increasingly important part 
of the problem of cervical cancer. The mounting frequency with which these diagnoses are 
made is directly related to the increased use of the Papanicolaou smear technique and use of 
large loop excision of the transformation zone.  
 




FIGO: International Federation of Gynecology and Obstetrics; 
SOG: Society of Gynecologic Oncologists (USA); 
JSOG: Japanese Society of Obstetrics & Gynecology; 
Fig. 1. Evolution of the definition of microinvasive carcinoma of the cervix 
Although definitive diagnosis of microinvasion must be done by histological evaluation of 
specimens obtained by conization or hysterectomy, some colposcopy signs could identify 
this situation. Reid pointed out some colposcopic and clinical warning signs of invasion: 
 Friable areas, with easy bleeding upon touch 
 Defined areas as colposcopically significant – with Reid index ≥ 5 – showing irregular 
surface 
 Superficial ulcers with white epithelium at edges 
 Atypical vessels 
 Mosaic or rough dotted area at extreme, particularly when showing large and irregular 
intercapillary distance 
 Groups of lesions with large extension and with characteristics of colposcopic lesion of 
high grade 
 Colposcopic lesions of high grade type penetrating more than 5 mm in the endocervical 
canal 
 Intra-epithelial cervical lesions of high grade on histology by biopsy in which the 
basement membrane cannot be clearly defined 
 Cyotological evidence of squamous cell carcinoma or of adenocarcinoma in situ 
Despite the efforts for colposcopic detection of microinvasive alterations, this diagnostic 
modality does not show a good predictive indicator of the severity of the cervical lesion and 
tends to underestimate microinvasive carcinoma. The colposcopic images, besides not being 
characteristic, are difficult to interpret and microinvasive lesions are often endocervical. 
Colposcopic signs are even more inconsistent when the focus of invasion is small and 
superficial.4, 5, 6 There are no specific colposcopic findings of microinvasive carcinoma. The 
findings resemble cases of in situ and invasive carcinoma. Colposcopy is better at identifying 
pre-malignant or frank invasive disease than microinvasive lesions. 
The determination of microinvasion should always be done by systematic histologic 
evaluation of a consistent sample of cervix, using serial sections in order to determine with 
precision the depth and extension of the invasion, besides the penetration of the 
lymphovascular space. Even with colposcopic lesion with guided biopsy of the cervix, 
sometimes there is no guarantee that the biopsied material is sufficient for defining the 
diagnosis. In the localization of the microinvasion, with the analysis of the conization 
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specimens of the cervix, the focus of the microinvasion from the basement membrane of the 
epithelium is found at the following sites: the ectocervix besides the last gland in 11% of 
cases, inside the transformation zone in 71% of cases (22% on the surface of the epithelium 
and 49% in the depth or glandular crypts) and in the endocervical canal in 18% of cases. 7 
The whole extension of cervical cancer screening programs have led to an increase in the 
detection of microinvasion, as well as the dissemination of the utilization of a diathermy 
loop for excision of altered areas and resection of the transformation zone in the 
investigation of suspect cases. 
The evaluation of the biopsy by an experienced pathologist is essential for the correct 
identification of microinvasion with its respective measurement and characterization of the 
presence or not of invasion of the lymphovascular space. Also, it is of great importance that 
the pathologist can determine the presence of compromise of the margins and the grade of 
these lesions. Therefore, for young patients with the intention of preserving fertility, the 
identification of these parameters can translate to conservative treatment. 
4. Treatment 
Based on the premise that the neoplastic cell with malignant differentiation has the potential 
to metastasize through the lymphatic and vascular systems, it should be takrm into 
consideration that this could occur even at initial stages of invasion of the basement 
membrane. Meanwhile, various lines of epidemiological evidence indicate stage IA1 as 
having a low potential for lymph node metastasis and good disease-free survival rates. Lee 
and et al. found that the lymphovascular space was compromised in 0.9% of cases when 
invasion was less than 1 mm and in 10.2 % when invasion was between 1 and 3 mm deep. 8 
Ostor et al. demonstrated compromise of the space lymphovascular in 3% and 15% when 
invasion was up to 1 mm and between 1 and 3 mm, respectively.9 
The requirements in relation to the involvement of the lymphovascular space with tumor 
cells are still points to ponder; therefore, understanding that doubt is part of the thought 
process, we propose the following reflections: (1) Why ignore the involvement of the 
lymphovascular space? (2) Why value the involvement of the lymphovascular space? 
Why ignore the involvement of the lymphovascular space? 
 Conflicting evidence 
 Studies not associating the involvement of the lymphovascular space with lymph node 
metastasis 
 Interpretation of invasion of the lymphovascular space is subjective 
 Inflammation and retraction artifacts can cause confusion 
Why value the involvement of the lymphovascular space? 
 Think of invasive tumor 
 Associated with greater probability of lymph node metastasis 
 Associated with worse prognosis – more radical treatment 
 Increased identification with increased serial sections 
The initial idea of Mestwerdt of performing serial histologic sections with detailed 
examination of the sections is still an interesting prerogative in this aspect. In 1975, a study 
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with serial sections of 30 microinvasive carcinomas of the cervix (invasion between 2 and 5 
mm) demonstrated that 30% had compromise of the lymphovascular space – based on the 
first of the blocks; but this percentage increased to 57% with serial sections. No patient 
showed lymph node metastasis.10 
5. Lymph nodes 
Although FIGO does not include the lymph node status in its staging system for cervical 
carcinoma, it is known that for patients treated surgically in initial stages, the presence of 
ganglion metastasis is the most important risk factor for recurrence and mortality. 11 In 
addition, an adequate knowledge of lymph node compromise is essential for the indication 
of adjuvant treatment. 
Traditionally, for lymph node evaluation, the technique proposed is bilateral 
retroperitoneal lymphadenectomy. However, this practice, associated with high rates of 
short- and long-term morbidity, has been questioned in initial stages, since a small 
portion of patients show lymphatic compromise. Studies with patients in stages IA1 and 
IA2 demonstrated an incidence of lymph node metastasis in 7.3% (0%-13.8%) of cases.12, 13 
In the work of Sevin et al. 14, no cases of lymph node invasion were found when analyzing 
110 cases of microinvasive carcinoma with stromal invasion less than or equal to 5 mm. 
What we can reflect on the positivity of the lymph nodes is that as the depth of stromal 
invasion increases, there is an increase in the percent of lymph nodes compromised with 
metastatic cells. Thus, some studies demonstrate the following relation between depth of 
invasion and lymph node metastasis: invasion up to 1 mm, presence of <1 to 1.5% of 
lymph nodes compromised; between 1 and 3 mm, <1 to 4.2%; between 3 and 5 mm, 
between 2 and 3.7%. 8,9 
Aimed at reducing the rate of complications of lymphadenectomy, the technique of sentinel 
lymph node biopsy (SLB), introduced by Cabañas, 15 has been studied in cases of cervical 
carcinoma. Studies evaluating the accuracy and applicability of sentinel lymph node biopsy 
in cervical carcinoma have shown promising results (high rates of detection and low false-
positive rates), mainly when analyzing cases of lesions less than 2 cm.16 Other authors have 
demonstrated a 94% rate of detection of sentinel lymph nodes associated with sensitivity 
and negative predictive value of 100%, for tumors less than 2 cm. 17 The recent study 
SENTICOL 18, in which SLB was carried out in a uniform manner by experienced surgeons, 
combining techniques that utilize blue dye and lymphoscintigraphy with technetium (Tc99), 
demonstrated a sensitivity of 92% and obtained ideal mapping in 75% of patients. These 
authors concluded that when utilizing the two techniques combined, a negative result in the 
sentinel lymph nodes on both sides indicates the absence of metastatic disease, with a 
negative predictive value of 98.2%. 
In accordance with studies in 2011, the use of laparoscopy in the detection and removal of 
sentinel lymph nodes (SL) is evidence-based and safe with either the use of blue dye or Tc99 
lymphoscintigraphy. When these two detection techniques were compared, Tc99 showed a 
significantly higher rate of identification of sentinel lymph nodes. 19 The identification of LS 
by SPECT-CT has also been the target of studies. The results to date suggest that this 
examination can increase the detection and improve the preoperative anatomic localization 
of LS, when compared to lymphoscintigraphy with Tc99. 20, 21 
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In relation to microinvasive disease, there are no studies only with this population, the focus 
of interest of the present chapter. A significant part of the works with initial cases includes 
patients between FIGO stages IA1 and IB1. Although current studies have shown 
encouraging results, SLB cannot yet be considered standard treatment for initial cases of 
cervical carcinoma. Its clinical impact must be demonstrated in randomized studies that 
compare outcomes such as disease-free survival and global survival between patients 
submitted to traditional pelvic lymphadenectomy and to the sentinel lymph node technique. 
Certainly, one important question in the context of microinvasive carcinoma is the search for 
more conservative therapies with the establishment of a certain balance between uterine 
preservation and disease-free surgical margins. On demonstrating a lower lymph node 
compromise in microinvasive carcinoma, especially when there is no involvement of the 
lymphovascular space, this balance becomes more appropriate.  
The primary treatment of cancer of the cervix and thereby of the microcarcinoma of the 
cervix is surgery, save exceptions of cases with clinical contraindications to surgery, where 
radiotherapy combined with chemotherapy and the possibility of brachytherapy are valid 
options. Extended radical hysterectomy with lymphadenectomia is the standard treatment 
for those women who do not want more children, certainly observing the considerations 
previously indicated, which authorize a more conservative approach. This standard 
treatment –radical hysterectomy– can be executed by the vaginal route, Schauta-Amreich or 
Schauta-Stoeckel surgery with videolaparoscopic radical pelvic lymphadenectomy, or by the 
abdominal route, Wertheim-Meigs surgery.  
Dargent surgery, radical trachelectomy with videolaparoscopic pelvic lymphadenectomy, is 
indicated in young patients who wish to preserve fertility, constituting a more radical 
alternative than conization. 22  
When the discussion of the treatment of cancer of the cervix includes specificities such as the 
case of microinvasion, it is also necessary to consider other specificities. In this point, we 
must focus on the characteristics of the disease, with the peculiarities of the stage (IA1 or 
IA2), of the histologic type and of the presence of invasion of the lymphovascular spaces, as 
well as on the characteristics of the patient, with possible clinical restrictions, with questions 
of preservation of fertility and with the consent of treatment options. 
For the cases with stage IA1 where we did not find any evidence of involvement of the 
lymphovascular space, conservative treatment – by conization of the cervix –can be an 
acceptable option, especially for those patients who wish to preserve fertility. 23, 24 The 
participation of the patient in agreement with the approach should always be pointed out; at 
this moment, concordance with a more radical treatment can be an option – with the choice 
of simple hysterectomy, for example. Current recommendations from the World Health 
Organization, without specification of histopathologic type, are simple hysterectomy for 
women with microinvasive cancer stage IA1.25 Risk for recurrence after this treatment is 1% 
and overall 5-year survival is 99%. 27 When faced with compromise by tumor cells in the 
lymphovascular space, the indication should be major radical treatment – consisting of total 
hysterectomy with parametrectomy, resection of the upper third of the vagina and pelvic 
lymphadenectomy.  
Those patients with stage IA2 have a greater potential of lymph node metastasis at this 
stage, which could also involve a more radical treatment. The cases where no invasion of the 
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lymphovascular space is observed, the complete excision of the lesion by extrafascial 
hysterectomy or, in selected cases and when there is desire for preservation of fertility, by 
conization with free margins can be an option. When fertility is not an issue, the treatment 
proposed here should also be considered, with an indication of hysterectomy. Alternatively, 
trachelectomy or radical hysterectomy can also be applied, without the need for pelvic 
lymphadenectomy. 26 
As in the previously mentioned cases of involvement of the lymphovascular space, also in 
the cases of stage IA2, there is an indication of radical hysterectomy with pelvic 
lymphadenectomy. When the preservation of fertility is desired, vaginal radical 
trachelectomy with extra-peritoneal or laparoscopic pelvic lymphadenectomy is the option. 
Risk of recurrence of IA2 tumors treated with radical hysterectomy and bilateral pelvic 
lymphadenectomy is 3–5% and overall 5-year survival is 96%.27  
6. Follow-up 
After treatment, the patients should have a regular periodic follow-up with clinical 
gynecologic examinations, oncotic colpocytology and colposcopy. Follow-up protocols after 
the conclusion of the initial treatment are variable, using a number of tests in a variety of 
intervals with debatable results. The components that should be considered for an ideal 
follow-up program are: (i) optimal interval for the follow-up; (ii) available tests for follow-
up; (iii) modifications in the course of the follow-up in accordance with the risk of 
recurrence identified in the primary treatment.  
The tests available for the follow-up are the following: anamnesis, physical examination, 
cervical cytology, ultrasonography, magnetic resonance, computed tomography, positron 
emission tomography (PET) and tumor markers. Physical examination and vaginal cytology 
are the most commonly used methods in the follow-up. The physical examination, 
especially, has led to a considerable number of detections in patients in which cyto-detection 
was low. To date, there is little definitive evidence of the most suitable strategy for follow-
up (for patients clinically free of disease after primary treatment ). Therefore, it is important 
that the patient have some understanding to facilitate the follow-up. Among these, general 
symptoms such as weight loss, loss of appetite, fatigue, pain, cough, dyspnea, confusion, 
and edema of legs (mainly unilateral), beside local symptoms such as bleeding and vaginal, 
vesical or anal secretion, distension or abdominal pain.28 
The periodicity recommended for the doctor visits is as follows: 3 to 4 months in the first 2 
years; every 6 months for the next 3 years; and annually after this period, maintaining a 
follow-up for 10 years. 
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1. Introduction 
Cervical cancer, the second most common cancer in women, develops through well-defined 
precursor lesions with potential to progress to invasive disease if not properly detected and 
eradicated. In cervical carcinogenesis, human papillomavirus (HPV) plays an important 
causal role. Besides the evidental causal role in cervical carcinogenesis, HPV is an important 
prognostic factor for disease progression as well (Syrjänen, 2000). Early invasive carcinoma 
is an intermediate state in the development of invasive carcinoma from a cervical 
intraepithelial neoplasia. According to clinical experience, the early stage of invasion has 
much better prognosis when compared to an advanced invasive cancer. This warrants the 
recognition of microinvasive carcinoma (MIC) as a separate entity among cervical cancer 
that is not visible at inspection, and therefore only diagnosed by histological examination of 
a biopsy specimen that contains the complete lesion (Wright et al., 1994).  
Mestwerdt was the first to notice that cervical cancers with less than 5 mm of invasion 
behave less malignant and therefore could be treated by less radical surgery. He named 
these tumours “Mikrokarcinom”. Mestwerdt also introduced tumour depth of 5 mm as a 
parameter of the management of cervical carcinoma and suggested a less radical surgery 
for such cases. Subsequent authors proposed different maximal depths as the upper limit 
of an invasive growth (Mestwerdt, 1947). Following Mestwerdt,s publication and before 
the most recent FIGO definition of stage IA cervical cancer in the 1994, an intense 
discussion has continued concerning the definition of microinvasion, terminology and 
treatment modalities as related to disease outcome, e.g. lymph node metastasis, 
reccurence and cancer death (Creasman, 1995). The latest FIGO definition of stage IA1 
cervical cancer is defined as cervical carcinoma confined to the uterus with stromal 
invasion less than 3.0 mm and stage IA2 cervical cancer with stromal invasion more than 
3.0 mm but not more than 5.0 mm, with limited horizontal spread beyond 7.0 mm (World 
Health Organization, 2006). Because of the effective use of screening, an increasing 
number of women are being diagnosed with cervical cancer in an early stage of the 
disease. However, many of these cases occur in younger women, for whom the 
preservation of fertility is desirable. More conservative methods have emerged as 
alternative treatment modalities for these women, as they may allow for future fertility, 
without having a considerable adverse effect on cure rates.  
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The objective of this review is to discuss the management of patients with microinvasive 
cervical cancer and present the Ljubljana experience on management of FIGO stage IA (both 
IA1 and IA2) cervical cancer. 
2. Management of stage IA cervical carcinoma 
Lesions of the microinvasive type present a paradox in that they breach the basement 
membrane yet are rarely associated with metastasis. Traditionally the presence of stromal 
invasion predetermines a belief that metastasis is imminent and radical surgery obligatory. 
There is now considerable debate on the necessity for obligate radicality by radical 
hysterectomy and lymphadenectomy or radical irradiation such that conservative 
management, simple hysterectomy or even therapeutic cone biopsy, are alternatives in most 
cases. Individualization of treatment to reduce therapy-associated early and late morbidity 
is the most current trend in cervical cancer surgery. Despite advances over the past 3 
decades in decreasing the morbidity of treatment, the cure rate associated with radical 
surgery (approximately 90%) has not changed appreciably. The limited risk of parametrial 
and nodes involvement in case of MIC unbalances the morbidity of radical hysterectomy 
and pelvic node removal. 
Figure 1 shows the treatment options for microinvasive carcinoma of the cervix, based on 
the latest guidelines within the ESGO community and prepared by ESGO Educational 
Committee (ESGO, 2010). 
Conization as definitive therapy should be reserved for patients who desire fertility 
preservation. The candidates for this procedure would be those patients with FIGO stage 
IA1 disease (less than or equal to 3 mm stromal invasion). The selection criteria for this 
conservative approach to definitive therapy should include squamous histology, negative 
conization margin, and adequate pathologic processing of the tissue specimen. The patient 
needs to be compliant with a follow-up regimen. In patients with 3 mm or less depth of 
stromal invasion who do not desire fertility preservation, a simple extrafascial hysterectomy 
can be performed. 
Patients with FIGO stage IA2 cervical carcinoma can be treated with modified radical 
hysterectomy and pelvic and para-aortic lymph node dissection. Selection of such patients 
for a modified radical hysterectomy include squamous histology with negative conization 
margins following adequate pathologic processing of tissue.  
Patients with positive cone margins should be treated as if they had frankly invasive 
disease and undergo a radical hysterectomy with pelvic and para-aortic lymph node 
dissection.  
The patients who are nonsurgical candidates or individuals not opting for surgical 
management should be treated with primary radiation therapy. 
The use of adjuvant radiation therapy in lymph node positive patients has been 
controversial. A recent studies indicates that postoperative radiotherapy in node positive 
cervix cancer significantly improves pelvic control, disease-free survival, and overall 
survival. 
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Stage IA1, LVSI negative:  
 Conization if preservation of fertility is 
desired 
or 
Simple (extrafascial, type A) hysterectomy 
with or  
without salpingoophorectomy 
Stage IA1 with extensive LVSI and Stage 
IA2: 
 
 Conization or radical trachelectomy 
if preservation of fertility is desired 
or 
Modified radical hysterectomy (type B) 
and 
Pelvic lymphadenectomy 
Stage IA1 or IA2 nonsurgical candidates:  
 Primary radiation therapy. 
Fig. 1. Treatment options for MIC: accurate pathologic evaluation and negative cone 
margins for 2009 FIGO staging. 
Reports describing primary radiotherapy for microinvasive cervical cancer are limited and 
generally include patients who have medical contraindications to surgery. As opposed to 
patients with larger volume invasive disease , brachytherapy is often the sole, or major, 
component of radiation used. Brachytherapy alone is an effective treatment for nonsurgical 
candidates with microinvasive cervical carcinoma. The incidence of lymph node metastasis 
and regional relapse following brachytherapy, is very low for small-volume invasive 
cervical carcinoma, particularly in those with maximal depth of stromal invasion less than 5 
mm (Greer et al., 1990). 
Recommended follow-up for patients with MIC after completed therapy is every 3 months 
during the first year, then every 6 months up to 5 years and annually afterwards. 
Investigations in addition to gynaecological examination, including cytology and 
colposcopy, should be performed depending on symptoms, local findings and general 
condition of the patient (ESGO, 2010). 
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3. The Ljubljana experience on management of stage IA cervical carcinoma 
and the clinical outcome of our patients 
The Ljubljana experience on management of stage IA (both IA1 and IA2) cervical cancer 
consists of accumulated experience during several observation periods. During the period of 
1960-1972, the surgical treatment in our institution followed the principle that cancer is 
cancer, therefore radical treatment is justified. During that period, 290 cases of stage IA 
cervical carcinoma were treated, the great majority by vaginal radical hysterectomy and 
abdominal radical hysterectomy with lymphadenectomy. Positive lymph nodes were found 
in none of these cases (Kovačič et al., 1989). 
Our accumulated experience on the minimal risk of metastatic spread and reccurence, 
improved understanding of the development of early stages of cervical carcinoma, and the 
increasing frequency of young women wishing to preserve fertility were the reasons for the 
increased use of conservative treatment. A conservative surgical approach for MIC, FIGO 
stage IA was adopted when a scoring system was implemented in 1979, based on the 
evaluation of morphological criteria and exact estimation of the tumor size (Rainer, 1978). 
This scoring system has been used since 1979 as the basis for selecting treatment for all 
patients with stage IA cervical carcinoma. Table 1 shows the Rainer’s scoring system. 
The present scoring system was established when there was no definitive international 
consensus on the classification of MIC. The definition was vague and the criteria for 
identification varied. The applied score enabled uniform estimation of all histological 
criteria in every case and was effective in making decisions about the treatment modalities 
in individual cases. To obtain an unbiased estimation of the tumor size and its various 
histological parameters, 70 cases of MIC were subjected to stereological analysis (Eržen et 
al., 1995). The results of this analysis were used to define the criteria for the scoring system. 
The depth of stromal invasion, mitotic activity, pattern of invasion, host defence reaction 
and lymph-vascular space invasion (LVSI) were evaluated and scored. The patient’s age and 
her wish to preserve fertility were also taken into consideration.  
During the first observation period (1960 – 1972), the cases with the depth of infiltration 
more than 3 mm were classified as stage IB. If the clinical data including the patient,s 
general condition and the surgeon,s competence were not taken into consideration, the 
following total scores were used as the criteria of selection for the different treatment 
modalities.  
Between 1989 and 1993 conization was the definitive treatment for patients with a score of 7 
points or less, simple vaginal or abdominal hysterectomy was performed in those who 
scored 8 to 12 points, and radical hysterectomy with lymphadenectomy was suggested in 
patients with more than 12 points, using the Rainer’s scoring system. According to this 
scoring system which was further modified in 1994 for MIC stage IA2, radical hysterectomy 
was no longer indicated. Until 1997 lymphadenectomy was performed only in patients with 
LVSI, and thereafter in all of the patients with MIC IA2. 
During the observation period from 1973 to 2009 the rate of conisation with/without 
pelvic lymphadenectomy as the sole mode of treatment of MIC, FIGO stage IA  
has increased continuously and was the definitive treatment for almost 75% of all our  
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Morphological criteria Points 
I.  Cellular type - large cell type 1 
 - keratinizing type 2 
 - small cell type 2 
II. Mitotic activity (per high power field) - 5 -10 mitoses 1 
 - more than 10 mitoses 2 
III. Type of invasion - pushing borders, singular buds 1 
 
- dropping off type
 




IV. Defence reaction - poor 1 
V. Capillary-like space invasion - present 10 
VI. Depth of invasion - less than 3 mm 2 
 - 3 to 5 mm 4 
 - more than 5 mm 8 
Table 1. Scoring of the morphological criteria of MIC  
patients. If resection margins were not disease-free or lateral clearance was not adequate, 
the suggested treatment was hysterectomy to avoid late recurrence. However the 
frequency of Wertheim radical hysterectomy and simple hysterectomy have declined 
accordingly. The Wertheim radical hysterectomy was performed only in 9,0 % of the 
cases, mostly due to incorrect preoperative diagnosis of invasive carcinoma, based on 
scanty biopsy material. The pelvic lymphadenectomy was performed in 11,2% of the 
cases, in these cases LVSI was present and the pelvic nodes were invariably free of cancer. 
The frequency of lymph node metastases in stage IA2 cervical cancer is reported to range 
from 0% to 9,7%. LVSI seems to play an important role in the risk of lymph node 
metastases in stage IA2 cervical cancer. The recent published article from Rogers LJ et al. 
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patients. If resection margins were not disease-free or lateral clearance was not adequate, 
the suggested treatment was hysterectomy to avoid late recurrence. However the 
frequency of Wertheim radical hysterectomy and simple hysterectomy have declined 
accordingly. The Wertheim radical hysterectomy was performed only in 9,0 % of the 
cases, mostly due to incorrect preoperative diagnosis of invasive carcinoma, based on 
scanty biopsy material. The pelvic lymphadenectomy was performed in 11,2% of the 
cases, in these cases LVSI was present and the pelvic nodes were invariably free of cancer. 
The frequency of lymph node metastases in stage IA2 cervical cancer is reported to range 
from 0% to 9,7%. LVSI seems to play an important role in the risk of lymph node 
metastases in stage IA2 cervical cancer. The recent published article from Rogers LJ et al. 
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suggests that the latest studies adhering to the FIGO definitions showed a 0,5% incidence 
of lymph node metastases in stage IA2 cervical carcinomas, which is not as high as was 
previously believed. The very low rate of positive lymph nodes in correctly staged IA2 
cases therefore cannot justify the inclusion of lymphadenectomy as part of standardised 
care for these patients (Eržen et al, 2001).  
The first abdominal radical trachelectomy in our Department was performed by Professor 
Novak in 1954, but it did not become part of the standardized protocol; it was performed 
only in a few cases. In 2008 radical trachelectomy (abdominal and laparoscopic) was re-
introduced and has been a treatment tool in our Department since. 
The Rainer’s scoring system has been used at the Department since 1979 as the basis for 
selecting the treatment option for all patients with stage IA cervical carcinoma, but has 
generally not gained acceptance. When all the unfavorable prognostic factors are discussed 
and excluded by the tumor board the treatment of patients with IA MIC wishing to preserve 
fertility is individualized (Smrkolj et al., 2012). 
4. Conclusion 
We suggest that treatment of MIC IA can be less radical, particularly for young women 
who want to preserve their fertility and anatomical integrity, especially if LVSI is absent. 
The treatment of stage IA should be based on the evaluation of prognostic factors in 
addition to an adequate assessment of the tumour size. Both parameters should be 
accurately evaluated by examination of numerous or serial step sections of cervical cones. 
Individualisation of treatment in patients wishing to preserve fertility should be done 
when all the unfavourable prognostic factors are excluded. Standardisation of the 
microscopic examination of the cervix is highly recommended. Cone margins should be 
carefully examined and proven disease-free. Cases with incorrect clinical estimation of the 
tumour size, associated with histological diagnosis of invasive carcinoma in punch 
biopsy, may still result in over-treatment when stage IA is found in cervical specimen 
after radical hysterectomy. Preoperative high resolution magnetic resonance imaging with 
an endovaginal coil or preoperative 3D-ultrasound perhaps could identify such patients 
with small tumour volume and might avoid unnecessary radical operation. According to 
our experience, follow-up of the patients after conization by regular pelvic examination, 
cytology and colposcopy is mandatory at least every six months for two years, and yearly 
thereafter. 
Correct diagnosis and adequate treatment of early invasive cervical carcinoma, stage IA, 
should take into account the existing information of the prognostic factors. This is essential 
to individualise the treatment to avoid unnecessary risks, as well as over- or under- 
treatment. Such prognostic factors include: adequate estimation of the tumour size, 
lymphatic vessel invasion, type of confluence of the invasion, mitotic activity, host defence 
reaction and accurate examination of the surgical margins. Unfortunately, the existing FIGO 
staging systems disregard some other important prognostic factors in early cervical 
carcinoma such as capillary-like space invasion, type of invasion and mitotic activity. The 
most frequently reported factors increasing the risk for lymph node metastasis, reccurence 
and cancer death are: depth and pattern of stromal invasion, involvement of lymphatic and 
vascular space, tumour volume and state of the resection margins. In addition to the above 
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listed major prognostic factors, the outcome of early invasive carcinoma of the uterine cervix 
could also be significantly affected by: subjectivity of microscopical examination and 
estimation of histological parameters in differential diagnosis, adequate sampling and 
technical preparation of all cervical biopsy specimen, particularly adequate handling and 
sampling of the cones and hysterectomy specimens. 
Each of these factors should be considered thoroughly when the prognosis of the disease is 
assessed, not just from the standpoint of eradicating the cancer, but also to avoid 
unnecessary over-treatment and with respect to the functional integrity of the patients 
wishing to preserve fertility. In the near future, the diagnostic procedure should also benefit 
from immunohistochemical and molecular methods used to predict the behaviour of all 
tumours classified as microinvasive carcinoma that reccur and progress to frankly invasive 
carcinomas. 
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1. Introduction 
Cervical cancer occurs in approximately 500,000 women and kills 288,000 women 
worldwide each year. Prognosis is highly dependent on disease stage at diagnosis. When 
detected early, cervical cancer is generally curable. Early lesions are treated surgically and 
locally advanced lesions are managed with concurrent cisplatin chemotherapy and pelvic 
radiation. Unfortunately, responses to chemoradiation are partial and are of short duration.  
Metastatic disease or recurrent lesions not amenable to radical local excision or regional 
radiation are treated with palliative chemotherapy. Current chemotherapeutic regimens are 
associated with significant side effects and only limited activity making the identification of 
active and tolerable novel targeted agents a high priority.  
The evidence supporting the biological rational to combine novel non-cytotoxic agents with 
chemoradiotherapy is strong, and drugs targeting different molecular pathways are 
currently under clinical development (EGFR inhibitors, COX-2 inhibitors, hypoxia targeted 
agents, etc). Early pre-clinical and clinical strategies also favor the use of vascular-targeted 
agents with the aim to normalize the abnormal tumor vasculature, increase tumor 
oxygenation, and reduce interstitial fluid pressure. The integration of these novel targeted 
therapies with chemoradiotherapy in clinical trials is discussed, as well as new and 
promising biomarkers to test drug activity (Herrera, 2008). 
2. Overexpression of epidermal growth factor type-1 receptor (EGF-R1) in 
cervical cancer: A possible therapeutic target for cervical carcinoma 
Overexpression of epidermal growth factor type-1 receptor (EGF-R1) has been found in 
more than 70% of carcinomas of the cervix.  
2.1 Cetuximab 
Cetuximab, a monoclonal antibody, binds specifically to the epidermal growth factor 
receptor (EGFR) and competitively inhibits the binding of epidermal growth factor and 
other ligands. Cetuximab is clinically approved for the treatment of EGFR-expressing 
metastatic colorectal cancer and advanced head and neck cancer. Cetuximab might be a 
novel and attractive therapeutic strategy in patients harboring chemotherapy-resistant, 
recurrent, or metastatic cervical cancer.  
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As anti-EGFR monoclonal antibodies sensitise tumours, Cetuximab's toxicity plus 
chemoradiation on cervical cancer cells which express different EGFR levels was 
investigated. This study showed that Cetuximab combined with chemoradiation, 
trastuzumab or MAPK inhibitors has useful applications for cervical cancer treatment, 
independently of EGFR expression (Meira, 2009). 
In cervical cancer the expression of EGFR is reported in up to 85% of the tumour cells. 
Therefore, Cetuximab monotherapy could be a new option in the treatment of patients with 
advanced cervical cancer. 
In a retrospective study, 5 patients with stage IIB to IVB cervical cancer were treated with 
Cetuximab monotherapy 250 mg/m² weekly after an initial loading dose of 400 mg/m² as 
third- to fifth-line therapy. Only one patient (20%) had a stable disease, and the other four a 
progressive disease. Four out of five patients (80%) developed an acneiform rash. The 
median survival time was 8.6 months. 
This study showed no advantage in the treatment with Cetuximab monotherapy in patients 
with advanced cervical cancer. Further studies are necessary to evaluate the significance of 
Cetuximab in the treatment of advanced cervical cancer (Hertlein, 2011). 
In a phase II GINECO trial, patients with advanced cervical squamous cell cancer or 
adenocarcinoma and at least one measurable target received intravenous cisplatin 50 mg/m² 
on day 1 plus topotecan 0.75 mg/m²/day from days 1 to 3 every 3 weeks combined with 
cetuximab (initial dose of 400 mg/m² followed by subsequent weekly dose of 250 mg/m²).  
Nineteen out of the 44 planned patients were accrued before the study was stopped early 
due to excessive toxicity. The most frequent adverse event was severe myelosuppression. 
The main grades 3-4 non-hematologic toxicities were infection (39%) and febrile neutropenia 
(28%), skin reactions (22%), renal toxicity (11%), and pulmonary embolism (11%). Five (28%) 
patients died during the treatment including 3 deaths related to treatment toxicity. Six (32%) 
evaluable patients achieved a partial response. The median times of progression free 
survival and overall survival were 172 and 220 days, respectively.  
In this phase II trial, the combination cisplatin - topotecan - cetuximab induced a high rate of 
serious adverse and/or fatal events at standard dose and schedule (Kurtz, 2009). 
2.2 Erlotinib 
A phase I trial was aimed to determine the maximum tolerated dose and related toxicity of 
erlotinib when administered concurrently with cisplatin and radiotherapy (CRT) for patients 
with locally advanced cervical squamous cell cancer. There was three cohorts of at least three 
patients receiving escalating doses of erlotinib combined with cisplatin (40 mg/m², weekly, 5 
cycles) and radiotherapy (external beam 4,500 cGy in 25 fractions, followed by 4 fractions/600 
cGy/weekly of brachytherapy) in squamous cell cervical carcinoma patients, stage IIB to IIIB. 
Fifteen patients were enrolled, 3 at dose level (DL) 50 mg, 4 at DL 100 mg, and 8 at DL 150 
mg. Patients presented median age 47 (36-59), stage IIB (46.2%) and IIIB (53.8%). Overall, 
erlotinib+CRT was well-tolerated. Three patients did not complete the planned schedule. 
One patient at DL 100 mg withdrew informed consent due to grade 2 rash; at DL 150 mg, 1 
patient presented Raynaud's Syndrome and had C interrupted, and another patient 
presented grade 4 hepatotoxicity. The latter was interpreted as dose limiting toxicity and a 
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new cohort of 150 mg was started. No further grade 4 toxicity occurred. Grade 3 toxicity 
occurred in 6 cases: diarrhea in 3 patients, rash in 2 patients, and leukopenia in 1 patient. 
Erlotinib +CRT did not lead to limiting in-field toxicity.  
This study showed that erlotinib + CRT was feasible to locally advanced squamous cell 
cervical cancer and was well tolerated. The maximum tolerated dose has been defined as 
150 mg (Nogueira-Rodrigues, 2008). 
A phase II trial of erlotinib in recurrent squamous cell carcinoma of the cervix was aimed to 
determine the proportion of patients with tumor response, the proportion who survived 
progression-free for at least 6 months and the frequency and severity of toxicities of patients 
with recurrent squamous cell carcinoma of the uterine cervix treated with erlotinib. This 
multicenter, open-label, single-arm trial evaluated the toxicity and efficacy of oral erlotinib 
at an initial dosage of 150 mg daily until progressive disease or adverse effects prohibited 
further therapy. 
Twenty-eight patients with squamous cell carcinoma were enrolled and 25 patients were 
evaluable. There were no objective responses, with 4 (16%) patients achieving stable disease; 
only 1 patient had a progression-free survival of 6 months (4%) or more. Erlotinib was well 
tolerated, with the most common drug-related adverse events being gastrointestinal 
toxicities, fatigue, and rash. This study showed that erlotinib was inactive as monotherapy 
in patients with recurrent squamous cell carcinoma of the uterine cervix (Schilder, 2009). 
2.3 Gefitinib 
Evidence suggests the epidermal growth factor receptor (EGFR) is expressed at moderate to 
high levels in cervical carcinomas. A multicenter, open-label, non-comparative phase II trial 
(study 1839IL/0075) investigated whether gefitinib (IRESSA), an EGFR tyrosine kinase 
inhibitor, is a potential second- or third-line treatment option for patients with recurring 
locoregionally advanced or metastatic cervical cancer. This study evaluated the clinical 
outcomes of 500 mg/day gefitinib. 
Thirty patients with squamous-cell carcinoma or adenocarcinoma were recruited from six 
centers in France. Of these, 28 patients were evaluable for efficacy. Although there were no 
objective responses, six (20%) patients experienced stable disease with a median duration of 
111.5 days. Median time to progression was 37 days and median overall survival was 107 
days. Disease control did not appear to correlate with levels of EGFR expression. Gefitinib 
was well tolerated, with the most common drug-related adverse events being skin and 
gastrointestinal toxicities. 
This study showed that gefitinib has only minimal monotherapy activity in recurrent disease 
resistant to standard treatment. However, the observation that 20% of patients treated with 
gefitinib had stable disease may warrant further investigation (Goncalves, 2008). 
3. NF-κB inhibition 
Nuclear factor-kappa B (NF-kappaB) is a transcription factor that plays a critical role across 
many cellular processes including embryonic and neuronal development, cell proliferation, 
apoptosis, and immune responses to infection and inflammation. Dysregulation of NF-
kappaB signaling is associated with inflammatory diseases and certain cancers.  
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Constitutive activation of NF-kappaB signaling has been found in some types of tumors 
including breast, colon, prostate, skin and lymphoid, hence therapeutic blockade of NF-
kappaB signaling in cancer cells provides an attractive strategy for the development of 
anticancer drugs. 
Miller and al. indicated that many currently approved pharmaceuticals have previously 
unappreciated effects on NF-kappaB signaling, which may contribute to anticancer 
therapeutic effects. Comprehensive profiling of approved drugs provides insight into their 
molecular mechanisms, thus providing a basis for drug repurposing (Miller, 2010). 
Kima and al. suggested that the HPV 16 E5 oncoprotein mediates cervical carcinogenesis at 
least in part via upregulation of COX-2 expression through NF-kappaB and AP-1, with NF-
kappaB playing a larger role (Kim, 2009). 
NF-kappaB activation is known to reduce the efficiency of chemotherapy in cancer 
treatment. Ursolic acid, a minimally toxic compound, has shown the capability to inhibit 
NF-kappaB activation in living cells. Li and al. investigated the effects and mechanisms of 
NF-kappaB inhibition by ursolic acid on chemotherapy treatment (Taxol or cisplatin) of 
cancerBy supplementing chemotherapy with minimally toxic ursolic acid, it is possible to 
improve the efficacy of cancer treatment by significantly reducing the necessary drug dose 
without sacrificing the treatment results (Li, 2010). 
This recent studies suggested that NF-kappaB may contribute to the resistance of human 
cervical cancer cells to cisplatin and highlight the potential use of combination therapy 
involving cisplatin and NF-kappaB inhibitors. 
4. Cyclooxygenase-2 inhibitor 
Evidence from clinical and preclinical studies indicates that COX-2-derived prostaglandins 
participate in carcinogenesis, inflammation, immune response suppression, apoptosis 
inhibition, angiogenesis, and tumor cell invasion and metastasis. Clinical trial results have 
demonstrated that selective inhibition of COX-2 can alter the development and the 
progression of cancer. In animal models, selective inhibition of COX-2 activity is associated 
with the enhanced radiation sensitivity of tumors without appreciably increasing the effects 
of radiation on normal tissue, and preclinical evidence suggests that the principal 
mechanism of radiation potentiation through selective COX-2 inhibition is the direct 
increase in cellular radiation sensitivity and the direct inhibition of tumor 
neovascularization (Choy, 2003).  
A phase I-II accrued 31 women with locally advanced cervical cancer to receive celecoxib 
400 mg by mouth twice per day for 2 weeks before and during chemoradiotherapy (CRT). 
Tumor oxygenation (HP(5)) and interstitial fluid pressure (IFP) were measured before and 2 
weeks after celecoxib administration alone. The median follow-up time was 2.7 years. 
The most common acute G3/4 toxicities were hematologic and gastrointestinal largely 
attributed to chemotherapy. Late G3/4 toxicity was seen in 4 of 31 patients, including 
fistulas in 3 patients. Within the first year of follow-up, 25 of 31 patients achieved complete 
response (CR), of whom 20 remained in CR at last follow-up. After 2 weeks of celecoxib 
administration before CRT, the median IFP decreased slightly, whereas HP(5) did not 
change significantly. No significant associations were seen between changes in HP(5) or IFP 
and response to treatment. 
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Celecoxib in combination with definitive CRT is associated with acceptable acute toxicity, 
but higher than expected late complications. Celecoxib is associated with a modest 
reduction in the angiogenic biomarker IFP, but this does not correspond with tumor 
response (Herrera, 2007). 
A phase II study determined the efficacy, patterns of initial failure and treatment-related 
acute toxicity rates in patients with locally advanced cancer of the cervix treated by oral 
celecoxib, intravenous cisplatin and 5-fluorouracil, and concurrent pelvic radiation therapy 
in patients with locally advanced cancer of the cervix.  
Eligible patients included FIGO Stage IIB-IVA or patients with FIGO Stage IB through IIA with 
biopsy proven pelvic node metastases or tumor size > or =5 cm. Celecoxib was prescribed at a 
dose of 400 mg twice daily for 1 year beginning on the first day of radiotherapy. Cisplatin (75 
mg/m²) and 5-FU (1g/m² for 4 days) were administered every 3 weeks times 3. A total of 84 
patients were accrued, of whom 78 were eligible and 77 were evaluable for toxicity.  
At 2 years, the estimated disease-free survival and overall survival rate for patients with 
advanced cervical cancer who underwent a combination of chemoradiotherapy and 
celecoxib treatment was 69% and 83%, respectively. Of the 78 patients, 24 had treatment 
failure and, of those patients, 18 had a component of locoregional failure as a site of first 
failure (Gaffney, 2007a). Toxicities were observed in the following areas: blood/bone 
marrow (16), gastrointestinal (14), pain (7), renal/genitourinary (6), cardiovascular (3), 
hemorrhage (1), and neurologic (1). For the first 75 evaluable patients, a toxicity failure was 
identified in 36 patients for a rate of 48% (Gaffney, 2007b). 
Thus, locoregional control continues to be problematic after chemoradiotherapy (Gaffney, 
2007a). Celecoxib at 400 mg twice daily together with concurrent cisplatin and 5-FU and 
pelvic radiotherapy has a high incidence of acute toxicities. The most frequent toxicities 
were hematologic (Gaffney, 2007b). 
Previous data demonstrate an association between cyclooxygenase activity and development 
of cervical cancer. A review investigated the role of cyclooxygenase-2 (COX-2) in the 
development of cervical cancer and potential therapeutic options targeting this pathway. 
Studies in vivo and in vitro confirm the role of COX-2 in the development of cervical cancer. 
In addition, COX-2 overexpression is associated with an increase in angiogenesis markers. 
Clinical correlation found that COX-2 overexpression in cervical cancer patients is a poor 
prognostic marker associated with increased risk for recurrent or metastatic disease. Despite 
early promise, two phase II trials in use of specific COX-2 inhibitors as radio-sensitizers in 
locally advanced cervical cancer demonstrated increased toxicity with no change in 
therapeutic effect. Results of studies using COX-2 inhibitors in pre-invasive cervical disease 
are encouraging (Young, 2008). 
Jung and al. evaluated 67 FIGO stage IB2-IVA cervical cancer patients treated with cisplatin-
based chemoradiotherapy (CCRT). The study group included patients who received 
rofecoxib (N=30) and the control group included patients who received CCRT only (N=37).  
There were no significant differences in toxicity between the two groups. The most common 
acute grade 3/4 toxicity was neutropenia. Grade 3/4 late toxicity was observed in 2 patients 
in the study group and 3 in the control group. There was no treatment-related deaths in 
either group. Six patients in the study group had treatment failure. In the control group, 6 
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patients experienced treatment failure. There were no differences in progression-free and 
overall survival between the 2 groups. 
This data indicated that rofecoxib, at a dose of 25 mg twice daily, has acceptable acute 
toxicity as a radiosensitizer during CCRT. Although rofecoxib was not efficacious as a 
radiosensitizer in the present study, the benefit of rofecoxib as a radiosensitizer should be 
further evaluated in a prospective study (Jung, 2009). 
5. Anti-angiogenesis agents 
Angiogenesis is central to cervical cancer development and progression. The dominant role of 
angiogenesis in cervical cancer seems to be directly related to HPV inhibition of p53 and 
stabilization of HIF-1 alpha, both of which increase vascular endothelial growth factor (VEGF).  
5.1 Bevacizumab 
Bevacizumab binding and subsequent inactivation of VEGF seem to shrink cervical tumors 
and delay progression without appreciable toxicity, and are therefore being studied in a 
Gynecologic Oncology Group (GOG) phase III trial. Other intracellular tyrosine kinase 
inhibitors (TKIs) of angiogenesis such as pazopanib are also encouraging, especially in lieu 
of their oral administration (Monk, 2010). 
The Gynecologic Oncology Group (GOG) conducted a phase II trial to assess the efficacy and 
tolerability of bevacizumab. Eligible patients had recurrent cervical cancer, measurable 
disease, and GOG performance status < or = 2. Treatment consisted of bevacizumab 15 mg/kg 
intravenously every 21 days until disease progression or prohibitive toxicity. Forty-six patients 
were enrolled. Grade 3 or 4 adverse events at least possibly related to bevacizumab included 
hypertension, thrombo-embolism, gastro-intestinal, anemia, other cardiovascular, vaginal 
bleeding, neutropenia, and fistula. One grade 5 infection was observed. Eleven patients 
(23.9%) survived progression free for at least 6 months, and five patients (10.9%) had partial 
responses. The median response duration was 6.21 months. The median PFS and overall 
survival times were 3.40 months and 7.29 months, respectively (Monk, 2009). 
A retrospective analysis of women with recurrent cervical cancer treated with bevacizumab 
combination therapy was performed. Six patients were identified. The patients had a 
median of 3 prior regimens. All of the patients had multisite, metastatic disease. The 
combination regimen included IV 5-fluorouracil in 5 (83%) patients and capecitabine in one 
(17%) subject. Treatment was well tolerated. Grade 4 toxicity occurred in one patient who 
developed neutropenic sepsis. Clinical benefit (CR, PR, or SD) was noted in 67% of the 
subjects. This included 1 (17%) complete response, 1 (17%) partial response and two (33%) 
patients with stable disease. The median time to progression for the four women who 
demonstrated clinical benefit was 4.3 months (Wright, 2006). 
5.2 Pazopanib 
Pazopanib is an oral multi-targeted  TKI that binds to the vascular endothelial growth factor 
receptor (VEGFR), platelet-derived growth factor receptor (PDGFR) and c-Kit or epidermal 
growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2/neu), 
responsible for angiogenesis, tumor growth and cell survival.  
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Pazopanib exhibited in vivo and in vitro activity against tumor growth and, in early clinical 
trials, was well tolerated with the main side effects being hypertension, fatigue and 
gastrointestinal disorders. Pazopanib showed clinical activity in several tumors including 
renal cell cancer (RCC), breast cancer, soft tissue sarcoma, thyroid cancer, hepatocellular 
cancer and cervical cancer (Schutz, 2011).  
A phase II open-label study compared pazopanib or lapatinib monotherapy with pazopanib 
plus lapatinib combination therapy in patients with advanced and recurrent cervical cancer.  
Patients with measurable stage IVB persistent/recurrent cervical carcinoma not amenable to 
curative therapy and at least one prior regimen in the metastatic setting were randomly 
assigned in a ratio of 1:1:1 to pazopanib at 800 mg once daily, lapatinib at 1,500 mg once daily, 
or lapatinib plus pazopanib combination therapy (lapatinib at 1,000 mg plus pazopanib at 400 
mg once daily or lapatinib at 1,500 mg plus pazopanib at 800 mg once daily).  
Of 230 patients enrolled, 152 were randomly assigned to the monotherapy arms: pazopanib 
(n = 74) or lapatinib (n = 78). Most patients (62%) had recurrent cancer. Pazopanib improved 
PFS (hazard ratio [HR], 0.66; 90% CI, 0.48 to 0.91; P = .013) and OS (HR, 0.67; 90% CI, 0.46 to 
0.99; P = .045). Median OS was 50.7 weeks and 39.1 weeks and RRs were 9% and 5% for 
pazopanib and lapatinib, respectively. The only grade 3 AE > 10% was diarrhea (11% 
pazopanib and 13% lapatinib). Grade 4 AEs were 9% (lapatinib) and 12% (pazopanib). 
This study confirms the activity of antiangiogenesis agents in advanced and recurrent 
cervical cancer and demonstrates the benefit of pazopanib based on the prolonged PFS and 
favorable toxicity profile. Further study of angiogenesis and its inhibition are ongoing 
(Monk, 2010). 
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The 20th century witnessed a great development of genetics and molecular biology, laying 
the foundations for a new era in medicine. The elucidation of the mechanism of heredity, for 
example, helped us understanding the connection between cells, chromosomes, DNA and 
the genetic code, an historical journey to the center of biology (Lander & Weinberg, 2000). 
This process strongly consolidated when “the central dogma of molecular biology” (Crick, 
1970) was proposed long time ago, whereby the genetic information flows from DNA to 
RNA to protein. Since then, however, our understanding in the molecular and cellular 
organization, as well as physiology of living systems has radically changed, partially 
challenging the validity of the central ‘dogma’– by the way, dogma strictly means a belief 
that people are expected to accept without any doubts, a word to be expectedly seen outside 
the scientific method lexicon – of molecular biology (Shapiro, 2009). The main paradigm is 
that cells are able to make decisions based on actively sensing their environment; hence, 
information processing in living systems can be regarded at least bidirectional. In any case, 
the recent sequencing of the human genome is a great milestone (Human Genome 
Sequencing, 2004), whereby the language of the “common thread of humanity” in this new 
medicine era is just “the end of the beginning” (Stein, 2004). 
Genomics studies the total DNA sequence of an organism. Of the approximately 3,000 
million base pairs that comprise the human genome, only 1% was firstly estimated to 
correspond to as low as 25,000 proteins (Southan, 2004), a number that has been changing 
since the initial sequence drafts of the Human Genome Project (HGP). One motivation 
behind genome-sequencing projects is the assumption that the nucleotide sequence of an 
organism provides a description of the genes, its products and interaction networks that 
orchestrate programs like those sustaining the metabolic activity of a cell or deploying a 
body plan. However, new discoveries in transcriptome functions significantly expand—and 
even challenge—the classical concept of the gene and how post-transcriptional molecular 
events are becoming key to understand gene regulation in higher eukaryotes.  
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The success of the HGP has provided a blueprint of genes encoding the entire human 
protein set potentially expressed in any of the approximately 230 cell types comprising 
the human proteome. Considering that both the current and sometimes limited 
knowledge of only two-thirds of the 20,300 protein-coding human genes mapped through 
the HGP is at hand (Legrain et al., 2011), the recently launched Human Proteome Project 
(HPP) aims to provide for the remaining one-third of proteins experimental evidence 
related to abundance, distribution, subcellular localization, functions, and interactions 
(Bustamante et al., 2011). 
In the current "post-genomic era" scientists aim not only to build a catalog of all genes, but 
also to translate the knowledge obtained into benefits for humanity (Collins et al., 2003). 
By examining tumors at the genomic, transcriptomic, and proteomic levels, for instance, it 
is possible to better understand cancer biology and improve patient care, diagnosis, 
prognosis, and therapy (Lin & Li, 2008). Importantly, one key development that has 
emerged between the interface of the HGP and the HPP is the area of functional genomics 
or transcriptomics, which aims to assign a function to all transcripts. But this is not a 
trivial task because talking about transcriptomes involves considering these as entities as 
diverse as the cell types, developmental stages, environmental conditions and 
pathological states that an organism harbors or faces. Therefore, we must include a global 
vision for the process of transcription, i.e. the process by which information contained in 
DNA is converted (or transcribed) into RNA and how this process is regulated by 
protein(s) (Fig. 1).  
Importantly, it should bear on mind that 57% - a scalable number up to 90% (Costa, 2010) - 
of the genome is transcribed into RNA but does not code for proteins (Frith et al., 2005). 
Moreover, very recently non-coding RNAs (microRNAs, small RNAs, small interfering 
RNAs or siRNAs as well as medium and large RNAs) have emerged as key elements in 
carcinogenesis. The amazing complexity of the transcriptome and its expansion (Mendes 
Soares & Valcarcel, 2006), has led to scientists eager to hunt transcriptomes. Fortunately, 
there are tools to examine the expression of genes at many levels, allowing us to globally 
understand complex diseases like cancer.  
The current manuscript introduces the most common techniques to study the transcription 
of the 1% protein-coding genes encoded in the human genome, followed by a review of 
microarray studies that had provided invaluable information of the carcinogenesis of 
cervical cancer (CC), the most and second most common cancer disease in women from the 
developing and developed world, respectively. The integration of all this information is 
very important to not only understand CC from a global perspective, but also to identify key 
tumor markers that could help for CC diagnosis, prognosis and/or therapy, as discussed in 
the last part of the manuscript. As for cancer progression involving noncoding RNAs – 
importantly considered the “masters of regulation” (Costa, 2010), the reader is encouraged 
to read an excellent recent review (Gibb et al., 2011). 
Importantly, CC is largely associated to Human Papillomavirus (HPV) infection, from 
which there are over hundred types but of these 40 infecting the genital tract and 15 of high-
risk related to the development of CC. Thus, HPV is a common sexually transmitted agent 
after a woman starts her first sexual relationship and responsible of ca. 30% of the global 
cancer burden associated to infective agents (20% of the total) (zur Hausen, 2009).  
 




Fig. 1. Role of transcription in the central ‘dogma’ of molecular biology. According to this 
‘dogma’, the genetic information flows from DNA to messenger RNA (mRNA) to proteins. 
The gene CDKN2A/p16INK4a, for example, is located at position “21.3” of the short arm of 
the human chromosome 9, which resides inside the nucleus. Upon activation by the 
transcription factor (E2F1), its mRNA is transcribed and the corresponding proteins are 
translated in the cytoplasm (CDKN2A encodes three but only two variants are displayed). 
The interplay between the genome, transcriptome and proteome is oversimplified. 
2. Probing the transcriptome 
The relationship between a particular molecule and cellular phenotype has allowed us to 
better understand the molecular mechanisms of complex diseases such as cancer. In the 
course of molecular biology many useful techniques to analyze DNA, RNA and proteins 
were developed. For about half century, reasonably, the practice of molecular biology was 
comfortable with its reductionism; however, in the coming era of genomics, the tendency to 
probe in a single experiment hundreds or thousands of biomolecules allows us talking of 
two mechanisms: (i) The “reductionist mechanism” employs tools to analyze one or few 
different molecules in a single experiment; it is a slow but comprehensive conclusions can be 
reliably obtained; (ii) The “holistic mechanism” allows the assessment of thousands of 
different molecules in a single experiment; it is a fast mechanism but the obtained 
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hypotheses remained to be tested (Coulton, 2004). While single gene analyses gradually 
shifted towards large mutational screens and complete genome mapping, whole genome 
sequencing moved towards bioinformatics with exhaustive functional genomics and 
proteomics data. Systems biology aims to understand this complexity. Ironically, the holism 
in systems biology has re-emerged out of the traditional molecular biology, carrying with it 
the reductionism-holism debate since the past years (Gatherer, 2010). Interestingly, it has been 
boldly argued that traditional molecular biology represents a greedy reductionist approach 
(to some authors a naively reductionist one) that requires either extensive complementation 
from, or even replacement by systems biology. However, as we discuss along the text, it is 
more meaningful to combine both approaches. 
The study of transcription is important because the levels of mRNA transcripts in a cell 
correlate frequently with the expression levels of the corresponding proteins. There are 
several techniques used in transcriptomics, which are based on gene amplification by the 
polymerase chain reaction (PCR), hybridization and sequencing. All these tools permit 
analyzing differential expression, and determine what transcripts are mainly expressed in 
cancerous tissue in comparison with normal tissue and vice versa. This is important because 
knowing what and how genes are differentially expressed suggests that these may play an 
important role in carcinogenesis. This scenario can be found in the case of proto-oncogenes 
and anti-oncogenes (or tumor suppressor genes) that promote and prevent cell growth, 
respectively. In other words, the levels of expression of many oncogenes (normally known 
as proto-oncogenes) may be very high and the levels of expression of tumor suppressor 
genes may be low. Following the reductionist and holistic classification, the most common 
techniques used in transcriptomics can be classified into high, medium, and low 
performance, with respect to its ability to analyze different molecules in a single experiment. 
2.1 Low-throughput techniques 
One of the first developed methods to detect a mRNA transcript was in situ hybridization 
(ISH) (Harrison et al., 1973). ISH requires labelling either fluorescently or radioactively a 
RNA or complementary DNA (cDNA) corresponding to the transcript of interest. Through 
the formation of hybrid cDNA:RNA or RNA:RNA duplexes, the amount of the specific 
transcript can be determined as well as its cellular position can be localized. Thereafter, the 
popular technique Northern Blot (NB) was developed. NB uses a labeled probe that 
recognizes the transcript of interest in a similar manner to the ISH, but the hybridization is 
performed on cellulose, because the RNA of a tissue is previously separated by 
electrophoresis and transferred to a special paper surface. If the transcript of interest forms a 
hybrid with the radioactively labeled probe, it will reveal the presence of a band in a 
autoradiography upon exposure (Alwine et al., 1977). Because of its sensitivity, this 
technique is commonly used in molecular biology. Another similar technique, called 
ribonuclease protection assay (RPA), is based on hybrid formation between the mRNA of 
the gene in question and a labeled probe (RNA or cDNA), being the non-hybridized single-
strand RNA part degraded by a RNAse enzyme (Berk & Sharp, 1977). This way, the hybrids 
can be detected because the RNA chain is radiolabelled; this method is 50 times more 
sensitive than NB (Bartlett, 2002).  
Another old technique is subtractive hybridization (SH), which employs single-strand RNA 
or cDNA labeled probes. Using SH one can remove commonly expressed genes between 
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two samples (e.g. cancerous and normal tissue) by hybrid formation between cDNA:RNA 
and identified those differentially expressed genes in a particular tissue (Zimmermann et al., 
1980). The tumor-suppresor gene p21WAF1/CIP1, also known as CDKN1A, involved in the 
negative regulation of the cell cycle as well as the induction of apoptosis, was identified 
using SH (el-Deiry et al, 1993). Finally, the Retro-Transcription coupled to PCR (RT-PCR) 
allows the amplification of a cDNA synthesized from a specific mRNA using a reverse 
transcriptase (Rappolee et al., 1988). RT-PCR can also be applied to tissues (in situ RT-PCR) 
similarly to the ISH but the sensitivity differs: While ISH can detect from 20 to 200 copies of 
transcript per cell, in situ RT-PCR can detect one transcript per cell (Bartlett, 2002). The 
enormous sensitivity of RT-PCR has allowed the development of a technique to quantify 
quickly and accurately the amount of transcripts in a given biological sample. It is called 
quantitative RT-PCR or Real-Time PCR (qRT-PCR) (Bustin, 2000). All these methods mainly 
based on hybridization and PCR can generally characterize one transcript per experiment. 
2.2 Medium-throughput techniques 
When a mRNA is converted to cDNA, the fragments obtained can be cloned or inserted into a 
vector (plasmid), which can be introduced into bacteria to obtain many copies of the transcript. 
At the end, the fragment of interest must be sequenced. In this way, various types of sequences 
can be generated: A EST (Expressed Sequence Tags) corresponds to an arbitrary portion of a 
cDNA sequence, i.e. a random sequence that allows identification of a transcript (Adams et al., 
1991), whereas "ORESTES" (Open Reading Frame Expressed Sequence Tags) contain an open 
reading frame, which generally corresponds to a central portion of the cDNA sequence (Dias 
Neto et al., 2000); it is also possible to alternatively clone the entire sequence of cDNA without 
tag (Strausberg et al., 2002). Importantly, all these partial or complete cDNA sequences had 
enabled the characterization of large numbers of transcripts and their differential expression 
depending on their frequency and tissue of origin.  
Similarly, the techniques of Differential Display (DD) and Representational Differential 
Analysis (RDA) permit the identification of differentially expressed transcripts e.g. coming 
from different sources or coming from the same source but subjected to different conditions. 
DD is essentially based on a series of RT-PCR amplifications where the transcripts of two 
samples are fluorescently or radioactively labeled, compared by electrophoresis, selected and 
finally sequenced (Liang & Pardee, 1992). The RDA technique is based on SH and RT-PCR, so 
that common transcripts between two samples are removed after the formation of hybrid 
cDNA:cDNA and genes only expressed in a tissue are amplified in a sensitive and accurate 
way (Hubank & Schatz, 1994). Since both techniques are of easy accessibility and use, their use 
has allowed the identification of many genes altered in cancer (Liang & Pardee, 2003; 
Hollestelle & Schutte, 2005). For example, while the Cyclin G was identified using the DD 
technique (Okamoto & Beach, 1994) the anti-oncogene PTEN was characterized through RDA 
(Li et al., 1997). The medium-throughput methods basically depend on sequencing and differ 
from those of low-performance because many transcripts can be characterized at a single 
experiment, but not as many as when using high-performance ones. 
2.3 High-throughput techniques 
In general, these methods are based on sequencing and hybridization. Sequencing includes 
Serial Analysis of Gene Expression (SAGE) and Massively Parallel Signature Sequencing 
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(MPSS) and, in the case of hybridization, the best example is DNA microarrays. SAGE is 
similar to the sequencing of ESTs or cDNA clones, but the performance is much higher 
because in a single vector a lot of small tags corresponding to different mRNAs can be 
inserted. After sequencing, the abundance of these tags can be measured doing a 
bioinformatics analysis, whereby the fold expression change of a gene in different 
tissues/conditions can be estimated (Velculescu et al., 1995). MPSS is similar to SAGE but 
the main difference is that in the former small tags are attached to microbead arrays, 
increasing the capacity of the system (Brenner et al., 2000). Although MPSS is similar to 
SAGE, the later method has been widely used, uncovering many genes with a potential role 
in cancer (Yamashita et al., 2008), and allowing the identification of known oncogenes such 
as ERBB2 and EGFR (Polyak & Riggins, 2001; Forrest et al., 2006). 
The DNA microarrays are a set of gene sequences (which may correspond to transcripts) 
arranged on a flat surface. There are two types of DNA microarrays: cDNA microarrays, in 
which transcripts of interest are amplified by PCR and deposited on sites identified in a 
paper or small glass slide (Schena et al., 1995) and oligonucleotide microarrays, in which 
small sequences corresponding to a gene are synthesized and arranged on a particular area 
of a slide (Lockhart et al., 1996; Singh-Gasson et al., 1999; Hughes et al., 2001). While the 
former arrays are normally produced in-house by researchers, the latter one are usually 
obtained from companies, being the most known “Affymetrix”. During the experiment, the 
mRNA of a tissue of interest is firstly converted into cDNA and labeled either radioactively 
or fluorescently. Then, through the formation of hybrids between the labeled cDNA and the 
unlabelled cDNA or oligonucleotides attached to the surface, differentially expressed genes 
between two samples can be identified. Finally, the ratios of frequency can be estimated 
using different bioinformatics methods. Both cDNA and oligonucleotide microarrays have 
been widely used, the difference lies in the number of genes per square centimeter: On 
paper there may be hundreds of genes, whereas in a glass slide it is possible to bear 
sequences representing up to 10,000 and 25,000 genes in the case of cDNA and 
oligonucleotide microarrays, respectively. This allows the simultaneous quantification of 
thousands of gene transcripts in two samples when they are tagged with different 
fluorophores, for example, if the transcripts from tumor cells are stained with red (e.g. Cy5) 
and those from normal cells with green (e.g. Cy3), upon locating spots on a cDNA 
microarray, while the red and green ones would respectively correspond to genes 
differentially expressed in the tumor and normal tissue, the yellow (and alike degrees of 
color) would correspond to genes similarly expressed in both tissues. This is usually done 
on cDNA microarrays because the spots can be compared directly in one experiment, but in 
the case of oligonucleotide microarrays, the spots are compared indirectly in separate 
experiments because the detection and analysis methods differ. In either case, the different 
spot intensities can be transformed into transcript levels present in each sample. The 
numerical data are analyzed with a computer and mathematical algorithms, allowing 
various genes to display a characteristic pattern or “Gene Expression Profile” (GEP) related 
to the phenotype of the different samples. Depending on the intensity in which the various 
genes from the GEP are expressed, the sample acquires a particular “expression signature”. 
The transcriptome should study not only the expression of transcripts, but also the DNA 
sites where transcription factors bind as well as chromatin modifications that regulate gene 
expression. Chromatin Immunoprecipitation (ChIP) is a old technique to identify genes that 
can be activated by a protein in vivo (Orlando, 2000), but can be of high-throughput when it 
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is coupled with: i) DNA microarrays (Ren et al., 2000), also known as "ChIP-on-Chip", for 
instance, many genes that can be activated by the transcription factors E2F have been 
identified (Bracken et al., 2004); or 2) Sequencing-based techniques like Paired-end di-tags 
(PET) that is equivalent to SAGE but in contrast to a tag, two gene extremes are joined (Ng et 
al., 2005). Using ChIP-PET, several TP53-regulated genes have been identified (Wei et al., 
2006). TP53 and E2F are the most important transcription factors known in cancer 
development, activating or deactivating genes involved in cell cycle and apoptosis. 
Last but not least, another successful tool combined with microarrays is Laser Capture 
Microdissection (LCM), which uses a laser beam targeted to specific tissue sections under 
microscopic control to isolate cell clusters, allowing the molecular comparison of cell 
populations that are histologically or pathologically distinct but topographically contiguous 
(Kalantari et al., 2009). The main limitation of this technique, however, is that it requires 
trained personnel to visually select cell populations of interest. One approach to increase 
dissection performance is to utilize molecular probes to facilitate the process. Expression 
microdissection (xMD) is such an example, where an antibody is used for cell targeting in 
place of an investigator (Tangrea et al., 2004; Hanson et al., 2011). In fact, large numbers of 
cells can be greatly analyzed by using the recently described SIVQ feature matching 
algorithm, making possible the development of a high-throughput cell procurement 
instrument. This approach permits histologically constrained morphologies (e.g. automated 
selection of only the malignant epithelium of solid tissue tumours) to be acquired in a semi-
autonomous fashion, allowing the generation of large, preparative quantities of DNA, RNA, 
or protein for subsequent high-throughput analysis. In fact, SIVQ–LCM holds unique 
potential as a discovery tool for molecular pathology, since individual cells with particular 
computer-defined morphologic features can be microdissected and profiled, thus generation 
new integrated and composite morphological data types (e.g. morpho-genomics or -
proteomics) (Hipp et al., 2011). Importantly, there is increasing evidence demonstrating the 
necessity of upfront malignant cell enrichment techniques for specific molecular profiles, 
being especially desirable for clinical trials that require accurate, disease cell-specific 
molecular measurements (Harrell et al., 2008; Klee et al., 2009; Silvestri et al., 2010). This 
technique has opened new and promising avenues to molecularly enquire histology and 
pathology in many fields of cancer research (Fuller et al., 2003; Domazet et al., 2008). 
All the techniques mentioned above (Fig. 2) have favorable characteristics, while the high-
throughput methods have a great capacity for data management; the low-throughput ones 
confer higher specificity, sensitivity, and reproducibility. Due to this, high- and medium-
performance techniques are complementary, but they must be validated with those of low-
performance. These tools have generated much information that should be integrated to 
extract biological meaning, allowing the complete characterization of the transcriptome of a 
cell. Indeed, a complete integrative analysis of the cancer transcriptome cannot only be 
obtained by analyzing the genome, transcriptional networks and the interactome, (Rhodes & 
Chinnaiyan, 2005), but also by delineating the subtypes of cancer obtained from DNA 
microarrays with relation to a particular phenotype.  
3. A brief overview on microarrays and cancer 
Microarrays are one of the most versatile tools used in transcriptomics, whereby many 
benefits for oncogenomics have been found. For example, thanks to the determination of  
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Fig. 2. Probing the transcriptome at different performances. a) Upon DNA transcription, 
messenger RNA (mRNA) molecules can be analyzed in a single experiment: i) For one or 
few transcripts, low-throughput methods include in situ hybridization (ISH), subtractive 
hybridization (SH), “Northern Blot” (NB), Ribonuclease-Protection Assay (RPA), Reverse-
Transcriptase Polymerase Chain Reaction (RT-PCR), in situ RT-PCR and quantitative or real 
time RT-PCR (qRT-PCR). ii) For various transcripts there are medium-throughput tools 
based on cDNA clones, Expressed Sequence Tags (ESTs), Open Reading Frame ESTs 
(ORESTES), Differential Display (DD) and Representative Differential Analysis (RDA). iii) 
For thousands of transcripts, Serial Analysis of Gene Expression (SAGE), Massive-Parallel 
Signature Sequencing as well as DNA and oligonucleotide microarrays are high-throughput 
approaches. b) Transcription regulation: To identify Transcription Factors (TF) that bind 
specifically to DNA sites, one can use Chromatin Immunoprecipitation in a low- (ChIP) or 
high-throughput manner when it is coupled to microarrays (ChIP-to-Chip) or Pair-End di-
Tags (ChIP-PET). These methods are classified according to the holism-reductionism 
approach. 
Gene Expression Profiles (GEPs) using DNA microarrays, a new molecular classification 
and subclassification, as well as clinical prediction and diagnosis of many cancer (sub)types 
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have been developed (Macoska, 2002; Ciro et al., 2003; Wadlow & Ramaswamy, 2005). 
Likewise, new potential markers for therapy have been identified and there is a better 
understanding of the molecular mechanisms of cancer (Clarke et al., 2004). There are classic 
studies that have demonstrated the potentials of microarray technology, for instance, one of 
the first reports was the molecular classification of human acute leukemias using an 
oligonucleotide microarray (Affymetrix) representing 6817 genes (Golub et al., 1999). In this 
study, 50 genes were found aid to distinguish between acute myeloid leukemia and acute 
lymphoblastic leukemia. To validate the gene set, 34 samples were analyzed without 
knowledge of its type (unsupervised analysis) and classified in their respective type with a 
high accuracy. This was a very important achievement because the right diagnosis of this 
cancer is often difficult but essential to discern because an effective treatment relies on an 
accurate identification of the cancer subtype. 
Another classical study was applied on the Diffuse Large-B-Cell Lymphoma since it is 
known that patients exhibit different prognoses and variable responses to therapy. Using a 
microarray containing over 18,000 cDNA clones, a GEP with little more than 100 genes and 
96 different samples was established (Alizadeh et al., 2000). This pattern allowed the 
classification of this cancer into two subtypes regarding the status of differentiation of B 
cells: one similar to germ B cells and other similar to activated B cells in vitro. Interestingly, 
the two subtypes showed a strong correlation with clinical prognosis, which was the best for 
the subtype bearing germinal B cells. These patients are usually treated with a combination 
of chemotherapy based on anthracyclines, but if they don´t have a good prognosis then a 
bone marrow transplantation is rather recommended. Therefore, the GEP of about hundred 
genes can help to determine what kind of treatment and prognosis a patient should have. 
Thereafter, this work was validated by using 240 samples that allowed the identification of 
only 17 genes capable to correlate disease with prognosis (Rosenwald et al., 2002). Similarly, 
another laboratory studied the prognosis of the same cancer type but whose patients 
received different treatments, allowing the identification of two groups of patients with 
different life expectancy for 5 years (72% good versus 12% bad prognosis) using only a 
predictor of 13 out of 6,817 genes included in a "Genechip" from Affymetrix (Shipp et al., 
2002). It is noteworthy that 3 tumor markers were detected in both the 17 and 13 gene 
predictors developed independently by those laboratories. 
The best example of GEPs, nonetheless, has been demonstrated in the prognosis of breast 
cancer. Using an oligonucleotide microarray of 25,000 and 78 samples of primary breast 
tumors obtained from patients with negative lymph node status for metastasis, a 70-gene 
"poor-prognosis" molecular signature was identified (van 't Veer et al., 2002). This 
signature corresponds to a high probability of developing metastasis in the short term and 
most likely die. What is interesting about this study is that tumors are not “good” nor 
“bad” when the disease progresses as was proposed not so long time ago with the clonal 
model of development (Couzin, 2003); rather, the malignant cell is destined to metastasize 
very early. Through this genetic signature, experts can decide what patients should 
receive adjuvant therapy consisting of Tamoxifen (an antagonist of the estrogen receptor 
in breast tissue via its active metabolite, hydroxytamoxifen). Shortly after, this study was 
clinically validated using 217 new samples, which reconfirmed that the signature of 70 
genes is the best criterion for deciding whether a patient requires adjuvant therapy or not 
(van de Vijver et al., 2002).  
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Since the first two studies were developed using samples from young patients with 
relatively early tumours from the same institution, it was not clear whether the 70-gene 
could also be applied to other patients. Interestingly, the TRANSBIG consortium, a network 
of 28 institutions promoting international collaboration in translational research across 11 
countries, independently validated the 70-gene signature using 302 samples from patients 
from different age groups (up to 61 years) and from 5 different European hospitals (Buyse et 
al., 2006). Despite its achievements, the same group questioned whether this 70-gene 
signature could be used as a standard high-throughput diagnostic test, so, using the samples 
from the first two mentioned reports, they validated a customized mini-array containing a 
reduced set of 1,900 probes known as the “MammaPrint” (Glas et al., 2006). The 
“MammaPrint” prognostic assay is currently being validated under the clinical MINDACT 
(Microarray in Node-Negative Disease May Avoid Chemotherapy) randomized trial that 
includes 6,000 patient samples from various centers, even though the 70-gene signature has 
been validated several times in patients with negative (Bueno-de-Mesquita et al., 2009) or 
positive (Mook et al., 2009) lymph-node status as well as from other populations, including 
Japanese (Ishitobi et al., 2010). Remarkably, the MammaPrint 70-gene signature, whose 
genes reflect the hallmarks of cancer (Tian et al., 2010), can be considered as a milestone in 
the personalized care for breast cancer patients (Slodkowska & Ross, 2009). 
4. Microarrays and cervical cancer 
The origin of cervical cancer (CC) is linked to the infection of High-Risk Human Papilloma 
Virus (HR-HPV) mainly type 16 and 18. The genome of these viruses contain 8 viral 
oncogenes, 2 of which code for the early-expressed oncoproteins E6 and E7 that inhibit the 
activity of the anti-oncoproteins p53 and pRb, respectively. This way, the oncoproteins 
deregulate the necessary balance between proliferation and apoptosis, promoting the 
development of cancer. These imbalances have been studied at the transcriptional level and 
in a comprehensive manner using microarrays in both clinical samples and cell lines derived 
from CC with and without therapy. Although there are much fewer reports of microarrays 
compared to other tissues e.g. for every CC microarray paper, there are 7 for breast cancer 
(Acevedo Rocha et al., 2007); these few studies have provided invaluable information on the 
molecular mechanisms of CC. 
4.1 Studying carcinogenesis using in vitro HPV models 
A key event in the development of CC is the infection by HR-HPVs. Using microarray 
technology, gene expression profiles in cell lines as well as keratinocytes containing HR-
HPVs have been assessed (Chang & Laimins, 2000; Nees et al., 2000; Nees et al., 2001; Duffy 
et al., 2003; Garner-Hamrick et al., 2004; Lee et al., 2004; Toussaint-Smith et al., 2004). 
Similarly, the overall effect upon infection of cultured human keratinocytes with low-risk 
HPVs (LR-HPVs) has been described (Thomas et al., 2001). Interestingly, in contrast to HR-
HPVs, LR-HPVs induce the overexpression of a larger number of genes from the family 
TGF- (Tumor Growth Factor) and apparently, LR-HPVs do not suppress interferon-
inducible genes (Thomas et al., 2001). This is very interesting as members of the TGF- 
family play a role as tumor suppressor genes (at least at the early development of CC) and 
interferons are key molecules that counteract viral infections mediated by the immune 
system. These findings help to explain why the LR-HPVs episomes, conversely to those of 
HR-HPVs, are easily eliminated in many cases. 
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Another important event in the carcinogenesis of CC is the integration of viral genomes into 
the cellular genome. It is known that upon viral DNA integration into the host genome, the 
E2 protein expression is usually lost. Since E2 normally represses both E6 and E7, its absence 
deregulates the latter oncoproteins. Using microarrays, the overall effect upon viral genome 
integration of HR-HPV type 16, 18, and 33 into cell lines and keratinocytes has been 
determined (Alazawi et al., 2002; Ruutu et al., 2002; Pett et al., 2006). Notably, these studies 
found that the integration of the viral genome into the host genome is a critical step because, 
besides the high chromosomal instability of the infected cells, interferon-inducible genes are 
accordingly activated, thus eliminating the cells containing mainly viral episomes but 
promoting the selection of the more unstable cells. 
In addition, the overall effect of expressing E2 in some cervical carcinoma cell lines has been 
also determined (Thierry et al., 2004), inducing in some cases cellular senescence or exit to 
the G0 cell cycle phase (Wells et al., 2003). Last but not least, the general effect of eliminating 
the gene E6AP, an important gene involved in the E6-mediated TP53 protein degradation, 
has been also assessed in multiple CC-derived (HPV+) cell lines (Kelley et al., 2005). All the 
studies mentioned in this section have identified significant changes in the expression 
patterns of hundreds of genes including cyclins, kinases, oncogenes, and anti-oncogenes; 
some known to be involved in CC but other previously unknown, so all these gathered 
information is essential to systematically study the HPV-mediated CC carcinogenesis. 
4.2 Studying carcinogenesis using patient samples 
To identify key genes in the development of CC several strategies have been followed. Some 
of them had focused on the progress of the lesions while others had compared their origin, 
i.e. squamous and/or glandular lesions vs normal tissue. In any case, these studies had 
allowed the identification of gene expression profiles useful for the molecular classification 
and subclassification of CC. 
In the first attempts to classify CC, an expression profile of only 18 differentially expressed 
genes involved in apoptosis, cell adhesion, and transcription regulation was found between 
cervical squamous cell carcinoma (SCC) and normal cervical tissue using a microarray of 
588 genes (Shim et al., 1998). In another interesting study, employing a 10,000-gene 
microarray, 40 genes allowed the classification of 34 samples of patients into a normal and a 
tumoral group (Wong et al., 2003). Moreover, from the 34 samples, 16 could be sub-classified 
as patients with grade IB and IIB tumors, from which four genes displayed key expression 
levels in both the previous classification and subclassification, suggesting their role as 
possible tumor markers (Wong et al., 2003). In a similar analysis but using only 1,276 genes 
together with 10 samples of SCC and 20 of cervical intraepithelial neoplasia grade 3 (CIN3), 
a gene expression profile showed that, from all the samples corresponding to CIN3, some 
correlated with the progression to cancer while others did not, implying the existence of a 
new subdivision of precancerous lesions histologically indistinguishable (Sopov et al., 2004). 
The selection and characterization of tumor samples is critical as this has permitted the 
establishment of significant gene expression differences between samples from squamous 
and glandular origin in both normal and pathological conditions (Contag et al., 2004). 
Obviously, these differences arise by the transcriptional activity of genes particularly 
expressed in the histological subtypes of CC, but other strategies had also compared the 
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Since the first two studies were developed using samples from young patients with 
relatively early tumours from the same institution, it was not clear whether the 70-gene 
could also be applied to other patients. Interestingly, the TRANSBIG consortium, a network 
of 28 institutions promoting international collaboration in translational research across 11 
countries, independently validated the 70-gene signature using 302 samples from patients 
from different age groups (up to 61 years) and from 5 different European hospitals (Buyse et 
al., 2006). Despite its achievements, the same group questioned whether this 70-gene 
signature could be used as a standard high-throughput diagnostic test, so, using the samples 
from the first two mentioned reports, they validated a customized mini-array containing a 
reduced set of 1,900 probes known as the “MammaPrint” (Glas et al., 2006). The 
“MammaPrint” prognostic assay is currently being validated under the clinical MINDACT 
(Microarray in Node-Negative Disease May Avoid Chemotherapy) randomized trial that 
includes 6,000 patient samples from various centers, even though the 70-gene signature has 
been validated several times in patients with negative (Bueno-de-Mesquita et al., 2009) or 
positive (Mook et al., 2009) lymph-node status as well as from other populations, including 
Japanese (Ishitobi et al., 2010). Remarkably, the MammaPrint 70-gene signature, whose 
genes reflect the hallmarks of cancer (Tian et al., 2010), can be considered as a milestone in 
the personalized care for breast cancer patients (Slodkowska & Ross, 2009). 
4. Microarrays and cervical cancer 
The origin of cervical cancer (CC) is linked to the infection of High-Risk Human Papilloma 
Virus (HR-HPV) mainly type 16 and 18. The genome of these viruses contain 8 viral 
oncogenes, 2 of which code for the early-expressed oncoproteins E6 and E7 that inhibit the 
activity of the anti-oncoproteins p53 and pRb, respectively. This way, the oncoproteins 
deregulate the necessary balance between proliferation and apoptosis, promoting the 
development of cancer. These imbalances have been studied at the transcriptional level and 
in a comprehensive manner using microarrays in both clinical samples and cell lines derived 
from CC with and without therapy. Although there are much fewer reports of microarrays 
compared to other tissues e.g. for every CC microarray paper, there are 7 for breast cancer 
(Acevedo Rocha et al., 2007); these few studies have provided invaluable information on the 
molecular mechanisms of CC. 
4.1 Studying carcinogenesis using in vitro HPV models 
A key event in the development of CC is the infection by HR-HPVs. Using microarray 
technology, gene expression profiles in cell lines as well as keratinocytes containing HR-
HPVs have been assessed (Chang & Laimins, 2000; Nees et al., 2000; Nees et al., 2001; Duffy 
et al., 2003; Garner-Hamrick et al., 2004; Lee et al., 2004; Toussaint-Smith et al., 2004). 
Similarly, the overall effect upon infection of cultured human keratinocytes with low-risk 
HPVs (LR-HPVs) has been described (Thomas et al., 2001). Interestingly, in contrast to HR-
HPVs, LR-HPVs induce the overexpression of a larger number of genes from the family 
TGF- (Tumor Growth Factor) and apparently, LR-HPVs do not suppress interferon-
inducible genes (Thomas et al., 2001). This is very interesting as members of the TGF- 
family play a role as tumor suppressor genes (at least at the early development of CC) and 
interferons are key molecules that counteract viral infections mediated by the immune 
system. These findings help to explain why the LR-HPVs episomes, conversely to those of 
HR-HPVs, are easily eliminated in many cases. 
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Another important event in the carcinogenesis of CC is the integration of viral genomes into 
the cellular genome. It is known that upon viral DNA integration into the host genome, the 
E2 protein expression is usually lost. Since E2 normally represses both E6 and E7, its absence 
deregulates the latter oncoproteins. Using microarrays, the overall effect upon viral genome 
integration of HR-HPV type 16, 18, and 33 into cell lines and keratinocytes has been 
determined (Alazawi et al., 2002; Ruutu et al., 2002; Pett et al., 2006). Notably, these studies 
found that the integration of the viral genome into the host genome is a critical step because, 
besides the high chromosomal instability of the infected cells, interferon-inducible genes are 
accordingly activated, thus eliminating the cells containing mainly viral episomes but 
promoting the selection of the more unstable cells. 
In addition, the overall effect of expressing E2 in some cervical carcinoma cell lines has been 
also determined (Thierry et al., 2004), inducing in some cases cellular senescence or exit to 
the G0 cell cycle phase (Wells et al., 2003). Last but not least, the general effect of eliminating 
the gene E6AP, an important gene involved in the E6-mediated TP53 protein degradation, 
has been also assessed in multiple CC-derived (HPV+) cell lines (Kelley et al., 2005). All the 
studies mentioned in this section have identified significant changes in the expression 
patterns of hundreds of genes including cyclins, kinases, oncogenes, and anti-oncogenes; 
some known to be involved in CC but other previously unknown, so all these gathered 
information is essential to systematically study the HPV-mediated CC carcinogenesis. 
4.2 Studying carcinogenesis using patient samples 
To identify key genes in the development of CC several strategies have been followed. Some 
of them had focused on the progress of the lesions while others had compared their origin, 
i.e. squamous and/or glandular lesions vs normal tissue. In any case, these studies had 
allowed the identification of gene expression profiles useful for the molecular classification 
and subclassification of CC. 
In the first attempts to classify CC, an expression profile of only 18 differentially expressed 
genes involved in apoptosis, cell adhesion, and transcription regulation was found between 
cervical squamous cell carcinoma (SCC) and normal cervical tissue using a microarray of 
588 genes (Shim et al., 1998). In another interesting study, employing a 10,000-gene 
microarray, 40 genes allowed the classification of 34 samples of patients into a normal and a 
tumoral group (Wong et al., 2003). Moreover, from the 34 samples, 16 could be sub-classified 
as patients with grade IB and IIB tumors, from which four genes displayed key expression 
levels in both the previous classification and subclassification, suggesting their role as 
possible tumor markers (Wong et al., 2003). In a similar analysis but using only 1,276 genes 
together with 10 samples of SCC and 20 of cervical intraepithelial neoplasia grade 3 (CIN3), 
a gene expression profile showed that, from all the samples corresponding to CIN3, some 
correlated with the progression to cancer while others did not, implying the existence of a 
new subdivision of precancerous lesions histologically indistinguishable (Sopov et al., 2004). 
The selection and characterization of tumor samples is critical as this has permitted the 
establishment of significant gene expression differences between samples from squamous 
and glandular origin in both normal and pathological conditions (Contag et al., 2004). 
Obviously, these differences arise by the transcriptional activity of genes particularly 
expressed in the histological subtypes of CC, but other strategies had also compared the 
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expression profiles between normal and squamous (Cheng et al., 2002b; Chen et al., 2003; 
Wong et al., 2006) or glandular (Chen et al., 2003; Fujimoto et al., 2004; Chao et al., 2006) 
tumor samples. Importantly, with a correct histological characterization of the samples, 
other factors can also be correlated, for example, using more than 40 samples derived from 
invasive CC (HPV+), it was found that a high burden of viral DNA correlates with high 
levels of E6 and E7 transcripts, poor prognosis, genomic instability and overexpression of 
more than 100 genes related to the cell cycle, from which many were identified as oncogenes 
and at least 50 target genes for the relevant E2F transcription factor family (Rosty et al., 
2005). Although the sample description in other studies has remained considerably poor 
(Ahn et al., 2004a; Guelaguetza Vázquez-Ortíz, 2005; Santin et al., 2005; Vazquez-Ortiz et al., 
2005a; Vazquez-Ortiz et al., 2005b), these also had generated long lists of genes possibly 
important for the molecular study of CC. 
Lastly, there are two more examples displaying the great power of microarray technology as 
these have enriched samples from cytological screening (Papanicolaou). For instance, by 
obtaining normal and cancerous cells from a cytobrush and from simple exfoliated cells, it 
was possible to identify known and potential tumor markers in epithelial cells (Hudelist et 
al., 2005) and CIN3 lesions (Steinau et al., 2005), respectively. 
4.3 Treatment 
In the CC treatment, besides surgery there is radiotherapy and chemotherapy. However, it's 
not possible to predict the individual response of patients. The ability of tumor cells to 
evade treatments suggests that there are different resistance-induced mechanisms. It is 
believed that by monitoring the genes involved in the resistance against therapy, will help 
not only to understand the molecular mechanisms of CC, but also to improve its treatment. 
Accordingly, depending on the gene expression profiles of tumor samples that indicate 
sensitivity to radiation or chemotherapy, it could be possible to classify patients, allowing a 
customized CC treatment (Chin et al., 2005). 
4.3.1 Radiation 
The survival of patients diagnosed with cervical cancer has been improved by combining 
radiotherapy and chemotherapy. However, it has been estimated that about 65% of patients 
can be cured with radiation alone (Usmani et al., 2005) but such patients have not been 
identified so far and therefore they suffer the unnecessary and lethal chemotherapy effects. 
The long-term goal of the first report using microarrays in combination with radiotherapy 
against CC, was to find a GEP that would help deciding whether a patient would benefit or 
not with this treatment, avoiding in this way chemotherapy (Achary et al., 2000). Using a 
microarray of 5,776 genes, 70 identified genes allowed the differentiation of two cell lines 
derived from a single carcinoma, which had been previously characterized as radiosensitive 
and radiotolerant. Interestingly, some genes were previously associated with a cellular 
response against radiation, suggesting a key role in therapy resistance (Achary et al., 2000). 
Likewise, it was possible to classify 19 samples with 100% accuracy in two groups: sensitive 
and tolerant to ionizing radiation (IR) by using 62 out of 23.000 (Kitahara et al., 2002). 
Moreover, from the genes identified in the previous study, it was found that low levels of 
the gene XRCC5, and its corresponding protein Ku80, correlated with a good prognosis in 
CC patients (Harima et al., 2003). Thereafter, but using instead 35 genes, the same group 
 
A Transcriptome- and Marker-Based Systemic Analysis of Cervical Cancer 
 
167 
classified samples from patients treated with radiation and hyperthermia in two groups: 
sensitive and tolerant (Harima et al., 2004). Importantly, not only the combined treatment 
offered a better prognosis than radiotherapy alone, but a long list of genes with a possible 
role in the molecular mechanisms associated with therapy was obtained. 
There are other studies where samples of patients with CC were classified in radiotolerant 
or radiosensitive (Wong et al., 2003), as well as in different radiosensitivity degrees (Tewari 
et al., 2005). In addition, in vitro studies using human keratinocytes (Chen et al., 2002), 
cervical carcinoma cell lines lacking HPV (Liu et al., 2003) and harboring HPV type either 16 
(Liu et al., 2003; Chung et al., 2005) or 18 (Crawford & Piwnica-Worms, 2001; Chaudhry et al., 
2003) have been also useful to improve the understanding of the molecular mechanisms that 
occur when tumor cells are treated with IR. Moreover, high levels of cyclin D1 mRNA (a 
molecule that promotes the progression of cell cycle) and low mRNA levels of the “Insulin-
like Growth Factor-Binding Protein 2” or IGFBP2 (protein that can inhibit or promote tumor 
growth in many cancers) (Hoeflich et al., 2001) correlate with a radioresistant phenotype in 
immortalized human keratinocytes and CC cell lines (Chen et al., 2002; Liu et al., 2003; 
Chung et al., 2005). Other up-regulated genes, primarily involved in the cell cycle, that were 
detected in patients and radio-resistant cell lines include GAPDH (Kitahara et al., 2002; 
Harima et al., 2004), E2F3 (Chaudhry et al., 2003; Liu et al., 2003), DDB1 (Chaudhry et al., 
2003; Wong et al., 2003) and ICAM5 (Achary et al., 2000; Chung et al., 2005). However, cyclin 
B1 and D1 have been determined to be overexpressed in immortalized human keratinocytes 
and several CC-derived radio-resistant cell lines (Chen et al., 2002; Liu et al., 2003), but 
suppressed in radiosensitive cell lines (Crawford & Piwnica-Worms, 2001; Chaudhry et al., 
2003). 
Unfortunately, is difficult to find a clear correlation of differentially expressed genes 
between different microarray studies related to radiation therapy because the response is 
not only different in every patient, but it also depends on the dose, type, time, etc. In spite of 
this, other radiation-related tumor markers (Haffty & Glazer, 2003) have also been detected 
including cyclin D1 (CCND1), the factor vascular endothelial growth factor (VEGF) and the 
proliferating cell nuclear antigen (PCNA), though in isolated studies (Chen et al., 2002; 
Chaudhry et al., 2003; Liu et al., 2003). 
4.3.2 Chemotherapy 
Similar to radiation, there are several studies but using instead chemical agents. For 
example, using cell lines derived from CC with and without HPV infection, the effect of 
anticancer substances that stop cell cycle like lovastatin has been study in a comprehensive 
manner (Dimitroulakos et al., 2002). Other chemicals have been used like the apoptosis-
inducing di-indol-methane (Carter et al., 2002), catechin EGCG (found in green tea) (Ahn et 
al., 2003), arsenic-derived (As2O3 and As4O6) (Ahn et al., 2004b), and platinum-derived 
compounds (Gatti et al., 2004) as well as the antibiotic zeocin (Hwang et al., 2005). In 
addition, several effects exerted by chemicals that inhibit the epidermal growth factor 
receptor (EGFR) oncogene (Woodworth et al., 2005) and phosphatidylinositol kinase 
(PIK3CA) (Lee et al., 2006) signaling pathways had been also assessed. However, since these 
compounds are highly toxic, with broad action spectra, similar to those of radiotherapy, 
only very slight correlations of activated or deactivated genes across all these studies can be 
observed. For example, the expression of pro-metastatic factor JAG2 is suppressed when CC 
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expression profiles between normal and squamous (Cheng et al., 2002b; Chen et al., 2003; 
Wong et al., 2006) or glandular (Chen et al., 2003; Fujimoto et al., 2004; Chao et al., 2006) 
tumor samples. Importantly, with a correct histological characterization of the samples, 
other factors can also be correlated, for example, using more than 40 samples derived from 
invasive CC (HPV+), it was found that a high burden of viral DNA correlates with high 
levels of E6 and E7 transcripts, poor prognosis, genomic instability and overexpression of 
more than 100 genes related to the cell cycle, from which many were identified as oncogenes 
and at least 50 target genes for the relevant E2F transcription factor family (Rosty et al., 
2005). Although the sample description in other studies has remained considerably poor 
(Ahn et al., 2004a; Guelaguetza Vázquez-Ortíz, 2005; Santin et al., 2005; Vazquez-Ortiz et al., 
2005a; Vazquez-Ortiz et al., 2005b), these also had generated long lists of genes possibly 
important for the molecular study of CC. 
Lastly, there are two more examples displaying the great power of microarray technology as 
these have enriched samples from cytological screening (Papanicolaou). For instance, by 
obtaining normal and cancerous cells from a cytobrush and from simple exfoliated cells, it 
was possible to identify known and potential tumor markers in epithelial cells (Hudelist et 
al., 2005) and CIN3 lesions (Steinau et al., 2005), respectively. 
4.3 Treatment 
In the CC treatment, besides surgery there is radiotherapy and chemotherapy. However, it's 
not possible to predict the individual response of patients. The ability of tumor cells to 
evade treatments suggests that there are different resistance-induced mechanisms. It is 
believed that by monitoring the genes involved in the resistance against therapy, will help 
not only to understand the molecular mechanisms of CC, but also to improve its treatment. 
Accordingly, depending on the gene expression profiles of tumor samples that indicate 
sensitivity to radiation or chemotherapy, it could be possible to classify patients, allowing a 
customized CC treatment (Chin et al., 2005). 
4.3.1 Radiation 
The survival of patients diagnosed with cervical cancer has been improved by combining 
radiotherapy and chemotherapy. However, it has been estimated that about 65% of patients 
can be cured with radiation alone (Usmani et al., 2005) but such patients have not been 
identified so far and therefore they suffer the unnecessary and lethal chemotherapy effects. 
The long-term goal of the first report using microarrays in combination with radiotherapy 
against CC, was to find a GEP that would help deciding whether a patient would benefit or 
not with this treatment, avoiding in this way chemotherapy (Achary et al., 2000). Using a 
microarray of 5,776 genes, 70 identified genes allowed the differentiation of two cell lines 
derived from a single carcinoma, which had been previously characterized as radiosensitive 
and radiotolerant. Interestingly, some genes were previously associated with a cellular 
response against radiation, suggesting a key role in therapy resistance (Achary et al., 2000). 
Likewise, it was possible to classify 19 samples with 100% accuracy in two groups: sensitive 
and tolerant to ionizing radiation (IR) by using 62 out of 23.000 (Kitahara et al., 2002). 
Moreover, from the genes identified in the previous study, it was found that low levels of 
the gene XRCC5, and its corresponding protein Ku80, correlated with a good prognosis in 
CC patients (Harima et al., 2003). Thereafter, but using instead 35 genes, the same group 
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classified samples from patients treated with radiation and hyperthermia in two groups: 
sensitive and tolerant (Harima et al., 2004). Importantly, not only the combined treatment 
offered a better prognosis than radiotherapy alone, but a long list of genes with a possible 
role in the molecular mechanisms associated with therapy was obtained. 
There are other studies where samples of patients with CC were classified in radiotolerant 
or radiosensitive (Wong et al., 2003), as well as in different radiosensitivity degrees (Tewari 
et al., 2005). In addition, in vitro studies using human keratinocytes (Chen et al., 2002), 
cervical carcinoma cell lines lacking HPV (Liu et al., 2003) and harboring HPV type either 16 
(Liu et al., 2003; Chung et al., 2005) or 18 (Crawford & Piwnica-Worms, 2001; Chaudhry et al., 
2003) have been also useful to improve the understanding of the molecular mechanisms that 
occur when tumor cells are treated with IR. Moreover, high levels of cyclin D1 mRNA (a 
molecule that promotes the progression of cell cycle) and low mRNA levels of the “Insulin-
like Growth Factor-Binding Protein 2” or IGFBP2 (protein that can inhibit or promote tumor 
growth in many cancers) (Hoeflich et al., 2001) correlate with a radioresistant phenotype in 
immortalized human keratinocytes and CC cell lines (Chen et al., 2002; Liu et al., 2003; 
Chung et al., 2005). Other up-regulated genes, primarily involved in the cell cycle, that were 
detected in patients and radio-resistant cell lines include GAPDH (Kitahara et al., 2002; 
Harima et al., 2004), E2F3 (Chaudhry et al., 2003; Liu et al., 2003), DDB1 (Chaudhry et al., 
2003; Wong et al., 2003) and ICAM5 (Achary et al., 2000; Chung et al., 2005). However, cyclin 
B1 and D1 have been determined to be overexpressed in immortalized human keratinocytes 
and several CC-derived radio-resistant cell lines (Chen et al., 2002; Liu et al., 2003), but 
suppressed in radiosensitive cell lines (Crawford & Piwnica-Worms, 2001; Chaudhry et al., 
2003). 
Unfortunately, is difficult to find a clear correlation of differentially expressed genes 
between different microarray studies related to radiation therapy because the response is 
not only different in every patient, but it also depends on the dose, type, time, etc. In spite of 
this, other radiation-related tumor markers (Haffty & Glazer, 2003) have also been detected 
including cyclin D1 (CCND1), the factor vascular endothelial growth factor (VEGF) and the 
proliferating cell nuclear antigen (PCNA), though in isolated studies (Chen et al., 2002; 
Chaudhry et al., 2003; Liu et al., 2003). 
4.3.2 Chemotherapy 
Similar to radiation, there are several studies but using instead chemical agents. For 
example, using cell lines derived from CC with and without HPV infection, the effect of 
anticancer substances that stop cell cycle like lovastatin has been study in a comprehensive 
manner (Dimitroulakos et al., 2002). Other chemicals have been used like the apoptosis-
inducing di-indol-methane (Carter et al., 2002), catechin EGCG (found in green tea) (Ahn et 
al., 2003), arsenic-derived (As2O3 and As4O6) (Ahn et al., 2004b), and platinum-derived 
compounds (Gatti et al., 2004) as well as the antibiotic zeocin (Hwang et al., 2005). In 
addition, several effects exerted by chemicals that inhibit the epidermal growth factor 
receptor (EGFR) oncogene (Woodworth et al., 2005) and phosphatidylinositol kinase 
(PIK3CA) (Lee et al., 2006) signaling pathways had been also assessed. However, since these 
compounds are highly toxic, with broad action spectra, similar to those of radiotherapy, 
only very slight correlations of activated or deactivated genes across all these studies can be 
observed. For example, the expression of pro-metastatic factor JAG2 is suppressed when CC 
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cell lines were treated with platinum-containing compounds (Gatti et al., 2004) or di-
indolymethane (Carter et al., 2002). Di-indolymethane (Carter et al., 2002) or arsenic 
compounds (Ahn et al., 2004b), on the other hand, suppressed the transcripts of the 
proliferation marker PCNA. 
It has been likewise reported that the transcription factor E2F4 can be suppressed by the 
competitive inhibition (in the ATP binding-site) of the EGFR (Woodworth et al., 2005) or 
simply using zeocin (Hwang et al., 2005). Another gene involved in cell proliferation is 
CHEK1, which can be suppressed by zeocin (Hwang et al., 2005) and derivatives of arsenic 
(Ahn et al., 2004b). Lastly, the membrane marker CD83 (antigen involved in immunologic 
response) has also been down-regulated using arsenic compounds (Ahn et al., 2004b) and 
EGCG (Ahn et al., 2003). Despite efforts to improve the prognosis of patients through the use 
of diverse chemotherapy regimens, radiation and their combinations, the quality of life, 
generally speaking, has not been yet improved significantly (Duenas-Gonzalez et al., 2003). 
Owed to this, the search for new tumor markers and the development of drugs specifically 
targeted against these molecules is an important step to control CC. 
5. A systematic view on cervical cancer 
Systems biology (SB) seeks to explain biological phenomena through the study of networks 
that emerge because of the interactions of the cellular and biochemical components of a cell 
or organism (Kitano, 2002). This can be achieved with the aid of bioinformatics, as it allows 
the integration of large amounts of information that are generated every day as well as the 
construction of biology-oriented mathematical models. In fact, not only transcriptional 
network models for the understanding of cancer have been simulated, but also the 
integration of microarray-derived data has been a useful tool for identifying gene modules 
involved in different cancer-altered pathways (Segal et al., 2005). Furthermore, it has been 
shown that cancer alterations can be better correlated when these are compared to different 
organisms, suggesting that combining data obtained from both cell lines and various 
techniques can provide more compelling ideas to understand biological phenomena. 
5.1 Systems biology and cervical cancer 
All available information from the cancer transcriptome could be easily correlated if the 
respective studies would share a universal language e.g. MIAME (Minimal Information 
About a Microarray Experiment) (Quackenbush, 2004).  
Most microarray reports and in particular those in CC, however, contain no standardized 
data. Using a database and different computational tools (Kent, 2002; Wain et al., 2004; 
Wheeler et al., 2008) to assign all genes the same nomenclature, it is nonetheless possible to 
assess their expression levels and correlate them in different scenarios. For example, from all 
the aforementioned CC microarray studies, when assessing only “on”/”off” expression, we 
observed genes commonly found between some studies (Table 1).  
Many of the genes in Table 1 have been implicated before in CC. Nevertheless, these genes 
can be related to other high performance techniques, such as the identification of tumor 
suppressor genes among a big set of genes that increase their expression during loss of 
tumorigenicity in HeLa cells (Mikheev et al., 2004) or the quantification of transcripts present 
in samples of CC (Frigessi et al., 2005) or normal cervix (Perez-Plasencia et al., 2005).  
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Up-regulated genes in cervical cancer Down-regulated genes in cervical cancer 
Gene References Gene References 
TOP2A 
(Nees et al., 2000), (Nees et al., 2001), (Garner-
Hamrick et al., 2004), (Thierry et al., 2004), 
(Sopov et al., 2004), (Chen et al., 2003), (Rosty 
et al., 2005), (Santin et al., 2005) 
CDKN1A
(Chang & Laimins, 2000), (Nees et al., 2000), 
(Nees et al., 2001), (Duffy et al., 2003), 
(Thierry et al., 2004), (Wells et al., 2003), 
(Kelley et al., 2005) 
CCNA2 
(Nees et al., 2000), (Nees et al., 2001), (Garner-
Hamrick et al., 2004), (Thierry et al., 2004), 
(Sopov et al., 2004), (Rosty et al., 2005), (Santin 
et al., 2005) 
FN1 
(Nees et al., 2000), (Nees et al., 2001), 
(Toussaint-Smith et al., 2004), (Kelley et al., 
2005), (Santin et al., 2005), (Hudelist et al., 
2005) 
CCNB1 
(Nees et al., 2000), (Nees et al., 2001), (Garner-
Hamrick et al., 2004), (Rosty et al., 2005), 
(Santin et al., 2005), (Vazquez-Ortiz et al., 
2005a), (Liu et al., 2003) 
TRIM22 
(Chang & Laimins, 2000), (Nees et al., 2001), 
(Duffy et al., 2003), (Pett et al., 2006), (Kelley 
et al., 2005), (Santin et al., 2005) 
CDKN2A 
(Nees et al., 2001), (Garner-Hamrick et al., 
2004), (Wong et al., 2006), (Rosty et al., 2005), 
(Santin et al., 2005) 
, (Hudelist et al., 2005) 
IL1RN 
(Chang & Laimins, 2000), (Duffy et al., 2003), 
(Ruutu et al., 2002), (Wong et al., 2006), 
(Santin et al., 2005) 
PLK1 
(Nees et al., 2000), (Nees et al., 2001), (Pett et 
al., 2006), (Wells et al., 2003), (Rosty et al., 
2005), (Santin et al., 2005) 
SPRR1A 
(Chang & Laimins, 2000), (Duffy et al., 2003), 
(Alazawi et al., 2002), (Wong et al., 2006), 
(Santin et al., 2005) 
BIRC5 
(Nees et al., 2000), (Nees et al., 2001), (Garner-
Hamrick et al., 2004), (Rosty et al., 2005), 
(Santin et al., 2005) 
TNC 
(Duffy et al., 2003), (Garner-Hamrick et al., 
2004), (Pett et al., 2006), (Kelley et al., 2005), 
(Santin et al., 2005) 
MCM2 
(Garner-Hamrick et al., 2004), (Wells et al., 
2003), (Wong et al., 2006), (Rosty et al., 2005), 
(Santin et al., 2005) 
IGFBP6 (Garner-Hamrick et al., 2004), (Wong et al., 2006), (Hudelist et al., 2005), (Liu et al., 2003) 
NEK2 
(Nees et al., 2001), (Garner-Hamrick et al., 
2004), (Thierry et al., 2004), (Rosty et al., 2005), 
(Santin et al., 2005) 
LCN2 (Chang & Laimins, 2000), (Nees et al., 2001), (Duffy et al., 2003), (Santin et al., 2005) 
BUB1 (Nees et al., 2001), (Garner-Hamrick et al., 2004), (Wells et al., 2003), (Rosty et al., 2005) ABCA1 
(Garner-Hamrick et al., 2004), (Kelley et al., 
2005), (Santin et al., 2005) 
CCNB2 (Garner-Hamrick et al., 2004), (Thierry et al., 2004), (Rosty et al., 2005), (Santin et al., 2005) BNIP2 
(Nees et al., 2001), (Thierry et al., 2004), 
(Wong et al., 2006) 
CDC2 (Nees et al., 2001), (Garner-Hamrick et al., 2004), (Wells et al., 2003), (Rosty et al., 2005) CSPG2 
(Duffy et al., 2003), (Ruutu et al., 2002), 
(Santin et al., 2005) 
CDC20 (Nees et al., 2001), (Wells et al., 2003), (Rosty et al., 2005), (Santin et al., 2005) DDB2 
(Duffy et al., 2003), (Thierry et al., 2004), 
(Kelley et al., 2005) 
CKS1B (Nees et al., 2001), (Thierry et al., 2004), (Rosty et al., 2005), (Santin et al., 2005) GSN 
(Garner-Hamrick et al., 2004), (Thierry et al., 
2004), (Kelley et al., 2005) 
E2F1 (Wells et al., 2003), (Rosty et al., 2005), (Santin et al., 2005), (Hudelist et al., 2005) INPP5D 
(Nees et al., 2001), (Duffy et al., 2003), (Wells 
et al., 2003) 
FOXM1 (Garner-Hamrick et al., 2004), (Thierry et al., 2004), (Rosty et al., 2005), (Santin et al., 2005) IVL 
(Duffy et al., 2003), (Garner-Hamrick et al., 
2004), (Wong et al., 2006) 
KRT18 (Garner-Hamrick et al., 2004), (Thierry et al., 2004), (Sopov et al., 2004), (Rosty et al., 2005) KLK7 
(Chang & Laimins, 2000), (Duffy et al., 2003), 
(Wong et al., 2006) 
MEST (Duffy et al., 2003), (Chen et al., 2003), (Rosty et al., 2005), (Santin et al., 2005) KRT4 
(Duffy et al., 2003), (Ruutu et al., 2002), 
(Wong et al., 2006) 
MKI67 
(Garner-Hamrick et al., 2004), (Thierry et al., 
2004), (Rosty et al., 2005), (Vazquez-Ortiz et al, 
2005b) 
KRT16 (Alazawi et al., 2002), (Ruutu et al., 2002), (Wong et al., 2006) 
MSH6 (Garner-Hamrick et al., 2004), (Sopov et al., 2004), (Rosty et al., 2005), (Santin et al., 2005) LAMA3 
(Chang & Laimins, 2000), (Kelley et al., 2005), 
(Santin et al., 2005) 
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cell lines were treated with platinum-containing compounds (Gatti et al., 2004) or di-
indolymethane (Carter et al., 2002). Di-indolymethane (Carter et al., 2002) or arsenic 
compounds (Ahn et al., 2004b), on the other hand, suppressed the transcripts of the 
proliferation marker PCNA. 
It has been likewise reported that the transcription factor E2F4 can be suppressed by the 
competitive inhibition (in the ATP binding-site) of the EGFR (Woodworth et al., 2005) or 
simply using zeocin (Hwang et al., 2005). Another gene involved in cell proliferation is 
CHEK1, which can be suppressed by zeocin (Hwang et al., 2005) and derivatives of arsenic 
(Ahn et al., 2004b). Lastly, the membrane marker CD83 (antigen involved in immunologic 
response) has also been down-regulated using arsenic compounds (Ahn et al., 2004b) and 
EGCG (Ahn et al., 2003). Despite efforts to improve the prognosis of patients through the use 
of diverse chemotherapy regimens, radiation and their combinations, the quality of life, 
generally speaking, has not been yet improved significantly (Duenas-Gonzalez et al., 2003). 
Owed to this, the search for new tumor markers and the development of drugs specifically 
targeted against these molecules is an important step to control CC. 
5. A systematic view on cervical cancer 
Systems biology (SB) seeks to explain biological phenomena through the study of networks 
that emerge because of the interactions of the cellular and biochemical components of a cell 
or organism (Kitano, 2002). This can be achieved with the aid of bioinformatics, as it allows 
the integration of large amounts of information that are generated every day as well as the 
construction of biology-oriented mathematical models. In fact, not only transcriptional 
network models for the understanding of cancer have been simulated, but also the 
integration of microarray-derived data has been a useful tool for identifying gene modules 
involved in different cancer-altered pathways (Segal et al., 2005). Furthermore, it has been 
shown that cancer alterations can be better correlated when these are compared to different 
organisms, suggesting that combining data obtained from both cell lines and various 
techniques can provide more compelling ideas to understand biological phenomena. 
5.1 Systems biology and cervical cancer 
All available information from the cancer transcriptome could be easily correlated if the 
respective studies would share a universal language e.g. MIAME (Minimal Information 
About a Microarray Experiment) (Quackenbush, 2004).  
Most microarray reports and in particular those in CC, however, contain no standardized 
data. Using a database and different computational tools (Kent, 2002; Wain et al., 2004; 
Wheeler et al., 2008) to assign all genes the same nomenclature, it is nonetheless possible to 
assess their expression levels and correlate them in different scenarios. For example, from all 
the aforementioned CC microarray studies, when assessing only “on”/”off” expression, we 
observed genes commonly found between some studies (Table 1).  
Many of the genes in Table 1 have been implicated before in CC. Nevertheless, these genes 
can be related to other high performance techniques, such as the identification of tumor 
suppressor genes among a big set of genes that increase their expression during loss of 
tumorigenicity in HeLa cells (Mikheev et al., 2004) or the quantification of transcripts present 
in samples of CC (Frigessi et al., 2005) or normal cervix (Perez-Plasencia et al., 2005).  
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Up-regulated genes in cervical cancer Down-regulated genes in cervical cancer 
Gene References Gene References 
TOP2A 
(Nees et al., 2000), (Nees et al., 2001), (Garner-
Hamrick et al., 2004), (Thierry et al., 2004), 
(Sopov et al., 2004), (Chen et al., 2003), (Rosty 
et al., 2005), (Santin et al., 2005) 
CDKN1A
(Chang & Laimins, 2000), (Nees et al., 2000), 
(Nees et al., 2001), (Duffy et al., 2003), 
(Thierry et al., 2004), (Wells et al., 2003), 
(Kelley et al., 2005) 
CCNA2 
(Nees et al., 2000), (Nees et al., 2001), (Garner-
Hamrick et al., 2004), (Thierry et al., 2004), 
(Sopov et al., 2004), (Rosty et al., 2005), (Santin 
et al., 2005) 
FN1 
(Nees et al., 2000), (Nees et al., 2001), 
(Toussaint-Smith et al., 2004), (Kelley et al., 
2005), (Santin et al., 2005), (Hudelist et al., 
2005) 
CCNB1 
(Nees et al., 2000), (Nees et al., 2001), (Garner-
Hamrick et al., 2004), (Rosty et al., 2005), 
(Santin et al., 2005), (Vazquez-Ortiz et al., 
2005a), (Liu et al., 2003) 
TRIM22 
(Chang & Laimins, 2000), (Nees et al., 2001), 
(Duffy et al., 2003), (Pett et al., 2006), (Kelley 
et al., 2005), (Santin et al., 2005) 
CDKN2A 
(Nees et al., 2001), (Garner-Hamrick et al., 
2004), (Wong et al., 2006), (Rosty et al., 2005), 
(Santin et al., 2005) 
, (Hudelist et al., 2005) 
IL1RN 
(Chang & Laimins, 2000), (Duffy et al., 2003), 
(Ruutu et al., 2002), (Wong et al., 2006), 
(Santin et al., 2005) 
PLK1 
(Nees et al., 2000), (Nees et al., 2001), (Pett et 
al., 2006), (Wells et al., 2003), (Rosty et al., 
2005), (Santin et al., 2005) 
SPRR1A 
(Chang & Laimins, 2000), (Duffy et al., 2003), 
(Alazawi et al., 2002), (Wong et al., 2006), 
(Santin et al., 2005) 
BIRC5 
(Nees et al., 2000), (Nees et al., 2001), (Garner-
Hamrick et al., 2004), (Rosty et al., 2005), 
(Santin et al., 2005) 
TNC 
(Duffy et al., 2003), (Garner-Hamrick et al., 
2004), (Pett et al., 2006), (Kelley et al., 2005), 
(Santin et al., 2005) 
MCM2 
(Garner-Hamrick et al., 2004), (Wells et al., 
2003), (Wong et al., 2006), (Rosty et al., 2005), 
(Santin et al., 2005) 
IGFBP6 (Garner-Hamrick et al., 2004), (Wong et al., 2006), (Hudelist et al., 2005), (Liu et al., 2003) 
NEK2 
(Nees et al., 2001), (Garner-Hamrick et al., 
2004), (Thierry et al., 2004), (Rosty et al., 2005), 
(Santin et al., 2005) 
LCN2 (Chang & Laimins, 2000), (Nees et al., 2001), (Duffy et al., 2003), (Santin et al., 2005) 
BUB1 (Nees et al., 2001), (Garner-Hamrick et al., 2004), (Wells et al., 2003), (Rosty et al., 2005) ABCA1 
(Garner-Hamrick et al., 2004), (Kelley et al., 
2005), (Santin et al., 2005) 
CCNB2 (Garner-Hamrick et al., 2004), (Thierry et al., 2004), (Rosty et al., 2005), (Santin et al., 2005) BNIP2 
(Nees et al., 2001), (Thierry et al., 2004), 
(Wong et al., 2006) 
CDC2 (Nees et al., 2001), (Garner-Hamrick et al., 2004), (Wells et al., 2003), (Rosty et al., 2005) CSPG2 
(Duffy et al., 2003), (Ruutu et al., 2002), 
(Santin et al., 2005) 
CDC20 (Nees et al., 2001), (Wells et al., 2003), (Rosty et al., 2005), (Santin et al., 2005) DDB2 
(Duffy et al., 2003), (Thierry et al., 2004), 
(Kelley et al., 2005) 
CKS1B (Nees et al., 2001), (Thierry et al., 2004), (Rosty et al., 2005), (Santin et al., 2005) GSN 
(Garner-Hamrick et al., 2004), (Thierry et al., 
2004), (Kelley et al., 2005) 
E2F1 (Wells et al., 2003), (Rosty et al., 2005), (Santin et al., 2005), (Hudelist et al., 2005) INPP5D 
(Nees et al., 2001), (Duffy et al., 2003), (Wells 
et al., 2003) 
FOXM1 (Garner-Hamrick et al., 2004), (Thierry et al., 2004), (Rosty et al., 2005), (Santin et al., 2005) IVL 
(Duffy et al., 2003), (Garner-Hamrick et al., 
2004), (Wong et al., 2006) 
KRT18 (Garner-Hamrick et al., 2004), (Thierry et al., 2004), (Sopov et al., 2004), (Rosty et al., 2005) KLK7 
(Chang & Laimins, 2000), (Duffy et al., 2003), 
(Wong et al., 2006) 
MEST (Duffy et al., 2003), (Chen et al., 2003), (Rosty et al., 2005), (Santin et al., 2005) KRT4 
(Duffy et al., 2003), (Ruutu et al., 2002), 
(Wong et al., 2006) 
MKI67 
(Garner-Hamrick et al., 2004), (Thierry et al., 
2004), (Rosty et al., 2005), (Vazquez-Ortiz et al, 
2005b) 
KRT16 (Alazawi et al., 2002), (Ruutu et al., 2002), (Wong et al., 2006) 
MSH6 (Garner-Hamrick et al., 2004), (Sopov et al., 2004), (Rosty et al., 2005), (Santin et al., 2005) LAMA3 
(Chang & Laimins, 2000), (Kelley et al., 2005), 
(Santin et al., 2005) 
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Up-regulated genes in cervical cancer Down-regulated genes in cervical cancer 
Gene References Gene References 
MYBL2 (Thierry et al., 2004), (Chen et al., 2003), (Rosty et al., 2005), (Santin et al., 2005) SMPG 
(Garner-Hamrick et al., 2004), (Wong et al., 
2006), (Santin et al., 2005) 
PRIM1 (Nees et al., 2001), (Garner-Hamrick et al., 2004), (Rosty et al., 2005), (Santin et al., 2005) PI3 
(Duffy et al., 2003), (Alazawi et al., 2002), 
(Santin et al., 2005) 
RRM2 (Nees et al., 2001), (Thierry et al., 2004), (Wong et al., 2006), (Rosty et al., 2005) PPP2R5B
(Garner-Hamrick et al., 2004), (Ruutu et al., 
2002), (Santin et al., 2005) 
SPARC (Nees et al., 2001), (Duffy et al., 2003), (Chen et al., 2003), (Ahn et al., 2004a) SERPINB2
(Chang & Laimins, 2000), (Ruutu et al., 2002), 
(Santin et al., 2005) 
TTK (Garner-Hamrick et al., 2004), (Wells et al., 2003), (Rosty et al., 2005), (Santin et al., 2005) SPRR2B 
(Duffy et al., 2003), (Wong et al., 2006), 
(Santin et al., 2005) 
VEGF 
(Garner-Hamrick et al., 2004), (Toussaint-
Smith et al., 2004), (Wong et al., 2006), 
(Vazquez-Ortiz et al., 2005a) 
SULT2B1 (Chang & Laimins, 2000), (Duffy et al., 2003), (Wong et al., 2006) 
Table 1. Genes primarily found to be up- or down-regulated in cervical cancer across 
different DNA microarray platforms comparing non-pathogenic vs tumor samples and cell 
lines. The internationally accepted nomenclature for each gene can be found in: 
http://www.genenames.org/ or http://cgap.nci.nih.gov/Genes/GeneFinder. 
Moreover, it is even possible to combine all this information with that derived of techniques 
of medium- (Nees et al., 1998; Cheng et al., 2002a; Brentani et al., 2003; Ahn et al., 2005; 
Ranamukhaarachchi et al., 2005; Seo et al., 2005; Sgarlato et al., 2005) and low- (Helliwell, 
2001; Keating et al., 2001; Follen et al., 2003; Gray & Herrington, 2004) performance in CC. 
In addition, the to-be-integrated information can be further correlated with genes that have 
been (a) implied as potential markers in several metastatic solid tumors, including some of 
uterine origin (Ramaswamy et al., 2003); (b) associated with cervical cancer and other kind of 
cancers whose somatic or germline mutations frequently favor the development of neoplasia 
(Forbes et al., 2006); or (c) proposed as common tumor proliferation markers overexpressed 
across microarray reports in very diverse tumor tissues (Whitfield et al., 2006). Last but not 
least, a more comprehensive systematic analysis of CC can be done by correlating gene up-
regulation mediated via the transcription factors E2F (Bracken et al., 2004) and TP53 (Wei et 
al., 2006), being this integration crucial for a general understanding of the transcriptional 
regulation during CC development because the functions E2F and TP53 are respectively 
altered by the oncoproteins E7 and E6. The idea of integrating all these additional 
supporting studies from many sources poses great potential in the diagnosis, prevention, 
and treatment of cancer as has been shown in liver carcinoma (Thorgeirsson et al., 2006). 
5.2 Systematic model of HPV-mediated cervical carcinogenesis 
The invaluable information provided by all the aforementioned microarray-based CC 
reports can be related to those additional supporting studies through an integrative disease 
model as the HPV-mediated cervix carcinogenesis develops in a complex multiple-step 
process (Sherman & Kurman, 1998; Klaes et al., 1999; zur Hausen, 2002; Sherman, 2003; Ahn 
et al., 2004a; Frazer, 2004; Pett et al., 2006; Snijders et al., 2006). It starts with the HR-HPV 
infection and episomes formation thereof, followed by the production of virions and/or the 
integration of the viral genome into the host one that can lead to precancerous and 
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cancerous lesions of squamous and/or glandular origin and ultimately to death. In other 
words, with this model (Fig. 3) it is not only possible to correlate the up/down regulation of  
 
Fig. 3. Cervix carcinogenesis systematic model. The various nomenclatures employed in the 
histopathology of cervical cancer are aligned by dashed lines and extended to key cellular 
and molecular events that occur during the transformation of the epithelium. The solid lines 
indicate a direct relationship between key events. A key event is the infection of cells in the 
basal membrane by HR-HPVs. These can turn into episomal bodies, which will be in charge 
of, on one hand, producing infective virions and, on the other, integrating into the genome 
of epithelial cells. Upon infection, an average of 2-3 years are necessary to develop cervical 
intraepithelial neoplasia of low- (CIN1/2) and/or high-grade (CIN3), often characterized by 
the integration of the viral genome, another key event for the disease progression as this 
often triggers the deregulation of the oncogenes E6 and E7, mayor chromosomal alterations 
and cellular immortalization. The immune system plays a key role during carcinogenesis 
since the majority of HR-HPV infections (80%) as well as most low-grade lesions (80%) 
regress. Due to this and the long periods of time between viral infection and the progression 
to invasive disease, the infection by HR-HPVs is necessary but not sufficient for the 
development of cervical cancer; in addition, the inactivation of anti-oncogenes (besides pRb 
and p53) and activation of oncogenes are necessary to consequently provoke changes at the 
(epi-)genomic, transcriptomic and protemic level. D = Displasia; L- or HSIL = Low- or High-
grade squamous intraepithelial lesion. 
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Up-regulated genes in cervical cancer Down-regulated genes in cervical cancer 
Gene References Gene References 
MYBL2 (Thierry et al., 2004), (Chen et al., 2003), (Rosty et al., 2005), (Santin et al., 2005) SMPG 
(Garner-Hamrick et al., 2004), (Wong et al., 
2006), (Santin et al., 2005) 
PRIM1 (Nees et al., 2001), (Garner-Hamrick et al., 2004), (Rosty et al., 2005), (Santin et al., 2005) PI3 
(Duffy et al., 2003), (Alazawi et al., 2002), 
(Santin et al., 2005) 
RRM2 (Nees et al., 2001), (Thierry et al., 2004), (Wong et al., 2006), (Rosty et al., 2005) PPP2R5B
(Garner-Hamrick et al., 2004), (Ruutu et al., 
2002), (Santin et al., 2005) 
SPARC (Nees et al., 2001), (Duffy et al., 2003), (Chen et al., 2003), (Ahn et al., 2004a) SERPINB2
(Chang & Laimins, 2000), (Ruutu et al., 2002), 
(Santin et al., 2005) 
TTK (Garner-Hamrick et al., 2004), (Wells et al., 2003), (Rosty et al., 2005), (Santin et al., 2005) SPRR2B 
(Duffy et al., 2003), (Wong et al., 2006), 
(Santin et al., 2005) 
VEGF 
(Garner-Hamrick et al., 2004), (Toussaint-
Smith et al., 2004), (Wong et al., 2006), 
(Vazquez-Ortiz et al., 2005a) 
SULT2B1 (Chang & Laimins, 2000), (Duffy et al., 2003), (Wong et al., 2006) 
Table 1. Genes primarily found to be up- or down-regulated in cervical cancer across 
different DNA microarray platforms comparing non-pathogenic vs tumor samples and cell 
lines. The internationally accepted nomenclature for each gene can be found in: 
http://www.genenames.org/ or http://cgap.nci.nih.gov/Genes/GeneFinder. 
Moreover, it is even possible to combine all this information with that derived of techniques 
of medium- (Nees et al., 1998; Cheng et al., 2002a; Brentani et al., 2003; Ahn et al., 2005; 
Ranamukhaarachchi et al., 2005; Seo et al., 2005; Sgarlato et al., 2005) and low- (Helliwell, 
2001; Keating et al., 2001; Follen et al., 2003; Gray & Herrington, 2004) performance in CC. 
In addition, the to-be-integrated information can be further correlated with genes that have 
been (a) implied as potential markers in several metastatic solid tumors, including some of 
uterine origin (Ramaswamy et al., 2003); (b) associated with cervical cancer and other kind of 
cancers whose somatic or germline mutations frequently favor the development of neoplasia 
(Forbes et al., 2006); or (c) proposed as common tumor proliferation markers overexpressed 
across microarray reports in very diverse tumor tissues (Whitfield et al., 2006). Last but not 
least, a more comprehensive systematic analysis of CC can be done by correlating gene up-
regulation mediated via the transcription factors E2F (Bracken et al., 2004) and TP53 (Wei et 
al., 2006), being this integration crucial for a general understanding of the transcriptional 
regulation during CC development because the functions E2F and TP53 are respectively 
altered by the oncoproteins E7 and E6. The idea of integrating all these additional 
supporting studies from many sources poses great potential in the diagnosis, prevention, 
and treatment of cancer as has been shown in liver carcinoma (Thorgeirsson et al., 2006). 
5.2 Systematic model of HPV-mediated cervical carcinogenesis 
The invaluable information provided by all the aforementioned microarray-based CC 
reports can be related to those additional supporting studies through an integrative disease 
model as the HPV-mediated cervix carcinogenesis develops in a complex multiple-step 
process (Sherman & Kurman, 1998; Klaes et al., 1999; zur Hausen, 2002; Sherman, 2003; Ahn 
et al., 2004a; Frazer, 2004; Pett et al., 2006; Snijders et al., 2006). It starts with the HR-HPV 
infection and episomes formation thereof, followed by the production of virions and/or the 
integration of the viral genome into the host one that can lead to precancerous and 
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cancerous lesions of squamous and/or glandular origin and ultimately to death. In other 
words, with this model (Fig. 3) it is not only possible to correlate the up/down regulation of  
 
Fig. 3. Cervix carcinogenesis systematic model. The various nomenclatures employed in the 
histopathology of cervical cancer are aligned by dashed lines and extended to key cellular 
and molecular events that occur during the transformation of the epithelium. The solid lines 
indicate a direct relationship between key events. A key event is the infection of cells in the 
basal membrane by HR-HPVs. These can turn into episomal bodies, which will be in charge 
of, on one hand, producing infective virions and, on the other, integrating into the genome 
of epithelial cells. Upon infection, an average of 2-3 years are necessary to develop cervical 
intraepithelial neoplasia of low- (CIN1/2) and/or high-grade (CIN3), often characterized by 
the integration of the viral genome, another key event for the disease progression as this 
often triggers the deregulation of the oncogenes E6 and E7, mayor chromosomal alterations 
and cellular immortalization. The immune system plays a key role during carcinogenesis 
since the majority of HR-HPV infections (80%) as well as most low-grade lesions (80%) 
regress. Due to this and the long periods of time between viral infection and the progression 
to invasive disease, the infection by HR-HPVs is necessary but not sufficient for the 
development of cervical cancer; in addition, the inactivation of anti-oncogenes (besides pRb 
and p53) and activation of oncogenes are necessary to consequently provoke changes at the 
(epi-)genomic, transcriptomic and protemic level. D = Displasia; L- or HSIL = Low- or High-
grade squamous intraepithelial lesion. 
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specific genes upon presence/absence of HR-HPVs episomes or genome integration as well 
as that of the oncoproteins E6 and/or E7, but also to identify specific carcinogenesis targets.  
Depending on the study, however, the gene correlation has to be carefully done, for 
example, the processes of cell differentiation and senescence (Nees et al., 2000; Wells et al., 
2003; Ranamukhaarachchi et al., 2005) have been considered as anti-cell proliferation 
molecular events (Gandarillas, 2000). Similarly, an indirect correlation could be observed for 
gene activation mediated by LR-HPVs (Thomas et al., 2001) but not HR-HPVs or E6 and E7 
oncogene suppression (Wells et al., 2003; Thierry et al., 2004; Kelley et al., 2005) by E2 
(Dowhanick et al., 1995) or RNA interference (Novina & Sharp, 2004). More importantly, 
nonetheless, as will be discussed in the coming subsections, this model allows the 
comparison of candidate tumor markers to data obtained from other CC studies at the 
genomic (Lazo, 1999; Wilting et al., 2006), transcriptomic (Martin et al., 2006), proteomic (Bae 
et al., 2005; Choi et al., 2005; Yim & Park, 2006) and epigenomic (Duenas-Gonzalez et al., 
2005; Sova et al., 2006) level.  
5.3 Up-regulated candidate tumor markers 
Although many genes frequently activated in CC have been reported using microarrays, 
other techniques and analyses strongly suggest that these are tumor markers. This can be 
illustrated with the inhibitor of cyclin-dependent kinases (CDKs) p16INK4a or CDKN2A, 
which is involved in cell cycle and has been categorized as a tumor marker in the 
development of CC (Keating et al., 2001). Overexpression of p16INK4a at both the transcript 
and protein level can be detected in samples of cervical dysplasia, squamous and glandular 
HR-HPV positive and negative lesions when compared with normal cervix by low-
throughput techniques (Martin et al., 2006). As summarized in Table 2, p16INK4a up-regulation 
has been also found using medium- (Brentani et al., 2003) and high-performance methods 
when the oncoprotein E7 is expressed in cell lines in vitro (Nees et al., 2001; Garner-Hamrick 
et al., 2004), in patient samples in vivo (Rosty et al., 2005) and when comparing tumors vs 
normal tissue (Hudelist et al., 2005; Rosty et al., 2005; Santin et al., 2005; Wong et al., 2006). 
Interestingly, p16INK4a is one of the genes that can display somatic mutations in CC; an 
abnormal status that has been linked to the development of cervical squamous cell cancer 
(SCC) (Forbes et al., 2006). Dozens of references in the literature demonstrate that the 
overexpression of p16INK4a is useful as a CC tumor marker; however, using patient samples, 
others have determined transcript inactivation due to strong hypermethylation on its 
promoter region (Duenas-Gonzalez et al., 2005). Although these findings are contradictory at 
first glance, some subpopulations of dysplastic cervical cells can also display epigenetic 
silencing of p16INK4a and associated low protein levels (Nuovo et al., 1999). This suggests that 
the expression of p16INK4a is inhibited in some cells within the tumor, whereas its 
overexpression can be abundant in other cells, most probably expressing the oncoprotein E7. 
In spite of this, the detection of p16INK4a is very useful in the cytological diagnosis of CC and, 
furthermore, recent evidence suggests that the determination of the p16INK4a protein may be 
even more useful than the already-established HR-HPVs detection in the cytological 
diagnosis (Nieh et al., 2005). 
Another important up-regulated gene is “survivin” or BIRC5 (Table 2). Although surviving 
expression is undetectable in normal adult tissues, its expression can be detected normally  
 
















































































(Garner-Hamrick et al., 2004), 
(Thierry et al., 2004), (Rosty et 
al., 2005), (Vazquez-Ortiz et 
al., 2005b) 









































(Nees et al., 2001), (Garner-
Hamrick et al., 2004), (Wong et 
al., 2006), (Rosty et al., 2005), 
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(Nees et al., 2000), (Nees et al., 
2001), (Garner-Hamrick et al., 
2004), (Rosty et al., 2005), 
(Santin et al., 2005), (Vazquez-
Ortiz et al., 2005a), (Liu et al., 
2003) 
(Brentani et al., 
2003) 
(Sgarlato et al., 
2005) (Cheng et 
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- - - 
PLK1 
(16p12.1) 
(Nees et al., 2000), (Nees et al., 
2001), (Pett et al., 2006), (Wells 
et al., 2003), (Rosty et al., 2005), 
(Santin et al., 2005) 
(Brentani et al., 












- - - - - 
CCNA2 
(4q25-31) 
(Nees et al., 2000), (Nees et al., 
2001), (Garner-Hamrick et al., 
2004), (Thierry et al., 2004), 
(Sopov et al., 2004), (Rosty et 
al., 2005), (Santin et al., 2005) 
(Brentani et al., 
2003) - - - - - - - - 
MSH6 
(2p16) 
(Garner-Hamrick et al., 2004), 
(Sopov et al., 2004), (Rosty et 
al., 2005), (Santin et al., 2005) 
(Ranamukhaar
























- - - - 
MAD2L1 
(4q27) 
(Nees et al., 2001), (Thierry et 
al., 2004), 
(Wells et al., 2003), (Rosty et 
al., 2005) 
(Brentani et al., 













- - - - - 
CKS1B 
(1q21.2) 
(Nees et al., 2001), (Thierry et 
al., 2004), (Rosty et al., 2005), 
(Santin et al., 2005) 












- - - 
SMC4L1 
(3q26.1) 
(Rosty et al., 2005), (Santin et 
al., 2005) 
(Brentani et al., 
2003) 
(Ranamukhaar
achchi et al., 
2005) 
- - - - - - - - 
ZWINT 
(10q21-22) 
(Thierry et al., 2004), (Rosty et 
al., 2005), (Santin et al., 2005) 
(Brentani et al., 
2003) (Sgarlato 
et al., 2005) 









(Nees et al., 2000), (Nees et al., 
2001), (Garner-Hamrick et al., 
2004), (Rosty et al., 2005), 
(Santin et al., 2005) 
(Brentani et al., 













- - - - - - 
 
Topics on Cervical Cancer with an Advocacy for Prevention 
 
172 
specific genes upon presence/absence of HR-HPVs episomes or genome integration as well 
as that of the oncoproteins E6 and/or E7, but also to identify specific carcinogenesis targets.  
Depending on the study, however, the gene correlation has to be carefully done, for 
example, the processes of cell differentiation and senescence (Nees et al., 2000; Wells et al., 
2003; Ranamukhaarachchi et al., 2005) have been considered as anti-cell proliferation 
molecular events (Gandarillas, 2000). Similarly, an indirect correlation could be observed for 
gene activation mediated by LR-HPVs (Thomas et al., 2001) but not HR-HPVs or E6 and E7 
oncogene suppression (Wells et al., 2003; Thierry et al., 2004; Kelley et al., 2005) by E2 
(Dowhanick et al., 1995) or RNA interference (Novina & Sharp, 2004). More importantly, 
nonetheless, as will be discussed in the coming subsections, this model allows the 
comparison of candidate tumor markers to data obtained from other CC studies at the 
genomic (Lazo, 1999; Wilting et al., 2006), transcriptomic (Martin et al., 2006), proteomic (Bae 
et al., 2005; Choi et al., 2005; Yim & Park, 2006) and epigenomic (Duenas-Gonzalez et al., 
2005; Sova et al., 2006) level.  
5.3 Up-regulated candidate tumor markers 
Although many genes frequently activated in CC have been reported using microarrays, 
other techniques and analyses strongly suggest that these are tumor markers. This can be 
illustrated with the inhibitor of cyclin-dependent kinases (CDKs) p16INK4a or CDKN2A, 
which is involved in cell cycle and has been categorized as a tumor marker in the 
development of CC (Keating et al., 2001). Overexpression of p16INK4a at both the transcript 
and protein level can be detected in samples of cervical dysplasia, squamous and glandular 
HR-HPV positive and negative lesions when compared with normal cervix by low-
throughput techniques (Martin et al., 2006). As summarized in Table 2, p16INK4a up-regulation 
has been also found using medium- (Brentani et al., 2003) and high-performance methods 
when the oncoprotein E7 is expressed in cell lines in vitro (Nees et al., 2001; Garner-Hamrick 
et al., 2004), in patient samples in vivo (Rosty et al., 2005) and when comparing tumors vs 
normal tissue (Hudelist et al., 2005; Rosty et al., 2005; Santin et al., 2005; Wong et al., 2006). 
Interestingly, p16INK4a is one of the genes that can display somatic mutations in CC; an 
abnormal status that has been linked to the development of cervical squamous cell cancer 
(SCC) (Forbes et al., 2006). Dozens of references in the literature demonstrate that the 
overexpression of p16INK4a is useful as a CC tumor marker; however, using patient samples, 
others have determined transcript inactivation due to strong hypermethylation on its 
promoter region (Duenas-Gonzalez et al., 2005). Although these findings are contradictory at 
first glance, some subpopulations of dysplastic cervical cells can also display epigenetic 
silencing of p16INK4a and associated low protein levels (Nuovo et al., 1999). This suggests that 
the expression of p16INK4a is inhibited in some cells within the tumor, whereas its 
overexpression can be abundant in other cells, most probably expressing the oncoprotein E7. 
In spite of this, the detection of p16INK4a is very useful in the cytological diagnosis of CC and, 
furthermore, recent evidence suggests that the determination of the p16INK4a protein may be 
even more useful than the already-established HR-HPVs detection in the cytological 
diagnosis (Nieh et al., 2005). 
Another important up-regulated gene is “survivin” or BIRC5 (Table 2). Although surviving 
expression is undetectable in normal adult tissues, its expression can be detected normally  
 
















































































(Garner-Hamrick et al., 2004), 
(Thierry et al., 2004), (Rosty et 
al., 2005), (Vazquez-Ortiz et 
al., 2005b) 









































(Nees et al., 2001), (Garner-
Hamrick et al., 2004), (Wong et 
al., 2006), (Rosty et al., 2005), 
(Santin et al., 2005), (Hudelist 
et al., 2005) 






















































(Nees et al., 2000), (Nees et al., 
2001), (Garner-Hamrick et al., 
2004), (Rosty et al., 2005), 
(Santin et al., 2005), (Vazquez-
Ortiz et al., 2005a), (Liu et al., 
2003) 
(Brentani et al., 
2003) 
(Sgarlato et al., 
2005) (Cheng et 
al., 2002a) 

























- - - 
PLK1 
(16p12.1) 
(Nees et al., 2000), (Nees et al., 
2001), (Pett et al., 2006), (Wells 
et al., 2003), (Rosty et al., 2005), 
(Santin et al., 2005) 
(Brentani et al., 












- - - - - 
CCNA2 
(4q25-31) 
(Nees et al., 2000), (Nees et al., 
2001), (Garner-Hamrick et al., 
2004), (Thierry et al., 2004), 
(Sopov et al., 2004), (Rosty et 
al., 2005), (Santin et al., 2005) 
(Brentani et al., 
2003) - - - - - - - - 
MSH6 
(2p16) 
(Garner-Hamrick et al., 2004), 
(Sopov et al., 2004), (Rosty et 
al., 2005), (Santin et al., 2005) 
(Ranamukhaar
























- - - - 
MAD2L1 
(4q27) 
(Nees et al., 2001), (Thierry et 
al., 2004), 
(Wells et al., 2003), (Rosty et 
al., 2005) 
(Brentani et al., 













- - - - - 
CKS1B 
(1q21.2) 
(Nees et al., 2001), (Thierry et 
al., 2004), (Rosty et al., 2005), 
(Santin et al., 2005) 












- - - 
SMC4L1 
(3q26.1) 
(Rosty et al., 2005), (Santin et 
al., 2005) 
(Brentani et al., 
2003) 
(Ranamukhaar
achchi et al., 
2005) 
- - - - - - - - 
ZWINT 
(10q21-22) 
(Thierry et al., 2004), (Rosty et 
al., 2005), (Santin et al., 2005) 
(Brentani et al., 
2003) (Sgarlato 
et al., 2005) 









(Nees et al., 2000), (Nees et al., 
2001), (Garner-Hamrick et al., 
2004), (Rosty et al., 2005), 
(Santin et al., 2005) 
(Brentani et al., 













- - - - - - 
 





(Thierry et al., 2004), (Chen et 
al., 2003), 
(Rosty et al., 2005), (Santin et 
al., 2005) 
(Brentani et al., 
2003) 
(Sgarlato et al., 
2005) 






































(Garner-Hamrick et al., 2004),





























(Nees et al., 2000), (Nees et al., 
2001), (Garner-Hamrick et al., 
2004), (Thierry et al., 2004), 
(Sopov et al., 2004), (Chen et 
al., 2003), 
(Rosty et al., 2005), (Santin et 
al., 2005) 
(Brentani et al., 





































(Garner-Hamrick et al., 2004), 
(Wells et al., 2003), (Wong et 
al., 2006), (Rosty et al., 2005), 
(Santin et al., 2005) 
(Brentani et al., 
2003) (Sgarlato 
et al., 2005) 















(Ruutu et al., 2002), (Chen et 
al., 2003), 
(Rosty et al., 2005), (Santin et 
al., 2005) 
























(Garner-Hamrick et al., 2004), 
(Alazawi et al., 2002), (Wong 
et al., 2006), 113 
(Brentani et al., 












(Garner-Hamrick et al., 2004), 
(Thierry et al., 2004), (Sopov et 
al., 2004), (Rosty et al., 2005) 
(Brentani et al., 









(Garner-Hamrick et al., 2004), 
(Toussaint-Smith et al., 2004), 
(Wong et al., 2006), (Vazquez-
























(Nees et al., 2001), (Duffy et al., 
2003), 
(Pett et al., 2006) 
- - - - - - - - - - - 
Table 2. Genes frequently reported as up-regulated in cervical cancer (CC). A) For each 
biological process, genes are listed in descending order by the mayor number of reports 
related to CC e.g. the gene MKI67 has been reported at least 190 times in CC. Genes in bold 
have been used as therapeutic targets in cancer, whereas genes in italics are not so known in 
CC. The chromosomal localization of the gene is shown in brackets. B) Techniques of high-
throughput are DNA microarrays; medium- DD, RDA and ESTs; and low- are tumor 
markers previously defined in CC. C) Genes proposed as metastasis markers (in solid 
tumors), tumoral cancer markers (due to frequent mutations) and proliferation markers 
(large number of cancers). D) Transcription factor (TF) that might regulate the 
corresponding gene. E) The analysis of the genome refers to the most common chromosomal 
gains in CC (1q, 3q, 5p, 8q, 20q and Xq); transcriptome to the importance of genes in CC; 
proteome to overexpressed proteins in CC and; epigenome to genes whose promoter has 
been found methylated in samples derived from CC. For gene nomenclature see Table 1. 
in embryogenesis and abnormally in cancer (mainly inhibiting apoptosis). Due to this, survivin 
has been generally proposed as a proliferation tumor marker in cancer (Whitfield et al., 2006) 
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and particularly in CC (Branca et al., 2005), opening promising therapeutic strategies (Altieri, 
2006). Other emergent useful target genes are the members 2 and 4 from the 
“minichromosome maintenance deficient” complex or MCM found, genes primary involved in 
DNA replication that have been considered useful for cancer diagnosis and therapy (Rosty et 
al., 2005; Santin et al., 2005). Similarly, other up-regulated genes that could be specifically 
targeted are the 2 topoisomerase or TOP2A (Whitfield et al., 2006), cyclin B1 or CCNB1 (Yuan 
et al., 2004), the kinase 1 polo type or PLK1 (Strebhardt & Ullrich, 2006) and keratin 19 or 
KRT19 (Chang et al., 2005). The transcripts of the latter gene have been abundantly estimated 
not only in CC-derived samples (Frigessi et al., 2005), but also determined as overexpressed at 
both the messenger (Alazawi et al., 2002; Brentani et al., 2003; Garner-Hamrick et al., 2004; 
Wong et al., 2006), and protein (Bae et al., 2005) level in cervical neoplasia compared to normal 
tissue. As KRT19, a protein part of the intermediate filaments of epithelial cells, KRT18 (Table 
2) could likewise play an important role in the molecular diagnosis of cancer. 
It should be noted that several genes reported in Table 2 only have been linked to CC using 
high and average performance techniques, such as the gene involved in the structural 
maintenance of chromosomes “SMC4L1”. As far as we known, a single report correlated the 
expression levels of this gene to esophageal squamous cancer (Yen et al., 2005), but a 
genomic analysis showed that chromosomal gains in the region 3q12.1- 28 (where SMC4L1 
lies) are most common in SCC (Wilting et al., 2006). This gene might be activated by E2F 
(Bracken et al., 2004), but it is desirable to check the expression levels of SMC4L1 with low-
yield techniques to determine its relevance in CC as well as for potential metastatic markers 
like LMNB1 or proliferation ones like MAD2L1 gene (Table 2).  
5.4 Down-regulated candidate tumor markers 
Using microarrays and other techniques it has been possible to find genes frequently down-
regulated in CC, suggesting that these may play a role as tumor markers e.g. the tumor 
suppressor gene p21WAF1/CIP1 or CDKN1A, which regulates the cell cycle via CDKs inhibition, 
senescence as well as TP53-dependent and -independent apoptosis (Table 3). Upon 
degradation or inactivation of the nuclear phosphoprotein TP53 by E6 or PLK1, respectively, 
the transcription of p21WAF1/CIP1 is reduced as observed in several types of cancer (Gartel & 
Radhakrishnan, 2005) and particularly in CC samples using DNA microarrays (Chang & 
Laimins, 2000; Nees et al., 2000; Nees et al., 2001; Duffy et al., 2003; Wells et al., 2003; Thierry 
et al., 2004; Kelley et al., 2005). In addition, it has been suggested that low p21WAF1/CIP1 
expression correlates with poor prognosis in cervical adenocarcinoma (AC) (Lu et al., 1998). 
Moreover, in samples derived from CC it has been observed a decrease in cell growth and 
induction of p21WAF1/CIP1 by platinum-based chemotherapy (Gatti et al., 2004) as well as 
radioimmunotherapy directed against KRT19 (Chang et al., 2005). 
Other down-regulated genes in CC include the gene desmoglein 1 or DSG1, which encodes 
a protein involved in the homeostasis of cell-cell epithelial junctions and belongs to the 
family of "cadherins”, proteins whose expression decreases as it progresses in many kinds of 
cancers, such as cervical cancer (de Boer et al., 1999). It has been determined that the 
expression of DSG1 increases in presence of LR-HPVs episomal bodies in human 
keratinocytes, but its expression levels highly decrease when HR-HPV episomes are present 
in cell lines and SCC samples. Moreover, DSG1 importantly lies in an area that often 
presents chromosomal losses during CC (Table 3) and has been assigned as a pro-apoptotic 
factor mediated by the caspase 3 in keratinocytes (Dusek et al., 2006).  
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Table 2. Genes frequently reported as up-regulated in cervical cancer (CC). A) For each 
biological process, genes are listed in descending order by the mayor number of reports 
related to CC e.g. the gene MKI67 has been reported at least 190 times in CC. Genes in bold 
have been used as therapeutic targets in cancer, whereas genes in italics are not so known in 
CC. The chromosomal localization of the gene is shown in brackets. B) Techniques of high-
throughput are DNA microarrays; medium- DD, RDA and ESTs; and low- are tumor 
markers previously defined in CC. C) Genes proposed as metastasis markers (in solid 
tumors), tumoral cancer markers (due to frequent mutations) and proliferation markers 
(large number of cancers). D) Transcription factor (TF) that might regulate the 
corresponding gene. E) The analysis of the genome refers to the most common chromosomal 
gains in CC (1q, 3q, 5p, 8q, 20q and Xq); transcriptome to the importance of genes in CC; 
proteome to overexpressed proteins in CC and; epigenome to genes whose promoter has 
been found methylated in samples derived from CC. For gene nomenclature see Table 1. 
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and particularly in CC (Branca et al., 2005), opening promising therapeutic strategies (Altieri, 
2006). Other emergent useful target genes are the members 2 and 4 from the 
“minichromosome maintenance deficient” complex or MCM found, genes primary involved in 
DNA replication that have been considered useful for cancer diagnosis and therapy (Rosty et 
al., 2005; Santin et al., 2005). Similarly, other up-regulated genes that could be specifically 
targeted are the 2 topoisomerase or TOP2A (Whitfield et al., 2006), cyclin B1 or CCNB1 (Yuan 
et al., 2004), the kinase 1 polo type or PLK1 (Strebhardt & Ullrich, 2006) and keratin 19 or 
KRT19 (Chang et al., 2005). The transcripts of the latter gene have been abundantly estimated 
not only in CC-derived samples (Frigessi et al., 2005), but also determined as overexpressed at 
both the messenger (Alazawi et al., 2002; Brentani et al., 2003; Garner-Hamrick et al., 2004; 
Wong et al., 2006), and protein (Bae et al., 2005) level in cervical neoplasia compared to normal 
tissue. As KRT19, a protein part of the intermediate filaments of epithelial cells, KRT18 (Table 
2) could likewise play an important role in the molecular diagnosis of cancer. 
It should be noted that several genes reported in Table 2 only have been linked to CC using 
high and average performance techniques, such as the gene involved in the structural 
maintenance of chromosomes “SMC4L1”. As far as we known, a single report correlated the 
expression levels of this gene to esophageal squamous cancer (Yen et al., 2005), but a 
genomic analysis showed that chromosomal gains in the region 3q12.1- 28 (where SMC4L1 
lies) are most common in SCC (Wilting et al., 2006). This gene might be activated by E2F 
(Bracken et al., 2004), but it is desirable to check the expression levels of SMC4L1 with low-
yield techniques to determine its relevance in CC as well as for potential metastatic markers 
like LMNB1 or proliferation ones like MAD2L1 gene (Table 2).  
5.4 Down-regulated candidate tumor markers 
Using microarrays and other techniques it has been possible to find genes frequently down-
regulated in CC, suggesting that these may play a role as tumor markers e.g. the tumor 
suppressor gene p21WAF1/CIP1 or CDKN1A, which regulates the cell cycle via CDKs inhibition, 
senescence as well as TP53-dependent and -independent apoptosis (Table 3). Upon 
degradation or inactivation of the nuclear phosphoprotein TP53 by E6 or PLK1, respectively, 
the transcription of p21WAF1/CIP1 is reduced as observed in several types of cancer (Gartel & 
Radhakrishnan, 2005) and particularly in CC samples using DNA microarrays (Chang & 
Laimins, 2000; Nees et al., 2000; Nees et al., 2001; Duffy et al., 2003; Wells et al., 2003; Thierry 
et al., 2004; Kelley et al., 2005). In addition, it has been suggested that low p21WAF1/CIP1 
expression correlates with poor prognosis in cervical adenocarcinoma (AC) (Lu et al., 1998). 
Moreover, in samples derived from CC it has been observed a decrease in cell growth and 
induction of p21WAF1/CIP1 by platinum-based chemotherapy (Gatti et al., 2004) as well as 
radioimmunotherapy directed against KRT19 (Chang et al., 2005). 
Other down-regulated genes in CC include the gene desmoglein 1 or DSG1, which encodes 
a protein involved in the homeostasis of cell-cell epithelial junctions and belongs to the 
family of "cadherins”, proteins whose expression decreases as it progresses in many kinds of 
cancers, such as cervical cancer (de Boer et al., 1999). It has been determined that the 
expression of DSG1 increases in presence of LR-HPVs episomal bodies in human 
keratinocytes, but its expression levels highly decrease when HR-HPV episomes are present 
in cell lines and SCC samples. Moreover, DSG1 importantly lies in an area that often 
presents chromosomal losses during CC (Table 3) and has been assigned as a pro-apoptotic 
factor mediated by the caspase 3 in keratinocytes (Dusek et al., 2006).  
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Table 3. Genes frequently reported as down-regulated in cervical cancer (CC). A) For each 
biological process, genes are listed in descending order by the mayor number of reports 
related to CC e.g. the gene CDKN1A has been reported at least 70 times in CC. Genes in bold 
represent increased expression levels upon different schemes of radio and/or 
chemotherapy, whereas genes in italics are not so known in CC. The chromosomal 
localization of the gene is shown in brackets. B) Techniques of high-throughput are mainly 
DNA microarrays; medium- DD, and ESTs; and low- are tumor markers previously defined 
in CC. C) Genes proposed as metastasis markers (in solid tumors) and tumoral cancer 
markers (due to frequent mutations). D) Transcription factor (TF) that might regulate the 
corresponding gene. E) The analysis of the genome refers to the most common chromosomal 
alterations in CC (2q, 3p, 4p, 5p, 5q, 6p, 6q, 11q, 13q, 18q and 19q). For gene nomenclature 
see Table 1. 
Another gene that could be of interest in CC is SERPINB2. The gene product is an inhibitor 
of the serine-type proteases like the plasminogen activator (also known as PLAU). On one 
hand, SERPINB2 suppression has been determined using both microarrays as well as 
genomic studies in CC (Table 3); but on the other, its expression in HeLa cells can stabilize 
the expression levels of the Rb protein and suppress the oncoproteins E6 and E7 of HPV18 
(Darnell et al., 2005). This suggests that low levels of SERPINB2 promote CC development, 
being this a potentially good molecular marker.  
Of genes not known in CC there are several examples, being the gene TRIM22 or 
“tripartite motif-containing 22”, which has been found down-regulated in at least 6 
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- - - - - (Wilting et al., 2006) 
DSG1 
(18q12.1) 
(Chang & Laimins, 2000), 
(Thomas et al., 2001), 
(Wong et al., 2006) 
- - - - - (Wilting et al., 2006) 
CSPG2 
(5q12-14) 
(Duffy et al., 2003), 
(Ruutu et al., 2002), 
(Santin et al., 2005) 
(Brentani et 
al., 2003) - - - - 









(Chang & Laimins, 2000), 
(Ruutu et al., 2002), 
(Santin et al., 2005) 
(Brentani et 
al., 2003) - - - - (Lazo, 1999) 
BNIP2 
(10q26.3) 
(Nees et al., 2001), 
(Thierry et al., 2004), 
(Wong et al., 2006) 










(Chang & Laimins, 2000), 
(Duffy et al., 2003), 
(Ruutu et al., 2002), 
(Wong et al., 2006), 
(Santin et al., 2005) 
- - - - - (Wilting et al., 2006) 
TRIM22 
(11p15) 
(Chang & Laimins, 2000), 
(Nees et al., 2001), (Duffy 
et al., 2003), (Pett et al., 
2006), (Kelley et al., 2005), 
(Santin et al., 2005) 















(Chang & Laimins, 2000), 
(Duffy et al., 2003), (Wong
et al., 2006) 
- - - - - (Lazo, 1999) 
KRT4 
(12p12-11) 
(Duffy et al., 2003), 
(Ruutu et al., 2002), 






- - - - 
KRT16 
(17q12–21) 
(Alazawi et al., 2002), 
(Ruutu et al., 2002), 
(Wong et al., 2006) 
(Brentani et 
al., 2003) - - - - - 
LAMA3 
(18q11.2) 
(Chang & Laimins, 2000), 
(Kelley et al., 2005), 
(Santin et al., 2005) 
- - - - - (Wilting et al., 2006) 
SPRR3 
(1q21-22) 
(Wong et al., 2006), 
(Santin et al., 2005), 
(Perez-Plasencia et al., 
2005) 
- - - - - - 
 





(Chang & Laimins, 2000), 
(Duffy et al., 2003), 
(Alazawi et al., 2002), 
(Wong et al., 2006), 
(Santin et al., 2005) 













(Nees et al., 2001), (Duffy 
et al., 2003), (Wells et al., 
2003) 
- - - - - (Wilting et al., 2006) 
IGFBP6 
(12q13) 
(Garner-Hamrick et al., 
2004), (Wong et al., 2006), 
(Hudelist et al., 2005), 
(Liu et al., 2003) 
- - - - - - 
PPP2R5B 
(11q12) 
(Garner-Hamrick et al., 
2004), (Ruutu et al., 2002), 
(Santin et al., 2005) 











(Garner-Hamrick et al., 
2004), (Wong et al., 2006), 
(Santin et al., 2005) 
(Seo et al., 
2005) - - - - - 
DDB2 
(11p12-11) 
(Duffy et al., 2003), 
(Thierry et al., 2004), 
(Kelley et al., 2005) 


















(Garner-Hamrick et al., 
2004), (Wong et al., 2006) - - 
(Ramaswamy

















(Chang & Laimins, 2000), 
(Nees et al., 2001), (Duffy 
et al., 2003), (Santin et al., 
2005) 
(Brentani et 
al., 2003) - - - - - 
Table 3. Genes frequently reported as down-regulated in cervical cancer (CC). A) For each 
biological process, genes are listed in descending order by the mayor number of reports 
related to CC e.g. the gene CDKN1A has been reported at least 70 times in CC. Genes in bold 
represent increased expression levels upon different schemes of radio and/or 
chemotherapy, whereas genes in italics are not so known in CC. The chromosomal 
localization of the gene is shown in brackets. B) Techniques of high-throughput are mainly 
DNA microarrays; medium- DD, and ESTs; and low- are tumor markers previously defined 
in CC. C) Genes proposed as metastasis markers (in solid tumors) and tumoral cancer 
markers (due to frequent mutations). D) Transcription factor (TF) that might regulate the 
corresponding gene. E) The analysis of the genome refers to the most common chromosomal 
alterations in CC (2q, 3p, 4p, 5p, 5q, 6p, 6q, 11q, 13q, 18q and 19q). For gene nomenclature 
see Table 1. 
Another gene that could be of interest in CC is SERPINB2. The gene product is an inhibitor 
of the serine-type proteases like the plasminogen activator (also known as PLAU). On one 
hand, SERPINB2 suppression has been determined using both microarrays as well as 
genomic studies in CC (Table 3); but on the other, its expression in HeLa cells can stabilize 
the expression levels of the Rb protein and suppress the oncoproteins E6 and E7 of HPV18 
(Darnell et al., 2005). This suggests that low levels of SERPINB2 promote CC development, 
being this a potentially good molecular marker.  
Of genes not known in CC there are several examples, being the gene TRIM22 or 
“tripartite motif-containing 22”, which has been found down-regulated in at least 6 
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microarray studies (Table 3). TRIM22 belongs to a conserved family of antiviral proteins, 
where the member 22 has been implicated in inhibiting the replication of the human 
immunodeficiency virus 1 (HIV1) (Nisole et al., 2005). This suggests that TRIM22 may be 
relevant in the immune response HR-HPVs and that these viruses may be responsible for 
its inhibition.  
Table 3 also lists genes from the epidermal differentiation complex (EDC, located in the 
band 21 of the long arm of chromosome 1), for instance, using SAGE, abundant transcripts 
of SPRR3 have been found in normal cervical tissue, but a low SPRR3 expression has been 
determined in tumor tissue using microarrays (Table 3). This suggests that SPRR3 and 
perhaps SPRR1A, which also belongs to the EDC, may be useful tumor markers in CC. Last, 
other suppressed genes in CC are IGFBP6 and RUNX1 (Table 3). While the first one is 
responsible for inactivating a potent growth factor similar to insulin (IGF2), a gene in turn 
required by IGFBP6 to reduce metastatic characteristics in tumors from different origin 
(Bach, 2005), the second gene belongs to a family of transcription factors that can inhibit 
angiogenesis (Sakakura et al., 2005). 
5.5 Candidate tumor markers in cervical cancer subtypes 
Although HPV-16-infections are more frequently detected than HPV-18 ones in squamous 
cell carcinoma (SCC), the latter ones are more often associated to adenocarcinoma of the 
cervix (AC), whose incidence is growing at the same time as SCC incidence. Interestingly, 
several genes with a clinically usefulness for the molecular differentiation between the two 
major histological subtypes of CC have been found using DNA microarrays (Table 4). The 
genes TACSTD1 and CEACAM5, which encode transmembrane proteins that transmit 
signals for development, motility and cell growth, for example, were found to be 
upregulated in AC compared to SCC (Chao et al., 2006). 
 
Up-regulated genes in squamous cell 
carcinoma Up-regulated genes in adenocarcinoma 
Gene Reference Gene Reference 
CRABP2 (Chao et al., 2006) BIRC3 (Fujimoto et al., 2004) 
NDRG1 (Chao et al., 2006) CEACAM1 (Fujimoto et al., 2004) 
CDH13 (Fujimoto et al., 2004) CEACAM5-7 (Chao et al., 2006) 
KRT13 (Chao et al., 2006) FOLR1 (Fujimoto et al., 2004) 
KRT15 (Chao et al., 2006) MSLN (Chao et al., 2006) 
PTHLH (Fujimoto et al., 2004) S100P (Chao et al., 2006) 
S100A9 (Chao et al., 2006) TACSTD1 (Chao et al., 2006) 
SPRR1B (Chao et al., 2006) TSPAN3 (Chao et al., 2006) 
Table 4. Genes with a possible clinical utility for the molecular differentiation between 
squamous cell carcinoma (SCC) and adenocarcinoma (AC) in cervical cancer. The 
internationally accepted nomenclature for each gene can be found in: 
http://www.genenames.org/ or http://cgap.nci.nih.gov/Genes/GeneFinder. 
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Furthermore, high levels of the corresponding proteins served by themselves as poor 
prognostic factors in patients with AC compared with SCC (Chao et al., 2006). Other genes 
for potential use as markers in CC that have been found with microarrays are:  
1. CRABP2 (belongs to the EDC and encodes the retinoic acid binding protein 2) has been 
identified as up-regulated in SSC compared to normal tissue (Shim et al., 1998; Seo et al., 
2005) and AC (Chao et al., 2006). 
2. NDRG1 (N-myc Downstream Regulated Gene 1) is involved in cell growth and 
differentiation and was found overexpressed in SCC compared to AC (Chao et al., 2006) 
and normal cervical tissue (Sgarlato et al., 2005). 
3. Other members of the “Carcinoembryonic antigen-related cell adhesion molecule” 
family such as the CEACAM-1, -5, -6, and -7, are shown as up-regulated in AC 
compared to SCC (Fujimoto et al., 2004; Chao et al., 2006). 
4. MSLN or mesothelin encodes a membrane glycoprotein involved in cell adhesion 
whose transcripts are detectable in normal tissue but abundant in tumors of glandular 
origin or HeLa cells. In CC, MSLN is overexpressed in AC compared to SCC (Chao et 
al., 2006) and in HPV-18-derived samples of SCC/AC compared to normal tissue (Rosty 
et al., 2005). It is worth noting that MSLN is a therapeutic target in various malignancies 
(Hassan et al., 2004).  
5. Finally, high expression levels of FOLR1 (folate receptor) have been associated with an 
AC phenotype (Fujimoto et al., 2004) and tumorigenicity in cell lines derived from AC 
(Mikheev et al., 2004). However, further studies are required to demonstrate the 
relevance of this receptor in both AC and SCC because it is known that via FOLR1 and 
folic acid, its ligand, some drugs can be bound and directed into over-expressing high 
levels of FOLR1, as suggested in several types of cancer (Kelemen, 2006).  
The aforementioned “tumoral markers” could be potentially important for the diagnosis, 
prevention, and treatment of CC because these were identified using cell lines from various 
sources as well as samples of SCC and/or AC for comparative studies with normal tissues. 
Last but not least, a recent and interesting CC review not only proposed a similar systematic 
model of HPV infection highlighting the current debate on the viral status as hallmark of 
disease progression (episomal vs integrated forms where HPV-18 genome integration seems 
to prevail in women with advance disease in contrast to HPV-16), but also provided 
overlapping and additional tumor markers at some of those analyzed herein (Woodman et 
al., 2007). Along these lines, it would be worth saying that cancer, including its hundred 
subtypes, is such a complex phenomenon (Vogelstein & Kinzler, 2004), which should be 
rather seen as an average of key molecular events displaying often specific hallmarks 
(Hanahan & Weinberg, 2000) of disease progression. 
6. Conclusions 
Thanks to the comparison of the cervix in normal and abnormal conditions via 
transcriptomics in general and particularly using DNA microarrays, it is possible to 
identify known and unknown clinically relevant genes for the disease progression. The 
next goal is to identify and validate specific tumor markers for profiling histo- and 
pathological subtypes. This will allow not only a molecular subclassification and more 
understanding of CC, but also choosing the right treatment for each patient according to 
its gene expression signature if there is prior knowledge about the most likely response 
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microarray studies (Table 3). TRIM22 belongs to a conserved family of antiviral proteins, 
where the member 22 has been implicated in inhibiting the replication of the human 
immunodeficiency virus 1 (HIV1) (Nisole et al., 2005). This suggests that TRIM22 may be 
relevant in the immune response HR-HPVs and that these viruses may be responsible for 
its inhibition.  
Table 3 also lists genes from the epidermal differentiation complex (EDC, located in the 
band 21 of the long arm of chromosome 1), for instance, using SAGE, abundant transcripts 
of SPRR3 have been found in normal cervical tissue, but a low SPRR3 expression has been 
determined in tumor tissue using microarrays (Table 3). This suggests that SPRR3 and 
perhaps SPRR1A, which also belongs to the EDC, may be useful tumor markers in CC. Last, 
other suppressed genes in CC are IGFBP6 and RUNX1 (Table 3). While the first one is 
responsible for inactivating a potent growth factor similar to insulin (IGF2), a gene in turn 
required by IGFBP6 to reduce metastatic characteristics in tumors from different origin 
(Bach, 2005), the second gene belongs to a family of transcription factors that can inhibit 
angiogenesis (Sakakura et al., 2005). 
5.5 Candidate tumor markers in cervical cancer subtypes 
Although HPV-16-infections are more frequently detected than HPV-18 ones in squamous 
cell carcinoma (SCC), the latter ones are more often associated to adenocarcinoma of the 
cervix (AC), whose incidence is growing at the same time as SCC incidence. Interestingly, 
several genes with a clinically usefulness for the molecular differentiation between the two 
major histological subtypes of CC have been found using DNA microarrays (Table 4). The 
genes TACSTD1 and CEACAM5, which encode transmembrane proteins that transmit 
signals for development, motility and cell growth, for example, were found to be 
upregulated in AC compared to SCC (Chao et al., 2006). 
 
Up-regulated genes in squamous cell 
carcinoma Up-regulated genes in adenocarcinoma 
Gene Reference Gene Reference 
CRABP2 (Chao et al., 2006) BIRC3 (Fujimoto et al., 2004) 
NDRG1 (Chao et al., 2006) CEACAM1 (Fujimoto et al., 2004) 
CDH13 (Fujimoto et al., 2004) CEACAM5-7 (Chao et al., 2006) 
KRT13 (Chao et al., 2006) FOLR1 (Fujimoto et al., 2004) 
KRT15 (Chao et al., 2006) MSLN (Chao et al., 2006) 
PTHLH (Fujimoto et al., 2004) S100P (Chao et al., 2006) 
S100A9 (Chao et al., 2006) TACSTD1 (Chao et al., 2006) 
SPRR1B (Chao et al., 2006) TSPAN3 (Chao et al., 2006) 
Table 4. Genes with a possible clinical utility for the molecular differentiation between 
squamous cell carcinoma (SCC) and adenocarcinoma (AC) in cervical cancer. The 
internationally accepted nomenclature for each gene can be found in: 
http://www.genenames.org/ or http://cgap.nci.nih.gov/Genes/GeneFinder. 
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Furthermore, high levels of the corresponding proteins served by themselves as poor 
prognostic factors in patients with AC compared with SCC (Chao et al., 2006). Other genes 
for potential use as markers in CC that have been found with microarrays are:  
1. CRABP2 (belongs to the EDC and encodes the retinoic acid binding protein 2) has been 
identified as up-regulated in SSC compared to normal tissue (Shim et al., 1998; Seo et al., 
2005) and AC (Chao et al., 2006). 
2. NDRG1 (N-myc Downstream Regulated Gene 1) is involved in cell growth and 
differentiation and was found overexpressed in SCC compared to AC (Chao et al., 2006) 
and normal cervical tissue (Sgarlato et al., 2005). 
3. Other members of the “Carcinoembryonic antigen-related cell adhesion molecule” 
family such as the CEACAM-1, -5, -6, and -7, are shown as up-regulated in AC 
compared to SCC (Fujimoto et al., 2004; Chao et al., 2006). 
4. MSLN or mesothelin encodes a membrane glycoprotein involved in cell adhesion 
whose transcripts are detectable in normal tissue but abundant in tumors of glandular 
origin or HeLa cells. In CC, MSLN is overexpressed in AC compared to SCC (Chao et 
al., 2006) and in HPV-18-derived samples of SCC/AC compared to normal tissue (Rosty 
et al., 2005). It is worth noting that MSLN is a therapeutic target in various malignancies 
(Hassan et al., 2004).  
5. Finally, high expression levels of FOLR1 (folate receptor) have been associated with an 
AC phenotype (Fujimoto et al., 2004) and tumorigenicity in cell lines derived from AC 
(Mikheev et al., 2004). However, further studies are required to demonstrate the 
relevance of this receptor in both AC and SCC because it is known that via FOLR1 and 
folic acid, its ligand, some drugs can be bound and directed into over-expressing high 
levels of FOLR1, as suggested in several types of cancer (Kelemen, 2006).  
The aforementioned “tumoral markers” could be potentially important for the diagnosis, 
prevention, and treatment of CC because these were identified using cell lines from various 
sources as well as samples of SCC and/or AC for comparative studies with normal tissues. 
Last but not least, a recent and interesting CC review not only proposed a similar systematic 
model of HPV infection highlighting the current debate on the viral status as hallmark of 
disease progression (episomal vs integrated forms where HPV-18 genome integration seems 
to prevail in women with advance disease in contrast to HPV-16), but also provided 
overlapping and additional tumor markers at some of those analyzed herein (Woodman et 
al., 2007). Along these lines, it would be worth saying that cancer, including its hundred 
subtypes, is such a complex phenomenon (Vogelstein & Kinzler, 2004), which should be 
rather seen as an average of key molecular events displaying often specific hallmarks 
(Hanahan & Weinberg, 2000) of disease progression. 
6. Conclusions 
Thanks to the comparison of the cervix in normal and abnormal conditions via 
transcriptomics in general and particularly using DNA microarrays, it is possible to 
identify known and unknown clinically relevant genes for the disease progression. The 
next goal is to identify and validate specific tumor markers for profiling histo- and 
pathological subtypes. This will allow not only a molecular subclassification and more 
understanding of CC, but also choosing the right treatment for each patient according to 
its gene expression signature if there is prior knowledge about the most likely response 
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she would have. This is the only way to fully understand more about this complex 
disease.  
The intention of this manuscript is to provide the reader a broad view of the transcriptome, 
an area that is developing rapidly, especially in cancer. It is worthwhile reemphasize that 
the transcriptome also consists of non-coding RNAs regulating the transcription of many 
genes and likewise acting as oncogenes or tumor suppressor genes. With such complexity, 
the best tackling to cancer will rely on predictive hypothesis, so it is important to take into 
account systems biology, which will allow us to better understand transcriptional networks 
and identify specific therapy targets for a tailored therapy. 
Although there are improved programs for the early diagnosis of CC as well as very 
effective prophylactic vaccines against HR-HPVs, the high mortality rates triggered by CC 
will not diminish soon, not even in the medium-term after optimizing CC monitoring 
programs and broadly executing vaccination schemes. An alternative for CC patients is 
therefore to look at those tumor markers that could aid in the stratification of the disease 
and therapy. Unfortunately, genomics and all its derivatives are exacerbating global 
inequalities in terms of scientific research and health between developed and developing 
countries since the first cause of death of women in the former countries is breast cancer 
whereas in the latter ones CC kills every 2 hours, on average, a Mexican woman in 
productive age. 
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Although there are improved programs for the early diagnosis of CC as well as very 
effective prophylactic vaccines against HR-HPVs, the high mortality rates triggered by CC 
will not diminish soon, not even in the medium-term after optimizing CC monitoring 
programs and broadly executing vaccination schemes. An alternative for CC patients is 
therefore to look at those tumor markers that could aid in the stratification of the disease 
and therapy. Unfortunately, genomics and all its derivatives are exacerbating global 
inequalities in terms of scientific research and health between developed and developing 
countries since the first cause of death of women in the former countries is breast cancer 
whereas in the latter ones CC kills every 2 hours, on average, a Mexican woman in 
productive age. 
7. Acknowledgments 
We thank the library at the MPI of Coal Research for financial support. 
8. References 
Acevedo Rocha CG, Alvarez E, Zafra de la Rosa G, Alvarez Navarro M & Gariglio P (2007) 
[Cervical cancer and DNA microarrays: tumour marker identification]. Ginecologia 
y Obstetricia de Mexico 75, 205-213. 
Achary MP, Jaggernauth W, Gross E, Alfieri A, Klinger HP & Vikram B (2000) Cell lines 
from the same cervical carcinoma but with different radiosensitivities exhibit 
different cDNA microarray patterns of gene expression. Cytogenetics and cell genetics 
91, 39-43. 
Adams MD, Kelley JM, Gocayne JD, Dubnick M, Polymeropoulos MH, Xiao H, Merril CR, 
Wu A, Olde B, Moreno RF & et al. (1991) Complementary DNA sequencing: 
expressed sequence tags and human genome project. Science 252, 1651-1656. 
Ahn WS, Bae SM, Lee JM, Namkoong SE, Han SJ, Cho YL, Nam GH, Seo JS, Kim CK & Kim 
YW (2004a) Searching for pathogenic gene functions to cervical cancer. Gynecologic 
oncology 93, 41-48. 
Ahn WS, Bae SM, Lee KH, Kim YW, Lee JM, Namkoong SE, Lee IP, Kim CK, Seo JS & Sin JI 
(2004b) Comparison of effects of As2O3 and As4O6 on cell growth inhibition and 
gene expression profiles by cDNA microarray analysis in SiHa cells. Oncology 
reports 12, 573-580. 
Ahn WS, Huh SW, Bae SM, Lee IP, Lee JM, Namkoong SE, Kim CK & Sin JI (2003) A major 
constituent of green tea, EGCG, inhibits the growth of a human cervical cancer cell 
 
A Transcriptome- and Marker-Based Systemic Analysis of Cervical Cancer 
 
181 
line, CaSki cells, through apoptosis, G(1) arrest, and regulation of gene expression. 
DNA and cell biology 22, 217-224. 
Ahn WS, Seo MJ, Bae SM, Lee JM, Namkoong SE, Kim CK & Kim YW (2005) Cellular 
process classification of human papillomavirus-16-positive SiHa cervical carcinoma 
cell using Gene Ontology. International journal of gynecological cancer: official journal 
of the International Gynecological Cancer Society 15, 94-106. 
Alazawi W, Pett M, Arch B, Scott L, Freeman T, Stanley MA & Coleman N (2002) Changes in 
cervical keratinocyte gene expression associated with integration of human 
papillomavirus 16. Cancer research 62, 6959-6965. 
Alizadeh AA, Eisen MB, Davis RE, Ma C, Lossos IS, Rosenwald A, Boldrick JC, Sabet H, 
Tran T, Yu X, Powell JI, Yang L, Marti GE, Moore T, Hudson J, Jr., Lu L, Lewis DB, 
Tibshirani R, Sherlock G, Chan WC, Greiner TC, Weisenburger DD, Armitage JO, 
Warnke R, Levy R, Wilson W, Grever MR, Byrd JC, Botstein D, Brown PO & Staudt 
LM (2000) Distinct types of diffuse large B-cell lymphoma identified by gene 
expression profiling. Nature 403, 503-511. 
Altieri DC (2006) Targeted therapy by disabling crossroad signaling networks: the survivin 
paradigm. Molecular cancer therapeutics 5, 478-482. 
Alwine JC, Kemp DJ & Stark GR (1977) Method for detection of specific RNAs in agarose 
gels by transfer to diazobenzyloxymethyl-paper and hybridization with DNA 
probes. Proceedings of the National Academy of Sciences of the United States of America 
74, 5350-5354. 
Bach LA (2005) IGFBP-6 five years on; not so 'forgotten'? Growth hormone & IGF research 15, 
185-192. 
Bae SM, Lee CH, Cho YL, Nam KH, Kim YW, Kim CK, Han BD, Lee YJ, Chun HJ & Ahn WS 
(2005) Two-dimensional gel analysis of protein expression profile in squamous 
cervical cancer patients. Gynecologic oncology 99, 26-35. 
Bartlett JM (2002) Approaches to the analysis of gene expression using mRNA: a technical 
overview. Molecular biotechnology 21, 149-160. 
Berk AJ & Sharp PA (1977) Sizing and mapping of early adenovirus mRNAs by gel 
electrophoresis of S1 endonuclease-digested hybrids. Cell 12, 721-732. 
Bracken AP, Ciro M, Cocito A & Helin K (2004) E2F target genes: unraveling the biology. 
Trends in Biochemical Sciences 29, 409-417. 
Branca M, Giorgi C, Santini D, Di Bonito L, Ciotti M, Costa S, Benedetto A, Casolati EA, 
Favalli C, Paba P, Di Bonito P, Mariani L, Syrjanen S, Bonifacio D, Accardi L, 
Zanconati F & Syrjanen K (2005) Survivin as a marker of cervical intraepithelial 
neoplasia and high-risk human papillomavirus and a predictor of virus clearance 
and prognosis in cervical cancer. American journal of clinical pathology 124, 113-121. 
Brenner S, Johnson M, Bridgham J, Golda G, Lloyd DH, Johnson D, Luo SJ, McCurdy S, Foy 
M, Ewan M, Roth R, George D, Eletr S, Albrecht G, Vermaas E, Williams SR, Moon 
K, Burcham T, Pallas M, DuBridge RB, Kirchner J, Fearon K, Mao J & Corcoran K 
(2000) Gene expression analysis by massively parallel signature sequencing (MPSS) 
on microbead arrays. Nature Biotechnology 18, 630-634. 
Brentani H, Caballero OL, Camargo AA, da Silva AM, da Silva WA, Jr., Dias Neto E, Grivet 
M, Gruber A, Guimaraes PE, Hide W, Iseli C, Jongeneel CV, Kelso J, Nagai MA, 
Ojopi EP, Osorio EC, Reis EM, Riggins GJ, Simpson AJ, de Souza S, Stevenson BJ, 
Strausberg RL, Tajara EH, Verjovski-Almeida S, Acencio ML, Bengtson MH, 
 
Topics on Cervical Cancer with an Advocacy for Prevention 
 
182 
Bettoni F, Bodmer WF, Briones MR, Camargo LP, Cavenee W, Cerutti JM, Coelho 
Andrade LE, Costa dos Santos PC, Ramos Costa MC, da Silva IT, Estecio MR, Sa 
Ferreira K, Furnari FB, Faria M, Jr., Galante PA, Guimaraes GS, Holanda AJ, 
Kimura ET, Leerkes MR, Lu X, Maciel RM, Martins EA, Massirer KB, Melo AS, 
Mestriner CA, Miracca EC, Miranda LL, Nobrega FG, Oliveira PS, Paquola AC, 
Pandolfi JR, Campos Pardini MI, Passetti F, Quackenbush J, Schnabel B, Sogayar 
MC, Souza JE, Valentini SR, Zaiats AC, Amaral EJ, Arnaldi LA, de Araujo AG, de 
Bessa SA, Bicknell DC, Ribeiro de Camaro ME, Carraro DM, Carrer H, Carvalho 
AF, Colin C, Costa F, Curcio C, Guerreiro da Silva ID, Pereira da Silva N, 
Dellamano M, El-Dorry H, Espreafico EM, Scattone Ferreira AJ, Ayres Ferreira C, 
Fortes MA, Gama AH, Giannella-Neto D, Giannella ML, Giorgi RR, Goldman GH, 
Goldman MH, Hackel C, Ho PL, Kimura EM, Kowalski LP, Krieger JE, Leite LC, 
Lopes A, Luna AM, Mackay A, Mari SK, Marques AA, Martins WK, Montagnini A, 
Mourao Neto M, Nascimento AL, Neville AM, Nobrega MP, O'Hare MJ, Otsuka 
AY, Ruas de Melo AI, Paco-Larson ML, Guimaraes Pereira G, Pesquero JB, Pessoa 
JG, Rahal P, Rainho CA, Rodrigues V, Rogatto SR, Romano CM, Romeiro JG, Rossi 
BM, Rusticci M, Guerra de Sa R, Sant' Anna SC, Sarmazo ML, Silva TC, Soares FA, 
Sonati Mde F, de Freitas Sousa J, Queiroz D, Valente V, Vettore AL, Villanova FE, 
Zago MA & Zalcberg H (2003) The generation and utilization of a cancer-oriented 
representation of the human transcriptome by using expressed sequence tags. 
Proceedings of the National Academy of Sciences of the United States of America 100, 
13418-13423. 
Bueno-de-Mesquita JM, Linn SC, Keijzer R, Wesseling J, Nuyten DS, van Krimpen C, Meijers 
C, de Graaf PW, Bos MM, Hart AA, Rutgers EJ, Peterse JL, Halfwerk H, de Groot R, 
Pronk A, Floore AN, Glas AM, Van't Veer LJ & van de Vijver MJ (2009) Validation 
of 70-gene prognosis signature in node-negative breast cancer. Breast cancer research 
and treatment 117, 483-495. 
Bustamante C, Cheng W & Mejia YX (2011) Revisiting the central dogma one molecule at a 
time. Cell 144, 480-497. 
Bustin SA (2000) Absolute quantification of mRNA using real-time reverse transcription 
polymerase chain reaction assays. Journal of molecular endocrinology 25, 169-193. 
Buyse M, Loi S, van't Veer L, Viale G, Delorenzi M, Glas AM, d'Assignies MS, Bergh J, 
Lidereau R, Ellis P, Harris A, Bogaerts J, Therasse P, Floore A, Amakrane M, Piette 
F, Rutgers E, Sotiriou C, Cardoso F & Piccart MJ (2006) Validation and clinical 
utility of a 70-gene prognostic signature for women with node-negative breast 
cancer. Journal of the National Cancer Institute 98, 1183-1192. 
Carter TH, Liu K, Ralph W, Jr., Chen D, Qi M, Fan S, Yuan F, Rosen EM & Auborn KJ (2002) 
Diindolylmethane alters gene expression in human keratinocytes in vitro. The 
Journal of nutrition 132, 3314-3324. 
Chang CH, Tsai LC, Chen ST, Yuan CC, Hung MW, Hsieh BT, Chao PL, Tsai TH & Lee TW 
(2005) Radioimmunotherapy and apoptotic induction on CK19-overexpressing 
human cervical carcinoma cells with Re-188-mAbCx-99. Anticancer research 25, 
2719-2728. 
Chang YE & Laimins LA (2000) Microarray analysis identifies interferon-inducible genes 
and Stat-1 as major transcriptional targets of human papillomavirus type 31. Journal 
of virology 74, 4174-4182. 
 
A Transcriptome- and Marker-Based Systemic Analysis of Cervical Cancer 
 
183 
Chao A, Wang TH, Lee YS, Hsueh S, Chao AS, Chang TC, Kung WH, Huang SL, Chao FY, 
Wei ML & Lai CH (2006) Molecular characterization of adenocarcinoma and 
squamous carcinoma of the uterine cervix using microarray analysis of gene 
expression. International journal of cancer 119, 91-98. 
Chaudhry MA, Chodosh LA, McKenna WG & Muschel RJ (2003) Gene expression profile of 
human cells irradiated in G1 and G2 phases of cell cycle. Cancer letters 195, 221-233. 
Chen X, Shen B, Xia L, Khaletzkiy A, Chu D, Wong JY & Li JJ (2002) Activation of nuclear 
factor kappaB in radioresistance of TP53-inactive human keratinocytes. Cancer 
research 62, 1213-1221. 
Chen Y, Miller C, Mosher R, Zhao X, Deeds J, Morrissey M, Bryant B, Yang D, Meyer R, 
Cronin F, Gostout BS, Smith-McCune K & Schlegel R (2003) Identification of 
cervical cancer markers by cDNA and tissue microarrays. Cancer research 63, 1927-
1935. 
Cheng Q, Lau WM, Chew SH, Ho TH, Tay SK & Hui KM (2002a) Identification of molecular 
markers for the early detection of human squamous cell carcinoma of the uterine 
cervix. British journal of cancer 86, 274-281. 
Cheng Q, Lau WM, Tay SK, Chew SH, Ho TH & Hui KM (2002b) Identification and 
characterization of genes involved in the carcinogenesis of human squamous cell 
cervical carcinoma. International journal of cancer 98, 419-426. 
Chin KV, Alabanza L, Fujii K, Kudoh K, Kita T, Kikuchi Y, Selvanayagam ZE, Wong YF, Lin 
Y & Shih WC (2005) Application of expression genomics for predicting treatment 
response in cancer. Annals of the New York Academy of Sciences 1058, 186-195. 
Choi YP, Kang S, Hong S, Xie X & Cho NH (2005) Proteomic analysis of progressive factors 
in uterine cervical cancer. Proteomics 5, 1481-1493. 
Chung YM, Kim BG, Park CS, Huh SJ, Kim J, Park JK, Cho SM, Kim BS, Kim JS, Yoo YD & 
Bae DS (2005) Increased expression of ICAM-3 is associated with radiation 
resistance in cervical cancer. International journal of cancer 117, 194-201. 
Ciro M, Bracken AP & Helin K (2003) Profiling cancer. Current opinion in cell biology 15, 213-
220. 
Clarke PA, te Poele R & Workman P (2004) Gene expression microarray technologies in the 
development of new therapeutic agents. European journal of cancer 40, 2560-2591. 
Collins FS, Green ED, Guttmacher AE & Guyer MS (2003) A vision for the future of 
genomics research. Nature 422, 835-847. 
Contag SA, Gostout BS, Clayton AC, Dixon MH, McGovern RM & Calhoun ES (2004) 
Comparison of gene expression in squamous cell carcinoma and adenocarcinoma 
of the uterine cervix. Gynecologic oncology 95, 610-617. 
Costa FF (2010) Non-coding RNAs: Meet thy masters. Bioessays 32, 599-608. 
Coulton G (2004) Are histochemistry and cytochemistry 'Omics'? Journal of molecular 
histology 35, 603-613. 
Couzin J (2003) Medicine. Tracing the steps of metastasis, cancer's menacing ballet. Science 
299, 1002-1006. 
Crawford DF & Piwnica-Worms H (2001) The G(2) DNA damage checkpoint delays 
expression of genes encoding mitotic regulators. The Journal of biological chemistry 
276, 37166-37177. 
Crick F (1970) Central dogma of molecular biology. Nature 227, 561-563. 
 
Topics on Cervical Cancer with an Advocacy for Prevention 
 
182 
Bettoni F, Bodmer WF, Briones MR, Camargo LP, Cavenee W, Cerutti JM, Coelho 
Andrade LE, Costa dos Santos PC, Ramos Costa MC, da Silva IT, Estecio MR, Sa 
Ferreira K, Furnari FB, Faria M, Jr., Galante PA, Guimaraes GS, Holanda AJ, 
Kimura ET, Leerkes MR, Lu X, Maciel RM, Martins EA, Massirer KB, Melo AS, 
Mestriner CA, Miracca EC, Miranda LL, Nobrega FG, Oliveira PS, Paquola AC, 
Pandolfi JR, Campos Pardini MI, Passetti F, Quackenbush J, Schnabel B, Sogayar 
MC, Souza JE, Valentini SR, Zaiats AC, Amaral EJ, Arnaldi LA, de Araujo AG, de 
Bessa SA, Bicknell DC, Ribeiro de Camaro ME, Carraro DM, Carrer H, Carvalho 
AF, Colin C, Costa F, Curcio C, Guerreiro da Silva ID, Pereira da Silva N, 
Dellamano M, El-Dorry H, Espreafico EM, Scattone Ferreira AJ, Ayres Ferreira C, 
Fortes MA, Gama AH, Giannella-Neto D, Giannella ML, Giorgi RR, Goldman GH, 
Goldman MH, Hackel C, Ho PL, Kimura EM, Kowalski LP, Krieger JE, Leite LC, 
Lopes A, Luna AM, Mackay A, Mari SK, Marques AA, Martins WK, Montagnini A, 
Mourao Neto M, Nascimento AL, Neville AM, Nobrega MP, O'Hare MJ, Otsuka 
AY, Ruas de Melo AI, Paco-Larson ML, Guimaraes Pereira G, Pesquero JB, Pessoa 
JG, Rahal P, Rainho CA, Rodrigues V, Rogatto SR, Romano CM, Romeiro JG, Rossi 
BM, Rusticci M, Guerra de Sa R, Sant' Anna SC, Sarmazo ML, Silva TC, Soares FA, 
Sonati Mde F, de Freitas Sousa J, Queiroz D, Valente V, Vettore AL, Villanova FE, 
Zago MA & Zalcberg H (2003) The generation and utilization of a cancer-oriented 
representation of the human transcriptome by using expressed sequence tags. 
Proceedings of the National Academy of Sciences of the United States of America 100, 
13418-13423. 
Bueno-de-Mesquita JM, Linn SC, Keijzer R, Wesseling J, Nuyten DS, van Krimpen C, Meijers 
C, de Graaf PW, Bos MM, Hart AA, Rutgers EJ, Peterse JL, Halfwerk H, de Groot R, 
Pronk A, Floore AN, Glas AM, Van't Veer LJ & van de Vijver MJ (2009) Validation 
of 70-gene prognosis signature in node-negative breast cancer. Breast cancer research 
and treatment 117, 483-495. 
Bustamante C, Cheng W & Mejia YX (2011) Revisiting the central dogma one molecule at a 
time. Cell 144, 480-497. 
Bustin SA (2000) Absolute quantification of mRNA using real-time reverse transcription 
polymerase chain reaction assays. Journal of molecular endocrinology 25, 169-193. 
Buyse M, Loi S, van't Veer L, Viale G, Delorenzi M, Glas AM, d'Assignies MS, Bergh J, 
Lidereau R, Ellis P, Harris A, Bogaerts J, Therasse P, Floore A, Amakrane M, Piette 
F, Rutgers E, Sotiriou C, Cardoso F & Piccart MJ (2006) Validation and clinical 
utility of a 70-gene prognostic signature for women with node-negative breast 
cancer. Journal of the National Cancer Institute 98, 1183-1192. 
Carter TH, Liu K, Ralph W, Jr., Chen D, Qi M, Fan S, Yuan F, Rosen EM & Auborn KJ (2002) 
Diindolylmethane alters gene expression in human keratinocytes in vitro. The 
Journal of nutrition 132, 3314-3324. 
Chang CH, Tsai LC, Chen ST, Yuan CC, Hung MW, Hsieh BT, Chao PL, Tsai TH & Lee TW 
(2005) Radioimmunotherapy and apoptotic induction on CK19-overexpressing 
human cervical carcinoma cells with Re-188-mAbCx-99. Anticancer research 25, 
2719-2728. 
Chang YE & Laimins LA (2000) Microarray analysis identifies interferon-inducible genes 
and Stat-1 as major transcriptional targets of human papillomavirus type 31. Journal 
of virology 74, 4174-4182. 
 
A Transcriptome- and Marker-Based Systemic Analysis of Cervical Cancer 
 
183 
Chao A, Wang TH, Lee YS, Hsueh S, Chao AS, Chang TC, Kung WH, Huang SL, Chao FY, 
Wei ML & Lai CH (2006) Molecular characterization of adenocarcinoma and 
squamous carcinoma of the uterine cervix using microarray analysis of gene 
expression. International journal of cancer 119, 91-98. 
Chaudhry MA, Chodosh LA, McKenna WG & Muschel RJ (2003) Gene expression profile of 
human cells irradiated in G1 and G2 phases of cell cycle. Cancer letters 195, 221-233. 
Chen X, Shen B, Xia L, Khaletzkiy A, Chu D, Wong JY & Li JJ (2002) Activation of nuclear 
factor kappaB in radioresistance of TP53-inactive human keratinocytes. Cancer 
research 62, 1213-1221. 
Chen Y, Miller C, Mosher R, Zhao X, Deeds J, Morrissey M, Bryant B, Yang D, Meyer R, 
Cronin F, Gostout BS, Smith-McCune K & Schlegel R (2003) Identification of 
cervical cancer markers by cDNA and tissue microarrays. Cancer research 63, 1927-
1935. 
Cheng Q, Lau WM, Chew SH, Ho TH, Tay SK & Hui KM (2002a) Identification of molecular 
markers for the early detection of human squamous cell carcinoma of the uterine 
cervix. British journal of cancer 86, 274-281. 
Cheng Q, Lau WM, Tay SK, Chew SH, Ho TH & Hui KM (2002b) Identification and 
characterization of genes involved in the carcinogenesis of human squamous cell 
cervical carcinoma. International journal of cancer 98, 419-426. 
Chin KV, Alabanza L, Fujii K, Kudoh K, Kita T, Kikuchi Y, Selvanayagam ZE, Wong YF, Lin 
Y & Shih WC (2005) Application of expression genomics for predicting treatment 
response in cancer. Annals of the New York Academy of Sciences 1058, 186-195. 
Choi YP, Kang S, Hong S, Xie X & Cho NH (2005) Proteomic analysis of progressive factors 
in uterine cervical cancer. Proteomics 5, 1481-1493. 
Chung YM, Kim BG, Park CS, Huh SJ, Kim J, Park JK, Cho SM, Kim BS, Kim JS, Yoo YD & 
Bae DS (2005) Increased expression of ICAM-3 is associated with radiation 
resistance in cervical cancer. International journal of cancer 117, 194-201. 
Ciro M, Bracken AP & Helin K (2003) Profiling cancer. Current opinion in cell biology 15, 213-
220. 
Clarke PA, te Poele R & Workman P (2004) Gene expression microarray technologies in the 
development of new therapeutic agents. European journal of cancer 40, 2560-2591. 
Collins FS, Green ED, Guttmacher AE & Guyer MS (2003) A vision for the future of 
genomics research. Nature 422, 835-847. 
Contag SA, Gostout BS, Clayton AC, Dixon MH, McGovern RM & Calhoun ES (2004) 
Comparison of gene expression in squamous cell carcinoma and adenocarcinoma 
of the uterine cervix. Gynecologic oncology 95, 610-617. 
Costa FF (2010) Non-coding RNAs: Meet thy masters. Bioessays 32, 599-608. 
Coulton G (2004) Are histochemistry and cytochemistry 'Omics'? Journal of molecular 
histology 35, 603-613. 
Couzin J (2003) Medicine. Tracing the steps of metastasis, cancer's menacing ballet. Science 
299, 1002-1006. 
Crawford DF & Piwnica-Worms H (2001) The G(2) DNA damage checkpoint delays 
expression of genes encoding mitotic regulators. The Journal of biological chemistry 
276, 37166-37177. 
Crick F (1970) Central dogma of molecular biology. Nature 227, 561-563. 
 
Topics on Cervical Cancer with an Advocacy for Prevention 
 
184 
Darnell GA, Antalis TM, Rose BR & Suhrbier A (2005) Silencing of integrated human 
papillomavirus type 18 oncogene transcription in cells expressing SerpinB2. Journal 
of virology 79, 4246-4256. 
de Boer CJ, van Dorst E, van Krieken H, Jansen-van Rhijn CM, Warnaar SO, Fleuren GJ & 
Litvinov SV (1999) Changing roles of cadherins and catenins during progression of 
squamous intraepithelial lesions in the uterine cervix. The American journal of 
pathology 155, 505-515. 
Dias Neto E, Correa RG, Verjovski-Almeida S, Briones MR, Nagai MA, da Silva W, Jr., Zago 
MA, Bordin S, Costa FF, Goldman GH, Carvalho AF, Matsukuma A, Baia GS, 
Simpson DH, Brunstein A, de Oliveira PS, Bucher P, Jongeneel CV, O'Hare MJ, 
Soares F, Brentani RR, Reis LF, de Souza SJ & Simpson AJ (2000) Shotgun 
sequencing of the human transcriptome with ORF expressed sequence tags. 
Proceedings of the National Academy of Sciences of the United States of America 97, 3491-
3496. 
Dimitroulakos J, Marhin WH, Tokunaga J, Irish J, Gullane P, Penn LZ & Kamel-Reid S (2002) 
Microarray and biochemical analysis of lovastatin-induced apoptosis of squamous 
cell carcinomas. Neoplasia 4, 337-346. 
Domazet B, Maclennan GT, Lopez-Beltran A, Montironi R & Cheng L (2008) Laser capture 
microdissection in the genomic and proteomic era: targeting the genetic basis of 
cancer. International journal of clinical and experimental pathology 1, 475-488. 
Dowhanick JJ, McBride AA & Howley PM (1995) Suppression of cellular proliferation by the 
papillomavirus E2 protein. Journal of virology 69, 7791-7799. 
Duenas-Gonzalez A, Cetina L, Mariscal I & de la Garza J (2003) Modern management of 
locally advanced cervical carcinoma. Cancer treatment reviews 29, 389-399. 
Duenas-Gonzalez A, Lizano M, Candelaria M, Cetina L, Arce C & Cervera E (2005) 
Epigenetics of cervical cancer. An overview and therapeutic perspectives. Molecular 
cancer 4, 38. 
Duffy CL, Phillips SL & Klingelhutz AJ (2003) Microarray analysis identifies differentiation-
associated genes regulated by human papillomavirus type 16 E6. Virology 314, 196-
205. 
Dusek RL, Getsios S, Chen F, Park JK, Amargo EV, Cryns VL & Green KJ (2006) The 
differentiation-dependent desmosomal cadherin desmoglein 1 is a novel caspase-3 
target that regulates apoptosis in keratinocytes. The Journal of biological chemistry 
281, 3614-3624. 
Follen M, Meyskens FL, Jr., Alvarez RD, Walker JL, Bell MC, Storthz KA, Sastry J, Roy K, 
Richards-Kortum R & Cornelison TL (2003) Cervical cancer chemoprevention, 
vaccines, and surrogate endpoint biomarkers. Cancer 98, 2044-2051. 
Forbes S, Clements J, Dawson E, Bamford S, Webb T, Dogan A, Flanagan A, Teague J, 
Wooster R, Futreal PA & Stratton MR (2006) Cosmic 2005. British journal of cancer 
94, 318-322. 
Forrest ARR, Taylor DF, Crowe ML, Chalk AM, Waddell NJ, Kolle G, Faulkner GJ, Rimantas 
K, Katayama S, Wells C, Kai C, Kawai J, Carninci P, Hayashizaki Y & Grimmond 
SM (2006) Genome-wide review of transcriptional complexity in mouse protein 
kinases and phosphatases. Genome Biology 7, R5. 
Frazer IH (2004) Prevention of cervical cancer through papillomavirus vaccination. Nature 
Reviews Immunology 4, 46-54. 
 
A Transcriptome- and Marker-Based Systemic Analysis of Cervical Cancer 
 
185 
Frigessi A, van de Wiel MA, Holden M, Svendsrud DH, Glad IK & Lyng H (2005) Genome-
wide estimation of transcript concentrations from spotted cDNA microarray data. 
Nucleic Acids Research 33, e143. 
Frith MC, Pheasant M & Mattick JS (2005) The amazing complexity of the human 
transcriptome. European journal of human genetics : EJHG 13, 894-897. 
Fujimoto T, Nishikawa A, Iwasaki M, Akutagawa N, Teramoto M & Kudo R (2004) Gene 
expression profiling in two morphologically different uterine cervical carcinoma 
cell lines derived from a single donor using a human cancer cDNA array. 
Gynecologic oncology 93, 446-453. 
Fuller AP, Palmer-Toy D, Erlander MG & Sgroi DC (2003) Laser capture microdissection 
and advanced molecular analysis of human breast cancer. Journal of mammary gland 
biology and neoplasia 8, 335-345. 
Gandarillas A (2000) Epidermal differentiation, apoptosis, and senescence: common 
pathways? Experimental gerontology 35, 53-62. 
Garner-Hamrick PA, Fostel JM, Chien WM, Banerjee NS, Chow LT, Broker TR & Fisher C 
(2004) Global effects of human papillomavirus type 18 E6/E7 in an organotypic 
keratinocyte culture system. Journal of virology 78, 9041-9050. 
Gartel AL & Radhakrishnan SK (2005) Lost in transcription: p21 repression, mechanisms, 
and consequences. Cancer research 65, 3980-3985. 
Gatherer D (2010) So what do we really mean when we say that systems biology is holistic? 
BMC systems biology 4, 22. 
Gatti L, Beretta GL, Carenini N, Corna E, Zunino F & Perego P (2004) Gene expression 
profiles in the cellular response to a multinuclear platinum complex. Cell Mol Life 
Sci 61, 973-981. 
Gibb EA, Brown CJ & Lam WL (2011) The functional role of long non-coding RNA in 
human carcinomas. Mol Cancer 10, 38. 
Glas AM, Floore A, Delahaye LJ, Witteveen AT, Pover RC, Bakx N, Lahti-Domenici JS, 
Bruinsma TJ, Warmoes MO, Bernards R, Wessels LF & Van't Veer LJ (2006) 
Converting a breast cancer microarray signature into a high-throughput diagnostic 
test. BMC Genomics 7, 278. 
Golub TR, Slonim DK, Tamayo P, Huard C, Gaasenbeek M, Mesirov JP, Coller H, Loh ML, 
Downing JR, Caligiuri MA, Bloomfield CD & Lander ES (1999) Molecular 
classification of cancer: class discovery and class prediction by gene expression 
monitoring. Science 286, 531-537. 
Gray LJ & Herrington CS (2004) Molecular markers for the prediction of progression of CIN 
lesions. International journal of gynecological pathology 23, 95-96. 
Guelaguetza Vázquez-Ortíz ea (2005) Análisis de expresión global del cáncer cérvico 
uterino: rutas metabólicas y genes alterados. Revista de Investigaciones Clinicas 57 
434-441. 
Haffty BG & Glazer PM (2003) Molecular markers in clinical radiation oncology. Oncogene 
22, 5915-5925. 
Hanahan D & Weinberg RA (2000) The hallmarks of cancer. Cell 100, 57-70. 
Hanson JC, Tangrea MA, Kim S, Armani MD, Pohida TJ, Bonner RF, Rodriguez-Canales J & 
Emmert-Buck MR (2011) Expression microdissection adapted to commercial laser 
dissection instruments. Nature protocols 6, 457-467. 
 
Topics on Cervical Cancer with an Advocacy for Prevention 
 
184 
Darnell GA, Antalis TM, Rose BR & Suhrbier A (2005) Silencing of integrated human 
papillomavirus type 18 oncogene transcription in cells expressing SerpinB2. Journal 
of virology 79, 4246-4256. 
de Boer CJ, van Dorst E, van Krieken H, Jansen-van Rhijn CM, Warnaar SO, Fleuren GJ & 
Litvinov SV (1999) Changing roles of cadherins and catenins during progression of 
squamous intraepithelial lesions in the uterine cervix. The American journal of 
pathology 155, 505-515. 
Dias Neto E, Correa RG, Verjovski-Almeida S, Briones MR, Nagai MA, da Silva W, Jr., Zago 
MA, Bordin S, Costa FF, Goldman GH, Carvalho AF, Matsukuma A, Baia GS, 
Simpson DH, Brunstein A, de Oliveira PS, Bucher P, Jongeneel CV, O'Hare MJ, 
Soares F, Brentani RR, Reis LF, de Souza SJ & Simpson AJ (2000) Shotgun 
sequencing of the human transcriptome with ORF expressed sequence tags. 
Proceedings of the National Academy of Sciences of the United States of America 97, 3491-
3496. 
Dimitroulakos J, Marhin WH, Tokunaga J, Irish J, Gullane P, Penn LZ & Kamel-Reid S (2002) 
Microarray and biochemical analysis of lovastatin-induced apoptosis of squamous 
cell carcinomas. Neoplasia 4, 337-346. 
Domazet B, Maclennan GT, Lopez-Beltran A, Montironi R & Cheng L (2008) Laser capture 
microdissection in the genomic and proteomic era: targeting the genetic basis of 
cancer. International journal of clinical and experimental pathology 1, 475-488. 
Dowhanick JJ, McBride AA & Howley PM (1995) Suppression of cellular proliferation by the 
papillomavirus E2 protein. Journal of virology 69, 7791-7799. 
Duenas-Gonzalez A, Cetina L, Mariscal I & de la Garza J (2003) Modern management of 
locally advanced cervical carcinoma. Cancer treatment reviews 29, 389-399. 
Duenas-Gonzalez A, Lizano M, Candelaria M, Cetina L, Arce C & Cervera E (2005) 
Epigenetics of cervical cancer. An overview and therapeutic perspectives. Molecular 
cancer 4, 38. 
Duffy CL, Phillips SL & Klingelhutz AJ (2003) Microarray analysis identifies differentiation-
associated genes regulated by human papillomavirus type 16 E6. Virology 314, 196-
205. 
Dusek RL, Getsios S, Chen F, Park JK, Amargo EV, Cryns VL & Green KJ (2006) The 
differentiation-dependent desmosomal cadherin desmoglein 1 is a novel caspase-3 
target that regulates apoptosis in keratinocytes. The Journal of biological chemistry 
281, 3614-3624. 
Follen M, Meyskens FL, Jr., Alvarez RD, Walker JL, Bell MC, Storthz KA, Sastry J, Roy K, 
Richards-Kortum R & Cornelison TL (2003) Cervical cancer chemoprevention, 
vaccines, and surrogate endpoint biomarkers. Cancer 98, 2044-2051. 
Forbes S, Clements J, Dawson E, Bamford S, Webb T, Dogan A, Flanagan A, Teague J, 
Wooster R, Futreal PA & Stratton MR (2006) Cosmic 2005. British journal of cancer 
94, 318-322. 
Forrest ARR, Taylor DF, Crowe ML, Chalk AM, Waddell NJ, Kolle G, Faulkner GJ, Rimantas 
K, Katayama S, Wells C, Kai C, Kawai J, Carninci P, Hayashizaki Y & Grimmond 
SM (2006) Genome-wide review of transcriptional complexity in mouse protein 
kinases and phosphatases. Genome Biology 7, R5. 
Frazer IH (2004) Prevention of cervical cancer through papillomavirus vaccination. Nature 
Reviews Immunology 4, 46-54. 
 
A Transcriptome- and Marker-Based Systemic Analysis of Cervical Cancer 
 
185 
Frigessi A, van de Wiel MA, Holden M, Svendsrud DH, Glad IK & Lyng H (2005) Genome-
wide estimation of transcript concentrations from spotted cDNA microarray data. 
Nucleic Acids Research 33, e143. 
Frith MC, Pheasant M & Mattick JS (2005) The amazing complexity of the human 
transcriptome. European journal of human genetics : EJHG 13, 894-897. 
Fujimoto T, Nishikawa A, Iwasaki M, Akutagawa N, Teramoto M & Kudo R (2004) Gene 
expression profiling in two morphologically different uterine cervical carcinoma 
cell lines derived from a single donor using a human cancer cDNA array. 
Gynecologic oncology 93, 446-453. 
Fuller AP, Palmer-Toy D, Erlander MG & Sgroi DC (2003) Laser capture microdissection 
and advanced molecular analysis of human breast cancer. Journal of mammary gland 
biology and neoplasia 8, 335-345. 
Gandarillas A (2000) Epidermal differentiation, apoptosis, and senescence: common 
pathways? Experimental gerontology 35, 53-62. 
Garner-Hamrick PA, Fostel JM, Chien WM, Banerjee NS, Chow LT, Broker TR & Fisher C 
(2004) Global effects of human papillomavirus type 18 E6/E7 in an organotypic 
keratinocyte culture system. Journal of virology 78, 9041-9050. 
Gartel AL & Radhakrishnan SK (2005) Lost in transcription: p21 repression, mechanisms, 
and consequences. Cancer research 65, 3980-3985. 
Gatherer D (2010) So what do we really mean when we say that systems biology is holistic? 
BMC systems biology 4, 22. 
Gatti L, Beretta GL, Carenini N, Corna E, Zunino F & Perego P (2004) Gene expression 
profiles in the cellular response to a multinuclear platinum complex. Cell Mol Life 
Sci 61, 973-981. 
Gibb EA, Brown CJ & Lam WL (2011) The functional role of long non-coding RNA in 
human carcinomas. Mol Cancer 10, 38. 
Glas AM, Floore A, Delahaye LJ, Witteveen AT, Pover RC, Bakx N, Lahti-Domenici JS, 
Bruinsma TJ, Warmoes MO, Bernards R, Wessels LF & Van't Veer LJ (2006) 
Converting a breast cancer microarray signature into a high-throughput diagnostic 
test. BMC Genomics 7, 278. 
Golub TR, Slonim DK, Tamayo P, Huard C, Gaasenbeek M, Mesirov JP, Coller H, Loh ML, 
Downing JR, Caligiuri MA, Bloomfield CD & Lander ES (1999) Molecular 
classification of cancer: class discovery and class prediction by gene expression 
monitoring. Science 286, 531-537. 
Gray LJ & Herrington CS (2004) Molecular markers for the prediction of progression of CIN 
lesions. International journal of gynecological pathology 23, 95-96. 
Guelaguetza Vázquez-Ortíz ea (2005) Análisis de expresión global del cáncer cérvico 
uterino: rutas metabólicas y genes alterados. Revista de Investigaciones Clinicas 57 
434-441. 
Haffty BG & Glazer PM (2003) Molecular markers in clinical radiation oncology. Oncogene 
22, 5915-5925. 
Hanahan D & Weinberg RA (2000) The hallmarks of cancer. Cell 100, 57-70. 
Hanson JC, Tangrea MA, Kim S, Armani MD, Pohida TJ, Bonner RF, Rodriguez-Canales J & 
Emmert-Buck MR (2011) Expression microdissection adapted to commercial laser 
dissection instruments. Nature protocols 6, 457-467. 
 
Topics on Cervical Cancer with an Advocacy for Prevention 
 
186 
Harima Y, Sawada S, Miyazaki Y, Kin K, Ishihara H, Imamura M, Sougawa M, Shikata N & 
Ohnishi T (2003) Expression of Ku80 in cervical cancer correlates with response to 
radiotherapy and survival. American journal of clinical oncology 26, e80-85. 
Harima Y, Togashi A, Horikoshi K, Imamura M, Sougawa M, Sawada S, Tsunoda T, 
Nakamura Y & Katagiri T (2004) Prediction of outcome of advanced cervical cancer 
to thermoradiotherapy according to expression profiles of 35 genes selected by 
cDNA microarray analysis. International journal of radiation oncology, biology, physics 
60, 237-248. 
Harrell JC, Dye WW, Harvell DM, Sartorius CA & Horwitz KB (2008) Contaminating cells 
alter gene signatures in whole organ versus laser capture microdissected tumors: a 
comparison of experimental breast cancers and their lymph node metastases. 
Clinical & experimental metastasis 25, 81-88. 
Harrison PR, Conkie D, Paul J & Jones K (1973) Localisation of cellular globin messenger 
RNA by in situ hybridisation to complementary DNA. FEBS letters 32, 109-112. 
Hassan R, Bera T & Pastan I (2004) Mesothelin: a new target for immunotherapy. Clinical 
cancer research 10, 3937-3942. 
Helliwell TR (2001) Molecular markers of metastasis in squamous carcinomas. The Journal of 
pathology 194, 289-293. 
Hipp J, Cheng J, Hanson JC, Yan W, Taylor P, Hu N, Rodriguez-Canales J, Tangrea MA, 
Emmert-Buck MR & Balis U (2011) SIVQ-aided laser capture microdissection: A 
tool for high-throughput expression profiling. Journal of pathology informatics 2, 19. 
Hoeflich A, Reisinger R, Lahm H, Kiess W, Blum WF, Kolb HJ, Weber MM & Wolf E (2001) 
Insulin-like growth factor-binding protein 2 in tumorigenesis: protector or 
promoter? Cancer research 61, 8601-8610. 
Hollestelle A & Schutte M (2005) Representational difference analysis as a tool in the search 
for new tumor suppressor genes. Methods in molecular medicine 103, 143-159. 
Hubank M & Schatz DG (1994) Identifying differences in mRNA expression by 
representational difference analysis of cDNA. Nucleic Acids Research 22, 5640-5648. 
Hudelist G, Czerwenka K, Singer C, Pischinger K, Kubista E & Manavi M (2005) cDNA 
array analysis of cytobrush-collected normal and malignant cervical epithelial cells: 
a feasibility study. Cancer genetics and cytogenetics 158, 35-42. 
Hughes TR, Mao M, Jones AR, Burchard J, Marton MJ, Shannon KW, Lefkowitz SM, Ziman 
M, Schelter JM, Meyer MR, Kobayashi S, Davis C, Dai HY, He YDD, Stephaniants 
SB, Cavet G, Walker WL, West A, Coffey E, Shoemaker DD, Stoughton R, 
Blanchard AP, Friend SH & Linsley PS (2001) Expression profiling using 
microarrays fabricated by an ink-jet oligonucleotide synthesizer. Nature 
Biotechnology 19, 342-347. 
Human Genome Sequencing C (2004) Finishing the euchromatic sequence of the human 
genome. Nature 431, 931-945. 
Hwang J, Kim YY, Huh S, Shim J, Park C, Kimm K, Choi DK, Park TK & Kim S (2005) The 
time-dependent serial gene response to Zeocin treatment involves caspase-
dependent apoptosis in HeLa cells. Microbiology and immunology 49, 331-342. 
Ishitobi M, Goranova TE, Komoike Y, Motomura K, Koyama H, Glas AM, van Lienen E, 
Inaji H, Van't Veer LJ & Kato K (2010) Clinical utility of the 70-gene MammaPrint 
profile in a Japanese population. Japanese journal of clinical oncology 40, 508-512. 
 
A Transcriptome- and Marker-Based Systemic Analysis of Cervical Cancer 
 
187 
Kalantari M, Garcia-Carranca A, Morales-Vazquez CD, Zuna R, Montiel DP, Calleja-Macias 
IE, Johansson B, Andersson S & Bernard HU (2009) Laser capture microdissection 
of cervical human papillomavirus infections: copy number of the virus in cancerous 
and normal tissue and heterogeneous DNA methylation. Virology 390, 261-267. 
Keating JT, Ince T & Crum CP (2001) Surrogate biomarkers of HPV infection in cervical 
neoplasia screening and diagnosis. Advances in anatomic pathology 8, 83-92. 
Kelemen LE (2006) The role of folate receptor alpha in cancer development, progression and 
treatment: cause, consequence or innocent bystander? International journal of cancer 
119, 243-250. 
Kelley ML, Keiger KE, Lee CJ & Huibregtse JM (2005) The global transcriptional effects of 
the human papillomavirus E6 protein in cervical carcinoma cell lines are mediated 
by the E6AP ubiquitin ligase. Journal of virology 79, 3737-3747. 
Kent WJ (2002) BLAT--the BLAST-like alignment tool. Genome research 12, 656-664. 
Kitahara O, Katagiri T, Tsunoda T, Harima Y & Nakamura Y (2002) Classification of 
sensitivity or resistance of cervical cancers to ionizing radiation according to 
expression profiles of 62 genes selected by cDNA microarray analysis. Neoplasia 4, 
295-303. 
Kitano H (2002) Systems biology: a brief overview. Science 295, 1662-1664. 
Klaes R, Woerner SM, Ridder R, Wentzensen N, Duerst M, Schneider A, Lotz B, Melsheimer 
P & von Knebel Doeberitz M (1999) Detection of high-risk cervical intraepithelial 
neoplasia and cervical cancer by amplification of transcripts derived from 
integrated papillomavirus oncogenes. Cancer research 59, 6132-6136. 
Klee EW, Erdogan S, Tillmans L, Kosari F, Sun Z, Wigle DA, Yang P, Aubry MC & 
Vasmatzis G (2009) Impact of sample acquisition and linear amplification on gene 
expression profiling of lung adenocarcinoma: laser capture micro-dissection cell-
sampling versus bulk tissue-sampling. BMC medical genomics 2, 13. 
Lander ES & Weinberg RA (2000) Genomics: journey to the center of biology. Science 287, 
1777-1782. 
Lazo PA (1999) The molecular genetics of cervical carcinoma. British journal of cancer 80, 
2008-2018. 
Lee CM, Fuhrman CB, Planelles V, Peltier MR, Gaffney DK, Soisson AP, Dodson MK, Tolley 
HD, Green CL & Zempolich KA (2006) Phosphatidylinositol 3-kinase inhibition by 
LY294002 radiosensitizes human cervical cancer cell lines. Clinical cancer research 12, 
250-256. 
Lee KA, Shim JH, Kho CW, Park SG, Park BC, Kim JW, Lim JS, Choe YK, Paik SG & Yoon 
DY (2004) Protein profiling and identification of modulators regulated by the E7 
oncogene in the C33A cell line by proteomics and genomics. Proteomics 4, 839-848. 
Legrain P, Aebersold R, Archakov A, Bairoch A, Bala K, Beretta L, Bergeron J, Borchers C, 
Corthals GL, Costello CE, Deutsch EW, Domon B, Hancock W, He F, Hochstrasser 
D, Marko-Varga G, Salekdeh GH, Sechi S, Snyder M, Srivastava S, Uhlen M, Hu 
CH, Yamamoto T, Paik YK & Omenn GS (2011) The human proteome project: 
Current state and future direction. Molecular & cellular proteomics. 
Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang SI, Puc J, Miliaresis C, Rodgers L, 
McCombie R, Bigner SH, Giovanella BC, Ittmann M, Tycko B, Hibshoosh H, Wigler 
MH & Parsons R (1997) PTEN, a putative protein tyrosine phosphatase gene 
mutated in human brain, breast, and prostate cancer. Science 275, 1943-1947. 
 
Topics on Cervical Cancer with an Advocacy for Prevention 
 
186 
Harima Y, Sawada S, Miyazaki Y, Kin K, Ishihara H, Imamura M, Sougawa M, Shikata N & 
Ohnishi T (2003) Expression of Ku80 in cervical cancer correlates with response to 
radiotherapy and survival. American journal of clinical oncology 26, e80-85. 
Harima Y, Togashi A, Horikoshi K, Imamura M, Sougawa M, Sawada S, Tsunoda T, 
Nakamura Y & Katagiri T (2004) Prediction of outcome of advanced cervical cancer 
to thermoradiotherapy according to expression profiles of 35 genes selected by 
cDNA microarray analysis. International journal of radiation oncology, biology, physics 
60, 237-248. 
Harrell JC, Dye WW, Harvell DM, Sartorius CA & Horwitz KB (2008) Contaminating cells 
alter gene signatures in whole organ versus laser capture microdissected tumors: a 
comparison of experimental breast cancers and their lymph node metastases. 
Clinical & experimental metastasis 25, 81-88. 
Harrison PR, Conkie D, Paul J & Jones K (1973) Localisation of cellular globin messenger 
RNA by in situ hybridisation to complementary DNA. FEBS letters 32, 109-112. 
Hassan R, Bera T & Pastan I (2004) Mesothelin: a new target for immunotherapy. Clinical 
cancer research 10, 3937-3942. 
Helliwell TR (2001) Molecular markers of metastasis in squamous carcinomas. The Journal of 
pathology 194, 289-293. 
Hipp J, Cheng J, Hanson JC, Yan W, Taylor P, Hu N, Rodriguez-Canales J, Tangrea MA, 
Emmert-Buck MR & Balis U (2011) SIVQ-aided laser capture microdissection: A 
tool for high-throughput expression profiling. Journal of pathology informatics 2, 19. 
Hoeflich A, Reisinger R, Lahm H, Kiess W, Blum WF, Kolb HJ, Weber MM & Wolf E (2001) 
Insulin-like growth factor-binding protein 2 in tumorigenesis: protector or 
promoter? Cancer research 61, 8601-8610. 
Hollestelle A & Schutte M (2005) Representational difference analysis as a tool in the search 
for new tumor suppressor genes. Methods in molecular medicine 103, 143-159. 
Hubank M & Schatz DG (1994) Identifying differences in mRNA expression by 
representational difference analysis of cDNA. Nucleic Acids Research 22, 5640-5648. 
Hudelist G, Czerwenka K, Singer C, Pischinger K, Kubista E & Manavi M (2005) cDNA 
array analysis of cytobrush-collected normal and malignant cervical epithelial cells: 
a feasibility study. Cancer genetics and cytogenetics 158, 35-42. 
Hughes TR, Mao M, Jones AR, Burchard J, Marton MJ, Shannon KW, Lefkowitz SM, Ziman 
M, Schelter JM, Meyer MR, Kobayashi S, Davis C, Dai HY, He YDD, Stephaniants 
SB, Cavet G, Walker WL, West A, Coffey E, Shoemaker DD, Stoughton R, 
Blanchard AP, Friend SH & Linsley PS (2001) Expression profiling using 
microarrays fabricated by an ink-jet oligonucleotide synthesizer. Nature 
Biotechnology 19, 342-347. 
Human Genome Sequencing C (2004) Finishing the euchromatic sequence of the human 
genome. Nature 431, 931-945. 
Hwang J, Kim YY, Huh S, Shim J, Park C, Kimm K, Choi DK, Park TK & Kim S (2005) The 
time-dependent serial gene response to Zeocin treatment involves caspase-
dependent apoptosis in HeLa cells. Microbiology and immunology 49, 331-342. 
Ishitobi M, Goranova TE, Komoike Y, Motomura K, Koyama H, Glas AM, van Lienen E, 
Inaji H, Van't Veer LJ & Kato K (2010) Clinical utility of the 70-gene MammaPrint 
profile in a Japanese population. Japanese journal of clinical oncology 40, 508-512. 
 
A Transcriptome- and Marker-Based Systemic Analysis of Cervical Cancer 
 
187 
Kalantari M, Garcia-Carranca A, Morales-Vazquez CD, Zuna R, Montiel DP, Calleja-Macias 
IE, Johansson B, Andersson S & Bernard HU (2009) Laser capture microdissection 
of cervical human papillomavirus infections: copy number of the virus in cancerous 
and normal tissue and heterogeneous DNA methylation. Virology 390, 261-267. 
Keating JT, Ince T & Crum CP (2001) Surrogate biomarkers of HPV infection in cervical 
neoplasia screening and diagnosis. Advances in anatomic pathology 8, 83-92. 
Kelemen LE (2006) The role of folate receptor alpha in cancer development, progression and 
treatment: cause, consequence or innocent bystander? International journal of cancer 
119, 243-250. 
Kelley ML, Keiger KE, Lee CJ & Huibregtse JM (2005) The global transcriptional effects of 
the human papillomavirus E6 protein in cervical carcinoma cell lines are mediated 
by the E6AP ubiquitin ligase. Journal of virology 79, 3737-3747. 
Kent WJ (2002) BLAT--the BLAST-like alignment tool. Genome research 12, 656-664. 
Kitahara O, Katagiri T, Tsunoda T, Harima Y & Nakamura Y (2002) Classification of 
sensitivity or resistance of cervical cancers to ionizing radiation according to 
expression profiles of 62 genes selected by cDNA microarray analysis. Neoplasia 4, 
295-303. 
Kitano H (2002) Systems biology: a brief overview. Science 295, 1662-1664. 
Klaes R, Woerner SM, Ridder R, Wentzensen N, Duerst M, Schneider A, Lotz B, Melsheimer 
P & von Knebel Doeberitz M (1999) Detection of high-risk cervical intraepithelial 
neoplasia and cervical cancer by amplification of transcripts derived from 
integrated papillomavirus oncogenes. Cancer research 59, 6132-6136. 
Klee EW, Erdogan S, Tillmans L, Kosari F, Sun Z, Wigle DA, Yang P, Aubry MC & 
Vasmatzis G (2009) Impact of sample acquisition and linear amplification on gene 
expression profiling of lung adenocarcinoma: laser capture micro-dissection cell-
sampling versus bulk tissue-sampling. BMC medical genomics 2, 13. 
Lander ES & Weinberg RA (2000) Genomics: journey to the center of biology. Science 287, 
1777-1782. 
Lazo PA (1999) The molecular genetics of cervical carcinoma. British journal of cancer 80, 
2008-2018. 
Lee CM, Fuhrman CB, Planelles V, Peltier MR, Gaffney DK, Soisson AP, Dodson MK, Tolley 
HD, Green CL & Zempolich KA (2006) Phosphatidylinositol 3-kinase inhibition by 
LY294002 radiosensitizes human cervical cancer cell lines. Clinical cancer research 12, 
250-256. 
Lee KA, Shim JH, Kho CW, Park SG, Park BC, Kim JW, Lim JS, Choe YK, Paik SG & Yoon 
DY (2004) Protein profiling and identification of modulators regulated by the E7 
oncogene in the C33A cell line by proteomics and genomics. Proteomics 4, 839-848. 
Legrain P, Aebersold R, Archakov A, Bairoch A, Bala K, Beretta L, Bergeron J, Borchers C, 
Corthals GL, Costello CE, Deutsch EW, Domon B, Hancock W, He F, Hochstrasser 
D, Marko-Varga G, Salekdeh GH, Sechi S, Snyder M, Srivastava S, Uhlen M, Hu 
CH, Yamamoto T, Paik YK & Omenn GS (2011) The human proteome project: 
Current state and future direction. Molecular & cellular proteomics. 
Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang SI, Puc J, Miliaresis C, Rodgers L, 
McCombie R, Bigner SH, Giovanella BC, Ittmann M, Tycko B, Hibshoosh H, Wigler 
MH & Parsons R (1997) PTEN, a putative protein tyrosine phosphatase gene 
mutated in human brain, breast, and prostate cancer. Science 275, 1943-1947. 
 
Topics on Cervical Cancer with an Advocacy for Prevention 
 
188 
Liang P & Pardee AB (1992) Differential display of eukaryotic messenger RNA by means of 
the polymerase chain reaction. Science 257, 967-971. 
Liang P & Pardee AB (2003) Analysing differential gene expression in cancer. Nature Reviews 
Cancer 3, 869-876. 
Lin J & Li M (2008) Molecular profiling in the age of cancer genomics. Expert review of 
molecular diagnostics 8, 263-276. 
Liu SS, Cheung AN & Ngan HY (2003) Differential gene expression in cervical cancer cell 
lines before and after ionizing radiation. International journal of oncology 22, 1091-
1099. 
Lockhart DJ, Dong HL, Byrne MC, Follettie MT, Gallo MV, Chee MS, Mittmann M, Wang 
CW, Kobayashi M, Horton H & Brown EL (1996) Expression monitoring by 
hybridization to high-density oligonucleotide arrays. Nature Biotechnology 14, 1675-
1680. 
Lu X, Toki T, Konishi I, Nikaido T & Fujii S (1998) Expression of p21WAF1/CIP1 in 
adenocarcinoma of the uterine cervix: a possible immunohistochemical marker of a 
favorable prognosis. Cancer 82, 2409-2417. 
Macoska JA (2002) The progressing clinical utility of DNA microarrays. CA Cancer J Clin 52, 
50-59. 
Martin CM, Astbury K & O'Leary JJ (2006) Molecular profiling of cervical neoplasia. Expert 
review of molecular diagnostics 6, 217-229. 
Mendes Soares LM & Valcarcel J (2006) The expanding transcriptome: the genome as the 
'Book of Sand'. The EMBO Journal 25, 923-931. 
Mikheev AM, Mikheeva SA, Liu B, Cohen P & Zarbl H (2004) A functional genomics 
approach for the identification of putative tumor suppressor genes: Dickkopf-1 as 
suppressor of HeLa cell transformation. Carcinogenesis 25, 47-59. 
Mook S, Schmidt MK, Viale G, Pruneri G, Eekhout I, Floore A, Glas AM, Bogaerts J, Cardoso 
F, Piccart-Gebhart MJ, Rutgers ET & Van't Veer LJ (2009) The 70-gene prognosis-
signature predicts disease outcome in breast cancer patients with 1-3 positive 
lymph nodes in an independent validation study. Breast cancer research and 
treatment 116, 295-302. 
Nees M, Geoghegan JM, Hyman T, Frank S, Miller L & Woodworth CD (2001) 
Papillomavirus type 16 oncogenes downregulate expression of interferon-
responsive genes and upregulate proliferation-associated and NF-kappaB-
responsive genes in cervical keratinocytes. Journal of virology 75, 4283-4296. 
Nees M, Geoghegan JM, Munson P, Prabhu V, Liu Y, Androphy E & Woodworth CD (2000) 
Human papillomavirus type 16 E6 and E7 proteins inhibit differentiation-
dependent expression of transforming growth factor-beta2 in cervical 
keratinocytes. Cancer research 60, 4289-4298. 
Nees M, van Wijngaarden E, Bakos E, Schneider A & Durst M (1998) Identification of novel 
molecular markers which correlate with HPV-induced tumor progression. 
Oncogene 16, 2447-2458. 
Ng P, Wei CL, Sung WK, Chiu KP, Lipovich L, Ang CC, Gupta S, Shahab A, Ridwan A, 
Wong CH, Liu ET & Ruan Y (2005) Gene identification signature (GIS) analysis for 
transcriptome characterization and genome annotation. Nature Methods 2, 105-111. 
Nieh S, Chen SF, Chu TY, Lai HC, Lin YS, Fu E & Gau CH (2005) Is p16(INK4A) expression 
more useful than human papillomavirus test to determine the outcome of atypical 
 
A Transcriptome- and Marker-Based Systemic Analysis of Cervical Cancer 
 
189 
squamous cells of undetermined significance-categorized Pap smear? A 
comparative analysis using abnormal cervical smears with follow-up biopsies. 
Gynecologic oncology 97, 35-40. 
Nisole S, Stoye JP & Saib A (2005) TRIM family proteins: retroviral restriction and antiviral 
defence. Nature Reviews Microbiology 3, 799-808. 
Novina CD & Sharp PA (2004) The RNAi revolution. Nature 430, 161-164. 
Nuovo GJ, Plaia TW, Belinsky SA, Baylin SB & Herman JG (1999) In situ detection of the 
hypermethylation-induced inactivation of the p16 gene as an early event in 
oncogenesis. Proceedings of the National Academy of Sciences of the United States of 
America 96, 12754-12759. 
Okamoto K & Beach D (1994) Cyclin-G Is a Transcriptional Target of the P53 Tumor-
Suppressor Protein. The EMBO Journal 13, 4816-4822. 
Orlando V (2000) Mapping chromosomal proteins in vivo by formaldehyde-crosslinked-
chromatin immunoprecipitation. Trends in Biochemical Sciences 25, 99-104. 
Perez-Plasencia C, Riggins G, Vazquez-Ortiz G, Moreno J, Arreola H, Hidalgo A, Pina-
Sanchez P & Salcedo M (2005) Characterization of the global profile of genes 
expressed in cervical epithelium by Serial Analysis of Gene Expression (SAGE). 
BMC Genomics 6, 130. 
Pett MR, Herdman MT, Palmer RD, Yeo GS, Shivji MK, Stanley MA & Coleman N (2006) 
Selection of cervical keratinocytes containing integrated HPV16 associates with 
episome loss and an endogenous antiviral response. Proceedings of the National 
Academy of Sciences of the United States of America 103, 3822-3827. 
Polyak K & Riggins GJ (2001) Gene discovery using the serial analysis of gene expression 
technique: Implications for cancer research. Journal of Clinical Oncology 19, 2948-
2958. 
Quackenbush J (2004) Data standards for 'omic' science. Nature Biotechnology 22, 613-614. 
Ramaswamy S, Ross KN, Lander ES & Golub TR (2003) A molecular signature of metastasis 
in primary solid tumors. Nature Genetics 33, 49-54. 
Ranamukhaarachchi DG, Unger ER, Vernon SD, Lee D & Rajeevan MS (2005) Gene 
expression profiling of dysplastic differentiation in cervical epithelial cells 
harboring human papillomavirus 16. Genomics 85, 727-738. 
Rappolee DA, Mark D, Banda MJ & Werb Z (1988) Wound macrophages express TGF-alpha 
and other growth factors in vivo: analysis by mRNA phenotyping. Science 241, 708-
712. 
Ren B, Robert F, Wyrick JJ, Aparicio O, Jennings EG, Simon I, Zeitlinger J, Schreiber J, 
Hannett N, Kanin E, Volkert TL, Wilson CJ, Bell SP & Young RA (2000) Genome-
wide location and function of DNA binding proteins. Science 290, 2306-+. 
Rhodes DR & Chinnaiyan AM (2005) Integrative analysis of the cancer transcriptome. Nature 
Genetics 37, S31-S37. 
Rosenwald A, Wright G, Chan WC, Connors JM, Campo E, Fisher RI, Gascoyne RD, Muller-
Hermelink HK, Smeland EB, Giltnane JM, Hurt EM, Zhao H, Averett L, Yang L, 
Wilson WH, Jaffe ES, Simon R, Klausner RD, Powell J, Duffey PL, Longo DL, 
Greiner TC, Weisenburger DD, Sanger WG, Dave BJ, Lynch JC, Vose J, Armitage 
JO, Montserrat E, Lopez-Guillermo A, Grogan TM, Miller TP, LeBlanc M, Ott G, 
Kvaloy S, Delabie J, Holte H, Krajci P, Stokke T & Staudt LM (2002) The use of 
 
Topics on Cervical Cancer with an Advocacy for Prevention 
 
188 
Liang P & Pardee AB (1992) Differential display of eukaryotic messenger RNA by means of 
the polymerase chain reaction. Science 257, 967-971. 
Liang P & Pardee AB (2003) Analysing differential gene expression in cancer. Nature Reviews 
Cancer 3, 869-876. 
Lin J & Li M (2008) Molecular profiling in the age of cancer genomics. Expert review of 
molecular diagnostics 8, 263-276. 
Liu SS, Cheung AN & Ngan HY (2003) Differential gene expression in cervical cancer cell 
lines before and after ionizing radiation. International journal of oncology 22, 1091-
1099. 
Lockhart DJ, Dong HL, Byrne MC, Follettie MT, Gallo MV, Chee MS, Mittmann M, Wang 
CW, Kobayashi M, Horton H & Brown EL (1996) Expression monitoring by 
hybridization to high-density oligonucleotide arrays. Nature Biotechnology 14, 1675-
1680. 
Lu X, Toki T, Konishi I, Nikaido T & Fujii S (1998) Expression of p21WAF1/CIP1 in 
adenocarcinoma of the uterine cervix: a possible immunohistochemical marker of a 
favorable prognosis. Cancer 82, 2409-2417. 
Macoska JA (2002) The progressing clinical utility of DNA microarrays. CA Cancer J Clin 52, 
50-59. 
Martin CM, Astbury K & O'Leary JJ (2006) Molecular profiling of cervical neoplasia. Expert 
review of molecular diagnostics 6, 217-229. 
Mendes Soares LM & Valcarcel J (2006) The expanding transcriptome: the genome as the 
'Book of Sand'. The EMBO Journal 25, 923-931. 
Mikheev AM, Mikheeva SA, Liu B, Cohen P & Zarbl H (2004) A functional genomics 
approach for the identification of putative tumor suppressor genes: Dickkopf-1 as 
suppressor of HeLa cell transformation. Carcinogenesis 25, 47-59. 
Mook S, Schmidt MK, Viale G, Pruneri G, Eekhout I, Floore A, Glas AM, Bogaerts J, Cardoso 
F, Piccart-Gebhart MJ, Rutgers ET & Van't Veer LJ (2009) The 70-gene prognosis-
signature predicts disease outcome in breast cancer patients with 1-3 positive 
lymph nodes in an independent validation study. Breast cancer research and 
treatment 116, 295-302. 
Nees M, Geoghegan JM, Hyman T, Frank S, Miller L & Woodworth CD (2001) 
Papillomavirus type 16 oncogenes downregulate expression of interferon-
responsive genes and upregulate proliferation-associated and NF-kappaB-
responsive genes in cervical keratinocytes. Journal of virology 75, 4283-4296. 
Nees M, Geoghegan JM, Munson P, Prabhu V, Liu Y, Androphy E & Woodworth CD (2000) 
Human papillomavirus type 16 E6 and E7 proteins inhibit differentiation-
dependent expression of transforming growth factor-beta2 in cervical 
keratinocytes. Cancer research 60, 4289-4298. 
Nees M, van Wijngaarden E, Bakos E, Schneider A & Durst M (1998) Identification of novel 
molecular markers which correlate with HPV-induced tumor progression. 
Oncogene 16, 2447-2458. 
Ng P, Wei CL, Sung WK, Chiu KP, Lipovich L, Ang CC, Gupta S, Shahab A, Ridwan A, 
Wong CH, Liu ET & Ruan Y (2005) Gene identification signature (GIS) analysis for 
transcriptome characterization and genome annotation. Nature Methods 2, 105-111. 
Nieh S, Chen SF, Chu TY, Lai HC, Lin YS, Fu E & Gau CH (2005) Is p16(INK4A) expression 
more useful than human papillomavirus test to determine the outcome of atypical 
 
A Transcriptome- and Marker-Based Systemic Analysis of Cervical Cancer 
 
189 
squamous cells of undetermined significance-categorized Pap smear? A 
comparative analysis using abnormal cervical smears with follow-up biopsies. 
Gynecologic oncology 97, 35-40. 
Nisole S, Stoye JP & Saib A (2005) TRIM family proteins: retroviral restriction and antiviral 
defence. Nature Reviews Microbiology 3, 799-808. 
Novina CD & Sharp PA (2004) The RNAi revolution. Nature 430, 161-164. 
Nuovo GJ, Plaia TW, Belinsky SA, Baylin SB & Herman JG (1999) In situ detection of the 
hypermethylation-induced inactivation of the p16 gene as an early event in 
oncogenesis. Proceedings of the National Academy of Sciences of the United States of 
America 96, 12754-12759. 
Okamoto K & Beach D (1994) Cyclin-G Is a Transcriptional Target of the P53 Tumor-
Suppressor Protein. The EMBO Journal 13, 4816-4822. 
Orlando V (2000) Mapping chromosomal proteins in vivo by formaldehyde-crosslinked-
chromatin immunoprecipitation. Trends in Biochemical Sciences 25, 99-104. 
Perez-Plasencia C, Riggins G, Vazquez-Ortiz G, Moreno J, Arreola H, Hidalgo A, Pina-
Sanchez P & Salcedo M (2005) Characterization of the global profile of genes 
expressed in cervical epithelium by Serial Analysis of Gene Expression (SAGE). 
BMC Genomics 6, 130. 
Pett MR, Herdman MT, Palmer RD, Yeo GS, Shivji MK, Stanley MA & Coleman N (2006) 
Selection of cervical keratinocytes containing integrated HPV16 associates with 
episome loss and an endogenous antiviral response. Proceedings of the National 
Academy of Sciences of the United States of America 103, 3822-3827. 
Polyak K & Riggins GJ (2001) Gene discovery using the serial analysis of gene expression 
technique: Implications for cancer research. Journal of Clinical Oncology 19, 2948-
2958. 
Quackenbush J (2004) Data standards for 'omic' science. Nature Biotechnology 22, 613-614. 
Ramaswamy S, Ross KN, Lander ES & Golub TR (2003) A molecular signature of metastasis 
in primary solid tumors. Nature Genetics 33, 49-54. 
Ranamukhaarachchi DG, Unger ER, Vernon SD, Lee D & Rajeevan MS (2005) Gene 
expression profiling of dysplastic differentiation in cervical epithelial cells 
harboring human papillomavirus 16. Genomics 85, 727-738. 
Rappolee DA, Mark D, Banda MJ & Werb Z (1988) Wound macrophages express TGF-alpha 
and other growth factors in vivo: analysis by mRNA phenotyping. Science 241, 708-
712. 
Ren B, Robert F, Wyrick JJ, Aparicio O, Jennings EG, Simon I, Zeitlinger J, Schreiber J, 
Hannett N, Kanin E, Volkert TL, Wilson CJ, Bell SP & Young RA (2000) Genome-
wide location and function of DNA binding proteins. Science 290, 2306-+. 
Rhodes DR & Chinnaiyan AM (2005) Integrative analysis of the cancer transcriptome. Nature 
Genetics 37, S31-S37. 
Rosenwald A, Wright G, Chan WC, Connors JM, Campo E, Fisher RI, Gascoyne RD, Muller-
Hermelink HK, Smeland EB, Giltnane JM, Hurt EM, Zhao H, Averett L, Yang L, 
Wilson WH, Jaffe ES, Simon R, Klausner RD, Powell J, Duffey PL, Longo DL, 
Greiner TC, Weisenburger DD, Sanger WG, Dave BJ, Lynch JC, Vose J, Armitage 
JO, Montserrat E, Lopez-Guillermo A, Grogan TM, Miller TP, LeBlanc M, Ott G, 
Kvaloy S, Delabie J, Holte H, Krajci P, Stokke T & Staudt LM (2002) The use of 
 
Topics on Cervical Cancer with an Advocacy for Prevention 
 
190 
molecular profiling to predict survival after chemotherapy for diffuse large-B-cell 
lymphoma. The New England journal of medicine 346, 1937-1947. 
Rosty C, Sheffer M, Tsafrir D, Stransky N, Tsafrir I, Peter M, de Cremoux P, de La 
Rochefordiere A, Salmon R, Dorval T, Thiery JP, Couturier J, Radvanyi F, Domany 
E & Sastre-Garau X (2005) Identification of a proliferation gene cluster associated 
with HPV E6/E7 expression level and viral DNA load in invasive cervical 
carcinoma. Oncogene 24, 7094-7104. 
Ruutu M, Peitsaro P, Johansson B & Syrjanen S (2002) Transcriptional profiling of a human 
papillomavirus 33-positive squamous epithelial cell line which acquired a selective 
growth advantage after viral integration. International journal of cancer 100, 318-326. 
Sakakura C, Hagiwara A, Miyagawa K, Nakashima S, Yoshikawa T, Kin S, Nakase Y, Ito K, 
Yamagishi H, Yazumi S, Chiba T & Ito Y (2005) Frequent downregulation of the 
runt domain transcription factors RUNX1, RUNX3 and their cofactor CBFB in 
gastric cancer. International journal of cancer 113, 221-228. 
Santin AD, Zhan F, Bignotti E, Siegel ER, Cane S, Bellone S, Palmieri M, Anfossi S, Thomas 
M, Burnett A, Kay HH, Roman JJ, O'Brien TJ, Tian E, Cannon MJ, Shaughnessy J, Jr. 
& Pecorelli S (2005) Gene expression profiles of primary HPV16- and HPV18-
infected early stage cervical cancers and normal cervical epithelium: identification 
of novel candidate molecular markers for cervical cancer diagnosis and therapy. 
Virology 331, 269-291. 
Schena M, Shalon D, Davis RW & Brown PO (1995) Quantitative Monitoring of Gene-
Expression Patterns with a Complementary-DNA Microarray. Science 270, 467-470. 
Segal E, Friedman N, Kaminski N, Regev A & Koller D (2005) From signatures to models: 
understanding cancer using microarrays. Nature Genetics 37 Suppl, S38-45. 
Seo MJ, Bae SM, Kim YW, Hur SY, Ro DY, Lee JM, Namkoong SE, Kim CK & Ahn WS (2005) 
New approaches to pathogenic gene function discovery with human squamous cell 
cervical carcinoma by gene ontology. Gynecologic oncology 96, 621-629. 
Sgarlato GD, Eastman CL & Sussman HH (2005) Panel of genes transcriptionally up-
regulated in squamous cell carcinoma of the cervix identified by representational 
difference analysis, confirmed by macroarray, and validated by real-time 
quantitative reverse transcription-PCR. Clinical chemistry 51, 27-34. 
Shapiro JA (2009) Revisiting the central dogma in the 21st century. Annals of the New York 
Academy of Sciences 1178, 6-28. 
Sherman ME (2003) Chapter 11: Future directions in cervical pathology. Journal of the 
National Cancer Institute. Monographs, 72-79. 
Sherman ME & Kurman RJ (1998) Intraepithelial carcinoma of the cervix: reflections on half 
a century of progress. Cancer 83, 2243-2246. 
Shim C, Zhang W, Rhee CH & Lee JH (1998) Profiling of differentially expressed genes in 
human primary cervical cancer by complementary DNA expression array. Clinical 
cancer research 4, 3045-3050. 
Shipp MA, Ross KN, Tamayo P, Weng AP, Kutok JL, Aguiar RC, Gaasenbeek M, Angelo M, 
Reich M, Pinkus GS, Ray TS, Koval MA, Last KW, Norton A, Lister TA, Mesirov J, 
Neuberg DS, Lander ES, Aster JC & Golub TR (2002) Diffuse large B-cell lymphoma 
outcome prediction by gene-expression profiling and supervised machine learning. 
Nature medicine 8, 68-74. 
 
A Transcriptome- and Marker-Based Systemic Analysis of Cervical Cancer 
 
191 
Silvestri A, Colombatti A, Calvert VS, Deng J, Mammano E, Belluco C, De Marchi F, Nitti D, 
Liotta LA, Petricoin EF & Pierobon M (2010) Protein pathway biomarker analysis of 
human cancer reveals requirement for upfront cellular-enrichment processing. 
Laboratory investigation; a journal of technical methods and pathology 90, 787-796. 
Singh-Gasson S, Green RD, Yue Y, Nelson C, Blattner F, Sussman MR & Cerrina F (1999) 
Maskless fabrication of light-directed oligonucleotide microarrays using a digital 
micromirror array. Nature Biotechnology 17, 974-978. 
Slodkowska EA & Ross JS (2009) MammaPrint 70-gene signature: another milestone in 
personalized medical care for breast cancer patients. Expert review of molecular 
diagnostics 9, 417-422. 
Snijders PJ, Steenbergen RD, Heideman DA & Meijer CJ (2006) HPV-mediated cervical 
carcinogenesis: concepts and clinical implications. The Journal of pathology 208, 152-
164. 
Sopov I, Sorensen T, Magbagbeolu M, Jansen L, Beer K, Kuhne-Heid R, Kirchmayr R, 
Schneider A & Durst M (2004) Detection of cancer-related gene expression profiles 
in severe cervical neoplasia. International journal of cancer 112, 33-43. 
Southan C (2004) Has the yo-yo stopped? An assessment of human protein-coding gene 
number. Proteomics 4, 1712-1726. 
Sova P, Feng Q, Geiss G, Wood T, Strauss R, Rudolf V, Lieber A & Kiviat N (2006) Discovery 
of novel methylation biomarkers in cervical carcinoma by global demethylation 
and microarray analysis. Cancer epidemiology, biomarkers & prevention 15, 114-123. 
Stein LD (2004) Human genome: end of the beginning. Nature 431, 915-916. 
Steinau M, Lee DR, Rajeevan MS, Vernon SD, Ruffin MT & Unger ER (2005) Gene 
expression profile of cervical tissue compared to exfoliated cells: impact on 
biomarker discovery. BMC Genomics 6, 64. 
Strausberg RL, Feingold EA, Grouse LH, Derge JG, Klausner RD, Collins FS, Wagner L, 
Shenmen CM, Schuler GD, Altschul SF, Zeeberg B, Buetow KH, Schaefer CF, Bhat 
NK, Hopkins RF, Jordan H, Moore T, Max SI, Wang J, Hsieh F, Diatchenko L, 
Marusina K, Farmer AA, Rubin GM, Hong L, Stapleton M, Soares MB, Bonaldo MF, 
Casavant TL, Scheetz TE, Brownstein MJ, Usdin TB, Toshiyuki S, Carninci P, 
Prange C, Raha SS, Loquellano NA, Peters GJ, Abramson RD, Mullahy SJ, Bosak 
SA, McEwan PJ, McKernan KJ, Malek JA, Gunaratne PH, Richards S, Worley KC, 
Hale S, Garcia AM, Gay LJ, Hulyk SW, Villalon DK, Muzny DM, Sodergren EJ, Lu 
X, Gibbs RA, Fahey J, Helton E, Ketteman M, Madan A, Rodrigues S, Sanchez A, 
Whiting M, Young AC, Shevchenko Y, Bouffard GG, Blakesley RW, Touchman JW, 
Green ED, Dickson MC, Rodriguez AC, Grimwood J, Schmutz J, Myers RM, 
Butterfield YS, Krzywinski MI, Skalska U, Smailus DE, Schnerch A, Schein JE, Jones 
SJ & Marra MA (2002) Generation and initial analysis of more than 15,000 full-
length human and mouse cDNA sequences. Proceedings of the National Academy of 
Sciences of the United States of America 99, 16899-16903. 
Strebhardt K & Ullrich A (2006) Targeting polo-like kinase 1 for cancer therapy. Nature 
Reviews Cancer 6, 321-330. 
Tangrea MA, Chuaqui RF, Gillespie JW, Ahram M, Gannot G, Wallis BS, Best CJ, Linehan 
WM, Liotta LA, Pohida TJ, Bonner RF & Emmert-Buck MR (2004) Expression 
microdissection: operator-independent retrieval of cells for molecular profiling. 
Diagnostic molecular pathology 13, 207-212. 
 
Topics on Cervical Cancer with an Advocacy for Prevention 
 
190 
molecular profiling to predict survival after chemotherapy for diffuse large-B-cell 
lymphoma. The New England journal of medicine 346, 1937-1947. 
Rosty C, Sheffer M, Tsafrir D, Stransky N, Tsafrir I, Peter M, de Cremoux P, de La 
Rochefordiere A, Salmon R, Dorval T, Thiery JP, Couturier J, Radvanyi F, Domany 
E & Sastre-Garau X (2005) Identification of a proliferation gene cluster associated 
with HPV E6/E7 expression level and viral DNA load in invasive cervical 
carcinoma. Oncogene 24, 7094-7104. 
Ruutu M, Peitsaro P, Johansson B & Syrjanen S (2002) Transcriptional profiling of a human 
papillomavirus 33-positive squamous epithelial cell line which acquired a selective 
growth advantage after viral integration. International journal of cancer 100, 318-326. 
Sakakura C, Hagiwara A, Miyagawa K, Nakashima S, Yoshikawa T, Kin S, Nakase Y, Ito K, 
Yamagishi H, Yazumi S, Chiba T & Ito Y (2005) Frequent downregulation of the 
runt domain transcription factors RUNX1, RUNX3 and their cofactor CBFB in 
gastric cancer. International journal of cancer 113, 221-228. 
Santin AD, Zhan F, Bignotti E, Siegel ER, Cane S, Bellone S, Palmieri M, Anfossi S, Thomas 
M, Burnett A, Kay HH, Roman JJ, O'Brien TJ, Tian E, Cannon MJ, Shaughnessy J, Jr. 
& Pecorelli S (2005) Gene expression profiles of primary HPV16- and HPV18-
infected early stage cervical cancers and normal cervical epithelium: identification 
of novel candidate molecular markers for cervical cancer diagnosis and therapy. 
Virology 331, 269-291. 
Schena M, Shalon D, Davis RW & Brown PO (1995) Quantitative Monitoring of Gene-
Expression Patterns with a Complementary-DNA Microarray. Science 270, 467-470. 
Segal E, Friedman N, Kaminski N, Regev A & Koller D (2005) From signatures to models: 
understanding cancer using microarrays. Nature Genetics 37 Suppl, S38-45. 
Seo MJ, Bae SM, Kim YW, Hur SY, Ro DY, Lee JM, Namkoong SE, Kim CK & Ahn WS (2005) 
New approaches to pathogenic gene function discovery with human squamous cell 
cervical carcinoma by gene ontology. Gynecologic oncology 96, 621-629. 
Sgarlato GD, Eastman CL & Sussman HH (2005) Panel of genes transcriptionally up-
regulated in squamous cell carcinoma of the cervix identified by representational 
difference analysis, confirmed by macroarray, and validated by real-time 
quantitative reverse transcription-PCR. Clinical chemistry 51, 27-34. 
Shapiro JA (2009) Revisiting the central dogma in the 21st century. Annals of the New York 
Academy of Sciences 1178, 6-28. 
Sherman ME (2003) Chapter 11: Future directions in cervical pathology. Journal of the 
National Cancer Institute. Monographs, 72-79. 
Sherman ME & Kurman RJ (1998) Intraepithelial carcinoma of the cervix: reflections on half 
a century of progress. Cancer 83, 2243-2246. 
Shim C, Zhang W, Rhee CH & Lee JH (1998) Profiling of differentially expressed genes in 
human primary cervical cancer by complementary DNA expression array. Clinical 
cancer research 4, 3045-3050. 
Shipp MA, Ross KN, Tamayo P, Weng AP, Kutok JL, Aguiar RC, Gaasenbeek M, Angelo M, 
Reich M, Pinkus GS, Ray TS, Koval MA, Last KW, Norton A, Lister TA, Mesirov J, 
Neuberg DS, Lander ES, Aster JC & Golub TR (2002) Diffuse large B-cell lymphoma 
outcome prediction by gene-expression profiling and supervised machine learning. 
Nature medicine 8, 68-74. 
 
A Transcriptome- and Marker-Based Systemic Analysis of Cervical Cancer 
 
191 
Silvestri A, Colombatti A, Calvert VS, Deng J, Mammano E, Belluco C, De Marchi F, Nitti D, 
Liotta LA, Petricoin EF & Pierobon M (2010) Protein pathway biomarker analysis of 
human cancer reveals requirement for upfront cellular-enrichment processing. 
Laboratory investigation; a journal of technical methods and pathology 90, 787-796. 
Singh-Gasson S, Green RD, Yue Y, Nelson C, Blattner F, Sussman MR & Cerrina F (1999) 
Maskless fabrication of light-directed oligonucleotide microarrays using a digital 
micromirror array. Nature Biotechnology 17, 974-978. 
Slodkowska EA & Ross JS (2009) MammaPrint 70-gene signature: another milestone in 
personalized medical care for breast cancer patients. Expert review of molecular 
diagnostics 9, 417-422. 
Snijders PJ, Steenbergen RD, Heideman DA & Meijer CJ (2006) HPV-mediated cervical 
carcinogenesis: concepts and clinical implications. The Journal of pathology 208, 152-
164. 
Sopov I, Sorensen T, Magbagbeolu M, Jansen L, Beer K, Kuhne-Heid R, Kirchmayr R, 
Schneider A & Durst M (2004) Detection of cancer-related gene expression profiles 
in severe cervical neoplasia. International journal of cancer 112, 33-43. 
Southan C (2004) Has the yo-yo stopped? An assessment of human protein-coding gene 
number. Proteomics 4, 1712-1726. 
Sova P, Feng Q, Geiss G, Wood T, Strauss R, Rudolf V, Lieber A & Kiviat N (2006) Discovery 
of novel methylation biomarkers in cervical carcinoma by global demethylation 
and microarray analysis. Cancer epidemiology, biomarkers & prevention 15, 114-123. 
Stein LD (2004) Human genome: end of the beginning. Nature 431, 915-916. 
Steinau M, Lee DR, Rajeevan MS, Vernon SD, Ruffin MT & Unger ER (2005) Gene 
expression profile of cervical tissue compared to exfoliated cells: impact on 
biomarker discovery. BMC Genomics 6, 64. 
Strausberg RL, Feingold EA, Grouse LH, Derge JG, Klausner RD, Collins FS, Wagner L, 
Shenmen CM, Schuler GD, Altschul SF, Zeeberg B, Buetow KH, Schaefer CF, Bhat 
NK, Hopkins RF, Jordan H, Moore T, Max SI, Wang J, Hsieh F, Diatchenko L, 
Marusina K, Farmer AA, Rubin GM, Hong L, Stapleton M, Soares MB, Bonaldo MF, 
Casavant TL, Scheetz TE, Brownstein MJ, Usdin TB, Toshiyuki S, Carninci P, 
Prange C, Raha SS, Loquellano NA, Peters GJ, Abramson RD, Mullahy SJ, Bosak 
SA, McEwan PJ, McKernan KJ, Malek JA, Gunaratne PH, Richards S, Worley KC, 
Hale S, Garcia AM, Gay LJ, Hulyk SW, Villalon DK, Muzny DM, Sodergren EJ, Lu 
X, Gibbs RA, Fahey J, Helton E, Ketteman M, Madan A, Rodrigues S, Sanchez A, 
Whiting M, Young AC, Shevchenko Y, Bouffard GG, Blakesley RW, Touchman JW, 
Green ED, Dickson MC, Rodriguez AC, Grimwood J, Schmutz J, Myers RM, 
Butterfield YS, Krzywinski MI, Skalska U, Smailus DE, Schnerch A, Schein JE, Jones 
SJ & Marra MA (2002) Generation and initial analysis of more than 15,000 full-
length human and mouse cDNA sequences. Proceedings of the National Academy of 
Sciences of the United States of America 99, 16899-16903. 
Strebhardt K & Ullrich A (2006) Targeting polo-like kinase 1 for cancer therapy. Nature 
Reviews Cancer 6, 321-330. 
Tangrea MA, Chuaqui RF, Gillespie JW, Ahram M, Gannot G, Wallis BS, Best CJ, Linehan 
WM, Liotta LA, Pohida TJ, Bonner RF & Emmert-Buck MR (2004) Expression 
microdissection: operator-independent retrieval of cells for molecular profiling. 
Diagnostic molecular pathology 13, 207-212. 
 
Topics on Cervical Cancer with an Advocacy for Prevention 
 
192 
Tewari D, Monk BJ, Al-Ghazi MS, Parker R, Heck JD, Burger RA & Fruehauf JP (2005) Gene 
expression profiling of in vitro radiation resistance in cervical carcinoma: a 
feasibility study. Gynecologic oncology 99, 84-91. 
Thierry F, Benotmane MA, Demeret C, Mori M, Teissier S & Desaintes C (2004) A genomic 
approach reveals a novel mitotic pathway in papillomavirus carcinogenesis. Cancer 
research 64, 895-903. 
Thomas JT, Oh ST, Terhune SS & Laimins LA (2001) Cellular changes induced by low-risk 
human papillomavirus type 11 in keratinocytes that stably maintain viral episomes. 
Journal of virology 75, 7564-7571. 
Thorgeirsson SS, Lee JS & Grisham JW (2006) Functional genomics of hepatocellular 
carcinoma. Hepatology 43, S145-150. 
Tian S, Roepman P, Van't Veer LJ, Bernards R, de Snoo F & Glas AM (2010) Biological 
functions of the genes in the mammaprint breast cancer profile reflect the 
hallmarks of cancer. Biomark Insights 5, 129-138. 
Toussaint-Smith E, Donner DB & Roman A (2004) Expression of human papillomavirus type 
16 E6 and E7 oncoproteins in primary foreskin keratinocytes is sufficient to alter the 
expression of angiogenic factors. Oncogene 23, 2988-2995. 
Usmani N, Foroudi F, Du J, Zakos C, Campbell H, Bryson P & Mackillop WJ (2005) An 
evidence-based estimate of the appropriate rate of utilization of radiotherapy for 
cancer of the cervix. International journal of radiation oncology, biology, physics 63, 812-
827. 
van 't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, Peterse HL, van der Kooy 
K, Marton MJ, Witteveen AT, Schreiber GJ, Kerkhoven RM, Roberts C, Linsley PS, 
Bernards R & Friend SH (2002) Gene expression profiling predicts clinical outcome 
of breast cancer. Nature 415, 530-536. 
van de Vijver MJ, He YD, van't Veer LJ, Dai H, Hart AA, Voskuil DW, Schreiber GJ, Peterse 
JL, Roberts C, Marton MJ, Parrish M, Atsma D, Witteveen A, Glas A, Delahaye L, 
van der Velde T, Bartelink H, Rodenhuis S, Rutgers ET, Friend SH & Bernards R 
(2002) A gene-expression signature as a predictor of survival in breast cancer. The 
New England journal of medicine 347, 1999-2009. 
Vazquez-Ortiz G, Ciudad CJ, Pina P, Vazquez K, Hidalgo A, Alatorre B, Garcia JA, 
Salamanca F, Peralta-Rodriguez R, Rangel A & Salcedo M (2005a) Gene 
identification by cDNA arrays in HPV-positive cervical cancer. Archives of medical 
research 36, 448-458. 
Vazquez-Ortiz G, Pina-Sanchez P, Vazquez K, Duenas A, Taja L, Mendoza P, Garcia JA & 
Salcedo M (2005b) Overexpression of cathepsin F, matrix metalloproteinases 11 and 
12 in cervical cancer. BMC Cancer 5, 68. 
Velculescu VE, Zhang L, Vogelstein B & Kinzler KW (1995) Serial Analysis of Gene-
Expression. Science 270, 484-487. 
Vogelstein B & Kinzler KW (2004) Cancer genes and the pathways they control. Nature 
medicine 10, 789-799. 
Wadlow R & Ramaswamy S (2005) DNA microarrays in clinical cancer research. Current 
molecular medicine 5, 111-120. 
Wain HM, Lush MJ, Ducluzeau F, Khodiyar VK & Povey S (2004) Genew: the Human Gene 
Nomenclature Database, 2004 updates. Nucleic Acids Research 32, D255-257. 
 
A Transcriptome- and Marker-Based Systemic Analysis of Cervical Cancer 
 
193 
Wei CL, Wu Q, Vega VB, Chiu KP, Ng P, Zhang T, Shahab A, Yong HC, Fu YT, Weng ZP, 
Liu JJ, Zhao XD, Chew JL, Lee YL, Kuznetsov VA, Sung WK, Miller LD, Lim B, Liu 
ET, Yu Q, Ng HH & Ruan YJ (2006) A global map of p53 transcription-factor 
binding sites in the human genome. Cell 124, 207-219. 
Wells SI, Aronow BJ, Wise TM, Williams SS, Couget JA & Howley PM (2003) Transcriptome 
signature of irreversible senescence in human papillomavirus-positive cervical 
cancer cells. Proceedings of the National Academy of Sciences of the United States of 
America 100, 7093-7098. 
Wheeler DL, Barrett T, Benson DA, Bryant SH, Canese K, Chetvernin V, Church DM, 
Dicuccio M, Edgar R, Federhen S, Feolo M, Geer LY, Helmberg W, Kapustin Y, 
Khovayko O, Landsman D, Lipman DJ, Madden TL, Maglott DR, Miller V, Ostell J, 
Pruitt KD, Schuler GD, Shumway M, Sequeira E, Sherry ST, Sirotkin K, Souvorov 
A, Starchenko G, Tatusov RL, Tatusova TA, Wagner L & Yaschenko E (2008) 
Database resources of the National Center for Biotechnology Information. Nucleic 
Acids Research 36, D13-21. 
Whitfield ML, George LK, Grant GD & Perou CM (2006) Common markers of proliferation. 
Nature Reviews Cancer 6, 99-106. 
Wilting SM, Snijders PJ, Meijer GA, Ylstra B, van den Ijssel PR, Snijders AM, Albertson DG, 
Coffa J, Schouten JP, van de Wiel MA, Meijer CJ & Steenbergen RD (2006) Increased 
gene copy numbers at chromosome 20q are frequent in both squamous cell 
carcinomas and adenocarcinomas of the cervix. The Journal of pathology 209, 220-230. 
Wong YF, Cheung TH, Tsao GS, Lo KW, Yim SF, Wang VW, Heung MM, Chan SC, Chan 
LK, Ho TW, Wong KW, Li C, Guo Y, Chung TK & Smith DI (2006) Genome-wide 
gene expression profiling of cervical cancer in Hong Kong women by 
oligonucleotide microarray. International journal of cancer 118, 2461-2469. 
Wong YF, Selvanayagam ZE, Wei N, Porter J, Vittal R, Hu R, Lin Y, Liao J, Shih JW, Cheung 
TH, Lo KW, Yim SF, Yip SK, Ngong DT, Siu N, Chan LK, Chan CS, Kong T, Kutlina 
E, McKinnon RD, Denhardt DT, Chin KV & Chung TK (2003) Expression genomics 
of cervical cancer: molecular classification and prediction of radiotherapy response 
by DNA microarray. Clinical cancer research 9, 5486-5492. 
Woodman CBJ, Collins SI & Young LS (2007) The natural history of cervical HPV infection: 
unresolved issues. Nature Reviews Cancer 7, 11-22. 
Woodworth CD, Michael E, Marker D, Allen S, Smith L & Nees M (2005) Inhibition of the 
epidermal growth factor receptor increases expression of genes that stimulate 
inflammation, apoptosis, and cell attachment. Molecular cancer therapeutics 4, 650-
658. 
Yamashita T, Honda M & Kaneko S (2008) Application of Serial Analysis of Gene Expression 
in cancer research. Current pharmaceutical biotechnology 9, 375-382. 
Yen CC, Chen YJ, Pan CC, Lu KH, Chen PC, Hsia JY, Chen JT, Wu YC, Hsu WH, Wang LS, 
Huang MH, Huang BS, Hu CP, Chen PM & Lin CH (2005) Copy number changes 
of target genes in chromosome 3q25.3-qter of esophageal squamous cell carcinoma: 
TP63 is amplified in early carcinogenesis but down-regulated as disease 
progressed. World journal of gastroenterology : WJG 11, 1267-1272. 
Yim EK & Park JS (2006) Role of proteomics in translational research in cervical cancer. 
Expert review of proteomics 3, 21-36. 
 
Topics on Cervical Cancer with an Advocacy for Prevention 
 
192 
Tewari D, Monk BJ, Al-Ghazi MS, Parker R, Heck JD, Burger RA & Fruehauf JP (2005) Gene 
expression profiling of in vitro radiation resistance in cervical carcinoma: a 
feasibility study. Gynecologic oncology 99, 84-91. 
Thierry F, Benotmane MA, Demeret C, Mori M, Teissier S & Desaintes C (2004) A genomic 
approach reveals a novel mitotic pathway in papillomavirus carcinogenesis. Cancer 
research 64, 895-903. 
Thomas JT, Oh ST, Terhune SS & Laimins LA (2001) Cellular changes induced by low-risk 
human papillomavirus type 11 in keratinocytes that stably maintain viral episomes. 
Journal of virology 75, 7564-7571. 
Thorgeirsson SS, Lee JS & Grisham JW (2006) Functional genomics of hepatocellular 
carcinoma. Hepatology 43, S145-150. 
Tian S, Roepman P, Van't Veer LJ, Bernards R, de Snoo F & Glas AM (2010) Biological 
functions of the genes in the mammaprint breast cancer profile reflect the 
hallmarks of cancer. Biomark Insights 5, 129-138. 
Toussaint-Smith E, Donner DB & Roman A (2004) Expression of human papillomavirus type 
16 E6 and E7 oncoproteins in primary foreskin keratinocytes is sufficient to alter the 
expression of angiogenic factors. Oncogene 23, 2988-2995. 
Usmani N, Foroudi F, Du J, Zakos C, Campbell H, Bryson P & Mackillop WJ (2005) An 
evidence-based estimate of the appropriate rate of utilization of radiotherapy for 
cancer of the cervix. International journal of radiation oncology, biology, physics 63, 812-
827. 
van 't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, Peterse HL, van der Kooy 
K, Marton MJ, Witteveen AT, Schreiber GJ, Kerkhoven RM, Roberts C, Linsley PS, 
Bernards R & Friend SH (2002) Gene expression profiling predicts clinical outcome 
of breast cancer. Nature 415, 530-536. 
van de Vijver MJ, He YD, van't Veer LJ, Dai H, Hart AA, Voskuil DW, Schreiber GJ, Peterse 
JL, Roberts C, Marton MJ, Parrish M, Atsma D, Witteveen A, Glas A, Delahaye L, 
van der Velde T, Bartelink H, Rodenhuis S, Rutgers ET, Friend SH & Bernards R 
(2002) A gene-expression signature as a predictor of survival in breast cancer. The 
New England journal of medicine 347, 1999-2009. 
Vazquez-Ortiz G, Ciudad CJ, Pina P, Vazquez K, Hidalgo A, Alatorre B, Garcia JA, 
Salamanca F, Peralta-Rodriguez R, Rangel A & Salcedo M (2005a) Gene 
identification by cDNA arrays in HPV-positive cervical cancer. Archives of medical 
research 36, 448-458. 
Vazquez-Ortiz G, Pina-Sanchez P, Vazquez K, Duenas A, Taja L, Mendoza P, Garcia JA & 
Salcedo M (2005b) Overexpression of cathepsin F, matrix metalloproteinases 11 and 
12 in cervical cancer. BMC Cancer 5, 68. 
Velculescu VE, Zhang L, Vogelstein B & Kinzler KW (1995) Serial Analysis of Gene-
Expression. Science 270, 484-487. 
Vogelstein B & Kinzler KW (2004) Cancer genes and the pathways they control. Nature 
medicine 10, 789-799. 
Wadlow R & Ramaswamy S (2005) DNA microarrays in clinical cancer research. Current 
molecular medicine 5, 111-120. 
Wain HM, Lush MJ, Ducluzeau F, Khodiyar VK & Povey S (2004) Genew: the Human Gene 
Nomenclature Database, 2004 updates. Nucleic Acids Research 32, D255-257. 
 
A Transcriptome- and Marker-Based Systemic Analysis of Cervical Cancer 
 
193 
Wei CL, Wu Q, Vega VB, Chiu KP, Ng P, Zhang T, Shahab A, Yong HC, Fu YT, Weng ZP, 
Liu JJ, Zhao XD, Chew JL, Lee YL, Kuznetsov VA, Sung WK, Miller LD, Lim B, Liu 
ET, Yu Q, Ng HH & Ruan YJ (2006) A global map of p53 transcription-factor 
binding sites in the human genome. Cell 124, 207-219. 
Wells SI, Aronow BJ, Wise TM, Williams SS, Couget JA & Howley PM (2003) Transcriptome 
signature of irreversible senescence in human papillomavirus-positive cervical 
cancer cells. Proceedings of the National Academy of Sciences of the United States of 
America 100, 7093-7098. 
Wheeler DL, Barrett T, Benson DA, Bryant SH, Canese K, Chetvernin V, Church DM, 
Dicuccio M, Edgar R, Federhen S, Feolo M, Geer LY, Helmberg W, Kapustin Y, 
Khovayko O, Landsman D, Lipman DJ, Madden TL, Maglott DR, Miller V, Ostell J, 
Pruitt KD, Schuler GD, Shumway M, Sequeira E, Sherry ST, Sirotkin K, Souvorov 
A, Starchenko G, Tatusov RL, Tatusova TA, Wagner L & Yaschenko E (2008) 
Database resources of the National Center for Biotechnology Information. Nucleic 
Acids Research 36, D13-21. 
Whitfield ML, George LK, Grant GD & Perou CM (2006) Common markers of proliferation. 
Nature Reviews Cancer 6, 99-106. 
Wilting SM, Snijders PJ, Meijer GA, Ylstra B, van den Ijssel PR, Snijders AM, Albertson DG, 
Coffa J, Schouten JP, van de Wiel MA, Meijer CJ & Steenbergen RD (2006) Increased 
gene copy numbers at chromosome 20q are frequent in both squamous cell 
carcinomas and adenocarcinomas of the cervix. The Journal of pathology 209, 220-230. 
Wong YF, Cheung TH, Tsao GS, Lo KW, Yim SF, Wang VW, Heung MM, Chan SC, Chan 
LK, Ho TW, Wong KW, Li C, Guo Y, Chung TK & Smith DI (2006) Genome-wide 
gene expression profiling of cervical cancer in Hong Kong women by 
oligonucleotide microarray. International journal of cancer 118, 2461-2469. 
Wong YF, Selvanayagam ZE, Wei N, Porter J, Vittal R, Hu R, Lin Y, Liao J, Shih JW, Cheung 
TH, Lo KW, Yim SF, Yip SK, Ngong DT, Siu N, Chan LK, Chan CS, Kong T, Kutlina 
E, McKinnon RD, Denhardt DT, Chin KV & Chung TK (2003) Expression genomics 
of cervical cancer: molecular classification and prediction of radiotherapy response 
by DNA microarray. Clinical cancer research 9, 5486-5492. 
Woodman CBJ, Collins SI & Young LS (2007) The natural history of cervical HPV infection: 
unresolved issues. Nature Reviews Cancer 7, 11-22. 
Woodworth CD, Michael E, Marker D, Allen S, Smith L & Nees M (2005) Inhibition of the 
epidermal growth factor receptor increases expression of genes that stimulate 
inflammation, apoptosis, and cell attachment. Molecular cancer therapeutics 4, 650-
658. 
Yamashita T, Honda M & Kaneko S (2008) Application of Serial Analysis of Gene Expression 
in cancer research. Current pharmaceutical biotechnology 9, 375-382. 
Yen CC, Chen YJ, Pan CC, Lu KH, Chen PC, Hsia JY, Chen JT, Wu YC, Hsu WH, Wang LS, 
Huang MH, Huang BS, Hu CP, Chen PM & Lin CH (2005) Copy number changes 
of target genes in chromosome 3q25.3-qter of esophageal squamous cell carcinoma: 
TP63 is amplified in early carcinogenesis but down-regulated as disease 
progressed. World journal of gastroenterology : WJG 11, 1267-1272. 
Yim EK & Park JS (2006) Role of proteomics in translational research in cervical cancer. 
Expert review of proteomics 3, 21-36. 
 
Topics on Cervical Cancer with an Advocacy for Prevention 
 
194 
Yuan J, Yan R, Kramer A, Eckerdt F, Roller M, Kaufmann M & Strebhardt K (2004) Cyclin B1 
depletion inhibits proliferation and induces apoptosis in human tumor cells. 
Oncogene 23, 5843-5852. 
Zimmermann CR, Orr WC, Leclerc RF, Barnard EC & Timberlake WE (1980) Molecular 
cloning and selection of genes regulated in Aspergillus development. Cell 21, 709-
715. 
zur Hausen H (2002) Papillomaviruses and cancer: from basic studies to clinical application. 
Nature Reviews Cancer 2, 342-350. 
zur Hausen H (2009) The search for infectious causes of human cancers: Where and why 
(Nobel lecutre). Angewandte Chemie International Edition 48, 5798-5808. 
12 
Evaluation of p53, p16INK4a and  
E-Cadherin Status as Biomarkers  
for Cervical Cancer Diagnosis 
M. El Mzibri1,*, M. Attaleb1, R. Ameziane El Hassani1,  
M. Khyatti2, L. Benbacer1, M. M. Ennaji3 and M. Amrani4 
1Unité de Biologie et Recherche Médicale,  
Centre National de l'Energie, des Sciences et  
Techniques Nucléaires (CNESTEN), Rabat 
2Laboratoire d’Onco-Virologie, Institut Pasteur du Maroc, Casablanca 
3Laboratoire Virologie Hygiène and Microbiologie,  
Faculté des Sciences et Techniques Mohammédia 
4Service d’Anatomie Pathologique, Institut National d’Oncologie, Rabat 
Morocco 
1. Introduction 
Worldwide, carcinoma of the uterine cervix is one of the most common malignancies 
among women. Incidence rates of this disease vary from about 5 cases per 100 000 women 
per year in many industrialized countries to more than 50 per 100 000 in some developing 
nations. Approximately 80% of all cases occur in less-developed countries, because 
prevention programs are either non-existent or poorly conducted (WHO, 2009). 
Furthermore, in the less developed areas of the world, cervical cancer begins to strike 
significantly among women as young as 25-30 years of age, clearly identifying this disease 
as the cancer priority in women. 
Clinical epidemiology have clearly identified that the association between infection with 
high-risk types of human papillomavirus (HPV) and high-grade cervical cancer 
precursors as well as cervical cancer is very strong (Wright Jr., 2006). However, even high-
risk HPV infection are widespread in the world, the majority of HPV-associated lesions 
such as cervical intraepithelial neoplasia (CIN) will remain stable or spontaneously 
regress over time (zur Hausen, 2000; Ferenczy, 2001; Holowaty, 1999; Syrjanen, 1996), 
suggesting that other genetic and epigenetic events are likely to be involved in cervical 
carcinogenesis. Indeed, genomic alterations leading to tumor suppressor gene inactivation 
and/or oncogene activation are the critical pathways in the development and progression 
of cervical cancer as well as the other types of cancer. In this field, p53, p16 and E-
cadherin are important proteins that play critical role in the development and the 
progression of cervical cancer. 
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2. Human papillomavirus and cervical cancer 
Association between HPV and cervical lesions and cancer has started in 1970s’ years after 
the hypothesis that cervical cancer may arise from infections with the virus found in 
condylomata acuminata (zur Hausen, 1975; 1976). Then epidemiological and clinical studies 
have clearly demonstrated that HPV are the major etiologic agents of neoplasia of the 
cutaneous and mucosal epithelia; HPV positivity in cervical cancer is estimated to be 
between 90% and 95% (zur Hausen, 1991; Munoz, 2003). Currently, there is compelling 
evidence to indicate that the development of human cervical cancer without involvement of 
the specific HPV is exceptional. 
Up to now, more than 200 HPV genotypes were recensed, but the interest is focused only on 
30 types that are closely associated to cervical lesions. Among them, 15 HPV types have 
been classified as high risk types (16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68, 73, and 82); 
three have been classified as probable high risk types (26, 53, and 66); and 12 have been 
classified as low risk types (6, 11, 40, 42, 43, 44, 54, 61, 70, 72, 81, and CP6108) (Munoz, 2003). 
Among the high risk HPV genotypes, HPV-16 is the most common in squamous cell 
carcinoma of the cervix (50–60%), followed by HPV-18, which is present in about 11–15% of 
cervical cancer cases (Munoz, 2003, Saranath, 2002).  
HPV genomes code for at least six different early and two late proteins. The structure of the 
genome and the characteristic properties of individual viral proteins have been well 
reviewed (zur Hausen, 2000; Stanley, 2010; Moody & Laimins, 2010). High-risk HPVs code 
for at least three proteins with growthstimulating and transforming properties (E5, E6, and 
E7). 
In the pathogenesis of cervical carcinoma we can identify three major factors. Two of them 
are related to the HPV presence, the effects of viral E6 and E7 proteins, and the 
consequences of HPV DNA integration in the cellular genome. The third factor is the 
accumulation of cellular genetic damage, not related to HPV, needed for tumour 
development (Lazo, 1999). 
Viral DNA integrated into host genome is found in all cases of cervical carcinoma (Bosch, 
1995), their metastasis and derivative cell lines (Cullen, 1991). 
HPV DNA integration into host chromatin is usually a necessary event in the pathogenesis 
of HPV-related cervical cancer. It is one of the key stages in malignant progression and is 
therefore a potential biomarker that precedes invasive disease. 
Many studies have demonstrated that the integrated HPV DNA is linearized between the E1 
and L1 genes. Upon viral integration, variable parts of the HPV genome are disrupted; 
fragments containing E2 and E4 ORFs are missing whereas the entire E1, E6 and E7 ORFs 
are integrated and retained (Raybould, 2011).  
HPV viral integration is made in such way that the viral regulatory region and the E6 and 
E7 genes are expressed from viral promoters, but with a different regulation, in which 
cellular factors might play an important role (Lazo, 1999; Raybould, 2011). In the normal 
HPV life-cycle expression of E5, E6 and E7 is tightly regulated within cells that are destined 
to be lost from surface epithelial layers, such that they do not pose a carcinogenic threat 
(Raybould, 2011) 
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E5 expression enhances oncogenic potential (Stoppler, 1996; Maufort, 2010) but the exact 
function of E5 remains poorly understood. E6 and E7 expression is essential for maintenance 
of the transformed state and malignant progression (Bosch, 1990; von Knebel Doeberitz, 
1988).  
The implication of E6 and E7 proteins in cervical cancer progression is mainly due 
through their interactions with hTERT, p53 and Retinoblastoma protein (pRB). hTERT is a 
catalytic subunit of Telomerase that acts to synthesise telomere ends of linear 
chromosomes during DNA replication. p53 is a transcription factor that regulates cell 
cycle arrest, apoptosis, senescence, DNA repair and cell metabolism; p53 activity is 
inhibited by ubiquitin ligase which also ubiquitinates p53 to initiate p53 degradation 
(Figure 1). In addition to inducing the rapid degradation of p53, E6 also binds to and 
degrades FADD, preventing the transmission of apoptotic signals via the Fas pathway 
(Filippova, 2004).  
pRB is a tumour suppressor protein and interacts with transcription factor E2F to repress the 
transcription of genes required for the S phase of the cell cycle (Figure 1). E7 can also bind to 
other connected proteins such as p107 and p130 (Raybould, 2011).  
Currently vaccination based strategy is an alternative method showed to be amore effective 
and practical approach than the implementation of regular and periodic cytological 
screening. Today it is very well established that intervention with vaccines permits already 
the statement that essential precursor lesions of this cancer are efficiently prevented (Zur 
Hausen, 2009). 
 
Fig. 1. Schematic representation of E6 and E7 activities in cervical cells 
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3. p53 expression and polymorphism in cervical cancer 
The human tumour suppressor gene p53 plays a key role in the cell's response to genotoxic 
stress and loss of this 'guardian of the genome' is an important step in carcinogenesis. The 
highly significant tumour suppressor gene, p53, is implicated in a wide range of human 
cancers, and is a multifunctional protein that plays critical roles in cellular responses to 
DNA damage, cellular senescence and apoptosis to maintain genomic stability of a cell 
(Kashima, 2007). p53 encodes a transcription factor at the centre of a network that maintains 
cellular integrity by the inhibition of cell growth and stimulation of apoptosis in response to 
cellular stresses such as DNA damage (Scheffner, 1990). 
Because mutation of the p53 gene is a relatively rare event in cervical cancer, p53 activity is 
mainly inhibited by the viral oncoprotein E6. It’s clearly identified that abrogation of p53 
function by the E6 protein of HPV is thought to be one of the major events in cervical 
carcinogenesis (Soussi, 2001). The viral E6 protein interacts with protein p53 and inhibits its 
activity, followed by proteolytic degradation through the ubiquitin pathway (Scheffner, 
1990; Werness, 1990).  
As shown if Figure 2, expression of p53 on cervical cancer biopsies showed that the p53 
immunoreactivity is detected especially in nuclei. The expression is greater in the peripheral 
cells of tumours.  
 
Fig. 2. Representative p53 immunohistochemical staining in epidermoid carcinoma 
Different studies showed that p53 expression did not correlate with tumour recurrence 
demonstrating that immunohistochemistry for p53 protein appears to provide no prognostic 
information for all patients with cervical cancer (Abd El All, 1999; Vasilescu, 2009; Abrahao, 
2011). However, it still remains a prognostic factor for the aggressive behavior of the 
tumour, when it exceeds more than 30% positivity in tumour cells nuclei (Vasilescu, 2009). 
Many studies, using different p53 monoclonal antibodies, have reported the lack of any 
association between p53 IHC expression and staging (Abd El All, 1999). Indeed, in HPV 
positive cervical carcinoma, the wild type p53 complex with E6 of HPV 16 or 18, is degraded 
and cannot be detected by IHC. In other cancers, Overexpression of p53 in tissues has 
generally been assumed to reflect accumulation of p53 mutations. 
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Several polymorphisms have been identified within the p53 gene, both in non-coding and 
coding regions and may represent an important contribution to cancer susceptibility and 
tumour behaviour (Costa, 2008). The common polymorphism is known at codon 72, with 
two alleles encoding either arginine (p53 Arg) or proline (p53 Pro) (Matlashewski, 1987). 
The genotype of p53 gene at codon 72 is detected by PCR with allele specific primers “ASP” 
that especially detects either the p53Pro or p53Arg allele. DNA is amplified in separate 
reactions with p53 Pro and p53 Arg primers. Example of resulting amplifications is reported 
in Figure 3. 
            M           p53 Arg/Arg              p53 Arg/Pro             p53 Pro/Pro  
 
Fig. 3. Analysis of p53 codon 72 polymorphism by PCR using allele specific primers  
Arg allele specific primers: 141 bp and Pro allele specific primers: 177 bp. M: 100 bp ladder. 
The Pro/Pro, Pro/Arg, and Arg/Arg frequencies have been reported in human cancers 
including lung, colorectal, breast, stomach, bladder, head and neck and oral, for their 
association with predisposition and subsequent increased susceptibility to the cancer. These 
studies have shown that the presence of Arg/Arg genotype has been associated with 
increased susceptibility to cervical cancer and Pro/Pro genotype is more frequent in lung 
cancers (Storey, 1998; Hamel, 2000; Tandle, 2001).  
This polymorphism occurs in the proline-rich domain of the p53 protein, which is necessary 
for the protein to fully induce apoptosis (Zhu, 2007). The functional difference between the 2 
alleles of this polymorphism is that the Arg/Arg genotype induces apoptosis with faster 
kinetics and suppresses transformation more efficiently than the Pro/Pro genotype (Kuroda, 
2007). In cervical cancer, different studies have investigated the effect of the codon 72 
polymorphism of p53 on the susceptibility to E6-mediated degradation. They reported that 
individuals homozygous for p53 Arg are more susceptible to HPV-associated carcinogenesis 
of the cervix than heterozygotes (Storey, 1998). However the relationship between the p53 
polymorphism and susceptibility of HPV infection as well as cervical cancer development is 
still unclear.  
Storey et al. (1998) showed that the codon 72 arginine variant of p53 encodes a protein that is 
more sensitive to HPV16 and HPV18 degradation than the proline variant. The biological 
and biochemical differences between the two p53 genotypes at codon 72 were demonstrated 
by a study showing that the arginine form of the protein was much more susceptible to HPV 
E6 mediated degradation than the proline form (Mitra, 2005; Oliveira, 2008). Moreover, 
Thomas et al. (1999), presented evidence that, in vitro, the p53 arginine variant induces 
apoptosis with faster kinetics and suppresses transformation more efficiently than the p53 
proline variant. These observations may have implications for the development of cancer in 
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Several polymorphisms have been identified within the p53 gene, both in non-coding and 
coding regions and may represent an important contribution to cancer susceptibility and 
tumour behaviour (Costa, 2008). The common polymorphism is known at codon 72, with 
two alleles encoding either arginine (p53 Arg) or proline (p53 Pro) (Matlashewski, 1987). 
The genotype of p53 gene at codon 72 is detected by PCR with allele specific primers “ASP” 
that especially detects either the p53Pro or p53Arg allele. DNA is amplified in separate 
reactions with p53 Pro and p53 Arg primers. Example of resulting amplifications is reported 
in Figure 3. 
            M           p53 Arg/Arg              p53 Arg/Pro             p53 Pro/Pro  
 
Fig. 3. Analysis of p53 codon 72 polymorphism by PCR using allele specific primers  
Arg allele specific primers: 141 bp and Pro allele specific primers: 177 bp. M: 100 bp ladder. 
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more sensitive to HPV16 and HPV18 degradation than the proline variant. The biological 
and biochemical differences between the two p53 genotypes at codon 72 were demonstrated 
by a study showing that the arginine form of the protein was much more susceptible to HPV 
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The case-control study conducted in 113 cancerous lesions and 100 healthy women from 
Morocco highlighted the absence of any association between p53 polymorphism at codon 72 
and cervical cancer development (Meftah El Khair, 2009). However reported data on the 
prevalence of p53 polymorphism in cervical cancer patients are controversial and the ethnic 
group characteristics seem to be an important reason for discrepancies in the frequency of 
this polymorphism (Brenna, 2004; Wang, 1999; Wu, 2004; Pegoraro, 2002; Klug, 2001; Szarka, 
2000; Agorastos, 2000; Hildesheim, 1998; Bhattacharya, 2002). Moreover, other potential 
confounding factors should be also considered including the sample size, the source of DNA 
and the detection techniques used. Another important reason for these discrepant results 
could be misclassification of the p53 polymorphism, due to inter-laboratory variations in 
protocols, affecting the ability to detect p53 polymorphisms (Brenna, 2004; Govan, 2007; 
Sousa, 2007).  
4. Epigenetic alteration and cervical cancer 
Cancer is a multi-factor process. Molecular analysis of tumours reveals genetic and 
epigenetic abnormalities. Genetic mutations, which alter DNA sequence, lead to constitute 
activation of some oncogenes (as RAS and RAF genes) and inhibition of some tumour 
suppressors (as p53 gene). Epigenetic mutations (epimutations) lead often to gene silencing 
without altering the DNA sequence. Alteration in expression of key genes through aberrant 
epigenetic regulation can lead to initiation, promotion and maintenance of carcinogenesis, 
and is even implicated in the generation of drug resistance. The significance of epigenetic 
alterations is used as predictive biomarkers and as new targets of anticancer therapy. 
Genetic information may not be the only relevant source of information in order to 
understand the molecular basis of disease. Epigenetic information may hold the key to a 
better understanding of various pathological conditions (Chahwan, 2011). 
Epigenetic mechanisms are essential for normal development and maintenance of tissue-
specific gene expression patterns in mammals. These include embryonic development, 
transcription, chromatin structure, X-chromosome inactivation, genomic imprinting, and 
chromosome stability (Watanabe, 2010). Epigenetic dysregulation, which may be passed 
from one generation to the next, are believed to be implicated in the promotion of 
tumorigenesis in cancers through the downregulation of tumour repressor genes (Hidemi, 
2011). Epigenetic aberrations, often observed in tumours, include changes in DNA 
methylation and histone modifications that influence the chromatin states and impact gene 
expression patterns. Methylation of cytosine bases in DNA is the main epigenetic event and 
is involved in most cellular physiopathological processes (Watanabe, 2010).  
The CpG islands, where Cytosine and Guanine are connected by a phosphodiester bond, are 
shorts stretches of DNA in which the frequency of the CG sequence is higher than other 
regions. CpG islands are mostly located in the upstream promoter and exon 1 region of over 
half of human genes (Lo, 2008). In mammals, the methylation process is achieved by the 
DNA methyltransferase (DNMT), that catalyses the transfer of the methyl group from S-
adenosyl L-methionine (SAM) to the cytosine in 5’-CG-3’ sequence.  
In cancer, abnormal hypermethylation of gene promoter CpG islands induces 
transcriptional silencing of tumour suppressor genes (Lo, 2008) and is by far the best-
categorised epigenetic change. 
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Inactivation of tumour suppressor genes by promoter hypermethylation has been 
recognized to be at least as common as gene disruption by mutation in tumorigenesis (Jones, 
2002). 
Multiple genes are hypermethylated in primary carcinomas as well as in carcinoma cell line 
and the methylation profile has strong associations with genetic and clinicopathological 
features (Lind, 2004). 
HPV regulates the methylation status of genes involved in the cell cycle regulation, 
apoptosis, DNA repair, cell adhesion and migration, development and differentiation, 
cellular signalling and metabolism (Anita Szalmás, 2009). 
The HPV oncoprotein E7 control cellular proliferation pathways through epigenetic 
mechanisms. Recently, it has been shown that E7 bind directly to the DNMT1 and activate 
its DNA methyltransferase activity. This direct association may lead to aberrant methylation 
of the genome followed by cellular transformation as a result of tumour suppressor gene 
silencing (Burgers, 2007). E7 can induce viral replication also through epigenetic changes. E7 
inhibits HDAC (histone deacetylase) binding to the E2F promoter resulting in activation of 
expression and facilitates HPV replication (Longworth, 2005). 
HPV can epigenetically regulate cell cycle via down regulation of p16INK4A, an inhibitor of 
cyclin dependent phosphorylation and inactivation of Rb (retinoblastoma) tumour 
suppressor protein. The occurrence of p16INK4A promoter hypermethylation is very low in 
low grade of cervical cancer and it increases moderately with the severity of the 
carcinogenetic stages (Wong, 1999; Gustafson, 2004).  
Cyclin A1 (CCNA1) is involved in cell cycle regulation and in repair of DNA doublestrand 
breaks. Kitkumthorn et al. (2006) have evaluated the epigenetic status of cyclin A1 in HPV-
associated cervical cancer. The authors demonstrated that cyclin A1 methylation is common 
in cervical cancer and is specific to the invasive phenotype indicating that hypermethylation 
of promoter of cyclin A1 is a potential tumour marker for early diagnosis of invasive 
cervical cancer (Kitkumthorn, 2006). 
E-cadherin is a transmembrane glycoprotein that mediates interactions between adjacent 
epithelial cells. Hypermethylation of CpG islands in E-cadherin promoter regions is 
associated with suppressed transcriptional activity and it is particularly found in various in 
invasive cervical cancers (Kang S 2006).  
5. Study of gene promoter methylation 
For gene-specific methylation analysis, a large number of techniques have been developed. 
Most early studies used methylation sensitive restriction enzymes to digest DNA followed 
by Southern detection or PCR amplification. Recently, bisulfite reaction based methods have 
become very popular. In these techniques, analysis of DNA methylation is based on bisulfite 
treatment of genomic DNA, which converts cytosine to uracil, but methylated cytosines 
remain unaltered in this process. Several techniques have been applied to analyse bisulfite-
modified DNA, with variation in sensitivity, amount of DNA needed. However, PCR based 
techniques are the fast, simple and reliable methods to assess the methylation status of 
DNA. After PCR amplification, uracil will be converted to thymidine, which will be 
determined by direct PCR sequencing (bisulfite sequencing) or methylation specific PCR 
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adenosyl L-methionine (SAM) to the cytosine in 5’-CG-3’ sequence.  
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in cervical cancer and is specific to the invasive phenotype indicating that hypermethylation 
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DNA. After PCR amplification, uracil will be converted to thymidine, which will be 
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(MSP-PCR) (Figure 4). In bisulfite sequencing, primers are designed not to contain any 
CpGs to avoid discrimination against methylated or unmethylated DNA. In MSP-PCR, two 
pairs of primers are designed, one of which is specific for methylated DNA (M) and the 
other for unmethylated DNA (U). 
After pyrosequencing or MSP-PCR, amplified fragments are usually cloned to determine the 
degree of methylation (Herman, 1996). 
Additionally, in order to identify unknown methylation hot-spots or methylated CpG 
islands in the genome, several of genome-wide screen methods have been invented such as 
Restriction Landmark Genomic Scanning for Methylation (RLGS-M), and CpG island 
microarray. 
 
Fig. 4. Schematic representation of bisulfite based modifications 
6. p16INK4a expression in cervical cancer 
The cellular tumour suppressor protein p16 has a central function in the regulation of cell 
cycle activation. The p16INK4a, the product of CDKN2A gene is a negative regulatory protein 
that regulates the progression of eukaryotic cells through the G1 phase of the cell cycle 
(Serrano, 1997). p16INK4a is a component of p16INK4a-Cdk4-6/CyclinD-pRb signalling 
pathway and is perturbed in many cancers. In these tumours, the functions of p16INK4a may 
be lost due to mutations or suppression of its transcription by promoter methylation 
(Gonzalgo, 1998). In high risk-HPV positive cervical cancer, the oncogene E7 disrupts 
pRb/E2F interaction, releases active E2F and induces the pRb degradation (Liuet, 2006). The 
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existence of the regulatory feedback in the pRb/p16 pathway leads to an overexpression of 
p16INK4a in cervical tumours (Ivanova, 2007). Klaes el al. (2001) have shown that 
overexpression of p16INK4a is a specific marker for dysplastic and neoplastic epithelial cells 
in the cervix. They have clearly demonstrated that use of p16INK4a immunostaining allows 
precise identification of cervical lesions and significantly reduce false-negative and -positive 
interpretation in cervical cancer screening. For theses reasons, p16INK4a expression is usually 
used in cervical neoplasia diagnosis (Klaes, 2001).  
Many studies have analyzed the presence of p16INK4a in cervical neoplasia and have found a 
relationship between p16INK4a expression and cervical neoplasia; raising hope that p16INK4a 
could represent a specific and sensitive marker for cervical neoplasia (Klaes, 2001; Milde-
Langosch, 2001; Riethdorf, 2004). A representative p16INK4a immunohistochemical staining 
in epidermoid carcinoma is given in Figure 5. It is generally believed that p16INK4a functions 
as Cdk-inhibitor in the nucleus. Klaes et al. have showed that 58 of 60 invasive cervical 
carcinomas expressed p16INK4a both in nuclei and cytoplasm (Klaes, 2001). Theses findings 
were corroborated with published data from Moroccan cases. Indeed, p16INK4a staining by 
IHC in 53 cervical cancer biopsies from Morocco showed that 92.4% had high level of 
p16INK4a expression with a predominance of both nuclear and cytoplasmic staining (El 
Hamdani, 2010). 
 
(Intense Nuclear staining of p16INK4a) 
Fig. 5. Representative p16 immunohistochemical staining in epidermoid carcinoma sample 
On the other hand, Ivanova et al. (2007) have clearly demonstrated that in normal cells 
p16INK4a localizes mainly in nuclei, the loss of p16INK4a nuclear staining in favour of 
cytoplasmic staining have been observed earlier in different tumours including cervical 
carcinomas and cervical cancer cell lines. 
Loss of p16INK4a protein expression, leading to overcome cell cycle arrest at senescence and 
immortalization, could be studied by evaluating the methylation status of its promoter 
(Ivanova, 2007).  
Indeed, hypermethylation of the promoter region of a tumour suppressor gene has been 
increasingly recognized as an alternative mechanism for inactivation of function of a tumour 
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suppressor gene. In this topic, hypermethylation of the p16 gene has been suggested to be a 
shared epigenetic alteration in multiple human cancers, including cervical cancer (Esteller, 
2001).  
An example of MSP analysis of the promoter regions of p16INK4a after bisulfite treatment is 
given if Figure 6. Using MSP and/or bisulfite sequencing, hypermethylation of p16INK4a 
gene was observed in 19 to 61% of invasive cervical carcinoma (Ivanova, 2007, Nehls, 2008; 
Attaleb, 2009). However, hypermthylation of p16INK4a promoter region is absent in DNA 
specimens from normal cervical swabs as well as cervical cell lines such as SiHa, HeLa, 
C33A and Caski (Attaleb, 2009). 
Moreover, the increased risk for disease progression was independent from clinical and 
pathological factors, suggesting that p16INK4a gene promoter methylation is an early event in 
cervical cancer development.  
Moreover, in HPV induced cervical cancer, the cell cycle activation is not mediated by Cdks 
but by E7-related Rb disruption. The p16 inactivation would not confer any further growth 
promoting effect, because in this cancer the HR-HPV oncogene E7 induces a permanent release 
of E2F from its binding to pRb, leading to continuous cell cycle activation (Nehls, 2008).  
Thus, hypermethylation of p16INK4a promoter gene may be a result of genetic and epigenetic 
events produced during the carcinogenesis steps of cervical cancer development, and when 
occurs, it did not affect the regulation of p16INK4a expression. Moreover, the high p16INK4a 
immunoreactivity with partial promoter hypermethylation needs to be further investigated. 
 
Fig. 6. MSP analysis of the promoter regions of p16INK4a 
The presence of a visible PCR product in lane U indicates the presence of unmethylated 
genes; the presence of a PCR product in lane M indicates the presence of methylated genes. 
Normal lymphocytes DNA (T) was used as a negative control for methylation. Cases 1 and 3 
were methylated at p16INK4a. M: 100 bp ladder. 
7. Expression of E-cadherin in cervical cancer 
Cadherins are a family of cell–cell adhesion molecules which can modulate epithelial 
phenotype and morphogenesis in a variety of tissues. E-cadherin is the major cadherin 
expressed on the surface of normal epithelial cells and plays a pivotal role in maintenance of 
normal adhesion in epithelial cells but has also been shown to suppress tumour invasion 
and participate in cell signalling (Chen, 2003; Virmani, 2001; Ziober, 2001). Cell adhesion is 
mediated through Ca2+-dependent homotypic binding. This transmembrane glycoprotein is 
encoded by CDH1 gene.  
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Based on its biological functions, E-cadherin is regarded as an invasion and metastasis 
suppressor. Loss of E-cadherin expression or function correlates with increased invasiveness 
and metastasis in carcinomas of several anatomical sites (Chen, 2003; Virmani, 2001). E-
cadherin-mediated cell adhesion system is inactivated by multiple mechanisms. It may be 
inactivated as a result of genetic alteration, reduced gene expression, changes of other 
cadherin–catenin complexes or posttranslational modification of the protein leading to 
cytoplasmic delocalization (Widschwendter, 2004; Oki, 2007).  
The expression of E-cadherin is impaired as squamous intraepithelial lesions progress to 
squamous cervical carcinoma (Laird, 2003). In cervical cancer, the presence and localisation 
of cytoplasmic E-cadherin were significantly correlated with CIN grade. In invasive types, 
the expression of E-cadherin was significantly reduced (Hirohashi, 1998) and this is mainly 
due to gene silencing by methylation processes (Nehls, 2008).  
E-cadherin expression, as well as p16INK4a expression, is usually used in cervical neoplasia 
diagnosis. In squamous cervical epithelium, E-cadherin is predominantly found at the cell-
to-cell borders in the basal and parabasal cell layers (Laird, 2003). However, E-cadherin 
expression is reduced during tumour progression and metastasis, and associated with poor 
prognosis in a variety of cancers (Karayiannakis, 1998; Sulzer, 1998; Zheng, 1999). A 
representative E-cadherin immunohistochemical staining in epidermoid carcinoma is given 
in Figure 7. 
Reported data showed that E-cadherin is moderately expressed in about 85% of informative 
cases with a main localisation at the cell membrane and cytoplasm (El Hamdani, 2010). 
Decrease or loss of E-cadherin expression is a common feature of many human epithelial 
cancers, including cervical cancer, although a decreased expression of this molecule has 
been described in metastasis, but not primary tumours (Carico, 2001).  
 
Moderate membranous staining of E-cadherin 
Fig. 7. Representative E-cadherin immunohistochemical staining in epidermoid carcinoma 
sample 
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Moderate membranous staining of E-cadherin 
Fig. 7. Representative E-cadherin immunohistochemical staining in epidermoid carcinoma 
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It’s widely accepted that hypermethylation plays a critical role in gene silencing. Promoter 
hypermethylation has been proposed as an explanation for the decrease of E-cadherin 
expression (Chen, 2003, Graff, 2000) and was even suggested as a potential marker for 
identifying cervical cancer patients at high risk for relapse (Widschwendter, 2004). 
Thus, methylation status of E-cadherin promoter has been studied to understand the 
implication of this gene silencing in cervical cancer development. Methylatio status was 
mainly studied using MSP analysis, as shown in Figure 8. Reported data showed that less 
than 50% of cervical cancer cases exhibited E-cadherin promoter hypermethylation at their 
CpG islands (Chen, 2003, Dong, 2001; Narayan, 2003; Attaleb, 2009). Moreover, E-cadherin 
promoter was also hypermethylated in 3 cervical cell lines (HeLa, SiHa and C33A) (Attaleb, 





Fig. 8. MSP analysis of the promoter regions of p16INK4a 
The presence of a visible PCR product in lane U indicates the presence of unmethylated 
genes; the presence of a PCR product in lane M indicates the presence of methylated genes. 
Normal lymphocytes DNA (T) was used as a negative control for methylation. Case 4 was 
unmethylated at E-cadherin. M: 100 bp ladder. 
8. Epigenetic based therapy 
In tumours, epigenetic silencing of genes involved in DNA damage response pathways, 
such as cell cycle control, apoptosis signalling and DNA repair, has the potential to 
influence drug resistance and clinical outcome following therapy (Teodoridis, 2004). 
Promoter hypermethylation and histone hypoacetylation contribute to this transcriptional 
inactivation. It is possible to reverse silencing using small molecule inhibitors. Such 
compounds, that can reverse this epigenetic inactivation, show anti tumour activity and 
can increase the sensitivity of drug resistant preclinical tumour models (Teodoridis, 2004). 
Hypomethylating and hyperacetylating drugs, HDAC (histone deacetylase) and DNMT 
inhibitors, can reverse epigenetic silencing and improve the cancer therapy (Hidemi, 
2011). 
The targeting of epigenetic pathways is an attractive therapeutic strategy and current 
clinical trials aim to improve efficacy of DNA hypomethylating drugs for e.g. by 
combination with standard chemotherapy. Key components in the regulation of DNA 
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methylation are DNA methyltransferases (DNMT1, 2, 3A and 3B) and methyl CpG-binding 
proteins, which recognize methyl cytosine residues and recruit transcriptional repressor 
complexes, including histone deacetylases (HDAC). Because of the interdependence of 
epigenetic processes, combinations of these approaches may have maximum clinical efficacy 
(Ferguson, 2011). 
Epigenetic therapy leads to gene reactivation in primary tumours of cervical cancer patients. 
A number of these reactivated genes have a definitive role as tumour suppressors (De la 
Cruz-Hernández, 2011). 
Hydralazine, a demethylating agent, was administrated in different doses to cohorts of 
previously untreated patients with histological diagnosis of cervical cancer in a phase I 
study. Hydralazine at doses between 50 and 150 mg/day is well tolerated and effective to 
demethylate and reactivate the expression of tumour suppressor genes without affecting 
global DNA methylation (Zambrano, 2005). 
Valproic acid, an HDAC inhibitor, exerted a growth inhibitory effect on cervical cancer cell 
line: HeLa, SiHa and CaSki (De la Cruz-Hernandez, 2007; Chen, 2006). These drugs led to an 
increase of p53 transcription, and increase its stabilisation due to acetylation at lysines 273 
and 282, protecting it from degradation by E6 (CruzHernandez, 2007). Valproic acid impede 
Akt1 and Akt2 expression, which leads to Akt deactivation and apoptotic cell death 
mediated through the caspase dependent pathway (Chen, 2006). 
The combined antineoplastic effect of the DNA methylation inhibitor hydralazine and the 
histone deacetylase inhibitor valproic acid leads to increase in the cytotoxicity of cisplatin, 
adriamycin or gemcitabine in human cervical cancer cell lines (ChavezBlanco, 2006). 
Also, epigenetic profiling using DNA methylation and histone analysis, can provide useful 
information for translational purposes, with a special emphasis on the potential use of DNA 
methylation marks for early disease detection and prognosis (Park, 2011) and for effective 
treatment strategies (Watanabe, 2010). 
9. Conclusion 
Identification of relevant biomarkers for early and specific diagnosis as well as the 
identification of promising therapeutic targets for molecular targeted therapy is a key role to 
improve cancer management worldwide.  
In cervical cancer, even the importance of combined cytology and HPV testing, the use of 
epigenetic alterations as biomarkers will be of a great interest to enhance cervical diagnosis. 
Since alterations of the cellular epigenome usually precede morphologic changes and 
genetic alterations, identification of related aberrant DNA methylation profiles according to 
specific anatomopathologic status may serve as a reasonable early diagnostic marker for 
cervical cancer diagnosis. 
Moreover, the crucial role of epigenetic alterations at an early stage in the carcinogenesis 
may be promising targets for the prevention or treatment of cancer. Thus, understanding the 
epigenetic derepression of oncogenes, or cancer-promoting genes, would be important for 
the development of epigenetic-based therapies used in combination with other therapies for 
cervical cancer treatment. 
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1. Introduction 
The insulin-like growth factor (IGF) family is organized in a complex regulatory network at 
the cellular and sub-cellular levels. In the human the IGF system has a key physiological role 
in the development of the organism and maintenance of normal cellular function during 
foetal and postnatal life. The IGF system consists of three ligands, IGF-I, IGF-II and Insulin; 
three cell membrane receptors, IGF-I receptor (IGF-IR), insulin receptor (IR), and IGF-II 
receptor (IGF-IIR); six high-affinity IGF binding proteins, IGFBP-1 through -6, their specific 
proteases (IGFBP proteases) and membrane receptors (IGFBP-R) (Fig. 1).  
IGF-I and IGF-II share a 62% homology in amino acid sequence and there is a 40% homology 
between the IGFs and proinsulin (Furstenberger & Senn, 2002). IGF-IR is a member of the 
family of the tyrosine kinase growth factor receptors and is highly homologous at the amino 
acid sequence level to the IR. The mature membrane receptor is a tetramer made of two α-
chains and two β-chains, with several disulfide bridges (LeRoith et al., 1995). The extracellular 
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Fig. 1. The IGF system. The IGF system consists of the receptors (IR, IGF-IR, IGF-IR/IR hybrids 
and IGF-IIR), the peptides (IGF-I, IGF-II and insulin), six high affinity IGFBPs (-1 to -6), IGFBP 
proteases and IGFBP receptors (IGFBP-R).  
cellular functions related to lysosome biogenesis and the regulation of growth and 
development. The IGF-IIR receptors recycle continuosly between two cellular pools and at 
steady state most of the receptor localize in endosomes and the remainder (approx. 10%) on 
the plasma membrane. Traditionally, the IGF-IIR was considered a scavenger receptor, 
regulating the extracellular IGF-II concentrations, but recent studies suggest that the IGF-IIR 
also functions in signal transduction and may play an important role in tumour progression 
(El-Shewy et al., 2006,). 
To add more complexity to the system, the IGFs in circulation and in the tissues, are 
associated with a family of six high affinity IGF-binding proteins (IGFBPs) that regulate the 
bioavailability of the IGFs (Baxter, 2000). The IGFBPs regulate the interaction of IGFs with 
the receptors. In human about 80% of circulating IGF-I is carried by IGFBP-3/acid label 
subunit complex (Lewitt et., 1994). All IGFBPs inhibit IGF action by sequestering IGFs and 
some IGFBPs (IGFBP-1, -3, -5) can also potentiate IGF action. The resulting change in the 
ratio of IGF to IGFBP modulates IGF/IGFBP/IGF receptor interactions and may play a role 
in normal and abnormal tissue proliferation (Mohan & Baylink, 2002).  
Overexpression of growth factors and/or their receptors is a common event in malignancy 
and provides the underlying mechanism for uncontrolled proliferation, one of the hallmarks 
of cancer (Hanahan & Weinberg, 2000). The IGF signalling system network is tightly 
controlled under normal physiological conditions and alterations that disrupt the delicate 
balance of the system can trigger a number of molecular events that can lead to malignancy. 
Many studies have involved the IGF system in carcinogenesis and tumour progression of 
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different cell types (LeRoith & Roberts, 2003). Many cancers have been shown to 
overexpress the IGF-I receptor and/or the ligands (IGF-I and IGF-II) and some combinations 
of the six IGF binding proteins (IGFBPs) (Samani et al., 2007). It appears that abnormal IGF-
IR activation can result in oncogene activation leading to increased cellular proliferation and 
malignancy. Although the IGFs are not in themselves tumorigenic factors, it has been shown 
that overexpression of IGF-II, as in the case of loss of imprinting (LOI) (Pavelic et al, 2002), 
can contribute to gynaecological malignancies like ovarian cancer (Murphy et al., 2006) and 
choriocarcinoma (Diaz et al., 2007).  
Compared to other types of cancer, like breast, colon, prostate, and lung, little research has 
been done on the relationship between the IGF family and cervical neoplasias, and by now, 
much remains to be learned. In this review, we will discuss some of the studies focused on 
the role of the components of the IGF system in the progression of cervical cancer and its 
potential utility as a diagnostic biomarker.  
2. The IGF system and cervical cancer 
Cervical cancer is the third most commonly diagnosed cancer and the fourth leading cause 
of cancer death in females worldwide, accounting for 9% (529,800) of the total new cancer 
cases and 8% (275,100) of the total cancer deaths among females in 2008. More than 85% of 
these cases and deaths occur in developing countries. Worldwide, the highest incidence 
rates are in Eastern, Western and Southern Africa, as well as South-Central Asia and South 
America (Jemal et al., 2011). In Colombia, cervical cancer is one of the most common causes 
of cancer mortality among women (Ferlay, 2010).  
Persistent infection with high-risk types of HPV (HR HPV) has been identified as the main 
risk factor for the development of cervical cancer and its precursor lesions, squamous 
intraepithelial lesions (SIL) (Walboomers et al., 1999; Muñoz et al., 2003). SILs precede the 
development of cervical cancer and are classified in two groups: low-grade SIL (LSIL), and 
high-grade SIL (HSIL) (Solomon et al., 2002) (Fig. 2). Although HPV infections are among 
the most frequent sexually transmitted diseases, infections are usually self-limited and 
revert spontaneously, with only a small group of women developing cervical cancer 
(Woodman et al., 2001). The evolution of infection to LSIL, HSIL and cancer is dependent on 
several factors, many of which remain to be identified. Despite intensive investigation, the 
tumor biology of this disease is still largely unknown. Although prognostic factors such as 
pelvic lymph node metastasis affects the outcome of cervical cancer, the variability in 
progression-free and overall survival (OS) among patients with similar clinical and 
pathological characteristics, makes it difficult to predict the outcome reliably (Huang et al., 
2008). Current research strives to determine why certain HPV-positive women develop 
cervical cancer while others do not (Schaffer et al., 2007).  
2.1 Serum levels of IGFs as cervical cancer biomarkers 
IGF-I is a potent mitogenic growth factor that plays a critical role during embryogenesis and 
development in human and animal species. Together with Growth Hormone (GH) 
constitute an axis that regulate postnatal growth and development in an endocrine, 
paracrine and autocrine mode of action. IGF-I is produced by numerous adult organs, with 
major contribution of liver to overall circulating IGF-I levels. After puberty, circulating IGF-I  
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Fig. 2. Schematic representation of cervical cancer and its precursor lesions. Low-grade 
squamous intraepithelial lesions (LSIL), High-grade squamous intraepithelial lesions 
(HSIL). 
levels decline, in contrast to IGF-II levels that remain elevated throughout adult life (Bang & 
Hall, 1992).  
The proliferative and anti-apoptotic effects of IGF-I observed in animal and cell cultures, 
made it an obvious risk factor candidate in cancer development. In attempt to find a reliable 
serum biomarker to predict occurrence, progression or prognosis of human cancer, scientists 
have investigated the correlation of serum IGF-I or IGFBP-3, the most abundant IGFBP in 
circulation, to the prevalence of a variety of cancers. Prospective and retrospective studies 
have demonstrated an association between high concentrations of serum IGF-I and 
increased risk for prostate and premenopausal breast cancer (Renehan et al., 2004), whereas 
an inverse association has been reported for certain types of cancer, including gastric (Lee et 
al., 1997), endometrial (Lacey et al., 2004), liver (Stuver et al., 2000), and contradictory results 
for lung cancer (Yu et al, 1999; Mazzoccoli et al., 1999; Renehan, 2004).  
With respect to cervical cancer, results have not shown consistency. Mathur et al. found that 
serum IGF-II levels were elevated, whereas IGFBP-3 levels were decreased, across the 
cervical lesion spectrum, and proposed that this could be used as an aid for early diagnosis 
and predicting prognosis of cervical cancer (Mathur et al., 2000, 2003, 2005). Two other 
epidemiological studies (Lee et al., 2010; Wu et al., 2003) did not find an association between 
IGFBP-3 levels and risk of squamous intraepithelial lesions, but on the other hand, a strong 
significant increase in the risk of low-grade or high-grade squamous intraepithelial lesions 
was observed for women with IGF-I serum levels in the highest versus the lowest quartiles.  
We conducted a case-control study on Colombian women with SIL and cervical cancer, and 
our findings illustrated an inverse association between cervical cancer risk and IGF-I 
circulating levels. In accordance to this result, IGF-I/IGFBP-3 molar ratio was also inversely 
associated with cervical carcinoma (Serrano et al., 2006). Similar results were obtained in a 
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study conducted in patients with diagnosed pre-cancer lesions where levels of IGF-I were 
inversely associated with risk of high-grade cervical intraepithelial neoplasia (Schaffer et al, 
2007).  
A recent prospective study reported a possible influence of the IGF axis on the natural 
history of oncogenic HPV and the development of cervical neoplasia (Harris et al., 2008). A 
high IGF-I/IGFBP-3 ratio was associated with increased persistence of oncogenic HPV 
infection [adjusted hazard ratio (AHR), 0.14; 95% confidence interval (95% CI), 0.04-0.57], 
whereas IGFBP-3 was inversely associated with both the incident detection of oncogenic 
HPV (AHR, 0.35; 95%CI, 0.13-0.93) and the incidence of oncogenic HPV positive cervical 
neoplasia (that is, squamous intraepithelial lesions at risk of progression; AHR, 0.07; 95% CI, 
0.01-0.66). We conducted a case-control study with in a prospective populational-based 
cohort of 2200 women, followed-up during 10 years. Results adjusted by age, menarche, 
smoking, parity and hormonal contraceptives, showed that high IGF-I serum levels were 
associated with persistence (lower vs. higher quartile: RR 2.60 95% CI 0.61–10.94) and 
prevalent (lower vs. higher quartile: RR 2.67, 95% CI 0.37–19.09) HPV infection, however, no 
significance was achieved, and no association can be demonstrated (Serrano et al., 2010b).  
A recent nested case-control study (151 cervical cancer cases, 443 controls), found an inverse 
correlation between IGFBP-3 serum levels in pregnant women and risk of cervical cancer 
[OR 0.43 (95% CI 0.21-0.86)], suggesting that IGFBP-3 measured in pregnancy may be a 
marker of lower risk of cervical cancer (Jeffreys et al., 2011). In early-stage cervical cancer 
patients, lower IGF-I levels seemed to be associated with worse overall survival rate, but 
was not of an independent value, and there was no relationship between IGFBP-3 levels and 
survival (Huang et al., 2008).  
It is unclear why increased serum IGF-I levels may have a protective effect on development 
of cervical cancer, whereas in breast and prostate cancer it has the opposite effect. One of the 
theories is that the natural history to cervical cancer, where infection with HPV plays a 
crucial role, differs from sex hormone-related cancers (Schaffer et al., 2007). Larger 
prospective investigations are indicated to better clarify these associations, including any 
potential HPV type-specific differences in the effects of IGFs.  
2.2 Aberrant expression of IGFs in cancer 
Several lines of evidence support an important role for the IGF system in tumor tissue. IGF-
IR activation is involved in several processes associated to oncogenic transformation, such 
as proliferation, migration and invasion (Coppola et al, 1994; Pavelic et al., 2002; Samani et 
al., 2007; Sell et al., 1994). IGF-I expression rarely occurs in tumoral cells, but can be 
produced by stromal cells surrounding the tumor. IGF-II, IGF-IR and certain IGFBPs are 
overexpressed in many primary tumors and cancer cell lines (Cullen et al., 1990; Hellawell et 
al., 2002; Werner & LeRoith, 1996). IGFBP-3 generally has, with some exceptions, a rather 
inhibiting effect on IGF action in tumor tissues (LeRoith & Roberts, 2003). 
Increased expression of IGF-I, IGF-II, IGF-IR, or combinations thereof have been 
documented in various malignancies including glioblastomas, neuroblastomas, 
meningiomas, medulloblastomas, carcinomas of the breast, malignancies of the 
gastrointestinal tract, such as colorectal and pancreatic carcinomas, and ovarian cancer 
(Samani et al., 2007). These data show that whereas a correlation between IGF-I/ IGF-II 
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expression levels and tumor progression could be consistently documented in some 
malignancies (e.g., colorectal, hepatocellular, and pancreatic carcinomas), no consistent 
correlation was seen in others (e.g., breast cancer). Moreover, in some cases, conflicting 
results were obtained in different studies that analyzed the same types of cancers (e.g., 
gliomas) (Samani et al., 2007). Overexpression of IGF-II has been reported in several 
malignancies. A study identified the loss of imprinting (LOI) of the gene, frequently 
observed in the colonic mucosa of colorectal carcinoma patients, as a risk factor for 
developing colorectal carcinoma (Cui et al., 2003). Overexpression of IGF-II and IGF-IR, was 
observed in gestational trophoblastic neoplasias, including hydatidiform moles and 
choriocarcinoma, correlating with the elevated IGF-II levels in the circulation (Díaz et al., 
2007), Taken as a whole, these studies suggest that the IGFs can play a paracrine and/or 
autocrine role in promoting tumor growth. 
IGF-IR may also form hybrid receptors with one α- and β- subunit from the IR. There are 
two IR isoforms formed by alternative splicing of exon 11, IR-A which lacks exon 11 and IR-
B which contains exon 11. IGF-I and IGF-II, bind to hybrid receptors IGF-IR/IR-A leading to 
mitogenic signaling. IGF-II and insulin bind to IR-A leading also to mitogenic signaling, 
whereas, activation of IR-B by insulin, or the hybrid IGF-IR/IR-B by IGF-I, results mostly in 
metabolic signaling. After in vitro and in vivo studies demonstrating that insulin may also 
play a significant and independent role in tumorigenesis, insulin is now receiving more 
attention in this regard (Gallagher & LeRoith, 2011).  
In the past few decades, accumulating evidence has established that insulin receptors (IRs) 
are usually abnormally expressed in cancer cells, where they mediate both the metabolic 
and nonmetabolic effects of insulin. Most recently, it was observed that splicing of the IR 
gene is altered in cancer cells, thus increasing IR-A/IR-B ratio, which affects the cell 
response to circulating IGFs and insulin (Belfiore et al., 2009). As it was mentioned earlier, 
many tumors overexpress IGF-II, which also signals through the IR-A isoform. An 
important role of the IGF-II/IR-A loop has been observed in gestational trophoblastic 
diseases. Both IGF-I and IGF-II stimulated JEG-3 choriocarcinoma cell invasion, although 
they signal through different receptors: IGF-I through IGF-IR, and IGF-II through IR-A. In 
JEG-3 cells, which predominantly express IR-A, IGF-II stimulated cell invasion more 
potently than insulin (Diaz et al., 2007). The effects of IGF-II may also be mediated by the 
IGF-IIR, as reported in trophoblast cells (MacKinnon et al., 2001), giving more relevance to 
the role of this receptor in signaling and tumorigenesis. 
2.2.1 Tissue expression of IGFs as risk or prognosis biomarkers in cervical cancer 
In a recent study the expression levels and activated status of IGF-IR were measured by 
immunohistochemistry in formalin-fixed and paraffin-embedded specimens. IGF-IR levels 
and phosphorylation status were significantly high in cervical intraepithelial neoplasia (CIN 
III) and invasive cancer specimens (Kuramoto et al., 2008). An interesting retrospective 
analysis of patients with early-stage cervical cancer evaluated IGF-IR expression levels by 
immunoflorescent stain. Authors found that high-grade expression of IGF-IR, is an 
independent predictor of cervical cancer death and recurrence, and when combined with 
elevated squamous cervical cancer antigen (SCC Ag) serum level, could further help 
identify the subgroup of patients at higher death risk. Colocalisation of IGF-I and IGF-IR in 
the cancerous tissues, and the lack of correlation between circulating IGF-I or IGFBP-3, and 
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IGF-IR overexpression in cervical cancer tissue, give support to a paracrine or autocrine 
function of the IGF system in early-stage cervical cancer, with the corresponding adverse 
IGF-I stimulation of IGF-IR signaling (Huang et al., 2008).  
Only few studies have addressed the analysis of gene expression on exfoliated cells. The 
remaining cellular material after preparation of routine Pap smear can be used for the search 
of new biomarkers at both the mRNA and protein levels. The use of cervical scrapes instead 
of biopsies for biomarker studies has several advantages, since this is a noninvasive 
procedure, the material obtained is not affected by stroma or other contaminants, as is the 
case in the analysis of tissue homogenates and can be the base for molecular epidemiology 
studies.  
In a study on cervical scrapes from SIL and cancer patients, we found no difference in IGF-II 
mRNA levels between cancer and normal cells, whereas at the protein level, IGF-II 
expression was reduced in cancer cervical scrapes (Serrano et al., 2007, 2010a). There is 
ample evidence that the levels of IGF-II mRNA differ from the protein. While IGF-II 
transcripts were higher than in normal tissue in prostate cancer (Tennant et al., 1996), Wilms 
tumors (Haselbacher et al., 1987), and glioblastomas and astrocytomas (Hultberg et al., 
1993), it was not the case for the protein. High levels of IGF-II protein, but not mRNA were 
found in pheocromocytomas (Haselbacher et al., 1987). These evidences indicate that 
regulation of IGF-II expression involves transcriptional mechanisms, as genomic imprinting, 
but also post-transcriptional regulation, that can occur through malignant progression. A 
member of the IGF-II mRNA binding protein family (IMP), IMP-3, has been reported to be 
an activator of IGF-II mRNA translation and therefore may play a critical role in IGF-II-
dependent cellular proliferation (Liao et al., 2005). IMPs were detected in various cancers; 
increased levels were found in ovarian cancer and correlated with prognosis. There are no 
studies about IMP in cervical cancer. 
Few studies have examined the expression of hybrid receptors in cervical cancer cells. In a 
recent study, we found that IR-A, IR-B and hybrid receptors coexist with IGF-IR in human 
papillomavirus-positive cervical cancer cells. Tyrosine phosphorylation of the receptors and 
activation of the MAPK and PI3-K pathways were observed upon ligand binding, which 
may explain the anti-apoptotic effect mediated by IGF-I in these cells (Serrano et al., 2008). 
Further studies are required to fully understand the significance of the hybrid receptors, 
especially IGF-IR/HR-A in cervical carcinogenesis and for the design of therapies to target 
their effects.  
2.2.2 The role of IGF in radioresistance in cervical cancer 
The crucial role of IGF-IR in promoting resistance to cancer treatments, such as radiation 
and chemotherapy, is well documented for several cancer types (Samani, et al., 2007). IGF-IR 
down-regulation by antisense nucleotides or its inhibition by tyrosine kinase inhibitors 
increases cancer cell sensitivity to both radiation and chemotherapy in a variety of 
malignancies. Some studies indicate an important role of IGF-IR in several pathways 
involved in the induction of radioresistance (Belfiore et al., 2009).  
The identification of the mechanisms underlying the effects of IGF-II/IGF-IR signaling in 
the induction of resistance to oxidative stress in cancer cells may provide useful information 
for the selection of the appropriate treatment strategy. In a study with advanced cervical 
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expression levels and tumor progression could be consistently documented in some 
malignancies (e.g., colorectal, hepatocellular, and pancreatic carcinomas), no consistent 
correlation was seen in others (e.g., breast cancer). Moreover, in some cases, conflicting 
results were obtained in different studies that analyzed the same types of cancers (e.g., 
gliomas) (Samani et al., 2007). Overexpression of IGF-II has been reported in several 
malignancies. A study identified the loss of imprinting (LOI) of the gene, frequently 
observed in the colonic mucosa of colorectal carcinoma patients, as a risk factor for 
developing colorectal carcinoma (Cui et al., 2003). Overexpression of IGF-II and IGF-IR, was 
observed in gestational trophoblastic neoplasias, including hydatidiform moles and 
choriocarcinoma, correlating with the elevated IGF-II levels in the circulation (Díaz et al., 
2007), Taken as a whole, these studies suggest that the IGFs can play a paracrine and/or 
autocrine role in promoting tumor growth. 
IGF-IR may also form hybrid receptors with one α- and β- subunit from the IR. There are 
two IR isoforms formed by alternative splicing of exon 11, IR-A which lacks exon 11 and IR-
B which contains exon 11. IGF-I and IGF-II, bind to hybrid receptors IGF-IR/IR-A leading to 
mitogenic signaling. IGF-II and insulin bind to IR-A leading also to mitogenic signaling, 
whereas, activation of IR-B by insulin, or the hybrid IGF-IR/IR-B by IGF-I, results mostly in 
metabolic signaling. After in vitro and in vivo studies demonstrating that insulin may also 
play a significant and independent role in tumorigenesis, insulin is now receiving more 
attention in this regard (Gallagher & LeRoith, 2011).  
In the past few decades, accumulating evidence has established that insulin receptors (IRs) 
are usually abnormally expressed in cancer cells, where they mediate both the metabolic 
and nonmetabolic effects of insulin. Most recently, it was observed that splicing of the IR 
gene is altered in cancer cells, thus increasing IR-A/IR-B ratio, which affects the cell 
response to circulating IGFs and insulin (Belfiore et al., 2009). As it was mentioned earlier, 
many tumors overexpress IGF-II, which also signals through the IR-A isoform. An 
important role of the IGF-II/IR-A loop has been observed in gestational trophoblastic 
diseases. Both IGF-I and IGF-II stimulated JEG-3 choriocarcinoma cell invasion, although 
they signal through different receptors: IGF-I through IGF-IR, and IGF-II through IR-A. In 
JEG-3 cells, which predominantly express IR-A, IGF-II stimulated cell invasion more 
potently than insulin (Diaz et al., 2007). The effects of IGF-II may also be mediated by the 
IGF-IIR, as reported in trophoblast cells (MacKinnon et al., 2001), giving more relevance to 
the role of this receptor in signaling and tumorigenesis. 
2.2.1 Tissue expression of IGFs as risk or prognosis biomarkers in cervical cancer 
In a recent study the expression levels and activated status of IGF-IR were measured by 
immunohistochemistry in formalin-fixed and paraffin-embedded specimens. IGF-IR levels 
and phosphorylation status were significantly high in cervical intraepithelial neoplasia (CIN 
III) and invasive cancer specimens (Kuramoto et al., 2008). An interesting retrospective 
analysis of patients with early-stage cervical cancer evaluated IGF-IR expression levels by 
immunoflorescent stain. Authors found that high-grade expression of IGF-IR, is an 
independent predictor of cervical cancer death and recurrence, and when combined with 
elevated squamous cervical cancer antigen (SCC Ag) serum level, could further help 
identify the subgroup of patients at higher death risk. Colocalisation of IGF-I and IGF-IR in 
the cancerous tissues, and the lack of correlation between circulating IGF-I or IGFBP-3, and 
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IGF-IR overexpression in cervical cancer tissue, give support to a paracrine or autocrine 
function of the IGF system in early-stage cervical cancer, with the corresponding adverse 
IGF-I stimulation of IGF-IR signaling (Huang et al., 2008).  
Only few studies have addressed the analysis of gene expression on exfoliated cells. The 
remaining cellular material after preparation of routine Pap smear can be used for the search 
of new biomarkers at both the mRNA and protein levels. The use of cervical scrapes instead 
of biopsies for biomarker studies has several advantages, since this is a noninvasive 
procedure, the material obtained is not affected by stroma or other contaminants, as is the 
case in the analysis of tissue homogenates and can be the base for molecular epidemiology 
studies.  
In a study on cervical scrapes from SIL and cancer patients, we found no difference in IGF-II 
mRNA levels between cancer and normal cells, whereas at the protein level, IGF-II 
expression was reduced in cancer cervical scrapes (Serrano et al., 2007, 2010a). There is 
ample evidence that the levels of IGF-II mRNA differ from the protein. While IGF-II 
transcripts were higher than in normal tissue in prostate cancer (Tennant et al., 1996), Wilms 
tumors (Haselbacher et al., 1987), and glioblastomas and astrocytomas (Hultberg et al., 
1993), it was not the case for the protein. High levels of IGF-II protein, but not mRNA were 
found in pheocromocytomas (Haselbacher et al., 1987). These evidences indicate that 
regulation of IGF-II expression involves transcriptional mechanisms, as genomic imprinting, 
but also post-transcriptional regulation, that can occur through malignant progression. A 
member of the IGF-II mRNA binding protein family (IMP), IMP-3, has been reported to be 
an activator of IGF-II mRNA translation and therefore may play a critical role in IGF-II-
dependent cellular proliferation (Liao et al., 2005). IMPs were detected in various cancers; 
increased levels were found in ovarian cancer and correlated with prognosis. There are no 
studies about IMP in cervical cancer. 
Few studies have examined the expression of hybrid receptors in cervical cancer cells. In a 
recent study, we found that IR-A, IR-B and hybrid receptors coexist with IGF-IR in human 
papillomavirus-positive cervical cancer cells. Tyrosine phosphorylation of the receptors and 
activation of the MAPK and PI3-K pathways were observed upon ligand binding, which 
may explain the anti-apoptotic effect mediated by IGF-I in these cells (Serrano et al., 2008). 
Further studies are required to fully understand the significance of the hybrid receptors, 
especially IGF-IR/HR-A in cervical carcinogenesis and for the design of therapies to target 
their effects.  
2.2.2 The role of IGF in radioresistance in cervical cancer 
The crucial role of IGF-IR in promoting resistance to cancer treatments, such as radiation 
and chemotherapy, is well documented for several cancer types (Samani, et al., 2007). IGF-IR 
down-regulation by antisense nucleotides or its inhibition by tyrosine kinase inhibitors 
increases cancer cell sensitivity to both radiation and chemotherapy in a variety of 
malignancies. Some studies indicate an important role of IGF-IR in several pathways 
involved in the induction of radioresistance (Belfiore et al., 2009).  
The identification of the mechanisms underlying the effects of IGF-II/IGF-IR signaling in 
the induction of resistance to oxidative stress in cancer cells may provide useful information 
for the selection of the appropriate treatment strategy. In a study with advanced cervical 
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cancer patients (CIN I-III), we found that tumor tissues co-expressing IGF-IR and IGF-II, 
showed an increase (4.6-fold) in the risk of developing resistance to radiotherapy. The 
increased expression of the glycolitic enzyme glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH) in these cancer tissues, demonstrated the metabolic shift to glycolisis under 
hypoxic conditions (Moreno-Acosta et al., 2010). Therefore, targeting IGF-II/IGF-IR 
signaling may be a desirable option in the treatment of tumors overexpressing the IGF-IR.  
3. Biomarkers for cervical cancer 
Biomarkers used for screening in cancer, usually consist of biomolecules that are released 
from tumors or precancerous lesions into the bloodstream, urine, or other means, they 
should have the property to survive the metabolic degradation to be measurable (Ahlquist, 
2010). Molecular changes that occur in the development of tumors may take several years; 
some biomarkers can be used to detect early stage disease. However, biomarkers are usually 
found at relatively low level compared to other biomolecules; research and validation as 
possible diagnostic tests depend critically on the ability to achieve measurements with high 
precision and sensitivity.  
Several biologic markers or indexes have been studied as potential tools to determine the 
prognosis and biological behaviour of various types of gynaecological neoplasias. From 
years the search of cervical cancer biomarkers has been fed through different techniques, 
such as immunohistochemistry (IHC), probably the most affordable and simple technology 
to detect many such biomarkers (McCluggage, 2002; Munoz et al., 2003). This fact prompted 
investigators to develop and test antibodies in a widespread range of neoplasic lesions. In 
this approach, some researchers found a two component system, denominated MaTu, 
consisting of an exogenous transmissible MX agent (coding for p58X protein) and an 
endogenous MN (coding for MN-protein) in HeLa cells (Závada et al., 1993). The association 
between MN protein (MN-p) expression and oncogenesis was suggested by its presence in 
neoplasms, and not in benign tissue (Brewer et al., 1996; Liao et al., 1994). Because HeLa is a 
cultured human uterine cervix carcinoma cell line, these authors concluded that MN-p had 
great use as a tumour marker in the evaluation of cervical carcinoma and could predict 
progression in precursor cervical intraepithelial neoplasic (CIN) lesions. Nonetheless, its 
utility was questioned as MN-p inmunostaining was not limited to neoplastic tissue, but 
found in adjacent basal cell hyperplasia, metaplasias and benign glandular epithelium (Liao 
et al., 1994; Resnick et al., 1996).  
Ki67, a nuclear proliferation associated antigen is expressed in the growth and synthesis 
phases of the cell cycle (G1, S, G2, and mitosis) but not in the resting phase, G0. The 
proportion of cells which express Ki67 (Ki67 index) is an excellent measure of neoplasm 
proliferation. Production of specific antibodies against recombinant DNA Ki67 antigen 
(MIB-1) confirmed the definite use of MIB-I immunoreactivity, exhibiting close correlation 
with CIN grade and providing additional risk prediction beyond HPV type (Resnick et al., 
1996). In low-grade CIN, anti-MIB-1 staining is not detected in superficial levels of 
epithelium, whereas in high-grade CIN full thickness staining is present. The authors´ 
hypothesis was that viral gene expression undergoes programmed cessation in superficial 
layers of low-grade CIN; therefore viral E6/E7 protein is no longer present to inhibit p53 
and the cells stop cycling (so Ki67 detection through anti-MIB-1 disappears). In high-grade 
CIN, viral expression of E6/E7 proceeds unabated often in absence of vegetative viral 
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functions leading to inhibition of p53 and uninhibited cell cycling (so Ki67 detection through 
anti-MIB-1 continues). In contrast with MN-p expression, anti-MIB-1 shows consistent 
results by most investigators and exhibits definitive, important associations with clinical 
outcome and basic carcinogenesis hypotheses in the uterine cervix (Costa, 1996). 
For several years, it has been known that high vascularity is characteristic of grade 3 CIN 
and invasive lesions, and angiogenesis has been associated as indicator of prognosis. The 
onset of angiogenesis in human cervical cancer occurring during the premalignant 
dysplastic stage is unique. An association between lymphatic high microvessel density with 
vascular invasion and a lower global survival rate has been described. There is a study 
demonstrating that microvessel density in carcinomas of the uterine cervix is a factor 
associated with poor prognosis (Tjalma et al., 1999). The authors showed that during the 
progression from noninvasive to microinvasive cervical carcinoma, the microvessel density 
increases significantly. However, the vessel density does not predict recurrence of 
noninvasive lesions. Once the tumour cells have passed the basal membrane, the tumour 
apparently switches to an angiogenic phenotype. Angiogenesis becomes a tumour initiator 
with prognostic potential (Tjalma et al., 1999). Measures of factor VIII, CD31, and vimentin, 
showed no association between microvessel count and lymph node invasion, depth of 
invasion, and histological differentiation. Nevertheless, these studies found an association 
between lymphatic vessel invasion and a larger number of newly formed vessels (Di Leo et 
al., 1998).  
Other studies have proposed anti-CD34 as a marker for evaluating angiogenesis in cervical 
cancer (Vieira et al., 2004, 2005). Anti-CD34 antibody is a highly sensitive marker for 
endothelial cell differentiation and has also been studied as a marker for vascular tumours 
(Stross et al., 1989; Traweek et al., 1991). Vieira et al. (Vieira et al., 2005) showed that this 
antibody was able to detect a number of microvessels on neoplasm of the uterine cervix 
better than anti-factor VIII. They suggested that anti-CD34 antibody reactivity in cervical 
carcinoma is associated with pathoanatomical features, as microvessel density or invasion, 
indicative of poorer prognosis and greater risk of recurrence (Vieira et al., 2005). Briefly, 
they showed lymphatic invasion in 40% of the cases, while vascular and perineural invasion 
was observed in 24% and 19% of the cases, in a population of 62 patients diagnosed with 
invasive cervical carcinoma, stages Ib and IIa. They also observed that 55% of women whose 
carcinoma presented high microvessel density had an undifferentiated type of cancer, 
suggesting that the presence of lymphatic invasion may associate with higher microvessel 
density. In general, different markers for angiogenesis may or may not present a statistically 
significant association with different pathoanatomic features of cervical cancer. These 
possible markers should be tested prospectively as a prognostic and predictive factor of the 
response to different therapies used in cervical carcinoma.  
On the other hand, a recent study explored the power of serum markers such as squamous 
cell carcinoma antigen (SCC), CYFRA 21-1, CA 125, immunosuppressive acidic protein 
(IAP) and vascular endothelial growth factor (VEGF) in patients with cervical cancer 
(Gadducci et al., 2008). Squamous cell carcinoma antigen comprises two similar proteins, 
SCC-1 and SCC-2, that posses protease inhibitory property: SCC-1 inhibits chymotrypsin 
and cathepsin L, while SCC-2 inhibits cathepsin G and mast cell chymase. Both proteins 
exert anti-apoptotic effects. The mechanism of protection of tumour cells from apoptosis 
involves the inhibition of caspase-3 activity and/or upstream proteases. SCC-1 and SCC-2 
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cancer patients (CIN I-III), we found that tumor tissues co-expressing IGF-IR and IGF-II, 
showed an increase (4.6-fold) in the risk of developing resistance to radiotherapy. The 
increased expression of the glycolitic enzyme glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH) in these cancer tissues, demonstrated the metabolic shift to glycolisis under 
hypoxic conditions (Moreno-Acosta et al., 2010). Therefore, targeting IGF-II/IGF-IR 
signaling may be a desirable option in the treatment of tumors overexpressing the IGF-IR.  
3. Biomarkers for cervical cancer 
Biomarkers used for screening in cancer, usually consist of biomolecules that are released 
from tumors or precancerous lesions into the bloodstream, urine, or other means, they 
should have the property to survive the metabolic degradation to be measurable (Ahlquist, 
2010). Molecular changes that occur in the development of tumors may take several years; 
some biomarkers can be used to detect early stage disease. However, biomarkers are usually 
found at relatively low level compared to other biomolecules; research and validation as 
possible diagnostic tests depend critically on the ability to achieve measurements with high 
precision and sensitivity.  
Several biologic markers or indexes have been studied as potential tools to determine the 
prognosis and biological behaviour of various types of gynaecological neoplasias. From 
years the search of cervical cancer biomarkers has been fed through different techniques, 
such as immunohistochemistry (IHC), probably the most affordable and simple technology 
to detect many such biomarkers (McCluggage, 2002; Munoz et al., 2003). This fact prompted 
investigators to develop and test antibodies in a widespread range of neoplasic lesions. In 
this approach, some researchers found a two component system, denominated MaTu, 
consisting of an exogenous transmissible MX agent (coding for p58X protein) and an 
endogenous MN (coding for MN-protein) in HeLa cells (Závada et al., 1993). The association 
between MN protein (MN-p) expression and oncogenesis was suggested by its presence in 
neoplasms, and not in benign tissue (Brewer et al., 1996; Liao et al., 1994). Because HeLa is a 
cultured human uterine cervix carcinoma cell line, these authors concluded that MN-p had 
great use as a tumour marker in the evaluation of cervical carcinoma and could predict 
progression in precursor cervical intraepithelial neoplasic (CIN) lesions. Nonetheless, its 
utility was questioned as MN-p inmunostaining was not limited to neoplastic tissue, but 
found in adjacent basal cell hyperplasia, metaplasias and benign glandular epithelium (Liao 
et al., 1994; Resnick et al., 1996).  
Ki67, a nuclear proliferation associated antigen is expressed in the growth and synthesis 
phases of the cell cycle (G1, S, G2, and mitosis) but not in the resting phase, G0. The 
proportion of cells which express Ki67 (Ki67 index) is an excellent measure of neoplasm 
proliferation. Production of specific antibodies against recombinant DNA Ki67 antigen 
(MIB-1) confirmed the definite use of MIB-I immunoreactivity, exhibiting close correlation 
with CIN grade and providing additional risk prediction beyond HPV type (Resnick et al., 
1996). In low-grade CIN, anti-MIB-1 staining is not detected in superficial levels of 
epithelium, whereas in high-grade CIN full thickness staining is present. The authors´ 
hypothesis was that viral gene expression undergoes programmed cessation in superficial 
layers of low-grade CIN; therefore viral E6/E7 protein is no longer present to inhibit p53 
and the cells stop cycling (so Ki67 detection through anti-MIB-1 disappears). In high-grade 
CIN, viral expression of E6/E7 proceeds unabated often in absence of vegetative viral 
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functions leading to inhibition of p53 and uninhibited cell cycling (so Ki67 detection through 
anti-MIB-1 continues). In contrast with MN-p expression, anti-MIB-1 shows consistent 
results by most investigators and exhibits definitive, important associations with clinical 
outcome and basic carcinogenesis hypotheses in the uterine cervix (Costa, 1996). 
For several years, it has been known that high vascularity is characteristic of grade 3 CIN 
and invasive lesions, and angiogenesis has been associated as indicator of prognosis. The 
onset of angiogenesis in human cervical cancer occurring during the premalignant 
dysplastic stage is unique. An association between lymphatic high microvessel density with 
vascular invasion and a lower global survival rate has been described. There is a study 
demonstrating that microvessel density in carcinomas of the uterine cervix is a factor 
associated with poor prognosis (Tjalma et al., 1999). The authors showed that during the 
progression from noninvasive to microinvasive cervical carcinoma, the microvessel density 
increases significantly. However, the vessel density does not predict recurrence of 
noninvasive lesions. Once the tumour cells have passed the basal membrane, the tumour 
apparently switches to an angiogenic phenotype. Angiogenesis becomes a tumour initiator 
with prognostic potential (Tjalma et al., 1999). Measures of factor VIII, CD31, and vimentin, 
showed no association between microvessel count and lymph node invasion, depth of 
invasion, and histological differentiation. Nevertheless, these studies found an association 
between lymphatic vessel invasion and a larger number of newly formed vessels (Di Leo et 
al., 1998).  
Other studies have proposed anti-CD34 as a marker for evaluating angiogenesis in cervical 
cancer (Vieira et al., 2004, 2005). Anti-CD34 antibody is a highly sensitive marker for 
endothelial cell differentiation and has also been studied as a marker for vascular tumours 
(Stross et al., 1989; Traweek et al., 1991). Vieira et al. (Vieira et al., 2005) showed that this 
antibody was able to detect a number of microvessels on neoplasm of the uterine cervix 
better than anti-factor VIII. They suggested that anti-CD34 antibody reactivity in cervical 
carcinoma is associated with pathoanatomical features, as microvessel density or invasion, 
indicative of poorer prognosis and greater risk of recurrence (Vieira et al., 2005). Briefly, 
they showed lymphatic invasion in 40% of the cases, while vascular and perineural invasion 
was observed in 24% and 19% of the cases, in a population of 62 patients diagnosed with 
invasive cervical carcinoma, stages Ib and IIa. They also observed that 55% of women whose 
carcinoma presented high microvessel density had an undifferentiated type of cancer, 
suggesting that the presence of lymphatic invasion may associate with higher microvessel 
density. In general, different markers for angiogenesis may or may not present a statistically 
significant association with different pathoanatomic features of cervical cancer. These 
possible markers should be tested prospectively as a prognostic and predictive factor of the 
response to different therapies used in cervical carcinoma.  
On the other hand, a recent study explored the power of serum markers such as squamous 
cell carcinoma antigen (SCC), CYFRA 21-1, CA 125, immunosuppressive acidic protein 
(IAP) and vascular endothelial growth factor (VEGF) in patients with cervical cancer 
(Gadducci et al., 2008). Squamous cell carcinoma antigen comprises two similar proteins, 
SCC-1 and SCC-2, that posses protease inhibitory property: SCC-1 inhibits chymotrypsin 
and cathepsin L, while SCC-2 inhibits cathepsin G and mast cell chymase. Both proteins 
exert anti-apoptotic effects. The mechanism of protection of tumour cells from apoptosis 
involves the inhibition of caspase-3 activity and/or upstream proteases. SCC-1 and SCC-2 
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reside in the citosol of squamous cells, and their presence in the sera of patients with 
advanced squamous cell carcinomas is mainly due to a passive release rather than an active 
secretory process into the circulation. Increased SCC levels have been observed in 28-88% of 
patients with squamous cell cervical cancer. Pre-treatment SCC levels reflect tumour stage 
and size, cervical stoma invasion, lymph-vascular space status, parametrial involvement 
and lymph node status; however, its clinical relevance is still debated. 
CA 125, an antigenic determinant of a high molecular weight glycoprotein, is recognized by 
a monoclonal antibody developed against a human ovarian cancer cell line. Elevated CA 125 
levels are detectable in 20-75% of patients with cervical adenocarcinoma and have been 
associated with advanced tumour stage, large tumour size, high histological grade, lymph 
node involvement and status. CA 125 is detected in normal adult fallopian tube, 
endometrium, endocervix and peritoneum, and in vitro studies showed that CA 125 
secretion by human mesothelial cell monolayers may be enhanced by the inflammatory 
cytokines interleukin-1 and tumour necrosis factor. However, the specificity of the antigen is 
not yet optimal, since elevated serum CA 125 can be found in benign gynaecological 
conditions, such as endometriosis and pelvic inflammatory disease, benign non-
gynaecological conditions, such as hepatitis, pancreatitis, renal failure and pleural effusion 
and non-gynaecological malignancies, including lung cancer, pancreatic cancer and non-
Hodgkin’s lymphoma. 
Serum levels of vascular endothelial factor (VEGF) are often elevated in patients with 
cervical cancer, and decrease significantly after successful treatment. However, the clinical 
relevance of serum VEGF is still investigational (Gadducci et al., 2008). 
New predictive biomarkers for cervical cancer are still necessary to improve the accuracy of 
screening and thereby reduce overtreatment and possibly improve cost-effectiveness of the 
treatment. Advances in molecular biology and high throughput technologies have heralded 
a new era in identification of biomarkers and molecular targets related to carcinogenesis to 
improve our understanding of the disease and will facilitate screening, early detection, 
management, and individualized targeted therapy. 
3.1 Proteomic studies 
Proteomics has emerged as a promising tool for unravelling protein signatures that are 
associated with a particular malignancy that can be useful biomarkers of the disease. High-
throughput technologies like surface-enhanced laser desorption and ionization-time of flight 
mass spectrometry (SELDI-TOF MS), nanoHPLC-MS/MS or the combination of one- or two-
dimensional gel electrophoresis (1-DE, 2-DE) methods with multidimensional 
chromatographic separation and MS provide a snapshot of the proteome. Validated protein 
biomarkers could be useful in early detection of disease, monitoring disease progression or 
monitoring response to treatment.  
3.1.1 Proteomic studies on body fluids 
After exploring markers in tissue, several studies have focused on biomarker discovery in 
body fluids which would be advantageous for eventual clinical implementation. Cervical 
mucous or cervical vaginal fluid (CVF) is potentially an ideal sample to screen for 
biomarkers for early detection of cervical cancer. As cervical mucous is produced in the 
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microenvironment where cervical neoplasia arises, it is likely to include proteins produced 
by the lesion as well as by the host in response to the lesion. Several studies have analyzed 
peptides and proteins present in human cervical mucous (Dasari et al., 2007; Pereira et al., 
2007; Tang et al., 2007). A recent study identified 151 new proteins that included proteins 
present in the lower female genital tract, such as HBD-2 and cathelicidin, two proteins that 
play an important role in the innate immunity of the cervicovagina (Zegels et al., 2009). 
Another recent study on cervical mucous proteome indicated that plasma proteins were 
abundant in cervical mucous (Panicker et al., 2010). The majority of proteins identified were 
categorized under metabolism and immune-response functional groups.  
In contrast to plasma samples, some authors discuss the advantages of cervical mucous as a 
potential source of concentrated biomarkers due to lesser dilution of the sample in CVF-
vaginal washings (volume ±50 mL) in comparison to plasma volume (±3 L) (Good et al., 
2007). In addition, altered biomarker expression patterns in plasma are often not very 
specific, as they may be associated with different pathologies, because plasma comes in 
contact with all organs of the body. In contrast, when using CVF samples, it is expected that 
expression patterns will directly correlate with gynaecological pathologies (Zegels et al., 
2009). However, it should be taken into account that CVF is a body fluid that can be highly 
influenced by many biological factors including menstruation, age, infection, sexual 
intercourse, usage of contraceptives, pregnancy, etc. Moreover, conditions of CVF collection 
and the experimental proteomic strategy could affect the proteome results. Although there 
are promising results, studies in biomarkers in body fluids have not reached consensus on 
peptides or proteins that have this feature. 
3.1.2 Membrane proteomic studies 
The main potential of proteomics in cancer research is not only derived from individual 
experiments, but from comparative studies between different types and states of cancer. 
There is a need to integrate proteomics, genomics and metabolomics with the aim of 
achieving a functional and comprehensive interpretation of clinical and pathological data. 
Comparative proteomic studies have provided tools for establishing some molecular 
mechanisms of cancer progression, either from normal to neoplasic cells, or from cancer 
models with different malignant phenotypes. Information obtained through proteomic 
analysis allows building extensive and comprehensive databases leading to discovery of 
tumor biomarkers. 
Metastasis represents the main cause of death in cancer patients; this multi–step process 
involves the acquisition of migrating and invasive phenotypes, where the plasma membrane 
displays a fundamental role. Membrane proteomic studies constitute an analytical challenge 
due to its heterogeneous composition, dynamic physicochemical characteristics and 
hydrophobicity; however, 60% of therapeutic targets are directed against membrane 
proteins. The study of well established cancer cell lines with different phenotypes allows the 
correlation between the IGF axis expression/activation with membrane protein expression 
measurements. In particular, cellular motility depends on the adaptive response to 
environment that extensively relies on key molecular elements of the plasma membrane and 
cytoskeleton, and therefore usually considered as tumour targets.  
Here we present novel results of studies on membrane proteomes of cervical cancer cell 
lines, differing in viral status and invasive phenotypes: HeLa, an invasive HPV positive cell 
 
Topics on Cervical Cancer with an Advocacy for Prevention 
 
224 
reside in the citosol of squamous cells, and their presence in the sera of patients with 
advanced squamous cell carcinomas is mainly due to a passive release rather than an active 
secretory process into the circulation. Increased SCC levels have been observed in 28-88% of 
patients with squamous cell cervical cancer. Pre-treatment SCC levels reflect tumour stage 
and size, cervical stoma invasion, lymph-vascular space status, parametrial involvement 
and lymph node status; however, its clinical relevance is still debated. 
CA 125, an antigenic determinant of a high molecular weight glycoprotein, is recognized by 
a monoclonal antibody developed against a human ovarian cancer cell line. Elevated CA 125 
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relevance of serum VEGF is still investigational (Gadducci et al., 2008). 
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screening and thereby reduce overtreatment and possibly improve cost-effectiveness of the 
treatment. Advances in molecular biology and high throughput technologies have heralded 
a new era in identification of biomarkers and molecular targets related to carcinogenesis to 
improve our understanding of the disease and will facilitate screening, early detection, 
management, and individualized targeted therapy. 
3.1 Proteomic studies 
Proteomics has emerged as a promising tool for unravelling protein signatures that are 
associated with a particular malignancy that can be useful biomarkers of the disease. High-
throughput technologies like surface-enhanced laser desorption and ionization-time of flight 
mass spectrometry (SELDI-TOF MS), nanoHPLC-MS/MS or the combination of one- or two-
dimensional gel electrophoresis (1-DE, 2-DE) methods with multidimensional 
chromatographic separation and MS provide a snapshot of the proteome. Validated protein 
biomarkers could be useful in early detection of disease, monitoring disease progression or 
monitoring response to treatment.  
3.1.1 Proteomic studies on body fluids 
After exploring markers in tissue, several studies have focused on biomarker discovery in 
body fluids which would be advantageous for eventual clinical implementation. Cervical 
mucous or cervical vaginal fluid (CVF) is potentially an ideal sample to screen for 
biomarkers for early detection of cervical cancer. As cervical mucous is produced in the 
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microenvironment where cervical neoplasia arises, it is likely to include proteins produced 
by the lesion as well as by the host in response to the lesion. Several studies have analyzed 
peptides and proteins present in human cervical mucous (Dasari et al., 2007; Pereira et al., 
2007; Tang et al., 2007). A recent study identified 151 new proteins that included proteins 
present in the lower female genital tract, such as HBD-2 and cathelicidin, two proteins that 
play an important role in the innate immunity of the cervicovagina (Zegels et al., 2009). 
Another recent study on cervical mucous proteome indicated that plasma proteins were 
abundant in cervical mucous (Panicker et al., 2010). The majority of proteins identified were 
categorized under metabolism and immune-response functional groups.  
In contrast to plasma samples, some authors discuss the advantages of cervical mucous as a 
potential source of concentrated biomarkers due to lesser dilution of the sample in CVF-
vaginal washings (volume ±50 mL) in comparison to plasma volume (±3 L) (Good et al., 
2007). In addition, altered biomarker expression patterns in plasma are often not very 
specific, as they may be associated with different pathologies, because plasma comes in 
contact with all organs of the body. In contrast, when using CVF samples, it is expected that 
expression patterns will directly correlate with gynaecological pathologies (Zegels et al., 
2009). However, it should be taken into account that CVF is a body fluid that can be highly 
influenced by many biological factors including menstruation, age, infection, sexual 
intercourse, usage of contraceptives, pregnancy, etc. Moreover, conditions of CVF collection 
and the experimental proteomic strategy could affect the proteome results. Although there 
are promising results, studies in biomarkers in body fluids have not reached consensus on 
peptides or proteins that have this feature. 
3.1.2 Membrane proteomic studies 
The main potential of proteomics in cancer research is not only derived from individual 
experiments, but from comparative studies between different types and states of cancer. 
There is a need to integrate proteomics, genomics and metabolomics with the aim of 
achieving a functional and comprehensive interpretation of clinical and pathological data. 
Comparative proteomic studies have provided tools for establishing some molecular 
mechanisms of cancer progression, either from normal to neoplasic cells, or from cancer 
models with different malignant phenotypes. Information obtained through proteomic 
analysis allows building extensive and comprehensive databases leading to discovery of 
tumor biomarkers. 
Metastasis represents the main cause of death in cancer patients; this multi–step process 
involves the acquisition of migrating and invasive phenotypes, where the plasma membrane 
displays a fundamental role. Membrane proteomic studies constitute an analytical challenge 
due to its heterogeneous composition, dynamic physicochemical characteristics and 
hydrophobicity; however, 60% of therapeutic targets are directed against membrane 
proteins. The study of well established cancer cell lines with different phenotypes allows the 
correlation between the IGF axis expression/activation with membrane protein expression 
measurements. In particular, cellular motility depends on the adaptive response to 
environment that extensively relies on key molecular elements of the plasma membrane and 
cytoskeleton, and therefore usually considered as tumour targets.  
Here we present novel results of studies on membrane proteomes of cervical cancer cell 
lines, differing in viral status and invasive phenotypes: HeLa, an invasive HPV positive cell 
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line, and C33-A, a non-invasive HPV negative cell line (Garay et al., 2010). C33-A cells 
express almost exclusively IR-A while HeLa express IGF-IR, IR-A and IR-B. Functional 
assays showed that IGF-I and IGF-II stimulate migration and invasion in HeLa but not in 
C33-A cervical cancer cells. In order to make comparisons between proteomic maps, we 
obtained proteomic maps of the two cell lines by two–dimensional electrophoresis (2-DE), 
and used the PDQuest (Bio-Rad®) and Progenesis SameSpot (Nonlinear Dynamics Ltd) 
softwares, to perform between-gel spot comparisons (Fig. 3 A,B). A total of 641 spots in C33-
A and 493 spots in HeLa proteomes were identified, with 399 spots matching between the 
two cell lines. This means that the whole proteomic profiles of cervical adenocarcinoma and 
cervical carcinoma cells share 80% of similarity, suggesting that the differences in 
occurrence, prognosis, dissemination and recurrence after treatment, may be related to a 
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Fig. 3. Proteomes and sub-proteomes of cervical cancer cells. Whole protein extracts from 
HeLa (A) and C33-A (B) and enriched membrane extracts from HeLa (C) and C33-A (D) 
were separated by two-dimensional electrophoresis (2-DE) on IPG NL strips pH 3-10 
followed by SDS-PAGE and stained with colloidal Coomassie Blue.  
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Frequently, whole proteomic profiles do not represent the complete map of the expressed 
proteins in a cell at a given moment; the concentration of some proteins can mask others less 
abundant but with pivotal biological roles. Study of sub-cellular compartments could 
improve the identification of a higher number of proteins and consequently a more efficient 
detection of therapeutic targets. We obtained enriched protein membrane extracts from 
HeLa and C33-A cells by cell surface biotin labelling followed by avidin purification and 
separation by 2-DE to obtain the corresponding membrane proteomes (Fig. 3 C, D).  
We detected 351 spots in HeLa sub-proteome, out of which 207 spots (41%) were present in 
the whole proteome and 144 spots corresponded to new proteins not visualized in the total 
proteome. With respect to C33-A, 395 spots were found in the membrane proteome where 
170 spots (43%) matched with the total proteome; additionally 255 new spots were detected. 
Furthermore, comparison of membrane-enriched proteomes, showed a 58% match between 
the two cell lines with 272 common proteins, out of which, 86 proteins were found to be 
differentially expressed (>3-fold). The invasive abilities of HeLa in opposition to C33-A cells, 
may be related to the observed differences in the membrane protein profile. 
In order to identify a higher number of proteins and overcome the limitations associated 
with the separation of membrane proteins by bi-dimensional electrophoresis, we conducted 
a multidimensional analysis of enriched membrane fractions. Proteins were separated by 
SDS-PAGE, each lane in the gel was cut and divided in equal fragments and digested with 
trypsin. The peptides were separated by reversed-phase liquid chromatography (LC) and 
analyzed in a hybrid quadrupole mass spectrometer–time of flight (Q-TOF) instrument. 
Bioinformatics analysis was performed using Mascot Distiler® and Proteome Software 
Scaffold, which allowed the identification of 44 and 56 proteins in HeLa and C33-A 
fractions, respectively.  
Results showed a differential or exclusive protein expression profile that correlated with cell 
phenotype. We identified 33 proteins exclusively expressed in C33-A cells that 
corresponded to cell cycle regulation, metabolism, stress response and immune system 
evasion, more related to a proliferative non-invasive phenotype. Meanwhile, 22 proteins 
exclusively expressed in HeLa cells, where mainly involved in cytoskeleton remodelling and 
associated with cell motility, according to the invasive phenotype. Among the new 
identified proteins, the more relevant in the regulation of metastatic properties, include: 
Filamin A and B, Myoferlin and the CD44 - Moesin complex, which have been previously 
associated with cell adhesion and tumour progression (Feng & Walsh, 2004; Ravid et al., 
2008; Bernatchez et al., 2007). 
To explore the relationships between the identified proteins and the IGF system, we used 
the STRING 8.3 database to examine the known or predicted protein-protein interactions 
among them. The interaction network was built including all the previously identified 
proteins in the membrane proteome and the members of the IGF system. The interaction 
network obtained for HeLa cells is visualized in Fig. 4. This analysis confirmed the 
interaction of some components of the membrane with members of the IGF family, and 
suggests a potential role in the promotion of the invasive phenotype display by these cells. 
In particular, this analysis confirmed a direct interaction between IGFBP-3 and the CD44 - 
Moesin complex, associated with cell adhesion and tumor progression, meaning a 
promising target for cervical cancer invasion and metastasis control. In conclusion, our  
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Fig. 4. Protein-protein interaction network representing the associations between the IGF 
system and identified membrane proteins expressed by the cervical cancer HeLa cell line. 
The network is visualized by STRING 8.3 database. Each circle represents an individual 
protein with the recognized abbreviated name. Connecting lines represent association.  
approach is unique as it considers the IGF receptors in a wider context within a protein 
network, and shows that the membrane is a rich reservoir for potential targets for cancer.  
4. Conclusion 
The evidence reviewed above shows that the IGF system plays a central role in many 
aspects of the development and progression of cervical cancer. The effects of components of 
the IGF axis in cervical carcinogenesis share some similarities with those observed in other 
types of cancer, however, clear differences exist that reflect specificities, possibly due to 
associations with oncogenic and nononcogenic HPV. The available data support 
dysregulation of the IGF system expression and signaling, that could promote the 
progression to a malignant phenotype. It is plausible to consider these molecules as 
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promising targets for cervical cancer invasion and metastasis control and source of valuable 
biomarkers of the disease, as deduced from the proteomic approach of membrane targets. 
Advances in molecular biology and high throughput technologies will improve our 
understanding of the disease and the search for reliable biomarkers that will facilitate 
screening, early detection, management, and individualized targeted therapy. 
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1. Introduction 
Viral infection is a very serious threat to humanity. It causes malicious diseases, such as 
HIV/AIDS, dengue, and Avian Influenza, therefore, novel method in virology to combat the 
viral infection is necessary. Bioinformatics provides outstanding tools for developing 
vaccines, PCR primers, mutation detection and drugs based design on genetic engineering 
principles. Those tools are mostly freeware. Algorithm from the computer science has made 
major contribution to them. Bioinformatics experiment greatly reduces the cost and time in 
wet laboratory experiment. Our lab has successfully designed PCR primers, vaccine, and 
mutations prediction. The vaccine design is elaborated for Dengue and HPV. The design has 
BLAST homology of more than 90%, and RSMD value of 0.1. Those data shown, that the 
design have identical structure with the native viral protein.  
However, their efficacy should be verified in the wet laboratory experiment. The future of 
medicine will greatly be shaped by advancement in bioinformatics (Tambunan et al, 2010). 
Moreover, we need to emphasize the needs to understand more about HPV genome and its 
protein expression.  
The human papillomavirus (HPV) is a family of sexually transmitted, double-stranded DNA 
viruses with over 100 different genotypes identified till date. It is associated with many 
different types of cancers including cervical, vaginal, head and neck, penile and anal cancer. 
With approximately 450,000 newly diagnosed cases each year and a 50% mortality rate, 
cervical cancer is the second most common cause of cancer-related death in women 
worldwide and it is almost always associated with HPV. Cervical cancer is the most 
common cancer of women in most developing countries, where it may account for as many 
as one fourth of female cancers. 
HPV genotypes are divided into the low risk and high risk categories based on the spectrum 
of lesions they induce. The low-risk types induce only benign genital warts and include 
HPV 6 and 11. The high-risk group containing HPV 16, 18, 31, 33, 45 and 56 is associated 
with the development of anogenital cancers and can be detected in 99% of cervical cancers , 
with HPV16 found in 50% of cases. 
A consistently effective and safe treatment for HPV infections is currently not yet available. 
Present therapeutic options are more directed at surgical eradication and/or by destroying 
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malignant lesions via physical or chemotherapeutical intervention. A majority of these 
treatments have been developed empirically, few have been thoroughly tested, but none of 
them are completely satisfactory. In attemps to find additional drugs in the treatment of 
cervical cancer, inhibitors of the histone deacetylases have received much attention due to 
their low cytotoxic profiles (Tambunan et al, 2010). 
Elaborating a methodological comparison between our computational approaches with the 
other bioinformatics labs. We will not compare our method directly with wet labs, because 
our method is developed to supplement it. Our objective is to find the optimal in silico HPV 
therapeutic design, and implement it in the wet laboratory.  
2. In silico HPV related research 
2.1 Detection of HPV genome 
This section will elaborate more on HPV Genome Annotation. The conserved region of HPV 
Genome needs to be annotated, in order to design a useful detection tools. Conventional 
method of detecting cervical cancer is done by carrying out cytological examination, which is 
more widely known as Pap smear. Due to rapid advancement of molecular biology, molecular 
based diagnostic and early detection methods on cervical cancer has been highly developed to 
replace conventional method of detection. Examples include polymerases chain reaction (PCR) 
and hybrid capture 1, 2 and 3. Hybrid capture 1 is liquid hybridization assaying method 
designed to detect 14 types of HPV, 9 of which are high risk (type 16, 18,31, 33, 35, 45, 51, 52, 
56), while the other 5 are low risk (type 6, 11, 42, 43, and 44). Hybrid capture 2 is a 
development of hybrid capture 1 which uses microtitre plates instead of tubes and is capable 
of detecting four additional types of viral oncogenic (type 39, 58, 59, and 68) (Clavel et al, 1998). 
Hybrid capture 3, similar to previous hybrid capture tests, relies on the formation of target 
HPV DNA-RNA probe heteroduplexes during the hybridization step in specimens containing 
sufficient HPV DNA. The chemiluminescent detection of these hybrids is by adding an 
alkaline phosphatase-conjugated monoclonal antibody, specific to the DNA-RNA complexes 
with dioxetane substrate in a 96-well enzyme-linked immunosorbent assay format (Lorinze 
and Anthony, 2001). Most of the above mentioned methods are spesific, sensitive, reliable, and 
easy to perform. Moreover, its routine application has been very much improved by the use of 
non-radioactive enzyme immunoassay detection procedure (Clavel et al, 1998). Modification of 
the Hybrid Capture method is expected to be achieved through the use of a customized 
oligonucleotide probe able to detect multiple high-risk HPV infection.  
There are 10 genes encoded in HPV genome. These gene may be classified into two groups, 
namely Gene E (early) which encodes regulatory proteins and Gene L (late) which encodes 
structural proteins. The region of L1 and L2 of Gene L is responsible for encoding capsid 
protein to be used as DNA envelope in HPV. The capsid protein will serves as protection 
system to HPV genetic materials. It is generally assumed that there are many nucleotides 
sequence in the region of L1 and L2 that is conserved throughout the evolution process of 
HPV (Dahlgren, 2005). 
2.1.1 Other labs approach 
Mendez-Tenorio and his group were using DNA fingerprinting. Identification of 
microorganisms by whole genome DNA fingerprinting was tested “in silico”. 94 HPV 
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genome sequences were submitted to virtual hybridization analysis on a DNA chip with 342 
probes. This Universal Fingerprinting Chip (UFC) constitutes a representative set of probes 
of all the possible 8-mer sequences having at least two internal and non-contiguous 
sequence differences between all them. A virtual hybridization analysis was performed in 
order to find the fingerprinting pattern that represents the signals produced for the 
hybridization of the probes allowing at most a single mismatch. All the fingerprints for each 
virus were compared against each other in order to obtain all the pairwise distances 
measures. A match-extension strategy was applied to identify only the shared signals 
corresponding to the hybridization of the probes with homologous sequences between two 
HPV genomes. A phylogenetic tree was constructed from the fingerprint distances using the 
Neighbor-Joining algorithm implemented in the program Phylip 3.61. This tree was 
compared with that produced from the alignment of whole genome HPV sequences 
calculated with the program Clustal_X 1.83. The similarities between both trees are 
suggesting that the UFC-8 is able to discriminate accurately between viral genomes. A 
fingerprint comparative analysis suggests that the UFC-8 can differentiate between HPV 
types and subtypes ( Méndez-Tenorio et al, 2006) 
Kaladhar and his group are working on annotation HPV-92 genome. Most of the biologists 
focus to explore innovations of their research in faster rate using developments in 
Information technology. The gene identification, characterization and modeling of the 
proteins in HPV 92 is done using bioinformatics tools. A complete genome of HPV-92 with 
NCBI’s accession number NC_004500 was submitted to FGENES V0, a viral gene prediction 
server, predicts six genes. These six genes are characterized as E6 oncoprotein, E7 
oncoprotein, E1 Replication protein, E2 Regulatory protein, L1 major capsid protein and L2 
minor capsid protein. Isoelectric points and Molecular weights of all the six proteins vary 
largely and the modeled structures are shown. The research can provide characterization 
and modeling of genome which can further implemented in drug designing methods using 
bioinformatics tools (Kaladhar et al, 2010). 
Eom and his group has interesting approach towards mapping HPV genome. They are 
using genetic mining algorithm. Classifying the type of HPV is very important to the treat of 
cervical cancer. The machine learning approach to mine the structure of HPV DNA 
sequence for effective classification of the HPV risk types has been introduced. The most 
informative subsequence segment sets and its weights with genetic algorithm to classify the 
risk types of each HPV has been determined and learnt. To resolve the problem of 
computational complexity of genetic algorithm, distributed intelligent data engineering 
platform based on active grid concept called IDEA@Home was used. The proposed genetic 
mining method, with the described platform, shows about 85.6% classification accuracy 
with relatively fast mining speed (Eom et al, 2004). 
Lee and his groups are using in silico DNA microarry for detecting HPV genome. DNA 
microarrays are widely used techniques in molecular biology and DNA computing area. It 
consists of the DNA sequences called probes, which are DNA complementaries to the genes 
of interest, on solid surfaces. And its reliability seriously depends on the quality of the probe 
sequences. Therefore, one must carefully choose the probe sets in target sequences. The 
probe design for DNA microarrays was formulated as the multi-objective optimization 
problem. Multi-objective evolutionary approach was proposed, which is known to be 
suitable for this kind of optimization problem. Since a multi-objective evolutionary 
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malignant lesions via physical or chemotherapeutical intervention. A majority of these 
treatments have been developed empirically, few have been thoroughly tested, but none of 
them are completely satisfactory. In attemps to find additional drugs in the treatment of 
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algorithm can find multiple solutions at a time, thermodynamic criteria was used to choose 
the most suitable one. For the experiments, the probe set generated by the proposed method 
is compared to the sequences used in commercial microarrays, which detects a set of 
Human Papillomavirus (HPV). The comparison result supports that the approach can be 
useful to optimize probe sequences (Lee et al, 2004). 
2.1.2 Our approach 
The aim of our study was to determine the conserved regions of late genes L1 and L2 from 
74 sequenced and published HPV genome (Icenogle, 1995). The result was used to predict 
candidate template for oligonucleotide probes that are specific on types of HPV, which 
cause cervical cancer. Nevertheless, the spesific purpose of this study is to design primer 
that is able to detach on the open reading frame region and also to develop a new assay for 
the detection of high risk HPV DNA.  
This study was carried out to determine the conserved regions of late genes from sequenced 
HPV types. HPV genome sequences were collected from the Los Alamos National 
Laboratory papillomavirus database. There are 74 types of HPV in the database, which have 
completely documented genome sequences as well as their translation product. Specific 
types of HPV, which may cause cervical cancer, are grouped into high risk or low risk, 
according to their risk potential. This classification may differ from one research 
methodology to another. In order to access a representative classification, three sets of 
classification were studied for this research. HPV type 16 and 18 are consistently grouped as 
high risk, while other types of HPV varied randomly. Sequence alignment was taken and 
the result shows 62 conserved regions as a primer template for L1 and L2 genes. These 
conserved regions were then subjected to BLASTn operation in order to search the 
conserved region with least similarity to low risk HPV and human genome.  
Finally, 7 selected conserved regions were examined for secondary structures using 
NetPrimer program. From this operation, only region 52 (5’-
ACAGGCTATGGTGCTATGGA-3’) met the criteria to be used as an oligonucleotide primer 
(Tambunan et al, 2007). 
Oligonucleotide primers are considered based upon certain properties, namely: they must 
not have potential secondary structures such as hairpins or dimmers have a GC content of 
45-60%; have a Tm between 52-58%; their 5' ends stability has to be greater than the stability 
of their 3' ends; be 17-25 nucleotides in length. From NetPrimer analysis results of seven 
regions, only region 52 meet with the above mentioned criteria. with a NetPrimer rating of 
100 (maxium) (Tambunan et al, 2007). The result is shown in table 1. Based on sequence 
similarity, 62 conserved regions were found. Out of the 62, 7 regions were then used as 
templates for primers used in detection of high and low risk HPV. From the 7 template 
candidates, only one met the criteria to be used as an oligonucleotide primer, namely region 
52. From the study, region 52 is predicted to be selective to be used in the detection of 
oncogenic Human papillomavirus. 
2.2 HPV vaccine design and its post translation studies 
A new paradigm of vaccine design is now emerging, following essential discoveries in 
immunology and the development of bioinformatics tools for T-cell epitope prediction from  
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primary protein sequences. One rationale for this new paradigm is that following exposure 
to a pathogen, epitope-specific memory T-cell clones are established. These clones respond 
rapidly and efficiently upon any subsequent infection, elaborating cytokines, killing infected 
host cells, and marshalling humoral and cellular defences against the pathogen. The most 
efficient immune response to some pathogens is derived from a number of different T cells 
that respond to an ensemble of pathogen-derived short peptides called epitopes. Whether an 
immune response is directed against a single immunodominant epitope or against many 
epitopes, the generation of a protective immune response does not require the development 
of T-cell memory to every possible peptide in the entire pathogen. T-cell response to the 
ensemble of epitopes, not the whole pathogen, is the source from which a protective 
immune response is derived. Similarly, if an individual is previously exposed to a language, 
upon hearing just a few words of that language he/she will usually recognize, for example, 
that French or English is being spoken. Complete mastery of the language is not required for 
this recognition. Using this analogy to describe epitopes, one could say that they are 
pathogen-specific 'words' that alert the immune system to the presence of a pathogen. It is 
now possible to envisage the design of vaccines based on an ensemble of epitopes (a string 
of words, a few sentences, a paragraph, or a chapter) derived from the genome of a 
pathogen, using tools that have been developed in the field of immuno-informatics (De 
Groot et al, 2002 ). Knowledge about immunology is crucial in designing vaccine. 
Immunoinformatics, which is a branch of Bioinformatics, is a flourishing field. 
The significant breakthrough in HPV vaccine research was accomplished, when capsid 
protein L1 and L2 was found to be able to assemble themselves to be Virus Like Particles 
(VLP) during cell expression. VLP is very similar to the native HPV particle, and it includes 
the conformation epitope that induce the viral neutralization antibody. This is very crucial 
for the immune system, in order to detect VLP as viral infection, and giving the proper 
response. Because VLP is coreless and didn't contain the viral DNA, then it is expected that 
it won't create infection. The produced VLPs are type 6,11, 16, 18, 31, 33, 35, 39, 45,and 58). 
One VLP Chimeric (cVLP) model has sucessfully induced Mice Cytotoxic T Cell, by joining 
E6 and E7 capsid protein in the VLP. Some scientist believes, that cVLP has huge potentials 
to be utilized as infection prevention (Kolls et al, 2000). 
Protein must be folded like its native conformation, in order to be activated as mature 
protein. The protein modification into its native conformation is called as post-translation 
modification. The polypeptide chain, which consisted of more than 200 residues, is usually 
folded into two or more globular domain. Most of the domain has 100 until 200 amino acid 
residues, and having diameter of ~25 Å (Voet et al, 1995). 
DNA vaccine is designed using choice of a suitable expression vector, ensuring optimal 
expression by codon optimization, engineering CpG motifs for enhancing immune 
responses and providing additional sequence signals for efficient translation. DNA vaccines 
have been one of the latest developments in vaccine technology. DNA vaccines are 
essentially plasmids capable of expressing an antigenicpeptide in the host. These expressed 
proteins are recognized as foreign in the cells of the body. They are processed by the host 
cells and displayed on their surface to alert the immune system and trigger body’s immune 
responses. DNA vaccines have become anattractive alternative to conventional methods due 
to the fact that it can elicit sustained cell-mediated as well as humoral immun responses, 
which is very much important in combating pathogenic organisms, especially intracellular 
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pathogens. Vaccine efficacy can be assessed by correlating the vaccine’s immunogenicity 
such as its ability to induce CD8+ or CD4+ T cells to the HPV oncoproteins with its ability to 
protect vaccinated animals against formation of tumors or to cause clearance of already 
established tumors. Recently several techniques like optimizing codons, CpG optimization 
and promoter and resistance gene insertion have been tried to enhance the immunogenicity 
of DNA vaccines (Gupta et al, 2009). 
2.2.1 Other labs approach 
Gupta and his group are working with DNA vaccine. There is a need to develop a new 
prophylactic DNA vaccine, which can work against different strains of HPVs and may lead 
to protection of cervical cancer against new pandemicviruses. Potential prophylactic DNA 
vaccine has been designed by using all the consensus epitopic sequences of HPVs L2 capsid 
protein and performed in silico cloning of multiepitopic antigenic DNA sequence in pVAX-1 
vector. Immunogenicity of vaccine has been enhanced by techniques like codon 
optimization, engineering CpG motifs, introducing promoters and co-injection with 
plasmids expressing immune-stimulatory molecules (Gupta et al, 2009). 
2.2.2 Our approach 
Unlike others, our laboratory is using chimeric protein for designing the vaccine. The cVLP 
HPV-16 ANN1, ANN2, HMM1, and HMM2 in silico vaccine design were discovered. The 
BLAST test towards them was generating 96% identity with native L1 HPV-16 protein. 
Therefore, it is expected that the vaccines could cause same level of immunogenicity with 
the native protein. The Ramacandran Plot of them showed that the disallowed region plot of 
non-glycine residue was less than 15%. Henceforth, the quality of the vaccine could be 
structuraly good. The VAST test toward them showed the RMSD of 0,1 Å, which shows that 
they have a high structural similarity.  
Based upon in silico predition, it was found that post-translational modification could occur 
at cVLP. During the formation of cVLP, the possible occurred post-translational 
modification is N-Glicocylation. It is because this modification has N-Xaa-S/T motif which 
found at our in silico detection method. Although it is expected to happen, it is predicted 
that this modification wouldn't affect the tability of the cVLP, because its epitope did not 
affected.  
Chimeric virus like particles (cVLP) has been developed as vaccine candidate for preventing 
cervical cancer. cVLPs are improvement of Virus Like Particles (VLP) by substituting the 
epitope of L1 HPV -18 and -52 protein to L1 HPV -16 protein. They are ANN1, ANN2, 
HMM1, and HMM2. The impact of post translation modification will be determined. Based 
on In Silico study, the dominant post translation modification is glycosylation (Tambunan et 
al 2007). 
However, the next step is to develop in silico plasmid vector for expressing cVLP at the 
euchariotic host cell. The necessary step is to conduct in vitro experimentation to construct 
the cVLP HPV L1 at the proper host cell. After the cVLP has sucessfully produced, we could 
conduct in vivo research to determine the immunogenicity of cVLP at the animal testing, for 
example at rabbits or mice. Figure 1 shows the amino acid sequence of our vaccine design, 
while figure 2 shows its 3D visualization.  
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Fig. 1. The sequence of Our ANN1 cVLP L1 HPV Vaccine design.  
 
Fig. 2. Our ANN1 cVLP L1 HPV Vaccine Design. The vaccine was visualized by using 
MacPymol application. The ribbons inside the chains are the vaccine backbone (Tambunan 
et al, 2010). 
2.3 HPV drugs design 
This section will elaborate more on Drugs design. Knowledge about protein receptor-
inhibitor interaction is very important for designing drugs. Computational Chemistry is the 
major supporting science in it. The structural modification of histones is playing important 
roles in the knowledge of HPV drug design.  
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However, we are going to explain more about drug design biochemistry background. The 
structural modification of histones is regulated mainly by acetylation/deacetylation of the 
N-terminal tail and is crucial in modulating gene expression, because it affects the 
interaction of DNA with transcription-regulatory non-nucleosomal protein complexes. 
The balance between the acetylated/deacetylated states of histones is mediated by two 
different sets of enzymes: histone acetyltransferases (HATs) and histone deacetylases 
(HDACs). HATs prefentially acetylate specific lysine substrates among other non-histones 
protein sub- strates and transcription factors, affecting DNA-binding properties and, in 
turn, altering gene transcription. HDACs restore the positive charge on lysine residues by 
removing acetyl groups and thus are involved primarily in the repression of gene 
transcription by compacting chromatin structure. Therefore, open lysine residues attach 
firmly to the phosphate backbone of the DNA, preventing transcription. In this tight 
conformation, transcription factors, regulatory complexes, and RNA polymerases cannot 
bind to DNA Acetylation relaxes the DNA conformation, making it accessible to 
transcription machinery. High levels of acetylation of core histones are seen in chromatin-
containing genes, which are highly transcribed genes; genes that are silent are associated 
with low levels of acetylation. Inappropriate silencing of critical genes can result in one or 
both hits of tumor suppressor gene inactivation in cancer. Members of the classical HDAC 
family fall into two different phylogenetic classes, namely class I and class II. The class I 
HDACs (HDAC1, HDAC2, HDAC3, and HDAC8) are most closely related to the yeast 
(Saccharomyces cerevisiae). Class II HDACs (HDAC4, HDAC5, HDAC6, HDAC7, HDAC9, 
and HDAC10) share domains with similarity to HDA1, another deacetylase found in yeast 
(de Ruitter et al, 2003). 
The inhibition of HDAC activity by a specific inhibitor induces growth arrest, 
differentiation, and apoptosis of transformed cells as well as several cancer cells (Subha et 
al, 2008). Recent studies were directed to investigate the molecular effects of HDAC 
inhibition on cervical carcinoma cells as well as on primary human foreskin keratino- 
cytes, separately immortalized with amphotropic retroviruses that carry the open reading 
frames of HPV 16 E6, E7 or E6/E7. In these experiments one could show that E6/E7 
oncogene function of human papillomavirus can be completely bypassed by HDAC 
inhibition. Both malignant and immortalized HPV 16/18-positive cells became blocked in 
G1/S transition despite ongoing viral gene expression. G1 arrest was accompanied by a 
down-regulation of cyclin D and cyclin A and a concomitant up regulation of the cyclin 
kinase inhibitors (CKI) p21 and p27. Binding of both CKIs led to a complete block of the 
cyclin-dependent kinase (cdk2) activity and in turn prevented binding of E7. This was 
intriguing with respect to the reversibility of HPV transformation process, since it is 
thought that the abrogation of the growth inhibitory function of p21 and p27 through E7 
represents a key event in HPV-induced carcinogenesis. HDAC inhibitors also trigger pRb 
degradation, while E2F expression remained unaffected. pRb degradation is an E7- 
specific phenomenon, since in E6-positive cells pRb only became hypophosphorylated. 
The presence of E2F under cell cycle arrest led to a classical “conflict situation” which 
finally induced apoptosis (Finzer et al, 2001; Finzer et al, 2002; Finzer et al, 2004). Hence, 
the knowledge how the transforming potential of HPV can be bypassed without 
switching off viral transcription could open new therapeutical perspectives for the 
treatment of cervical cancer (Acharya et al, 2006). The drug design on HPV are mainly 
tampering with the reactivity of E(early) protein.  
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Fig. 1. The sequence of Our ANN1 cVLP L1 HPV Vaccine design.  
 
Fig. 2. Our ANN1 cVLP L1 HPV Vaccine Design. The vaccine was visualized by using 
MacPymol application. The ribbons inside the chains are the vaccine backbone (Tambunan 
et al, 2010). 
2.3 HPV drugs design 
This section will elaborate more on Drugs design. Knowledge about protein receptor-
inhibitor interaction is very important for designing drugs. Computational Chemistry is the 
major supporting science in it. The structural modification of histones is playing important 
roles in the knowledge of HPV drug design.  
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the knowledge how the transforming potential of HPV can be bypassed without 
switching off viral transcription could open new therapeutical perspectives for the 
treatment of cervical cancer (Acharya et al, 2006). The drug design on HPV are mainly 
tampering with the reactivity of E(early) protein.  
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2.3.1 Other labs approach 
Rehmi and his group are mainly working on E2 proteins. The E2 protein from HPV 16 was 
selected as a molecular target and its known structures were exploited for broad scope of 
“hits” to be identified in the screening process. They compared both structure-based and 
ligand-based design approaches for virtual screening. Databases enriched in natural 
compounds were used for virtual screening based on molecular docking. In this study, they 
identified novel classes of HPV inhibitors by means of a structure-based drug-design 
protocol involving Pharmacophore based virtual screening with molecular docking 
simulation (Rehmi et al, 2009). 
Baleja and his group have different approach, because they are using E6 protein as vaccine 
template. The E6 protein from the high-risk HPV types represents an attractive target for 
intervention because of its roles in viral propagation and cellular transformation. E6 
functions in part by interaction with human cellular proteins, several of which possess a 
helical E6-binding motif. The role for each amino acid in this motif for binding E6 has been 
tested through structure determination and site-directed mutagenesis. These structural and 
molecular biological approaches defined the spatial geometry of functional groups 
necessary for binding to E6. This E6-binding information (the E6-binding pharmacophore) 
was transferred into a three-dimensional query format suitable for computational screening 
of large chemical databases. Compounds were identified and tested using in vitro and cell 
culture-based assays. Several compounds selectively inhibited E6 interaction with the E6-
binding protein E6AP and interfered with the ability of E6 to promote p53 degradation. 
Such compounds provide leads for the development of new pharmacologic agents to treat 
papillomavirus infections and their associated cancers (Baleja et al, 2006).  
2.3.2 Our approach 
Our approach was done by Identification of a better Homo sapiens Class II HDAC inhibitor. 
The aim of this work is to analyze the interaction of Homo sapiens class II HDACs with 
SAHA and TSA that are already in the phase I/II clinical trials based on their binding 
affinity and pharmacological properties. Since, no theoretical works have been carried out in 
identifying the properties and specificity, we intend to identify the group that could act as 
potential binding inhibitors. 
In this paper, we present homology models of six Homo sapiens Class II HDACs (HDAC4, 
HDAC5, HDAC6, HDAC7, HDAC9, and HDAC10) that are validated by comparison with 
the X-ray structure of HDAC4 and HDAC7, which became available during the course of 
our study. Two HDAC inhibitors (SAHA and TSA) are docked to the six homology models. 
The pharmacological properties of SAHA and TSA were identified using Molinspiration, 
Osiris Property, Tox- Boxes, and Toxmatch-v1.06. Therefore, the molecular binding 
interactions between the histone deacetylases with SAHA and TSA were analyzed to 
provide some insights into the molecular interactions and designing new HDAC inhibitors. 
The certain types of HPV are involved in the development of cervical cancer. In attempts to 
find additional drugs in the treatment of cervical cancer, inhibitors of the histone 
deacetylases (HDAC) have received much attention due to their low cytotoxic profiles and 
the E6/E7 oncogene function of human papilomavirus can be completely by passed by 
HDAC inhibition. The histone deacetylase inhibitors can induce growth arrest, 
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differentiation and apoptosis of cancer cells. HDAC class I and class II are considered the 
main targets for cancer. Therefore, the six HDACs class II was modelled and about two 
inhibitors (SAHA and TSA) were docked using AutoDock 4.2, to each of the inhibitor in 
order to identify the pharmacological properties. Based on the results of docking, SAHA 
and TSA were able to bind with zinc ion in HDACs models as a drug target. SAHA was 
satisfied almost all the properties i.e., binding affinity, the Drug-Likeness value and Drug 
Score with 70% oral bioavailability and the carbonyl group of these compound fits well into 
the active site of the target where the zinc is present. Hence, SAHA could be developed as 
potential inhibitors of class II HDACs and valuable cervical cancer drug candidate 
(Tambunan et al, 2010).  
 
Fig. 3. 2D Structure of SAHA and TSA. SAHA and TSA are hydroxamic acid derivatives that 
can be HDAV inhibitors. 
Each ligand shows different affinity with class II HDAC, for example SAHA compound 
show best affinity with HDAC 5 based on Autodock calculation, and HDAC 10 based on 
APBS calculation. Whereas the same compound was found to be rank 2 with HDAC7 (-7.42 
kcal/mol) based on AutoDock calculation and HDAC6 (-213.60 kJ/mol) based on APBS 
calculation, and rank 3 (-6.72 kcal/mol) with HDAC10 (AutoDock) and HDAC7 (-203.21 
kJ/mol, APBS). Local free binding energy obtained from AutoDock of Homo sapiens class II 
HDACs complexed with an inhibitor showed that SAHA is a weaker inhibitor of HDACs 
than TSA. But, global binding energy of Homo sapiens class II HDACs and inhibitors 
obtained from APBS, showed that TSA to be a weaker inhibitor of HDACs than SAHA. 
There are differences in binding energy calculated with AutoDock 
 and APBS; this is because AutoDock does not calculate columbic contribution from all of 
atoms in protein like APBS. 
The further descriptor analysis and the toxicity prediction helped in the identification of the 
better inhibitor. Drug Score and the Drug-Likeness are the two properties that are important 
for considering a compound to become a successful drug. TSA had a drug score of 0.37 and 
drug likeness property score of 1.24, which is higher than those for SAHA with respective 
scores of 0.35 and -8.87. The molecular weight of SAHA was 264.32 g/mol and that of TSA 
was 302.37 g/mol (Table 1), between the preferred range of molecular weight for drug  
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Fig. 4. Structures of docked SAHA with Homo sapiens Class II HDACs. Three Conformations 
of Structures of docked SAHA with (A)HDAC4, (B) HDAC5, (C) HDAC6, (D) HDAC7, (E) 
HDAC9 and (F) HDAC10. A surface representation of catalytic domain of Homo sapiens 
Class II HDACs bound to SAHA. The zinc ion is shown as gray sphere. SAHA are shown as 
stick models colored as per docked type: red, blue, and yellow. Amino acids coordinating 
the zinc and forming the trihedrally coordinates are shown as sticks. Some catalytic domain 
of Homo sapiens Class II HDACs residues interacting with the docked SAHA are shown as 
stick models. In HDAC4-SAHA, HDAC5-SAHA, HDAC6-SAHA and HDAC7-SAHA 
complexes, SAHA binds the catalytic zinc ion in a bidentate fashion, with its carbonyl and 
hydroxyl bound to catalytic zinc ion. Whereas, in HDAC9-SAHA and HDAC10-SAHA 
complexes bind the catalytic zinc ion in a monodentate fashion, with its carbonyl bound to 
catalytic zinc ion. 
 




Fig. 5. Structures of docked TSA with HDAC Class II Homo sapiens. Three Conformations of 
Structures of docked TSA with (A) HDAC4, (B) HDAC5, (C) HDAC6, (D) HDAC7, (E) 
HDAC9 and (F) HDAC10. A surface representation of catalytic domain of Homo sapiens 
Class II HDACs bound to TSA. The zinc ion is shown as gray sphere. TSA are shown as stick 
models colored as per docked type: red, blue, and yellow. Amino acids coordinating the 
zinc and forming the trihedrally coordinates are shown as sticks. Some catalytic domain of 
Homo sapiens Class II HDACs residues interacting with the docked TSA are shown as stick 
models. Except HDAC5-TSA complex, all of Homo sapiens class II HDACs-TSA complexes 
bind the catalytic zinc ion in a monodentate fashion. 
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likeness property (160-480 g/mol). TSA was having tumorigenic property. SAHA was the 
compound that had the acceptable range for toxicity risk. These values were also taken into 
account to decide the best inhibitor. Thus, SAHA was the best drug candidate than TSA and 
also found to possess better global binding affinity score. 
 The ADME-TOX box results showed that the SAHA has an oral bioavailability of more than 
70% i.e., good solubility and stability. It acts as a non-substrate and non-inhibitor of P-gp. 
SAHA does not undergo significant first-pass metabolism.  
The three-dimensional models for six class II histone deacetylases (HDAC4, HDAC5, 
HDAC6, HDAC7, HDAC9, and HDAC10), which were built using homology modeling and 
validated by bioinformatics techniques and by comparison to an X-ray structures, were 
docked to SAHA and TSA. Our studies provide the structural view of the catalytic domain 
of a class II HDAC and reveal for this subclass specific features: (i) novel zinc binding motif 
that is likely to be involved in substrate binding and/or protein-protein interactions and 
may provide a site for modulation of activity, and (ii) a unique active site topology in 
catalytic activity. SAHA and TSA predicted to inhibit the class II HDACs are effective to all 
forms HDACs. SAHA was satisfied almost all the properties i.e., binding affinity scores of 
SAHA in the six class II HDAC enzymes was -156.94 kJ/mol, -171.77 kJ/mol, -213.60 
kJ/mol, -203.21 kJ/mol, -179.29 kJ/mol & -263.15 kJ/mol respectively, the Drug Likeness 
value (1.24) and drug score (0.37) with 70% oral bioavailability and the carbonyl group of 
these com- pounds fits well into the active site of the target where the zinc is present. Hence, 
SAHA could be developed as potential inhibitors of class II HDACs and valuable anti cancer 
agents. 
3. Conclusion 
The IT industry has provided strong and robust computing power, with low cost 
expediture. Nowadays, a powerful low cost multiprocessor computers are available,which 
made the modeling of complicated proteins and sophisticated drug design possible. The 
major computer operating system, such as MacOSX, Linux, and Windows are already 
supporting open source bioinformatics software. They could do the functionalities of the 
commercial software, with the same robustness. Nowadays, the field of bioinformatics is 
growing. The In Silico (Bioinformatics) experiment will be considered as important as wet 
experiment by biologist and/or biotechnologist. The In silico approach did not designed to 
replace wet experiment, but it’s in order to supplement it. Open source implementation will 
help bioinformaticians to solve viral threat in efficient and effective manner. There will be 
more robust bioinformatics tools available in the future for solving crucial virology related 
problems. Our laboratory has successfully designing primer and vaccine for therapeutics. 
However, the efficacy of the design must be proven in the wet labs experiment. Synthesizing 
them by using latest molecular biology instrument is crucial for progressing towards clinical 
trial. Conducting it will require us to form strong cooperation with faculty of medicine in 
our university. We already have cooperation with them, and will verify our design in the 
future. 
HPV Bioinformatics is a growing and developing field. Our labs has sucessfully developed 
HPV Genome detection, Vaccine, and drugs design. We found 7 conserve region candidates 
for PCR design, HPV L1 cVLP for vaccine design, and SAHA/TSA drug design. In silico 
PCR Primer, Vaccine, and drugs design are possible with the newest development in 
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algorithm and programming. Our labs and others has successfully developed them. The 
next challenges would be implementing them in the wet laboratory research. 
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3. Conclusion 
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help bioinformaticians to solve viral threat in efficient and effective manner. There will be 
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problems. Our laboratory has successfully designing primer and vaccine for therapeutics. 
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algorithm and programming. Our labs and others has successfully developed them. The 
next challenges would be implementing them in the wet laboratory research. 
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1. Introduction 
Programmed cell death (PCD) is a basic biological phenomenon that plays an important role 
during development, preservation of tissue homeostasis, and elimination of damaged cells. 
Several nomenclature systems have been proposed to classify PCD. One widely accepted 
system describes three major morphologies of programmed cell death, and classifies PCD as 
type I, apoptosis; type II, autophagy; and type III, programmed necrosis1,2.  
Type I, apoptotic cell death, acts as part of a quality-control and repair mechanism by 
elimination of unwanted, genetically damaged, or senescent cells, and as such is critically 
important for the development of organisms. Highly conserved in both plants and animals, 
it is also the cell-death mechanism best characterized at both genetic and biochemical 
levels3. Type II, autophagic cell death, is a catabolic process conserved among all eukaryotes 
from yeast to mammals4; it is a mechanism by which organelles are removed. Autophagic 
cell death is the primary degradation mechanism for long-lived proteins, and thus maintains 
quality control for proteins and organelles to enhance survival under conditions of scarcity 
or starvation. Type III, programmed necrosis, is a passive process that usually affects large 
fields of cells; in contrast, apoptosis and autophagy are controlled and energy-dependent 
and can affect individual cells or clusters of cells. Perhaps the most remarkable characteristic 
of programmed necrosis is that this death outcome appears as a distinct entity, not by 
exclusive engagement of selected effectors, but rather, by combinatorial use of the effectors 
shared with other cell-death outcomes. 
Although all three types of PCD can occur normally as a homeostatic mechanism to 
maintain the cell population in tissues, dysregulation of the delicate balance between cell life 
and PCD has tremendous pathological implications. The type of cell death that occurs 
depends on the stimulus and the cellular context, because every cell-death program is a net 
result of self-propagating signals and other signals that suppress the other cell-death 
programs2. Deficient cell death is frequently involved in early cancer development and 
tumour resistance to chemotherapy or radiotherapy5. Increasingly, evidence suggests that 
PCD is closely related to anti-cancer therapy. The cancer therapy is improved by targeting 
the PCD pathway. 
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Cervical cancer is the most prevalent malignancy of the female reproductive system. Several 
randomized controlled studies have shown survival benefits of platinum-based neoadjuvant 
chemotherapy followed by radical surgery in locally advanced cervical cancer. Survival 
benefit of neoadjuvant chemotherapy depends on high chemoresponsiveness. Considerable 
evidence indicates that platinum can kill cells through the induction of apoptosis; however, 
cancer cells, in their relentless drive to survive, hijack cell processes, resulting in resistance 
to apoptosis. This resistance underlies not only tumorigenesis, but also the inherent 
resistance of certain cancers to chemotherapy and radiotherapy. Fortunately, in addition to 
inducing apoptosis, a number of chemotherapeutic agents have been shown to induce 
nonapoptotic forms of cell death. The significance of nonapoptotic cell death in 
chemotherapy, and the mechanisms by which it is induced remain less well understood. 
Given the fact that most cancer cells have defects in the response to induction of apoptosis, it 
would be desirable if therapeutic agents could kill cancer cells resistant to apoptosis through 
alternative mechanisms. 
In this chapter, we firstly review the main features and functions of all three types of 
programmed cell death, and further elucidate the intricate relationship between apoptosis, 
autophagy and necrosis. We discuss the dual roles of autophagy in cancer and highlighted 
their relationship to tumor suppression and tumor progression. We also review several key 
autophagic mediators that play pivotal roles in autophagic signaling networks in cancer. 
Understanding the signaling pathways involved in the regulation of autophagy as well as 
the autophagy process itself represents new directions in the development of cervical cancer 
therapies. 
2. Basic features of PCD 
Programmed cell death displays several cellular phenotypes affecting various intracellular 
organelles and membranes, and the cell nucleus. For example, the well-characterized 
processes of cytoplasmic and chromatin condensation, nuclear fragmentation, membrane 
blebbing, and formation of membrane-bound apoptotic bodies are part of apoptosis. 
Autophagy involves the formation of a double-membrane vesicle which encapsulates 
cytoplasm and organelles, and fuses with lysosomes, thus resulting in the degradation of the 
vesicle contents. Programmed necrosis is characterized by the presence of swelling 
organelles followed by the appearance of “empty” spaces in the cytoplasm that merge and 
make connections with the extracellular space. The plasma membrane is fragmented, but the 
nucleus is relatively preserved6. 
2.1 Apoptosis 
The major biochemical features of apoptosis are activation of intracellular proteases 
especially caspases, and internucleosomal DNA fragmentation. Changes in several cell 
surface molecules also ensure that apoptotic cells are immediately recognized and 
phagocytized by neighboring cells in tissues, with the result that many cells can be deleted 
from tissues in relatively short time. Therefore, apoptosis results in the orderly elimination 
of cells without generating an inflammatory response7.  
The apoptosis cascade can be initiated via two major pathways, involving either activation 
of death receptors in response to ligand binding (extrinsic or death-receptor pathway), or 
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the release of proapoptotic proteins, such as cytochrome c, from mitochondria to cytosol 
(intrinsic or mitochondrial pathway)8. Some evidence has indicated that the two pathways 
are linked and that molecules involved in one pathway can influence the other9. The death 
receptor pathway is activated through the tumour necrosis factor (TNF) family of cytokine 
receptors, and has a fundamental role in maintaining tissue homeostasis, particularly in 
immune recognition. The Bcl-2 family of proteins plays a central role in controlling the 
mitochondrial pathway. Different members of the Bcl-2 family localize to the cytoplasm or 
to different subcellular compartments in healthy cells. However, upon receiving a death 
stimulus, most of these proteins carry out their functions at various intracellular 
membranes, particularly the endoplasmic reticulum (ER) and mitochondrial membranes. 
More than 20 members of this family have been identified to date in humans, including 
suppressors (Bcl-2, Bcl-XL, Mcl-1, Bfl-1/A1, Bcl-W, Bcl-G) and promoters (Bax, Bak, Bok, 
Bad, Bid, Bik, Bim, Bcl-Xs, Krk, Mtd, Nip3, Nix, Nora, Bcl-B) of apoptosis10.  
The central players in both pathways are the caspases (the cysteine-dependent, aspartate-
specific family of proteases), which also function as the executioner in apoptotic cell death11. 
Regulated at the post-translational level, caspases are synthesized as pro-caspases. Under 
stimulation of pro-apoptotic signals from different sources, pro-caspases are digested by 
protease to become active caspases. Mitochondrial dynamics contribute substantially to 
apoptotic pathways by stimulation of caspases, and by chromosomal fragmentation12,13.  
The extrinsic pathway is triggered at the cell surface through cytokine-induced death by 
receptor-mediated activation of caspase-8 or caspase-10, followed by activation of caspase-3 
and -73. The intrinsic pathway is characterized by mitochondrial dysfunction, resulting in 
cytochrome c release followed by formation of apoptosomes and subsequent activation of 
caspase-9 followed by caspases-3 and -7. Bid connects the extrinsic and intrinsic pathways. 
Cleavage of Bid by caspase-8 produces a truncated Bid fragment14 that initiates mitochondrial 
outer membrane permeabilization (MOMP) through the multidomain pro-death molecules 
Bax or Bak15. In turn, Bax/Bak translocation to mitochondria induces the release of cytochrome 
c into the cytosol and subsequent activation of the executioner caspases. 
An additional pathway involves T-cell-mediated cytotoxicity and perforin-granzyme-
dependent cell death. The perforin/granzyme pathway can induce apoptosis via either 
granzyme A or granzyme B. The granzyme A pathway activates a parallel, caspase-
independent cell-death pathway via single-stranded-DNA damage16. The extrinsic, intrinsic, 
and granzyme B pathways converge on the same terminal pathway.  
2.2 Autophagy 
Autophagy is a physiological process that plays an important role in the turnover of cellular 
proteins and other macromolecules. Moreover, it is the major catabolic route for eukaryotic 
cells to salvage essential molecules, and to maintain an adequate amino acid level to sustain 
protein synthesis during nutritional deprivation17. It is characterized by mitochondrial 
dilation, extensive intracellular membrane remodeling, and the generation of 
autophagosomes, large organelles that engulf various cellular constituents in double or 
multiple membranes. Autophagosomes subsequently fuse with lysosomes to become 
autolysosomes, where sequestered cellular components are digested18. Amino acids and 
fatty acids generated by this process can be used for protein synthesis, or can be oxidized by 
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the mitochondrial electron transport chain to produce ATP for cell survival under starvation 
conditions19. In addition to promoting cell survival, autophagy can lead to cell death.  
Based on the mechanisms used for the delivery of cargo to lysosomes, autophagy has been 
classified into three different types: macroautophagy, microautophagy, and chaperone-
mediated autophagy (CMA)20. Unlike apoptosis, which relies on the activation of caspases that 
cleave hundreds of target proteins21, autophagic cell death is caspase-independent22. Indeed, 
autophagic cell death has been demonstrated in cells with profound defects in the apoptosis 
machinery23 and in cells grown in the presence of caspase inhibitors24. Cells undergoing 
autophagic cell death look different from cells undergoing apoptosis. The characteristic 
cellular morphology of apoptosis results from caspase cleavage of cytoskeletal and other 
structural proteins21; apoptotic cells show early degradation of the cytoskeleton, but preserve 
organelles until fairly late in the process. In contrast, autophagic cell death is associated with 
accumulation of large numbers of autophagic vesicles, which degrade organelles early in the 
process, while the cytoskeleton remains intact and functional until late in the process25.  
Morphologic changes, such as chromatin condensation or membrane blebbing, may also 
occur in autophagic cell death, but there is no DNA fragmentation or formation of apoptotic 
bodies26. Over 30 ATG genes have been identified in yeast and at least 11 (ATG1, 3, 4, 5, 6, 7, 
8, 9, 10, 12 and 16) have orthologs in mammals, ATG6 is also known as BECN1 (Beclin 1) and 
ATG8 is commonly called LC3 in mammals. 
2.3 Programmed necrosis 
Accumulating evidence supports a ‘sequence’ of events that characterize necrotic cell death 
at both the phenomenological and the biochemical level, thereby reflecting a programmed 
course of events in the dying necrotic cell, and contributing to a definition of necrotic cell 
death. In addition, in some circumstances the ‘occurrence’ of necrotic cell death is also 
programmed. Type III PCD, programmed necrosis, is not due to one well-described 
signalling cascade, but is the result of interplay between several signalling pathways.  
The lack of caspase and lysosomal involvement distinguishes programmed necrosis from 
other types PCD. Programmed necrosis is characterized by early swelling of intracellular 
organelles such as mitochondria, ER, and Golgi apparatus, followed by loss of plasma 
membrane integrity. After signalling- or damage-induced lesions, necrosis can include signs 
of controlled processes such as mitochondrial dysfunction, enhanced generation of reactive 
oxygen species, ATP depletion, or proteolysis by calpains and cathepsins27. In addition, 
programmed necrosis is also typically associated with nuclear degradation that is 
accompanied by the release of nuclear factors such as high mobility group box 1 (HMGB1) 
that triggers a potent inflammatory response28,29. Recent reports describe that this 
programmed necrosis is firmly regulated and, depending on the cell-death system and/or 
PCD insult, implicates different proteins, such as TRAIL, TRADD, TRAF2, JNK1, RIP1, 
XRCC1, AIF, calpains, Bax, or Drp16,30-32. 
3. PCD-based therapeutic strategies against cancer 
Deregulation of the cellular pathways leading to PCD in mammals can cause a number of 
disease states, including neurodegenerative diseases, autoimmunity, and most prominently, 
various cancers33.  
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3.1 Apoptosis based therapeutic strategies 
Apoptosis is a major defense mechanism against malignant transformation. In fact, failures 
in normal apoptotic pathways contribute to carcinogenesis by creating a permissive 
environment for genetic instability and the accumulation of gene mutations. Tumour cells 
use a variety of molecular mechanisms to suppress apoptosis.  
Cancer cells can acquire resistance to apoptosis by the expression of anti-apoptotic proteins 
such as Bcl-2 or by the down-regulation or mutation of pro-apoptotic proteins such as Bax. The 
expression of both Bcl-2 and Bax are regulated by the product of the P53 tumour suppressor 
gene, a transcription factor that regulates the cell cycle, and which mutation occurs in over half 
of all human tumors. Among the remaining tumors, although they may process a wild-type 
P53, the pathways of P53-induced cell-cycle arrest and apoptosis are deficient. Therefore, P53 
serves as a unique molecular target for cancer therapy. PRIMA-1 (P53 reactivation and 
induction of massive apoptosis) is the second class of compounds reported to have the 
capability of restoring tumor-suppressor function to mutant P53, and it does not appear to 
have an effect on wild-type P53. This makes PRIMA-1 unique among all the 
chemotherapeutics currently used in the clinic34. In addition, p73 belongs to a small but 
important family of p53-related proteins (p53, p63, p73). The Trp73 gene contains two 
promoters that drive the expression of two major groups of p73 isoforms with opposing 
cellular actions: The TAp73 isoforms contain the p73 transactivation domain (TA) and exhibit 
proapoptotic activities, whereas the ∆Np73 isoforms lacking the N-terminal TA domain are 
anti-apoptotic. It has been proposed that a loss of p73 function might lead to tumorigenesis35, 
and that TAp73 down-regulation may be coupled with ∆Np73 up-regulation in some tumors36. 
Therefore, ∆Np73 is a marker of poor prognosis in many cancers, and pharmacological 
attempts are being made to inhibit ∆Np73 expression. Another mechanism of apoptosis-
suppression in cancer involves evasion of immune surveillance37. 
An agent that can selectively induce cell death in transformed cells without affecting normal 
cells would be an ideal anti-cancer chemotherapeutic agent. In fact, the molecular mechanisms 
that control and execute apoptotic cell death in cancer growth and resistance have been 
coming into focus and are enabling a new era of drug development for cancer treatment38.  
A variety of experimental approaches have been explored in the development of anti-cancer 
compounds that block Bcl-2 function. These include the use of antisense oligonucleotides to 
Bcl-2 that target gene expression at the mRNA level, peptides that mimic BH3 domains and 
bind to the pocket of Bcl-2 where pro-apoptotic BH3-only proteins would normally bind, and 
small molecule inhibitors of Bcl-2 function. The first attempt to introduce an agent that 
specifically targets Bcl-2 was made by Genta with their antisense DNA agent, oblimersen. On 
the basis of preclinical studies that found that antisense inhibition of Bcl2 levels could induce 
death in cancer cell lines, they designed a phosphorothioate DNA molecule complementary to 
Bcl2. More recently, in a study of chronic lymphocytic leukaemia (CLL), an improvement in 
response rate was observed in relapsed CLL patients when oblimersen was added to 
fludarabine and cyclophosphamide39. Albeit limited and not as diverse, some studies have also 
designed gene therapy approaches to enhance the activities of pro-death Bcl-2 proteins. 
Adenoviral vectors expressing these genes have recently been constructed with the goal of 
delivering them into cancer cells. Adenovirus-mediated overexpression of Bax, Bcl-Xs, Bik and 
others has been a successful strategy for killing various cancer cell lines40,41. In addition, Cancer 
cells produce higher levels of ROS (reactive oxygen species) than normal cells due to increased 
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of controlled processes such as mitochondrial dysfunction, enhanced generation of reactive 
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accompanied by the release of nuclear factors such as high mobility group box 1 (HMGB1) 
that triggers a potent inflammatory response28,29. Recent reports describe that this 
programmed necrosis is firmly regulated and, depending on the cell-death system and/or 
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disease states, including neurodegenerative diseases, autoimmunity, and most prominently, 
various cancers33.  
 
Therapeutic Exploitation of Targeting Programmed Cell Death for Cervical Cancer 
 
257 
3.1 Apoptosis based therapeutic strategies 
Apoptosis is a major defense mechanism against malignant transformation. In fact, failures 
in normal apoptotic pathways contribute to carcinogenesis by creating a permissive 
environment for genetic instability and the accumulation of gene mutations. Tumour cells 
use a variety of molecular mechanisms to suppress apoptosis.  
Cancer cells can acquire resistance to apoptosis by the expression of anti-apoptotic proteins 
such as Bcl-2 or by the down-regulation or mutation of pro-apoptotic proteins such as Bax. The 
expression of both Bcl-2 and Bax are regulated by the product of the P53 tumour suppressor 
gene, a transcription factor that regulates the cell cycle, and which mutation occurs in over half 
of all human tumors. Among the remaining tumors, although they may process a wild-type 
P53, the pathways of P53-induced cell-cycle arrest and apoptosis are deficient. Therefore, P53 
serves as a unique molecular target for cancer therapy. PRIMA-1 (P53 reactivation and 
induction of massive apoptosis) is the second class of compounds reported to have the 
capability of restoring tumor-suppressor function to mutant P53, and it does not appear to 
have an effect on wild-type P53. This makes PRIMA-1 unique among all the 
chemotherapeutics currently used in the clinic34. In addition, p73 belongs to a small but 
important family of p53-related proteins (p53, p63, p73). The Trp73 gene contains two 
promoters that drive the expression of two major groups of p73 isoforms with opposing 
cellular actions: The TAp73 isoforms contain the p73 transactivation domain (TA) and exhibit 
proapoptotic activities, whereas the ∆Np73 isoforms lacking the N-terminal TA domain are 
anti-apoptotic. It has been proposed that a loss of p73 function might lead to tumorigenesis35, 
and that TAp73 down-regulation may be coupled with ∆Np73 up-regulation in some tumors36. 
Therefore, ∆Np73 is a marker of poor prognosis in many cancers, and pharmacological 
attempts are being made to inhibit ∆Np73 expression. Another mechanism of apoptosis-
suppression in cancer involves evasion of immune surveillance37. 
An agent that can selectively induce cell death in transformed cells without affecting normal 
cells would be an ideal anti-cancer chemotherapeutic agent. In fact, the molecular mechanisms 
that control and execute apoptotic cell death in cancer growth and resistance have been 
coming into focus and are enabling a new era of drug development for cancer treatment38.  
A variety of experimental approaches have been explored in the development of anti-cancer 
compounds that block Bcl-2 function. These include the use of antisense oligonucleotides to 
Bcl-2 that target gene expression at the mRNA level, peptides that mimic BH3 domains and 
bind to the pocket of Bcl-2 where pro-apoptotic BH3-only proteins would normally bind, and 
small molecule inhibitors of Bcl-2 function. The first attempt to introduce an agent that 
specifically targets Bcl-2 was made by Genta with their antisense DNA agent, oblimersen. On 
the basis of preclinical studies that found that antisense inhibition of Bcl2 levels could induce 
death in cancer cell lines, they designed a phosphorothioate DNA molecule complementary to 
Bcl2. More recently, in a study of chronic lymphocytic leukaemia (CLL), an improvement in 
response rate was observed in relapsed CLL patients when oblimersen was added to 
fludarabine and cyclophosphamide39. Albeit limited and not as diverse, some studies have also 
designed gene therapy approaches to enhance the activities of pro-death Bcl-2 proteins. 
Adenoviral vectors expressing these genes have recently been constructed with the goal of 
delivering them into cancer cells. Adenovirus-mediated overexpression of Bax, Bcl-Xs, Bik and 
others has been a successful strategy for killing various cancer cell lines40,41. In addition, Cancer 
cells produce higher levels of ROS (reactive oxygen species) than normal cells due to increased 
 
Topics on Cervical Cancer with an Advocacy for Prevention 
 
258 
metabolic stress and proliferative rate.42-44 Excessive ROS production may increase the 
permeability of lysosomal membranes, leading to release of lysosomal proteases, which 
further contribute to mitochondrial membrane impairment11 and cancer progression43-45. It has 
been reported42 that increasing ROS generation selectively sensitizes oncogenically 
transformed cells to β-phenylethyl-isothiocyanate-induced cell death, suggesting that 
increasing ROS generation in cancer cells could be a strategy for cancer therapy.  
The selective activation of caspases might be a valuable strategy for combating cancer where 
pathogensis is related to insufficient cell death. Several strategies that trigger caspase 
activation have been developed, and several drugs that act in this way are currently being 
tested in preclinical trials. Therapeutic strategies have included adenovirus-mediated 
expression of caspases-3, -6, -8 and -9, which has resulted in both in vivo and in vitro anti-
tumourogenic activities46. In addition, adenoviral gene therapy approaches have also been 
used in the delivery of caspase constructs that can be activated on demand by the addition 
of a compound readily able to penetrate the cell membrane. The strategy relies on the fusion 
of caspases to one or chimeric “death switches”, which can be activated by chemical 
inducers of dimerization specific for a given construct47. There is considerable evidence that 
cysteine cathepsins play an important role in executing the apoptotic program in several 
tumour cell lines induced by death ligands such as TNF-,49 or TNF-related apoptosis 
inducing ligand (TRAIL)50. In the last few years, an apoptosis inducing agent, TRAIL, that 
was shown to target cancer cells specifically without damaging normal cells and tissues has 
received special interest in cancer therapy. Several groups recently discovered a cathepsin-
mediated proteolytic event in the apoptotic pathway triggered by TRAIL. First, the 
inhibition of TRAIL-induced apoptosis was observed upon treatment of oral squamous 
carcinoma cells with cathepsin inhibitors51. Subsequently, the pathway for apoptosis 
induction through Bid activation was confirmed in several other tumour cell lines50,52,53.  
3.2 Autophagy based therapeutic strategies 
In tumour cells in which the quality control mechanisms of both apoptosis and autophagy 
are disabled, failure to maintain energy homeostasis accelerates the generation of damaged 
cells54. This failure of protein/organelle quality control to curtail the accumulation of 
damaged proteins and organelles through autophagy may have a broad impact on cellular 
functions, leading either directly or indirectly to genome damage that promotes 
tumourigenesis. This may mean that autophagy is one of the mechanisms that contribute to 
the breakdown of cell growth control in cancer 55.  
In contrast to the potential cancer-promoting effect of autophagy, numerous observations 
have demonstrated that loss-of-function mutations in the autophagy pathway are associated 
with tumour progression56,57. Furthermore, constitutive activation of the PI3K pathway is 
one of the most common events in human cancer58, and the downstream kinase mTOR 
restricts autophagy induction in response to starvation59. Although many human cancers 
exhibit mutations in pro-autophagy genes, and several tumour suppressor genes (e.g., 
DAPK, PTEN, and TP53) can stimulate autophagy60, the molecular mechanism through 
which autophagy inhibits oncogenesis is currently unclear.  
Therapeutically induced autophagic cell death is another method for tumour-cell killing. 
Especially in apoptosis-defective cells, autophagy is often induced by cytotoxic drugs; the 
excessive cellular damage and attempt to remediate that damage through progressive 
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autophagy can promote autophagic cell death23. Inhibition of autophagy is important in 
cancer therapy. The process of cancer metastasis necessarily requires that tumour cells 
survive in isolation from the primary tumour, without its nutrient support system. Thus, 
early metastases may be particularly susceptible to inhibition of autophagy.  
Potential synergy with proteasome inhibitors is another reason for the use of autophagy 
inhibitors. The ubiquitin-mediated proteasome protein degradation pathway is functionally 
compensatory with protein turnover by lysosomal degradation through the autophagy 
pathway61,62. Therefore, protein degradation that is mediated by autophagy and 
proteasomes may be lethally exclusive to tumour cells with a high metabolic rate, or with 
increased susceptibility to the production of unfolded proteins. The ubiquitin-proteasome 
pathway is an intracellular proteolytic system which regulates the degradation of a broad 
spectrum of intracellular proteins, including diverse regulators of cell proliferation or 
apoptosis. Both bortezomid- and lenalidomide-based therapies are especially active, with 
bortezomib in particular being shown to provide a platform for combination, which is able 
to overcome resistance in this setting. Bortezomib，a first-in-class proteasome 
inhibitor，represents the prototypic member of a class of peptide boronate proteasome 
inhibitors of 26S proteasome activity, and has been approved by the US Food and Drug 
Administration, shows efficacy in treating multiple myeloma63.  
3.3 Programmed necrosis based therapeutic strategies 
Type III PCD, programmed necrosis, is usually defined in a negative fashion, as a type of 
cell demise that involves rupture of the plasma membrane without the hallmarks of 
apoptosis and without massive autophagic vacuolization. Necrosis lacks specific 
biochemical markers apart from the presence of plasma membrane permeabilization, and 
can be detected only by electron microscopy. Necrosis is considered to be harmful because it 
is often associated with pathological cell loss and because of the ability of necrotic cells to 
promote local inflammation that may support tumour growth64. However, necrotic cell 
death is induced in cancer cells by the therapeutic administration of alkylating DNA 
damaging agents65 and photosensitizing molecules that preferentially accumulate in tumour 
cells and generate ROS following excitation with light from various spectra66,67. 
4. The relationship of PCD to cervical cancer therapy 
The ultimate goal of anticancer therapy is to kill cancer cells quickly and effectively. Over 
the past two decades, it has become clear that cell death, in both malignant and non-
malignant cells, can be an active, regulated program. Thus, elucidation of the programmed 
cell-death pathways will provide new insight into tumour biology, revealing novel 
strategies for combating cancer. Tumour cells can only persist if they ignore the requirement 
for senescence that is imposed on all cells of organisms. Failure to execute PCD is usually a 
reflection of defective or absent molecular components of the cell-death machinery. Cervical 
cancer is second only to breast cancer in women as the most common of gynecologic 
malignancies, and it remains one of the most important causes of mortality in women 
worldwide. In recent years, cervical cancer has been affecting younger women. Because 
radiation therapy will negatively affect ovarian function in women of reproductive age, 
chemotherapy for cervical cancer has been receiving increased attention from clinicians. 
Although platinum-based neoadjuvant chemotherapy is an attractive option for 
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chemotherapy given prior to surgery, and can reduce tumor size and lead to improvement 
in overall survival, cancer cells often harbor mutations that confer resistance to apoptosis, 
suggesting the need for other therapeutic approaches that would exploit non-apoptotic cell 
modes of death or enhance cell apoptosis for cervical cancer therapy. 
4.1 Apoptosis autophagy and cervical cancer therapy 
The mechanism of tumour cell killing by an anti-cancer agent determines the way that the 
agent selects for resistance to the therapy. A drug that induces apoptosis might provide 
quite different selective pressures on the tumour cell compared with a drug that induces 
autophagic cell death. Thus, drugs with different mechanisms of action would be expected 
to have different levels of efficacy against a particular tumour68. On the other hand, the close 
connections between the apoptosis machinery and other PCD machinery under 
investigation would be expected to result in simultaneous activation of these PCD processes.  
When treating cancer, we often use drugs that cause severe damage to the cell. Regulation of 
PCD using caspase activators/inhibitors can constitute a treatment for cancer or for other 
PCD defective/excessive diseases69. Blockage of caspase activation causes degradation of 
catalase; the resultant increase in ROS generation leads to cell death. Degradation of catalase 
is also mediated by autophagy, thus suggesting a role for autophagy in caspase-
independent cell death70. So, when cancer cells are treated, the induction of autophagy, and 
the interactions between autophagy and apoptosis could have profound effects on the 
outcome for the tumour cell.  
Some connections occur upstream of the apoptotic and autophagic machinery where 
signalling pathways regulate both processes. For example, the autophagy gene beclin1 is part 
of a Type III PI3 kinase complex that is required for the formation of the autophagic vesicle, 
and that interacts with Bcl-2. A study found that the protein level of Beclin1 is lower in cervical 
cancer tissues than in normal tissues, and is closely related to pelvic lymph node metastases 
and histologic tumor grade71. Overexpression of Beclin1 in human cervical cancer SiHa and 
HeLa cell lines may induce the massive cells from to autophagy and inhibit tumor cell 
growth72,73. Another experiment indicates that beclin1 may be the critical molecular switch that 
plays an important role in fine tuning the autophagy and apoptosis through caspase-9 in 
cervical cancer cells72. Beclin1 also interacts with the other major anti-apoptotic Bcl family 
protein (Bcl-xL). It has been shown that autophagy can be regulated by this interaction. In 
addition to inhibiting apoptosis by binding to and interfering with the action of the pro-
apoptotic proteins Bax and Bak, Bcl-2/Bcl-xL also inhibits autophagy by binding with beclin1. 
This latter interaction is particularly important in the regulation of starvation-induced 
autophagy74. Bcl-2 can inhibit autophagy not only by interacting with beclin1, but also by 
blocking calcium release from the ER75. Conversely, DRAM (damage-regulated autophagy 
modulator), a well known component of the autophagic machinery, is essential also for p53-
mediated apoptosis76. Similarly, activation of the PI3 kinase/Akt pathway, a well-known way 
to inhibit apoptosis, also inhibits autophagy77. Thus important signalling pathways apparently 
simultaneously increase and decrease both autophagy and apoptosis. In our laboratory, we 
achieved stable transfectants expressing Beclin1 in cervical cancer CaSki cells, and observed 
that Beclin1 induced cell arrest in the G0/G1 phase. We then selected several drugs that can 
induce apoptosis to cancer cells by various mechanisms, including a anti-microtubule agent 
(paclitaxel), a platinum agent (cisplatin), an anti-metabolite (5-fluorouracil), and an 
 
Therapeutic Exploitation of Targeting Programmed Cell Death for Cervical Cancer 
 
261 
anthracycline (epirubicin), to detect the role of Beclin1 in chemosensitivity. We found that 
Beclin1 overexpression in CaSki cells reduced cell survival following exposure to all four anti-
cancer drugs. However, down-regulation of endogenous Beclin1 by siRNA in the CaSki cells 
did not lead to obvious resistance to the anti-cancer drugs. Taken together, these data provide 
evidence that Beclin1 is associated with chemosensitivity and the level of expression causes 
changes in response to chemotherapeutic drugs in cervical cancer, at least in vitro, despite the 
distinct damage mechanisms to cancer cells of these drugs78, 79. 
It has been suggested the mitochondrion may be the central organelle that integrates apoptosis 
and autophagy80. A positive feedback mechanism can be elicited by the activation and 
maturation of pre-apoptotic factors from autophagic processes in mitochondria, and lead to 
cell destruction through apoptotic and autophagic mechanisms. Autophagy can stop cells 
from undergoing apoptosis by sequestration of damaged mitochondria81. Moreover, some of 
the signals that are involved in apoptosis may also be involved in autophagy. For example, in 
both apoptosis and autophagy, there is the coordinated regulation of Akt and p70S6 kinase. 
Other proteins that may be part of the network connecting the two types of cell death include 
DAPK, Beclin1, BNIP3, HSpin1, or protymosin-α82. In our previous study73, we found that both 
autophagy and apoptosis were activated during carboplatin-induced death of cervical cancer 
cells. Beclin1 may act as an orchestrator, integrating apoptotic and autophagic activities. 
Another study demonstrated that autophagy and apoptosis contribute to etoposide-induced 
CaSki cervical cancer cell death, and autophagy may be the predominant mechanism of 
etoposide-induced cell death83. In addition, multiple death stimuli converge on mitochondria 
to provoke MOMP and release of apoptogenic factors such as cytochrome c, Smac/Diablo, 
Omi/HtrA2, Endonuclease G (Endo G), or AIF. Once released into the cytosol, these proteins 
initiate apoptosis, autophagy, or programmed necrosis30,31,84.  
4.2 Programmed necrosis and cervical cancer therapy 
Increasing evidence indicates that programmed necrosis can occur as a result of the 
activation of specific signal transduction cascades, and subsequently can be actualized only 
on inhibition of apoptosis and/or autophagy. Thus, it might be therapeutically desirable to 
trigger necrotic cell death in tumour cells that might have been selected to resist apoptotic or 
autophagic cell death.  
Studies suggest that cell death that usually manifests with an apoptotic morphology can be 
shifted to a more necrotic morphology when caspase activation is prevented by 
pharmacological inhibitors, or by the elimination of essential caspase activators such as 
Apaf-185. In some situations, caspase inhibition can even sensitize cells to the induction of 
necrosis, thereby reducing the dose of TNFa required to kill some cell lines86. A study found 
that heat treatment can induce cervical cancer CaSki cell apoptosis and necrosis87. Of the 
thermal conditions, 45C exhibited the best induction of apoptosis, while 47C induced 
direct fierce necrosis. This was further demonstrated by examining the expression level of 
several key apoptosis-related genes: caspase-3, Smac and Survivin. During apoptosis, 
caspase-3 and Smac levels were up-regulated, whereas anti-apoptotic Survivin was down-
regulated, enhancing programmed cell death. Similarly, inhibition of autophagy by 
transfection with constitutively active Akt protein kinase, or knockout of one of the alleles 
encoding the Beclin1 protein also determines a shift from type II (autophagy) to type III 
(programmed necrosis) cell death56. Another study88 also suggests that necrotic cell death 
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Omi/HtrA2, Endonuclease G (Endo G), or AIF. Once released into the cytosol, these proteins 
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Increasing evidence indicates that programmed necrosis can occur as a result of the 
activation of specific signal transduction cascades, and subsequently can be actualized only 
on inhibition of apoptosis and/or autophagy. Thus, it might be therapeutically desirable to 
trigger necrotic cell death in tumour cells that might have been selected to resist apoptotic or 
autophagic cell death.  
Studies suggest that cell death that usually manifests with an apoptotic morphology can be 
shifted to a more necrotic morphology when caspase activation is prevented by 
pharmacological inhibitors, or by the elimination of essential caspase activators such as 
Apaf-185. In some situations, caspase inhibition can even sensitize cells to the induction of 
necrosis, thereby reducing the dose of TNFa required to kill some cell lines86. A study found 
that heat treatment can induce cervical cancer CaSki cell apoptosis and necrosis87. Of the 
thermal conditions, 45C exhibited the best induction of apoptosis, while 47C induced 
direct fierce necrosis. This was further demonstrated by examining the expression level of 
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caspase-3 and Smac levels were up-regulated, whereas anti-apoptotic Survivin was down-
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transfection with constitutively active Akt protein kinase, or knockout of one of the alleles 
encoding the Beclin1 protein also determines a shift from type II (autophagy) to type III 
(programmed necrosis) cell death56. Another study88 also suggests that necrotic cell death 
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induces an immune response against the dying cell through the release of pro-inflammatory 
cytokines, which help to initiate the repair of damaged tissue. In this way, programmed 
necrosis differs fundamentally from apoptosis. Death by programmed necrosis is passive, 
causes cellular contents to be released into the extracellular space, and often causes 
inflammation. In addition, oxidative-stress-induced cell death is not completely blocked by 
inhibiting either apoptosis or autophagy. Indeed, in the hypoxic region of a tumour, where 
both apoptosis and autophagy are inhibited, increased necrosis with infiltration of 
macrophages and production of cytokines and chemokines has been observed in mouse 
models56. What specifically triggers necrosis is unknown, but ATP production insufficient to 
maintain plasma-membrane integrity results in metabolic catastrophe, making cell lysis 
highly probable89. Thus, it is also reasonable to assume that cells under oxidative stress 
could undergo cell death through multiple pathways including necrosis.  
5. Summary 
PCD is a genetically regulated process that allows for the maintenance of tissue homeostasis 
and cell numbers, and provides protection against damaged or infected cells that threaten 
this balance. It is becoming increasingly clear that PCD is involved in cancer formation and 
survival; the process of PCD responds to several forms of cancer treatments. Elimination of 
cancer cells might occur not only via apoptosis, but could also be mediated by other forms 
of cell death such as autophagy and programmed necrosis. In recent years, the PCD-based 
pharmacological therapies were mainly focused on apoptosis and the main regulators of this 
PCD pathway, the caspase family of cysteine proteases. Drug resistance limits the 
effectiveness of existing medical treatments, and is still a major challenge in the current 
research on PCD. To better understand the pathology and the potential therapeutic 
strategies for human cancer that are characterized by enhanced cell death, it is crucial to 
elucidate the death mechanism(s) directly involved in each cancer. Treatment should 
depend on the actual mechanism of cell death that plays a role in disease onset. Modulation 
of the autophagic pathway may be a novel way of sensitizing cervical cancer cells to anti-
cancer drug therapy90, and further studies of autophagy, apoptosis and necrosis may 
provide new insights into the mechanisms accommodating or contributing to PCD, thereby 
unveiling new strategies for cervical cancer therapy. 
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Worldwide cervical cancer is the second most common malignancy in women with nearly a 
half million new cases diagnosed and 250,000 deaths each year Almost 80% of cases occur in 
low-income countries, where cervical cancer is the most common cancer in women (WHO, 
2009). In spite of recent advances in the development of new anticancer agents, cancer 
continues to be one of the major causes of death worldwide. Resistance to chemotherapeutic 
agents remains a principal obstacle in the successful treatment of cancer. Therefore, 
development and search of novel and effective anticancer agents to overcome resistance 
have become very important issues.  
As other cancers, radiotherapy and chemotherapy are the conventional cancer treatment 
used nowadays and remain the routine method for the treatment of cervical cancer. These 
approaches present sole limits related to the cost, problems of unstable efficiency and 
severe side effects whose reduce the quality of life and discourage patients to observe 
medication protocols which then lead to the progression of cancer and associated 
complications. In addition, many of these treatments present limited anti-cancer activities 
                                                 
* Corresponding Author 
 
Topics on Cervical Cancer with an Advocacy for Prevention 
 
266 
[70] Yu L, Wan F, Dutta S, Welsh S, Liu Z, Freundt E, et al. Autophagic programmed cell 
death by selective catalase degradation. Proc Natl Acad Sci USA 2006;103:4952–7. 
[71] Wang ZH, Peng ZL, Duan ZL, Liu H. Expression and clinical significance of autophagy 
gene Beclin1 in cervical squamous cell carcinoma. Sichuan Da Xue Xue Bao Yi Xue 
Ban 2006;37: 860–3. 
[72] Wang ZH, Xu L, Duan ZL, Zeng LQ, Yan NH, Peng ZL. Beclin 1-mediated 
macroautophagy involves regulation of caspase-9 expression in cervical cancer 
HeLa cells. Gynecol Oncol 2007;107:107–13. 
[73] Sun Y, Zhang J, Peng ZL. Beclin1 induces autophagy and its potential contributions to 
sensitizes SiHa cells to carboplatin therapy. Int J Gynecol Cancer 2009;19:772-6. 
[74] Pattingre S, Tassa A, Qu X, Garuti R, Liang XH, Mizushima N, et al. Bcl-2 antiapoptotic 
proteins inhibit beclin 1-dependent autophagy. Cell 2005;122:927–39. 
[75] Hoyer-Hansen M, Bastholm L, Szyniarowski P, Campanella M, Szabadkai G, Farkas T, 
et al. Control of macroautophagy by calcium, calmodulin-dependent kinase kinase-
beta, and Bcl-2. Mol Cell 2007;25:193–205. 
[76] Crighton D, Wilkinson S, O’Prey J, Syed N, Smith P, Harrison PR, et al. DRAM, a p53-
induced modulator of autophagy, is critical for apoptosis. Cell 2006;126:121–34. 
[77] Mathew R, Karantza-Wadsworth V, White E. Role of autophagy in cancer. Nat Rev 
Cancer 2007;7:961-7. 
[78] Sun Y, Liu JH, Jin L, Lin SM, Yang Y, Sui YX, Shi H. Over-expression of the Beclin1 gene 
upregulates chemosensitivity to anti-cancer drugs by enhancing therapy induced 
apoptosis in cervix squamous carcinoma CaSki cells. Cancer Lett 2010;294:204-10 
[79] Sun Y, Jin L, Liu J, Lin S, Yang Y, Sui Y, Shi H. Effect of autophagy on paclitaxel-
induced CaSki cell death. Zhong Nan Da Xue Xue Bao Yi Xue Ban 2010;35:557-65. 
[80] Jin SK. Autophagy, mitochondrial quality control, and oncogenesis.Autophagy 
2006;2:80-4. 
[81] Ravikumar B, Berger Z, Vacher C, O’Kane CJ, Rubinsztein DC. Rapamycin pre-
treatment protects against apoptosis. Hum Mol Genet 2006;15:1209–16. 
[82] Klionsky DJ, Emr SD. Autophagy as a regulated pathway of cellular degradation. 
Science 2000;290:1717–21. 
[83] Lee SB, Tong SY, Kim JJ, Um SJ, Park JS. Caspase-independent autophagic cytotoxicity 
in etoposide-treated CaSki cervical carcinoma cells. DNA Cell Biol 2007;26:713-20. 
[84] Boya P, Gonzalez-Polo RA, Casares N, Perfettini JL, Dessen P, Larochette N, et al. 
Inhibition of macroautophagy triggers apoptosis. Mol Cell Biol 2005;25:1025–40. 
[85] Golstein P, Kroemer G. Redundant cell death mechanisms as relics and backups. Cell 
Death Differ 2005;12 (Suppl 2): 1490–6. 
[86] Degterev A, Yuan J. Expansion and evolution of cell death programmes. Nat Rev Mol 
Cell Bio 2008;9:378-90. 
[87] Zhou J, Wang X, Du L, Zhao L, Lei F, Ouyang W, Zhang Y, Liao Y, Tang J. Effect of 
hyperthermia on the apoptosis and proliferation of CaSki cells. Mol Med Report 
2011;4:187-91 
[88] Zong WX, Ditsworth D, Bauer DE, Wang ZQ, Thompson CB. Alkylating DNA damage 
stimulates a regulated form of necrotic cell death. Genes Dev 2004;18:1272–82. 
[89] Jin S, Dipaola RS, Mathew R, White E. Metabolic catastrophe as a means to cancer cell 
death. J Cell Sci 2007;120:379–83. 
[90] Sun Y, Liu JH, Sui YX, Jin L, Yang Y, Lin SM, Shi H. Beclin1 Over-expression Inhibitis 
Proliferation, Invasion and Migration of CaSki Cervical Cancer Cells. Asian Pacific 
J Cancer Prev 2011;12:1269-73 
16 
Antiproliferative Effect and Induction  
of Apoptosis by Inula viscosa L. and  
Retama monosperma L. Extracts in  
Human Cervical Cancer Cells 
L. Benbacer1, N. Merghoub1,2,3, H. El Btaouri3, S. Gmouh4,  
M. Attaleb1, H. Morjani3, S. Amzazi2 and M. El Mzibri1,* 
1Unité de Biologie et Recherche Médicale,  
Centre National de l'Energie, des Sciences et  
Techniques Nucléaires (CNESTEN), Rabat 
2Laboratoire de Biochimie-Immuniologie,  
Faculté des Sciences, Rabat 
3MEDyC CNRS UMR 6237,  
UFR Sciences et UFR Pharmacie, Reims 
4Unités d’Appui Technique à la Recherche Scientifique,  
Centre National pour la Recherche  




Worldwide cervical cancer is the second most common malignancy in women with nearly a 
half million new cases diagnosed and 250,000 deaths each year Almost 80% of cases occur in 
low-income countries, where cervical cancer is the most common cancer in women (WHO, 
2009). In spite of recent advances in the development of new anticancer agents, cancer 
continues to be one of the major causes of death worldwide. Resistance to chemotherapeutic 
agents remains a principal obstacle in the successful treatment of cancer. Therefore, 
development and search of novel and effective anticancer agents to overcome resistance 
have become very important issues.  
As other cancers, radiotherapy and chemotherapy are the conventional cancer treatment 
used nowadays and remain the routine method for the treatment of cervical cancer. These 
approaches present sole limits related to the cost, problems of unstable efficiency and 
severe side effects whose reduce the quality of life and discourage patients to observe 
medication protocols which then lead to the progression of cancer and associated 
complications. In addition, many of these treatments present limited anti-cancer activities 
                                                 
* Corresponding Author 
 
Topics on Cervical Cancer with an Advocacy for Prevention 
 
268 
(Mans, 2000). Therefore, development and search of novel and effective anticancer agents 
to overcome resistance and without severe side effects have become very important 
issues.  
During last decades, natural products have been an important source of chemotherapeutics, 
more than half of effective cancer drugs can be traced to natural origins (Ma, 2009). 
Approximately 60% of drugs currently used for cancer treatment have been isolated from 
natural products (Gordaliza, 2007; Newman, 2007). Currently, medicinal plants constitute a 
common alternative for cancer treatment in many countries around the world (Gerson-
Cwilich, 2006; Tascilar, 2006). 
Many candidate compounds that are able to arrest proliferation and induce apoptosis in 
neoplastic cells have been discovered. These include Vinca Alkaloids; Taxus diterpenes; 
Camptotheca Alkaloids; and Podophyllum lignans. Currently, there are 16 new plant-derived 
compounds being tested in clinical trials and of these 13 are being tested in phase I or II, and 
3 are in phase III. Among these compounds, flavopiridol, isolated from the Indian tree 
Dysoxylum binectariferum and mesoindigo, isolated from the Chinese plant Indigofera 
tinctoria, have been shown to exhibit anti-cancer effects with lesser toxicity than 
conventional drugs (Saklani A, 2008). 
In Morocco, medicinal plants have always been associated with cultural behaviour and 
traditional knowledge. Herbal remedies are frequently used to treat a large variety of 
ailments and symptoms, like a fever, inflammation, and pain (Gonzalez-Tejero, 2008). 
However, there is little information about their anti-cancer properties.  
Drug discovery from natural sources involves a multidisciplinary approach combining 
ethnobotanical, phytochemical and biological techniques to provide new chemical 
compounds for the development of new drugs against various pharmacological targets, 
including cancer and related complications. Cytotoxic screening models provide 
important preliminary data to select plant extracts with potential antineoplastic 
properties. The initial screenings are cell-based assays using established cell lines, in 
which the toxic effects of plant extracts or isolated compounds can be measured. Most of 
the clinically used antitumor agents possess significant cytotoxic activity in cell culture 
systems (Cardellina, 1999).  
In the course to contribute to development of new anticancer drugs against cervical 
cancer, the human cervical carcinoma SiHa and HeLa cell lines, has been used as a model 
system in this study for screening promising plant materials from folk Moroccan medicine 
possessing anticancer effect. Thus, seven medicinal plants: Inula viscosa L. (Ait.), Retama 
monosperma L. (Boiss.), Ormenis mixta L. (Dumont.), Ormenis eriolepis Coss., Rhamnus 
lycioides L., Berberis hispanica Bois. and Urginea maritima L. (Baker.) were collected and 
evaluated for the in vitro cytotoxic effect against SiHa and HeLa cell lines. The selection 
was made on the basis of their reputation as folk medicines and ethnobotanic 
informations to treat different illnesses and diseases. The selected plants have been 
described to exhibit several biological activities. However, the antiproliferative and 
apoptotic effects of these plants against cervical cancer cells have not yet been explored. 
The second part of this study, the most active plants were then selected and were 
evaluated for their potential antiproliferative effects against SiHa and HeLa cells. Furthers 
assays were used to elucidate its cytotoxic mechanism. 
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2. Materials and methods 
2.1 Plant species 
Seven plant species were collected from different regions of Morocco and were identified by 
Dr. M. Fennane from the Scientific Institute of Rabat. Voucher specimens are kept in the 
herbarium of institute. Table 1 shows the ethnobotanical data of the investigated plant 
species, including botanical names, local names, ethnomedical uses, as well as the plant 
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antihelmintic, abortive and 
disinfectant (Benrahmoune, 
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No information available 
Berberis hispanica 
Bois and Reut. 
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abortive, vipers bites, 
aphrodisiac, cough, 
bronchitis and the jaundice, 
diuretic and internal 
tumours (Bellakhdar, 1997)
Cytotoxic and antimalarial 
activities (Sathiyamoorthy, 
1999) 
Table 1. Ethnobotanical data and some reported pharmacological activities of plants species 
used in this study. 
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2.2 Plant extracts preparation 
The seven Plants were dried and ground finely. 20g of each powdered plant were extracted 
by absolute methanol (100 ml, three times) for 72 h at room temperature. The extracts were 
evaporated to dryness under reduced pressure at 40°C. A total of 40 mg of obtained extract 
were dissolved in dimethyl sulfoxide (DMSO) to give a solution stock to 40 mg/ml and 
conserved at -20°C until use.  
In second part of the study, the most actives plants were submitted to extraction with 
solvents with different polarities. Inula viscosa L. and Retama monosperma L. were extracted 
successively in a Soxhlet with n-hexane and methanol. The resulting extracts were then 
evaporated by Rotavapor to give dried extracts. The methanol concentrated extract was 
dissolved in distilled water and was successively extracted with dichloromethane and ethyl 
acetate. The solvent was evaporated to obtain the crudes extracts, and kept in the dark at +4 °C 
until tested. 
2.3 Cell lines 
Human cervical cancer SiHa and HeLa cell lines were used in this study. Cells were grown 
as monolayers in Minimum Essential Medium (MEM) supplemented with 10% heat-
inactivated fetal calf serum and 1% Penicillin-Spreptomycin mixture. Cultures were 
maintained at 37°C in 5% CO2. SiHa and HeLa cell lines were kindly provided by Dr. P. 
Coursaget, INSERM U618, University François Rabelais, Tours, France. 
2.4 Cytotoxicity assay 
Cytotoxicity of the plant extracts was determined using the MTT Assay as described 
previously (Mosmann, 1983). Cells were seeded in 96-well microplates. After 24 h of culture, 
the cells were treated with different concentrations ranging from 15.6 to 500 μg/ml, in 
quadruplicate for 48h or 72h incubation. 10μL MTT (5mg/mL) was added to each well. 
After 4 hours incubation, 150μL DMSO were added to dissolve purple formazan crystals, 
and absorbance was then determined using a spectrophotometer at 590nm. Mitomycin C 
and vinblastin (~ 95 % HPLC, sigma-Aldrich) were used as a positive control. 
2.5 Detection of the morphological changes associated with apoptosis 
SiHa and HeLa cells were cultured on glass chamber slides in 2 well plates and were treated 
with the IV-HE, IV-DF and Rm-DF for 24h , 48h and 72h at a concentration of 20µg/ml. 
After incubation, cells were washed with PBS twice and fixed with (4% paraformaldehyde 
and 0.1% Triton X-100) for 5 min. The cells were then washed with PBS and incubated with 
Hoecsht 33342 (10µg/ml) (Sigma) at 37 °C for 30min. The cells were visualized through 
fluorescence inverted microscope (Axiovert 200M Zeiss, Germany) equipped with an LD 
achroplan 40X objective. The images were collected with a CCD cooled camera (Coolsnap 
HQ, Ropper Scientific). 
2.6 Mitochondrial membrane potential (∆Ψm ) measurement 
Analysis of mitochondrial membrane potential was carried out using the lipophilic cationic 
probe, JC-1 (Molecular Probes, Eugene, OR) whose monomer emits at 530 nm (green) after 
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excitation at 500 nm. Depending on the mitochondrial membrane potential, JC-1 is able to 
form J-aggregates respectively from green to yellow-orange fluorescence emission (590 nm) 
as mitochondrial membrane becomes more polarized. Therefore, the I590nm/I530nm emission 
ratio value allows observation of mitochondrial dysfunction. SiHa and HeLa cells were 
treated with the extract for 24 h or 48h. JC-1 reagent (10µM) was added for 20 min at 37 °C in 
the dark. Cells were then washed with PBS and centrifuged at 1500 rpm, 4°C for 5 min. The 
pellet was resuspended in 1 ml ice-cold PBS and the measurements were performed using 
the Spectrofluorometer (RF-5301PC, Shimadzu, Tokyo, Japan). Residual mitochondrial 
potential as percentage of control was expressed as follows: (R treated/R control) x 100; R = 
I590 nm/I530 nm.  
2.7 Reactive oxygene species (ROS) production 
Production of ROS (reactive oxygen species) was monitored via oxidation of the 
carboxydichlorofluorescein analog probe, C2938. SiHa and HeLa cells (2 x105) were seeded 
into a 6-well plate and treated with the appropriate concentration of the extract for 24 h. 
Control and treated cells were washed and stained with 10 µM C2938 (30 min, 37C). 
Fluorescence emission from the oxidized probe was quantified with a 
Spectrofluorophotometer (RF-5301PC, Shimadzu) (excitation: 488±1 nm; emission: 518±1 
nm). 
2.8 Western blot analysis 
Cells were treated with 20 µg/ml of extracts for (24h, 48h and 72h), scrapped, washed with 
PBS and lysed in ice-cold lysis buffer (10 mM Tris pH 7.4, 150 mM NaCl, 5 mM EDTA, 1 mM 
Na3VO4, 1mM dithiothreitol, 10µg/ml Leupeptin , 10µg/ml aprotinin, 10% glycerol, 1%Brij 
(v/v)) , placed on ice for 20 and centrifuged at 14,000g for 15 min at 4 °C. The amount of 
protein was determined using the Bio-Rad protein quantification kit. Equal amounts of 
proteins (25-30µg/ml) was subjected to electrophorese on SDS-polyacrylamide gels and, 
transferred to a Nitrocellulose membrane by electroblotting. After blocking non-specific 
sites, the membrane was incubated overnight with appropriate primary antibodies: 
Monoclonal anti- pro-Caspase 3 (1/700), Monoclonal anti-β actin (dilution 1/5000), 
Monoclonal anti-BCl2 (1/700) and polyclonal anti- PARP (1/1000). Horseradish peroxidase-
conjugated goat anti-rabbit or anti-mouse IgG were used as secondary antibodies and 
proteins were detected using an enhanced chemiluminescence (ECL) kit.  
2.9 Gas chromatography/mass spectrometry (GC/MS) analysis 
The identification of the compounds from I. viscosa hexanic fraction (IV-HE) and R. 
monosperma dichloromethane fraction (Rm-DF) was performed by (GC/MS) analysis using a 
Hewlett Packard 5890 II Gaz Chromatograph, equipped with a HP 5972 Mass selective 
detector and a VB5 ( 5% phenyl ; 95% methylpolisyloxane) capillary column (30 m, 0.25 mm, 
film thickness 0.25 µm). Injection volume was 1 µl with a splitless; the injector and detector 
temperatures was held constant at 250. For GC/MS detection an electron ionization system 
with ionization energy of 70 eV was used. Helium was used as the carrier gas with an inlet 
pressure of 10.48 psi, corresponding to a flow rate of 1.0 ml/min. The analytical conditions 
worked the following programme: oven temperature from 60 to 280°C at rate of 16°C min -1, 
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the final temperature of 300°C was held for 10 min. Tentative identification of the 
compounds was based on the comparison of their relative retention time and spectral mass 
with those of Nist and Wiley7 library data of the GC/MS system.  
2.10 Statistical analysis 
Data are presented as means ± SD of at least triplicate or quadruplicate determinations of 
three different assays. The statistical analysis was performed by student’s-test with 
Microsoft excel software. Significant differences are indicated by *p < 0.05; **p < 0.01; ***p < 
0.001. 
3. Results and discussion 
3.1 Cytotoxic effect of the medicinal plants extracts from Morocco 
Crude extracts of selected plants were made by exhaustive methanol extraction. These 
plants extracts were tested for their potential cytotoxic effects, SiHa and HeLa cells were 
treated with plants extracts at different concentrations ranging from 15 to 500 μg/ml for 48h. 
The cells viability were determined by MTT assay. Among the 7 medicinal plant extracts, 
methanolic extract from Inula viscosa L. and Retama monosperma L. have been found to 
exhibit marked cytotoxic effect on both SiHa and HeLa cell lines. Their IC50 values were 
54±12 and 99±1 µg/ml in SiHa cells and 60±8 and 112±4 µg/ml in HeLa cells, respectively. 
The methanolic extract of Ormenis eriolepis Coss., Ormenis mixta L. and Berberis hispanica 
Boiss. have lower cytotoxic effect on the cancer cell lines tested (Table 2). However, Urginea 
maritime L. and Rhamnus lycioides L. had insignificant or no cytotoxic effects at tested 
concentration with IC50 ˃500µ/ml. 
 
Methanolic extracts 
IC50 ± SD (μg/ml) 
SiHa HeLa 
Inula viscosa L. 54 ± 12 60 ± 8 
Ormenis eriolepis Coss. 94 ± 4 112 ± 4 
Ormenis mixta L. 383 ± 26 311± 14 
Berberis hispanica Boiss. 178 ± 5 224 ± 10 
Retama Monosperma L. 99 ± 1 96 ± 4 
Urginea maritime L. › 500 › 500 
Rhamnus lycioides L. › 500 › 500 
Mitomycin C 6 ± 1 1 ± 0.30 
Table 2. Cytotoxic activity of methanolic extracts of some medicinal plants from Morocco on 
SiHa and HeLa cervical cancer cell lines. 
Inula viscosa L. (Ait.) and Retama monosperma L. methanolic extracts showed the highest 
cytotoxic activity with lowest IC50 values. Previous studies have reported interesting 
biological activities with potential therapeutic applications of these plants. Inula viscosa L. is 
used in Moroccan folk medicine as antihelmintic, diuretic, anemia and as cataplasm for 
rheumatic pain (Hmamouchi, 2001), tuberculosis, expectorant and treatment of bronchitis 
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(Bellakhdar, 1997). The aerial part of this plant is used as decoction in the treatment of 
diabetes, hypertension and renal diseases (Eddouks, 2002). This plant has been described to 
exhibit several biological activities such as anti-inflammatory (Hernández, 2007), 
antimicrobial (Maoz, 1998) and antifungal effects (Cafarchia, 2002). Retama monosperma L. is 
used in the traditional medicine of many countries, as a purgative, vermifuge, antihelmintic 
and abortive (Bellakhdar, 1997). Moreover, it has been reported that Retama Genus for a 
various pharmacological effects, including an hypoglycemic and diuretic (Maghrani, 2005a; 
Maghrani, 2005b), cytotoxic (Conforti, 2004; Hayet, 2007; López-Lázaro, 2000), antioxidant 
and antiviral (Edziri, 2010) and antihypertensive (Eddouks, 2007). 
Cells were exposed to different concentrations of extracts for 48h. Data are expressed as IC50 
values (µg/ml) and are means ± SD of three experiments. Mitomycine was used as positive 
control.  
The cytotoxic effect of extracts from Inula viscosa L. and Retama monosperma L. 
As evidenced by MTT assays, we found that hexanic (IV-HE) and dichloromethane (IV-DF) 
extracts from Inula viscosa were able to inhibit cell growth in dose-dependent manner after 
72h of treatment, in both cell lines. The IC50 values for IV-HE on SiHa and HeLa were 
9.56±1.68 and 13.17±0.79 μg/ml, respectively. However, for IV-DF, the IC50 values on SiHa 
and HeLa were respectively 6.54±1.46 and 22.04±3.31 μg/ml. Retama monosperma 
dichloromethane fraction (Rm-DF) was the most active extract, exhibiting also cytotoxic 
activity against both cells lines in dose-dependent manner. Values of IC50 obtained were 14± 
and 21±µg/ml, in SiHa and HeLa cell lines respectively (Table 3). The American National 
Cancer Institute assigns a significant cytotoxic effect of promising anticancer product for 
future bio-guided studies if it exerts an IC50 value ˂30 μg/ml (Suffnes, 1990). The obtained 
results indicate that IV-HE and IV-DF and Rm-DF were shown to induce significant and 





Retama monosperma L. extracts   
Hexane extract (Rm-HE) › 80 › 80 
Methanol extract (Rm-ME) › 80 › 80 
Dichloromethane fraction (Rm-DF) 14.57±4.15 21.33±7.88 
Acetate ethyle fraction (Rm-AF) 27.54±5.64 77.47±2.25 
Inula viscosa L. extracts   
Hexane extract (IV-HE) 9.56 ± 1.68  13.17±0.79 
Methanol extract (IV-ME) 52.83±3.28  › 80 
Dichloromethane fraction (IV-DF) 6.54±1.46  22.04±3.31 
Ethyl acetate fraction (IV-AF) 63.62±10.55  › 80 
Vinblastin 10.88±0.78  6.28±0,35 
Table 3. Cytotoxic effect of extracts and fractions of Retama monosperma L. and Inula viscosa L. 
extracts against SiHa and HeLa cervical cancer cells.  
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Cells were exposed to different concentrations of extracts for 72h. As determined by MTT 
assay. Data are expressed as IC50 values (µg/ml) and are means ± SD of three experiments. 
Vinblastin was used as a positive control.  
3.2 Chemical identification of plants extracts 
Analyses of the most active extracts by gas chromatography (GC) coupled with and GC-
mass spectrometry (MS) revealed the presence of a sesquiterpene acid: isocostic acid 
(46.05%) and two sesquiterpenes lactones: tomentosin (33.27%) and inuviscolide (13.04%), as 
major compounds in IV-HE extract (Table 4). In the fact, Inula viscosa L. is source of a 
number of bioactives compounds as well as flavonoids (Hernandez, 2007) and sesquiterpene 
derivatives (Fontana, 2007).  
 
Extracts Compounds RT Area (%) 
IV-HE 
1-Amino-1-ortho-chlorophenyl-2-(2-quinoxalinyl)ethene 12.79 0.21 
3-(4'-Methoxyphenyl)-1-acetyl-2-phenylindolizine 24.99 1.68 
Isocostic acid 40.56 46.05 





Iso-velleral 46.26 1.87 
6,9,12,15-Docosatetraenoic acid, methyl ester 46.82 0.37 
Quercetin 7,3',4'-trimethoxy 46.93 0.22 
Tomentosin 47.27 33.27 
Inuviscolide 47.39 13.04 
Tetracosane  54.32 0.77 
6-Imino-8-(3',5'-dichlorolphenyl)-3,4-dihydro-2H, 6H-
pyrimido[2,1-β][1,3]thiazine-7-carbonitrile 57.78 0.39 
IV-DF 
Benzeneacetic acid, α',4-bis[(trimethylsilyl)oxy]-, trimethylsilyl 
ester  18 .91 10.44 
9H-pyrrolo[3',4':3,4]pyrrolo[2,1-a]phthalazine-9,11(10H)-
dione,10-ethyl-8-phenyl 24.99 47.85 
Isocostic acid 40.56 2.29 
1 ,2-longidione 44.54 5.03 
10 hydroxy-1 ,4,5,8-Tetramethyl anthrone 44.84 2.54 
Chiapin B 46.27 1.55 
2,4,7 Trimethyl-5 ,6-diphenyl-1H-isoindol-1 ,3(2H)-dione 47.01 9.12 
Tomentosin 47.26 13.93 
Methyl 2,3-Dideoxy-4-O-propargyl-6-O-(tert-butyldimethylsilyl)-
α-D-erythro-hex-2-enopyranoside 55.92 7.24 
Area (%):(%): area percentage (peak area relative to the total peak area percentage). 
RT : Retention time (min).  
Table 4. Compounds present within Inula viscosa L. extracts identified by CG/MS. 
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However, CG/MS analysis of Rm-DF (Table 5) revealed the presence of five known 
quinolizidine alkaloids as well as, sparteine (10.97%), L- methyl cytisine (9.11%), 17-
oxosparteine (3.49%), lupanine (0.93%) and anagyrine (39.63%). The Retama species have 
been reported to contain alkaloids (Abdel Halim, 1997) and flavonoids (Kassem, 2000). 
Fifteen quinolizidine and 3 dipiperidine alkaloids were isolated from the leaves of flowering 
plants of R. monosperma collected from Morocco (Touati, 1996). 
 
Extracts Compounds RT Area(%) 
Rm-DF 
α-Pinene 9,89 2.73 
1,8-Cineole 13,79 8.03 
Benzeneacetic acid, α,4-bis[(trimethylsilyl)oxy]-, 18.91 4.71 
trimethylsilyl ester  
9H-pyrrolo[3',4':3,4]pyrrolo[2,1-a]phthalazine-9, 24.99 19.05 
11(10H)-dione,10-ethyl-8-phenyl  
Sparteine 38,98 10.97 
Hexadecanoic acid 42,71 0.86 
L methyl cytisine 44,23 9.11 
17- oxosparteine 46,67 3.49 
4-(N-(3-trifluoromethylphenyl)-amino)-5,6-dimethyl-
7H-pyrro[2.3-d]pyrimidine 47.78 0.50 
Lupanine 48,78 0.93 
Anagyrine 53 ,73 39.63 
Area (%):(%): area percentage (peak area relative to the total peak area percentage). 
RT : Retention time (min). 
Table 5. Compounds present within R. monosperma L. extracts identified by CG/MS. 
3.3 Molecular mechanisms of apoptosis signalling pathways 
Induction of apoptosis constitute an important mechanism for anticancer effects of many 
naturally occurring and synthetic agents. Activation of apoptotic pathways seems to be an 
effective strategy against tumor progression (Brown, 2005). The caspase pathway plays a 
pivotal role in the induction, transduction and amplification of intracellular apoptotic 
signals. Among the caspase family proteins, capase-3 is responsible for the proteolytic 
cleavage of many key proteins such as PARP, which is considered as a marker of apoptosis 
(Kothakota, 1997; Wang, 2005).  
3.4 IV-HE, IV-DF and Rm-DF induced apoptosis in SiHa and HeLa cells 
In order to determine whether plant extracts induced cell death was due to apoptosis, we 
analyzed chromatin condensation and nuclear fragmentation by Hoechst 33342 staining and 
fluorescence microscopy (Kerr, 1994). SiHa and HeLa cells were treated with IV-HE, IV-DF 
and Rm-DF for 24h, 48h and 72h. As shown in Figure 1, the rate of apoptotic cells was 
increased significantly in a time-dependant manner after treatment with IV-HE, IV-DF and 
Rm-DF (Figure.1). 
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Cells were exposed to different concentrations of extracts for 72h. As determined by MTT 
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Fig. 1. IV-HE, IV-DF and Rm-DF induce apoptosis of cervical cancer cells. SiHa (A) and 
HeLa (B) cells were treated IV-HE, IV-DF and Rm-DF and stained with Hoechst 33342. 
Condensed, fragmented nuclei and apoptotic bodies were seen in the treated cells. The 
stained nuclei were visualized and photographed with an inverted fluorescence microscope 
(Axiovert 200M Zeiss). Data represent at least two experiments (Magnification: x 400). 
3.5 Expression of Pro-caspase, Bcl2 and PARP cleavage 
Inula viscosa and Retama monosperma extracts were able to induce apoptosis in HeLa and 
SiHa cells as evidenced by western blot analysis. Activation of caspase-3 causes 
the cleavage of poly-(ADP-ribose)-polymerase (PARP), a hallmark of apoptosis, to produce 
an 85 kDa fragment during apoptosis (Tewari, 1995). After treatment of cells, a procaspase-3 
cleavage and cleavage of poly (ADP-ribose) polymerase (PARP) were observed in time- and 
dose-dependent manner. IV-HE, IV-DF and Rm-DF caused the proteolytic cleavage of PARP 
with accumulation of the 85 kDa fragment in SiHa and HeLa cells (Figure 2.A; 2.B). This  
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Fig. 2. Expression of Pro-caspase 3 , Bcl-2 and PARP proteins in HeLa and SiHa treated-cells 
analysed by Western blot. After treatment with 20µg/ml of IV-HE, IV-DF (A) and Rm-DF 
(B) during 24h and 48 h or 72h, cell lysates were prepared and the proteins were separated 
on SDS-polyacrylamide gel and transferred into nitrocellulose membranes. The membranes 
were probed with the indicated antibodies. β-actin was used as a control for protein loading. 
The results shown here were from two or three representative experiments. 
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suggests that apoptosis induced by IV-HE, IV-DF and Rm-DF could be associated with a 
caspase-dependent pathway.  
The activation and function of caspases are regulated by various key of molecules, such as 
inhibitors of apoptosis protein, Bcl-2 protein family. Increased expression of the anti-
apoptotic protein Bcl-2 causes resistance to chemotherapeutic drugs, while decreasing Bcl-2 
expression may promote apoptotic responses to anticancer drugs (Reed J.C., 1994). Our 
investigations showed a significant decrease in Bcl-2 expression after 24h treatment with IV-
HE, IV-DF and Rm-DF (Figure 2A, 2B).  
3.6 Statut of mitochondrial membrane potential 
Mitochondrial dysfunction has been shown to participate in the induction of apoptosis. 
Indeed, opening of the mitochondrial permeability transition pore has been demonstrated to 
induce depolarization of the transmembrane potential (ΔΨm), release of apoptogenic factors 
and loss of oxidative phosphorylation (Zimmermann, 2001). To characterize the effect of IV-
HE, IV-DF and Rm-DF on the mitochondrial apoptotic pathway, we measured the 
mitochondrial membrane potential (∆Ψm) in SiHa and HeLa cells after treatment for 24h. As 
shown in (Figure.3), IV-HE, IV-DF and Rm-DF, induced a significant decrease in 




Fig. 3. Mitochondrial membrane potential state in treated cells with IV-HE, IV-DF and Rm-
DF, measured by spectrofluorometry and JC-1 probe in SiHa (A) and HeLa (B). Cells are 
treated with 20µg/ml of extracts for 24h as described in Materials and Methods. The results 
are presented as the mean ± SD of three independent experiments. 
3.7 Measurement of ROS production 
Mitochondria are a source of ROS during apoptosis and reduced mitochondria membrane 
potential leads to increased generation of ROS and apoptosis (Zamzami, 1995). We 
investigate whether the intracellular ROS are involved in the signal transduction 
pathways of apoptosis. ROS generation was measured after cells treatment with IV-HE, 
IV-DF and Rm-DF (20µg/ml) for 24h, using a ROS-sensitive fluorescent C2938 probe. 
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Tested extracts showed a dose-dependent increase in the intracellular ROS production 
when compared to the control (Figure.4). This indicate that ROS generation induced by 






Fig. 4. ROS production in treated cells with IV-HE, IV-DF and Rm-DF, using an oxydation-
sensitive fluorescent C2938 probe in SiHa (A) and HeLa (B). Cells are treated with 20µg/ml 
of extracts for 24h as described in Materials and Methods. The results are presented as the 
mean ± SD of three independent experiments. 
Taken together, these results show clearly that the hexanic extract of Inula viscosa and 
dichloromethane fractions of both Inula viscosa and Retama monosperma have cytotoxic effects 
against cervical cancer cell lines SiHa and Hela by inducing apoptotic process. Previous 
studies have showed that some plant extracts with pronounced cytotoxic in vitro had 
marked effects in vivo and showed promising potential to be used as an anticancer drugs. 
Indeed, sesquiterpene lactones, isolated from Carpesium rosulatum, have recently been 
largely studied for their pharmacological proprieties as anti-neoplastic agents (Ma G, 2009; 
Moon, 2011; Robinson, 2008; Taylor, 2008). Sesquiterpenes lactones, artemisinin, 
thapsigargin and parthenolide and many of their synthetic derivatives, are in advanced 
stage for clinical trials (Ghantous, 2010). 
Phytochemicals contained in Inula viscosa L. extracts including like tomentosin and 
inuviscolide, as evidenced by CG/MS analysis, have been shown recently to possess an 
antiproliferative and apoptotic effects on human melanoma cell lines (Rozenblat, 2008).  
Quinolizidine alkaloids are known to present in Retama monosperma as main active 
constituents. Quinolizidine alkaloids contained in the dichloromethane fraction of Retama 
monosperma L. extract, may act as potential in vitro cytotoxic agents against human 
cervical cancer cells through the induction of apoptosis. In fact, previous reports have 
shown that quinolizidine alkaloids have been found to elicit a range of biological activities, 
including antiviral (Ding, 2006), antihypoglycemic (Brukwicki, 2009) and anti-tumoral 
(Zhang, 2010) activities. 
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The hexanic extract of Inula viscosa and dichloromethane fractions of both Inula viscosa and 
Retama monosperma showed pronounced cytotoxic effects against cervical cancer cell lines 
through the inhibition of proliferation and induction of apoptosis caspase-dependent and 
involving a mitochondria-mediated signaling pathway. Our findings suggest that these 
extracts might provide compounds which could be potential sources of anticancer drug 
leads. Further investigation into the isolation, characterization and mechanism of cytotoxic 
compounds from the selected plants extracts and in vivo are necessary. Moreover it will be 
interesting to use some in vivo models to evaluate the anti-tumor activity of these plant 
extracts.  
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leads. Further investigation into the isolation, characterization and mechanism of cytotoxic 
compounds from the selected plants extracts and in vivo are necessary. Moreover it will be 
interesting to use some in vivo models to evaluate the anti-tumor activity of these plant 
extracts.  
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